-- phpMyAdmin SQL Dump
-- version 4.8.4
-- https://www.phpmyadmin.net/
--
-- Host: 127.0.0.1:3306
-- Generation Time: Jul 07, 2020 at 04:08 AM
-- Server version: 5.7.19
-- PHP Version: 7.3.1

SET SQL_MODE = "NO_AUTO_VALUE_ON_ZERO";
SET AUTOCOMMIT = 0;
START TRANSACTION;
SET time_zone = "+00:00";


/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8mb4 */;

--
-- Database: `spharma_1`
--

-- --------------------------------------------------------

--
-- Table structure for table `accounts`
--

DROP TABLE IF EXISTS `accounts`;
CREATE TABLE IF NOT EXISTS `accounts` (
  `id` int(10) NOT NULL AUTO_INCREMENT,
  `account_name` varchar(80) NOT NULL,
  `account_code` varchar(100) NOT NULL,
  `account_type` int(11) NOT NULL,
  `description` varchar(100) NOT NULL,
  `updated_at` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP,
  `created_at` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=4 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `accounts`
--

INSERT INTO `accounts` (`id`, `account_name`, `account_code`, `account_type`, `description`, `updated_at`, `created_at`) VALUES
(1, 'Receivable', '11025', 2, 'description', '2019-04-26 04:28:04', '0000-00-00 00:00:00'),
(2, 'Income of Sales', '22222', 3, 'account payable', '2019-04-26 13:11:29', '2019-04-26 04:29:34'),
(3, 'Inventory Control', '444444', 4, 'description', '2019-04-26 04:30:33', '2019-04-26 04:30:23');

-- --------------------------------------------------------

--
-- Table structure for table `account_types`
--

DROP TABLE IF EXISTS `account_types`;
CREATE TABLE IF NOT EXISTS `account_types` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `account_types` varchar(100) NOT NULL,
  `description` varchar(150) NOT NULL,
  `updated_at` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP,
  `created_at` timestamp NOT NULL DEFAULT '0000-00-00 00:00:00',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `adjustments`
--

DROP TABLE IF EXISTS `adjustments`;
CREATE TABLE IF NOT EXISTS `adjustments` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `date` date NOT NULL,
  `item` int(11) NOT NULL,
  `real_amount` decimal(10,2) NOT NULL DEFAULT '0.00',
  `reason` text,
  `location` int(4) NOT NULL,
  `barcode` varchar(100) DEFAULT NULL,
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  `varities` int(11) DEFAULT NULL,
  `package_id` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=26 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `adjustments`
--

INSERT INTO `adjustments` (`id`, `date`, `item`, `real_amount`, `reason`, `location`, `barcode`, `updated_at`, `created_at`, `varities`, `package_id`) VALUES
(10, '2018-01-02', 413, '40.00', 'klkjdklsjfldsjs', 1, 'no-barcode', NULL, NULL, NULL, NULL),
(11, '2018-01-02', 426, '18.00', 'skljsdklfjsdlkfj', 1, '10001842601', NULL, NULL, NULL, NULL),
(12, '2018-01-02', 426, '18.00', 'skljsdklfjsdlkfj', 1, '10001842601', NULL, NULL, NULL, NULL),
(13, '2018-01-02', 426, '14.00', 'skljsdklfjsdlkfj', 1, '10001842601', NULL, NULL, NULL, NULL),
(14, '2019-04-28', 413, '25.00', 'Description', 2, 'no-barcode', NULL, NULL, NULL, NULL),
(15, '2019-04-28', 413, '25.00', 'Description', 2, 'no-barcode', NULL, NULL, NULL, NULL),
(16, '2019-04-28', 413, '6.00', 'Description', 2, 'no-barcode', NULL, NULL, NULL, NULL),
(17, '2019-04-27', 413, '40.00', 'bad things happen', 2, 'no-barcode', NULL, NULL, NULL, NULL),
(18, '2019-04-27', 413, '36.00', 'bad things happen', 2, 'no-barcode', NULL, NULL, NULL, NULL),
(19, '2019-04-29', 413, '85.00', 'lkskdjflkjsdlkjfksdlf', 1, 'no-barcode', '2019-04-29', NULL, NULL, NULL),
(20, '2020-04-24', 1, '6.00', NULL, 1, NULL, NULL, NULL, 283, NULL),
(21, '2020-04-24', 1, '8.00', NULL, 1, NULL, NULL, NULL, 283, 1),
(22, '2020-04-24', 1, '8.00', NULL, 1, NULL, NULL, NULL, 283, 1),
(23, '2020-04-24', 1, '8.00', NULL, 1, NULL, NULL, NULL, 283, 1),
(24, '2020-04-24', 1, '10.00', NULL, 1, NULL, NULL, NULL, 283, 1),
(25, '2020-04-24', 1, '20.00', NULL, 1, NULL, NULL, NULL, 283, 1);

-- --------------------------------------------------------

--
-- Table structure for table `adverse_effects`
--

DROP TABLE IF EXISTS `adverse_effects`;
CREATE TABLE IF NOT EXISTS `adverse_effects` (
  `id` int(11) NOT NULL,
  `drug` int(11) NOT NULL,
  `effect` varchar(150) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `appointment_date`
--

DROP TABLE IF EXISTS `appointment_date`;
CREATE TABLE IF NOT EXISTS `appointment_date` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `appointment_date` varchar(150) DEFAULT NULL,
  `appointment_reason` varchar(150) DEFAULT NULL,
  `customer` int(11) NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=3 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `appointment_date`
--

INSERT INTO `appointment_date` (`id`, `appointment_date`, `appointment_reason`, `customer`) VALUES
(1, '2020-02-25', 'what a reason', 26),
(2, '2020-02-25', 'lskdjskdjfldsf', 26);

-- --------------------------------------------------------

--
-- Table structure for table `app_settings`
--

DROP TABLE IF EXISTS `app_settings`;
CREATE TABLE IF NOT EXISTS `app_settings` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `name` varchar(150) NOT NULL,
  `value` int(11) NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `begining_balance`
--

DROP TABLE IF EXISTS `begining_balance`;
CREATE TABLE IF NOT EXISTS `begining_balance` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `item` int(11) NOT NULL,
  `period` int(11) NOT NULL DEFAULT '0',
  `date` date DEFAULT NULL,
  `unit_cost` decimal(10,2) NOT NULL DEFAULT '0.00',
  `balance` decimal(10,2) NOT NULL DEFAULT '0.00',
  `valuation` decimal(10,2) NOT NULL DEFAULT '0.00',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `companys`
--

DROP TABLE IF EXISTS `companys`;
CREATE TABLE IF NOT EXISTS `companys` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `company_name` varchar(50) DEFAULT NULL,
  `company_code` varchar(50) DEFAULT NULL,
  `description` varchar(150) DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP,
  `created_at` timestamp NULL DEFAULT CURRENT_TIMESTAMP,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=5 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `companys`
--

INSERT INTO `companys` (`id`, `company_name`, `company_code`, `description`, `updated_at`, `created_at`) VALUES
(1, 'Adidas', '103', 'best shoe maker ever', '2019-06-14 18:07:30', '2019-06-14 17:59:28'),
(2, 'Nick', '105', 'nick', '2019-06-14 18:07:53', '2019-06-14 18:07:53'),
(3, 'Reebook', 'M102', 'made in america', '2019-07-02 03:22:43', '2019-07-02 03:22:43'),
(4, 'new', NULL, NULL, '2019-07-18 05:17:36', '2019-07-18 05:17:08');

-- --------------------------------------------------------

--
-- Table structure for table `configurations`
--

DROP TABLE IF EXISTS `configurations`;
CREATE TABLE IF NOT EXISTS `configurations` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `configuration_name` varchar(45) DEFAULT NULL,
  `configuration_value` varchar(45) DEFAULT NULL,
  `created_at` datetime DEFAULT NULL,
  `updated_at` datetime DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=2 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `configurations`
--

INSERT INTO `configurations` (`id`, `configuration_name`, `configuration_value`, `created_at`, `updated_at`) VALUES
(1, 'pricing', 'fifo', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `cost_profit`
--

DROP TABLE IF EXISTS `cost_profit`;
CREATE TABLE IF NOT EXISTS `cost_profit` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `sale_id` int(11) NOT NULL,
  `item` int(11) NOT NULL,
  `item_cost` decimal(10,2) NOT NULL DEFAULT '0.00',
  `item_selling_price` decimal(10,2) NOT NULL DEFAULT '0.00',
  `profit` decimal(10,2) NOT NULL DEFAULT '0.00',
  `date` date NOT NULL,
  `status` varchar(20) DEFAULT 'active',
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  `qty` decimal(10,2) DEFAULT NULL,
  `item_unit_cost` decimal(10,2) DEFAULT NULL,
  `item_unit_price` decimal(10,2) DEFAULT NULL,
  `item_variant` int(11) DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=423 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `cost_profit`
--

INSERT INTO `cost_profit` (`id`, `sale_id`, `item`, `item_cost`, `item_selling_price`, `profit`, `date`, `status`, `updated_at`, `created_at`, `qty`, `item_unit_cost`, `item_unit_price`, `item_variant`) VALUES
(325, 913, 2, '0.00', '0.00', '0.00', '2018-01-02', 'active', NULL, NULL, '1.00', '0.00', '0.00', 0),
(326, 914, 1, '0.00', '0.00', '0.00', '2018-01-02', 'active', NULL, NULL, '1.00', '0.00', '50.00', 0),
(327, 915, 5, '16.00', '0.00', '-16.00', '2018-01-02', 'active', NULL, NULL, '2.00', '8.00', '0.00', 0),
(328, 916, 5, '16.00', '0.00', '-16.00', '2018-01-02', 'active', NULL, NULL, '2.00', '8.00', '0.00', 0),
(329, 917, 5, '16.00', '40.00', '24.00', '2018-01-02', 'active', NULL, NULL, '2.00', '8.00', '20.00', 0),
(330, 918, 5, '48.00', '120.00', '72.00', '2018-01-02', 'active', NULL, NULL, '6.00', '8.00', '20.00', 0),
(331, 919, 5, '8.00', '20.00', '12.00', '2018-01-02', 'active', NULL, NULL, '1.00', '8.00', '20.00', 0),
(332, 920, 5, '8.00', '40.00', '32.00', '2018-01-02', 'active', NULL, NULL, '1.00', '8.00', '20.00', 0),
(333, 920, 5, '20.00', '40.00', '20.00', '2018-01-02', 'active', NULL, NULL, '1.00', '20.00', '20.00', 0),
(334, 921, 5, '8.00', '40.00', '12.00', '2018-01-02', 'active', NULL, NULL, '1.00', '8.00', '20.00', 0),
(335, 921, 5, '20.00', '40.00', '20.00', '2018-01-02', 'active', NULL, NULL, '1.00', '20.00', '20.00', 0),
(336, 922, 5, '8.00', '20.00', '12.00', '2018-01-02', 'active', NULL, NULL, '1.00', '8.00', '20.00', 0),
(337, 922, 5, '20.00', '60.00', '40.00', '2018-01-02', 'active', NULL, NULL, '1.00', '20.00', '20.00', 0),
(338, 923, 5, '8.00', '20.00', '12.00', '2018-01-02', 'active', NULL, NULL, '1.00', '8.00', '20.00', 0),
(339, 923, 5, '20.00', '60.00', '0.00', '2018-01-02', 'active', NULL, NULL, '1.00', '20.00', '20.00', 0),
(340, 924, 5, '16.00', '40.00', '24.00', '2018-01-02', 'active', NULL, NULL, '2.00', '8.00', '20.00', 0),
(341, 924, 5, '40.00', '40.00', '0.00', '2018-01-02', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(342, 925, 5, '8.00', '20.00', '12.00', '2018-01-02', 'active', NULL, NULL, '1.00', '8.00', '20.00', 0),
(343, 925, 5, '20.00', '20.00', '0.00', '2018-01-02', 'active', NULL, NULL, '1.00', '20.00', '20.00', 0),
(344, 926, 5, '16.00', '40.00', '24.00', '2018-01-02', 'active', NULL, NULL, '2.00', '8.00', '20.00', 0),
(345, 926, 5, '20.00', '20.00', '0.00', '2018-01-02', 'active', NULL, NULL, '1.00', '20.00', '20.00', 0),
(346, 927, 5, '12.29', '20.00', '7.71', '2018-01-02', 'active', NULL, NULL, '1.00', '12.29', '20.00', 0),
(347, 927, 5, '12.29', '20.00', '7.71', '2018-01-02', 'active', NULL, NULL, '1.00', '12.29', '20.00', 0),
(348, 928, 5, '24.58', '40.00', '15.42', '2018-01-02', 'active', NULL, NULL, '2.00', '12.29', '20.00', 0),
(349, 928, 5, '12.29', '20.00', '7.71', '2018-01-02', 'active', NULL, NULL, '1.00', '12.29', '20.00', 0),
(350, 929, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(351, 930, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(352, 931, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(353, 932, 1, '39.00', '0.00', '-39.00', '2018-01-02', 'active', NULL, NULL, '3.00', '13.00', '50.00', 0),
(354, 933, 1, '39.00', '0.00', '-39.00', '2018-01-02', 'active', NULL, NULL, '3.00', '13.00', '50.00', 0),
(355, 934, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(356, 935, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(357, 936, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(358, 937, 2, '103.01', '0.00', '-103.01', '2018-01-02', 'active', NULL, NULL, '1.00', '103.01', '0.00', 0),
(359, 938, 2, '103.01', '0.00', '-103.01', '2018-01-02', 'active', NULL, NULL, '1.00', '103.01', '0.00', 0),
(360, 938, 3, '0.00', '0.00', '0.00', '2018-01-02', 'active', NULL, NULL, '0.00', '20.62', '50.00', 0),
(361, 938, 3, '0.00', '0.00', '0.00', '2018-01-02', 'active', NULL, NULL, '0.00', '20.62', '50.00', 0),
(362, 938, 3, '20.62', '50.00', '29.38', '2018-01-02', 'active', NULL, NULL, '1.00', '20.62', '50.00', 0),
(363, 939, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(364, 939, 2, '103.01', '0.00', '-103.01', '2018-01-02', 'active', NULL, NULL, '1.00', '103.01', '0.00', 0),
(365, 940, 2, '103.01', '0.00', '-103.01', '2018-01-02', 'active', NULL, NULL, '1.00', '103.01', '0.00', 0),
(366, 941, 2, '103.01', '0.00', '-103.01', '2018-01-02', 'active', NULL, NULL, '1.00', '103.01', '0.00', 0),
(367, 941, 3, '0.00', '0.00', '0.00', '2018-01-02', 'active', NULL, NULL, '0.00', '20.62', '50.00', 0),
(368, 941, 3, '0.00', '0.00', '0.00', '2018-01-02', 'active', NULL, NULL, '0.00', '20.62', '50.00', 0),
(369, 941, 3, '20.62', '50.00', '29.38', '2018-01-02', 'active', NULL, NULL, '1.00', '20.62', '50.00', 0),
(370, 942, 1, '52.00', '0.00', '-52.00', '2018-01-02', 'active', NULL, NULL, '4.00', '13.00', '50.00', 0),
(371, 942, 2, '309.03', '0.00', '-309.03', '2018-01-02', 'active', NULL, NULL, '3.00', '103.01', '0.00', 0),
(372, 943, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(373, 944, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(374, 945, 6, '60.00', '0.00', '-60.00', '2018-01-02', 'active', NULL, NULL, '1.00', '60.00', '0.00', 0),
(375, 946, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(376, 948, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(377, 949, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(378, 950, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(379, 951, 1, '26.00', '0.00', '-26.00', '2018-01-02', 'active', NULL, NULL, '2.00', '13.00', '50.00', 0),
(380, 952, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(381, 953, 1, '13.00', '0.00', '-13.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(382, 954, 1, '13.00', '50.00', '37.00', '2018-01-02', 'active', NULL, NULL, '1.00', '13.00', '50.00', 0),
(383, 955, 1, '26.00', '100.00', '74.00', '2018-01-02', 'active', NULL, NULL, '2.00', '13.00', '50.00', 0),
(384, 956, 2, '80.00', '0.00', '-80.00', '2018-01-02', 'active', NULL, NULL, '1.00', '80.00', '0.00', 0),
(385, 957, 3, '0.00', '0.00', '0.00', '2018-01-02', 'active', NULL, NULL, '0.00', '0.00', '50.00', 0),
(386, 957, 3, '0.00', '0.00', '0.00', '2018-01-02', 'active', NULL, NULL, '0.00', '30.00', '50.00', 0),
(387, 957, 3, '160.00', '200.00', '40.00', '2018-01-02', 'active', NULL, NULL, '4.00', '40.00', '50.00', 0),
(388, 958, 1, '40.00', '100.00', '60.00', '2018-01-02', 'active', NULL, NULL, '2.00', '20.00', '50.00', 0),
(389, 959, 1, '120.00', '180.00', '60.00', '2018-01-02', 'active', NULL, NULL, '6.00', '20.00', '30.00', 0),
(390, 960, 1, '60.00', '90.00', '30.00', '2018-01-02', 'active', NULL, NULL, '3.00', '20.00', '30.00', 0),
(391, 961, 1, '80.00', '120.00', '40.00', '2018-01-02', 'active', NULL, NULL, '4.00', '20.00', '30.00', 0),
(392, 967, 1, '20.00', '30.00', '10.00', '2018-01-02', 'active', NULL, NULL, '1.00', '20.00', '30.00', 0),
(393, 969, 1, '80.00', '120.00', '40.00', '2018-01-02', 'active', NULL, NULL, '4.00', '20.00', '30.00', 0),
(394, 970, 1, '20.00', '30.00', '10.00', '2018-01-02', 'active', NULL, NULL, '1.00', '20.00', '30.00', 0),
(395, 971, 1, '20.00', '30.00', '10.00', '2018-01-02', 'active', NULL, NULL, '1.00', '20.00', '30.00', 0),
(396, 972, 1, '20.00', '30.00', '10.00', '2018-01-02', 'active', NULL, NULL, '1.00', '20.00', '30.00', 0),
(397, 974, 1, '60.00', '60.00', '0.00', '2018-01-02', 'active', NULL, NULL, '3.00', '20.00', '20.00', 0),
(398, 975, 1, '20.00', '20.00', '0.00', '2018-01-02', 'active', NULL, NULL, '1.00', '20.00', '20.00', 0),
(399, 976, 1, '40.00', '40.00', '0.00', '2018-01-02', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(400, 977, 1, '40.00', '40.00', '0.00', '2018-01-02', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(401, 978, 1, '80.00', '80.00', '0.00', '2018-01-02', 'active', NULL, NULL, '4.00', '20.00', '20.00', 0),
(402, 979, 1, '60.00', '60.00', '0.00', '2020-05-24', 'active', NULL, NULL, '3.00', '20.00', '20.00', 0),
(403, 980, 1, '40.00', '40.00', '0.00', '2020-05-24', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(404, 982, 1, '60.00', '60.00', '0.00', '2020-05-24', 'active', NULL, NULL, '3.00', '20.00', '20.00', 0),
(405, 983, 1, '40.00', '40.00', '0.00', '2020-05-24', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(406, 984, 1, '40.00', '40.00', '0.00', '2020-05-24', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(407, 985, 1, '40.00', '40.00', '0.00', '2020-05-24', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(408, 986, 1, '20.00', '20.00', '0.00', '2020-05-24', 'active', NULL, NULL, '1.00', '20.00', '20.00', 0),
(409, 987, 1, '40.00', '40.00', '0.00', '2020-05-24', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(410, 988, 1, '40.00', '40.00', '0.00', '2020-05-24', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(411, 989, 1, '20.00', '20.00', '0.00', '2020-05-24', 'active', NULL, NULL, '1.00', '20.00', '20.00', 0),
(412, 990, 1, '40.00', '40.00', '0.00', '2020-05-24', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(413, 991, 1, '40.00', '40.00', '0.00', '2020-05-24', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(414, 992, 1, '40.00', '40.00', '0.00', '2020-05-24', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(415, 993, 1, '20.00', '20.00', '0.00', '2020-05-24', 'active', NULL, NULL, '1.00', '20.00', '20.00', 0),
(416, 994, 1, '40.00', '40.00', '0.00', '2020-05-24', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(417, 995, 1, '20.00', '20.00', '0.00', '2020-05-24', 'active', NULL, NULL, '1.00', '20.00', '20.00', 0),
(418, 996, 1, '40.00', '40.00', '0.00', '2020-05-28', 'active', NULL, NULL, '2.00', '20.00', '20.00', 0),
(419, 997, 1, '11.51', '20.00', '8.49', '2020-05-28', 'active', NULL, NULL, '1.00', '11.51', '20.00', 0),
(420, 998, 1, '15.00', '20.00', '5.00', '2020-05-28', 'active', NULL, NULL, '1.00', '15.00', '20.00', 0),
(421, 999, 1, '15.00', '20.00', '5.00', '2020-05-28', 'active', NULL, NULL, '1.00', '15.00', '20.00', 0),
(422, 1000, 1, '15.00', '20.00', '5.00', '2020-05-28', 'active', NULL, NULL, '1.00', '15.00', '20.00', 317);

-- --------------------------------------------------------

--
-- Table structure for table `current_transactions`
--

DROP TABLE IF EXISTS `current_transactions`;
CREATE TABLE IF NOT EXISTS `current_transactions` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `user_id` int(11) NOT NULL,
  `barcode` varchar(150) DEFAULT NULL,
  `qty` int(11) NOT NULL DEFAULT '1',
  `item_id` int(11) NOT NULL,
  `variant_barcode` varchar(70) NOT NULL,
  `unit_price` decimal(10,2) NOT NULL,
  `package_tracking` int(2) NOT NULL,
  `unit_price_variant` decimal(10,2) NOT NULL,
  `variants` int(10) NOT NULL,
  `main_item_name` varchar(100) NOT NULL,
  `item_name` varchar(100) NOT NULL,
  `barcode_main` varchar(100) NOT NULL,
  `barcode_id` int(10) DEFAULT NULL,
  `color` varchar(100) DEFAULT NULL,
  `package` int(11) DEFAULT NULL,
  `package_name` varchar(100) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=93 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `current_transactions`
--

INSERT INTO `current_transactions` (`id`, `user_id`, `barcode`, `qty`, `item_id`, `variant_barcode`, `unit_price`, `package_tracking`, `unit_price_variant`, `variants`, `main_item_name`, `item_name`, `barcode_main`, `barcode_id`, `color`, `package`, `package_name`) VALUES
(90, 1, '1011-1-317', 175, 1, '', '20.00', 1, '20.00', 1, 'Abacavirs  Tablet', 'Abacavirs  Tablet', '', 317, NULL, NULL, NULL),
(91, 1, '1011-1-318', 5, 1, '', '30.00', 1, '30.00', 1, 'Abacavirs  Syrup', 'Abacavirs  Syrup', '', 318, NULL, NULL, NULL),
(92, 1, '-', 2, 12, '', '0.00', 0, '0.00', 0, 'Amoxicillin', 'Amoxicillin', '', NULL, NULL, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `customers`
--

DROP TABLE IF EXISTS `customers`;
CREATE TABLE IF NOT EXISTS `customers` (
  `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT,
  `customer_name` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `account_number` varchar(191) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `mobile` varchar(191) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `telephone` varchar(150) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `address` varchar(191) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `city` varchar(191) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `neighborhood` varchar(191) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `occupation` varchar(191) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `account_receivable` int(11) NOT NULL DEFAULT '0',
  `account_payable` int(11) NOT NULL DEFAULT '0',
  `balance` decimal(10,2) NOT NULL DEFAULT '0.00',
  `remark` varchar(150) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `image` varchar(150) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  `date_of_birth` date DEFAULT NULL,
  `age` int(11) DEFAULT NULL,
  `marital_status` varchar(50) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `pregnant` varchar(50) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `trimester` varchar(50) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `blood_type` varchar(50) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `gender` varchar(8) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `RegularCustomer` varchar(5) COLLATE utf8mb4_unicode_ci DEFAULT 'No',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=29 DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `customers`
--

INSERT INTO `customers` (`id`, `customer_name`, `account_number`, `mobile`, `telephone`, `address`, `city`, `neighborhood`, `occupation`, `account_receivable`, `account_payable`, `balance`, `remark`, `image`, `created_at`, `updated_at`, `date_of_birth`, `age`, `marital_status`, `pregnant`, `trimester`, `blood_type`, `gender`, `RegularCustomer`) VALUES
(1, 'Guest', '1231', NULL, 'tesle', 'addd', NULL, NULL, NULL, 0, 0, '644.00', NULL, NULL, NULL, '2019-05-01 08:07:30', NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'No'),
(18, 'merhawi', '3333333333', '4444444444', '111111111111', 'Zoba Anseba', 'asmara', NULL, NULL, 1, 0, '-249.00', '66666', NULL, NULL, '2020-02-25 04:07:03', NULL, 23, NULL, NULL, NULL, NULL, 'male', NULL),
(20, 'Customer 10121', 'ccc', 'dd', 'aa', 'bb', NULL, NULL, NULL, 0, 0, '380.00', 'rema', NULL, NULL, '2019-05-01 09:40:10', NULL, NULL, NULL, NULL, NULL, NULL, 'female', 'No'),
(21, 'p1', '2134444', 'mob3424', '123', 'address', NULL, NULL, NULL, 0, 0, '150.00', NULL, NULL, NULL, '2019-05-25 06:52:32', '2019-05-15', 20, NULL, NULL, NULL, NULL, NULL, 'No'),
(22, 'luwam', '1154596', '07172670', '119362', NULL, NULL, NULL, NULL, 0, 0, '0.00', 'luwam', NULL, NULL, '2019-05-25 11:45:33', '1997-03-13', 22, '22', 'pregnant', 'first', NULL, 'female', 'No'),
(24, 'merhawi Tsegay mmmmm', '1154596', '07202020', '115560', 'Zoba Anseba', 'Asmara', 'forovia', 'computer eng', 0, 0, '200.00', 'merhawi', 'pharmacy/SS-Attractive Man-002.jpg', NULL, '2020-02-25 04:06:47', '1997-03-13', 23, '22', NULL, NULL, NULL, 'male', NULL),
(26, 'Simon Okubagiorgis Manna', '10001245', '07506294', NULL, 'Debub', 'Asmara', NULL, NULL, 0, 0, '-1200.00', 'needs regular checkup', NULL, NULL, '2020-02-28 23:31:53', NULL, 12, NULL, 'yes', NULL, NULL, 'female', 'yes'),
(27, 'febu', '114545', '07556562', NULL, 'zoba_anseba', 'keren', NULL, NULL, 0, 0, '200.00', 'becareful', NULL, NULL, '2019-09-03 12:56:51', NULL, 21, NULL, 'yes', 'second', 'a-', 'female', NULL),
(28, 'aman', NULL, '07154546', NULL, 'zoba_debub', 'mendefera', NULL, NULL, 0, 0, '60.00', 'was good person', NULL, NULL, '2019-09-03 12:17:16', NULL, 25, NULL, NULL, 'third', 'o-', 'male', NULL);

-- --------------------------------------------------------

--
-- Table structure for table `daily_vital_signs`
--

DROP TABLE IF EXISTS `daily_vital_signs`;
CREATE TABLE IF NOT EXISTS `daily_vital_signs` (
  `id` int(11) NOT NULL,
  `bp_max` decimal(5,2) DEFAULT NULL,
  `bp_min` decimal(5,2) DEFAULT NULL,
  `spo2` varchar(45) DEFAULT NULL,
  `sugar` decimal(8,2) DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  `updated_at` date DEFAULT NULL,
  `weight` decimal(5,2) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `damageds`
--

DROP TABLE IF EXISTS `damageds`;
CREATE TABLE IF NOT EXISTS `damageds` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `date` date NOT NULL,
  `amount` decimal(10,2) NOT NULL DEFAULT '0.00',
  `description` text,
  `updated_at` date NOT NULL,
  `created_at` date NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `damages`
--

DROP TABLE IF EXISTS `damages`;
CREATE TABLE IF NOT EXISTS `damages` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `date` date NOT NULL,
  `item` int(11) NOT NULL,
  `amount` decimal(10,2) NOT NULL DEFAULT '0.00',
  `reason` text,
  `barcode` varchar(50) DEFAULT NULL,
  `remark` varchar(150) DEFAULT NULL,
  `location` int(11) NOT NULL DEFAULT '1',
  `shop` decimal(10,2) NOT NULL DEFAULT '0.00',
  `store` decimal(10,2) NOT NULL DEFAULT '0.00',
  `status` varchar(20) NOT NULL DEFAULT 'active',
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  `variant` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=14 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `damages`
--

INSERT INTO `damages` (`id`, `date`, `item`, `amount`, `reason`, `barcode`, `remark`, `location`, `shop`, `store`, `status`, `updated_at`, `created_at`, `variant`) VALUES
(1, '2019-04-22', 413, '5.00', 'broken', 'no-barcode', 'sad', 1, '0.00', '0.00', 'void', '2019-04-28', NULL, NULL),
(2, '2019-04-27', 413, '10.00', 'bad things happen', 'no-barcode', 'Remlakjslkdjskljflsdf', 1, '0.00', '0.00', 'active', NULL, NULL, NULL),
(3, '2019-04-27', 413, '7.00', 'bad things happen', 'no-barcode', 'Remlakjslkdjskljflsdf', 1, '0.00', '0.00', 'active', NULL, NULL, NULL),
(4, '2019-04-27', 413, '4.00', 'Reason', 'no-barcode', 'slkdjfslkdjfsljflsdjlsdfjksldf', 1, '0.00', '0.00', 'void', '2019-04-29', NULL, NULL),
(5, '2019-04-29', 413, '6.00', 'Descrip', 'no-barcode', 'skdlkdjflsdjflsd', 1, '0.00', '0.00', 'void', '2019-04-29', NULL, NULL),
(6, '2019-04-29', 413, '3.00', 'bad things happen', 'no-barcode', 'Remalkdfjlks', 1, '0.00', '0.00', 'void', '2019-04-29', NULL, NULL),
(7, '2019-04-29', 413, '10.00', 'bad things happen', 'no-barcode', 'nothings', 1, '0.00', '0.00', 'void', '2019-04-29', NULL, NULL),
(8, '2020-04-24', 1, '2.00', 'sigmen', NULL, 'rekmslkdfm', 1, '0.00', '0.00', 'active', '2020-04-24', '2020-04-24', 283),
(9, '2020-04-24', 1, '1.00', 'sigmen', NULL, 'rekmslkdfm', 1, '0.00', '0.00', 'active', '2020-04-24', '2020-04-24', 283),
(10, '2020-04-24', 1, '2.00', NULL, NULL, NULL, 1, '0.00', '0.00', 'active', '2020-04-24', '2020-04-24', 283),
(11, '2020-04-24', 1, '1.00', NULL, NULL, NULL, 1, '0.00', '0.00', 'active', '2020-04-24', '2020-04-24', 283),
(12, '2020-04-24', 1, '1.00', NULL, NULL, NULL, 1, '0.00', '0.00', 'active', '2020-04-24', '2020-04-24', 283),
(13, '2020-04-25', 1, '2.00', NULL, NULL, NULL, 1, '0.00', '0.00', 'active', '2020-04-25', '2020-04-25', 283);

-- --------------------------------------------------------

--
-- Table structure for table `damage_items`
--

DROP TABLE IF EXISTS `damage_items`;
CREATE TABLE IF NOT EXISTS `damage_items` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `item` int(11) NOT NULL,
  `amount` decimal(10,0) NOT NULL,
  `damage_id` int(11) NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `data`
--

DROP TABLE IF EXISTS `data`;
CREATE TABLE IF NOT EXISTS `data` (
  `id` int(5) NOT NULL AUTO_INCREMENT,
  `name` varchar(110) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `diagnosis_list`
--

DROP TABLE IF EXISTS `diagnosis_list`;
CREATE TABLE IF NOT EXISTS `diagnosis_list` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `customer` int(11) NOT NULL,
  `date` date DEFAULT NULL,
  `disease` varchar(150) NOT NULL,
  `description` varchar(145) DEFAULT NULL,
  `status` varchar(45) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT CURRENT_TIMESTAMP,
  `updated_at` timestamp NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=3 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `diagnosis_list`
--

INSERT INTO `diagnosis_list` (`id`, `customer`, `date`, `disease`, `description`, `status`, `created_at`, `updated_at`) VALUES
(1, 24, '2019-05-25', 'cold', 'cold', 'normal', NULL, '2019-05-25 15:26:46'),
(2, 24, '2019-05-25', 'TB', 'TB', 'sever', '2019-05-25 15:22:30', '2019-05-25 15:26:48');

-- --------------------------------------------------------

--
-- Table structure for table `dosage_uses`
--

DROP TABLE IF EXISTS `dosage_uses`;
CREATE TABLE IF NOT EXISTS `dosage_uses` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `drug` int(11) NOT NULL,
  `dosing_uses` varchar(150) DEFAULT NULL,
  `type` varchar(20) DEFAULT 'dosage or usage',
  `created_at` date DEFAULT NULL,
  `updated_at` date DEFAULT NULL,
  `user` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `drug_allergy`
--

DROP TABLE IF EXISTS `drug_allergy`;
CREATE TABLE IF NOT EXISTS `drug_allergy` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `customer` int(11) DEFAULT NULL,
  `allergy` varchar(255) DEFAULT NULL,
  `drug` varchar(50) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=15 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `drug_allergy`
--

INSERT INTO `drug_allergy` (`id`, `customer`, `allergy`, `drug`) VALUES
(8, 28, 'test', 'test'),
(9, 18, 'skin rush', 'amo'),
(10, 24, 'Allergies', 'Abacavir'),
(11, 24, 'allergy to asprin', 'Aspirin'),
(12, 24, 'allergy to asprin', 'Amoxicillin'),
(13, 26, 'Skin Rushes', 'Abacavir'),
(14, 26, 'Nausea', 'Atenolol');

-- --------------------------------------------------------

--
-- Table structure for table `drug_barcodes`
--

DROP TABLE IF EXISTS `drug_barcodes`;
CREATE TABLE IF NOT EXISTS `drug_barcodes` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `Drug` int(11) NOT NULL,
  `barcode` varchar(150) NOT NULL,
  `is_main` int(4) NOT NULL,
  `current_qty` decimal(10,2) NOT NULL DEFAULT '0.00',
  `expire_date` date DEFAULT NULL,
  `location` int(5) NOT NULL DEFAULT '1',
  `available` varchar(10) NOT NULL DEFAULT 'true',
  `package_id` int(11) NOT NULL DEFAULT '1',
  `shop` decimal(10,2) NOT NULL DEFAULT '0.00',
  `store` decimal(10,2) NOT NULL DEFAULT '0.00',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=299 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `drug_barcodes`
--

INSERT INTO `drug_barcodes` (`id`, `Drug`, `barcode`, `is_main`, `current_qty`, `expire_date`, `location`, `available`, `package_id`, `shop`, `store`) VALUES
(177, 425, 'no-barcode', 1, '85.00', NULL, 1, 'true', 1, '-1.00', '25.00'),
(178, 425, 'no-barcode', 1, '25.00', NULL, 2, 'true', 1, '0.00', '25.00'),
(201, 432, '10001843201', 1, '100.00', NULL, 1, 'true', 1, '100.00', '200.00'),
(202, 413, '10001941301', 1, '100.00', NULL, 1, 'true', 1, '92.00', '158.00'),
(207, 414, '10001841401', 1, '100.00', NULL, 1, 'true', 1, '80.00', '300.00'),
(208, 414, 'sljfklsjklsj', 0, '200.00', NULL, 1, 'true', 1, '200.00', '340.00'),
(209, 443, '1234', 1, '100.00', NULL, 1, 'true', 1, '160.00', '240.00'),
(210, 443, '654', 0, '20.00', NULL, 1, 'true', 1, '110.00', '165.00'),
(211, 415, 'No Barcode', 1, '100.00', NULL, 1, 'true', 1, '95.00', '50.00'),
(212, 442, 'No Barcode', 1, '61.00', NULL, 1, 'true', 1, '61.00', '95.00'),
(213, 427, '10001842701', 1, '140.00', NULL, 1, 'true', 1, '134.00', '160.00'),
(214, 423, '10001842301', 1, '100.00', NULL, 1, 'true', 1, '100.00', '120.00'),
(215, 507, '10001850701', 1, '15.00', NULL, 1, 'true', 1, '15.00', '20.00'),
(227, 521, 'no-barcode', 1, '15.00', NULL, 1, 'true', 1, '15.00', '51.00'),
(229, 523, 'no-barcode', 1, '15.00', NULL, 1, 'true', 1, '15.00', '51.00'),
(230, 525, '10000152501', 1, '120.00', NULL, 1, 'true', 1, '120.00', '120.00'),
(232, 527, '10000252701', 1, '15.00', NULL, 1, 'true', 1, '15.00', '15.00'),
(234, 529, 'no-barcode', 1, '15.00', NULL, 1, 'true', 1, '15.00', '15.00'),
(235, 530, 'no-barcode', 1, '15.00', NULL, 1, 'true', 1, '15.00', '15.00'),
(236, 531, 'no-barcode', 1, '15.00', NULL, 1, 'true', 1, '15.00', '15.00'),
(237, 532, 'no-barcode', 1, '15.00', NULL, 1, 'true', 1, '15.00', '15.00'),
(238, 533, '10000653301', 1, '125.00', NULL, 1, 'true', 1, '125.00', '152.00'),
(241, 536, '10000653601', 1, '125.00', NULL, 1, 'true', 1, '125.00', '152.00'),
(285, 581, '10000258101', 1, '45.00', NULL, 1, 'true', 1, '45.00', '54.00'),
(289, 585, '10000258501', 1, '45.00', NULL, 1, 'true', 1, '45.00', '54.00'),
(290, 586, '10000258601', 1, '45.00', NULL, 1, 'true', 1, '45.00', '50.00'),
(291, 587, '10000258701', 1, '45.00', NULL, 1, 'true', 1, '45.00', '50.00'),
(292, 588, '10000258801', 1, '45.00', NULL, 1, 'true', 1, '45.00', '50.00'),
(293, 589, '10000258901', 1, '50.00', NULL, 1, 'true', 1, '50.00', '50.00'),
(296, 592, 'no-barcode', 1, '52.00', NULL, 1, 'true', 1, '52.00', '25.00'),
(297, 593, 'no-barcode', 1, '52.00', NULL, 1, 'true', 1, '52.00', '25.00'),
(298, 594, '10000259401', 1, '15.00', NULL, 1, 'true', 1, '15.00', '15.00');

-- --------------------------------------------------------

--
-- Table structure for table `drug_categories`
--

DROP TABLE IF EXISTS `drug_categories`;
CREATE TABLE IF NOT EXISTS `drug_categories` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `category_name` varchar(50) DEFAULT NULL,
  `DrugCategory_code` varchar(50) DEFAULT NULL,
  `description` varchar(100) NOT NULL,
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE CURRENT_TIMESTAMP,
  `created_at` timestamp NULL DEFAULT NULL ON UPDATE CURRENT_TIMESTAMP,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=8 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `drug_categories`
--

INSERT INTO `drug_categories` (`id`, `category_name`, `DrugCategory_code`, `description`, `updated_at`, `created_at`) VALUES
(0, 'unCategorized Drug', '0', '', NULL, NULL),
(1, 'amaney1', '1', 'amaney', '2019-05-23 09:51:13', '2019-05-23 12:51:13'),
(2, 'pharmacy', '123456', 'medication', '2019-05-23 09:54:33', '2019-05-23 12:54:33'),
(3, 'hope', '123456123', 'nice', '2019-05-23 09:54:50', '2019-05-23 12:54:50'),
(4, 'love', '15', 'deadly', '2019-05-23 09:53:35', '2019-05-23 12:53:35'),
(5, 'faith', '13', 'fine', '2019-05-23 09:53:52', '2019-05-23 12:53:52'),
(6, 'cold', '123456', 'fair', '2019-05-23 09:54:18', '2019-05-23 12:54:18'),
(7, 'unCategorized Drug', '0', '', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `drug_dosage`
--

DROP TABLE IF EXISTS `drug_dosage`;
CREATE TABLE IF NOT EXISTS `drug_dosage` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `drug_id` int(11) DEFAULT NULL,
  `drug_dosage` varchar(45) DEFAULT NULL,
  `uom` smallint(6) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=25 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `drug_dosage`
--

INSERT INTO `drug_dosage` (`id`, `drug_id`, `drug_dosage`, `uom`) VALUES
(10, 521, 'Merhawi', 12),
(12, 523, 'Merhawi', 11),
(13, 525, '1', 12),
(15, 527, '12', NULL),
(17, 529, '1', NULL),
(18, 530, '1', NULL),
(19, 531, '1', NULL),
(20, 532, '1', NULL),
(21, 533, '15', NULL),
(22, 536, '15', 1),
(23, 581, NULL, 1),
(24, 581, NULL, 1);

-- --------------------------------------------------------

--
-- Table structure for table `drug_duration`
--

DROP TABLE IF EXISTS `drug_duration`;
CREATE TABLE IF NOT EXISTS `drug_duration` (
  `id` int(11) NOT NULL,
  `duration` varchar(45) DEFAULT NULL,
  `description` varchar(45) DEFAULT NULL,
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `drug_history`
--

DROP TABLE IF EXISTS `drug_history`;
CREATE TABLE IF NOT EXISTS `drug_history` (
  `id` int(10) UNSIGNED ZEROFILL NOT NULL AUTO_INCREMENT,
  `customer` int(11) DEFAULT NULL,
  `drug_taken` varchar(50) DEFAULT NULL,
  `disease` varchar(50) DEFAULT NULL,
  `from_date` date DEFAULT NULL,
  `to_date` date DEFAULT NULL,
  `currently_taking` varchar(12) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=21 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `drug_history`
--

INSERT INTO `drug_history` (`id`, `customer`, `drug_taken`, `disease`, `from_date`, `to_date`, `currently_taking`) VALUES
(0000000015, 28, 'test', 'cold', '2019-06-17', '2019-06-24', 'Yes'),
(0000000016, 18, 'tb', 'tb', '2019-09-03', '2019-09-04', 'Yes'),
(0000000017, 24, 'Abacavir', 'Diabetes', '2020-02-25', '2020-02-29', 'Completed'),
(0000000018, 26, 'Amlodipine', '100', '2020-02-25', '2020-03-07', 'Completed'),
(0000000019, 26, 'Amlodipine', 'diabetic', '2020-02-18', '2020-02-29', 'Taking'),
(0000000020, 26, 'Aspirin', 'diabetic', '2020-02-18', '2020-02-29', 'Taking');

-- --------------------------------------------------------

--
-- Table structure for table `drug_interations`
--

DROP TABLE IF EXISTS `drug_interations`;
CREATE TABLE IF NOT EXISTS `drug_interations` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `drug1` int(11) NOT NULL,
  `drug2` int(11) NOT NULL,
  `drug3` int(11) DEFAULT NULL,
  `drug4` int(11) DEFAULT NULL,
  `Effects` varchar(150) NOT NULL,
  `created_at` date DEFAULT NULL,
  `updated_at` date DEFAULT NULL,
  `user` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `drug_location`
--

DROP TABLE IF EXISTS `drug_location`;
CREATE TABLE IF NOT EXISTS `drug_location` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `drug` int(11) NOT NULL,
  `location` int(11) NOT NULL DEFAULT '1',
  `qty` decimal(10,2) NOT NULL DEFAULT '0.00',
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=3 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `drug_location`
--

INSERT INTO `drug_location` (`id`, `drug`, `location`, `qty`, `updated_at`, `created_at`) VALUES
(1, 413, 1, '85.00', NULL, NULL),
(2, 413, 2, '0.00', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `drug_perscription`
--

DROP TABLE IF EXISTS `drug_perscription`;
CREATE TABLE IF NOT EXISTS `drug_perscription` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `customer` int(11) DEFAULT NULL,
  `perscriber` varchar(50) DEFAULT NULL,
  `drug` varchar(50) DEFAULT NULL,
  `date` date DEFAULT NULL,
  `reason` varchar(255) DEFAULT NULL,
  `perscriber_position` varchar(50) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=5 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `drug_perscription`
--

INSERT INTO `drug_perscription` (`id`, `customer`, `perscriber`, `drug`, `date`, `reason`, `perscriber_position`) VALUES
(1, 24, 'simon', 'Amoxicillin', '2020-02-25', NULL, 'Medical Practitioner'),
(2, 26, 'klkdsjf', 'Amiodarone', '2020-02-11', NULL, 'Nurse Practitioner'),
(3, 18, 'sldkjfslkj', 'Asparaginase', '2020-02-25', NULL, 'intern Practitioner'),
(4, 26, 'simon', 'Amoxicillin', '2020-02-29', NULL, 'Medical Practitioner');

-- --------------------------------------------------------

--
-- Table structure for table `drug_side_effects`
--

DROP TABLE IF EXISTS `drug_side_effects`;
CREATE TABLE IF NOT EXISTS `drug_side_effects` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `drug` int(11) DEFAULT NULL,
  `effect` varchar(45) DEFAULT NULL,
  `effect_tig` varchar(50) CHARACTER SET utf8 DEFAULT NULL,
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=26 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `drug_side_effects`
--

INSERT INTO `drug_side_effects` (`id`, `drug`, `effect`, `effect_tig`, `updated_at`, `created_at`) VALUES
(2, 521, 'side effect mera', NULL, NULL, NULL),
(3, 523, 'side effect mera', NULL, NULL, NULL),
(4, 525, 'simon side effect', NULL, NULL, NULL),
(5, 527, 'death', NULL, NULL, NULL),
(6, 529, NULL, NULL, NULL, NULL),
(7, 530, NULL, NULL, NULL, NULL),
(8, 531, NULL, NULL, NULL, NULL),
(9, 532, NULL, NULL, NULL, NULL),
(10, 533, 'skin rush', NULL, NULL, NULL),
(11, 536, 'skin rush', NULL, NULL, NULL),
(12, 581, 'skin', NULL, NULL, NULL),
(13, 581, 'head ache', NULL, NULL, NULL),
(14, 585, 'skin', NULL, NULL, NULL),
(15, 585, 'head ache', NULL, NULL, NULL),
(16, 586, NULL, NULL, NULL, NULL),
(17, 587, NULL, NULL, NULL, NULL),
(18, 588, NULL, NULL, NULL, NULL),
(19, 589, 'head ache', NULL, NULL, NULL),
(20, 589, 'hunger', NULL, NULL, NULL),
(21, 592, 'head ache', 'ሕማም ርአሲ', NULL, NULL),
(22, 593, 'head ache', 'ሕማም ርአሲ', NULL, NULL),
(23, 594, NULL, NULL, NULL, NULL),
(24, 10, NULL, NULL, NULL, NULL),
(25, 12, NULL, NULL, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `drug_uom`
--

DROP TABLE IF EXISTS `drug_uom`;
CREATE TABLE IF NOT EXISTS `drug_uom` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `drug` int(11) DEFAULT NULL,
  `uom` varchar(40) DEFAULT NULL,
  `price` decimal(10,2) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  `ratio` decimal(10,2) DEFAULT NULL,
  `cost` decimal(10,0) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=25 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `drug_uom`
--

INSERT INTO `drug_uom` (`id`, `drug`, `uom`, `price`, `created_at`, `updated_at`, `ratio`, `cost`) VALUES
(9, 521, '12', '23.00', NULL, NULL, NULL, '12'),
(11, 523, '12', '23.00', NULL, NULL, NULL, '12'),
(12, 525, '2', '5.00', NULL, NULL, NULL, '3'),
(13, 527, 'mg', '20.00', NULL, NULL, NULL, '15'),
(15, 529, NULL, '150.00', NULL, NULL, NULL, '12'),
(16, 530, NULL, '150.00', NULL, NULL, NULL, '12'),
(17, 531, NULL, '150.00', NULL, NULL, NULL, '12'),
(18, 532, NULL, '150.00', NULL, NULL, NULL, '12'),
(19, 533, 'mg', '15.00', NULL, NULL, NULL, '11'),
(21, 536, 'mg', '15.00', NULL, NULL, NULL, '11'),
(23, 581, 'ml', '60.00', NULL, NULL, NULL, '54'),
(24, 581, 'ml', '65.00', NULL, NULL, NULL, '60');

-- --------------------------------------------------------

--
-- Table structure for table `drug_varities`
--

DROP TABLE IF EXISTS `drug_varities`;
CREATE TABLE IF NOT EXISTS `drug_varities` (
  `drug_id` int(11) DEFAULT NULL,
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `route` varchar(50) DEFAULT NULL,
  `dosage` varchar(50) DEFAULT NULL,
  `uom` varchar(50) DEFAULT NULL,
  `unit_cost` decimal(10,2) DEFAULT NULL,
  `unit_price` decimal(10,2) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT CURRENT_TIMESTAMP,
  `updated_at` timestamp NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP,
  `uod` varchar(50) DEFAULT NULL,
  `min_qty_var` int(11) DEFAULT NULL,
  `current_qty_var` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=33 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `drug_varities`
--

INSERT INTO `drug_varities` (`drug_id`, `id`, `route`, `dosage`, `uom`, `unit_cost`, `unit_price`, `created_at`, `updated_at`, `uod`, `min_qty_var`, `current_qty_var`) VALUES
(585, 1, 'tablet', NULL, 'ml', '54.00', '60.00', '2019-05-25 06:12:40', '2019-05-25 06:12:40', NULL, NULL, NULL),
(585, 2, 'injectable', NULL, 'ml', '60.00', '65.00', '2019-05-25 06:12:40', '2019-05-25 06:12:40', NULL, NULL, NULL),
(586, 3, 'tablet', '15', 'mg', '56.00', '60.00', '2019-05-25 11:30:04', '2019-05-25 11:30:04', NULL, NULL, NULL),
(586, 4, 'injectable', '45', 'ml', '80.00', '100.00', '2019-05-25 11:30:04', '2019-05-25 11:30:04', NULL, NULL, NULL),
(586, 5, 'syrup', '45', 'mg', '70.00', '80.00', '2019-05-25 11:30:04', '2019-05-25 11:30:04', NULL, NULL, NULL),
(587, 6, 'tablet', '15', 'mg', '56.00', '60.00', '2019-05-25 11:32:08', '2019-05-25 11:32:08', NULL, NULL, NULL),
(587, 7, 'injectable', '45', 'ml', '80.00', '100.00', '2019-05-25 11:32:08', '2019-05-25 11:32:08', NULL, NULL, NULL),
(587, 8, 'syrup', '45', 'mg', '70.00', '80.00', '2019-05-25 11:32:08', '2019-05-25 11:32:08', NULL, NULL, NULL),
(588, 9, 'tablet', '15', 'mg', '56.00', '60.00', '2019-05-25 11:32:44', '2019-05-25 11:32:44', NULL, NULL, NULL),
(588, 10, 'injectable', '45', 'ml', '80.00', '100.00', '2019-05-25 11:32:44', '2019-05-25 11:32:44', NULL, NULL, NULL),
(588, 11, 'syrup', '45', 'mg', '70.00', '80.00', '2019-05-25 11:32:44', '2019-05-25 11:32:44', NULL, NULL, NULL),
(589, 12, 'tablet', '15', 'mg', '50.00', '55.00', '2019-05-25 11:43:33', '2019-05-25 11:43:33', NULL, NULL, NULL),
(589, 13, 'injectable', '20', 'ml', '60.00', '65.00', '2019-05-25 11:43:33', '2019-05-25 11:43:33', NULL, NULL, NULL),
(589, 14, 'wrap', '45', 'ml', '60.00', '65.00', '2019-05-25 11:43:33', '2019-05-25 11:43:33', NULL, NULL, NULL),
(592, 15, 'tablet', '15', 'mg', '45.00', '45.00', '2019-05-25 11:52:44', '2019-05-25 11:52:44', NULL, NULL, NULL),
(593, 16, 'tablet', '15', 'mg', '45.00', '45.00', '2019-05-25 13:10:21', '2019-05-25 13:10:21', NULL, NULL, NULL),
(594, 17, 'tablet', '2', 'mg', '15.00', '15.00', '2019-05-25 14:53:47', '2019-05-25 14:53:47', NULL, NULL, NULL),
(10, 18, 'tablet', '12', 'mg', '12.00', '14.00', '2019-09-10 15:17:02', '2019-09-10 15:17:02', 'box', 13, 14),
(10, 19, 'tablet', '12', 'mg', '12.00', '14.00', '2019-09-10 15:18:42', '2019-09-10 15:18:42', 'box', 13, 14),
(10, 20, 'tablet', '12', 'mg', '12.00', '14.00', '2019-09-10 15:19:01', '2019-09-10 15:19:01', 'box', 13, 14),
(10, 21, 'tablet', '12', 'mg', '12.00', '14.00', '2019-09-10 15:19:01', '2019-09-10 15:19:01', 'box', 13, 14),
(12, 22, 'tablet', '10', 'mg', '10.00', '20.00', '2019-09-10 15:46:11', '2019-09-10 15:46:11', 'box', 40, 30),
(1, 23, 'Injectable', '100', 'mg', '100.00', '120.00', '2020-03-03 14:27:16', '2020-03-03 14:27:16', 'box', 150, 200),
(3, 24, 'Wrap', '10', 'mg', '10.00', '20.00', '2020-03-04 04:56:52', '2020-03-04 04:56:52', 'strip', 50, 40),
(3, 25, 'Tablet', '1', 'mg', '2.00', '3.00', '2020-03-04 05:02:20', '2020-03-04 05:02:20', 'Strip', 5, 4),
(1, 26, 'Tablet', '50', 'ml', '50.00', '10.00', '2020-03-22 08:36:42', '2020-03-22 08:36:42', 'Strip', 200, 150),
(1, 30, 'Syrup', '10', 'mg', '10.00', '20.00', '2020-03-22 08:57:04', '2020-03-22 08:57:04', 'Bottle', 100, 140),
(1, 31, 'Injectable', '19', 'ml', '15.00', '18.00', '2020-03-22 08:58:50', '2020-03-22 08:58:50', 'Strip', 20, 19),
(1, 32, 'Wrap', '40', 'mg', '60.00', '70.00', '2020-03-22 09:00:44', '2020-03-22 09:00:44', 'Box', 90, 80);

-- --------------------------------------------------------

--
-- Table structure for table `drug_warning`
--

DROP TABLE IF EXISTS `drug_warning`;
CREATE TABLE IF NOT EXISTS `drug_warning` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `warning` varchar(150) DEFAULT NULL,
  `type` varchar(45) DEFAULT NULL,
  `warning_tig` varchar(150) DEFAULT NULL,
  `type_tig` varchar(45) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `drug_warnings`
--

DROP TABLE IF EXISTS `drug_warnings`;
CREATE TABLE IF NOT EXISTS `drug_warnings` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `drug` int(11) DEFAULT NULL,
  `warning` text,
  `type` varchar(45) DEFAULT 'take, avoid, reduce',
  `should` text,
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=39 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `drug_warnings`
--

INSERT INTO `drug_warnings` (`id`, `drug`, `warning`, `type`, `should`, `updated_at`, `created_at`) VALUES
(5, 521, 'warm mera', 'take, avoid, reduce', NULL, NULL, NULL),
(7, 523, 'warm mera', 'take, avoid, reduce', NULL, NULL, NULL),
(8, 525, 'simon warning', 'take, avoid, reduce', NULL, NULL, NULL),
(9, 527, 'danger', 'take, avoid, reduce', NULL, NULL, NULL),
(10, 529, NULL, NULL, NULL, NULL, NULL),
(11, 530, NULL, NULL, NULL, NULL, NULL),
(12, 531, NULL, NULL, NULL, NULL, NULL),
(13, 532, NULL, NULL, NULL, NULL, NULL),
(14, 533, 'fish', 'food', 'tablet', NULL, NULL),
(15, 536, 'fish', 'food', 'tablet', NULL, NULL),
(16, 581, 'milk', 'drink', 'tablet', NULL, NULL),
(17, 581, 'fish', 'other', 'injectable', NULL, NULL),
(18, 585, 'milk', 'drink', 'tablet', NULL, NULL),
(19, 585, 'fish', 'other', 'injectable', NULL, NULL),
(20, 586, 'fish', 'food', 'tablet', NULL, NULL),
(21, 586, 'milk', 'drink', 'injectable', NULL, NULL),
(22, 586, 'alchol', 'drink', 'wrap', NULL, NULL),
(23, 587, 'fish', 'food', 'tablet', NULL, NULL),
(24, 587, 'milk', 'drink', 'injectable', NULL, NULL),
(25, 587, 'alchol', 'drink', 'wrap', NULL, NULL),
(26, 588, 'fish', 'food', 'tablet', NULL, NULL),
(27, 588, 'milk', 'drink', 'injectable', NULL, NULL),
(28, 588, 'alchol', 'drink', 'wrap', NULL, NULL),
(29, 589, 'milk', 'drink', 'tablet', NULL, NULL),
(30, 589, 'water', 'drink', 'injectable', NULL, NULL),
(33, 592, 'fish test4', 'food', 'tablet', NULL, NULL),
(34, 593, 'fish test4', 'food', 'tablet', NULL, NULL),
(35, 594, NULL, NULL, NULL, NULL, NULL),
(36, 10, NULL, NULL, NULL, NULL, NULL),
(37, 12, NULL, NULL, NULL, NULL, NULL),
(38, 1, NULL, NULL, NULL, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `emp`
--

DROP TABLE IF EXISTS `emp`;
CREATE TABLE IF NOT EXISTS `emp` (
  `id` int(8) NOT NULL AUTO_INCREMENT,
  `name` varchar(100) DEFAULT NULL,
  `salary` decimal(10,2) NOT NULL DEFAULT '0.00',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=3 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `emp`
--

INSERT INTO `emp` (`id`, `name`, `salary`) VALUES
(1, 'sigmen', '10000.00'),
(2, 'tekle', '30000.00');

-- --------------------------------------------------------

--
-- Table structure for table `expenses`
--

DROP TABLE IF EXISTS `expenses`;
CREATE TABLE IF NOT EXISTS `expenses` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `expense_name` varchar(150) NOT NULL,
  `date` date NOT NULL,
  `amount` decimal(10,2) NOT NULL DEFAULT '0.00',
  `remark` varchar(150) DEFAULT NULL,
  `user` int(11) NOT NULL DEFAULT '1',
  `status` varchar(20) NOT NULL DEFAULT 'active',
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=32 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `expenses`
--

INSERT INTO `expenses` (`id`, `expense_name`, `date`, `amount`, `remark`, `user`, `status`, `updated_at`, `created_at`) VALUES
(17, 'fata', '2019-04-20', '30.00', 'kdfjsdkfjdslf', 1, 'active', NULL, NULL),
(18, 'merhawi', '2017-04-14', '5000.00', 'amekrjakl', 1, 'active', NULL, NULL),
(19, 'Damage of Headphones', '2019-04-22', '87.05', 'broken', 1, 'active', '2019-04-22', '2019-04-22'),
(20, 'Damage of Headphones', '2019-04-27', '229.50', 'bad things happen', 1, 'active', '2019-04-27', '2019-04-27'),
(21, 'Damage of Headphones', '2019-04-27', '160.65', 'bad things happen', 1, 'active', '2019-04-27', '2019-04-27'),
(22, 'Damage of Headphones', '2019-04-27', '91.80', 'Reason', 1, 'active', '2019-04-27', '2019-04-27'),
(23, 'Damage of Headphones', '2019-04-29', '135.66', 'Descrip', 1, 'active', '2019-04-29', '2019-04-29'),
(24, 'Damage of Headphones', '2019-04-29', '67.83', 'bad things happen', 1, 'active', '2019-04-29', '2019-04-29'),
(25, 'Damage of Headphones', '2019-04-29', '226.10', 'bad things happen', 1, 'active', '2019-04-29', '2019-04-29'),
(26, 'Damage of Abacavir', '2020-04-24', '26.00', 'sigmen', 1, 'active', '2020-04-24', '2020-04-24'),
(27, 'Damage of Abacavir', '2020-04-24', '13.00', 'sigmen', 1, 'active', '2020-04-24', '2020-04-24'),
(28, 'Damage of Abacavir', '2020-04-24', '26.00', NULL, 1, 'active', '2020-04-24', '2020-04-24'),
(29, 'Damage of Abacavir', '2020-04-24', '13.00', NULL, 1, 'active', '2020-04-24', '2020-04-24'),
(30, 'Damage of Abacavir', '2020-04-24', '13.00', NULL, 1, 'active', '2020-04-24', '2020-04-24'),
(31, 'Damage of Abacavir', '2020-04-25', '26.00', NULL, 1, 'active', '2020-04-25', '2020-04-25');

-- --------------------------------------------------------

--
-- Table structure for table `food_drugs`
--

DROP TABLE IF EXISTS `food_drugs`;
CREATE TABLE IF NOT EXISTS `food_drugs` (
  `id` int(11) NOT NULL,
  `food` varchar(45) NOT NULL,
  `effect` varchar(45) NOT NULL,
  `created_at` date DEFAULT NULL,
  `updated_at` date DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `frequency`
--

DROP TABLE IF EXISTS `frequency`;
CREATE TABLE IF NOT EXISTS `frequency` (
  `id` int(11) NOT NULL,
  `frequency` varchar(45) DEFAULT NULL,
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `general_ledger`
--

DROP TABLE IF EXISTS `general_ledger`;
CREATE TABLE IF NOT EXISTS `general_ledger` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `account_id` int(11) NOT NULL,
  `debit_amount` decimal(10,2) NOT NULL,
  `credit_amount` decimal(10,2) NOT NULL,
  `ref` varchar(150) NOT NULL,
  `date` date NOT NULL,
  `remark` varchar(150) NOT NULL,
  `updated_at` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP,
  `created_at` timestamp NOT NULL DEFAULT '0000-00-00 00:00:00',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `interactions`
--

DROP TABLE IF EXISTS `interactions`;
CREATE TABLE IF NOT EXISTS `interactions` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `drug_id` int(11) DEFAULT NULL,
  `status` varchar(50) DEFAULT NULL,
  `drug` int(50) DEFAULT NULL,
  `description` text,
  `created_at` timestamp NOT NULL,
  `updated_at` timestamp NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM AUTO_INCREMENT=797 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `interactions`
--

INSERT INTO `interactions` (`id`, `drug_id`, `status`, `drug`, `description`, `created_at`, `updated_at`) VALUES
(32, 1, 'Contraindicated', 189, 'tenofovir is a complete regimen for HIV and should not be administered with other antiretrovirals', '2019-11-05 22:02:49', '2019-11-05 22:02:49'),
(33, 1, 'Monitor Closely', 16, 'atazanavir and abacavir both increase risk of immune reconstitution syndrome.', '2019-11-05 22:06:03', '2019-11-05 22:06:03'),
(34, 1, 'Monitor Closely', 77, 'efavirenz and abacavir both increase risk of immune reconstitution syndrome.', '2019-11-05 22:07:52', '2019-11-05 22:07:52'),
(35, 1, 'Monitor Closely', 112, 'lamivudine and abacavir both increase risk of immune reconstitution syndrome.', '2019-11-05 22:09:29', '2019-11-05 22:09:29'),
(36, 1, 'Monitor Closely', 140, 'nevirapine and abacavir both increase risk of immune reconstitution syndrome.', '2019-11-05 22:10:34', '2019-11-05 22:10:34'),
(37, 1, 'Monitor Closely', 177, 'ritonavir and abacavir both increase risk of immune reconstitution syndrome.', '2019-11-05 22:11:16', '2019-11-05 22:11:16'),
(38, 1, 'Monitor Closely', 177, 'ritonavir and abacavir both increase risk of immune reconstitution syndrome.', '2019-11-05 22:11:19', '2019-11-05 22:11:19'),
(39, 1, 'Monitor Closely', 189, 'tenofovir and abacavir both increase risk of immune reconstitution syndrome.', '2019-11-05 22:12:30', '2019-11-05 22:12:30'),
(40, 1, 'Monitor Closely', 189, 'tenofovir and abacavir both increase risk of immune reconstitution syndrome.', '2019-11-05 22:12:32', '2019-11-05 22:12:32'),
(41, 1, 'Monitor Closely', 209, 'zidovudine and abacavir both increase risk of immune reconstitution syndrome.', '2019-11-05 22:13:27', '2019-11-05 22:13:27'),
(42, 2, 'Monitor Closely', 15, 'Either increases levels of the other by other\nComment:Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other\'s renal tubular secretion,resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.', '2019-11-06 13:26:44', '2019-11-06 13:26:44'),
(43, 2, 'Monitor Closely', 38, 'acetazolamide will increase the level or effect of carbamazepine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/monitor. Monitor plasma levels when used concomitantly', '2019-11-06 13:33:05', '2019-11-06 13:33:05'),
(44, 2, 'Monitor Closely', 173, 'acetazolamide will increase the level or effect of quinidine by passive rental tubular reabsorption basic urine', '2019-11-06 13:43:59', '2019-11-06 13:43:59'),
(45, 2, 'Monitor Closely', 185, ':Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other\'s renal tubular secretion,resulting in increased plasma levels.CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.', '2019-11-06 13:46:51', '2019-11-06 13:46:51'),
(46, 2, 'Monitor Closely', 197, 'acetazolamide will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism.', '2019-11-06 13:50:14', '2019-11-06 13:50:14'),
(47, 2, 'Monitor Closely', 197, 'acetazolamide will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism.', '2019-11-06 13:50:16', '2019-11-06 13:50:16'),
(48, 2, 'Minor', 19, 'acetazolamide decreases effects of atracurium by pharmacodynamic antagonism.Minor/significance unknown', '2019-11-06 13:54:30', '2019-11-06 13:54:30'),
(49, 2, 'Minor', 159, 'acetazolamide,phenyton. Mechanism:pharmacodynamic synergism.Minor/significance unknown.Increased risk of anticonvulsant induced osteomalacia.', '2019-11-06 14:04:02', '2019-11-06 14:04:02'),
(50, 2, 'Minor', 159, 'acetazolamide,phenyton. Mechanism:pharmacodynamic synergism.Minor/significance unknown.Increased risk of anticonvulsant induced osteomalacia.', '2019-11-06 14:04:04', '2019-11-06 14:04:04'),
(51, 4, 'Serious - Use Alternative', 138, 'acyclovir and neomycin PO both increase nephrotoxicity and/or ototoxicity.Avoid or use alternative drug.', '2019-11-06 14:15:47', '2019-11-06 14:15:47'),
(54, 4, 'Monitor Closely', 48, 'acyclovir and cisplatin bothincrease nephrotoxicity and/or ototoxicity.', '2019-11-06 14:23:10', '2019-11-06 14:23:10'),
(53, 4, 'Monitor Closely', 12, 'amoxicillin,acyclovir.Either increase levels of the other by decreasing renal clearance', '2019-11-06 14:20:38', '2019-11-06 14:20:38'),
(55, 4, 'Monitor Closely', 189, 'Either increase toxicity of the other by decreasing renal clearance.Use caution/monitor.Toxicity may result from coadministration of emtricitabine and tenofovir with other drugs that are also primarily excreted by glomerular and/or active tubular secretion', '2019-11-06 14:30:54', '2019-11-06 14:30:54'),
(56, 4, 'Minor', 15, 'aspirin will increase the level or effect of acyclovir by acidic(anionic)drug competition for renal tubular clearance.Minor/significance unknown', '2019-11-06 14:39:59', '2019-11-06 14:39:59'),
(57, 4, 'Minor', 40, 'ceftazidime will increase the level or effect of acyclovir by acidic(anionic)drug competition for renal tubular clearance.Minor/significance unknown', '2019-11-06 14:43:06', '2019-11-06 14:43:06'),
(71, 4, 'Minor', 185, 'sulfasalazine will increase the level or effect of acyclovir by acidic(anionic)drug competition for renal tubular clearance.Minor/significance unknown', '2019-11-06 15:01:20', '2019-11-06 15:01:20'),
(72, 5, 'Monitor Closely', 159, 'phenytoin decreases levels of albendazole by increasing methabolism.use caution/monitor.phenytoin decreases levels of albendazol active matabolites;monitor for decreased efficacy', '2019-11-06 15:07:19', '2019-11-06 15:07:19'),
(60, 4, 'Minor', 101, 'Hydrochlorothiazide will increase the level or effect of acyclovir by acidic(anionic)drug competition for renal tubular clearance.Minor/significance unknown', '2019-11-06 14:49:50', '2019-11-06 14:49:50'),
(61, 4, 'Minor', 105, 'ibuprofen will increase the level or effect of acyclovir by acidic(anionic)drug competition for renal tubular clearance.Minor/significance unknown', '2019-11-06 14:50:23', '2019-11-06 14:50:23'),
(73, 5, 'Minor', 162, 'praziquantel increases levels of albendazole by unspecified interaction mechanism.minor/significance unknown', '2019-11-06 15:10:17', '2019-11-06 15:10:17'),
(63, 4, 'Minor', 107, 'indomethacin will increase the level or effect of acyclovir by acidic(anionic)drug competition for renal tubular clearance.Minor/significance unknown', '2019-11-06 14:52:04', '2019-11-06 14:52:04'),
(74, 6, 'Serious - Use Alternative', 37, 'catopril,allopurinol.mechanism: unknown. Avoid or use alternative drug. risk of anaphylaxis,stevens johnson syndrom.', '2019-11-06 20:13:04', '2019-11-06 20:13:04'),
(75, 6, 'Serious - Use Alternative', 206, 'allopurinol increases effects of warfarin by decreasing methabolism. Avoid or use alternative drug.', '2019-11-06 20:15:55', '2019-11-06 20:15:55'),
(76, 6, 'Monitor Closely', 12, 'allopurinol decreases toxicity of amoxicillin by other (see comment). Use caution/monior.\ncomment:allopurinol may increase potential for allergic or hypersensitivity reactions to amoxicillin', '2019-11-06 20:19:32', '2019-11-06 20:19:32'),
(67, 4, 'Minor', 136, 'naproxen will increase the level or effect of acyclovir by acidic(anionic)drug competition for renal tubular clearance.Minor/significance unknown', '2019-11-06 14:55:03', '2019-11-06 14:55:03'),
(69, 4, 'Minor', 185, 'sulfasalazine will increase the level or effect of acyclovir by acidic(anionic)drug competition for renal tubular clearance.Minor/significance unknown', '2019-11-06 14:58:57', '2019-11-06 14:58:57'),
(79, 6, 'Monitor Closely', 81, 'ethambutol decreases effects of allopurinol by other (see comment). use caution/monitor.\ncomment:hyperuricemia reported with ethambutol and precipitation of gout reported;uric acid lowering agents may be require dosage adjustment.', '2019-11-06 20:25:33', '2019-11-06 20:25:33'),
(78, 6, 'Monitor Closely', 57, 'allopurinol increases toxicity of cyclophosphamide by decreasing metabolism.Use caution monitor', '2019-11-06 20:21:32', '2019-11-06 20:21:32'),
(80, 6, 'Monitor Closely', 103, 'combination may increase risk of myelosuppresion.', '2019-11-06 20:27:36', '2019-11-06 20:27:36'),
(81, 6, 'Monitor Closely', 125, 'allopurinol increases levels of mercaptopurine by decreasing metabolism.Use caution/monitor.potential for increased myelosuppression.', '2019-11-06 20:30:20', '2019-11-06 20:30:20'),
(82, 8, 'Serious - Use Alternative', 6, 'allopurinol increases levels of theophylline by decreasinf metabolism.Avoid or use alternative drug.', '2019-11-06 20:46:25', '2019-11-06 20:46:25'),
(83, 8, 'Serious - Use Alternative', 38, 'carbamazepine will decrease the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Avoid or use alternative drug.', '2019-11-06 20:48:59', '2019-11-06 20:48:59'),
(86, 8, 'Serious - Use Alternative', 49, 'clarithromycin will increase the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Avoid or use alternative drug.', '2019-11-06 21:29:56', '2019-11-06 21:29:56'),
(87, 8, 'Serious - Use Alternative', 80, 'erythromycin stearate will increase the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Avoid or use alternative drug.', '2019-11-06 21:31:18', '2019-11-06 21:31:18'),
(88, 8, 'Serious - Use Alternative', 110, 'ketoconazole will increase the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Avoid or use alternative drug.', '2019-11-06 21:32:13', '2019-11-06 21:32:13'),
(85, 8, 'Serious - Use Alternative', 47, 'ciprofloxacin will increase the level or effect of theophylline by affecting hepatic enzyme CYP1A2 methabolism. Avoid or use alternative drug.\nconcomitant use of theophylline and ciprofloxacin has decreased theophylline clearance and increased plasma levels and symptoms of toxicity.\nserious and fatal reactions have included cardiac arrest,seizure,status epilepticus, and respiratory failure.if concomitant use cannot be avoided,monitor theophylline levels and adjust dosage as needed.', '2019-11-06 20:59:50', '2019-11-06 20:59:50'),
(91, 8, 'Monitor Closely', 17, 'Comment:beta blockers (esp.non selective)\nantagonize theophylline effects,while at the same time increasing  theophylline levels and toxicity (mechanism:decreased theophylline metabolism). smoking increase risk interaction.', '2019-11-06 21:39:38', '2019-11-06 21:39:38'),
(90, 8, 'Monitor Closely', 16, 'atazanavir will increase the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Use caution monitor', '2019-11-06 21:35:24', '2019-11-06 21:35:24'),
(92, 8, 'Monitor Closely', 38, 'carbamazepine will decrease the level or effect of theophylline by affecting hepatic enzyme CYP1A2 methabolism', '2019-11-06 21:42:23', '2019-11-06 21:42:23'),
(93, 8, 'Monitor Closely', 62, 'darunavir will increase the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Use caution/monitor.', '2019-11-06 21:44:48', '2019-11-06 21:44:48'),
(94, 8, 'Monitor Closely', 77, 'efavirenz will decrease the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Use caution/monitor.', '2019-11-08 17:40:43', '2019-11-08 17:40:43'),
(95, 8, 'Monitor Closely', 189, 'tenofovir DF increases levels of theophylline by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Modify therapy/monitor closely. cobicistat is a substratesvfor which elevated plasma concentrations are associated with serious and/or life-threatening events', '2019-11-08 17:46:26', '2019-11-08 17:46:26'),
(96, 8, 'Monitor Closely', 80, 'erythromycin stearate will increases the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP1A2 methabolism.use caution/monitor.', '2019-11-08 17:49:07', '2019-11-08 17:49:07'),
(97, 8, 'Monitor Closely', 85, 'etravirine will decrease the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 methabolism.use caution/monitor.', '2019-11-08 17:50:12', '2019-11-08 17:50:12'),
(98, 8, 'Monitor Closely', 90, 'fluconazole will increase the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 methabolism.use caution/monitor.', '2019-11-08 17:51:12', '2019-11-08 17:51:12'),
(99, 8, 'Monitor Closely', 98, 'griseofulvin will decrease the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 methabolism.use caution/monitor.', '2019-11-08 17:52:02', '2019-11-08 17:52:02'),
(100, 8, 'Monitor Closely', 102, 'hydrocortisone will decrease the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.use caution/monitor.', '2019-11-08 17:52:55', '2019-11-08 17:52:55'),
(101, 8, 'Monitor Closely', 108, 'isoniazid will increase the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP1A2 metabolism.use caution/monitor.', '2019-11-08 17:54:22', '2019-11-08 17:54:22'),
(102, 8, 'Monitor Closely', 111, 'Comment: Beta blockers (esp.non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). smoking increases risk interaction.', '2019-11-08 17:58:17', '2019-11-08 17:58:17'),
(103, 8, 'Monitor Closely', 129, 'methylprednisolone will decrease the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.use caution/monitor', '2019-11-08 18:00:42', '2019-11-08 18:00:42'),
(104, 8, 'Monitor Closely', 131, 'metronidazole will increase the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.use caution/monitor', '2019-11-08 18:01:37', '2019-11-08 18:01:37'),
(105, 8, 'Monitor Closely', 140, 'nevirapine will decrease the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.use caution/monitor', '2019-11-08 18:02:34', '2019-11-08 18:02:34'),
(106, 8, 'Monitor Closely', 141, 'nifedipine will increase the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.use caution/monitor', '2019-11-08 18:03:32', '2019-11-08 18:03:32'),
(107, 8, 'Monitor Closely', 159, 'phenytoin will decrease the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.use caution/monitor', '2019-11-08 18:04:33', '2019-11-08 18:04:33'),
(108, 8, 'Monitor Closely', 163, 'prednisolone will decrease the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.use caution/monitor', '2019-11-08 18:05:21', '2019-11-08 18:05:21'),
(109, 8, 'Monitor Closely', 177, 'ritonavir will increase the level or effect of theophylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.use caution/monitor', '2019-11-08 18:05:59', '2019-11-08 18:05:59'),
(111, 8, 'Monitor Closely', 202, 'verapamil will increase the level or effect of theophylline by affecting hepatic enzyme CYP1A2 metabolism.use caution/monitor', '2019-11-08 18:07:06', '2019-11-08 18:07:06'),
(112, 8, 'Minor', 9, 'amiodarone increases the levels of theophylline by decreasing metabolism.Minor/Significance Unknown', '2019-11-08 18:09:21', '2019-11-08 18:09:21'),
(113, 8, 'Minor', 42, 'theophylline increases levels of cetirizine by decreasing elimination.Minor/Significance Unknown', '2019-11-08 18:11:12', '2019-11-08 18:11:12'),
(114, 8, 'Minor', 49, 'clarithromycin increases levels of theophylline by decreasing methabolism.Minor/Significance Unknown', '2019-11-08 18:12:53', '2019-11-08 18:12:53'),
(115, 8, 'Minor', 146, 'omeprazole will decrease the level or effect of theophylline by affecting hepatic enzyme CYP1A2 metabolism.    Minor/Significance Unknown', '2019-11-08 18:16:58', '2019-11-08 18:16:58'),
(119, 9, 'Contraindicated', 165, 'amiodarone and procainamide both increase QTc interval.Contraindicated.', '2019-11-08 18:24:05', '2019-11-08 18:24:05'),
(118, 9, 'Contraindicated', 99, 'amiodarone and haloperidol both increase QTc interval.Contraindicated.', '2019-11-08 18:23:26', '2019-11-08 18:23:26'),
(120, 9, 'Contraindicated', 177, 'ritonavir will increase the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Contraindicated.', '2019-11-08 18:26:56', '2019-11-08 18:26:56'),
(121, 9, 'Contraindicated', 195, 'thioridazine and amiodarone both increase QTc interval.Contraindicated.', '2019-11-08 18:28:45', '2019-11-08 18:28:45'),
(122, 9, 'Serious - Use Alternative', 10, 'amitriptyline and amiodarone both increase QTc interval.Avoid or Use Alternative Drug.', '2019-11-08 18:30:33', '2019-11-08 18:30:33'),
(123, 9, 'Serious - Use Alternative', 16, 'atazanavir will increase the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.', '2019-11-08 18:32:16', '2019-11-08 18:32:16'),
(124, 9, 'Serious - Use Alternative', 38, 'carbamazepine will decrease the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.', '2019-11-08 18:33:25', '2019-11-08 18:33:25'),
(125, 9, 'Serious - Use Alternative', 46, 'amiodarone and chlorpromazine both increase QTc interval.Avoid or Use Alternative Drug.', '2019-11-08 18:34:44', '2019-11-08 18:34:44'),
(126, 9, 'Serious - Use Alternative', 49, 'clarithromycin will increase the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.May result in prolongation of QT interval', '2019-11-08 18:38:25', '2019-11-08 18:38:25'),
(127, 9, 'Serious - Use Alternative', 56, 'amiodarone will increase the level or effect of colchicine by P-glycoprotein(MDR1) efflux transporter.Avoid or Use Alternative Drug.Avoid use of colchicine with P-gp inhibitors.if coadministration is necessary,decrease colchicine dose or frequency as recommended in prescribing information.Use of any colchicine in conjunction with P-gp inhibitors is contraindicated in patients with renal or hepatic impairment.', '2019-11-08 18:48:16', '2019-11-08 18:48:16'),
(128, 9, 'Serious - Use Alternative', 56, 'amiodarone will increase the level or effect of colchicine by P-glycoprotein(MDR1) efflux transporter.Avoid or Use Alternative Drug.Avoid use of colchicine with P-gp inhibitors.if coadministration is necessary,decrease colchicine dose or frequency as recommended in prescribing information.Use of any colchicine in conjunction with P-gp inhibitors is contraindicated in patients with renal or hepatic impairment.', '2019-11-08 18:48:17', '2019-11-08 18:48:17'),
(129, 9, 'Serious - Use Alternative', 69, 'amiodarone will increase the level or effect of digoxin by P-glycoprotein(MDR1) efflux transporter.Avoid or Use Alternative Drug.Amiodarone increases PO digoxin serum concentrations by ~ 70% and IV digoxin by ~17%;measure digoxin levels before initiating amiodarone and reduce PO digoxin dose by 30-50%;decrease IV digoxin dose by 15-30%', '2019-11-08 18:56:46', '2019-11-08 18:56:46'),
(130, 9, 'Serious - Use Alternative', 77, 'efavirenz will decrease the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.', '2019-11-08 18:58:50', '2019-11-08 18:58:50'),
(131, 9, 'Serious - Use Alternative', 80, 'erythromycin stearate will increase the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.', '2019-11-08 19:00:13', '2019-11-08 19:00:13'),
(132, 9, 'Serious - Use Alternative', 85, 'etravirine will decrease the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.', '2019-11-08 19:01:00', '2019-11-08 19:01:00'),
(133, 9, 'Serious - Use Alternative', 88, 'amiodarone will increase the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.if coadministration of CYP3A4 inhibitors with fentanyl is necessary,monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.', '2019-11-08 19:07:54', '2019-11-08 19:07:54'),
(134, 9, 'Serious - Use Alternative', 90, 'fluconazole will increase the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.coadministration can cause additive effects on QT prolongation.', '2019-11-08 19:12:16', '2019-11-08 19:12:16'),
(135, 9, 'Serious - Use Alternative', 92, 'amiodarone and fluoxetine both increase QTc interval.Avoid or Use Alternative Drug.', '2019-11-08 19:13:46', '2019-11-08 19:13:46'),
(136, 9, 'Serious - Use Alternative', 110, 'ketoconazole will increase the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.', '2019-11-08 19:15:48', '2019-11-08 19:15:48'),
(137, 9, 'Serious - Use Alternative', 114, 'amiodarone and levofloxacin both increase QTc interval.Avoid or Use Alternative Drug.', '2019-11-08 19:17:01', '2019-11-08 19:17:01'),
(138, 9, 'Serious - Use Alternative', 132, 'amiodarone will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.coadministration moderate CYP3A4 inhibitors with midazolam intranasal causes higher midazolam systemic exposure,which may prolong sedation.', '2019-11-08 19:24:43', '2019-11-08 19:24:43'),
(139, 9, 'Serious - Use Alternative', 145, 'amiodarone and ofloxacin both increase QTc interval.Avoid or Use Alternative Drug.', '2019-11-08 19:25:58', '2019-11-08 19:25:58'),
(140, 9, 'Serious - Use Alternative', 165, 'amiodarone will increase the level or effect of procainamide by basic (cationic) drug competition for renal tubular clearance .Avoid or Use Alternative Drug.', '2019-11-08 19:29:01', '2019-11-08 19:29:01'),
(141, 9, 'Serious - Use Alternative', 173, 'quinidine will increase the level or effect of amiodarone by basic (cationic) drug competition for renal tubular clearance .Avoid or Use Alternative Drug.', '2019-11-08 19:32:14', '2019-11-08 19:32:14'),
(142, 9, 'Serious - Use Alternative', 181, 'amiodarone increases toxicity of simvastatin by decreasing metabolism.Avoid or Use Alternative Drug.\nDo not exceed simvastatin 20mg daily when given concurrently. Potential for increased risk of myopathy/rhabdomyolysis', '2019-11-08 19:37:38', '2019-11-08 19:37:38'),
(143, 9, 'Serious - Use Alternative', 195, 'amiodarone will increase the level or effect of thioridazine by affecting hepatic enzyme CPY2D6 metabolism.Avoid or Use Alternative Drug.', '2019-11-08 19:40:29', '2019-11-08 19:40:29'),
(144, 9, 'Serious - Use Alternative', 206, 'amiodarone increases the levels of warfarin by decreasing  metabolism.Avoid or Use Alternative Drug.', '2019-11-08 19:41:57', '2019-11-08 19:41:57'),
(145, 9, 'Monitor Closely', 10, 'amiodarone will increase the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-09 13:42:34', '2019-11-09 13:42:34'),
(146, 9, 'Monitor Closely', 17, 'Mechanism:pharmacodynamic synergism.Use Caution/Monitor.Risk of cardiotoxicity with bradycardia.', '2019-11-09 13:45:37', '2019-11-09 13:45:37'),
(147, 9, 'Monitor Closely', 18, 'amiodarone will increase the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-09 13:49:39', '2019-11-09 13:49:39'),
(148, 9, 'Monitor Closely', 22, 'azithromycin will increase the level or effect of amiodaroneby P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-09 13:50:56', '2019-11-09 13:50:56'),
(149, 9, 'Monitor Closely', 37, 'amiodarone,captopril.\neither increases effects of the others by pharmacodynamic synergism.Use Caution/Monitor.both drugs lower blood pressure.Monitor blood pressure.', '2019-11-09 14:00:38', '2019-11-09 14:00:38'),
(150, 9, 'Monitor Closely', 47, 'amiodarone and ciprofloxacin both increase QTc interval.Use Caution/Monitor. ciprofloxacin elicits minimal effects on QT interval. Caution if used combination with other drugs know to affect QT interval or in patients with other risk factors.', '2019-11-09 14:05:38', '2019-11-09 14:05:38'),
(151, 9, 'Monitor Closely', 62, 'darunavir will increase the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.clinical monitoring is recommended up on coadministration with antiarrhythmics.', '2019-11-09 14:13:12', '2019-11-09 14:13:12'),
(152, 9, 'Monitor Closely', 72, 'amiodarone will increase the level or effect of docetaxel by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-09 14:16:01', '2019-11-09 14:16:01'),
(154, 9, 'Monitor Closely', 84, 'amiodarone will increase the level or effect of etoposide by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-10 09:50:01', '2019-11-10 09:50:01'),
(155, 9, 'Monitor Closely', 85, 'amiodarone will increase the level or effect of etravirine by affecting hepatic enzyme CYP2C9/10 metabolism.Use Caution/Monitor.', '2019-11-10 09:51:59', '2019-11-10 09:51:59'),
(156, 9, 'Monitor Closely', 92, 'amiodarone will increase the level or effect of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism.Use Caution/Monitor.', '2019-11-10 19:12:51', '2019-11-10 19:12:51'),
(157, 9, 'Monitor Closely', 98, 'griseofulvin will decrease the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-10 19:16:58', '2019-11-10 19:16:58'),
(158, 9, 'Monitor Closely', 99, 'amiodarone will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism.Use Caution/Monitor.concurrent administration of amiodarone and haloperidol is not recommended due to the potent for inducing life-threatening arrhythmias.if concurrent use cannot be avoided,cautious dosing and telemetric monitoring is advised.', '2019-11-10 19:21:55', '2019-11-10 19:21:55'),
(159, 9, 'Monitor Closely', 101, 'amiodarone will increase the level or effect of hydrochlorothiazide by basic (cationic) drug competition for renal tubular clearance.Use Caution/Monitor.', '2019-11-10 19:24:38', '2019-11-10 19:24:38'),
(160, 9, 'Monitor Closely', 102, 'hydrocortisone will decrease the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-10 19:26:59', '2019-11-10 19:26:59'),
(161, 9, 'Monitor Closely', 108, 'isoniazid will increase the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-10 19:29:52', '2019-11-10 19:29:52'),
(162, 9, 'Monitor Closely', 111, 'pharmacodynamic synergism.Use Caution/Monitor.Risk of cardiotoxicity with bradycardia.', '2019-11-10 19:32:37', '2019-11-10 19:32:37'),
(163, 9, 'Monitor Closely', 118, 'amiodarone will increase the level or effect of loperamide by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-10 19:36:17', '2019-11-10 19:36:17'),
(164, 9, 'Monitor Closely', 129, 'methylprednisolone will decrease the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-10 19:40:41', '2019-11-10 19:40:41'),
(165, 9, 'Monitor Closely', 131, 'metronidazole will increase the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-10 19:42:00', '2019-11-10 19:42:00'),
(166, 9, 'Monitor Closely', 133, 'amiodarone will increase the level or effect of morphine by affecting hepatic enzyme CYP2D6 metabolism.Use Caution/Monitor.', '2019-11-10 19:44:12', '2019-11-10 19:44:12'),
(167, 9, 'Monitor Closely', 140, 'nevirapine will decrease the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-10 19:46:35', '2019-11-10 19:46:35'),
(168, 9, 'Monitor Closely', 141, 'nifedipine will increase the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-10 19:47:27', '2019-11-10 19:47:27'),
(169, 9, 'Monitor Closely', 145, 'amiodarone will increase the level or effect of ofloxacin by basic (cationic) drug competition for renal tubular clearance .Use Caution/Monitor.', '2019-11-10 19:50:12', '2019-11-10 19:50:12'),
(170, 9, 'Monitor Closely', 159, 'amiodarone will increase the level or effect of phenytoin by affecting hepatic enzyme CYP2C9/10 metabolism.Use Caution/Monitor.', '2019-11-10 19:56:51', '2019-11-10 19:56:51'),
(171, 9, 'Monitor Closely', 174, 'amiodarone will increase the level or effect of quinine by basic (cationic) drug competition for renal tubular clearance .Use Caution/Monitor.', '2019-11-10 20:00:14', '2019-11-10 20:00:14'),
(172, 9, 'Monitor Closely', 197, 'amiodarone will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism .Use Caution/Monitor.', '2019-11-10 20:14:54', '2019-11-10 20:14:54'),
(173, 9, 'Monitor Closely', 198, 'amiodarone decrease effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism.Use Caution/Monitor.decreased conversion of tramadol to active metabolite', '2019-11-10 20:18:43', '2019-11-10 20:18:43'),
(174, 9, 'Monitor Closely', 202, 'verapamil will increase the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism .Use Caution/Monitor.', '2019-11-10 20:20:25', '2019-11-10 20:20:25'),
(175, 9, 'Monitor Closely', 203, 'amiodarone will increase the level or effect of vinblastine by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-10 20:21:35', '2019-11-10 20:21:35'),
(176, 9, 'Monitor Closely', 204, 'amiodarone will increase the level or effect of vincristine by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-10 20:22:16', '2019-11-10 20:22:16'),
(177, 9, 'Monitor Closely', 206, 'amiodarone will increase the level or effect of warafin by affecting hepatic enzyme CYP2C9/10 metabolism.Use Caution/Monitor.', '2019-11-10 20:23:28', '2019-11-10 20:23:28'),
(178, 9, 'Minor', 46, 'amiodarone will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism.Minor/Significance Unknown.', '2019-11-10 20:27:55', '2019-11-10 20:27:55'),
(179, 9, 'Minor', 93, 'amiodarone will increase the level or effect of fluphenazine by affecting hepatic enzyme CYP2D6 metabolism.Minor/Significance Unknown.', '2019-11-10 20:32:08', '2019-11-10 20:32:08'),
(180, 9, 'Minor', 105, 'amiodarone will increase the level or effect of ibuprofen by affecting hepatic enzyme CYP2C9/10 metabolism .Minor/Significance Unknown.', '2019-11-10 20:33:26', '2019-11-10 20:33:26'),
(181, 10, 'Contraindicated', 165, 'amitriptyline and procainamide both increase QTc interval.Contraindicated.', '2019-11-10 20:43:39', '2019-11-10 20:43:39'),
(182, 10, 'Contraindicated', 166, 'amitriptyline and procarbazine both increase serotonin levels.Contraindicated.combination is contraindicated with in 2 weeks of MAOI use.', '2019-11-10 20:45:47', '2019-11-10 20:45:47'),
(183, 10, 'Contraindicated', 173, 'amitriptyline and quinidine both increase QTc interval. Contraindicated', '2019-11-10 20:46:57', '2019-11-10 20:46:57'),
(184, 10, 'Serious - Use Alternative', 9, 'amitriptyline and amiodarone both increase QTc interval. Avoid or Use Alternative Drug.', '2019-11-10 20:48:47', '2019-11-10 20:48:47'),
(185, 10, 'Serious - Use Alternative', 46, 'amitriptyline and chlorpromazine both increase QTc interval. Avoid or Use Alternative Drug.', '2019-11-10 20:50:36', '2019-11-10 20:50:36'),
(186, 10, 'Serious - Use Alternative', 49, 'clarithromycin will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Drug.', '2019-11-10 20:52:43', '2019-11-10 20:52:43'),
(187, 10, 'Serious - Use Alternative', 71, 'Comment:tricyclic antidepressants increase or decrease effects of sympathomimetics,by blocking reuptake of NE,or blocking uptake of indirect sympathomimetics in to the adrenergic neuron.', '2019-11-10 20:58:57', '2019-11-10 20:58:57'),
(188, 10, 'Serious - Use Alternative', 80, 'amitriptyline and erythromycin stearate both increase QTc interval. Avoid or Use Alternative Drug.', '2019-11-10 21:04:28', '2019-11-10 21:04:28'),
(189, 10, 'Serious - Use Alternative', 90, 'amitriptyline and fluconazole both increase QTc interval. Avoid or Use Alternative Drug.', '2019-11-10 21:05:17', '2019-11-10 21:05:17'),
(190, 10, 'Serious - Use Alternative', 92, 'fluoxetine will increase the level or effect of amitriptyline by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternative Drug.', '2019-11-10 21:07:28', '2019-11-10 21:07:28'),
(191, 10, 'Serious - Use Alternative', 99, 'amitriptyline and haloperidol both increase QTc interval. Avoid or Use Alternative Drug.', '2019-11-10 21:09:49', '2019-11-10 21:09:49'),
(192, 10, 'Serious - Use Alternative', 110, 'amitriptyline and ketoconazole both increase QTc interval. Avoid or Use Alternative Drug.', '2019-11-10 21:11:32', '2019-11-10 21:11:32'),
(193, 10, 'Serious - Use Alternative', 158, 'Comment:tricyclic antidepressants increase or decrease effects of sympathomimetics,by blocking reuptake of NE,or blocking uptake of indirect sympathomimetics in to the adrenergic neuron.', '2019-11-10 21:17:26', '2019-11-10 21:17:26'),
(194, 10, 'Serious - Use Alternative', 173, 'quinidine will increase the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Avoid or Use Alternative Drug.', '2019-11-10 21:20:56', '2019-11-10 21:20:56'),
(195, 10, 'Serious - Use Alternative', 191, 'Comment:tricyclic antidepressants increase or decrease effects of sympathomimetics,by blocking reuptake of NE,or blocking uptake of indirect sympathomimetics in to the adrenergic neuron.', '2019-11-10 21:22:46', '2019-11-10 21:22:46'),
(196, 10, 'Serious - Use Alternative', 195, 'amitriptyline and thioridazine both increase QTc interval.Avoid or Use Alternative Drug.', '2019-11-10 21:23:50', '2019-11-10 21:23:50'),
(197, 10, 'Serious - Use Alternative', 207, 'Comment:tricyclic antidepressants increase or decrease effects of sympathomimetics,by blocking reuptake of NE,or blocking uptake of indirect sympathomimetics in to the adrenergic neuron.', '2019-11-10 21:26:36', '2019-11-10 21:26:36'),
(198, 10, 'Monitor Closely', 9, 'amiodarone will increase the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-10 21:29:36', '2019-11-10 21:29:36'),
(199, 10, 'Monitor Closely', 16, 'atazanavir will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-10 21:31:54', '2019-11-10 21:31:54'),
(200, 10, 'Monitor Closely', 18, 'atorvastatin will increase the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-10 21:33:28', '2019-11-10 21:33:28'),
(201, 10, 'Monitor Closely', 19, 'atracurium and amitriptyline both decrease cholinergic effects/trasmission.Use Caution/Monitor.', '2019-11-10 21:35:08', '2019-11-10 21:35:08'),
(202, 10, 'Monitor Closely', 22, 'amitriptyline and azithromycin both increase QTc interval.Use Caution/Monitor.', '2019-11-10 21:36:23', '2019-11-10 21:36:23'),
(203, 10, 'Monitor Closely', 38, 'carbamazepine will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-10 21:40:09', '2019-11-10 21:40:09'),
(204, 10, 'Monitor Closely', 45, 'chlorpheniramine and amitriptyline both increase sedation.Use Caution/Monitor.', '2019-11-10 21:42:19', '2019-11-10 21:42:19'),
(205, 10, 'Monitor Closely', 49, 'clarithromycin will increase the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-10 21:44:08', '2019-11-10 21:44:08'),
(206, 10, 'Monitor Closely', 53, 'clotrimazole will decrease the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-10 21:45:49', '2019-11-10 21:45:49'),
(207, 10, 'Monitor Closely', 62, 'darunavir will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.coadministration with SSRIs .TCAs,or trazodone may require dose titration of antidepressant to desire effect (eg,using the lowest feasible initial or maintenance dose).Monitor for antidepressant response.', '2019-11-10 21:53:27', '2019-11-10 21:53:27'),
(208, 10, 'Monitor Closely', 66, 'diazepam and amitriptyline both increase sedation.Use Caution/Monitor.', '2019-11-10 21:55:53', '2019-11-10 21:55:53'),
(209, 10, 'Monitor Closely', 71, 'amitriptyline increases dobutamine decreases sedation.effect of interaction is not clear,use caution. Use Caution/Monitor.', '2019-11-10 21:59:27', '2019-11-10 21:59:27'),
(210, 10, 'Monitor Closely', 77, 'efavirenz will increase the level or effect of amitriptyline by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.', '2019-11-10 22:01:33', '2019-11-10 22:01:33'),
(211, 10, 'Monitor Closely', 85, 'etravirine will increase the level or effect of amitriptyline by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.', '2019-11-11 08:33:05', '2019-11-11 08:33:05'),
(212, 10, 'Monitor Closely', 90, 'fluconazol will increase the level or effect of amitriptyline by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.', '2019-11-11 08:35:30', '2019-11-11 08:35:30'),
(213, 10, 'Monitor Closely', 92, 'amitriptyline and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.', '2019-11-11 08:37:15', '2019-11-11 08:37:15'),
(214, 10, 'Monitor Closely', 99, 'haloperidol and amitriptyline both increase sedation.Use Caution/Monitor.', '2019-11-11 08:40:33', '2019-11-11 08:40:33'),
(215, 10, 'Monitor Closely', 108, 'isoniazidl will increase the level or effect of amitriptyline by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.', '2019-11-11 08:43:58', '2019-11-11 08:43:58'),
(216, 10, 'Monitor Closely', 110, 'ketoconazole will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-11 08:46:21', '2019-11-11 08:46:21'),
(217, 10, 'Monitor Closely', 114, 'amitriptyline and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.', '2019-11-11 08:47:59', '2019-11-11 08:47:59'),
(218, 10, 'Monitor Closely', 120, 'lorazepam and amitriptyline both increase sedation.Use Caution/Monitor..', '2019-11-11 08:49:43', '2019-11-11 08:49:43'),
(219, 10, 'Monitor Closely', 132, 'midazolam will increase the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor..', '2019-11-11 08:53:50', '2019-11-11 08:53:50'),
(220, 10, 'Monitor Closely', 132, 'midazolaml and amitriptyline both increase sedation.Use Caution/Monitor.', '2019-11-11 08:54:54', '2019-11-11 08:54:54'),
(221, 10, 'Monitor Closely', 133, 'morphine and amitriptyline both increase sedation.Use Caution/Monitor.', '2019-11-11 08:56:02', '2019-11-11 08:56:02'),
(222, 10, 'Monitor Closely', 133, 'morphine and amitriptyline both increase serotonin levels.Modify Therapy/Monitor Closely.', '2019-11-11 08:57:13', '2019-11-11 08:57:13'),
(223, 10, 'Monitor Closely', 139, 'neostigmine increases and amitriptyline decreases cholinergic effects/transmission.effect of interaction is not clear,use caution.Modify Therapy/Monitor Closely.', '2019-11-11 09:00:36', '2019-11-11 09:00:36'),
(224, 10, 'Monitor Closely', 141, 'nifedipine will decrease the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-11 09:01:52', '2019-11-11 09:01:52'),
(225, 10, 'Monitor Closely', 145, 'amitriptyline and ofloxacin both increase QTc interval.Modify Therapy/Monitor Closely.', '2019-11-11 09:04:04', '2019-11-11 09:04:04'),
(226, 10, 'Monitor Closely', 177, 'ombitasvir/paritaprevir/ritonavir will increase the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.paritaprevir and retonavir inhibit P-gp substrates.', '2019-11-11 09:08:37', '2019-11-11 09:08:37'),
(227, 10, 'Monitor Closely', 158, 'amitriptyline increases and phenylephrine decreases sedation.effect of interaction is not clear,use caution.UseCaution/Monitor.', '2019-11-11 09:14:28', '2019-11-11 09:14:28'),
(228, 10, 'Monitor Closely', 159, 'phenytoin will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.monitor therapeutic efficacy of amitriptyline;an increased dose may be required.serum phenytoin levels should be obtained when tricyclic antidepressant agents are added to therapy due to the potential for impaired phenytoin metabolism and decreased seizure threshold. tricyclic antidepressants when given concomitantly with anticonvulsants can increase CNC depression.', '2019-11-11 09:22:13', '2019-11-11 09:22:13'),
(229, 10, 'Monitor Closely', 159, 'phenytoin will decrease the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.monitor therapeutic efficacy of amitriptyline;an increased dose may be required.serum phenytoin levels should be obtained when tricyclic antidepressant agents are added to therapy due to the potential for impaired phenytoin metabolism and decreased seizure threshold. tricyclic antidepressants when given concomitantly with anticonvulsants can increase CNC depression.', '2019-11-11 09:25:12', '2019-11-11 09:25:12'),
(230, 10, 'Monitor Closely', 160, 'pilocarpine increases and amitriptyline decreases cholinergic effects/transmission.effect of interaction is not clear,use caution.Modify Therapy/Monitor Closely.', '2019-11-11 09:27:11', '2019-11-11 09:27:11'),
(231, 10, 'Monitor Closely', 168, 'propofol and amitriptyline both increase sedation.Use Caution/Monitor.', '2019-11-11 09:29:21', '2019-11-11 09:29:21'),
(232, 10, 'Monitor Closely', 174, 'amitriptyline and quinine both increase QTc interval. Use Caution/Monitor.', '2019-11-11 09:31:20', '2019-11-11 09:31:20'),
(233, 10, 'Monitor Closely', 177, 'ritonavir will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.. Use Caution/Monitor.', '2019-11-11 09:33:03', '2019-11-11 09:33:03'),
(234, 10, 'Monitor Closely', 177, 'ritonavir will increase the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-11 09:33:54', '2019-11-11 09:33:54'),
(235, 10, 'Monitor Closely', 181, 'simvastatin will increase the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-11 09:35:37', '2019-11-11 09:35:37'),
(236, 10, 'Monitor Closely', 183, 'spironolactone will increase the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-11 09:38:09', '2019-11-11 09:38:09'),
(237, 10, 'Monitor Closely', 191, 'amitriptyline increases and terbutaline decreases sedation.effect of interaction is not clear,use caution.UseCaution/Monitor.', '2019-11-11 09:42:09', '2019-11-11 09:42:09'),
(238, 10, 'Monitor Closely', 195, 'thioridazine and amitriptyline both increase sedation.Use Caution/Monitor.', '2019-11-11 09:45:14', '2019-11-11 09:45:14'),
(239, 10, 'Monitor Closely', 198, 'tramadol and amitriptyline both increase sedation.Use Caution/Monitor.', '2019-11-11 09:46:24', '2019-11-11 09:46:24'),
(240, 10, 'Monitor Closely', 198, 'tramadol and amitriptyline both increase serotonin levels.Modify Therapy/Monitor Closely.', '2019-11-11 09:49:48', '2019-11-11 09:49:48'),
(241, 10, 'Monitor Closely', 202, 'verapamil will increase the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor.the frequency and severity of amitriptyline adverse effects(sedation,anticholinergic effects and orthostatic hypotension) may be increased.cardiac dysrhythmic effects may be additive.', '2019-11-11 09:55:14', '2019-11-11 09:55:14'),
(242, 10, 'Monitor Closely', 207, 'amitriptyline increases and xylometazoline decreases sedation.effect of interaction is not clear,use caution.UseCaution/Monitor.', '2019-11-11 09:57:34', '2019-11-11 09:57:34'),
(250, 10, 'Minor', 85, 'etravirine  will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unkown', '2019-11-11 10:21:21', '2019-11-11 10:21:21'),
(251, 10, 'Minor', 97, 'amitriptyline increases effects of glimepiride by pharmacodynamic .Minor/Significance Unkown', '2019-11-11 10:24:26', '2019-11-11 10:24:26'),
(252, 10, 'Minor', 98, 'griseofulvin will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism .Minor/Significance Unkown', '2019-11-11 10:27:36', '2019-11-11 10:27:36'),
(246, 10, 'Minor', 38, 'carbamazepine decreases levels of amitriptyline by increasing metabolism.Minor/Significance Unknown.', '2019-11-11 10:16:12', '2019-11-11 10:16:12'),
(247, 10, 'Minor', 46, 'either increase levels of the other by decreasing metabolism.Minor/Significance Unknown.additive anticholinergic effects.', '2019-11-11 10:17:11', '2019-11-11 10:17:11'),
(253, 10, 'Minor', 102, 'hydrocortisone will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism .Minor/Significance Unkown', '2019-11-11 10:28:30', '2019-11-11 10:28:30'),
(249, 10, 'Minor', 46, 'either increase levels of the other by pharmacodynamic synergism.Minor/Significance Unknown.additive anticholinergic effects.', '2019-11-11 10:18:02', '2019-11-11 10:18:02'),
(254, 10, 'Minor', 108, 'isoniazid will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism .Minor/Significance Unkown', '2019-11-11 10:29:35', '2019-11-11 10:29:35'),
(255, 10, 'Minor', 129, 'methylprednisolone will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism .Minor/Significance Unknown', '2019-11-11 10:32:51', '2019-11-11 10:32:51'),
(256, 10, 'Minor', 131, 'metronidazole will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism .Minor/Significance Unknown', '2019-11-11 10:34:52', '2019-11-11 10:34:52'),
(257, 10, 'Minor', 140, 'nevirapine will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism .Minor/Significance Unknown', '2019-11-11 10:36:36', '2019-11-11 10:36:36'),
(258, 10, 'Minor', 141, 'nifedipine will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism .Minor/Significance Unknown', '2019-11-11 10:37:16', '2019-11-11 10:37:16'),
(259, 10, 'Minor', 163, 'prednisolone will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism .Minor/Significance Unknown', '2019-11-11 10:39:33', '2019-11-11 10:39:33'),
(260, 10, 'Minor', 168, 'mechanism:unspecified interaction mechanism .Minor/Significance/Unknown.risk of arrhythmias or hypotension', '2019-11-11 10:42:27', '2019-11-11 10:42:27'),
(261, 10, 'Minor', 195, 'either increase levels of the other by decreasing metabolism.Minor/Significance Unknown.additive anticholinergic effects.', '2019-11-11 10:45:57', '2019-11-11 10:45:57'),
(262, 10, 'Minor', 195, 'either increase levels of the other by pharmacodnamic synergism.Minor/Significance Unknown.additive anticholinergic effects.', '2019-11-11 10:47:09', '2019-11-11 10:47:09'),
(263, 10, 'Minor', 202, 'verapamil will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism .Minor/Significance Unknown', '2019-11-11 10:48:32', '2019-11-11 10:48:32'),
(264, 10, 'Minor', 202, 'verapamil increases levels of amitriptyline by decreasing metabolism.Minor/Significance Unknown', '2019-11-11 10:49:40', '2019-11-11 10:49:40'),
(265, 11, 'Serious - Use Alternative', 141, 'nifedipine will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.', '2019-11-11 10:55:57', '2019-11-11 10:55:57'),
(266, 11, 'Serious - Use Alternative', 181, 'amlodipine increses levels of simvastatin by other(see comment). Avoid or Use Alternative Drug.\nComment:benefits of combination therapy should be carefully weighed against the potential risks of combination.potential for increased risk of myopathy/rhabdomyolysis.limit simvastatin dose to no more than 20mg/day when used concurrently.', '2019-11-11 11:01:08', '2019-11-11 11:01:08'),
(267, 11, 'Monitor Closely', 17, 'atenolol and amlodipine both increase antihypertensive channel blocking.Modify Therapy/Monitor Closely.', '2019-11-11 11:43:58', '2019-11-11 11:43:58'),
(268, 11, 'Monitor Closely', 38, 'carbamazepine will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Modify Therapy/Monitor Closely.', '2019-11-11 11:46:40', '2019-11-11 11:46:40'),
(269, 11, 'Monitor Closely', 49, 'clarithromycin will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.increased effect of calcium channel lockers may lead to hypotension,edema,decreased HR,and acute kidney injury due to reduced renal blood flow.', '2019-11-11 11:50:42', '2019-11-11 11:50:42'),
(270, 11, 'Monitor Closely', 62, 'darunavir  will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely', '2019-11-11 11:52:59', '2019-11-11 11:52:59'),
(271, 11, 'Monitor Closely', 62, 'darunavir  will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor', '2019-11-11 11:53:48', '2019-11-11 11:53:48'),
(272, 11, 'Monitor Closely', 77, 'efavirenz  will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor', '2019-11-11 11:55:27', '2019-11-11 11:55:27');
INSERT INTO `interactions` (`id`, `drug_id`, `status`, `drug`, `description`, `created_at`, `updated_at`) VALUES
(273, 11, 'Monitor Closely', 80, 'erythromycin stearate  will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor', '2019-11-11 11:57:10', '2019-11-11 11:57:10'),
(274, 11, 'Monitor Closely', 90, 'fluconazole  will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor', '2019-11-11 11:58:23', '2019-11-11 11:58:23'),
(275, 11, 'Monitor Closely', 98, 'griseofulvin  will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor', '2019-11-11 11:59:04', '2019-11-11 11:59:04'),
(276, 11, 'Monitor Closely', 110, 'ketoconazole  will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor', '2019-11-11 12:00:10', '2019-11-11 12:00:10'),
(277, 11, 'Monitor Closely', 111, 'labetalol and amlodipine both increase antihypertensive channel blocking.Modify Therapy/Monitor Closely.', '2019-11-11 12:01:11', '2019-11-11 12:01:11'),
(278, 11, 'Monitor Closely', 113, 'levodopa increses effects of amlodipine by pharmacodynamic synergism.Use Caution/Monitor.consider decreasing dosage of antihypertensive agent.', '2019-11-11 12:11:17', '2019-11-11 12:11:17'),
(279, 11, 'Monitor Closely', 140, 'nevirapine will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-11 12:13:57', '2019-11-11 12:13:57'),
(280, 11, 'Monitor Closely', 141, 'nifedipine and amlodipine both increase antihypertensive channel blocking.Use Caution/Monitor.', '2019-11-11 12:15:30', '2019-11-11 12:15:30'),
(281, 11, 'Monitor Closely', 143, 'amlodipine increses effects of nitroprusside sodium by pharmacodynamic synergism.Use Caution/Monitor.', '2019-11-11 12:17:59', '2019-11-11 12:17:59'),
(282, 11, 'Monitor Closely', 177, 'ritonavir will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Modify Therapy/Monitor Closely.decrease dose of calcium channel blocker;dose of amlodipine should be decreased by at least 50%;clinical monitoring of patients is recommended for edema and/ or signs and symptoms of hypotension.if such events occur,consider further dose reduction of calcium channel blocker or switching to alternative to calcium channel blocker.', '2019-11-11 12:26:26', '2019-11-11 12:26:26'),
(283, 11, 'Monitor Closely', 159, 'amlodipine will increase the level or effect of phenytoin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.', '2019-11-11 12:30:09', '2019-11-11 12:30:09'),
(284, 11, 'Monitor Closely', 177, 'ritronavir will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor', '2019-11-11 12:34:40', '2019-11-11 12:34:40'),
(285, 11, 'Monitor Closely', 197, 'amlodipine will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor', '2019-11-11 12:37:53', '2019-11-11 12:37:53'),
(286, 11, 'Monitor Closely', 202, 'amlodipine and verapamil both increase antihypertensive channel blocking.Use Caution/Monitor', '2019-11-11 12:40:22', '2019-11-11 12:40:22'),
(287, 11, 'Minor', 16, 'atazanavir will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-11 12:42:50', '2019-11-11 12:42:50'),
(288, 11, 'Minor', 19, 'amlodipine increases effects of atracurium by pharmacodynamic synergism.Minor/Significance Unknown.Ca channel blockers interfere w/Ach release from prejunctional axon.', '2019-11-11 12:46:56', '2019-11-11 12:46:56'),
(289, 11, 'Minor', 85, 'etravirine will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-11 12:49:19', '2019-11-11 12:49:19'),
(290, 12, 'Serious - Use Alternative', 76, 'doxycycline decreases effects of amoxicillin by pharmacodynamic antagonism.Avoid or Use Alternative Drug.tetracyclines may interfere with the bactericidal action of penicillins.monitor for decreased therapeutic effects of penicillins if concomitantly used with a tetracycline.', '2019-11-11 13:00:52', '2019-11-11 13:00:52'),
(291, 12, 'Monitor Closely', 4, 'either increases levels of the other by decreasing renal clearance.Use Caution/Monitor.', '2019-11-11 14:03:37', '2019-11-11 14:03:37'),
(292, 12, 'Monitor Closely', 6, 'allopurinol decreases toxicity of amoxicillin by other(see comment).Use Caution/Monitor.\ncomment:allopurinol may increase potential for allergic or hypersensitivity reactions to amoxicillin.', '2019-11-11 14:06:54', '2019-11-11 14:06:54'),
(293, 12, 'Monitor Closely', 15, 'either increases levels of the other by plasma protein binding competition.Use Caution/Monitor.', '2019-11-11 14:08:21', '2019-11-11 14:08:21'),
(294, 12, 'Monitor Closely', 15, 'either increases levels of the other by decreasing renal clearance.Use Caution/Monitor.', '2019-11-11 14:09:07', '2019-11-11 14:09:07'),
(295, 12, 'Monitor Closely', 101, 'either increases levels of the other by decreasing renal clearance.Use Caution/Monitor.', '2019-11-11 14:13:03', '2019-11-11 14:13:03'),
(296, 12, 'Monitor Closely', 185, 'either increases levels of the other by plasma protein binding competition.Use Caution/Monitor.', '2019-11-11 14:18:43', '2019-11-11 14:18:43'),
(297, 12, 'Monitor Closely', 185, 'either increases levels of the other by decreasing renal clearance.Use Caution/Monitor.', '2019-11-11 14:19:23', '2019-11-11 14:19:23'),
(298, 12, 'Monitor Closely', 206, 'amoxicillin increases effects of warfarin by other(see comment). Use Caution/Monitor.\ncomment:amoxicillin may enhance anticoagulant effect of vitamin K antagonists', '2019-11-11 14:22:24', '2019-11-11 14:22:24'),
(299, 12, 'Minor', 22, 'azithromycin decreases effects of amoxicillin by pharmacodynamic antagonism.Minor/Significance Unknown.', '2019-11-11 14:25:46', '2019-11-11 14:25:46'),
(300, 12, 'Minor', 44, 'chloramphenicol decreases effects of amoxicillin by pharmacodynamic antagonism.Minor/Significance Unknown.', '2019-11-11 14:27:10', '2019-11-11 14:27:10'),
(301, 12, 'Minor', 49, 'clarithromycin decreases effects of amoxicillin by pharmacodynamic antagonism.Minor/Significance Unknown.', '2019-11-11 14:27:57', '2019-11-11 14:27:57'),
(302, 12, 'Minor', 80, 'erythromycin stearate decreases effects of amoxicillin by pharmacodynamic antagonism.Minor/Significance Unknown.', '2019-11-11 14:29:41', '2019-11-11 14:29:41'),
(303, 13, 'Serious - Use Alternative', 76, 'doxycycline decreases effects of ampicillin by pharmacodynamic antagonism.Avoid or Use Alternative Drug.tetracyclines may interfere with the bactericidal action of penicillins if concomitantly used with a tetracycline.', '2019-11-11 14:36:25', '2019-11-11 14:36:25'),
(304, 13, 'Monitor Closely', 15, 'either increases levels of the other by plasma protein binding competition.Use Caution/Monitor.', '2019-11-11 14:40:53', '2019-11-11 14:40:53'),
(305, 13, 'Monitor Closely', 105, 'ibuprofen will decrease the level or effect of ampicillin by increasing gastric pH.applies only to oral form of both agents.Use Caution/Monitor.', '2019-11-11 14:46:16', '2019-11-11 14:46:16'),
(306, 13, 'Monitor Closely', 146, 'omeprazole will decrease the level or effect of ampicillin by increasing gastric pH.applies only to oral form of both agents.Use Caution/Monitor.', '2019-11-11 14:48:34', '2019-11-11 14:48:34'),
(307, 13, 'Monitor Closely', 183, 'ampicillin increases effects of spironolactone by unspecified interaction mechanism.Use Caution/Monitor.hyperkalemia', '2019-11-11 14:52:59', '2019-11-11 14:52:59'),
(308, 13, 'Monitor Closely', 185, 'either increases levels of the other by plasma protein binding competition.Use Caution/Monitor.', '2019-11-11 14:55:20', '2019-11-11 14:55:20'),
(309, 13, 'Monitor Closely', 185, 'either increases levels of the other by decreasing renal clearance.Use Caution/Monitor.', '2019-11-11 14:56:19', '2019-11-11 14:56:19'),
(310, 13, 'Monitor Closely', 206, 'ampicillin increases effects of warfarin by other(see comment) .Use Caution/Monitor.\ncomment:decr vitamin K-producing intestinal flora may increase INR after a few days', '2019-11-11 14:58:49', '2019-11-11 14:58:49'),
(311, 13, 'Minor', 6, 'mechanism:unknown.Minor/Significance Unknown.increased incidence of rash.', '2019-11-11 15:00:24', '2019-11-11 15:00:24'),
(312, 13, 'Minor', 17, 'ampicillin decreases levels of atenolol by inhibition of GI absorption.applies only to oral form of both agents.Minor/Significance Unknown.', '2019-11-11 15:02:56', '2019-11-11 15:02:56'),
(313, 13, 'Minor', 22, 'azithromycin decreases effects of ampicillinl by  pharmacodynamic antagonism.Minor/Significance Unknown.', '2019-11-11 15:04:47', '2019-11-11 15:04:47'),
(314, 13, 'Minor', 44, 'chloramphenicol decreases effects of ampicillinl by  pharmacodynamic antagonism.Minor/Significance Unknown.', '2019-11-11 15:05:47', '2019-11-11 15:05:47'),
(315, 13, 'Minor', 49, 'clarithromycin decreases effects of ampicillinl by  pharmacodynamic antagonism.Minor/Significance Unknown.', '2019-11-11 15:07:02', '2019-11-11 15:07:02'),
(316, 13, 'Minor', 80, 'erythromycin sterate decreases effects of ampicillinl by  pharmacodynamic antagonism.Minor/Significance Unknown.', '2019-11-11 15:08:03', '2019-11-11 15:08:03'),
(317, 13, 'Minor', 101, 'hydrochlorothiazide increases levels of ampicillin by decreasing renal clearance.Minor/Significance Unknown.', '2019-11-11 15:10:37', '2019-11-11 15:10:37'),
(318, 14, 'Monitor Closely', 204, 'asparaginase increases levels of vincristine by unknown mechanism. Use Caution/Monitor.administration of asparaginase concurrently or prior to vincristine may result in decreased hepatic metabolism of vincristine and cause additive neurotoxicity.administration of asparaginase after  vincristine may lessen this effect; vincristine should be given 12-24 hours prior to L-asparaginase', '2019-11-11 15:24:06', '2019-11-11 15:24:06'),
(320, 15, 'Serious - Use Alternative', 37, 'aspirin,captopril.pharmacodynamic antagonism.Avoid or Use Alternative Drug.coadministration may result in a significant decrease in renal function.NSAIDs may diminish the antihypertensive effect of ACE inhibitors.the mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins', '2019-11-11 15:34:49', '2019-11-11 15:34:49'),
(321, 15, 'Serious - Use Alternative', 105, 'ibuprofen increases toxicity of aspirin by anticoagulation.Avoid or Use Alternative Drug.increases risk of bleeding', '2019-11-11 15:37:29', '2019-11-11 15:37:29'),
(322, 15, 'Monitor Closely', 2, 'either increases levels of the other by other(see comment). Use Caution/Monitor.\ncomment:carbonic anhydrase inhibitors(CAIs) and salicylates inhibit each other\'s renal tubular secretion,resulting in increased plasma levels.CAIs also shift salicylates from plasma to the CNS,leading to potential neurotoxicity.', '2019-11-11 16:18:03', '2019-11-11 16:18:03'),
(323, 15, 'Monitor Closely', 2, 'mechanism:passive renal tubular reabsorption due to increased pH.Use Caution/Monitor.salicylate levels increased at moderate doses;risk of CNS toxicity.salicylate levels decreased at large doses(d/t increased renal excretion of unchanged salicylate acid).', '2019-11-11 16:22:57', '2019-11-11 16:22:57'),
(324, 15, 'Monitor Closely', 12, 'either increases levels of the other by plasma protein binding competition.Use Caution/Monitor.', '2019-11-11 16:25:13', '2019-11-11 16:25:13'),
(325, 15, 'Monitor Closely', 12, 'either increases levels of the other by decreasing renal clearance.Use Caution/Monitor.', '2019-11-11 16:25:52', '2019-11-11 16:25:52'),
(326, 15, 'Monitor Closely', 17, 'atenolol and aspirin both increase serum potassium.Use Caution/Monitor.', '2019-11-11 16:28:04', '2019-11-11 16:28:04'),
(327, 15, 'Monitor Closely', 17, 'aspirin decreases effects of atenolol by pharmacodynamic antagonism.Use Caution/Monitor.long term(>1 wk) NSAID use.NSAIDs decrease prostaglandin synthesis.', '2019-11-11 16:31:19', '2019-11-11 16:31:19'),
(328, 15, 'Monitor Closely', 37, 'either increases toxicity of the other by other(see comment). Use Caution/Monitor.\ncomment:may result in renal function deterioration,particularly with high dose aspirin,elderly or volume depleted individuals.', '2019-11-11 17:22:05', '2019-11-11 17:22:05'),
(329, 15, 'Monitor Closely', 47, 'aspirin decreases levels of ciprofloxacin by other(see comment). Use Caution/Monitor.\ncomment:buffered aspirin may decrease absorption of quinolones.consider administrating 2hr before or 6hr after,buffered aspirin administration', '2019-11-11 17:27:46', '2019-11-11 17:27:46'),
(330, 15, 'Monitor Closely', 69, 'aspirin and digoxin both increase serum potassium.Use Caution/Monitor.', '2019-11-11 17:32:36', '2019-11-11 17:32:36'),
(331, 15, 'Monitor Closely', 71, 'aspirin increases and dobutamine decreases serum potassium.effect of interaction is not clear ,use caution.Use Caution/Monitor.', '2019-11-11 17:35:12', '2019-11-11 17:35:12'),
(332, 15, 'Monitor Closely', 92, 'either increases toxicity of the other by pharmacodynamic synergism.Use Caution/Monitor. increased risk of upper GI bleeding.SSRIs inhib.serotonin uptake by platelets.', '2019-11-11 17:42:29', '2019-11-11 17:42:29'),
(333, 15, 'Monitor Closely', 95, 'aspirin increases and furosemide decreases serum potassium.effect interaction is not clear,use caution.Use Caution/Monitor.', '2019-11-12 19:30:13', '2019-11-12 19:30:13'),
(336, 15, 'Monitor Closely', 98, 'griseofulvin decreases levels of aspirin by unknown mechanism.Use Caution/Monitor.', '2019-11-12 19:35:09', '2019-11-12 19:35:09'),
(335, 15, 'Monitor Closely', 97, 'aspirin increases effects of glimepiride by unknown mechanism.Use Caution/Monitor.Risk of hypoglyceima', '2019-11-12 19:33:35', '2019-11-12 19:33:35'),
(337, 15, 'Monitor Closely', 101, 'aspirin increases and hydrochlorothiazide decreases serum potassium.effect of interaction is not clear,use caution.Use Caution/Monitor.', '2019-11-12 19:38:01', '2019-11-12 19:38:01'),
(338, 15, 'Monitor Closely', 102, 'either increases toxicity of the other by pharmacodynamic synergism.Use Caution/Monitor.increased risk of GI ulceration.', '2019-11-12 19:39:42', '2019-11-12 19:39:42'),
(339, 15, 'Monitor Closely', 105, 'aspirin and ibuprofen both increase anticoagulation.Use Caution/Monitor.', '2019-11-12 19:41:06', '2019-11-12 19:41:06'),
(340, 15, 'Monitor Closely', 105, 'aspirin and ibuprofen both increase serum potassium.Use Caution/Monitor.', '2019-11-12 19:41:35', '2019-11-12 19:41:35'),
(341, 15, 'Monitor Closely', 107, 'aspirin and indomethacin both increase anticoagulation .Use Caution/Monitor.', '2019-11-12 19:43:11', '2019-11-12 19:43:11'),
(342, 15, 'Monitor Closely', 107, 'aspirin and indomethacin both increase serum potassium .Use Caution/Monitor.', '2019-11-12 19:43:41', '2019-11-12 19:43:41'),
(343, 15, 'Monitor Closely', 111, 'aspirin and labetalol both increase serum potassium .Use Caution/Monitor.', '2019-11-12 19:44:53', '2019-11-12 19:44:53'),
(344, 15, 'Monitor Closely', 111, 'aspirin decreases effects of labetalol by pharmacodynamic antagonism.Use Caution/Monitor.long term(>1 wk) NSAID use.NSAIDs decrease prostaglandin synthesis.', '2019-11-12 19:46:26', '2019-11-12 19:46:26'),
(345, 15, 'Monitor Closely', 129, 'either increases toxicity of the other by pharmacodynamic synergism.Use Caution/Monitor.increased risk of GI ulceration.', '2019-11-12 19:50:49', '2019-11-12 19:50:49'),
(346, 15, 'Monitor Closely', 136, 'aspirin and naproxen both increase anticoagulation.Use Caution/Monitor', '2019-11-12 19:53:20', '2019-11-12 19:53:20'),
(347, 15, 'Monitor Closely', 136, 'aspirin and naproxen both increase serum potassium.Use Caution/Monitor', '2019-11-12 19:54:38', '2019-11-12 19:54:38'),
(348, 15, 'Monitor Closely', 163, 'either increases toxicity of the other by pharmacodynamic synergism.Use Caution/Monitor.increased risk of GI ulceration.', '2019-11-12 20:05:02', '2019-11-12 20:05:02'),
(349, 15, 'Monitor Closely', 183, 'aspirin and spironolactone both increase serum potassium.Modify Therapy/Monitor Closely.', '2019-11-12 20:09:33', '2019-11-12 20:09:33'),
(350, 15, 'Monitor Closely', 183, 'aspirin decreases effects of spironolactone by unspecified interaction mechanism. Use Caution/Monitor. When used to concomitantly, spironolactone dose may need to be titrated to higher maintenance dose and the patient should be observed closely to determine if the desired effect is obtained.', '2019-11-12 20:13:44', '2019-11-12 20:13:44'),
(351, 15, 'Monitor Closely', 185, 'aspirin and sulfasalazine both increase anticoagulation. Use Caution/Monitor.', '2019-11-12 20:16:05', '2019-11-12 20:16:05'),
(352, 15, 'Monitor Closely', 191, 'aspirin increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.', '2019-11-12 20:18:18', '2019-11-12 20:18:18'),
(353, 15, 'Monitor Closely', 200, 'aspirin increases levels of valproic acid by plasma protein binding competition.Use Caution/Monitor.', '2019-11-12 20:22:53', '2019-11-12 20:22:53'),
(354, 15, 'Monitor Closely', 206, 'warfarin and aspirin both increase anticoagulation.Modify Therapy/Monitor Closely.the need for simultaneous use of low-dose aspirin and warfarin are common for patients with cardiovascular disease;monitor closely.', '2019-11-12 20:26:39', '2019-11-12 20:26:39'),
(355, 15, 'Minor', 4, 'aspirin will increase the level or effect of acyclovir by acidic(anionic) drug competition for renal tubular clearance.Minor/Significance Unknown.', '2019-11-12 20:29:23', '2019-11-12 20:29:23'),
(356, 15, 'Minor', 40, 'ceftazidime will increase the level or effect of aspirin by acidic(anionic) drug competition for renal tubular clearance.Minor/Significance Unknown.', '2019-11-12 20:34:17', '2019-11-12 20:34:17'),
(357, 15, 'Minor', 95, 'aspirin decreases effects of furosemide by pharmacodynamic antagonism.Minor/Significance Unknown.NSAIDs decrease prostaglandin synthesis.', '2019-11-12 20:52:03', '2019-11-12 20:52:03'),
(358, 15, 'Minor', 97, 'aspirin increases levels of glimepiride by plasma protein binding competition.Minor/Significance Unknown.Large dose of salicylate.', '2019-11-12 20:54:27', '2019-11-12 20:54:27'),
(359, 15, 'Minor', 101, 'hydrochlorothiazide will increase the level or effect of aspirin by acidic(anionic) drug competition for renal tubular clearance.Minor/Significance Unknown.', '2019-11-12 20:56:02', '2019-11-12 20:56:02'),
(360, 15, 'Minor', 102, 'hydrocortisone decreases levels of aspirin by increasing renal clearance.Minor/Significance Unknown.', '2019-11-12 20:57:40', '2019-11-12 20:57:40'),
(361, 15, 'Minor', 105, 'aspirin will increase the level or effect of ibuprofen by acidic(anionic) drug competition for renal tubular clearance.Minor/Significance Unknown.', '2019-11-12 20:59:27', '2019-11-12 20:59:27'),
(362, 15, 'Minor', 107, 'aspirin will increase the level or effect of indomethacin by acidic(anionic) drug competition for renal tubular clearance.Minor/Significance Unknown.', '2019-11-12 21:00:10', '2019-11-12 21:00:10'),
(363, 15, 'Minor', 129, 'methylprednisolone decreases levels of aspirin by increasing renal clearance.Minor/Significance Unknown.', '2019-11-12 21:02:14', '2019-11-12 21:02:14'),
(364, 15, 'Minor', 136, 'aspirin will increase the level or effect of naproxen by acidic(anionic) drug competition for renal tubular clearance.Minor/Significance Unknown.', '2019-11-12 21:03:25', '2019-11-12 21:03:25'),
(365, 15, 'Minor', 145, 'comment:risk of CNS stimulation/seizure.\nmechanism:displacement of GABA from receptors in brain.', '2019-11-12 21:05:30', '2019-11-12 21:05:30'),
(366, 15, 'Minor', 163, 'prednisolone decreases levels of aspirin by increasing renal clearance.Minor/Significance Unknown.', '2019-11-12 21:11:06', '2019-11-12 21:11:06'),
(367, 15, 'Minor', 185, 'aspirin will increase the level or effect of sulfasalazine by acidic(anionic) drug competition for renal tubular clearance.Minor/Significance Unknown.', '2019-11-12 21:38:35', '2019-11-12 21:38:35'),
(368, 15, 'Minor', 202, 'verapamil increase effects of aspirin by unknown mechanism.Minor/Significance Unknown.enhanced antiplatelet activity.', '2019-11-12 22:55:51', '2019-11-12 22:55:51'),
(369, 16, 'Contraindicated', 38, 'carbamazepine will decrease the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Contraindicated.', '2019-11-12 23:02:42', '2019-11-12 23:02:42'),
(370, 16, 'Contraindicated', 80, 'atazanavir will increase the level or effect of erythromycin stearate by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Contraindicated.', '2019-11-12 23:07:00', '2019-11-12 23:07:00'),
(371, 16, 'Contraindicated', 132, 'atazanavir will increase the levels of midazoalm by decreasing metaboism .Contraindicated.', '2019-11-12 23:10:07', '2019-11-12 23:10:07'),
(372, 16, 'Contraindicated', 159, 'phenytoin will decrease the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Contraindicated.', '2019-11-12 23:11:58', '2019-11-12 23:11:58'),
(373, 16, 'Contraindicated', 181, 'atazanavir will increase the level or effect of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Contraindicated.\ncontraindicated.increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure', '2019-11-12 23:25:20', '2019-11-12 23:25:20'),
(374, 16, 'Serious - Use Alternative', 9, 'atazanavir will increase the level or effect of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.', '2019-11-12 23:30:05', '2019-11-12 23:30:05'),
(375, 16, 'Serious - Use Alternative', 15, 'aspirin will decrease the level or effect of ataznavir by increasing gastric pH.applies only to oral form of both agents.Avoid or Use Alternative Drug.atazanavir solubility decreases as pH increases.reduced plasma concentrations of atazanavir are expected if antacids or buffered medications are coadministered.administer atazanavir 2 hr before or 1 hr after these medications.', '2019-11-12 23:48:41', '2019-11-12 23:48:41'),
(376, 16, 'Serious - Use Alternative', 56, 'atazanavir will increase the level or effect of colchicine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.Avoid use of colchicine with strong CYP3A4 inhibitors.if coadministration is necessary,decrease colchicine dose or frequency as recommended in prescribing information.use of any colchicine product in conjunction with strong CYP3A4 inhibitors is contraindicated in patients with renal or hepatic impairment.', '2019-11-14 17:06:18', '2019-11-14 17:06:18'),
(377, 16, 'Serious - Use Alternative', 87, 'famotidine will decrease the level or effect of ataznavir by increasing gastric pH.applies only to oral form of both agents.Avoid or Use Alternative Drug.atazanavir solubility decreases as pH increases.substantially reduced plasma concentrations of atazanavir are expected if H2 receptor antagonists (H2RA) are coadministered.for treatment-naive patients,take atazanavir simultaneously with the H2RA or at least 10 h afterward.see dosage adjustment recommendations if coadministered in treatment experienced patients.', '2019-11-14 17:19:30', '2019-11-14 17:19:30'),
(378, 16, 'Serious - Use Alternative', 88, 'atazanavir will increase the  level or effect of fantanyl affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.if coadministration of CYP3A4 inhibitors with fentanyl is necessary,monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.', '2019-11-14 17:35:54', '2019-11-14 17:35:54'),
(379, 16, 'Serious - Use Alternative', 105, 'ibuprofen will decrease the level or effect of ataznavir by increasing gastric pH.applies only to oral form of both agents.Avoid or Use Alternative Drug.atazanavir solubility decreases as pH increases.substantially reduced plasma concentrations of atazanavir are expected if H2 receptor antagonists (H2RA) are coadministered.for treatment-naive patients,take atazanavir simultaneously with the H2RA or at least 10 h afterward.see dosage adjustment recommendations if coadministered in treatment experienced patients.', '2019-11-14 17:39:41', '2019-11-14 17:39:41'),
(380, 16, 'Serious - Use Alternative', 146, 'ibuprofen will decrease the level or effect of ataznavir by increasing gastric pH.applies only to oral form of both agents.Avoid or Use Alternative Drug.atazanavir solubility decreases as pH increases.substantially reduced plasma concentrations of atazanavir are expected if PPIs are coadministered.PPI dose should not exceed a dose comparable to omeprazole 20 mg and must be taken~12 h before atazanavir/ritronvir in treatment naive patients.PPIs are not recommended in treatment-experienced taking atazanavir.', '2019-11-14 17:59:42', '2019-11-14 17:59:42'),
(381, 16, 'Monitor Closely', 1, 'atazanavir and abacavir both increase risk of immune reconstitution syndrome.Use Caution/Monitor.', '2019-11-14 18:06:52', '2019-11-14 18:06:52'),
(382, 16, 'Monitor Closely', 10, 'atazanavir will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 18:10:36', '2019-11-14 18:10:36'),
(383, 16, 'Monitor Closely', 10, 'atazanavir increases the levels of amitriptyline by unspecified interaction mechanism.Use Caution/Monitor.', '2019-11-14 18:11:58', '2019-11-14 18:11:58'),
(384, 16, 'Monitor Closely', 17, 'atazanavir increases effects of atenolol by pharmacodynamic synergism.Use Caution/Monitor.increased risk of hypotension,bradycardia,AV block, and prolonged PR interval.consider lowering beta blocker dose.', '2019-11-14 18:17:19', '2019-11-14 18:17:19'),
(385, 16, 'Monitor Closely', 18, 'atazanavir will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor', '2019-11-14 18:19:04', '2019-11-14 18:19:04'),
(386, 16, 'Monitor Closely', 32, 'atazanavir increases levels of bromocriptine by decreasing metabolism.Use Caution/Monitor', '2019-11-14 18:21:44', '2019-11-14 18:21:44'),
(387, 16, 'Monitor Closely', 38, 'atazanavir will increase the level or effect of carbamazepine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.Monitor plasma levels when used concomitantly.', '2019-11-14 18:24:51', '2019-11-14 18:24:51'),
(388, 16, 'Monitor Closely', 49, 'clarithromycin will increase the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 18:27:08', '2019-11-14 18:27:08'),
(389, 16, 'Monitor Closely', 52, 'atazanavir will increases levels of clonazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Modify Therapy/Monitor Closely.potential for increased toxicity.use alternatives if available.consider lowering benzodiazepine dose.', '2019-11-14 18:31:20', '2019-11-14 18:31:20'),
(390, 16, 'Monitor Closely', 62, 'atazanavir will increase the level or effect of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 18:35:30', '2019-11-14 18:35:30'),
(391, 16, 'Monitor Closely', 62, 'atazanavir and darunavir both increase risk of immune reconstitution syndrome.Use Caution/Monitor.', '2019-11-14 18:37:25', '2019-11-14 18:37:25'),
(392, 16, 'Monitor Closely', 66, 'atazanavir will increases levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Modify Therapy/Monitor Closely.potential for increased toxicity.use alternatives if available.consider lowering benzodiazepine dose.', '2019-11-14 18:40:24', '2019-11-14 18:40:24'),
(393, 16, 'Monitor Closely', 69, 'atazanavir increases effects of digoxin by pharmacodynamic synergism.Use Caution/Monitor.increased risk of AV block.', '2019-11-14 18:43:51', '2019-11-14 18:43:51'),
(394, 16, 'Monitor Closely', 77, 'atazanavir and efavirenz both increase risk of immune reconstitution syndrome.Use Caution/Monitor', '2019-11-14 18:47:09', '2019-11-14 18:47:09'),
(395, 16, 'Monitor Closely', 80, 'erythromycin stearate  will increase the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 18:53:31', '2019-11-14 18:53:31'),
(396, 16, 'Monitor Closely', 83, 'atazanavir will increases levels of ethosuximide by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.potential for increased toxicity.', '2019-11-14 18:56:47', '2019-11-14 18:56:47'),
(397, 16, 'Monitor Closely', 84, 'atazanavir will increases levels of etoposide by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 18:58:17', '2019-11-14 18:58:17'),
(398, 16, 'Monitor Closely', 85, 'atazanavir will increases levels of etravirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 18:59:53', '2019-11-14 18:59:53'),
(399, 16, 'Monitor Closely', 97, 'atazanavir decreases effects of glimepiride by other(see comment).Use Caution/Monitor.\ncomment:reports of hyperglycemia due to insulin resistance with protease inhibitors.', '2019-11-14 19:05:12', '2019-11-14 19:05:12'),
(400, 16, 'Monitor Closely', 102, 'atazanavir will increase the level or effect of hydrocortisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 19:06:56', '2019-11-14 19:06:56'),
(401, 16, 'Monitor Closely', 108, 'isoniazid will increase the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 19:08:33', '2019-11-14 19:08:33'),
(402, 16, 'Monitor Closely', 110, 'ketoconazole will increase the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 19:10:11', '2019-11-14 19:10:11'),
(403, 16, 'Monitor Closely', 111, 'atazanavir increases effects of labetalol by pharmacodynamic synergism.Use Caution/Monitor.increased risk of hypotension,bradycardia,AV block,and prolonged PR interval.consider lowering beta blocker dose.', '2019-11-14 19:14:13', '2019-11-14 19:14:13'),
(404, 16, 'Monitor Closely', 119, 'atazanavir will increase the level or effect of lopinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor', '2019-11-14 19:16:18', '2019-11-14 19:16:18'),
(405, 16, 'Monitor Closely', 129, 'atazanavir will increase the level or effect of methylprednisolone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor', '2019-11-14 19:21:21', '2019-11-14 19:21:21'),
(406, 16, 'Monitor Closely', 132, 'atazanavir will increase the level or effect of midazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor', '2019-11-14 19:21:54', '2019-11-14 19:21:54'),
(407, 16, 'Monitor Closely', 140, 'atazanavir and nevirapine both increase risk of immune reconstitution syndrome.Use Caution/Monitor', '2019-11-14 19:25:03', '2019-11-14 19:25:03'),
(408, 16, 'Monitor Closely', 177, 'atazanavir will increase the level or the effect of ombitasvir/paritaprevir/ritonavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Modify Therapy/Monitor Closely.increased levels of paritaprevir when coadministered with atazanavir/ritonavir;give atazanavir 300mg (without ritonavir) in the morning when coadministered with Technivine', '2019-11-14 19:35:38', '2019-11-14 19:35:38'),
(409, 16, 'Monitor Closely', 163, 'atazanavir will increase the level or effect of prednisolone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 19:38:19', '2019-11-14 19:38:19'),
(410, 16, 'Monitor Closely', 173, 'atazanavir will increase the level or effect of quinidine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 19:39:20', '2019-11-14 19:39:20'),
(411, 16, 'Monitor Closely', 177, 'atazanavir will increase the level or effect of ritonavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 19:40:31', '2019-11-14 19:40:31'),
(412, 16, 'Monitor Closely', 177, 'atazanavir and ritonavir both increase risk of immune reconstitution syndrome.Use Caution/Monitor.', '2019-11-14 19:41:47', '2019-11-14 19:41:47'),
(413, 16, 'Monitor Closely', 197, 'atazanavir will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 19:45:13', '2019-11-14 19:45:13'),
(414, 16, 'Monitor Closely', 198, 'atazanavir increases levels of tramadol by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.potential for increased toxicity.', '2019-11-14 19:47:27', '2019-11-14 19:47:27'),
(415, 16, 'Monitor Closely', 202, 'atazanavir will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 19:50:39', '2019-11-14 19:50:39'),
(416, 16, 'Monitor Closely', 202, 'verapamil will increase the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.Caution advised,may increase risk of AV block.', '2019-11-14 19:52:30', '2019-11-14 19:52:30'),
(417, 16, 'Monitor Closely', 206, 'atazanavir will increase the level or effect of warfarin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-14 19:53:41', '2019-11-14 19:53:41'),
(418, 16, 'Monitor Closely', 209, 'atazanavir and zidovudine both increase risk of immune reconstitution syndrome.Use Caution/Monitor', '2019-11-14 19:54:54', '2019-11-14 19:54:54'),
(419, 16, 'Minor', 11, 'atazanavir will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 19:57:15', '2019-11-14 19:57:15'),
(420, 16, 'Minor', 49, 'atazanavir will increase the level or effect of clarithromycin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 19:59:20', '2019-11-14 19:59:20'),
(421, 16, 'Minor', 61, 'atazanavir will increase the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:00:35', '2019-11-14 20:00:35'),
(422, 16, 'Minor', 62, 'farunavir will increase the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:02:22', '2019-11-14 20:02:22'),
(423, 16, 'Minor', 72, 'atazanavir will increase the level or effect of docetaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:04:09', '2019-11-14 20:04:09'),
(424, 16, 'Minor', 77, 'atazanavir will increase the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:05:06', '2019-11-14 20:05:06'),
(425, 16, 'Minor', 77, 'efavirenz decreases levels of atazanavir by unspecified interaction mechanism.Minor/Significance Unknown.may be coadministered;see atazanavir monograph for dosing info.', '2019-11-14 20:08:48', '2019-11-14 20:08:48'),
(426, 16, 'Minor', 85, 'etravirine will decrease the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.packaging labeling statetes that etravirin and atazanavir/ritonavir can be coadministered without dose adjustments.decrease in atazanavir not clinically relevant when all three drugs are used.', '2019-11-14 20:15:53', '2019-11-14 20:15:53'),
(427, 16, 'Minor', 85, 'etravirine will decrease the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.packaging labeling states that etravirine and atazanavir/ritonavir can be coadministered without dose adjustments.decrease in atazanavir not clinically relevant when all three drugs are used.', '2019-11-14 20:17:36', '2019-11-14 20:17:36'),
(428, 16, 'Minor', 90, 'fluconazole will increase the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:19:50', '2019-11-14 20:19:50'),
(429, 16, 'Minor', 98, 'griseofulvin will decrease the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:21:22', '2019-11-14 20:21:22'),
(430, 16, 'Minor', 102, 'hydrocortisone will decrease the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:22:11', '2019-11-14 20:22:11'),
(431, 16, 'Minor', 110, 'atazanavir will increase the level or effect of ketoconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:23:28', '2019-11-14 20:23:28'),
(432, 16, 'Minor', 129, 'methylprednisolone will decrease the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:25:34', '2019-11-14 20:25:34'),
(433, 16, 'Minor', 131, 'metronidazole will increase the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:26:16', '2019-11-14 20:26:16'),
(434, 16, 'Minor', 140, 'nevirapine will decrease the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:27:22', '2019-11-14 20:27:22'),
(435, 16, 'Minor', 141, 'atazanavir will increase the level or effect of nifedipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:28:12', '2019-11-14 20:28:12'),
(436, 16, 'Minor', 141, 'nifedipine will increase the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:29:14', '2019-11-14 20:29:14'),
(437, 16, 'Minor', 163, 'prednisolone will decrease the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:31:18', '2019-11-14 20:31:18'),
(441, 16, 'Minor', 177, 'ritonavir will increase the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:34:41', '2019-11-14 20:34:41'),
(440, 16, 'Minor', 174, 'atazanavir will increase the level or effect of quinine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:33:41', '2019-11-14 20:33:41'),
(442, 16, 'Minor', 203, 'atazanavir will increase the level or effect of vinblastine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:36:11', '2019-11-14 20:36:11'),
(443, 16, 'Minor', 204, 'atazanavir will increase the level or effect of vincristine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:36:41', '2019-11-14 20:36:41'),
(444, 16, 'Minor', 205, 'atazanavir will increase the level or effect of vinorelbine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Minor/Significance Unknown.', '2019-11-14 20:37:21', '2019-11-14 20:37:21'),
(445, 17, 'Serious - Use Alternative', 69, 'either decrease toxicity of the other by unspecified interaction mechanism.Avoid or Use Alternative Drug.Can increase risk of bradycardia.', '2019-11-14 21:02:12', '2019-11-14 21:02:12'),
(446, 17, 'Serious - Use Alternative', 111, 'atenaolol and labetalol increase antihypertensive channel blocking.Avoid or Use Alternative Drug.', '2019-11-14 21:07:08', '2019-11-14 21:07:08'),
(447, 17, 'Serious - Use Alternative', 202, 'either increase toxicity of the other by unspecified interaction mechanism.Avoid or Use Alternative Drug.Can increase risk of bradycardia.', '2019-11-14 21:09:01', '2019-11-14 21:09:01'),
(452, 17, 'Monitor Closely', 15, 'aspirin and atenolol and aspirin both increase serum potassium.Use Caution/Monitor.', '2019-11-14 21:29:17', '2019-11-14 21:29:17'),
(451, 17, 'Monitor Closely', 9, 'mechanism:pharmacodynamic synergism.Use Caution/Monitor.Risk of cardiotoxicity with bradycardia.', '2019-11-14 21:25:11', '2019-11-14 21:25:11'),
(450, 17, 'Monitor Closely', 11, 'atenolol and amlodipine both increase antihypertensive channel blocking.Modify Therapy/Monitor Closely.', '2019-11-14 21:24:33', '2019-11-14 21:24:33'),
(453, 17, 'Monitor Closely', 15, 'aspirin decreases effects of atenolol by pharmacodynamic antagonism.Use Caution/Monitor.long term(>1 wk) NSAID use.NSAIDs decrease prostaglandin synthesis.', '2019-11-14 21:32:02', '2019-11-14 21:32:02'),
(454, 17, 'Monitor Closely', 111, 'atenolol and labetalol both increase serum potassium.Use Caution/Monitor', '2019-11-14 21:37:06', '2019-11-14 21:37:06'),
(455, 17, 'Monitor Closely', 113, 'levodopa increases effects of atenolol by pharmacodynamic synergism.Use Caution/Monitor.consider decreasing dosage of antihypertensive agent.', '2019-11-14 21:40:12', '2019-11-14 21:40:12'),
(456, 17, 'Monitor Closely', 136, 'atenolol and naproxen both increase serum potassium.Use Caution/Monitor', '2019-11-14 21:43:54', '2019-11-14 21:43:54'),
(457, 17, 'Monitor Closely', 136, 'naproxen decreases effects of atenolol by pharmacodynamic antagonism.Use Caution/Monitor.long term (>1 wk) NSAID use.NSAIDs decrease prostaglandin synthesis.', '2019-11-14 21:46:41', '2019-11-14 21:46:41'),
(458, 17, 'Monitor Closely', 141, 'atenolol and nefedipine both increase antihypertensive channel blocking.Modify Therapy/Monitor Closely.', '2019-11-14 21:47:42', '2019-11-14 21:47:42'),
(459, 17, 'Monitor Closely', 168, 'either increase effects of the other by pharmacodynamic synergism.Use Caution/Monitor.Risk of hypotension.', '2019-11-14 21:54:11', '2019-11-14 21:54:11'),
(460, 17, 'Monitor Closely', 183, 'atenolol and spironolactone both increase serum potassium.Modify Therapy/Monitor Closely.', '2019-11-14 21:57:05', '2019-11-14 21:57:05'),
(461, 17, 'Monitor Closely', 185, 'atenolol and sulfasalazine both increase serum potassium.Modify Therapy/Monitor Closely.', '2019-11-14 21:57:59', '2019-11-14 21:57:59'),
(462, 17, 'Monitor Closely', 185, 'sulfasalazine decreases effects of atenolol by pharmacodynamic antagonism.Use Caution/Monitor.long term (>1 wk) NSAID use.NSAIDs decrease prostaglandin synthesis', '2019-11-14 21:58:49', '2019-11-14 21:58:49'),
(463, 17, 'Monitor Closely', 191, 'atenolol increses and terbutaline decreases serum potassium.effect of interaction is not clear,use caution.Use Caution/Monitor.', '2019-11-14 22:01:25', '2019-11-14 22:01:25'),
(464, 17, 'Monitor Closely', 191, 'atenolol decreases effects of terbutaline by pharmacodynamic antagonism.Use Caution/Monitor.', '2019-11-14 22:02:57', '2019-11-14 22:02:57'),
(465, 17, 'Monitor Closely', 8, 'comment: beta blockers(esp.non selective) antagonize theophylline effects,while at the same time increasing theophylline levels and toxicity(mechanism:decreased theophylline metabolism ).smoking increases risk of interaction.', '2019-11-14 22:08:21', '2019-11-14 22:08:21'),
(466, 17, 'Monitor Closely', 202, 'atenolol and verapamil both increase antihypertensive channel blocking.Modify Therapy/Monitor Closely.', '2019-11-14 22:10:03', '2019-11-14 22:10:03'),
(467, 17, 'Minor', 139, 'either increase effects of the other by pharmacodynamic synergism.Minor/Significance Unknown.additive bradycardia.', '2019-11-14 22:18:55', '2019-11-14 22:18:55'),
(468, 17, 'Minor', 160, 'pilocarpine increases effects of atenolol by pharmacodynamic synergism.Minor/Significance Unknown.', '2019-11-14 22:21:44', '2019-11-14 22:21:44'),
(469, 18, 'Serious - Use Alternative', 38, 'carbamazepine will decrease the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.', '2019-11-14 22:28:22', '2019-11-14 22:28:22'),
(470, 18, 'Serious - Use Alternative', 49, 'clarithromycin will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug. do not exceed atorvastatin dose of 20 mg/day when coadministered with clarithromycin', '2019-11-14 22:31:17', '2019-11-14 22:31:17'),
(471, 18, 'Serious - Use Alternative', 49, 'clarithromycin will increase the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter.Avoid or Use Alternative Drug.do not exceed atorvastatin dose of 20mg/day when coadministered with clarithromycin', '2019-11-14 22:35:17', '2019-11-14 22:35:17'),
(472, 18, 'Serious - Use Alternative', 49, 'clarithromycin increases toxicity of atorvastatin by other (see comment).Avoid or Use Alternative Drug.\ncomment:OATP1B1 inhibitors may increase risk of myopathy', '2019-11-14 22:38:10', '2019-11-14 22:38:10'),
(473, 18, 'Serious - Use Alternative', 56, 'either increases toxicity of the other by pharmacodynamic synergism.Avoid or Use Alternative Drug.increased risk of rhabdomyolysis', '2019-11-14 22:40:27', '2019-11-14 22:40:27'),
(474, 18, 'Serious - Use Alternative', 80, 'erythromycin stearate will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug', '2019-11-15 18:15:09', '2019-11-15 18:15:09'),
(475, 18, 'Serious - Use Alternative', 80, 'erythromycin stearate increases toxicity of atorvastatin by other (see comment).Avoid or Use Alternative Drug. comment:OATP1B1 inhibitors may increase risk of myopathy', '2019-11-15 18:16:23', '2019-11-15 18:16:23'),
(476, 18, 'Serious - Use Alternative', 110, 'ketoconazole increases toxicity of atorvastatin by other (see comment).Avoid or Use Alternative Drug. comment:OATP1B1 inhibitors may increase risk of myopathy', '2019-11-15 18:18:32', '2019-11-15 18:18:32'),
(477, 18, 'Serious - Use Alternative', 110, 'ketoconazole will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug', '2019-11-15 18:19:32', '2019-11-15 18:19:32'),
(478, 18, 'Serious - Use Alternative', 119, 'lopinavir increases of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug. if coadministration cannot be avoided,limit atorvastatin dose to 20 mg/day and monitor for signs and symptoms of toxicity,including liver function tests abnormalities,myalgia and rhabdomyolysis.', '2019-11-15 18:25:50', '2019-11-15 18:25:50'),
(479, 18, 'Serious - Use Alternative', 173, 'quinidine will increase the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter.Avoid or Use Alternative Drug.', '2019-11-15 18:28:00', '2019-11-15 18:28:00'),
(480, 18, 'Serious - Use Alternative', 177, 'ritonavir increases toxicity of atorvastatin by other (see comment).Avoid or Use Alternative Drug. comment:OATP1B1 inhibitors may increase risk of myopathy', '2019-11-15 18:29:40', '2019-11-15 18:29:40'),
(481, 18, 'Monitor Closely', 9, 'amiodarone will increase the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor', '2019-11-15 18:31:42', '2019-11-15 18:31:42'),
(482, 18, 'Monitor Closely', 10, 'atorvastatin will increase the level or effect of amitriptyline  by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor', '2019-11-15 18:32:45', '2019-11-15 18:32:45'),
(483, 18, 'Monitor Closely', 16, 'atazanavir will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor', '2019-11-15 18:34:18', '2019-11-15 18:34:18'),
(484, 18, 'Monitor Closely', 22, 'azithromycin will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.if this combination is used,closely monitor for evidence of atorvastatin toxicity(eg,muscle aches or pains,renal dysfunction).', '2019-11-15 18:36:54', '2019-11-15 18:36:54'),
(485, 18, 'Monitor Closely', 38, 'carbamaazepine increases toxicity of atorvastatin by other (see comment).Use Caution/Monitor. comment:OATP1B1 inhibitors may increase risk of myopathy', '2019-11-15 18:39:31', '2019-11-15 18:39:31'),
(486, 18, 'Monitor Closely', 53, 'clotrimazole will decrease the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor', '2019-11-15 18:41:36', '2019-11-15 18:41:36'),
(487, 18, 'Monitor Closely', 53, 'clotrimazole increases toxicity of atorvastatin by other (see comment).Use Caution/Monitor. comment:OATP1B1 inhibitors may increase risk of myopathy', '2019-11-15 18:42:40', '2019-11-15 18:42:40'),
(488, 18, 'Monitor Closely', 62, 'darunavir will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Modify Therapy/Monitor Closely.for HMG-CoA reductase inhibitors that are not contraindicated with darunavir,dose should not exceed 20 mg/day.', '2019-11-15 18:49:03', '2019-11-15 18:49:03'),
(489, 18, 'Monitor Closely', 69, 'atorvastatin will increase the level or effect of digoxin by \nP-glycoprotein(MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-15 18:53:16', '2019-11-15 18:53:16'),
(490, 18, 'Monitor Closely', 72, 'atorvastatin will increase the level or effect of docetaxel by \nP-glycoprotein(MDR1) efflux transporter.Use Caution/Monitor.', '2019-11-15 18:54:02', '2019-11-15 18:54:02'),
(491, 18, 'Monitor Closely', 77, 'efavirenz will decrease the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2019-11-15 18:55:25', '2019-11-15 18:55:25'),
(492, 18, 'Monitor Closely', 80, 'erythromycin stearate will increase the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.', '2019-11-15 18:58:32', '2019-11-15 18:58:32');
INSERT INTO `interactions` (`id`, `drug_id`, `status`, `drug`, `description`, `created_at`, `updated_at`) VALUES
(493, 18, 'Monitor Closely', 84, 'etoposide will increase the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.', '2019-11-15 18:59:58', '2019-11-15 18:59:58'),
(494, 18, 'Monitor Closely', 85, 'etravirine will decrease the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.', '2019-11-15 19:01:45', '2019-11-15 19:01:45'),
(495, 18, 'Monitor Closely', 90, 'fluconazole will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.', '2019-11-15 19:10:33', '2019-11-15 19:10:33'),
(496, 18, 'Monitor Closely', 98, 'griseofulvin will decrease the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.', '2019-11-15 19:11:59', '2019-11-15 19:11:59'),
(497, 18, 'Monitor Closely', 102, 'hydrocortisone will decrease the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.', '2019-11-15 19:12:46', '2019-11-15 19:12:46'),
(498, 18, 'Monitor Closely', 102, 'atorvastatin will increase the level or effect of hydrocortisone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.', '2019-11-15 19:14:08', '2019-11-15 19:14:08'),
(499, 18, 'Monitor Closely', 108, 'isoniazid will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.', '2019-11-15 19:15:37', '2019-11-15 19:15:37'),
(500, 23, 'Monitor Closely', 95, 'belcomethasone, inhaled increases toxicity of furosemide by increasing elimination. Use Caution/Monitor. Corticosteroids may increase the hypkalemic effects of loop diuretics', '2020-03-20 14:57:51', '2020-03-20 14:57:51'),
(501, 23, 'Monitor Closely', 101, 'belcomethasone, inhaled increases toxicity of hydrochlorothiazide by increasing elimination. Use Caution/Monitor. Corticosteroids may increase the hypkalemic effects of loop diuretics', '2020-03-20 14:59:22', '2020-03-20 14:59:22'),
(502, 26, 'Serious - Use Alternative', 17, 'atenolol and betaxolol both increase anti-hypertensive channel blocking. Avoid or Use alternative drug.', '2020-03-20 15:04:54', '2020-03-20 15:04:54'),
(503, 26, 'Serious - Use Alternative', 69, 'digoxin and betaxolol . Either increase toxicity of the other by unspecified interaction mechanism. Avoid or use Alternative drug. Can increase risk of bradycardia.', '2020-03-20 15:07:11', '2020-03-20 15:07:11'),
(504, 26, 'Serious - Use Alternative', 111, 'betaxolol and labetalol both increase anti-hypertensive channel blocking. Avoid or Use alternative drug.', '2020-03-20 15:08:42', '2020-03-20 15:08:42'),
(505, 26, 'Serious - Use Alternative', 169, 'betaxolol and propranolol both increase anti-hypertensive channel blocking. Avoid or Use alternative drug.', '2020-03-20 15:10:10', '2020-03-20 15:10:10'),
(506, 26, 'Serious - Use Alternative', 196, 'betaxolol and timolol both increase anti-hypertensive channel blocking. Avoid or Use alternative drug.', '2020-03-20 15:10:54', '2020-03-20 15:10:54'),
(507, 26, 'Serious - Use Alternative', 202, 'betaxolol and timolol.  Either increase toxicity of the other by unspecified interaction mechanism. Avoid or use Alternative drug. Can increase risk of bradycardia.', '2020-03-20 15:11:49', '2020-03-20 15:11:49'),
(508, 30, 'Monitor Closely', 159, 'bleomycin decreases levels of phenytoin by increasing metabolism. Use caution/Monitor.', '2020-03-20 15:20:28', '2020-03-20 15:20:28'),
(509, 30, 'Monitor Closely', 189, 'bleomycin increases levels of tenofovir DF by decreasing renal clearance. Use caution/Monitor.', '2020-03-20 15:21:26', '2020-03-20 15:21:26'),
(510, 31, 'Contraindicated', 166, 'procarbazine, brimonidine, Contraindicated', '2020-03-20 15:24:35', '2020-03-20 15:24:35'),
(511, 31, 'Monitor Closely', 69, 'brimonidine increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor Closely.', '2020-03-20 15:26:37', '2020-03-20 15:26:37'),
(512, 31, 'Monitor Closely', 10, 'amitriptyline decreases effects of brimonidine  by pharmacodynamic antagonism. Minor.', '2020-03-20 15:30:51', '2020-03-20 15:30:51'),
(513, 31, 'Monitor Closely', 11, 'brimonidine increases effects of amlodipine by pharmacodynamic synergism. Minor', '2020-03-20 15:31:49', '2020-03-20 15:31:49'),
(514, 31, 'Monitor Closely', 17, 'brimonidine increases effects of atenolol by pharmacodynamic synergism. Minor', '2020-03-20 15:32:36', '2020-03-20 15:32:36'),
(515, 31, 'Monitor Closely', 26, 'brimonidine increases effects of betaxolol by pharmacodynamic synergism. Minor', '2020-03-20 15:33:30', '2020-03-20 15:33:30'),
(516, 31, 'Monitor Closely', 46, 'brimonidine increases effects of chlorpromazine by pharmacodynamic synergism. Minor. Increased CNS depression.', '2020-03-20 15:35:43', '2020-03-20 15:35:43'),
(517, 32, 'Contraindicated', 158, 'bromocriptine, phenylephrine PO. Mechanism: pharmacodymic synergism. Contraindicated. Additive vasospasm; risk of hypertension.', '2020-03-20 15:40:21', '2020-03-20 15:40:21'),
(518, 32, 'Contraindicated', 186, 'bromocriptine, sumatriptan. Either increase toxicity of the other by pharmacodynamic synergism. Contraindicated. Vasoconstrictive effects of triptans and bromocriptine may be additive. Drugs should not be used within 24h of one another.', '2020-03-20 15:43:35', '2020-03-20 15:43:35'),
(519, 32, 'Serious - Use Alternative', 46, 'chlorpromazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use alternative drug.', '2020-03-20 15:45:18', '2020-03-20 15:45:18'),
(520, 32, 'Serious - Use Alternative', 77, 'efavirenz increases levels of bromocriptine by decreasing metabolism. Avoid or Use alternative drug. Competitive inhibition of CYP3A4 might lead to vasospasm and ischemia.', '2020-03-20 15:47:36', '2020-03-20 15:47:36'),
(521, 32, 'Serious - Use Alternative', 93, 'fluphenazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use alternative drug.', '2020-03-20 15:48:46', '2020-03-20 15:48:46'),
(522, 32, 'Serious - Use Alternative', 99, 'haloperidol decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use alternative drug.', '2020-03-20 15:49:39', '2020-03-20 15:49:39'),
(524, 32, 'Serious - Use Alternative', 167, 'promethazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use alternative drug.', '2020-03-20 15:53:04', '2020-03-20 15:53:04'),
(525, 32, 'Serious - Use Alternative', 195, 'thioridazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use alternative drug.', '2020-03-20 15:53:47', '2020-03-20 15:53:47'),
(527, 32, 'Monitor Closely', 16, 'atazanavir increases levels of bromocriptine by decreasing metabolism. Use caution /Minor.', '2020-03-20 15:56:49', '2020-03-20 15:56:49'),
(529, 32, 'Monitor Closely', 37, 'captropil, bromocriptine. \nEither increase toxicity of the other by pharmacodynamic synergism.Use caution /Minor. Both drugs lower blood pressure. Monitor blood pressure.', '2020-03-20 15:59:55', '2020-03-20 15:59:55'),
(530, 32, 'Monitor Closely', 49, 'Clarithromycin increases levels of bromocriptine by decreasing metabolism. Use caution /Minor.', '2020-03-20 16:00:31', '2020-03-20 16:00:31'),
(531, 32, 'Monitor Closely', 71, 'bromocriptine, dobutamine. Either increase toxicity of the other by pharmacodynamic synergism.Use caution/Monitor. Hypertension, V tach.', '2020-03-20 16:02:47', '2020-03-20 16:02:47'),
(532, 32, 'Monitor Closely', 73, 'bromocriptine and dopamine both increase dopaminergic effects. Use Caution/Monitor', '2020-03-20 16:03:48', '2020-03-20 16:03:48'),
(533, 33, 'Monitor Closely', 37, 'bupivacaine, captopril. Either increase effects of the other by pharmacodynamic synergism. Use Caution/Monitor. both drugs lower blood pressure. Monitor blood pressure.', '2020-03-20 16:08:19', '2020-03-20 16:08:19'),
(534, 33, 'Monitor Closely', 140, 'nevirapine will decrease the level of or effect of bupivacaine by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Use Caution/Monitor.', '2020-03-20 16:10:02', '2020-03-20 16:10:02'),
(535, 33, 'Monitor Closely', 169, 'pharmacodynamic synergism. Use caution/Monitor.', '2020-03-20 16:11:10', '2020-03-20 16:11:10'),
(536, 33, 'Monitor Closely', 196, 'pharmacodynamic synergism. Use caution/Monitor.', '2020-03-20 16:11:43', '2020-03-20 16:11:43'),
(537, 34, 'Contraindicated', 166, 'increase effects of caffeine by pharmacodynamic synergism. Contraindicated. Caffeine ca produce severe hypertensive crises or dangerous cardiac arrhythmias if administered to patients taking a MAOI. All preparations containing caffeine should be used sparingly.', '2020-05-31 17:14:35', '2020-05-31 17:14:35'),
(538, 34, 'Monitor Closely', 10, 'amitriptyline increases caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor', '2020-05-31 17:16:44', '2020-05-31 17:16:44'),
(539, 34, 'Monitor Closely', 12, 'amoxapine increases caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor', '2020-05-31 17:17:29', '2020-05-31 17:17:29'),
(540, 34, 'Monitor Closely', 45, 'chlorpheniramine increases caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor', '2020-05-31 17:22:00', '2020-05-31 17:22:00'),
(541, 34, 'Monitor Closely', 47, 'Ciprofloxacin will increase the level or effect of caffeine by affecting hepatic enzyme CYP1A2 metabolism. Use caution/Monitor. The hepatic metabolism of caffeine may be decreased by ciprofloxacin; pharmacologic effects of caffeine may be increased.', '2020-05-31 17:27:25', '2020-05-31 17:27:25'),
(542, 34, 'Monitor Closely', 52, 'clonazepam increases caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor', '2020-05-31 17:28:48', '2020-05-31 17:28:48'),
(543, 34, 'Monitor Closely', 55, 'codeine increases caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor', '2020-05-31 17:29:30', '2020-05-31 17:29:30'),
(544, 34, 'Monitor Closely', 71, 'dobutamine increases caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor', '2020-05-31 17:32:59', '2020-05-31 17:32:59'),
(545, 34, 'Monitor Closely', 73, 'dopamine and caffeine both decrease sedation. Use Caution/Monitor', '2020-05-31 17:35:44', '2020-05-31 17:35:44'),
(546, 34, 'Monitor Closely', 79, 'epinephrine and caffeine both decrease sedation. Use Caution/Monitor', '2020-05-31 17:37:32', '2020-05-31 17:37:32'),
(551, 34, 'Monitor Closely', 93, 'fluphenazine and caffeine both decrease sedation. Use Caution/Monitor', '2020-05-31 23:49:54', '2020-05-31 23:49:54'),
(548, 34, 'Monitor Closely', 94, 'formoterol and caffeine both decrease sedation. Use Caution/Monitor', '2020-05-31 17:40:20', '2020-05-31 17:40:20'),
(549, 34, 'Monitor Closely', 99, 'haloperidol increases and caffeine decrease sedation. Use Caution/Monitor', '2020-05-31 17:42:35', '2020-05-31 17:42:35'),
(550, 34, 'Monitor Closely', 115, 'caffeine decreases level of levothyroxine by inhibition of GI absorbtion. Applies only to oral form of both agents. Use caution/Monitor.', '2020-05-31 17:45:16', '2020-05-31 17:45:16'),
(552, 35, 'Serious - Use Alternative', 206, 'capecitabine increases effects of warfarin by unspecified interaction mechanism. Avoid or Use alternative drug. Monitor INR and prothrombin time.', '2020-06-01 01:17:55', '2020-06-01 01:17:55'),
(553, 35, 'Monitor Closely', 7, 'aluminum hydroxide increases levels of capecitabine by enhancing GI absorbtion. Applies only to oral form of both agents. Use caution/Monitor.', '2020-06-01 01:19:41', '2020-06-01 01:19:41'),
(554, 35, 'Monitor Closely', 67, 'capecitabine will increase the level or effect of declofenac by affecting hepatic enzyme CYP2C9/10 methabolism. Use caution/Monitor. Do not exceed diclofenac dose of 50 mg BID.', '2020-06-01 01:22:30', '2020-06-01 01:22:30'),
(555, 35, 'Monitor Closely', 159, 'capecitabine will increase the level or effect of phenytoin by unknown mechanism. Use caution/Monitor. Based on case reports.', '2020-06-01 01:24:47', '2020-06-01 01:24:47'),
(556, 35, 'Monitor Closely', 171, 'capecitabine will increase the level or effect of protamine by unspecified mechanism. Use caution/Monitor.', '2020-06-01 01:25:34', '2020-06-01 01:25:34'),
(557, 36, 'Serious - Use Alternative', 19, 'capreomycin increases effects of atracurium by pharmacodynamic synergism. Avoid or use alternative drug. Risk of respiratory depression.', '2020-06-01 02:24:38', '2020-06-01 02:24:38'),
(558, 36, 'Serious - Use Alternative', 138, 'capreomycin and neomycin PO both increase nephrotoxicity and/or ototoxicity. Avoid or use alternative drug.', '2020-06-01 02:25:58', '2020-06-01 02:25:58'),
(559, 36, 'Serious - Use Alternative', 201, 'capreomycin increases effects of vecuronium by pharmacodynamic synergism. Avoid or use alternative drug. Risk of respiratory depression.', '2020-06-01 02:27:38', '2020-06-01 02:27:38'),
(560, 36, 'Monitor Closely', 4, 'capreomycin and acyclovir PO both increase nephrotoxicity and/or ototoxicity. Avoid or use alternative drug.', '2020-06-01 02:28:39', '2020-06-01 02:28:39'),
(561, 36, 'Monitor Closely', 48, 'capreomycin and cisplatin PO both increase nephrotoxicity and/or ototoxicity. Avoid or use alternative drug.', '2020-06-01 02:29:30', '2020-06-01 02:29:30'),
(562, 36, 'Monitor Closely', 96, 'capreomycin and gentamycin both increase nephrotoxicity and/or ototoxicity. Avoid or use alternative drug.', '2020-06-01 02:30:39', '2020-06-01 02:30:39'),
(563, 36, 'Monitor Closely', 189, 'capreomycin and tenofovir both increase nephrotoxicity and/or ototoxicity. Avoid or use alternative drug.', '2020-06-01 02:32:15', '2020-06-01 02:32:15'),
(564, 36, 'Monitor Closely', 152, 'capreomycin and paromomycin both increase nephrotoxicity and/or ototoxicity. Avoid or use alternative drug.', '2020-06-01 02:33:12', '2020-06-01 02:33:12'),
(565, 36, 'Monitor Closely', 154, 'capreomycin and pentamidine both increase nephrotoxicity and/or ototoxicity. Avoid or use alternative drug.', '2020-06-01 02:33:42', '2020-06-01 02:33:42'),
(566, 36, 'Monitor Closely', 184, 'capreomycin and streptomycin both increase nephrotoxicity and/or ototoxicity. Avoid or use alternative drug.', '2020-06-01 02:34:08', '2020-06-01 02:34:08'),
(567, 37, 'Serious - Use Alternative', 67, 'diclofenac, captopril. pharmacodynamic antagonism. Avoid or use alternative drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins.', '2020-06-01 02:41:08', '2020-06-01 02:41:08'),
(568, 37, 'Serious - Use Alternative', 105, 'ibuprofen, captopril. pharmacodynamic antagonism. Avoid or use alternative drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins.', '2020-06-01 02:42:39', '2020-06-01 02:42:39'),
(569, 37, 'Serious - Use Alternative', 107, 'indomethacin, captopril. pharmacodynamic antagonism. Avoid or use alternative drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins.', '2020-06-01 02:43:16', '2020-06-01 02:43:16'),
(570, 37, 'Serious - Use Alternative', 136, 'naproxen, captopril. pharmacodynamic antagonism. Avoid or use alternative drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins.', '2020-06-01 02:44:44', '2020-06-01 02:44:44'),
(571, 37, 'Monitor Closely', 47, 'captopril increases toxicity of ciprofloxacin by mechanism: unspecified interaction mechanism. Use caution/Monitor. ACE inhibitors increase arrhythmogenic potential of ciprofloxacin. Monitor ECG and QT interval.', '2020-06-01 02:53:02', '2020-06-01 02:53:02'),
(572, 37, 'Monitor Closely', 69, 'captopril increases levels of digoxin by unspecified interaction mechanism. Use caution/Monitor.', '2020-06-01 02:57:06', '2020-06-01 02:57:06'),
(573, 37, 'Monitor Closely', 105, 'captopril, ibuprofen. Either increases toxicity of the other by other. Use caution or monitor. Comment:- may result in renal function deterioration, particularly in elderly or volume depleted individuals.', '2020-06-01 03:42:34', '2020-06-01 03:42:34'),
(574, 37, 'Monitor Closely', 107, 'captopril, indomethacin. Either increases toxicity of the other by other. Use caution or monitor. Comment:- may result in renal function deterioration, particularly in elderly or volume depleted individuals.', '2020-06-01 03:43:21', '2020-06-01 03:43:21'),
(575, 37, 'Monitor Closely', 113, 'levodopa increases effects of captopril by pharmacodynamic synergism. Use caution/monitor. Considere decreasing dosage of antihypertensive agent.', '2020-06-01 03:45:47', '2020-06-01 03:45:47'),
(576, 37, 'Monitor Closely', 117, 'captopril increases toxicity of lithium by unknown mechanism. Use caution/monitor. ACE inhibitor induced Na+ depletion may increase reabsorbtion of lithium from renal tubule. Monitor lithium levels', '2020-06-01 03:48:01', '2020-06-01 03:48:01'),
(577, 37, 'Monitor Closely', 133, 'captopril, morphine. either increases effects of the others by pharmacodynamic synergism.Use Caution/Monitor.both drugs lower blood pressure.Monitor blood pressure.', '2020-06-01 03:50:45', '2020-06-01 03:50:45'),
(578, 37, 'Monitor Closely', 136, 'captopril, morphine. increases toxicity of the other by other. Use Caution/Monitor. comment:may result in renal function deterioration,particularly with high dose aspirin,elderly or volume depleted individuals.', '2020-06-01 03:52:18', '2020-06-01 03:52:18'),
(579, 37, 'Monitor Closely', 168, 'captopril, propofol. either increases effects of the others by pharmacodynamic synergism.Use Caution/Monitor.both drugs lower blood pressure.Monitor blood pressure.', '2020-06-01 03:54:52', '2020-06-01 03:54:52'),
(580, 38, 'Contraindicated', 62, 'Carbamazepine will decrease the level or effect of darunavir by affecting  hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with carbamazepine may result in loss of therapeutic effect and development of resistance to darunavir.', '2020-06-01 04:20:10', '2020-06-01 04:20:10'),
(581, 38, 'Contraindicated', 77, 'Carbamazepine will decrease the level or effect of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of Carbamazepine with NNRTIs may result in a loss of virologic response and possible resistance to the NNRTI. a decrease in AUC is observed for both carbamazepine(27%) and efavirenz(36%) when coadministered.', '2020-06-01 04:23:48', '2020-06-01 04:23:48'),
(582, 38, 'Contraindicated', 85, 'Carbamazepine will decrease the level or effect of etravirine by affecting hepatic/intestinal enzyme CYP2C9/10 metabolism. Contraindicated. Coadministration of Carbamazepine with NNRTIs may result in a loss of virologic response and possible resistance to the NNRTI.', '2020-06-01 04:26:11', '2020-06-01 04:26:11'),
(583, 38, 'Contraindicated', 140, 'Carbamazepine will decrease the level or effect of nevirapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of Carbamazepine with NNRTIs may result in a loss of virologic response and possible resistance to the NNRTI.', '2020-06-01 04:28:07', '2020-06-01 04:28:07'),
(584, 38, 'Contraindicated', 162, 'Carbamazepine will decrease the level or effect of praziquantel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP450 inducers significantly decrease praziquantel blood levels.', '2020-06-01 04:30:48', '2020-06-01 04:30:48'),
(585, 38, 'Contraindicated', 166, 'Carbamazepine will increase the toxicity of procarbazine by unknown mechanism. Contraindicated. D/C MAO inhibitor 2 weeks before.', '2020-06-01 04:32:21', '2020-06-01 04:32:21'),
(586, 38, 'Serious - Use Alternative', 56, 'Carbamazepine will decrease the level or effect of colchicine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or use alternative.', '2020-06-01 04:48:04', '2020-06-01 04:48:04'),
(587, 38, 'Serious - Use Alternative', 66, 'carbamazepine will decrease the level or effect of diazepam by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Avoid or use alternative drug.', '2020-06-01 04:49:45', '2020-06-01 04:49:45'),
(588, 38, 'Serious - Use Alternative', 80, 'erythromycin will increase the level or effect of carbamazepine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or use alternative drug.', '2020-06-01 04:52:16', '2020-06-01 04:52:16'),
(589, 38, 'Serious - Use Alternative', 101, 'carbamazepine , hydrochlorothiazide.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use alternative drug. Increased risk of systemic hyponatremia.', '2020-06-01 05:42:04', '2020-06-01 05:42:04'),
(590, 38, 'Serious - Use Alternative', 101, 'carbamazepine , hydrochlorothiazide.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use alternative drug. Increased risk of systemic hyponatremia.', '2020-06-01 05:42:04', '2020-06-01 05:42:04'),
(591, 38, 'Serious - Use Alternative', 102, 'carbamazepine , will decrease the level or effect of hydrocortisone by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Avoid or use alternative drug.', '2020-06-01 05:43:03', '2020-06-01 05:43:03'),
(592, 38, 'Serious - Use Alternative', 102, 'carbamazepine , will decrease the level or effect of hydrocortisone by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Avoid or use alternative drug.', '2020-06-01 05:43:03', '2020-06-01 05:43:03'),
(593, 38, 'Serious - Use Alternative', 110, 'ketoconazole will increase the level or effect of carbamazepine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or use alternative drug. Monitor plasma levels when used concomitantly.', '2020-06-01 05:45:11', '2020-06-01 05:45:11'),
(594, 38, 'Serious - Use Alternative', 202, 'carbamazepine will decrease the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Avoid or use alternative drug.', '2020-06-01 05:49:14', '2020-06-01 05:49:14'),
(595, 39, 'Monitor Closely', 43, 'carmustine, chlorambucil.\nEither increases toxicity of the other by pharmacodynamic synergism. Use caution/monitor. Additive myelosuppression.', '2020-06-01 05:54:45', '2020-06-01 05:54:45'),
(596, 39, 'Monitor Closely', 48, 'carmustine, cisplatin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use caution/monitor. Additive myelosuppression.', '2020-06-01 05:55:36', '2020-06-01 05:55:36'),
(597, 39, 'Monitor Closely', 69, 'carmustine, decreases levels of digoxin by inhibition of GI absorbtion. Applies only to oral form of both agents. Use caution/monitor patients for loss of clinical efficacy of digoxin while receiving antineoplastic therapy.', '2020-06-01 05:57:51', '2020-06-01 05:57:51'),
(598, 39, 'Monitor Closely', 103, 'carmustine, cisplatin. Use caution/monitor.\ncombination may increase risk of myeosuppression.', '2020-06-01 05:59:06', '2020-06-01 05:59:06'),
(599, 40, 'Monitor Closely', 206, 'ceftazidime increases effects of warfarin by other.\nUse caution/monitor. Decr vitamin k producing intestinal flora may increase INR after a few days.', '2020-06-01 06:02:57', '2020-06-01 06:02:57'),
(600, 41, 'Monitor Closely', 206, 'ceftriaxone increases effects of warfarin by anticoagulation. Avoid or use alternative drug. cephalosporins may decrease prothrombin activity.', '2020-06-01 06:10:36', '2020-06-01 06:10:36'),
(601, 41, 'Monitor Closely', 76, 'doxycycline decrease effects of ceftriaxone by pharmacodynamic antagonism. Use caution/moitor. bacteriostatic agents may inhibit the effects of bacterial agents.', '2020-06-01 06:12:40', '2020-06-01 06:12:40'),
(602, 41, 'Monitor Closely', 95, 'Ceftriaxone increases toxicity of furosemide by pharmacodynamic synergism. minor/significance unknown. Increased risk of nephrotoxicity.', '2020-06-01 06:14:33', '2020-06-01 06:14:33'),
(603, 42, 'Monitor Closely', 22, 'azithromycin will increase the level or effect of cetirizine by P-glycoprotein (MDR1) efflux transporter. Use caution/Monitor.', '2020-06-01 06:17:06', '2020-06-01 06:17:06'),
(604, 42, 'Monitor Closely', 177, 'ritronavir will increase the level or effect of cetirizine by decreasing metabolism. Use caution/Monitor.', '2020-06-01 06:19:10', '2020-06-01 06:19:10'),
(605, 43, 'Monitor Closely', 48, 'chlorambucil, cisplatin. Either increases toxicity of the other by pharmacodynamic synergism. Use caution/monitor. Additive myelosuppression.', '2020-06-01 06:29:19', '2020-06-01 06:29:19'),
(606, 43, 'Monitor Closely', 103, 'chlorambucil, hydroxyurea. Use caution/Monitor. Combination may increase risk of myelosuppression.', '2020-06-01 06:31:01', '2020-06-01 06:31:01'),
(607, 44, 'Serious - Use Alternative', 123, 'chloramphenicol will increase the level or effect of mefloquine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or use alternative drug. Potential for increased toxicity. Avoid coadministration during and for 15 weeks after discontinuing mefloquine.', '2020-06-01 06:35:02', '2020-06-01 06:35:02'),
(608, 44, 'Serious - Use Alternative', 206, 'chloramphenicol decreases effects of warfarin by decreasing metabolism. Avoid using or use alternative drug.', '2020-06-01 06:36:16', '2020-06-01 06:36:16'),
(609, 44, 'Monitor Closely', 41, 'chloramphenicol decreases effects of ceftriaxone by pharmacodynamic antagonism. Use caution/monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.', '2020-06-01 06:41:41', '2020-06-01 06:41:41'),
(610, 44, 'Monitor Closely', 161, 'chloramphenicol decreases effects of piperacillin by pharmacodynamic antagonism. Use caution/monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.', '2020-06-01 06:42:47', '2020-06-01 06:42:47'),
(611, 44, 'Minor', 97, 'chloramphenicol increases levels of glimepiride by decreasing metabolism. Minor/significance unknown.', '2020-06-01 06:45:08', '2020-06-01 06:45:08'),
(612, 45, 'Monitor Closely', 12, 'chlorpheniramine and amoxicillin both increase sedation.Use Caution/Monitor.', '2020-06-01 09:42:58', '2020-06-01 09:42:58'),
(613, 45, 'Monitor Closely', 66, 'chlorpheniramine and diazepam both increase sedation.Use Caution/Monitor.', '2020-06-01 09:45:19', '2020-06-01 09:45:19'),
(614, 45, 'Monitor Closely', 73, 'chlorpheniramine increase and dopamine decrease sedation.Use Caution/Monitor.', '2020-06-01 09:46:13', '2020-06-01 09:46:13'),
(615, 45, 'Monitor Closely', 79, 'chlorpheniramine increase and epinephrine decrease sedation.Use Caution/Monitor.', '2020-06-01 09:46:57', '2020-06-01 09:46:57'),
(616, 45, 'Monitor Closely', 120, 'chlorpheniramine and lorazepam both increase sedation..Use Caution/Monitor.', '2020-06-01 09:49:02', '2020-06-01 09:49:02'),
(617, 45, 'Monitor Closely', 133, 'chlorpheniramine and morphine both increase sedation..Use Caution/Monitor.', '2020-06-01 09:50:11', '2020-06-01 09:50:11'),
(618, 45, 'Monitor Closely', 168, 'chlorpheniramine and propofol both increase sedation..Use Caution/Monitor.', '2020-06-01 09:50:46', '2020-06-01 09:50:46'),
(619, 45, 'Monitor Closely', 195, 'chlorpheniramine and thioridazine both increase sedation..Use Caution/Monitor.', '2020-06-01 09:51:46', '2020-06-01 09:51:46'),
(620, 46, 'Contraindicated', 73, 'chlorpromazine decreases effects of dopamine by pharmacodynamic antagonism. Avoid or Use alternative drug. Contraindicated.', '2020-06-01 09:57:10', '2020-06-01 09:57:10'),
(621, 46, 'Contraindicated', 128, 'chlorpromazine decreases effects of methyldopa by pharmacodynamic antagonism. Avoid or Use alternative drug. Contraindicated.', '2020-06-01 09:58:06', '2020-06-01 09:58:06'),
(622, 46, 'Contraindicated', 154, 'pentamidine and chlorpromazine both increase QTc interval. Contraindicated.', '2020-06-01 09:59:17', '2020-06-01 09:59:17'),
(623, 46, 'Contraindicated', 165, 'procainamide and chlorpromazine both increase QTc interval. Contraindicated.', '2020-06-01 10:00:07', '2020-06-01 10:00:07'),
(624, 46, 'Contraindicated', 173, 'quinidine and chlorpromazine both increase QTc interval. Contraindicated.', '2020-06-01 10:00:57', '2020-06-01 10:00:57'),
(625, 46, 'Contraindicated', 9, 'amiodarone and chlorpromazine both increase QTc interval. Contraindicated.', '2020-06-01 10:01:46', '2020-06-01 10:01:46'),
(626, 46, 'Contraindicated', 79, 'epinephrine and chlorpromazine both increase QTc interval. Avoid or Use Alternative Drug.', '2020-06-01 10:03:27', '2020-06-01 10:03:27'),
(627, 46, 'Serious - Use Alternative', 80, 'erythromycin and chlorpromazine both increase QTc interval. Avoid or Use Alternative Drug.', '2020-06-01 10:04:14', '2020-06-01 10:04:14'),
(628, 46, 'Serious - Use Alternative', 88, 'fentanyl, chlorpromazine. Either increase effects of the other by pharmacodynamics synergism. Avoid or use alternative drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants may cause respiratory depression, hypotension, profound sedation, coma, and or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respirator depression & profound sedation.', '2020-06-01 10:08:19', '2020-06-01 10:08:19'),
(629, 46, 'Serious - Use Alternative', 92, 'fluoxetine will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or use alternative drug.', '2020-06-01 10:10:00', '2020-06-01 10:10:00'),
(630, 46, 'Serious - Use Alternative', 94, 'formoterol and chlorpromazine both increase QTc interval. Avoid or Use Alternative Drug.', '2020-06-01 10:10:56', '2020-06-01 10:10:56'),
(631, 46, 'Serious - Use Alternative', 99, 'haloperidol and chlorpromazine both increase QTc interval. Avoid or Use Alternative Drug.', '2020-06-01 10:11:31', '2020-06-01 10:11:31'),
(632, 46, 'Serious - Use Alternative', 110, 'ketoconazole and chlorpromazine both increase QTc interval. Avoid or Use Alternative Drug.', '2020-06-01 10:12:08', '2020-06-01 10:12:08'),
(633, 46, 'Serious - Use Alternative', 113, 'chlorpromazine decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use alternative drug.', '2020-06-01 10:12:46', '2020-06-01 10:12:46'),
(634, 46, 'Serious - Use Alternative', 173, 'chlorpromazine, quinidine.\neither increase levels of the other by pharmacodynamic synergism. Avoid or Use Alternative Drug. Additive cardiac effects.', '2020-06-01 10:16:06', '2020-06-01 10:16:06'),
(635, 46, 'Serious - Use Alternative', 195, 'thioridazine and chlorpromazine both increase QTc interval.Avoid or Use Alternative Drug.', '2020-06-01 10:18:24', '2020-06-01 10:18:24'),
(636, 47, 'Serious - Use Alternative', 7, 'aspirin decreases levels of ciprofloxacin by inhibition of GI absorbtion. Applies only to oral form of both agents. Avoid or Use alternative drug. Separate by 2 hours.', '2020-06-02 09:51:28', '2020-06-02 09:51:28'),
(637, 47, 'Serious - Use Alternative', 123, 'mefloquine and ciprofloxacin both increase QTc interval.Use QTc interval. Avoid or Use alternative drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.', '2020-06-02 09:56:25', '2020-06-02 09:56:25'),
(638, 47, 'Serious - Use Alternative', 206, 'ciprofloxacin will increase the level or effect of theophylline by affecting hepatic enzyme CYP1A2 methabolism. Avoid or use alternative drug. Quinolone antibiotics such as ciprofloxacin may enhance the anticoagulant effects of warfarin. Important to monitor INR/prothrombin time and toxic effects of warfarin. Patients receiving this combination should be closely monitored for adverse effects.', '2020-06-02 10:00:11', '2020-06-02 10:00:11'),
(639, 47, 'Serious - Use Alternative', 67, 'Diclofenac, ciprofloxacin.\nModify Therapy/Monitor closely. Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones.', '2020-06-02 10:03:38', '2020-06-02 10:03:38'),
(640, 47, 'Monitor Closely', 92, 'Fluoxetine and ciprofloxacin both increase QTc interval. Modify therapy/ Monitor Closely.', '2020-06-02 10:05:31', '2020-06-02 10:05:31'),
(642, 47, 'Monitor Closely', 97, 'ciprofloxacin will increase the effects of glimepiride by pharmacodynamic synergism. Use caution/Monitor. Hyper and hypoglycemia have been reported in patients treated concomitantly with quinolones and antidiabetic agents. careful monitoring of blood glucose is recommended.', '2020-06-02 10:11:30', '2020-06-02 10:11:30'),
(643, 47, 'Monitor Closely', 102, 'ciprofloxacin and hydrocorisone both increase other. Use caution / Monitor. Co-administration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.', '2020-06-02 10:18:46', '2020-06-02 10:18:46'),
(644, 47, 'Monitor Closely', 105, 'ciprofloxacin, ibuprofen. Modify Therapy/Monitor closely. Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones.', '2020-06-02 10:20:17', '2020-06-02 10:20:17'),
(645, 47, 'Monitor Closely', 173, 'ciprofloxacin and quinidine both increase  QTc interval.Use Caution/Monitor. Ciprofloxacin elicits minimal effects on QT interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors.', '2020-06-02 10:27:39', '2020-06-02 10:27:39'),
(646, 47, 'Monitor Closely', 173, 'ciprofloxacin and quinine both increase  QTc interval.Use Caution/Monitor. Ciprofloxacin elicits minimal effects on QT interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors.', '2020-06-02 10:28:05', '2020-06-02 10:28:05'),
(647, 42, 'Monitor Closely', 132, 'midazolam intranasal, Cetirizine. \nEither increase effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor closely. Concomitant use of barbiturates, alcohol or other CNS', '2020-06-03 03:41:41', '2020-06-03 03:41:41'),
(648, 42, 'Monitor Closely', 132, 'midazolam intranasal, Cetirizine. \nEither increase effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor closely. Concomitant use of barbiturates, alcohol or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation or apnea and may contribute to profound and/or prolonged drug effect.', '2020-06-03 03:43:06', '2020-06-03 03:43:06'),
(649, 42, 'Monitor Closely', 177, 'ritonavir increase levels of cetirizine by decreasing metabolism. Use caution/Monitor.', '2020-06-03 04:49:47', '2020-06-03 04:49:47'),
(650, 42, 'Monitor Closely', 8, 'theophyline increases levels of cetirizine by decreasing elimination. Minor/Significance Unkown.', '2020-06-03 04:51:09', '2020-06-03 04:51:09'),
(651, 48, 'Monitor Closely', 127, 'cetirizine methotrexate both increase nephrotoxity and/or ototoxicity. Use caution/Monitor.', '2020-06-03 04:59:16', '2020-06-03 04:59:16'),
(652, 48, 'Monitor Closely', 189, 'cisplatin and tenofovir DF both increase nephrotoxicity and/or ototoxicity. Use caution/Monitor.', '2020-06-03 05:01:04', '2020-06-03 05:01:04'),
(653, 49, 'Contraindicated', 154, 'Clarithromycin and pentamidine both increase QTc interval. Contraindicated.', '2020-06-03 05:10:41', '2020-06-03 05:10:41'),
(654, 49, 'Contraindicated', 173, 'Clarithromycin and quinidine both increase QTc interval. Contraindicated.', '2020-06-03 05:11:11', '2020-06-03 05:11:11'),
(655, 49, 'Serious - Use Alternative', 12, 'Clarithromycin and amoxapine both increase QTc interval. Avoid or use alternative drug.', '2020-06-03 05:12:22', '2020-06-03 05:12:22'),
(656, 49, 'Serious - Use Alternative', 56, 'clarithromycin will increase the level or effect of colchicine by other. Avoid or Use alternative drug. colchicine is a P-gp and CYP3A4 substrate. Avoid or use with drugs that are both P-gp and strong CYP3A4 inhibitors. If coadministration is necessary, decrease colchicine dose or frequency as recommended in prescribing information. Use of any colchicine product in conjunction with strong CYP3A4 inhibitors is contraindicated in patients with renal or hepatic impairement.', '2020-06-03 05:18:29', '2020-06-03 05:18:29'),
(657, 49, 'Serious - Use Alternative', 64, 'clarithromycin will increase the level or effect of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use alternative drug.', '2020-06-03 05:21:40', '2020-06-03 05:21:40'),
(658, 49, 'Serious - Use Alternative', 66, 'clarithromycin will increase the level or effect of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use alternative drug.', '2020-06-03 05:22:15', '2020-06-03 05:22:15'),
(659, 49, 'Serious - Use Alternative', 69, 'clarithromycin will increase the level or effect of diazepam by affecting by altering intestinal flora. Applies only to oral form of both agents. Avoid or Use alternative drug.', '2020-06-03 05:23:38', '2020-06-03 05:23:38'),
(660, 49, 'Serious - Use Alternative', 79, 'clarithromycin and epinephrine both increase QTc interval . Avoid or Use alternative drug.', '2020-06-03 05:25:02', '2020-06-03 05:25:02'),
(661, 49, 'Serious - Use Alternative', 80, 'clarithromycin and erythromycin both increase QTc interval . Avoid or Use alternative drug.', '2020-06-03 05:26:24', '2020-06-03 05:26:24'),
(662, 49, 'Serious - Use Alternative', 88, 'clarithromycin  will increase the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug. If coadminstration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.', '2020-06-03 05:46:28', '2020-06-03 05:46:28'),
(663, 49, 'Serious - Use Alternative', 90, 'clarithromycin and fluconazole both increase QTc interval. Avoid or use alternative drug.', '2020-06-03 05:47:33', '2020-06-03 05:47:33'),
(664, 49, 'Serious - Use Alternative', 94, 'clarithromycin and formoterol both increase QTc interval. Avoid or use alternative drug.', '2020-06-03 05:48:25', '2020-06-03 05:48:25'),
(665, 49, 'Serious - Use Alternative', 102, 'clarithromycin will increase the level or effect of hydrocortisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or use alternative drug.', '2020-06-03 05:50:15', '2020-06-03 05:50:15'),
(666, 49, 'Serious - Use Alternative', 110, 'clarithromycin and ketoconazole both increase QTc interval. Avoid or use alternative drug.', '2020-06-03 05:51:20', '2020-06-03 05:51:20'),
(667, 49, 'Serious - Use Alternative', 206, 'clarithromycin increases effects of warfarin by decreasing methabolism. Avoid or use alternative drug.', '2020-06-03 05:54:50', '2020-06-03 05:54:50'),
(668, 49, 'Serious - Use Alternative', 177, 'clarithromycin increases effects of ritonavir affecting hepatic/intestinal enzyme CYP3A4 methabolism. Avoid or use alternative drug.', '2020-06-03 05:58:27', '2020-06-03 05:58:27'),
(669, 49, 'Serious - Use Alternative', 173, 'clarithromycin increases effects of quinidine affecting hepatic/intestinal enzyme CYP3A4 methabolism. Avoid or use alternative drug.', '2020-06-03 05:59:22', '2020-06-03 05:59:22'),
(670, 49, 'Serious - Use Alternative', 165, 'clarithromycin and procainamide both increase QTc interval . Avoid or Use alternative drug.', '2020-06-03 06:00:16', '2020-06-03 06:00:16'),
(671, 50, 'Serious - Use Alternative', 19, 'clindamycin increases effects of atracurium by pharmacodyamic synergism. Avoid or Use alternative drug. Risk of respiratory depression.', '2020-06-03 06:11:15', '2020-06-03 06:11:15'),
(672, 50, 'Serious - Use Alternative', 69, 'clindamycin increases effects of digoxin by altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.', '2020-06-03 06:15:21', '2020-06-03 06:15:21'),
(674, 50, 'Minor', 80, 'clindamycin, erythromycin base. Either decrease effects of the other by pharmacodynamic antagonism. Minor/Significance unknown.', '2020-06-03 06:22:13', '2020-06-03 06:22:13'),
(675, 52, 'Monitor Closely', 10, 'clonazepam and amitriptyline both increases sedation. Use Caution/Monitor', '2020-06-04 01:00:12', '2020-06-04 01:00:12'),
(676, 52, 'Monitor Closely', 45, 'clonazepam and chlorpheniramine both increases sedation. Use Caution/Monitor', '2020-06-04 01:04:19', '2020-06-04 01:04:19'),
(677, 52, 'Monitor Closely', 46, 'clonazepam and chlorpromazine both increases sedation. Use Caution/Monitor', '2020-06-04 01:04:51', '2020-06-04 01:04:51'),
(678, 52, 'Monitor Closely', 66, 'clonazepam and diazepam both increases sedation. Use Caution/Monitor', '2020-06-04 01:06:27', '2020-06-04 01:06:27'),
(679, 52, 'Monitor Closely', 79, 'clonazepam and diazepam both decreases sedation. Use Caution/Monitor', '2020-06-04 01:07:42', '2020-06-04 01:07:42'),
(680, 52, 'Monitor Closely', 99, 'clonazepam and haloperidol both decreases sedation. Use Caution/Monitor', '2020-06-04 01:08:24', '2020-06-04 01:08:24'),
(681, 52, 'Monitor Closely', 133, 'clonazepam and morphine both increase sedation. Use Caution/Monitor', '2020-06-04 01:10:42', '2020-06-04 01:10:42'),
(682, 52, 'Monitor Closely', 148, 'clonazepam and morphine both increase sedation. Use Caution/Monitor', '2020-06-04 01:11:29', '2020-06-04 01:11:29'),
(683, 52, 'Monitor Closely', 158, 'clonazepam increase  and phenylephrine decrease sedation.  Effect of interaction is not clear, use caution. Use Caution/Monitor', '2020-06-04 01:13:03', '2020-06-04 01:13:03'),
(684, 52, 'Monitor Closely', 195, 'clonazepam and thioridazine both increases sedation. Use Caution/Monitor', '2020-06-04 01:14:27', '2020-06-04 01:14:27'),
(685, 53, 'Contraindicated', 132, 'clotrimazole will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme. CYP3A4 metabolism. Avoid or use alternative drug.', '2020-06-04 02:56:55', '2020-06-04 02:56:55'),
(686, 53, 'Contraindicated', 206, 'clotrimazole increases levels of warfarin by decreasing metabolism. Avoid or use alternative drug.', '2020-06-04 02:57:52', '2020-06-04 02:57:52'),
(687, 53, 'Monitor Closely', 69, 'clotrimazole will decrease the level or effect of digoxin by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor', '2020-06-04 02:59:18', '2020-06-04 02:59:18'),
(688, 53, 'Monitor Closely', 102, 'clotrimazole will decrease the level or effect of hydrocortisone by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor', '2020-06-04 03:00:29', '2020-06-04 03:00:29'),
(689, 53, 'Monitor Closely', 106, 'clotrimazole will decrease the level or effect of imatinib by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor', '2020-06-04 03:00:59', '2020-06-04 03:00:59'),
(690, 53, 'Monitor Closely', 118, 'clotrimazole will decrease the level or effect of loperamide by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor', '2020-06-04 04:49:40', '2020-06-04 04:49:40'),
(691, 53, 'Monitor Closely', 177, 'clotrimazole will decrease the level or effect of ritonavir by P-glycoprotein (MDR1) efflux transporter.Use Caution/Monitor', '2020-06-04 04:50:40', '2020-06-04 04:50:40'),
(692, 53, 'Monitor Closely', 181, 'clotrimazole will decrease the level or effect of ritonavir.Use Caution/Monitor.', '2020-06-04 04:51:37', '2020-06-04 04:51:37'),
(693, 53, 'Monitor Closely', 138, 'clotrimazole will decrease the level or effect of neomycin.Use Caution/Monitor.', '2020-06-04 04:52:24', '2020-06-04 04:52:24'),
(694, 55, 'Serious - Use Alternative', 88, 'either increases effects of the other by pharmacodynamic synergism. Avoid or Use alternative drug. coadministration with other CNS depressants, such as skeletal muschle relaxants, may cause respiratory depression, hpotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression & profound sedation.', '2020-06-04 04:59:48', '2020-06-04 04:59:48'),
(695, 55, 'Serious - Use Alternative', 166, 'procarbazine increases toxicity of codeine by unknown mechanism. Avoid or Use alternative drug. MAOIs may potentiate CNS depression and hypo-tension. Do not use within 14 days of MAOI use.', '2020-06-04 06:00:01', '2020-06-04 06:00:01'),
(696, 55, 'Serious - Use Alternative', 198, 'tramadol, codeine. Avoid or Use alternative drug. it may provoke withdrawal Sx. in pts. who are currently opiate dependent.', '2020-06-04 06:13:24', '2020-06-04 06:13:24'),
(697, 55, 'Monitor Closely', 92, 'fluoxetine will decrease the level or effect of codeine by affecting hepatic enzyme CYP2D6 metabolism. Use caution/Monitor. Prevents conversion of codeine to its active metabolite morphine.', '2020-06-04 06:16:34', '2020-06-04 06:16:34'),
(698, 55, 'Monitor Closely', 93, 'codeine and fluphenazine both inceases sedation. Use Caution/Monitor', '2020-06-04 06:17:55', '2020-06-04 06:17:55'),
(699, 55, 'Monitor Closely', 94, 'codeine  increases formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor', '2020-06-04 06:18:41', '2020-06-04 06:18:41'),
(700, 55, 'Monitor Closely', 110, 'ketoconazole will decrease the level or effect of codeine by affecting hepatic enzyme CYP2D6 metabolism. Use caution/Monitor. Prevents conversion of codeine to its active metabolite morphine.', '2020-06-04 06:19:52', '2020-06-04 06:19:52'),
(701, 55, 'Monitor Closely', 106, 'imatinib will decrease the level or effect of codeine by affecting hepatic enzyme CYP2D6 metabolism. Use caution/Monitor. Prevents conversion of codeine to its active metabolite morphine.', '2020-06-04 06:21:35', '2020-06-04 06:21:35'),
(702, 56, 'Serious - Use Alternative', 62, 'darunavir will increase the level or effect of colchicine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug.Avoid use of colchicine with strong CYP3A4 inhibitors.if coadministration is necessary,decrease colchicine dose or frequency as recommended in prescribing information.use of any colchicine product in conjunction with strong CYP3A4 inhibitors is contraindicated in patients with renal or hepatic impairment.', '2020-06-07 09:19:00', '2020-06-07 09:19:00'),
(703, 56, 'Serious - Use Alternative', 69, 'Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use alternative drug. Increased risk of rhabdomyolysis.', '2020-06-07 09:22:52', '2020-06-07 09:22:52'),
(704, 56, 'Serious - Use Alternative', 80, 'erthromycin will increase the level or effect of colchicine by other. Avoid or Use alternative drug. colchicine is a P-gp and CYP3A4 substrate. Avoid or use with drugs that are both P-gp and strong CYP3A4 inhibitors. If coadministration is necessary, decrease colchicine dose or frequency as recommended in prescribing information. Use of any colchicine product in conjunction with strong CYP3A4 inhibitors is contraindicated in patients with renal or hepatic impairement.', '2020-06-07 09:24:27', '2020-06-07 09:24:27'),
(705, 56, 'Serious - Use Alternative', 110, 'ketoconazole will increase the level or effect of colchicine by other. Avoid or Use alternative drug. colchicine is a P-gp and CYP3A4 substrate. Avoid or use with drugs that are both P-gp and strong CYP3A4 inhibitors. If coadministration is necessary, decrease colchicine dose or frequency as recommended in prescribing information. Use of any colchicine product in conjunction with strong CYP3A4 inhibitors is contraindicated in patients with renal or hepatic impairement.', '2020-06-07 09:26:39', '2020-06-07 09:26:39'),
(706, 56, 'Serious - Use Alternative', 119, 'lopinavir will increase the level or effect of colchicine by other. Avoid or Use alternative drug. colchicine is a P-gp and CYP3A4 substrate. Avoid or use with drugs that are both P-gp and strong CYP3A4 inhibitors. If coadministration is necessary, decrease colchicine dose or frequency as recommended in prescribing information. Use of any colchicine product in conjunction with strong CYP3A4 inhibitors is contraindicated in patients with renal or hepatic impairement.', '2020-06-07 09:27:38', '2020-06-07 09:27:38'),
(707, 56, 'Serious - Use Alternative', 173, 'quinidine will increase the level or effect of colchicine by P-glycoprotein(MDR1) efflux transporter.Avoid or Use Alternative Drug.Avoid use of colchicine with P-gp inhibitors.if coadministration is necessary,decrease colchicine dose or frequency as recommended in prescribing information.Use of any colchicine in conjunction with P-gp inhibitors is contraindicated in patients with renal or hepatic impairment.', '2020-06-07 09:29:13', '2020-06-07 09:29:13'),
(708, 56, 'Serious - Use Alternative', 174, 'quinine will increase the level or effect of colchicine by P-glycoprotein(MDR1) efflux transporter.Avoid or Use Alternative Drug.Avoid use of colchicine with P-gp inhibitors.if coadministration is necessary,decrease colchicine dose or frequency as recommended in prescribing information.Use of any colchicine in conjunction with P-gp inhibitors is contraindicated in patients with renal or hepatic impairment.', '2020-06-07 09:29:46', '2020-06-07 09:29:46');
INSERT INTO `interactions` (`id`, `drug_id`, `status`, `drug`, `description`, `created_at`, `updated_at`) VALUES
(709, 56, 'Serious - Use Alternative', 177, 'ritonavir will increase the level or effect of colchicine by other. Avoid or Use alternative drug. colchicine is a P-gp and CYP3A4 substrate. Avoid or use with drugs that are both P-gp and strong CYP3A4 inhibitors. If coadministration is necessary, decrease colchicine dose or frequency as recommended in prescribing information. Use of any colchicine product in conjunction with strong CYP3A4 inhibitors is contraindicated in patients with renal or hepatic impairement.', '2020-06-07 09:30:56', '2020-06-07 09:30:56'),
(710, 56, 'Monitor Closely', 85, 'etravirine will decrease the level or effect of colchicine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/monitor.', '2020-06-07 09:35:23', '2020-06-07 09:35:23'),
(711, 56, 'Monitor Closely', 140, 'nevirapine will decrease the level or effect of colchicine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/monitor.', '2020-06-07 09:37:54', '2020-06-07 09:37:54'),
(712, 56, 'Monitor Closely', 159, 'phenytoin will decrease the level or effect of colchicine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/monitor.', '2020-06-07 09:38:40', '2020-06-07 09:38:40'),
(713, 57, 'Monitor Closely', 69, 'cyclophosphamide will decrease the levels of digoxin by inhibition of GI absorbtion. Applies only to oral form of both agents. Use caution/Monitor.', '2020-06-07 09:47:54', '2020-06-07 09:47:54'),
(714, 57, 'Monitor Closely', 103, 'cyclophosphamide, hydroxyurea.Use caution/Monitor. Combination may increase risk of myelosuppression.', '2020-06-07 09:49:13', '2020-06-07 09:49:13'),
(715, 57, 'Monitor Closely', 177, 'ritronavir will increase the level or effect of cyclophosphamide by affecting hepatic enzyme CYP2B6 metabolism. Use caution/Monitor.', '2020-06-07 09:51:45', '2020-06-07 09:51:45'),
(716, 57, 'Monitor Closely', 206, 'cyclophosphamide will increase the level or effect of warfarin by unknown mechanism. Use caution/Monitor.', '2020-06-07 09:53:24', '2020-06-07 09:53:24'),
(717, 58, 'Monitor Closely', 82, 'cycloserine, ethionamide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use caution/monitor. Enhanced CNS toxicity; risk of seizure.', '2020-06-07 09:56:04', '2020-06-07 09:56:04'),
(718, 58, 'Monitor Closely', 108, 'isoniazid increases toxicity of cycloserine by decreasing metabolism. Use caution/Monitor. increased CNS toxicity; risk of seizure.', '2020-06-07 09:57:23', '2020-06-07 09:57:23'),
(719, 59, 'Monitor Closely', 69, 'cytarabine decreases levels of digoxin by inhibition of GI absorbtion. Applies only to oral form of both agents. Use caution/Monitor. Cytarabine may decrease digoxin absorbtion even several days after stopping chemotherapy. Digoxin capsules and digitoxin do not appear to be affected.', '2020-06-07 10:01:34', '2020-06-07 10:01:34'),
(720, 59, 'Monitor Closely', 103, 'cytarabine, hydroxyurea. Use caution/Monitor. Combination may increase risk of myelosuppression.', '2020-06-07 10:03:07', '2020-06-07 10:03:07'),
(721, 60, 'Monitor Closely', 103, 'dactinomycin, hydroxyurea. Use caution/Monitor. Combination may increase risk of myelosuppression.', '2020-06-07 11:55:45', '2020-06-07 11:55:45'),
(724, 61, 'Serious - Use Alternative', 105, 'ibuprofen will decrease the level or effect of dapsone by increasing gastric pH. applies only to oral form of both agents. Avoid or use alternative drug.', '2020-06-07 12:01:10', '2020-06-07 12:01:10'),
(723, 61, 'Serious - Use Alternative', 123, 'mefloquine will increase toxicity of dapsone by unspecified interaction mechanism. Avoid or use alternative drug. Increased risk of hemolytic reactions.', '2020-06-07 12:00:39', '2020-06-07 12:00:39'),
(725, 61, 'Monitor Closely', 38, 'carbamazepine will increase the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 12:02:33', '2020-06-07 12:02:33'),
(726, 61, 'Monitor Closely', 69, 'dapsone will increase the level or effect of digoxin by altering intestinal flora. Applies only to oral form of both agents. Use caution/Monitor.', '2020-06-07 12:04:54', '2020-06-07 12:04:54'),
(727, 61, 'Monitor Closely', 77, 'efavirenz will decrease the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 12:05:53', '2020-06-07 12:05:53'),
(728, 61, 'Monitor Closely', 80, 'erythromycin will decrease the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 12:06:33', '2020-06-07 12:06:33'),
(729, 61, 'Monitor Closely', 108, 'isoniazid will decrease the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 12:07:03', '2020-06-07 12:07:03'),
(730, 61, 'Monitor Closely', 110, 'ketoconazole will decrease the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 12:07:34', '2020-06-07 12:07:34'),
(731, 61, 'Minor', 62, 'darunavir will increase the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 12:08:48', '2020-06-07 12:08:48'),
(732, 61, 'Minor', 90, 'fluconazole will increase the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.', '2020-06-07 12:09:40', '2020-06-07 12:09:40'),
(733, 61, 'Minor', 102, 'hydrocortisone will decrease the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.', '2020-06-07 12:10:31', '2020-06-07 12:10:31'),
(734, 61, 'Minor', 131, 'metronidazole will increase the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP2E1 metabolism. Minor/Significance Unknown.', '2020-06-07 12:11:39', '2020-06-07 12:11:39'),
(735, 61, 'Minor', 140, 'nevirapine will decrease the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.', '2020-06-07 12:12:33', '2020-06-07 12:12:33'),
(736, 61, 'Minor', 159, 'phenytoin will decrease the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.', '2020-06-07 12:13:25', '2020-06-07 12:13:25'),
(737, 61, 'Minor', 177, 'ritonavir will increase the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.', '2020-06-07 12:14:16', '2020-06-07 12:14:16'),
(738, 62, 'Contraindicated', 80, 'darunavir will decrease the level or effect of erythromycin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.', '2020-06-07 13:10:48', '2020-06-07 13:10:48'),
(739, 62, 'Contraindicated', 132, 'darunavir will increase the level or effect of erythromycin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.', '2020-06-07 13:11:58', '2020-06-07 13:11:58'),
(740, 62, 'Contraindicated', 159, 'phenytoin will decrease the level or effect of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.', '2020-06-07 13:13:24', '2020-06-07 13:13:24'),
(741, 62, 'Serious - Use Alternative', 66, 'darunavir increases the levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Avoid or Use Alternative Drug. Use alternatives.', '2020-06-07 13:16:16', '2020-06-07 13:16:16'),
(743, 62, 'Serious - Use Alternative', 77, 'darunavir will decrease the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternative Drug. Coadministration with efavirenz may result in loss of therapeutic effect and development of resistancee to darunavir.', '2020-06-07 13:19:31', '2020-06-07 13:19:31'),
(744, 62, 'Serious - Use Alternative', 85, 'etravirine will decrease the level or effect of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternative Drug. Coadministration with nevirapine may result in loss of therapeutic effect and development of resistancee to darunavir.', '2020-06-07 13:20:51', '2020-06-07 13:20:51'),
(745, 62, 'Serious - Use Alternative', 110, 'ketoconazole, Darunavir.\nEither increase effects of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or use alternative drug. Specific dosage recommendations for ketoconazole are not available when coadministered with darunavir.', '2020-06-07 13:23:39', '2020-06-07 13:23:39'),
(746, 62, 'Serious - Use Alternative', 119, 'lopinavir decreases levels of darunavir by increasing metabolism. Avoid or Use alternative drug.', '2020-06-07 13:24:49', '2020-06-07 13:24:49'),
(747, 62, 'Serious - Use Alternative', 123, 'darunavir will decrease the level or effect of mefloquine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternative Drug. Potential for increased toxicity. Avoid coadministration during and for 15 weeks after discontinuing mefloquine.', '2020-06-07 13:27:11', '2020-06-07 13:27:11'),
(748, 62, 'Serious - Use Alternative', 140, 'nevirapine will decrease the level or effect of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternative Drug. Coadministration with nevirapine may result in loss of therapeutic effect and development of resistancee to darunavir.', '2020-06-07 13:28:47', '2020-06-07 13:28:47'),
(749, 62, 'Monitor Closely', 64, 'dexamethasone will decrease the level or effect of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.', '2020-06-07 13:31:37', '2020-06-07 13:31:37'),
(750, 62, 'Monitor Closely', 77, 'Darunavir and efavirenz both increase risk of immunue reconstitution syndrome. Use caution/Monitor.', '2020-06-07 13:33:25', '2020-06-07 13:33:25'),
(751, 62, 'Monitor Closely', 80, 'erythromycin will increase the level or effect of darunavir by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Use caution/monitor.', '2020-06-07 13:34:28', '2020-06-07 13:34:28'),
(752, 62, 'Monitor Closely', 85, 'darunavir will increase the level or effect of etravirine by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Use caution/monitor.', '2020-06-07 13:35:13', '2020-06-07 13:35:13'),
(753, 62, 'Monitor Closely', 88, 'darunavir will increase the level or effect of etravirine by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Modify Therapy/Monitor Closely. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor for respiratory depression & sedation at frequent intervals and consider fentanyl dose adjustments until stable drug affects are achieved.', '2020-06-07 13:37:30', '2020-06-07 13:37:30'),
(754, 62, 'Monitor Closely', 92, 'darunavir will increase the level or effect of fluoxetine by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Use caution/Monitor. Coadministration with SSRIs, TCAs, or trazodone may require dose titration of antidepressant to desired effect. Monitor for antidepressant response.', '2020-06-07 13:40:42', '2020-06-07 13:40:42'),
(755, 62, 'Monitor Closely', 97, 'darunavir will increase the level or effect of glimepiride. Use caution/Monitor. Reports of hyperglycemia due to insulin resistance with protease inhibitors.', '2020-06-07 13:42:48', '2020-06-07 13:42:48'),
(756, 62, 'Monitor Closely', 102, 'darunavir will increase the level or effect of hydrocortisone by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Use caution/Monitor.', '2020-06-07 13:44:01', '2020-06-07 13:44:01'),
(757, 62, 'Monitor Closely', 108, 'isoniazid will increase the level or effect of darunavir by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Use caution/monitor.', '2020-06-07 16:21:43', '2020-06-07 16:21:43'),
(758, 63, 'Monitor Closely', 7, 'deferoxamine decreases levels of aluminum hydroxide by inhibition of GI absorbtion. Applies only to oral form of both agents. Use caution/Monitor. Deferoxamine chelates iron; its affinity for other minerals is unknown.', '2020-06-07 16:26:22', '2020-06-07 16:26:22'),
(760, 64, 'Serious - Use Alternative', 80, 'erythromycin will increase the level or effect of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use alternative drug.', '2020-06-07 16:30:57', '2020-06-07 16:30:57'),
(761, 64, 'Serious - Use Alternative', 110, 'ketoconazole will increase the level or effect of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use alternative drug.', '2020-06-07 16:31:40', '2020-06-07 16:31:40'),
(762, 64, 'Serious - Use Alternative', 173, 'quinidine will increase the level or effect of dexamethasone by affecting by P-glycoprotein (MDR1) efflux transporter . Avoid or Use alternative drug.', '2020-06-07 16:33:32', '2020-06-07 16:33:32'),
(765, 64, 'Monitor Closely', 67, 'diclofenac, dexamethasone. Either increases toxicity of the other by pharmacodynamic synergism. Use caution/monitor. Increased risk of GI ulceration.', '2020-06-07 16:38:20', '2020-06-07 16:38:20'),
(764, 64, 'Monitor Closely', 77, 'efavirenz will decrease the level or effect of Dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 16:37:37', '2020-06-07 16:37:37'),
(766, 64, 'Monitor Closely', 88, 'dexamethasone will decrease the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.', '2020-06-07 16:39:37', '2020-06-07 16:39:37'),
(767, 64, 'Monitor Closely', 102, 'dexamethasone will decrease the level or effect of hydrocortisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.', '2020-06-07 16:40:14', '2020-06-07 16:40:14'),
(768, 64, 'Monitor Closely', 105, 'ibuprofen, dexamethasone. Either increases toxicity of the other by pharmacodynamic synergism. Use caution/monitor. Increased risk of GI ulceration.', '2020-06-07 16:40:45', '2020-06-07 16:40:45'),
(769, 64, 'Monitor Closely', 110, 'ketoconazole will increase the level or effect of dexamethasone by affecting by P-glycoprotein (MDR1) efflux transporter . Use caution/Monitor.', '2020-06-07 16:41:59', '2020-06-07 16:41:59'),
(770, 64, 'Monitor Closely', 114, 'dexamethasone and levofloxacin both increase the other. Use caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase the risk of tendon rupture.', '2020-06-07 16:44:01', '2020-06-07 16:44:01'),
(771, 64, 'Monitor Closely', 119, 'Dexamethasone will decrease the level or effect of lopinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 16:45:12', '2020-06-07 16:45:12'),
(772, 64, 'Monitor Closely', 132, 'Dexamethasone will decrease the level or effect of midazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 16:46:20', '2020-06-07 16:46:20'),
(773, 64, 'Monitor Closely', 136, 'naproxen, dexamethasone. Either increases toxicity of the other by pharmacodynamic synergism. Use caution/monitor. Increased risk of GI ulceration.', '2020-06-07 16:47:20', '2020-06-07 16:47:20'),
(774, 64, 'Monitor Closely', 140, 'nevirapine will decrease the level or effect of Dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 16:48:20', '2020-06-07 16:48:20'),
(775, 64, 'Monitor Closely', 159, 'phenytoin will decrease the level or effect of Dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 16:49:17', '2020-06-07 16:49:17'),
(776, 64, 'Monitor Closely', 177, 'ritonavir will increase the level or effect of Dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 16:49:58', '2020-06-07 16:49:58'),
(777, 64, 'Monitor Closely', 206, 'Dexamethasone will decrease the level or effect of warfarin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 16:50:55', '2020-06-07 16:50:55'),
(778, 64, 'Minor', 174, 'Dexamethasone will decrease the level or effect of quinine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 16:51:31', '2020-06-07 16:51:31'),
(779, 66, 'Serious - Use Alternative', 80, 'erythromycin will increases levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or use alternative drug.', '2020-06-07 17:34:28', '2020-06-07 17:34:28'),
(780, 66, 'Serious - Use Alternative', 110, 'ketoconazole will increases levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or use alternative drug.', '2020-06-07 17:35:06', '2020-06-07 17:35:06'),
(781, 66, 'Monitor Closely', 77, 'efavirenz will decreases levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 17:36:38', '2020-06-07 17:36:38'),
(782, 66, 'Monitor Closely', 85, 'etravirine will decrease levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 17:37:09', '2020-06-07 17:37:09'),
(783, 66, 'Monitor Closely', 92, 'fluoxtine will decrease levels of diazepam by affecting hepatic/intestinal enzyme CYP2C19 metabolism. Use caution/Monitor.', '2020-06-07 17:38:08', '2020-06-07 17:38:08'),
(784, 66, 'Monitor Closely', 108, 'isoniazid will increase levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use caution/Monitor.', '2020-06-07 17:39:09', '2020-06-07 17:39:09'),
(785, 66, 'Monitor Closely', 119, 'lopinavir increases levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify therapy/Monitor closely.', '2020-06-07 17:40:03', '2020-06-07 17:40:03'),
(786, 66, 'Monitor Closely', 119, 'metronidazole will increase levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism.Use Caution/Monitor.', '2020-06-07 17:41:15', '2020-06-07 17:41:15'),
(787, 66, 'Monitor Closely', 132, 'diazepam and midazolam both increase sedation. Use Caution/Monitor.', '2020-06-07 17:41:53', '2020-06-07 17:41:53'),
(788, 66, 'Monitor Closely', 132, 'diazepam and morphine both increase sedation. Use Caution/Monitor.', '2020-06-07 17:42:09', '2020-06-07 17:42:09'),
(789, 66, 'Monitor Closely', 140, 'nevirapine will decrease the level or effect of diazepam by affecting hepatic/intestinal enzyme CYP3A4 methabolism. Use Caution/Monitor.', '2020-06-07 18:17:07', '2020-06-07 18:17:07'),
(790, 66, 'Monitor Closely', 163, 'predinisone will decrease the level or effect of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.', '2020-06-07 18:18:27', '2020-06-07 18:18:27'),
(791, 66, 'Monitor Closely', 168, 'diazepam and propofol both increase sedation. Use Caution/Monitor.', '2020-06-07 18:19:15', '2020-06-07 18:19:15'),
(792, 66, 'Monitor Closely', 177, 'ritonavir increases levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify therapy/Monitor closely.', '2020-06-07 18:20:49', '2020-06-07 18:20:49'),
(793, 66, 'Monitor Closely', 195, 'diazepam and thioridazine both increase sedation.Use Caution/Monitor.', '2020-06-07 18:21:39', '2020-06-07 18:21:39'),
(794, 66, 'Monitor Closely', 197, 'diazepam will decrease the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.', '2020-06-07 18:22:55', '2020-06-07 18:22:55'),
(796, 66, 'Minor', 85, 'etravirine will decrease the level or effect of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.', '2020-06-07 18:25:10', '2020-06-07 18:25:10');

-- --------------------------------------------------------

--
-- Table structure for table `inventory_at_date`
--

DROP TABLE IF EXISTS `inventory_at_date`;
CREATE TABLE IF NOT EXISTS `inventory_at_date` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `item` int(11) NOT NULL,
  `date` date NOT NULL,
  `qty` decimal(10,2) NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `inventory_record`
--

DROP TABLE IF EXISTS `inventory_record`;
CREATE TABLE IF NOT EXISTS `inventory_record` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `item` int(11) NOT NULL,
  `activity` varchar(120) DEFAULT NULL,
  `date` date DEFAULT NULL,
  `units_received` decimal(10,2) NOT NULL DEFAULT '0.00',
  `units_sold` decimal(10,2) NOT NULL DEFAULT '0.00',
  `qty_previous` decimal(10,2) NOT NULL DEFAULT '0.00',
  `qty_on_hand` decimal(10,2) NOT NULL DEFAULT '0.00',
  `unit_cost` decimal(10,2) NOT NULL DEFAULT '0.00',
  `previous_cost` decimal(10,2) NOT NULL DEFAULT '0.00',
  `total_cost` decimal(10,2) DEFAULT NULL,
  `location` int(10) NOT NULL DEFAULT '1',
  `vendor` int(11) DEFAULT NULL,
  `user` int(4) NOT NULL DEFAULT '1',
  `ref_id` int(11) NOT NULL DEFAULT '0',
  `status` varchar(20) NOT NULL DEFAULT 'active',
  `item_variant` int(11) NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=1967 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `inventory_record`
--

INSERT INTO `inventory_record` (`id`, `item`, `activity`, `date`, `units_received`, `units_sold`, `qty_previous`, `qty_on_hand`, `unit_cost`, `previous_cost`, `total_cost`, `location`, `vendor`, `user`, `ref_id`, `status`, `item_variant`) VALUES
(1924, 1, 'Purchase', '2020-05-24', '10.00', '0.00', '0.00', '90.00', '20.00', '20.00', '200.00', 1, 8, 1, 346, 'active', 318),
(1925, 1, 'Purchase', '2020-05-24', '10.00', '0.00', '90.00', '310.00', '10.32', '10.00', '103.23', 1, 8, 1, 347, 'active', 317),
(1926, 1, 'Sale', '2018-01-02', '0.00', '3.00', '20.00', '20.00', '0.00', '0.00', '0.00', 1, 0, 1, 974, 'active', 0),
(1927, 1, 'Sale', '2018-01-02', '0.00', '1.00', '17.00', '17.00', '0.00', '0.00', '0.00', 1, 0, 1, 975, 'active', 0),
(1928, 1, 'Sale', '2018-01-02', '0.00', '2.00', '16.00', '16.00', '0.00', '0.00', '0.00', 1, 0, 1, 976, 'active', 0),
(1929, 1, 'Purchase', '2020-05-24', '10.00', '0.00', '14.00', '314.00', '10.63', '10.32', '106.28', 1, 8, 1, 348, 'active', 317),
(1930, 1, 'Sale', '2018-01-02', '0.00', '2.00', '10.00', '10.00', '0.00', '0.00', '0.00', 1, 0, 1, 977, 'active', 0),
(1931, 1, 'Sale', '2018-01-02', '0.00', '4.00', '8.00', '8.00', '0.00', '0.00', '0.00', 1, 0, 1, 978, 'active', 0),
(1932, 1, 'Sale', '2020-05-24', '0.00', '3.00', '4.00', '4.00', '0.00', '0.00', '0.00', 1, 0, 1, 979, 'active', 0),
(1933, 1, 'Sale', '2020-05-24', '0.00', '2.00', '1.00', '1.00', '0.00', '0.00', '0.00', 1, 0, 1, 980, 'active', 0),
(1934, 1, 'Sale', '2020-05-24', '0.00', '3.00', '-1.00', '-1.00', '0.00', '0.00', '0.00', 1, 0, 1, 982, 'active', 0),
(1935, 1, 'Sale', '2020-05-24', '0.00', '2.00', '-4.00', '-4.00', '0.00', '0.00', '0.00', 1, 0, 1, 983, 'active', 0),
(1936, 1, 'Sale', '2020-05-24', '0.00', '2.00', '-6.00', '-6.00', '0.00', '0.00', '0.00', 1, 0, 1, 984, 'active', 0),
(1937, 1, 'Purchase', '2020-05-24', '10.00', '0.00', '-8.00', '306.00', '10.94', '10.63', '109.36', 1, 8, 1, 349, 'active', 317),
(1938, 1, 'Sale', '2020-05-24', '0.00', '2.00', '306.00', '306.00', '0.00', '0.00', '0.00', 1, 0, 1, 985, 'active', 0),
(1939, 1, 'Sale', '2020-05-24', '0.00', '1.00', '0.00', '0.00', '0.00', '0.00', '0.00', 1, 0, 1, 986, 'active', 0),
(1940, 1, 'Sale', '2020-05-24', '0.00', '2.00', '-1.00', '-1.00', '0.00', '0.00', '0.00', 1, 0, 1, 987, 'active', 0),
(1941, 1, 'Sale', '2020-05-24', '0.00', '2.00', '-3.00', '-3.00', '0.00', '0.00', '0.00', 1, 0, 1, 988, 'active', 0),
(1942, 1, 'Sale', '2020-05-24', '0.00', '1.00', '-5.00', '-5.00', '0.00', '0.00', '0.00', 1, 0, 1, 989, 'active', 0),
(1943, 1, 'Sale', '2020-05-24', '0.00', '2.00', '-6.00', '-6.00', '0.00', '0.00', '0.00', 1, 0, 1, 990, 'active', 0),
(1944, 1, 'Purchase', '2020-05-24', '20.00', '0.00', '-8.00', '316.00', '11.51', '10.94', '230.27', 1, 8, 1, 350, 'active', 317),
(1945, 1, 'Sale', '2020-05-24', '0.00', '2.00', '316.00', '-12.00', '0.00', '0.00', '0.00', 1, 0, 1, 991, 'active', 0),
(1946, 1, 'Sale', '2020-05-24', '0.00', '2.00', '10.00', '6.00', '0.00', '0.00', '0.00', 1, 0, 1, 992, 'active', 0),
(1947, 1, 'Sale', '2020-05-24', '0.00', '1.00', '8.00', '6.00', '0.00', '0.00', '0.00', 1, 0, 1, 993, 'active', 0),
(1948, 1, 'Sale', '2020-05-24', '0.00', '2.00', '7.00', '5.00', '0.00', '0.00', '0.00', 1, 0, 1, 994, 'active', 0),
(1949, 1, 'Sale', '2020-05-24', '0.00', '1.00', '5.00', '4.00', '0.00', '0.00', '0.00', 1, 0, 1, 995, 'active', 0),
(1950, 1, 'Sale', '2020-05-28', '0.00', '2.00', '4.00', '2.00', '0.00', '0.00', '0.00', 1, 0, 1, 996, 'active', 0),
(1951, 1, 'Sale', '2020-05-28', '0.00', '1.00', '2.00', '1.00', '0.00', '0.00', '0.00', 1, 0, 1, 997, 'active', 0),
(1952, 1, 'Sale', '2020-05-28', '0.00', '1.00', '1.00', '0.00', '0.00', '0.00', '0.00', 1, 0, 1, 998, 'active', 0),
(1953, 1, 'Sale', '2020-05-28', '0.00', '1.00', '0.00', '-1.00', '0.00', '0.00', '0.00', 1, 0, 1, 999, 'active', 0),
(1954, 1, 'Sale', '2020-05-28', '0.00', '1.00', '-1.00', '-2.00', '0.00', '0.00', '0.00', 1, 0, 1, 1000, 'active', 0),
(1955, 1, 'Purchase', '2020-05-28', '10.00', '0.00', '-2.00', '312.00', '11.78', '11.51', '117.82', 1, 8, 1, 351, 'active', 317),
(1956, 1, 'Purchase', '2020-05-28', '10.00', '0.00', '0.00', '322.00', '12.04', '11.78', '120.35', 1, 8, 1, 352, 'active', 317),
(1957, 4, 'Purchase', '2020-05-28', '10.00', '0.00', '10.00', '20.00', '15.00', '10.00', '150.00', 1, 8, 1, 355, 'active', 0),
(1958, 1, 'Purchase', '2020-05-28', '10.00', '0.00', '10.00', '100.00', '20.00', '20.00', '200.00', 1, 8, 1, 356, 'active', 318),
(1959, 1, 'Purchase', '2020-05-28', '10.00', '0.00', '100.00', '110.00', '21.82', '20.00', '218.18', 1, 8, 1, 357, 'active', 318),
(1960, 1, 'Purchase', '2020-05-28', '10.00', '0.00', '110.00', '332.00', '12.88', '12.04', '128.82', 1, 8, 1, 358, 'active', 317),
(1961, 1, 'Purchase', '2020-05-28', '10.00', '0.00', '332.00', '342.00', '13.67', '12.88', '136.73', 1, 8, 1, 359, 'active', 317),
(1962, 1, 'Purchase', '2020-05-28', '10.00', '0.00', '50.00', '352.00', '14.42', '13.67', '144.18', 1, 8, 1, 360, 'active', 317),
(1963, 1, 'Purchase', '2020-05-28', '10.00', '0.00', '60.00', '362.00', '15.13', '14.42', '151.27', 1, 8, 1, 361, 'active', 317),
(1964, 1, 'Purchase', '2020-05-28', '10.00', '0.00', '70.00', '120.00', '23.33', '21.82', '233.35', 1, 8, 1, 362, 'active', 318),
(1965, 1, 'Purchase', '2020-05-28', '20.00', '0.00', '80.00', '382.00', '15.38', '15.13', '307.70', 1, 8, 1, 363, 'active', 317),
(1966, 1, 'Transfer in', '2020-05-29', '2.00', '2.00', '0.00', '120.00', '23.33', '23.33', '32.00', 1, NULL, 1, 149, 'active', 0);

-- --------------------------------------------------------

--
-- Table structure for table `items`
--

DROP TABLE IF EXISTS `items`;
CREATE TABLE IF NOT EXISTS `items` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `item_name` text,
  `PregnancyRiskCategory` varchar(100) DEFAULT NULL,
  `drug_interaction` text,
  `affected` text,
  `food_interaction` text,
  `category` int(10) NOT NULL,
  `min_qty` decimal(10,2) NOT NULL DEFAULT '0.00',
  `unit_cost` decimal(10,2) NOT NULL,
  `unit_price` decimal(10,2) NOT NULL,
  `current_amount` decimal(10,2) NOT NULL DEFAULT '0.00',
  `valuation` decimal(10,2) NOT NULL DEFAULT '0.00',
  `barcode_main` varchar(50) CHARACTER SET utf8mb4 COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `barcode_generation` varchar(100) CHARACTER SET utf8mb4 COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `description` varchar(150) CHARACTER SET utf8mb4 COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `image` varchar(150) CHARACTER SET utf8mb4 COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `income_account` int(11) NOT NULL DEFAULT '0',
  `expense_account` int(11) NOT NULL DEFAULT '0',
  `inventory_account` int(11) NOT NULL DEFAULT '0',
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  `national_drug_code` varchar(45) CHARACTER SET utf8mb4 COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `item_name_tig` varchar(150) CHARACTER SET utf8mb4 COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `item_code` varchar(191) CHARACTER SET utf8mb4 COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `qty_shop` decimal(10,2) DEFAULT '0.00',
  `qty_store` decimal(10,2) DEFAULT '0.00',
  `item_order` int(100) DEFAULT NULL,
  `company` varchar(100) DEFAULT NULL,
  `owner` varchar(100) DEFAULT NULL,
  `variants` varchar(50) DEFAULT NULL,
  `package_tracking` int(3) DEFAULT NULL,
  `active` int(20) DEFAULT '1',
  `other_attrib` varchar(50) DEFAULT NULL,
  `remark` text,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=210 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `items`
--

INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(1, 'Abacavirs', ' C ', '¤ (Atazanavir) Protease Inhibitors may decrease the serum concentration of Abacavir.¤ (Batimastat) May decrease the serum concentration of Abacavir.¤ (Darunavir) Protease Inhibitors may decrease the serum concentration of Abacavir.¤ (Fosamprenavir) Protease Inhibitors may decrease the serum concentration of Abacavir.¤ (Indinavir) Protease Inhibitors may decrease the serum concentration of Abacavir.¤ (Isoflurophate) May decrease the serum concentration of Abacavir.¤ (Lopinavir) Protease Inhibitors may decrease the serum concentration of Abacavir.¤ (Methadone) Methadone may diminish the therapeutic effect of Abacavir. Abacavir may decrease the serum concentration of Methadone.¤ (Nelfinavir) Protease Inhibitors may decrease the serum concentration of Abacavir.¤ (Ribavirin) May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.¤ (Ritonavir) Protease Inhibitors may decrease the serum concentration of Abacavir.¤ (Saquinavir) Protease Inhibitors may decrease the serum concentration of Abacavir.¤ (Simeprevir) May decrease the serum concentration of Abacavir.¤ (Tipranavir) Protease Inhibitors may decrease the serum concentration of Abacavir.', 'yes', '¤ Abacavir is partly metabolised through the alcohol-dehydrogenase enzyme system.\n¤ Alcohol significantly increases abacavir\'s area under the curve (about 41%).\n¤ Avoid alcohol.\n¤ Take without regard to meals.', 18, '100.00', '16.00', '30.00', '100.00', '0.00', '0101811400823', 'Generate Company Barcode', 'this is descriptions', '', 0, 0, 0, NULL, '2020-05-29 11:51:04', 'ACs', NULL, NULL, '68.00', '32.00', NULL, NULL, NULL, 'true', 1, 1, NULL, NULL),
(2, 'Acetazolamide ', 'C ', '¤ (Acetylsalicylic acid) May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.¤ (Alfentanil) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Aminosalicylic Acid) Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Exceptions: Brinzolamide; Dorzolamide.¤ (Amphetamine) May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Benzphetamine) May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.¤ (Bismuth Subsalicylate) Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Exceptions: Brinzolamide; Dorzolamide.¤ (Brinzolamide) May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.¤ (Buprenorphine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Butabarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Butethal) May enhance the hypotensive effect of Hypotensive Agents.¤ (Butorphanol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Carbamazepine) May increase the serum concentration of CarBAMazepine. Exceptions: Brinzolamide; Dorzolamide.¤ (Cathinone) Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines.¤ (Codeine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Dextroamphetamine) May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.¤ (Diclofenamide) May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.¤ (Dihydrocodeine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Dorzolamide) May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.¤ (Duloxetine) Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.¤ (Ethoxzolamide) May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.¤ (Fentanyl) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Flecainide) Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide.¤ (Fosphenytoin) May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically~ the risk for osteomalacia or rickets may be increased. Exceptions: Brinzolamide; Dorzolamide.¤ (Heptabarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Hexobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Hydromorphone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Levorphanol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Lisdexamfetamine) May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.¤ (Lithium) Carbonic Anhydrase Inhibitors may decrease the serum concentration of Lithium.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Magnesium salicylate) Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Exceptions: Brinzolamide; Dorzolamide.¤ (Mefloquine) Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.¤ (Memantine) Carbonic Anhydrase Inhibitors may decrease the excretion of Memantine.¤ (Metformin) May enhance the adverse/toxic effect of MetFORMIN. Specifically~ the risk of developing lactic acidosis may be increased. Exceptions: Brinzolamide; Dorzolamide.¤ (Methadone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Methamphetamine) May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.¤ (Methazolamide) May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.¤ (Methenamine hippurate) May diminish the therapeutic effect of Methenamine.¤ (Methenamine mandelate) May diminish the therapeutic effect of Methenamine.¤ (Methohexital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Mianserin) May diminish the therapeutic effect of Anticonvulsants.¤ (Morphine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Nalbuphine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Orlistat) May decrease the serum concentration of Anticonvulsants.¤ (Oxycodone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Oxymorphone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Pentobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Pethidine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Phendimetrazine) May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.¤ (Phentermine) May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.¤ (Phenytoin) May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically~ the risk for osteomalacia or rickets may be increased. Exceptions: Brinzolamide; Dorzolamide.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Primidone) May enhance the adverse/toxic effect of Primidone. Specifically~ osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone. Exceptions: Brinzolamide; Dorzolamide.¤ (Pseudoephedrine) May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).¤ (Quinidine) Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.¤ (Remifentanil) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Risperidone) Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.¤ (Salicylate-sodium) May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.¤ (Salsalate) Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Exceptions: Brinzolamide; Dorzolamide.¤ (Secobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Sodium bicarbonate) AcetaZOLAMIDE may enhance the adverse/toxic effect of Sodium Bicarbonate. Specifically~ the risk of renal calculus formation may be increased.¤ (Sufentanil) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Tapentadol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Topiramate) May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.¤ (Tramadol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Triprolidine) May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).¤ (Zonisamide) May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.', 'yes', '¤ Drink plenty of liquids.\n¤ Take with food; at least 6 hours before bedtime.', 1, '0.00', '0.00', '0.00', '0.00', '0.00', '010181140082', NULL, NULL, '', 0, 0, 0, NULL, '2020-05-17 10:01:58', NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 1, 1, NULL, NULL),
(3, 'Acetylcysteine', ' B ', '', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '5000.00', '', 'Has Its own Barcode', 'wolkdjsdkljflds', '', 0, 0, 0, NULL, '2020-05-17 10:02:46', 'NDDDD', NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(4, 'Acyclovir', ' B ', '', '', '', 0, '0.00', '15.00', '0.00', '20.00', '0.00', '1111', 'Generate Company Barcode', NULL, '', 0, 0, 0, NULL, '2020-05-29 01:26:22', NULL, NULL, NULL, '7.00', '3.00', NULL, NULL, NULL, 'true', 0, 1, NULL, NULL),
(5, 'Albendazole ', ' C ', '¤ (Carbamazepine) May decrease serum concentrations of the active metabolite(s) of Albendazole.¤ (Phenobarbital) May decrease serum concentrations of the active metabolite(s) of Albendazole.¤ (Phenytoin) Phenytoin may decrease serum concentrations of the active metabolite(s) of Albendazole.', 'yes', '', 2, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, '2020-05-13 00:33:25', NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(6, 'Allopurinol ', 'C ', '¤ (Acenocoumarol) May enhance the anticoagulant effect of Vitamin K Antagonists.¤ (Aluminum hydroxide) May decrease the absorption of Allopurinol. Exceptions: Sodium Bicarbonate.¤ (Aminophylline) May increase the serum concentration of Theophylline Derivatives.¤ (Amoxicillin) Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.¤ (Ampicillin) May enhance the potential for allergic or hypersensitivity reactions to Ampicillin.¤ (Azathioprine) Allopurinol may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. More specifically~ allopurinol may increase mercaptopurine serum concentrations and promote formation of active thioguanine nucleotides.¤ (Azilsartan medoxomil) Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Benazepril) ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.¤ (Bendamustine) Allopurinol may enhance the adverse/toxic effect of Bendamustine. Specifically~ the risk of severe skin reactions may be enhanced.¤ (Bendroflumethiazide) Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Bumetanide) Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically~ Loop Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Calcium carbonate) May decrease the absorption of Allopurinol. Exceptions: Sodium Bicarbonate.¤ (Captopril) ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.¤ (Carbamazepine) Allopurinol may increase the serum concentration of CarBAMazepine.¤ (Chlorothiazide) Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Chlorpropamide) Allopurinol may increase the serum concentration of ChlorproPAMIDE.¤ (Chlorthalidone) Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Cilazapril) ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.¤ (Cyclophosphamide) Allopurinol may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ bone marrow suppression.¤ (Didanosine) Allopurinol may increase the serum concentration of Didanosine.¤ (Enalapril) ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.¤ (Ethacrynic acid) Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically~ Loop Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Fosinopril) ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.¤ (Furosemide) Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically~ Loop Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Hydrochlorothiazide) Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Indapamide) Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Lisinopril) ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.¤ (Magnesium oxide) May decrease the absorption of Allopurinol. Exceptions: Sodium Bicarbonate.¤ (Mercaptopurine) Allopurinol may increase the serum concentration of Mercaptopurine. Allopurinol may also promote formation of active thioguanine nucleotides.¤ (Methyclothiazide) Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Metolazone) Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Moexipril) ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.¤ (Perindopril) ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.¤ (Quinapril) ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.¤ (Ramipril) ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.¤ (Theophylline) May increase the serum concentration of Theophylline Derivatives.¤ (Torasemide) Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically~ Loop Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Trandolapril) ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.', 'yes', '¤ Avoid alcohol.\n¤ Take with a full glass of water.\n¤ Take with food.', 2, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, '2020-05-17 07:39:19', NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(7, 'Aluminium + Magnesium Hydroxide ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(8, 'Aminophylline / Theophylline Ethylenediamine ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(9, 'Amiodarone ', ' D ', '¤ (Acebutolol) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Acenocoumarol) May enhance the anticoagulant effect of Vitamin K Antagonists. Amiodarone may increase the serum concentration of Vitamin K Antagonists.¤ (Afatinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.¤ (Agalsidase beta) May diminish the therapeutic effect of Agalsidase Beta.¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Atazanavir) Atazanavir may increase the serum concentration of Amiodarone.¤ (Atenolol) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Atorvastatin) May decrease the metabolism of HMG-CoA Reductase Inhibitors.¤ (Bendroflumethiazide) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Betaxolol) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Bisoprolol) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Boceprevir) May increase the serum concentration of Amiodarone.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Bosutinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.¤ (Brentuximab vedotin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.¤ (Bretylium) May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.¤ (Carteolol) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Carvedilol) CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically~ concentrations of the S-carvedilol enantiomer may be increased.¤ (Cholestyramine) Bile Acid Sequestrants may decrease the bioavailability of Amiodarone.¤ (Cimetidine) Cimetidine may increase the serum concentration of Amiodarone.¤ (Clopidogrel) May decrease serum concentrations of the active metabolite(s) of Clopidogrel.¤ (Codeine) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.¤ (Colchicine) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Colesevelam) Bile Acid Sequestrants may decrease the bioavailability of Amiodarone.¤ (Colestipol) Bile Acid Sequestrants may decrease the bioavailability of Amiodarone.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Cyclophosphamide) Cyclophosphamide may enhance the adverse/toxic effect of Amiodarone. Specifically~ the risk of pulmonary toxicity may be enhanced.¤ (Dabigatran etexilate) Amiodarone may increase the serum concentration of Dabigatran Etexilate.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Darunavir) May increase the serum concentration of Amiodarone.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Digoxin) May increase the serum concentration of Cardiac Glycosides.¤ (Diltiazem) Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported.¤ (Disopyramide) May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).¤ (Dronabinol) CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.¤ (Esmolol) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Etravirine) May decrease the serum concentration of Amiodarone.¤ (Everolimus) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.¤ (Fesoterodine) CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.¤ (Fingolimod) May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).¤ (Flecainide) Amiodarone may enhance the QTc-prolonging effect of Flecainide. Amiodarone may increase the serum concentration of Flecainide.¤ (Fluvastatin) May decrease the metabolism of HMG-CoA Reductase Inhibitors.¤ (Fosamprenavir) May increase the serum concentration of Amiodarone.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Fosphenytoin) May enhance the QTc-prolonging effect of Amiodarone. Amiodarone may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Amiodarone.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Indinavir) Indinavir may increase the serum concentration of Amiodarone.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Labetalol) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Lacosamide) Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.¤ (Ledipasvir) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Lopinavir) May enhance the QTc-prolonging effect of Amiodarone. Lopinavir may increase the serum concentration of Amiodarone. More specifically~ Lopinavir/Ritonavir may increase the serum concentration of Amiodarone.¤ (Loratadine) May increase the serum concentration of Loratadine.¤ (Lovastatin) May decrease the metabolism of HMG-CoA Reductase Inhibitors.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Metoprolol) CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.¤ (Mifepristone) May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.¤ (Mipomersen) Amiodarone may enhance the hepatotoxic effect of Mipomersen.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nadolol) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Nebivolol) CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.¤ (Nelfinavir) Nelfinavir may increase the serum concentration of Amiodarone.¤ (Orlistat) Orlistat may decrease the absorption of Amiodarone.¤ (Pazopanib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.¤ (Penbutolol) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Phenytoin) May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Amiodarone.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Pindolol) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Porfimer) Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.¤ (Procainamide) May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).¤ (Procaine) May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).¤ (Propafenone) Amiodarone may enhance the adverse/toxic effect of Propafenone. Specifically~ the combination may result in altered cardiac conduction and repolarization. Amiodarone may increase the serum concentration of Propafenone.¤ (Propranolol) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (prucalopride) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.¤ (Quinidine) May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).¤ (Rifampicin) Rifampin may decrease serum concentrations of the active metabolite(s) of Amiodarone. Specifically~ desethylamiodarone concentrations may decrease. Rifampin may decrease the serum concentration of Amiodarone.¤ (Rifaximin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.¤ (Ritonavir) Ritonavir may increase the serum concentration of Amiodarone.¤ (Rivaroxaban) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.¤ (Rosuvastatin) May decrease the metabolism of HMG-CoA Reductase Inhibitors.¤ (Ruxolitinib) May enhance the bradycardic effect of Bradycardia-Causing Agents.¤ (Saquinavir) May enhance the QTc-prolonging effect of Amiodarone. Saquinavir may increase the serum concentration of Amiodarone.¤ (Silodosin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Simvastatin) May decrease the metabolism of HMG-CoA Reductase Inhibitors.¤ (Sofosbuvir) May enhance the bradycardic effect of Amiodarone.¤ (Tamoxifen) CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.¤ (Telaprevir) May enhance the adverse/toxic effect of Amiodarone. Telaprevir may increase the serum concentration of Amiodarone.¤ (Thioridazine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Timolol) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Tipranavir) Tipranavir may increase the serum concentration of Amiodarone.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tofacitinib) May enhance the bradycardic effect of Bradycardia-Causing Agents.¤ (Topotecan) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.¤ (Tramadol) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Verteporfin) Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.', 'yes', '¤ Grapefruit and grapefruit juice should be avoided throughout treatment.\n¤ Grapefruit can significantly increase serum levels of this product.\n¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(10, 'Amitriptyline', ' C ', '¤ (Acepromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Acetophenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Aclidinium) May enhance the anticholinergic effect of Anticholinergic Agents.¤ (Altretamine) May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.¤ (Amisulpride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Amphetamine) Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.¤ (Aripiprazole) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Batimastat) May increase the serum concentration of Tricyclic Antidepressants.¤ (Benzquinamide) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Buprenorphine) CNS Depressants may enhance the CNS depressant effect of Buprenorphine.¤ (Bupropion) May decrease the metabolism of Tricyclic Antidepressants.¤ (Butabarbital) May increase the metabolism of Tricyclic Antidepressants.¤ (Butethal) May increase the metabolism of Tricyclic Antidepressants.¤ (Carbamazepine) May increase the metabolism of Tricyclic Antidepressants.¤ (Carphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Cathinone) Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.¤ (Chlormezanone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Chlorpromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Chlorprothixene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Cimetidine) May decrease the metabolism of Tricyclic Antidepressants.¤ (Cinacalcet) May increase the serum concentration of Tricyclic Antidepressants.¤ (Cisapride) Amitriptyline may enhance the arrhythmogenic effect of Cisapride.¤ (Citalopram) Tricyclic Antidepressants may enhance the adverse/toxic effect of Citalopram. Tricyclic Antidepressants may increase the serum concentration of Citalopram. Citalopram may increase the serum concentration of Tricyclic Antidepressants.¤ (Clozapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Dapoxetine) May enhance the adverse/toxic effect of Serotonin Modulators.¤ (Darunavir) May increase the serum concentration of CYP2D6 Substrates.¤ (Desmopressin) Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.¤ (Dexmethylphenidate) May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Droperidol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Duloxetine) May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. DULoxetine may decrease the metabolism of Tricyclic Antidepressants.¤ (Escitalopram) Tricyclic Antidepressants may enhance the adverse/toxic effect of Escitalopram. Escitalopram may increase the serum concentration of Tricyclic Antidepressants.¤ (Fencamfamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluconazole) May enhance the QTc-prolonging effect of Fluconazole. Fluconazole may increase the serum concentration of Amitriptyline.¤ (Fluoxetine) May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.¤ (Flupentixol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluspirilene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluvoxamine) May enhance the adverse/toxic effect of Tricyclic Antidepressants. FluvoxaMINE may increase the serum concentration of Tricyclic Antidepressants.¤ (Haloperidol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Heptabarbital) May increase the metabolism of Tricyclic Antidepressants.¤ (Hexobarbital) May increase the metabolism of Tricyclic Antidepressants.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Isoflurophate) May increase the serum concentration of Tricyclic Antidepressants.¤ (Itopride) Anticholinergic Agents may diminish the therapeutic effect of Itopride.¤ (Linezolid) May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.¤ (Lithium) May enhance the neurotoxic effect of Tricyclic Antidepressants.¤ (Loxapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Mesoridazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Methohexital) May increase the metabolism of Tricyclic Antidepressants.¤ (Methotrimeprazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Methylphenidate) May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.¤ (Metoclopramide) May enhance the adverse/toxic effect of Tricyclic Antidepressants.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mianserin) May enhance the anticholinergic effect of Anticholinergic Agents.¤ (Mifepristone) May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).¤ (Mirabegron) Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.¤ (Molindone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Olanzapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ondansetron) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Paliperidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Panobinostat) May increase the serum concentration of CYP2D6 Substrates.¤ (Paroxetine) May enhance the adverse/toxic effect of Tricyclic Antidepressants. PARoxetine may increase the serum concentration of Tricyclic Antidepressants.¤ (Peginterferon alfa-2b) May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.¤ (Pentobarbital) May increase the metabolism of Tricyclic Antidepressants.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Perphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Pimozide) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Piperacetazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Potassium Chloride) Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.¤ (Pramipexole) CNS Depressants may enhance the sedative effect of Pramipexole.¤ (Pramlintide) May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.¤ (Primidone) May increase the metabolism of Tricyclic Antidepressants.¤ (Prochlorperazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Promazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Quetiapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Quinidine) Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.¤ (Remoxipride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Reserpine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Risperidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ropinirole) CNS Depressants may enhance the sedative effect of ROPINIRole.¤ (Rotigotine) CNS Depressants may enhance the sedative effect of Rotigotine.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Secobarbital) May increase the metabolism of Tricyclic Antidepressants.¤ (Secretin) Anticholinergic Agents may diminish the therapeutic effect of Secretin.¤ (Sertindole) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Sertraline) May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants.¤ (Simeprevir) May increase the serum concentration of Tricyclic Antidepressants.¤ (Sulpiride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Thioridazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Thiothixene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Tiotropium) Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.¤ (Topiramate) Topiramate may enhance the CNS depressant effect of Amitriptyline. Topiramate may increase serum concentrations of the active metabolite(s) of Amitriptyline. Topiramate may increase the serum concentration of Amitriptyline.¤ (Tramadol) Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.¤ (Trifluoperazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Triflupromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Yohimbine) Tricyclic Antidepressants may increase the serum concentration of Yohimbine.¤ (Ziprasidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.¤ (Zuclopenthixol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', 'yes', '¤ Avoid alcohol.\n¤ Avoid excessive quantities of coffee or tea (caffeine).\n¤ Avoid St.John\'s Wort.\n¤ Take with food to reduce irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', 'Has Its own Barcode', 'description', '', 0, 0, 0, NULL, '2019-09-10 12:19:01', NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(11, 'Amlodipine ', ' C ', '¤ (Alfuzosin) May enhance the hypotensive effect of Antihypertensives.¤ (Amifostine) Antihypertensives may enhance the hypotensive effect of Amifostine.¤ (Amobarbital) Barbiturates may increase the metabolism of Calcium Channel Blockers.¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Atracurium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Batimastat) May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Butabarbital) Barbiturates may increase the metabolism of Calcium Channel Blockers.¤ (Butalbital) Barbiturates may increase the metabolism of Calcium Channel Blockers.¤ (Butethal) May increase the metabolism of Calcium Channel Blockers.¤ (Calcium Acetate) Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.¤ (Calcium carbonate) Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.¤ (Calcium Chloride) Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.¤ (Carbamazepine) May increase the metabolism of Calcium Channel Blockers (Dihydropyridine).¤ (Cimetidine) Cimetidine may increase the serum concentration of Calcium Channel Blockers.¤ (Cisatracurium Besylate) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Clarithromycin) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Clopidogrel) Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dapoxetine) May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Diazoxide) May enhance the hypotensive effect of Antihypertensives.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Doxazosin) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Duloxetine) Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.¤ (Efavirenz) May decrease the serum concentration of Calcium Channel Blockers.¤ (Fluconazole) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Fosphenytoin) Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.¤ (Heptabarbital) May increase the metabolism of Calcium Channel Blockers.¤ (Hexobarbital) May increase the metabolism of Calcium Channel Blockers.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Isoflurophate) May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).¤ (Itraconazole) Antifungal Agents (Azole Derivatives~ Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically~ itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Magnesium oxide) May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Magnesium salicylate) May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Melatonin) May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).¤ (Methohexital) May increase the metabolism of Calcium Channel Blockers.¤ (Methylphenidate) May diminish the antihypertensive effect of Antihypertensives.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nafcillin) May increase the metabolism of Calcium Channel Blockers.¤ (Nitroprusside) May enhance the hypotensive effect of Nitroprusside.¤ (Obinutuzumab) Antihypertensives may enhance the hypotensive effect of Obinutuzumab.¤ (Pancuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Pentobarbital) Barbiturates may increase the metabolism of Calcium Channel Blockers.¤ (Pentoxifylline) May enhance the hypotensive effect of Antihypertensives.¤ (Phenobarbital) Barbiturates may increase the metabolism of Calcium Channel Blockers.¤ (Phenoxybenzamine) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Phentolamine) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Phenytoin) May increase the serum concentration of Phenytoin.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Posaconazole) Antifungal Agents (Azole Derivatives~ Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically~ itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.¤ (Prazosin) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Primidone) May increase the metabolism of Calcium Channel Blockers.¤ (Quinidine) May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.¤ (Rifampicin) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Rifapentine) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Risperidone) Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.¤ (Rituximab) Antihypertensives may enhance the hypotensive effect of RiTUXimab.¤ (Rocuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Secobarbital) May increase the metabolism of Calcium Channel Blockers.¤ (Silodosin) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).¤ (Simvastatin) AmLODIPine may increase the serum concentration of Simvastatin.¤ (Sulfisoxazole) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Tadalafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Tamsulosin) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Telithromycin) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Terazosin) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Vardenafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Vecuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Voriconazole) Antifungal Agents (Azole Derivatives~ Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically~ itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.¤ (Yohimbine) May diminish the antihypertensive effect of Antihypertensives.', 'yes', '¤ Avoid natural licorice.\n¤ Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of amlodipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of amlodipine and may cause toxicity. Avoid grapefruit products while on this medication. \n¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, '2020-05-14 15:05:03', NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(12, 'Amoxicillin', ' B ', '¤ (Acenocoumarol) May enhance the anticoagulant effect of Vitamin K Antagonists.¤ (Allopurinol) Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.¤ (Amikacin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Biotin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Doxycycline) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Kanamycin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Methotrexate) May increase the serum concentration of Methotrexate.¤ (Minocycline) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Mycophenolate mofetil) May decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.¤ (Mycophenolic acid) May decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.¤ (Neomycin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Probenecid) Probenecid may increase the serum concentration of Penicillins.¤ (Streptomycin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Tetracycline) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', 'yes', '¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', 'Has Its own Barcode', NULL, '', 0, 0, 0, NULL, '2019-09-10 12:46:11', NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(13, 'Ampicillin Sodium ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(14, 'Asparaginase ', ' C ', '', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(15, 'Aspirin ', ' C in first and second trimester and D in third trimester ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, '2020-04-20 10:34:36', NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(16, 'Atazanavir ', ' B ', '¤ (Abacavir) Protease Inhibitors may decrease the serum concentration of Abacavir.¤ (Acetohexamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (ado-trastuzumab emtansine) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically~ strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.¤ (Alfuzosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.¤ (Almotriptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.¤ (Alogliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Alosetron) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.¤ (Alprazolam) Protease Inhibitors may increase the serum concentration of ALPRAZolam.¤ (Aluminum hydroxide) May decrease the absorption of Atazanavir.¤ (Amiodarone) Atazanavir may increase the serum concentration of Amiodarone.¤ (Apixaban) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.¤ (Aripiprazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.¤ (Astemizole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole.¤ (Atorvastatin) Protease Inhibitors may increase the serum concentration of AtorvaSTATin.¤ (Avanafil) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.¤ (Axitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.¤ (Batimastat) May increase the serum concentration of other Protease Inhibitors.¤ (Bedaquiline) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.¤ (Belinostat) Atazanavir may increase the serum concentration of Belinostat.¤ (Boceprevir) May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir.¤ (Bortezomib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.¤ (Bosentan) May increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Atazanavir.¤ (Bosutinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.¤ (Brentuximab vedotin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.¤ (Brinzolamide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.¤ (Buprenorphine) May increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir.¤ (Cabazitaxel) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.¤ (Cabozantinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.¤ (Calcium carbonate) May decrease the absorption of Atazanavir.¤ (Canagliflozin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Carbamazepine) May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.¤ (Chlorpropamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Cilostazol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.¤ (Cimetidine) H2-Antagonists may decrease the serum concentration of Atazanavir.¤ (Cisapride) Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.¤ (Clarithromycin) Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Colchicine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Conivaptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.¤ (Crizotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.¤ (Cyclophosphamide) Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dapoxetine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine.¤ (Dasatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Delavirdine) May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.¤ (Desogestrel) May increase the serum concentration of Contraceptives (Progestins).¤ (Didanosine) May decrease the serum concentration of Didanosine. Reported with enteric coated didanosine capsules. Didanosine may decrease the serum concentration of Atazanavir. Specifically~ the buffered formulation of didanosine may decrease atazanavir absorption.¤ (Digoxin) Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Disulfiram) May diminish the therapeutic effect of Disulfiram.¤ (Domperidone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone.¤ (Dronabinol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronabinol.¤ (Dronedarone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.¤ (Drospirenone) May increase the serum concentration of Contraceptives (Progestins).¤ (Dutasteride) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.¤ (Efavirenz) May decrease the serum concentration of Atazanavir.¤ (Eliglustat) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eliglustat.¤ (Enfuvirtide) May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.¤ (Eplerenone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.¤ (Erlotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.¤ (Esomeprazole) Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.¤ (Ethynodiol) May increase the serum concentration of Contraceptives (Progestins).¤ (Etonogestrel) May increase the serum concentration of Contraceptives (Progestins).¤ (Etravirine) Atazanavir may increase the serum concentration of Etravirine. Etravirine may decrease the serum concentration of Atazanavir.¤ (Everolimus) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.¤ (Famotidine) H2-Antagonists may decrease the serum concentration of Atazanavir.¤ (Fentanyl) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Fesoterodine) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.¤ (Fluvastatin) Atazanavir may increase the serum concentration of Fluvastatin.¤ (Gliclazide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glimepiride) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Gliquidone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glyburide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Guanfacine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.¤ (Halofantrine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.¤ (Hydrocodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.¤ (Ifosfamide) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.¤ (Iloperidone) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically~ concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.¤ (Imatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib.¤ (Indinavir) May enhance the adverse/toxic effect of Indinavir. Indinavir may enhance the adverse/toxic effect of Atazanavir.¤ (Insulin Aspart) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Detemir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glargine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glulisine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Lispro) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Regular) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin~ isophane) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Irinotecan) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan.¤ (Isoflurophate) May increase the serum concentration of other Protease Inhibitors.¤ (Ivacaftor) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.¤ (Ixabepilone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.¤ (Lacosamide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide.¤ (Lamotrigine) May decrease the serum concentration of LamoTRIgine.¤ (Lansoprazole) Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.¤ (Lapatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.¤ (Lercanidipine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine.¤ (Levobupivacaine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine.¤ (Levomilnacipran) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.¤ (Levonorgestrel) May increase the serum concentration of Contraceptives (Progestins).¤ (Linagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Lomitapide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.¤ (Lovastatin) Protease Inhibitors may increase the serum concentration of Lovastatin.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Lurasidone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.¤ (MACITENTAN) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan.¤ (Magnesium oxide) May decrease the absorption of Atazanavir.¤ (Maraviroc) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.¤ (Medroxyprogesterone Acetate) May increase the serum concentration of Contraceptives (Progestins).¤ (Mestranol) May increase the serum concentration of Contraceptives (Progestins).¤ (Metformin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Methylprednisolone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Midazolam) Protease Inhibitors may increase the serum concentration of Midazolam.¤ (Mifepristone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.¤ (Minocycline) Minocycline may decrease the serum concentration of Atazanavir.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nefazodone) Protease Inhibitors may increase the serum concentration of Nefazodone.¤ (Nevirapine) May increase the serum concentration of Nevirapine. Nevirapine may decrease the serum concentration of Atazanavir.¤ (Nilotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.¤ (Nisoldipine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.¤ (Nizatidine) H2-Antagonists may decrease the serum concentration of Atazanavir.¤ (Norelgestromin) May increase the serum concentration of Contraceptives (Progestins).¤ (Norethindrone) May increase the serum concentration of Contraceptives (Progestins).¤ (Norgestimate) May increase the serum concentration of Contraceptives (Progestins).¤ (Omeprazole) Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.¤ (Ospemifene) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.¤ (Oxybutynin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin.¤ (Oxycodone) CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased.¤ (Panobinostat) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.¤ (Pantoprazole) Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.¤ (Paricalcitol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.¤ (Pazopanib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of PAZOPanib.¤ (Pimecrolimus) CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.¤ (Pimozide) Protease Inhibitors may increase the serum concentration of Pimozide.¤ (Pitavastatin) Atazanavir may increase the serum concentration of Pitavastatin.¤ (Ponatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.¤ (Posaconazole) May increase the serum concentration of Atazanavir.¤ (Pranlukast) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast.¤ (Prasugrel) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.¤ (Prednisone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE.¤ (Propafenone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.¤ (Quetiapine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of QUEtiapine.¤ (Quinidine) May increase the serum concentration of QuiNIDine.¤ (Rabeprazole) Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.¤ (Ranitidine) H2-Antagonists may decrease the serum concentration of Atazanavir.¤ (Ranolazine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.¤ (Regorafenib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.¤ (Repaglinide) May increase the serum concentration of Repaglinide.¤ (Retapamulin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.¤ (Rifabutin) Atazanavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Atazanavir may increase the serum concentration of Rifabutin.¤ (Rifampicin) Rifampin may decrease the serum concentration of Atazanavir.¤ (Rilpivirine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rilpivirine.¤ (Riociguat) Protease Inhibitors may increase the serum concentration of Riociguat.¤ (Rivaroxaban) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. For clarithromycin~ refer to more specific clarithromycin-rivaroxaban monograph recommendations.¤ (Romidepsin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.¤ (Rosiglitazone) May increase the serum concentration of Rosiglitazone.¤ (Rosuvastatin) Protease Inhibitors may increase the serum concentration of Rosuvastatin.¤ (Ruxolitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.¤ (Salmeterol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.¤ (Saxagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Sildenafil) Protease Inhibitors may increase the serum concentration of Sildenafil.¤ (Silodosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of other Protease Inhibitors.¤ (Simvastatin) Protease Inhibitors may increase the serum concentration of Simvastatin.¤ (Sodium bicarbonate) Antacids may decrease the absorption of Atazanavir.¤ (Sorafenib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.¤ (Suvorexant) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant.¤ (Tadalafil) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.¤ (Tamsulosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.¤ (Telaprevir) Atazanavir may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Atazanavir.¤ (Temsirolimus) Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus~ the active metabolite~ may be increased~ likely due to inhibition of CYP-mediated metabolism.¤ (Tenofovir) May increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Atazanavir.¤ (Terfenadine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Terfenadine.¤ (Ticagrelor) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.¤ (Tipranavir) May decrease the serum concentration of Protease Inhibitors.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tofacitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.¤ (Tolbutamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Tolterodine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.¤ (Tolvaptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.¤ (Toremifene) CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.¤ (Trabectedin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin.¤ (Trazodone) Atazanavir may increase the serum concentration of TraZODone.¤ (Triazolam) Protease Inhibitors may increase the serum concentration of Triazolam.¤ (Ulipristal) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.¤ (Vardenafil) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.¤ (Vemurafenib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.¤ (Vilazodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.¤ (Vildagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Vorapaxar) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar.¤ (Voriconazole) May decrease the serum concentration of Voriconazole. Atazanavir may increase the serum concentration of Voriconazole. Voriconazole may decrease the serum concentration of Atazanavir.¤ (Warfarin) Atazanavir may increase the serum concentration of Warfarin.¤ (Zidovudine) Protease Inhibitors may decrease the serum concentration of Zidovudine.¤ (Zopiclone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.¤ (Zuclopenthixol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.', 'yes', '¤ Administration with food reduces pharmacokinetic variability.\n¤ Food increases product absorption.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(17, 'Atenolol ', ' D ', '¤ (Acetylcholine) Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.¤ (Amifostine) Antihypertensives may enhance the hypotensive effect of Amifostine.¤ (Amiodarone) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Ampicillin) May decrease the bioavailability of Atenolol.¤ (Bretylium) May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.¤ (Bupivacaine) Beta-Blockers may increase the serum concentration of Bupivacaine.¤ (Butabarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Butethal) May enhance the hypotensive effect of Hypotensive Agents.¤ (Carbachol) Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.¤ (Diazoxide) May enhance the hypotensive effect of Antihypertensives.¤ (Dipyridamole) May enhance the bradycardic effect of Beta-Blockers.¤ (Disopyramide) May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.¤ (Dronedarone) May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6.¤ (Duloxetine) Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.¤ (Fingolimod) Beta-Blockers may enhance the bradycardic effect of Fingolimod.¤ (Floctafenine) May enhance the adverse/toxic effect of Beta-Blockers.¤ (Glycopyrrolate) May increase the serum concentration of Atenolol.¤ (Heptabarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Hexobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Lacosamide) Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.¤ (Mepivacaine) Beta-Blockers may increase the serum concentration of Mepivacaine.¤ (Methacholine) Beta-Blockers may enhance the adverse/toxic effect of Methacholine.¤ (Methohexital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Methylphenidate) May diminish the antihypertensive effect of Antihypertensives.¤ (Midodrine) Beta-Blockers may enhance the bradycardic effect of Midodrine.¤ (Obinutuzumab) Antihypertensives may enhance the hypotensive effect of Obinutuzumab.¤ (Pentobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Pentoxifylline) May enhance the hypotensive effect of Antihypertensives.¤ (Primidone) May enhance the hypotensive effect of Hypotensive Agents.¤ (Regorafenib) May enhance the bradycardic effect of Beta-Blockers.¤ (Reserpine) May enhance the hypotensive effect of Beta-Blockers.¤ (Risperidone) Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.¤ (Rituximab) Antihypertensives may enhance the hypotensive effect of RiTUXimab.¤ (Rivastigmine) May enhance the bradycardic effect of Beta-Blockers.¤ (Ruxolitinib) May enhance the bradycardic effect of Bradycardia-Causing Agents.¤ (Secobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Tadalafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Tofacitinib) May enhance the bradycardic effect of Bradycardia-Causing Agents.¤ (Vardenafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Yohimbine) May diminish the antihypertensive effect of Antihypertensives.', 'yes', '¤ Consult your doctor before taking large amounts of Vitamin K (Green leafy vegetables).\n¤ Take 30-60 minutes before meals, take at the same time each day.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(18, 'Atorvastatin ', ' x ', '¤ (Afatinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.¤ (Aliskiren) AtorvaSTATin may increase the serum concentration of Aliskiren.¤ (Aluminum hydroxide) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Amiodarone) May decrease the metabolism of HMG-CoA Reductase Inhibitors.¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Atazanavir) Protease Inhibitors may increase the serum concentration of AtorvaSTATin.¤ (Batimastat) May increase the serum concentration of AtorvaSTATin.¤ (Bezafibrate) May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically~ bezafibrate may increase the serum concentration of fluvastatin¤ (Boceprevir) May increase the serum concentration of AtorvaSTATin.¤ (Bosentan) May increase the metabolism of HMG-CoA Reductase Inhibitors.¤ (Bosutinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.¤ (Brentuximab vedotin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.¤ (Calcium carbonate) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Cholestyramine) Bile Acid Sequestrants may decrease the serum concentration of AtorvaSTATin.¤ (Cimetidine) May enhance the adverse/toxic effect of Cimetidine. Specifically~ there is a theoretical potential for enhanced effects on reducing endogenous steroid activity.¤ (Clarithromycin) May increase the serum concentration of AtorvaSTATin.¤ (Colchicine) May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Colesevelam) Bile Acid Sequestrants may decrease the serum concentration of AtorvaSTATin.¤ (Colestipol) Bile Acid Sequestrants may decrease the serum concentration of AtorvaSTATin.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dabigatran etexilate) AtorvaSTATin may decrease the serum concentration of Dabigatran Etexilate.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Danazol) May increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Daptomycin) HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically~ the risk of skeletal muscle toxicity may be increased.¤ (Darunavir) Protease Inhibitors may increase the serum concentration of AtorvaSTATin.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Digoxin) May increase the serum concentration of Digoxin.¤ (Diltiazem) May increase the serum concentration of Diltiazem. Diltiazem may increase the serum concentration of AtorvaSTATin.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Dronedarone) May increase the serum concentration of AtorvaSTATin.¤ (Efavirenz) May decrease the serum concentration of AtorvaSTATin.¤ (Eltrombopag) May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.¤ (Etravirine) May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin~ lovastatin and simvastatin. Conversely~ levels of fluvastatin may be increased.¤ (Everolimus) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.¤ (Fluconazole) Fluconazole may increase the serum concentration of AtorvaSTATin.¤ (Fosamprenavir) Protease Inhibitors may increase the serum concentration of AtorvaSTATin.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Fosphenytoin) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Gemfibrozil) May enhance the myopathic (rhabdomyolysis) effect of AtorvaSTATin. Gemfibrozil may increase the serum concentration of AtorvaSTATin.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Indinavir) Protease Inhibitors may increase the serum concentration of AtorvaSTATin.¤ (Isoflurophate) May increase the serum concentration of AtorvaSTATin.¤ (Itraconazole) May increase the serum concentration of AtorvaSTATin.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Ledipasvir) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Lopinavir) Protease Inhibitors may increase the serum concentration of AtorvaSTATin.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Magnesium oxide) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Midazolam) May increase the serum concentration of Midazolam.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nelfinavir) Protease Inhibitors may increase the serum concentration of AtorvaSTATin.¤ (Niacin) May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.¤ (Pazopanib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.¤ (Phenytoin) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Posaconazole) May increase the serum concentration of AtorvaSTATin.¤ (prucalopride) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.¤ (Quinine) May increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Raltegravir) May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors.¤ (Ranolazine) Ranolazine may increase the serum concentration of AtorvaSTATin.¤ (Rifaximin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.¤ (Ritonavir) Protease Inhibitors may increase the serum concentration of AtorvaSTATin.¤ (Rivaroxaban) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.¤ (Saquinavir) Protease Inhibitors may increase the serum concentration of AtorvaSTATin.¤ (Sildenafil) May decrease the metabolism of HMG-CoA Reductase Inhibitors.¤ (Silodosin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of AtorvaSTATin.¤ (Spironolactone) May enhance the adverse/toxic effect of Spironolactone. Specifically~ there is a theoretical potential for enhanced effects on reducing endogenous steroid activity.¤ (Sulfisoxazole) Erythromycin (Systemic) may increase the serum concentration of AtorvaSTATin.¤ (Telaprevir) May increase the serum concentration of AtorvaSTATin.¤ (Telithromycin) Telithromycin may increase the serum concentration of AtorvaSTATin.¤ (Teriflunomide) May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.¤ (Tipranavir) Tipranavir may increase the serum concentration of AtorvaSTATin.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Topotecan) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.¤ (Trabectedin) HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.¤ (Verapamil) AtorvaSTATin may increase the serum concentration of Verapamil. Verapamil may increase the serum concentration of AtorvaSTATin.¤ (Voriconazole) Voriconazole may increase the serum concentration of AtorvaSTATin.', 'yes', '¤ Avoid alcohol.\n¤ Avoid drastic changes in dietary habit.\n¤ Avoid taking grapefruit or grapefruit juice throughout treatment. Grapefruit can significantly increase serum levels of this product.\n¤ Food may decrease maximum plasma levels and area under the curve, but this is clinically inconsequential according to the manufacturer.\n¤ Take with low fat meal.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(19, 'Atracurium ', ' C ', '¤ (Amikacin) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Amlodipine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Amrinone) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Arbekacin) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Bepridil) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Capreomycin) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Colistimethate) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Felodipine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Flunarizine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Framycetin) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Gabapentin) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Gentamicin) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Isradipine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Kanamycin) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Lamotrigine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Lercanidipine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Lithium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Magnesium Sulfate) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Neomycin) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Netilmicin) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Nicardipine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Nimodipine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Nisoldipine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Nitrendipine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Perhexiline) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Prenylamine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Procainamide) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Quinidine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Quinine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Ribostamycin) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Risedronate) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Spectinomycin) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Spironolactone) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Streptomycin) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Tobramycin) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Vancomycin) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Verapamil) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(20, 'Atropine Sulfate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(21, 'Azathioprine Sodium ', ' D ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(22, 'Azithromycin ', ' B ', '', 'yes', '¤ Do not take Aluminum or magnesium antacids or supplements while on this medication.\n¤ Take on empty stomach: 1 hour before or 2 hours after meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(23, 'Beclomethasone Dipropionate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, '2020-03-22 04:42:13', NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(24, 'Beractant ', 'Not applicable ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, '2020-03-22 04:42:13', NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(25, 'Betamethasone Valerate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(26, 'Betaxolol Hydrochloride ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(27, 'Biclutomide ', ' x ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(28, 'Biperiden Hydrochloride ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(29, 'Bisacodyl ', ' C ', '¤ (Aluminum hydroxide) Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine. Gastric irritation and/or cramps may occur.¤ (Calcium carbonate) Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine. Gastric irritation and/or cramps may occur.¤ (Magnesium oxide) May diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine. Gastric irritation and/or cramps may occur.¤ (Sodium bicarbonate) Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine. Gastric irritation and/or cramps may occur.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(30, 'Bleomycin Sulfate ', ' D ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(31, 'Brimonidine Tartrate ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(32, 'Bromocriptine ', ' C ', '¤ (Acetohexamide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Acetylsalicylic acid) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.¤ (Amisulpride) Anti-Parkinson\'s Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride. Amisulpride may diminish the therapeutic effect of Anti-Parkinson\'s Agents (Dopamine Agonist).¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Batimastat) May increase the serum concentration of Ergot Derivatives.¤ (Buformin) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Bupropion) Anti-Parkinson\'s Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion.¤ (Chlorpropamide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dapoxetine) May enhance the adverse/toxic effect of Serotonin Modulators.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Dihydrotestosterone) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Ethanol) Alcohol (Ethyl) may enhance the adverse/toxic effect of Bromocriptine. Bromocriptine may enhance the adverse/toxic effect of Alcohol (Ethyl).¤ (Exenatide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Gliclazide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Glimepiride) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Glipizide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Glucagon recombinant) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Glyburide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Insulin Aspart) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin Glargine) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin Lispro) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin~ isophane) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin~ porcine) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Isoflurophate) May increase the serum concentration of Ergot Derivatives.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Lanreotide) Somatostatin Analogs may increase the serum concentration of Bromocriptine. Somatostatin Analogs may also delay bromocriptine absorption and time to maximum plasma concentrations.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Lorcaserin) May enhance the adverse/toxic effect of Ergot Derivatives. Specifically~ use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Methylphenidate) May enhance the adverse/toxic effect of Anti-Parkinson\'s Agents (Dopamine Agonist).¤ (Metoclopramide) May diminish the therapeutic effect of Anti-Parkinson\'s Agents (Dopamine Agonist).¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Mitiglinide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Nateglinide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Nitroglycerin) Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.¤ (Octreotide) Somatostatin Analogs may increase the serum concentration of Bromocriptine. Somatostatin Analogs may also delay bromocriptine absorption and time to maximum plasma concentrations.¤ (Oxandrolone) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.¤ (Pasireotide) Somatostatin Analogs may increase the serum concentration of Bromocriptine. Somatostatin Analogs may also delay bromocriptine absorption and time to maximum plasma concentrations.¤ (Pegvisomant) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.¤ (Phenformin) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Pioglitazone) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Repaglinide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Salicylate-sodium) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.¤ (Simeprevir) May increase the serum concentration of Ergot Derivatives.¤ (Sulodexide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Testosterone) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.¤ (Tolbutamide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', 'yes', '¤ Avoid alcohol.\n¤ Take with food to reduce irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(33, 'Bupivacaine Hydrochloride ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(34, 'Caffeine Citrate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(35, 'Capecitabine ', ' D ', '¤ (Acenocoumarol) May increase the serum concentration of Vitamin K Antagonists.¤ (Bosentan) CYP2C9 Inhibitors (Strong) may increase the serum concentration of Bosentan.¤ (Carvedilol) CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically~ concentrations of the S-carvedilol enantiomer may be increased.¤ (Cimetidine) Cimetidine may increase serum concentrations of the active metabolite(s) of Capecitabine. Specifically~ concentrations of fluorouracil may be increased.¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Dronabinol) CYP2C9 Inhibitors (Strong) may increase the serum concentration of Dronabinol.¤ (Fosphenytoin) Capecitabine may increase the serum concentration of Fosphenytoin.¤ (Lacosamide) CYP2C9 Inhibitors (Strong) may increase the serum concentration of Lacosamide.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Ospemifene) CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ospemifene.¤ (Phenytoin) May increase the serum concentration of Phenytoin.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.', 'yes', '¤ Take 12 hours apart, within 30 minutes of the end of breakfast and dinner to reduce nausea.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(36, 'Capreomycin Sulfate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(37, 'Captopril ', ' D ', '¤ (Acetylsalicylic acid) May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems~ whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.¤ (Alfuzosin) May enhance the hypotensive effect of Antihypertensives.¤ (Aliskiren) May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors.¤ (Allopurinol) ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.¤ (Aluminum hydroxide) May decrease the serum concentration of Captopril.¤ (Amifostine) Antihypertensives may enhance the hypotensive effect of Amifostine.¤ (Aprotinin) May diminish the antihypertensive effect of ACE Inhibitors.¤ (Azathioprine) ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.¤ (Butabarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Butethal) May enhance the hypotensive effect of Hypotensive Agents.¤ (Calcium carbonate) May decrease the serum concentration of Captopril.¤ (Canagliflozin) May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.¤ (Dapoxetine) May enhance the orthostatic hypotensive effect of ACE Inhibitors.¤ (Darunavir) May increase the serum concentration of CYP2D6 Substrates.¤ (Diazoxide) May enhance the hypotensive effect of Antihypertensives.¤ (Duloxetine) Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.¤ (Eplerenone) May enhance the hyperkalemic effect of ACE Inhibitors.¤ (Everolimus) May enhance the adverse/toxic effect of ACE Inhibitors. Specifically~ the risk of angioedema may be increased.¤ (Heparin) May enhance the hyperkalemic effect of ACE Inhibitors.¤ (Heptabarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Hexobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Icatibant) May diminish the antihypertensive effect of ACE Inhibitors.¤ (Lithium) ACE Inhibitors may increase the serum concentration of Lithium.¤ (Magnesium oxide) May decrease the serum concentration of Captopril.¤ (Methohexital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Methylphenidate) May diminish the antihypertensive effect of Antihypertensives.¤ (Obinutuzumab) Antihypertensives may enhance the hypotensive effect of Obinutuzumab.¤ (Panobinostat) May increase the serum concentration of CYP2D6 Substrates.¤ (Peginterferon alfa-2b) May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.¤ (Pentobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Pentoxifylline) May enhance the hypotensive effect of Antihypertensives.¤ (Primidone) May enhance the hypotensive effect of Hypotensive Agents.¤ (Risperidone) Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.¤ (Rituximab) Antihypertensives may enhance the hypotensive effect of RiTUXimab.¤ (Salicylate-sodium) May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems~ whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.¤ (Secobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Sirolimus) May enhance the adverse/toxic effect of ACE Inhibitors.¤ (Sodium bicarbonate) Antacids may decrease the serum concentration of Captopril.¤ (Tadalafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Temsirolimus) May enhance the adverse/toxic effect of ACE Inhibitors.¤ (Tizanidine) May enhance the hypotensive effect of ACE Inhibitors.¤ (Tolvaptan) May enhance the hyperkalemic effect of ACE Inhibitors.¤ (Trimethoprim) May enhance the hyperkalemic effect of ACE Inhibitors.¤ (Vardenafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Yohimbine) May diminish the antihypertensive effect of Antihypertensives.', 'yes', '¤ Captopril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia. \n¤ Food decreases absorption by 25 - 40%. Clinical significance is debatable. \n¤ Herbs that may attenuate the antihypertensive effect of captopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice. \n¤ High salt intake may attenuate the antihypertensive effect of captopril. ', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(38, 'Carbamazepine ', ' D ', '¤ (Acenocoumarol) May decrease the serum concentration of Vitamin K Antagonists.¤ (Acetaminophen) May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.¤ (Acetazolamide) May increase the serum concentration of CarBAMazepine. Exceptions: Brinzolamide; Dorzolamide.¤ (Adenosine) CarBAMazepine may enhance the adverse/toxic effect of Adenosine. Specifically~ the risk of higher degree heart block may be increased.¤ (Afatinib) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.¤ (Albendazole) May decrease serum concentrations of the active metabolite(s) of Albendazole.¤ (Allopurinol) Allopurinol may increase the serum concentration of CarBAMazepine.¤ (Aminophylline) Theophylline Derivatives may decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Theophylline Derivatives.¤ (Amitriptyline) May increase the metabolism of Tricyclic Antidepressants.¤ (Amlodipine) May increase the metabolism of Calcium Channel Blockers (Dihydropyridine).¤ (Amoxapine) May increase the metabolism of Tricyclic Antidepressants.¤ (Apixaban) CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.¤ (Apremilast) CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast.¤ (Aripiprazole) CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.¤ (Artemether) CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically~ dihydroartemisinin concentrations may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether.¤ (Atazanavir) May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.¤ (Axitinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.¤ (Azilsartan medoxomil) Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.¤ (Batimastat) CarBAMazepine may increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.¤ (bazedoxifene) CarBAMazepine may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or~ if bazedoxifene is combined with estrogen therapy~ an increased risk of endometrial hyperplasia.¤ (Bedaquiline) CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.¤ (Bendamustine) CYP1A2 Inducers (Strong) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.¤ (Bendroflumethiazide) Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.¤ (Boceprevir) CarBAMazepine may decrease the serum concentration of Boceprevir.¤ (Bortezomib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Bosutinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.¤ (Brentuximab vedotin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.¤ (Buprenorphine) CNS Depressants may enhance the CNS depressant effect of Buprenorphine.¤ (Butalbital) May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.¤ (Cabozantinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.¤ (Canagliflozin) CarBAMazepine may decrease the serum concentration of Canagliflozin.¤ (Caspofungin) Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.¤ (Chlorothiazide) Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.¤ (Chlorthalidone) Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.¤ (Cimetidine) Cimetidine may increase the serum concentration of CarBAMazepine. The serum carbamazepine concentration might return to normal within one week of starting cimetidine.¤ (Citalopram) May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.¤ (Clarithromycin) CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.¤ (Clomipramine) CarBAMazepine may increase the serum concentration of ClomiPRAMINE.¤ (Clozapine) May enhance the myelosuppressive effect of CloZAPine. CarBAMazepine may decrease the serum concentration of CloZAPine.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Crizotinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.¤ (Dabigatran etexilate) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Danazol) May decrease the metabolism of CarBAMazepine.¤ (Darunavir) May increase the serum concentration of CarBAMazepine.¤ (Dasatinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Delavirdine) May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.¤ (Desipramine) May increase the metabolism of Tricyclic Antidepressants.¤ (Desmopressin) May enhance the adverse/toxic effect of Desmopressin.¤ (Desogestrel) May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.¤ (Diclofenamide) May increase the serum concentration of CarBAMazepine. Exceptions: Brinzolamide; Dorzolamide.¤ (Dihydrocodeine) May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.¤ (Diltiazem) May decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of CarBAMazepine.¤ (Dolutegravir) CarBAMazepine may decrease the serum concentration of Dolutegravir.¤ (Doxycycline) May decrease the serum concentration of Doxycycline.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronabinol.¤ (Dronedarone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.¤ (Droperidol) May enhance the CNS depressant effect of CNS Depressants.¤ (Drospirenone) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Eliglustat) CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat.¤ (Enzalutamide) CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.¤ (Erlotinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Erlotinib.¤ (Escitalopram) May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.¤ (Ethinyl Estradiol) May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.¤ (Ethoxzolamide) May increase the serum concentration of CarBAMazepine. Exceptions: Brinzolamide; Dorzolamide.¤ (Ethynodiol) May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.¤ (Etonogestrel) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Etravirine) May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.¤ (Everolimus) CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.¤ (Exemestane) CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.¤ (Ezogabine) CarBAMazepine may decrease the serum concentration of Ezogabine.¤ (Felbamate) CarBAMazepine may decrease the serum concentration of Felbamate. Felbamate may decrease the serum concentration of CarBAMazepine.¤ (Felodipine) May increase the metabolism of Calcium Channel Blockers (Dihydropyridine).¤ (Fentanyl) CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.¤ (Fingolimod) CarBAMazepine may decrease the serum concentration of Fingolimod.¤ (Fluconazole) Fluconazole may increase the serum concentration of CarBAMazepine.¤ (Flunarizine) CarBAMazepine may decrease the serum concentration of Flunarizine.¤ (Fluoxetine) May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.¤ (Fluvoxamine) May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.¤ (Fosamprenavir) May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.¤ (Fosphenytoin) CarBAMazepine may decrease the serum concentration of Fosphenytoin. CarBAMazepine may increase the serum concentration of Fosphenytoin. Possibly by competitive inhibition at sites of metabolism. Fosphenytoin may decrease the serum concentration of CarBAMazepine.¤ (Gefitinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.¤ (Guanfacine) CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.¤ (Haloperidol) May increase the metabolism of Haloperidol.¤ (Hydrochlorothiazide) Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Imatinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.¤ (Indapamide) Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.¤ (Indinavir) May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.¤ (Irinotecan) CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan.¤ (Isocarboxazid) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Isoflurophate) CarBAMazepine may increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.¤ (Isometheptene) May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.¤ (Isoniazid) May decrease the metabolism of CarBAMazepine.¤ (Isradipine) May increase the metabolism of Calcium Channel Blockers (Dihydropyridine).¤ (Itraconazole) CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.¤ (Ivacaftor) CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.¤ (Ixabepilone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.¤ (Lacosamide) CarBAMazepine may enhance the AV-blocking effect of Lacosamide. CarBAMazepine may decrease the serum concentration of Lacosamide.¤ (Lamotrigine) LamoTRIgine may enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may increase the metabolism of LamoTRIgine.¤ (Lapatinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.¤ (Ledipasvir) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir.¤ (Levonorgestrel) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Levothyroxine) May decrease the serum concentration of Thyroid Products.¤ (Linagliptin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.¤ (Linezolid) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Liothyronine) May decrease the serum concentration of Thyroid Products.¤ (Liotrix) May decrease the serum concentration of Thyroid Products.¤ (Lithium) CarBAMazepine may enhance the adverse/toxic effect of Lithium.¤ (Lopinavir) CarBAMazepine may decrease the serum concentration of Lopinavir.¤ (Loxapine) Loxapine may increase serum concentrations of the active metabolite(s) of CarBAMazepine.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Lumefantrine) CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumefantrine.¤ (Lurasidone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.¤ (MACITENTAN) CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan.¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Maraviroc) CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.¤ (Mebendazole) CarBAMazepine may decrease the serum concentration of Mebendazole.¤ (Medroxyprogesterone Acetate) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Mefloquine) Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.¤ (Mestranol) May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.¤ (Methadone) May increase the metabolism of Methadone.¤ (Methazolamide) Carbonic Anhydrase Inhibitors may increase the serum concentration of CarBAMazepine.¤ (Methotrimeprazine) CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.¤ (Methyclothiazide) Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.¤ (Methylprednisolone) CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.¤ (Metolazone) Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mianserin) May diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Mianserin.¤ (Mifepristone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Moclobemide) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Nefazodone) CarBAMazepine may decrease the serum concentration of Nefazodone. Concentrations of active Nefazodone metabolites may also be reduced. Nefazodone may increase the serum concentration of CarBAMazepine. Also~ concentrations of the active CarBAMazepine epoxide metabolite may be reduced.¤ (Nelfinavir) May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.¤ (Nevirapine) May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.¤ (Nifedipine) CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.¤ (Nilotinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.¤ (Nimodipine) May increase the metabolism of Calcium Channel Blockers (Dihydropyridine).¤ (Nisoldipine) CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.¤ (Norelgestromin) May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.¤ (Norethindrone) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Norgestimate) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Nortriptyline) May increase the metabolism of Tricyclic Antidepressants.¤ (Orlistat) May decrease the serum concentration of Anticonvulsants.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Oxcarbazepine) CarBAMazepine may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically~ concentrations of the major active 10-monohydroxy metabolite may be reduced.¤ (Paliperidone) CarBAMazepine may decrease the serum concentration of Paliperidone.¤ (Panobinostat) CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat.¤ (Paroxetine) May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.¤ (Pazopanib) CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib.¤ (Perampanel) CarBAMazepine may decrease the serum concentration of Perampanel.¤ (Phenelzine) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Phenytoin) May decrease the serum concentration of Phenytoin. CarBAMazepine may increase the serum concentration of Phenytoin. Possibly by competitive inhibition at sites of metabolism. Phenytoin may decrease the serum concentration of CarBAMazepine.¤ (Pirfenidone) CYP1A2 Inducers (Strong) may decrease the serum concentration of Pirfenidone.¤ (Pomalidomide) CYP1A2 Inducers (Strong) may decrease the serum concentration of Pomalidomide.¤ (Ponatinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib.¤ (Pramipexole) CNS Depressants may enhance the sedative effect of Pramipexole.¤ (Praziquantel) CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.¤ (Prednisone) CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE.¤ (Procarbazine) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Protriptyline) May increase the metabolism of Tricyclic Antidepressants.¤ (Quetiapine) May increase serum concentrations of the active metabolite(s) of CarBAMazepine. CarBAMazepine may decrease the serum concentration of QUEtiapine.¤ (Quinine) May decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of CarBAMazepine.¤ (Ranolazine) CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.¤ (Rasagiline) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Regorafenib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.¤ (Rilpivirine) May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.¤ (Risperidone) CarBAMazepine may decrease the serum concentration of RisperiDONE.¤ (Ritonavir) May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.¤ (Rivaroxaban) CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.¤ (Roflumilast) CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.¤ (Romidepsin) CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.¤ (Rotigotine) CNS Depressants may enhance the sedative effect of Rotigotine.¤ (Rufinamide) CarBAMazepine may decrease the serum concentration of Rufinamide. Rufinamide may decrease the serum concentration of CarBAMazepine.¤ (Saquinavir) May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.¤ (Saxagliptin) CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.¤ (Selegiline) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Sertraline) May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) CarBAMazepine may increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.¤ (Sofosbuvir) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir.¤ (Sorafenib) CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.¤ (Sulfisoxazole) Macrolide Antibiotics may decrease the metabolism of CarBAMazepine.¤ (Sunitinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.¤ (Suvorexant) CYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant.¤ (Tadalafil) CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Tedizolid Phosphate) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Telaprevir) CarBAMazepine may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of CarBAMazepine.¤ (Telithromycin) Macrolide Antibiotics may decrease the metabolism of CarBAMazepine.¤ (Temsirolimus) CarBAMazepine may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite~ sirolimus~ are also likely to be decreased (and maybe to an even greater degree).¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Theophylline) Theophylline Derivatives may decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Theophylline Derivatives.¤ (Ticagrelor) CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.¤ (Tipranavir) May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tofacitinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.¤ (Tolvaptan) CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.¤ (Topiramate) May decrease the serum concentration of Topiramate.¤ (Toremifene) CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.¤ (Trabectedin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin.¤ (Tramadol) TraMADol may enhance the CNS depressant effect of CarBAMazepine. TraMADol may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of TraMADol.¤ (Tranylcypromine) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Treprostinil) CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.¤ (Ulipristal) CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.¤ (Valproic Acid) Valproic Acid and Derivatives may increase serum concentrations of the active metabolite(s) of CarBAMazepine. Parent carbamazepine concentrations may be increased~ decreased~ or unchanged. CarBAMazepine may decrease the serum concentration of Valproic Acid and Derivatives.¤ (Vandetanib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.¤ (Vecuronium) CarBAMazepine may decrease the serum concentration of Vecuronium.¤ (Vemurafenib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.¤ (Vilazodone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.¤ (Vorapaxar) CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar.¤ (Voriconazole) CarBAMazepine may decrease the serum concentration of Voriconazole.¤ (Ziprasidone) May decrease the serum concentration of Ziprasidone.¤ (Zolpidem) Zolpidem may enhance the CNS depressant effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Zolpidem.¤ (Zuclopenthixol) CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.', 'yes', '¤ Avoid alcohol.\n¤ Avoid taking grapefruit or grapefruit juice throughout treatment.\n¤ Grapefruit can significantly increase serum levels of this product.\n¤ Take with food, increases availability and reduces irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(39, 'Carmustine ', ' D ', '¤ (Cimetidine) May enhance the myelosuppressive effect of Carmustine.¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (L-Phenylalanine) Melphalan may enhance the adverse/toxic effect of Carmustine. Specifically~ melphalan may sensitize patients to carmustine lung toxicity.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Melphalan) May enhance the adverse/toxic effect of Carmustine. Specifically~ melphalan may sensitize patients to carmustine lung toxicity.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.', 'yes', '¤ Echinacea', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(40, 'Ceftazidime ', ' B ', '¤ (Acenocoumarol) May enhance the anticoagulant effect of Vitamin K Antagonists.¤ (Amikacin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Arbekacin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Framycetin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Gentamicin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Kanamycin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Neomycin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Netilmicin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Probenecid) May increase the serum concentration of Cephalosporins.¤ (Ribostamycin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Spectinomycin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Streptomycin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Tobramycin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(41, 'Ceftriaxone ', ' B ', '¤ (Acenocoumarol) May enhance the anticoagulant effect of Vitamin K Antagonists.¤ (Amikacin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Arbekacin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Calcium Acetate) Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.¤ (Calcium Chloride) Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.¤ (Framycetin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Gentamicin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Kanamycin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Neomycin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Netilmicin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Probenecid) Probenecid may increase the serum concentration of Cephalosporins.¤ (Ribostamycin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Spectinomycin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Streptomycin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Tobramycin) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(42, 'Cetirizine ', ' B ', '¤ (Aclidinium) May enhance the anticholinergic effect of Anticholinergic Agents.¤ (Amphetamine) May diminish the sedative effect of Antihistamines.¤ (Benzylpenicilloyl Polylysine) Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.¤ (Betahistine) Antihistamines may diminish the therapeutic effect of Betahistine.¤ (Buprenorphine) CNS Depressants may enhance the CNS depressant effect of Buprenorphine.¤ (Cathinone) May diminish the sedative effect of Antihistamines.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Droperidol) May enhance the CNS depressant effect of CNS Depressants.¤ (Hyaluronidase) Antihistamines may diminish the therapeutic effect of Hyaluronidase.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Itopride) Anticholinergic Agents may diminish the therapeutic effect of Itopride.¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Methotrimeprazine) CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.¤ (Metoclopramide) Anticholinergic Agents may diminish the therapeutic effect of Metoclopramide.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mianserin) May enhance the anticholinergic effect of Anticholinergic Agents.¤ (Mirabegron) Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.¤ (Mirtazapine) CNS Depressants may enhance the CNS depressant effect of Mirtazapine.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Potassium Chloride) Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.¤ (Pramipexole) CNS Depressants may enhance the sedative effect of Pramipexole.¤ (Pramlintide) May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.¤ (Ropinirole) CNS Depressants may enhance the sedative effect of ROPINIRole.¤ (Rotigotine) CNS Depressants may enhance the sedative effect of Rotigotine.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Secretin) Anticholinergic Agents may diminish the therapeutic effect of Secretin.¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Tiotropium) Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.¤ (Topiramate) Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.', 'yes', '¤ Avoid alcohol.\n¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(43, 'Chlorambucil ', ' D ', '¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.', 'yes', '¤ Drink liberally.\n¤ Echinacea should be used with caution, if at all, in patients receiving therapeutic immunosuppressants. Monitor for reduced efficacy of the immunosuppressant during concomitant use.\n¤ Food reduces bioavailability.\n¤ Take on an empty stomach.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(44, 'Chloramphenicol ', ' C ', '¤ (Acenocoumarol) May enhance the anticoagulant effect of Vitamin K Antagonists. Chloramphenicol may increase the serum concentration of Vitamin K Antagonists.¤ (Amobarbital) Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.¤ (Butabarbital) Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.¤ (Butalbital) Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.¤ (Butethal) May increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.¤ (Chlorpropamide) May decrease the metabolism of Sulfonylureas.¤ (Cilostazol) CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.¤ (Citalopram) CYP2C19 Inhibitors (Strong) may increase the serum concentration of Citalopram.¤ (Clopidogrel) CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Cyanocobalamin) May diminish the therapeutic effect of Vitamin B12.¤ (Ethanol) May enhance the adverse/toxic effect of Alcohol (Ethyl).¤ (Gliclazide) May decrease the metabolism of Sulfonylureas.¤ (Glimepiride) May decrease the metabolism of Sulfonylureas.¤ (Glipizide) May decrease the metabolism of Sulfonylureas.¤ (Glyburide) May decrease the metabolism of Sulfonylureas.¤ (Heptabarbital) May increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.¤ (Hexobarbital) May increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.¤ (Hydroxocobalamin) May diminish the therapeutic effect of Vitamin B12.¤ (Methohexital) May increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.¤ (Pentobarbital) Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.¤ (Phenobarbital) Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.¤ (Primidone) May increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.¤ (Rifampicin) Rifampin may increase the metabolism of Chloramphenicol.¤ (Secobarbital) Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.¤ (Tolazamide) May decrease the metabolism of Sulfonylureas.¤ (Tolbutamide) May decrease the metabolism of Sulfonylureas.¤ (Voriconazole) Chloramphenicol may increase the serum concentration of Voriconazole.', 'yes', '¤ Take on an empty stomach.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(45, 'Chlorpheniramine ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(46, 'Chlorpromazine ', ' C ', '¤ (Aclidinium) May enhance the anticholinergic effect of Anticholinergic Agents.¤ (Almotriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Aluminum hydroxide) May decrease the absorption of Antipsychotic Agents (Phenothiazines).¤ (Amisulpride) Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride.¤ (Amitriptyline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Amoxapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Amphetamine) May diminish the stimulatory effect of Amphetamines.¤ (Aripiprazole) CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.¤ (Benzphetamine) May diminish the stimulatory effect of Amphetamines.¤ (Buprenorphine) CNS Depressants may enhance the CNS depressant effect of Buprenorphine.¤ (Buspirone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Cabergoline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Calcium carbonate) May decrease the absorption of Antipsychotic Agents (Phenothiazines).¤ (Cathinone) Antipsychotic Agents may diminish the stimulatory effect of Amphetamines.¤ (Citalopram) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Clomipramine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Codeine) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.¤ (Cyclobenzaprine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Darunavir) May increase the serum concentration of CYP2D6 Substrates.¤ (Desipramine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Desmopressin) May enhance the adverse/toxic effect of Desmopressin.¤ (Desvenlafaxine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Dextroamphetamine) May diminish the stimulatory effect of Amphetamines.¤ (Dextromethorphan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Dihydroergotamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Donepezil) Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Droperidol) May enhance the CNS depressant effect of CNS Depressants.¤ (Duloxetine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Eletriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ergoloid mesylate) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ergonovine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ergotamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Escitalopram) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fentanyl) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fesoterodine) CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.¤ (Fluoxetine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluvoxamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Frovatriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Galantamine) Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.¤ (Haloperidol) ChlorproMAZINE may enhance the QTc-prolonging effect of Haloperidol. ChlorproMAZINE may increase the serum concentration of Haloperidol. Haloperidol may increase the serum concentration of ChlorproMAZINE.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Imipramine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Isocarboxazid) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Itopride) Anticholinergic Agents may diminish the therapeutic effect of Itopride.¤ (Levomilnacipran) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Linezolid) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Lisdexamfetamine) May diminish the stimulatory effect of Amphetamines.¤ (Lithium) May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.¤ (Lorcaserin) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Magnesium oxide) May decrease the absorption of Antipsychotic Agents (Phenothiazines).¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Maprotiline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Mequitazine) Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.¤ (Methadone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Methamphetamine) May diminish the stimulatory effect of Amphetamines.¤ (Methotrimeprazine) CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.¤ (Methylergometrine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Methylphenidate) May enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents.¤ (Metoclopramide) May enhance the adverse/toxic effect of Antipsychotic Agents.¤ (Metoprolol) CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mifepristone) May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.¤ (Milnacipran) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Mirabegron) Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.¤ (Mirtazapine) CNS Depressants may enhance the CNS depressant effect of Mirtazapine.¤ (Moclobemide) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Naratriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Nebivolol) CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.¤ (Nefazodone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Nortriptyline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Panobinostat) May increase the serum concentration of CYP2D6 Substrates.¤ (Paroxetine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Peginterferon alfa-2b) May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Pethidine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Phendimetrazine) May diminish the stimulatory effect of Amphetamines.¤ (Phenelzine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Phentermine) May diminish the stimulatory effect of Amphetamines.¤ (Porfimer) Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.¤ (Potassium Chloride) Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.¤ (Pramlintide) May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.¤ (Procarbazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Promethazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Protriptyline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Rasagiline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Rivastigmine) Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.¤ (Rizatriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Secretin) Anticholinergic Agents may diminish the therapeutic effect of Secretin.¤ (Selegiline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Sertraline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Sulpiride) Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride.¤ (Sumatriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tamoxifen) CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Tedizolid Phosphate) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Tetrabenazine) Tetrabenazine may enhance the adverse/toxic effect of Antipsychotic Agents.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Thiopental) Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.¤ (Thioridazine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Tiotropium) Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.¤ (Topiramate) Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.¤ (Tramadol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Tranylcypromine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Trimipramine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Valproic Acid) May increase the serum concentration of Valproic Acid and Derivatives.¤ (Venlafaxine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Verteporfin) Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.¤ (Vilazodone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Zolmitriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.', 'yes', '¤ Avoid alcohol.\n¤ Take with food to reduce irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(47, 'Ciprofloxacin ', ' C ', '', 'yes', '¤ Avoid excessive quantities of coffee or tea (Caffeine).\n¤ Avoid milk, calcium containing dairy products, iron, magnesium, zinc, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.\n¤ Take with a full glass of water.\n¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(48, 'Cisplatin ', ' D ', '¤ (Amikacin) May enhance the nephrotoxic effect of Aminoglycosides.¤ (Arbekacin) CISplatin may enhance the nephrotoxic effect of Aminoglycosides.¤ (Bumetanide) Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Ethacrynic acid) Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.¤ (Framycetin) CISplatin may enhance the nephrotoxic effect of Aminoglycosides.¤ (Furosemide) Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.¤ (Gentamicin) CISplatin may enhance the nephrotoxic effect of Aminoglycosides.¤ (Kanamycin) CISplatin may enhance the nephrotoxic effect of Aminoglycosides.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Neomycin) CISplatin may enhance the nephrotoxic effect of Aminoglycosides.¤ (Netilmicin) CISplatin may enhance the nephrotoxic effect of Aminoglycosides.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Ribostamycin) CISplatin may enhance the nephrotoxic effect of Aminoglycosides.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Spectinomycin) CISplatin may enhance the nephrotoxic effect of Aminoglycosides.¤ (Streptomycin) CISplatin may enhance the nephrotoxic effect of Aminoglycosides.¤ (Tobramycin) CISplatin may enhance the nephrotoxic effect of Aminoglycosides.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Topotecan) Platinum Derivatives may enhance the adverse/toxic effect of Topotecan.¤ (Torasemide) Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.¤ (Vinorelbine) May enhance the adverse/toxic effect of Vinorelbine. Specifically~ the combination may be associated with a higher risk of granulocytopenia.', 'yes', '¤ Echinacea should be used with caution, if at all, in patients receiving therapeutic immunosuppressants. Monitor for reduced efficacy of the immunosuppressant during concomitant use. ', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(49, 'Clarithromycin ', ' C ', '¤ (ado-trastuzumab emtansine) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically~ strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.¤ (Afatinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.¤ (Alfentanil) Macrolide Antibiotics may increase the serum concentration of Alfentanil.¤ (Alfuzosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.¤ (Almotriptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.¤ (Alosetron) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.¤ (Alprazolam) Macrolide Antibiotics may increase the serum concentration of ALPRAZolam.¤ (Amlodipine) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Amrinone) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Apixaban) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.¤ (Aripiprazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.¤ (Astemizole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole.¤ (Atazanavir) Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Atorvastatin) May increase the serum concentration of AtorvaSTATin.¤ (Avanafil) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.¤ (Axitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.¤ (Batimastat) May diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Bedaquiline) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.¤ (Bepridil) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Boceprevir) May increase the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Boceprevir.¤ (Bortezomib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.¤ (Bosentan) CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.¤ (Bosutinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.¤ (Brentuximab vedotin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.¤ (Brinzolamide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.¤ (Buspirone) Macrolide Antibiotics may decrease the metabolism of BusPIRone.¤ (Cabazitaxel) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.¤ (Cabergoline) May increase the serum concentration of Cabergoline.¤ (Cabozantinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.¤ (Carbamazepine) CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.¤ (Cilostazol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.¤ (Cisapride) Macrolide Antibiotics may decrease the metabolism of Cisapride.¤ (Clopidogrel) Macrolide Antibiotics may diminish the therapeutic effect of Clopidogrel.¤ (Clozapine) Macrolide Antibiotics may decrease the metabolism of CloZAPine.¤ (Colchicine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Conivaptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.¤ (Crizotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.¤ (Dabigatran etexilate) Clarithromycin may increase the serum concentration of Dabigatran Etexilate.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dapoxetine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine.¤ (Darunavir) Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Dasatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dihydroergotamine) May increase the serum concentration of Dihydroergotamine.¤ (Disopyramide) Macrolide Antibiotics may enhance the QTc-prolonging effect of Disopyramide. Macrolide Antibiotics may decrease the metabolism of Disopyramide.¤ (Domperidone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone.¤ (Dronabinol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronabinol.¤ (Dronedarone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.¤ (Dutasteride) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.¤ (Efavirenz) May decrease the serum concentration of Clarithromycin.¤ (Eletriptan) Macrolide Antibiotics may decrease the metabolism of Eletriptan.¤ (Enzalutamide) CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.¤ (Eplerenone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.¤ (Ergotamine) May increase the serum concentration of Ergotamine.¤ (Erlotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.¤ (Estazolam) Macrolide Antibiotics may increase the serum concentration of Estazolam.¤ (Etravirine) CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.¤ (Everolimus) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.¤ (Felodipine) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Fentanyl) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Fesoterodine) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.¤ (Flunarizine) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Fosamprenavir) Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Fosphenytoin) CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.¤ (Gabapentin) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Glipizide) May increase the serum concentration of GlipiZIDE.¤ (Glyburide) May increase the serum concentration of GlyBURIDE.¤ (Guanfacine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.¤ (Halofantrine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.¤ (Hydrocodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.¤ (Ifosfamide) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.¤ (Imatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib.¤ (Indinavir) Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Irinotecan) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan.¤ (Isoflurophate) May diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Isradipine) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Ivacaftor) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.¤ (Ixabepilone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.¤ (Lacosamide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide.¤ (Lamotrigine) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Lapatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.¤ (Ledipasvir) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.¤ (Lercanidipine) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Levobupivacaine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine.¤ (Levomilnacipran) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.¤ (Lomitapide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.¤ (Lopinavir) Clarithromycin may enhance the QTc-prolonging effect of Lopinavir. Lopinavir may diminish the therapeutic effect of Clarithromycin. Specifically~ lopinavir may decrease the formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness. Clarithromycin may increase the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Clarithromycin.¤ (Lovastatin) May increase the serum concentration of Lovastatin.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Lurasidone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.¤ (MACITENTAN) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan.¤ (Magnesium Sulfate) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Maraviroc) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.¤ (Methylprednisolone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Midazolam) Macrolide Antibiotics may increase the serum concentration of Midazolam.¤ (Mifepristone) May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Modafinil) CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.¤ (Nafcillin) CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.¤ (Nelfinavir) Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Nicardipine) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Nilotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.¤ (Nimodipine) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Nisoldipine) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Nitrendipine) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Ospemifene) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.¤ (Oxybutynin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin.¤ (Oxycodone) CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased.¤ (Panobinostat) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.¤ (Paricalcitol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.¤ (Pazopanib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.¤ (Perhexiline) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Phenobarbital) CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.¤ (Phenytoin) CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.¤ (Pimecrolimus) CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.¤ (Pimozide) Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin.¤ (Pitavastatin) Clarithromycin may increase the serum concentration of Pitavastatin.¤ (Ponatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.¤ (Pranlukast) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast.¤ (Prasugrel) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.¤ (Pravastatin) May increase the serum concentration of Pravastatin.¤ (Prednisone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE.¤ (Prenylamine) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Primidone) CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.¤ (prucalopride) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.¤ (Quinidine) Macrolide Antibiotics may enhance the QTc-prolonging effect of QuiNIDine. Macrolide Antibiotics may increase the serum concentration of QuiNIDine.¤ (Quinine) Macrolide Antibiotics may increase the serum concentration of QuiNINE.¤ (Ranolazine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.¤ (Regorafenib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.¤ (Repaglinide) Macrolide Antibiotics may increase the serum concentration of Repaglinide.¤ (Retapamulin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.¤ (Rifampicin) CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.¤ (Rifapentine) CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.¤ (Rifaximin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.¤ (Rilpivirine) Macrolide Antibiotics may increase the serum concentration of Rilpivirine.¤ (Risedronate) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Ritonavir) Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Rivaroxaban) Clarithromycin may increase the serum concentration of Rivaroxaban.¤ (Ruxolitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.¤ (Salmeterol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.¤ (Saquinavir) Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Saxagliptin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.¤ (Sildenafil) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.¤ (Silodosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Simvastatin) May increase the serum concentration of Simvastatin.¤ (Sirolimus) Macrolide Antibiotics may decrease the metabolism of Sirolimus.¤ (Suvorexant) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant.¤ (Tadalafil) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.¤ (Tamsulosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.¤ (Telaprevir) Clarithromycin may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Clarithromycin.¤ (Temsirolimus) Macrolide Antibiotics may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus~ the active metabolite~ may be increased~ likely due to inhibition of CYP-mediated metabolism.¤ (Terfenadine) Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine.¤ (Ticagrelor) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.¤ (Tipranavir) Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tofacitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.¤ (Tolterodine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.¤ (Tolvaptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.¤ (Topotecan) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.¤ (Toremifene) CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.¤ (Trabectedin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin.¤ (Triazolam) Macrolide Antibiotics may increase the serum concentration of Triazolam.¤ (Ulipristal) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.¤ (Vardenafil) May increase the serum concentration of Vardenafil.¤ (Vemurafenib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.¤ (Verapamil) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Vilazodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.¤ (Vorapaxar) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar.¤ (Zidovudine) May enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine.¤ (Zopiclone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.', 'yes', '¤ Biaxin - take without regard to meals (however absorption appears to be improved when drug is taken with food).\n¤ Biaxin XL - take with a meal, taking it on an empty stomach is associated with total product exposure 30% inferior to that observed when administered with food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(50, 'Clindamycin Phosphate ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(51, 'Clomifene citrate ', ' x ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(52, 'Clonazepam ', ' D ', '¤ (Aminophylline) Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Buprenorphine) CNS Depressants may enhance the CNS depressant effect of Buprenorphine.¤ (Clozapine) May enhance the adverse/toxic effect of CloZAPine.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Cosyntropin) May enhance the hepatotoxic effect of ClonazePAM.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Droperidol) May enhance the CNS depressant effect of CNS Depressants.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Fosphenytoin) May increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Gamma Hydroxybutyric Acid) May enhance the CNS depressant effect of Sodium Oxybate.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Mefloquine) Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.¤ (Methadone) May enhance the CNS depressant effect of Methadone.¤ (Methotrimeprazine) CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Mirtazapine) CNS Depressants may enhance the CNS depressant effect of Mirtazapine.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Olanzapine) OLANZapine may enhance the adverse/toxic effect of Benzodiazepines.¤ (Orlistat) Orlistat may decrease the serum concentration of Anticonvulsants. Exceptions: Fosphenytoin; PENTobarbital; Thiopental.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Phenytoin) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Pramipexole) CNS Depressants may enhance the sedative effect of Pramipexole.¤ (Ropinirole) CNS Depressants may enhance the sedative effect of ROPINIRole.¤ (Rotigotine) CNS Depressants may enhance the sedative effect of Rotigotine.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Teduglutide) May increase the serum concentration of Benzodiazepines.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Theophylline) Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Vigabatrin) May enhance the CNS depressant effect of ClonazePAM. Vigabatrin may increase the serum concentration of ClonazePAM.¤ (Yohimbine) May diminish the therapeutic effect of Antianxiety Agents.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.', 'yes', '¤ Avoid alcohol.\n¤ Avoid excessive quantities of coffee or tea (Caffeine).\n¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(53, 'Clotrimazole ', 'B (topical); C (oral) ', '¤ (Aripiprazole) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.¤ (Avanafil) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.¤ (Bosentan) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosentan.¤ (Bosutinib) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.¤ (Cilostazol) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.¤ (Colchicine) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Dapoxetine) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.¤ (Dofetilide) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dofetilide.¤ (Domperidone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone.¤ (Dronabinol) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.¤ (Eliglustat) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.¤ (Eplerenone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.¤ (Everolimus) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.¤ (Fentanyl) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Halofantrine) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.¤ (Hydrocodone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.¤ (Ifosfamide) CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.¤ (Imatinib) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Imatinib.¤ (Ivacaftor) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.¤ (Lomitapide) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.¤ (Lurasidone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.¤ (Oxycodone) CYP3A4 Inhibitors (Moderate) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased.¤ (Pimecrolimus) CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.¤ (Pimozide) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.¤ (Propafenone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.¤ (Ranolazine) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.¤ (Rivaroxaban) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rivaroxaban. This warning is more specifically for drugs that are inhibitors of both CYP3A4 and P-glycoprotein. For erythromycin~ refer to more specific erythromycin-rivaroxaban monograph recommendations.¤ (Salmeterol) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.¤ (Saxagliptin) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.¤ (Simeprevir) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir.¤ (Suvorexant) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant.¤ (Tolvaptan) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.¤ (Trabectedin) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin.¤ (Ulipristal) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal.¤ (Vilazodone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.¤ (Zopiclone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone.¤ (Zuclopenthixol) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(54, 'Cloxacillin Sodium ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(55, 'Codeine Phosphate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(56, 'Colchicine ', ' C ', '¤ (Abiraterone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Amiodarone) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Aprepitant) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Atazanavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Atorvastatin) May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Bezafibrate) Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine.¤ (Bicalutamide) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Biotin) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Boceprevir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Carvedilol) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Choline) Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine.¤ (Cimetidine) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Clarithromycin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Clotrimazole) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Crizotinib) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Cyanocobalamin) May decrease the serum concentration of Cyanocobalamin.¤ (Darunavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Delavirdine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Desipramine) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Digoxin) Digoxin may increase the serum concentration of Colchicine.¤ (Diltiazem) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Dipyridamole) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Dronedarone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Eliglustat) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Fenofibrate) Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine.¤ (Fluconazole) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Fluvastatin) May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Fosamprenavir) Fosamprenavir may increase the serum concentration of Colchicine.¤ (Fosaprepitant) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Gemfibrozil) Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine.¤ (Indinavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Isavuconazonium) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Itraconazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Ivacaftor) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Lapatinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Ledipasvir) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Lomitapide) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Lopinavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Lovastatin) May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Mefloquine) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Nefazodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Nelfinavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Nilotinib) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Norfloxacin) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Pitavastatin) May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Posaconazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Pravastatin) May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Progesterone) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Propranolol) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Quinidine) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Quinine) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Ranolazine) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Reserpine) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Ritonavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Rosuvastatin) May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Saquinavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Simeprevir) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Simvastatin) May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Sulfisoxazole) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Sunitinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Tamoxifen) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Telaprevir) May increase the serum concentration of Colchicine.¤ (Telithromycin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Tetracycline) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Tipranavir) Tipranavir may increase the serum concentration of Colchicine.¤ (Vandetanib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Vemurafenib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Voriconazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', 'yes', '¤ Avoid alcohol since it increases uric acid levels.\n¤ Drink liberally.\n¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(57, 'Cyclophosphamide ', ' C ', '¤ (Allopurinol) Allopurinol may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ bone marrow suppression.¤ (Amiodarone) Cyclophosphamide may enhance the adverse/toxic effect of Amiodarone. Specifically~ the risk of pulmonary toxicity may be enhanced.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Atazanavir) Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Azathioprine) May enhance the hepatotoxic effect of Cyclophosphamide.¤ (Azilsartan medoxomil) Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.¤ (Batimastat) May enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Belimumab) May enhance the adverse/toxic effect of Cyclophosphamide.¤ (Bendroflumethiazide) Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.¤ (Chlorothiazide) Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.¤ (Chlorthalidone) Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Dabrafenib) May decrease the serum concentration of CYP2B6 Substrates.¤ (Darunavir) Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Daunorubicin) May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline~ Systemic).¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Epirubicin) May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline~ Systemic).¤ (Etanercept) Etanercept may enhance the adverse/toxic effect of Cyclophosphamide. An increased risk of solid cancer development may be present.¤ (Filgrastim) Filgrastim may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the risk of pulmonary toxicity may be enhanced.¤ (Fosamprenavir) Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Hydrochlorothiazide) Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Idarubicin) May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline~ Systemic).¤ (Indapamide) Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.¤ (Indinavir) Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Isoflurophate) May enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Lopinavir) Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Methyclothiazide) Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.¤ (Metolazone) Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Nelfinavir) Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Pentostatin) May enhance the cardiotoxic effect of Cyclophosphamide.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Quazepam) May increase the serum concentration of CYP2B6 Substrates.¤ (Ritonavir) Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Saquinavir) Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Sargramostim) May enhance the adverse/toxic effect of Sargramostim. Specifically~ the risk of pulmonary toxicity may be enhanced.¤ (Simeprevir) May enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Succinylcholine) May increase the serum concentration of Succinylcholine.¤ (Tipranavir) Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.', 'yes', '¤ Drink liberally- 2 to 3 liters/day.\n¤ Take with food to reduce irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(58, 'Cycloserine ', ' C ', '¤ (Ethanol) Alcohol (Ethyl) may enhance the neurotoxic effect of CycloSERINE. Specifically~ the risk for seizures may be increased.¤ (Ethionamide) May enhance the adverse/toxic effect of CycloSERINE.¤ (Isoniazid) May enhance the adverse/toxic effect of CycloSERINE. Specifically~ CNS toxicity may be enhanced.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(59, 'Cytarabine ', ' D ', '¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Flucytosine) Cytarabine (Conventional) may diminish the therapeutic effect of Flucytosine.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(60, 'Dactinomycine ', ' D ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(61, 'Dapsone ', ' C ', '', 'yes', '¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(62, 'Darunavir ', ' B ', '¤ (Abacavir) Protease Inhibitors may decrease the serum concentration of Abacavir.¤ (Acetohexamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (ado-trastuzumab emtansine) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically~ strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.¤ (Afatinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.¤ (Alfuzosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.¤ (Almotriptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.¤ (Alogliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Alosetron) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.¤ (Alprazolam) Protease Inhibitors may increase the serum concentration of ALPRAZolam.¤ (Amiodarone) May increase the serum concentration of Amiodarone.¤ (Amitriptyline) May increase the serum concentration of CYP2D6 Substrates.¤ (Amoxapine) May increase the serum concentration of CYP2D6 Substrates.¤ (Apixaban) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.¤ (Aripiprazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.¤ (Astemizole) Darunavir may increase the serum concentration of Astemizole.¤ (Atomoxetine) May increase the serum concentration of CYP2D6 Substrates.¤ (Atorvastatin) Protease Inhibitors may increase the serum concentration of AtorvaSTATin.¤ (Avanafil) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.¤ (Axitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.¤ (Batimastat) May increase the serum concentration of other Protease Inhibitors.¤ (Bedaquiline) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.¤ (Boceprevir) May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir.¤ (Bortezomib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.¤ (Bosentan) Bosentan may decrease the serum concentration of Darunavir. Darunavir may increase the serum concentration of Bosentan.¤ (Bosutinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.¤ (Brentuximab vedotin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.¤ (Brinzolamide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.¤ (Cabazitaxel) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.¤ (Cabozantinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.¤ (Canagliflozin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Captopril) May increase the serum concentration of CYP2D6 Substrates.¤ (Carbamazepine) May increase the serum concentration of CarBAMazepine.¤ (Carvedilol) May increase the serum concentration of CYP2D6 Substrates.¤ (Chlorphenamine) May increase the serum concentration of CYP2D6 Substrates.¤ (Chlorpromazine) May increase the serum concentration of CYP2D6 Substrates.¤ (Chlorpropamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Cilostazol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.¤ (Cisapride) Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.¤ (Clarithromycin) Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Clomipramine) May increase the serum concentration of CYP2D6 Substrates.¤ (Colchicine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Conivaptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.¤ (Crizotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.¤ (Cyclophosphamide) Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Dabigatran etexilate) P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dapoxetine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine.¤ (Dasatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Delavirdine) May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.¤ (Desipramine) May increase the serum concentration of CYP2D6 Substrates.¤ (Desogestrel) May decrease the serum concentration of Contraceptives (Progestins).¤ (Dextromethorphan) May increase the serum concentration of CYP2D6 Substrates.¤ (Didanosine) May decrease the serum concentration of Didanosine. More specifically~ this interaction is likely due to the effects of food (with which darunavir/ritonavir are taken) on didanosine~ which is supposed to be given on an empty stomach.¤ (Digoxin) Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Dofetilide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dofetilide.¤ (Domperidone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone.¤ (Dronabinol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronabinol.¤ (Dronedarone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.¤ (Drospirenone) May decrease the serum concentration of Contraceptives (Progestins).¤ (Duloxetine) May increase the serum concentration of CYP2D6 Substrates.¤ (Dutasteride) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.¤ (Efavirenz) Darunavir may increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Darunavir.¤ (Eliglustat) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eliglustat.¤ (Enfuvirtide) May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.¤ (Eplerenone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.¤ (Erlotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.¤ (Ethynodiol) May decrease the serum concentration of Contraceptives (Progestins).¤ (Etonogestrel) May decrease the serum concentration of Contraceptives (Progestins).¤ (Etravirine) Darunavir may decrease the serum concentration of Etravirine.¤ (Everolimus) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.¤ (Fentanyl) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Fesoterodine) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.¤ (Flecainide) May increase the serum concentration of CYP2D6 Substrates.¤ (Fluoxetine) May increase the serum concentration of CYP2D6 Substrates.¤ (Fluvoxamine) May increase the serum concentration of CYP2D6 Substrates.¤ (Fosphenytoin) May decrease the serum concentration of Darunavir.¤ (Gliclazide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glimepiride) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Gliquidone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glyburide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Guanfacine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.¤ (Halofantrine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.¤ (Hydrocodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.¤ (Ifosfamide) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.¤ (Iloperidone) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically~ concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.¤ (Imatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib.¤ (Imipramine) May increase the serum concentration of CYP2D6 Substrates.¤ (Insulin Aspart) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Detemir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glargine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glulisine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Lispro) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Regular) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin~ isophane) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Irinotecan) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan.¤ (Isoflurophate) May increase the serum concentration of other Protease Inhibitors.¤ (Itraconazole) May increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Darunavir.¤ (Ivacaftor) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.¤ (Ixabepilone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.¤ (Lacosamide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide.¤ (Lapatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.¤ (Ledipasvir) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.¤ (Lercanidipine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine.¤ (Levobupivacaine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine.¤ (Levomilnacipran) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.¤ (Levonorgestrel) May decrease the serum concentration of Contraceptives (Progestins).¤ (Linagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Lomitapide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.¤ (Lopinavir) May decrease the serum concentration of Darunavir. Darunavir may increase the serum concentration of lopinavir¤ (Lovastatin) Protease Inhibitors may increase the serum concentration of Lovastatin.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Lumefantrine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.¤ (Lurasidone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.¤ (MACITENTAN) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan.¤ (Maprotiline) May increase the serum concentration of CYP2D6 Substrates.¤ (Maraviroc) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.¤ (Medroxyprogesterone Acetate) May decrease the serum concentration of Contraceptives (Progestins).¤ (Mestranol) May decrease the serum concentration of Norethindrone.¤ (Metformin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Methadone) May decrease the serum concentration of Methadone. More specifically~ the combination of Darunavir and Ritonavir may decrease Methadone serum concentrations.¤ (Methamphetamine) May increase the serum concentration of CYP2D6 Substrates.¤ (Methylprednisolone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Metoprolol) May increase the serum concentration of CYP2D6 Substrates.¤ (Mexiletine) May increase the serum concentration of CYP2D6 Substrates.¤ (Midazolam) Protease Inhibitors may increase the serum concentration of Midazolam.¤ (Mifepristone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nefazodone) Protease Inhibitors may increase the serum concentration of Nefazodone.¤ (Nevirapine) May increase the serum concentration of Nevirapine. Nevirapine may increase the serum concentration of Darunavir.¤ (Nilotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.¤ (Nisoldipine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.¤ (Norelgestromin) May decrease the serum concentration of Contraceptives (Progestins).¤ (Norethindrone) May decrease the serum concentration of Norethindrone.¤ (Norgestimate) May decrease the serum concentration of Contraceptives (Progestins).¤ (Nortriptyline) May increase the serum concentration of CYP2D6 Substrates.¤ (Ospemifene) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.¤ (Oxybutynin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin.¤ (Oxycodone) CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased.¤ (Panobinostat) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.¤ (Paricalcitol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.¤ (Paroxetine) May decrease the serum concentration of PARoxetine.¤ (Pazopanib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.¤ (Perphenazine) May increase the serum concentration of CYP2D6 Substrates.¤ (Phenobarbital) May decrease the serum concentration of PHENobarbital.¤ (Phenytoin) May decrease the serum concentration of Phenytoin.¤ (Pimecrolimus) CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.¤ (Pimozide) Protease Inhibitors may increase the serum concentration of Pimozide.¤ (Ponatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.¤ (Pranlukast) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast.¤ (Prasugrel) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.¤ (Pravastatin) May increase the serum concentration of Pravastatin. This effect has only been demonstrated with darunavir/ritonavir. The individual contributions of darunavir and ritonavir are unknown.¤ (Prednisone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE.¤ (Primaquine) May increase the serum concentration of CYP2D6 Substrates.¤ (Procainamide) May increase the serum concentration of CYP2D6 Substrates.¤ (Procaine) May increase the serum concentration of CYP2D6 Substrates.¤ (Promazine) May increase the serum concentration of CYP2D6 Substrates.¤ (Promethazine) May increase the serum concentration of CYP2D6 Substrates.¤ (Propafenone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.¤ (Propranolol) May increase the serum concentration of CYP2D6 Substrates.¤ (Protriptyline) May increase the serum concentration of CYP2D6 Substrates.¤ (prucalopride) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.¤ (Quetiapine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of QUEtiapine.¤ (Quinidine) May increase the serum concentration of QuiNIDine.¤ (Ranolazine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.¤ (Regorafenib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.¤ (Repaglinide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Retapamulin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.¤ (Rifabutin) Darunavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Darunavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Darunavir.¤ (Rifampicin) Rifampin may decrease the serum concentration of Darunavir.¤ (Rifaximin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.¤ (Rilpivirine) Darunavir may increase the serum concentration of Rilpivirine.¤ (Riociguat) Protease Inhibitors may increase the serum concentration of Riociguat.¤ (Risperidone) May increase the serum concentration of CYP2D6 Substrates.¤ (Rivaroxaban) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. For clarithromycin~ refer to more specific clarithromycin-rivaroxaban monograph recommendations.¤ (Romidepsin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.¤ (Rosuvastatin) Protease Inhibitors may increase the serum concentration of Rosuvastatin.¤ (Ruxolitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.¤ (Salmeterol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.¤ (Saquinavir) Saquinavir may decrease the serum concentration of Darunavir.¤ (Saxagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Sertraline) May decrease the serum concentration of Sertraline.¤ (Sildenafil) Protease Inhibitors may increase the serum concentration of Sildenafil.¤ (Silodosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of other Protease Inhibitors.¤ (Simvastatin) Protease Inhibitors may increase the serum concentration of Simvastatin.¤ (Sorafenib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.¤ (Suvorexant) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant.¤ (Tadalafil) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.¤ (Tamsulosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.¤ (Telaprevir) Darunavir may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Darunavir.¤ (Temsirolimus) Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus~ the active metabolite~ may be increased~ likely due to inhibition of CYP-mediated metabolism.¤ (Tenofovir) May increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Darunavir.¤ (Terfenadine) Darunavir may increase the serum concentration of Terfenadine.¤ (Tetrabenazine) May increase the serum concentration of CYP2D6 Substrates.¤ (Thioridazine) May increase the serum concentration of CYP2D6 Substrates.¤ (Ticagrelor) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.¤ (Timolol) May increase the serum concentration of CYP2D6 Substrates.¤ (Tipranavir) May decrease the serum concentration of Protease Inhibitors.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tofacitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.¤ (Tolbutamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Tolterodine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.¤ (Tolvaptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.¤ (Topotecan) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.¤ (Toremifene) CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.¤ (Trabectedin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin.¤ (Trazodone) Darunavir may increase the serum concentration of TraZODone.¤ (Triazolam) Protease Inhibitors may increase the serum concentration of Triazolam.¤ (Ulipristal) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.¤ (Vardenafil) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.¤ (Vemurafenib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.¤ (Vilazodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.¤ (Vildagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Vorapaxar) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar.¤ (Voriconazole) May decrease the serum concentration of Voriconazole.¤ (Warfarin) Darunavir may decrease the serum concentration of Warfarin.¤ (Zidovudine) Protease Inhibitors may decrease the serum concentration of Zidovudine.¤ (Zopiclone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.¤ (Zuclopenthixol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.', 'yes', '¤ Take with food - better absorption (+30%). ', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(63, 'Deferoxamine mesylate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(64, 'Dexamethasone Sodium ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(65, 'Dextromethrophan ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(66, 'Diazepam ', ' D ', '¤ (Alfentanil) May enhance the CNS depressant effect of Alfentanil. Hypotension may also occur.¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Buprenorphine) CNS Depressants may enhance the CNS depressant effect of Buprenorphine.¤ (Clozapine) Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Cosyntropin) May enhance the hepatotoxic effect of Diazepam.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Disulfiram) Disulfiram may increase the serum concentration of Diazepam.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Droperidol) May enhance the CNS depressant effect of CNS Depressants.¤ (Etravirine) May decrease the serum concentration of Diazepam. Etravirine may increase the serum concentration of Diazepam.¤ (Fosamprenavir) May increase the serum concentration of Diazepam.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (LULICONAZOLE) May increase the serum concentration of CYP2C19 Substrates.¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Mefloquine) Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.¤ (Methadone) Benzodiazepines may enhance the CNS depressant effect of Methadone.¤ (Methotrimeprazine) CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Mirtazapine) CNS Depressants may enhance the CNS depressant effect of Mirtazapine.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Olanzapine) May enhance the adverse/toxic effect of Benzodiazepines.¤ (Orlistat) Orlistat may decrease the serum concentration of Anticonvulsants. Exceptions: Fosphenytoin; PENTobarbital; Thiopental.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Pramipexole) CNS Depressants may enhance the sedative effect of Pramipexole.¤ (Ritonavir) Ritonavir may increase the serum concentration of Diazepam.¤ (Ropinirole) CNS Depressants may enhance the sedative effect of ROPINIRole.¤ (Rotigotine) CNS Depressants may enhance the sedative effect of Rotigotine.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Saquinavir) May increase the serum concentration of Diazepam.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Teduglutide) May increase the serum concentration of Benzodiazepines.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Yohimbine) May diminish the therapeutic effect of Antianxiety Agents.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.', 'yes', '¤ Avoid alcohol.\n¤ Avoid excessive quantities of coffee or tea (caffeine).\n¤ Avoid taking with grapefruit or grapefruit juice as grapefruit can significantly increase serum levels of this product.\n¤ Take with food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(67, 'Diclofenac Sodium ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(68, 'Dicyclomine Hydrochloride ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(69, 'Digoxin ', ' C ', '¤ (Acarbose) Acarbose may decrease the serum concentration of Digoxin.¤ (Adenosine) Digoxin may enhance the adverse/toxic effect of Adenosine.¤ (Amikacin) May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).¤ (Amiodarone) May increase the serum concentration of Cardiac Glycosides.¤ (Amphotericin B) May enhance the adverse/toxic effect of Cardiac Glycosides.¤ (Arbekacin) May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).¤ (Atazanavir) Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Atorvastatin) May increase the serum concentration of Digoxin.¤ (Batimastat) May increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Boceprevir) May increase the serum concentration of Digoxin.¤ (Bretylium) May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.¤ (Calcidiol) May increase the serum concentration of Cardiac Glycosides.¤ (Calcitriol) May increase the serum concentration of Cardiac Glycosides.¤ (Carbimazole) May increase the serum concentration of Cardiac Glycosides.¤ (Carvedilol) Digoxin may enhance the bradycardic effect of Carvedilol. Carvedilol may increase the serum concentration of Digoxin.¤ (Celecoxib) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Cholecalciferol) May increase the serum concentration of Cardiac Glycosides.¤ (Clonidine) May enhance the AV-blocking effect of Cardiac Glycosides. Sinus node dysfunction may also be enhanced.¤ (Colchicine) Digoxin may increase the serum concentration of Colchicine.¤ (Colesevelam) May decrease the absorption of Cardiac Glycosides. Exceptions: Colesevelam.¤ (Conivaptan) May increase the serum concentration of Digoxin.¤ (Darunavir) Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Diflunisal) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Dihydrotachysterol) May increase the serum concentration of Cardiac Glycosides.¤ (Dronedarone) Digoxin may enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin.¤ (Eliglustat) May increase the serum concentration of Digoxin.¤ (Epoprostenol) May increase the serum concentration of Digoxin.¤ (Ergocalciferol) May increase the serum concentration of Cardiac Glycosides.¤ (Etodolac) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Etravirine) May increase the serum concentration of Digoxin.¤ (Ezogabine) May increase the serum concentration of Digoxin. More specifically~ the N-acetyl metabolite of ezogabine may increase digoxin concentrations.¤ (Fenoprofen) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Flecainide) May increase the serum concentration of Digoxin.¤ (Floctafenine) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Fosamprenavir) Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Framycetin) May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).¤ (Gentamicin) May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).¤ (Glycopyrrolate) May increase the serum concentration of Digoxin. This effect is specific to digoxin administered as slow dissolution oral tablets.¤ (Ibuprofen) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Indinavir) Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Indomethacin) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Isavuconazonium) Isavuconazonium Sulfate may increase the serum concentration of Digoxin.¤ (Isoflurophate) May increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Itraconazole) May increase the serum concentration of Cardiac Glycosides.¤ (Kanamycin) May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).¤ (Kaolin) May decrease the serum concentration of Cardiac Glycosides.¤ (Ketoprofen) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Ketorolac) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Lacosamide) Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.¤ (Lenalidomide) May increase the serum concentration of Digoxin.¤ (Lopinavir) Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Mefenamic acid) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Meloxicam) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Methimazole) May increase the serum concentration of Cardiac Glycosides.¤ (Midodrine) Cardiac Glycosides may enhance the bradycardic effect of Midodrine.¤ (Mifepristone) May increase the serum concentration of Digoxin.¤ (Milnacipran) May enhance the adverse/toxic effect of Digoxin. The risk of postural hypotension and tachycardia may be increased~ particularly with IV digoxin.¤ (Mirabegron) May increase the serum concentration of Digoxin.¤ (Nabumetone) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Naproxen) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Nefazodone) May increase the serum concentration of Digoxin.¤ (Nelfinavir) Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Neomycin) May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).¤ (Netilmicin) May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).¤ (Nifedipine) May increase the serum concentration of Digoxin.¤ (Oxaprozin) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Paricalcitol) May enhance the adverse/toxic effect of Digoxin.¤ (Penicillamine) May decrease the serum concentration of Digoxin.¤ (Piroxicam) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Posaconazole) May increase the serum concentration of Digoxin.¤ (Propafenone) May increase the serum concentration of Cardiac Glycosides.¤ (Propylthiouracil) May increase the serum concentration of Cardiac Glycosides.¤ (Quinidine) May increase the serum concentration of Cardiac Glycosides.¤ (Quinine) May increase the serum concentration of Digoxin.¤ (Ranolazine) Ranolazine may increase the serum concentration of Digoxin.¤ (Regorafenib) May enhance the bradycardic effect of Digoxin.¤ (Reserpine) May enhance the adverse/toxic effect of Cardiac Glycosides.¤ (Ribostamycin) May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).¤ (Ritonavir) Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Ruxolitinib) May enhance the bradycardic effect of Bradycardia-Causing Agents.¤ (Saquinavir) Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Simeprevir) May increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Sitagliptin) May increase the serum concentration of Digoxin.¤ (Spectinomycin) May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).¤ (Spironolactone) May increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations~ falsely increasing or decreasing Digoxin concentrations.¤ (Streptomycin) May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).¤ (Sucralfate) Sucralfate may decrease the serum concentration of Digoxin. Specifically~ sucralfate may decrease the absorption of digoxin.¤ (Sulfamethoxazole) Trimethoprim may increase the serum concentration of Digoxin.¤ (Sulindac) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Telaprevir) May increase the serum concentration of Digoxin.¤ (Telmisartan) May increase the serum concentration of Cardiac Glycosides.¤ (Tiaprofenic acid) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Ticagrelor) May increase the serum concentration of Digoxin.¤ (Tipranavir) Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Tobramycin) May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).¤ (Tofacitinib) May enhance the bradycardic effect of Bradycardia-Causing Agents.¤ (Tolmetin) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Tolvaptan) May increase the serum concentration of Digoxin.¤ (Trimethoprim) May increase the serum concentration of Digoxin.¤ (Vandetanib) May increase the serum concentration of Digoxin.¤ (Vilazodone) May increase the serum concentration of Digoxin.', 'yes', '¤ Avoid avocado.\n¤ Avoid bran and high fiber foods within 2 hours of taking this medication.\n¤ Avoid excess salt/sodium unless otherwise instructed by your physician.\n¤ Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.\n¤ Avoid salt substitutes containing potassium.\n¤ Limit garlic, ginger, gingko, and horse chestnut.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(70, 'Dimercaprol ', ' C ', '¤ (Ferric Carboxymaltose) May enhance the nephrotoxic effect of Iron Salts.¤ (Iron) May enhance the nephrotoxic effect of Iron Salts.¤ (Iron Dextran) May enhance the nephrotoxic effect of Iron Salts.¤ (Iron sucrose) May enhance the nephrotoxic effect of Iron Salts.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(71, 'Dobutamine ', ' C ', '¤ (Acebutolol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Aminophylline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Amphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Arformoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (armodafinil) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Articaine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Atomoxetine) AtoMOXetine may enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.¤ (Benzphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Caffeine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Calcium Acetate) Calcium Salts may diminish the therapeutic effect of DOBUTamine.¤ (Calcium carbonate) Calcium Salts may diminish the therapeutic effect of DOBUTamine.¤ (Calcium Chloride) Calcium Salts may diminish the therapeutic effect of DOBUTamine.¤ (Chlorphentermine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Clenbuterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Cocaine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dexmethylphenidate) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dextroamphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Diethylpropion) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dihydrocodeine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dipivefrin) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dopamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Doxapram) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dronabinol) Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.¤ (Epinephrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Fenoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Fluticasone furoate) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Formoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Indacaterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Iobenguane) May diminish the therapeutic effect of Iobenguane I 123.¤ (Ipratropium bromide) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Isometheptene) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Isoprenaline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Labetalol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Levonordefrin) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Linezolid) Linezolid may enhance the hypertensive effect of Sympathomimetics.¤ (Lisdexamfetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Mephentermine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Metaraminol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Methamphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Methoxamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Methylphenidate) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Midodrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Modafinil) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Nabilone) Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.¤ (Naphazoline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Norepinephrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Orciprenaline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Oxymetazoline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phendimetrazine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Pheniramine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phenmetrazine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phentermine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phenylephrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phenylpropanolamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Pirbuterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Propylhexedrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Pseudoephedrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Ritodrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Salbutamol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Salmeterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Tedizolid Phosphate) Tedizolid may enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.¤ (Terbutaline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Theophylline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Triprolidine) May enhance the adverse/toxic effect of other Sympathomimetics.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(72, 'Docetaxel ', ' D ', '¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Dronedarone) May increase the serum concentration of DOCEtaxel.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Itraconazole) Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of DOCEtaxel. Fluconazole and isavuconazonium considerations are addressed in separate monographs.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Posaconazole) Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of DOCEtaxel. Fluconazole and isavuconazonium considerations are addressed in separate monographs.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Sorafenib) SORAfenib may increase the serum concentration of DOCEtaxel.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.¤ (Voriconazole) Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of DOCEtaxel. Fluconazole and isavuconazonium considerations are addressed in separate monographs.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(73, 'Dopamine Hydrochloride ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(74, 'Dorzolamide ', ' C ', '¤ (Acetazolamide) May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.¤ (Diclofenamide) May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.¤ (Ethoxzolamide) May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(75, 'Doxorubicin Hydrochloride ', ' D ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(76, 'Doxycycline ', ' D ', '¤ (Aluminum hydroxide) May decrease the absorption of Tetracycline Derivatives.¤ (Amdinocillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Amobarbital) Barbiturates may decrease the serum concentration of Doxycycline.¤ (Amoxicillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Ampicillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Azidocillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Azlocillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Bacampicillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Benzylpenicillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Bismuth Subsalicylate) May decrease the serum concentration of Tetracycline Derivatives.¤ (Butabarbital) Barbiturates may decrease the serum concentration of Doxycycline.¤ (Butalbital) Barbiturates may decrease the serum concentration of Doxycycline.¤ (Butethal) May decrease the serum concentration of Doxycycline.¤ (Calcium carbonate) May decrease the absorption of Tetracycline Derivatives.¤ (Carbamazepine) May decrease the serum concentration of Doxycycline.¤ (Carbenicillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Cloxacillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Colesevelam) May decrease the absorption of Tetracycline Derivatives.¤ (Cyclacillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Dicloxacillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Flucloxacillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Fosphenytoin) May decrease the serum concentration of Doxycycline.¤ (Heptabarbital) May decrease the serum concentration of Doxycycline.¤ (Hetacillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Hexobarbital) May decrease the serum concentration of Doxycycline.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Magnesium oxide) May decrease the absorption of Tetracycline Derivatives.¤ (Methohexital) May decrease the serum concentration of Doxycycline.¤ (Meticillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Mezlocillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Mipomersen) Tetracycline Derivatives may enhance the hepatotoxic effect of Mipomersen.¤ (Nafcillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Oxacillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Penicillin V) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Pentobarbital) May decrease the serum concentration of Doxycycline.¤ (Phenobarbital) Barbiturates may decrease the serum concentration of Doxycycline.¤ (Phenytoin) Phenytoin may decrease the serum concentration of Doxycycline.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Piperacillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Pivampicillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Pivmecillinam) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Porfimer) Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.¤ (Primidone) May decrease the serum concentration of Doxycycline.¤ (Quinapril) May decrease the serum concentration of Tetracycline Derivatives.¤ (Rifampicin) Rifampin may decrease the serum concentration of Doxycycline.¤ (Secobarbital) May decrease the serum concentration of Doxycycline.¤ (Sucralfate) May decrease the absorption of Tetracycline Derivatives.¤ (Ticarcillin) Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.¤ (Verteporfin) Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.', 'yes', '¤ Avoid alcohol.\n¤ Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.\n¤ Take with a full glass of water Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(77, 'Efavirenz ', ' D ', '¤ (Acenocoumarol) May decrease the serum concentration of Vitamin K Antagonists. Efavirenz may increase the serum concentration of Vitamin K Antagonists.¤ (Amlodipine) May decrease the serum concentration of Calcium Channel Blockers.¤ (Artemether) May decrease the serum concentration of Artemether. Concentrations of dihydroartemisinin (active metabolite of artemether) may also be decreased by efavirenz¤ (Atazanavir) May decrease the serum concentration of Atazanavir.¤ (Atorvastatin) May decrease the serum concentration of AtorvaSTATin.¤ (Atovaquone) May decrease the serum concentration of Atovaquone.¤ (Boceprevir) Boceprevir may increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Boceprevir.¤ (Buprenorphine) May decrease serum concentrations of the active metabolite(s) of Buprenorphine. Efavirenz may decrease the serum concentration of Buprenorphine.¤ (Bupropion) May decrease the serum concentration of BuPROPion.¤ (Canagliflozin) May decrease the serum concentration of Canagliflozin.¤ (Clarithromycin) May decrease the serum concentration of Clarithromycin.¤ (Clevidipine) May decrease the serum concentration of Calcium Channel Blockers.¤ (Darunavir) Darunavir may increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Darunavir.¤ (Delavirdine) Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Efavirenz. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Efavirenz.¤ (Desogestrel) May decrease the serum concentration of Contraceptives (Progestins).¤ (Diltiazem) May decrease the serum concentration of Diltiazem.¤ (Dolutegravir) May decrease the serum concentration of Dolutegravir.¤ (Drospirenone) May decrease the serum concentration of Contraceptives (Progestins).¤ (Ethanol) May enhance the adverse/toxic effect of Alcohol (Ethyl). Efavirenz may decrease the serum concentration of Alcohol (Ethyl).¤ (Ethynodiol) May decrease the serum concentration of Contraceptives (Progestins).¤ (Etonogestrel) May diminish the therapeutic effect of Etonogestrel.¤ (Etravirine) Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Efavirenz. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Efavirenz.¤ (Everolimus) May decrease the serum concentration of Everolimus.¤ (Felodipine) May decrease the serum concentration of Calcium Channel Blockers.¤ (Fosamprenavir) May decrease serum concentrations of the active metabolite(s) of Fosamprenavir.¤ (Fosphenytoin) May increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Efavirenz.¤ (Indinavir) May decrease the serum concentration of Indinavir.¤ (Isradipine) May decrease the serum concentration of Calcium Channel Blockers.¤ (Itraconazole) May decrease the serum concentration of Itraconazole.¤ (Levonorgestrel) May decrease the serum concentration of Contraceptives (Progestins).¤ (Lopinavir) May decrease the serum concentration of Lopinavir.¤ (Lovastatin) May decrease the serum concentration of Lovastatin.¤ (Lumefantrine) May decrease the serum concentration of Artemether. Concentrations of dihydroartemisinin (active metabolite of artemether) may also be decreased by efavirenz¤ (Maraviroc) May decrease the serum concentration of Maraviroc. Of note~ this effect only applies in the absence of a strong CYP3A4 inhibitor¤ (Medroxyprogesterone Acetate) May decrease the serum concentration of Contraceptives (Progestins).¤ (Mestranol) May decrease the serum concentration of Contraceptives (Progestins).¤ (Mifepristone) Mifepristone may increase the serum concentration of Efavirenz.¤ (Nevirapine) May enhance the adverse/toxic effect of Nevirapine. Nevirapine may enhance the adverse/toxic effect of Efavirenz. Nevirapine may decrease the serum concentration of Efavirenz.¤ (Nifedipine) May decrease the serum concentration of Calcium Channel Blockers.¤ (Nimodipine) May decrease the serum concentration of Calcium Channel Blockers.¤ (Norelgestromin) May decrease the serum concentration of Contraceptives (Progestins).¤ (Norethindrone) May decrease the serum concentration of Contraceptives (Progestins).¤ (Norgestimate) May decrease serum concentrations of the active metabolite(s) of Norgestimate.¤ (Phenytoin) May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Efavirenz.¤ (Posaconazole) May decrease the serum concentration of Posaconazole.¤ (Pravastatin) May decrease the serum concentration of Pravastatin.¤ (Proguanil) May decrease the serum concentration of Atovaquone.¤ (Rifampicin) Rifampin may decrease the serum concentration of Efavirenz.¤ (Rilpivirine) Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Efavirenz. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Efavirenz.¤ (Ritonavir) May enhance the adverse/toxic effect of Ritonavir. Efavirenz may increase the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of Efavirenz.¤ (Saquinavir) Saquinavir may enhance the adverse/toxic effect of Efavirenz. Efavirenz may decrease the serum concentration of Saquinavir.¤ (Sertraline) May decrease the serum concentration of Sertraline.¤ (Simvastatin) May decrease the serum concentration of Simvastatin.¤ (Sirolimus) May decrease the serum concentration of Sirolimus.¤ (Telaprevir) May decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Efavirenz.¤ (Ulipristal) May decrease the serum concentration of Ulipristal.¤ (Voriconazole) May decrease the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Efavirenz.', 'yes', '¤ Avoid excessive or chronic alcohol consumption.\n¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(78, 'Enalapril Maleate ', 'C first trimester; D second and third trimester ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(79, 'Epinephrine Hydrochloride ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(80, 'Erythromycin Stearate / Succinate ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(81, 'Ethambutol ', 'B ', '¤ (Aluminum hydroxide) May decrease the absorption of Ethambutol.', 'yes', '¤ Take with food to reduce irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(82, 'Ethionamide Hydrochloride ', 'D ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(83, 'Ethosuximide ', ' C ', '¤ (Amphetamine) Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Benzphetamine) Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Buprenorphine) CNS Depressants may enhance the CNS depressant effect of Buprenorphine.¤ (Cathinone) May diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dextroamphetamine) Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Droperidol) May enhance the CNS depressant effect of CNS Depressants.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Fosphenytoin) Ethosuximide may enhance the CNS depressant effect of Fosphenytoin. Ethosuximide may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Ethosuximide.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Lisdexamfetamine) Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Mefloquine) Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.¤ (Methamphetamine) Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.¤ (Methotrimeprazine) CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mianserin) May diminish the therapeutic effect of Anticonvulsants.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Mirtazapine) CNS Depressants may enhance the CNS depressant effect of Mirtazapine.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Orlistat) May decrease the serum concentration of Anticonvulsants.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Phendimetrazine) Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.¤ (Phentermine) Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.¤ (Phenytoin) May enhance the CNS depressant effect of Phenytoin. Ethosuximide may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Ethosuximide.¤ (Pramipexole) CNS Depressants may enhance the sedative effect of Pramipexole.¤ (Ropinirole) CNS Depressants may enhance the sedative effect of ROPINIRole.¤ (Rotigotine) CNS Depressants may enhance the sedative effect of Rotigotine.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Valproic Acid) May decrease the serum concentration of Valproic Acid and Derivatives. Valproic Acid and Derivatives may increase the serum concentration of Ethosuximide.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.', 'yes', '¤ Avoid alcohol.\n¤ Take with food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(84, 'Etoposide ', 'D ', '¤ (Acenocoumarol) May enhance the anticoagulant effect of Vitamin K Antagonists.¤ (Amobarbital) Barbiturates may decrease the serum concentration of Etoposide.¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Atovaquone) May increase the serum concentration of Etoposide.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Butabarbital) Barbiturates may decrease the serum concentration of Etoposide.¤ (Butalbital) Barbiturates may decrease the serum concentration of Etoposide.¤ (Butethal) May decrease the serum concentration of Etoposide.¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Fosphenytoin) May decrease the serum concentration of Etoposide.¤ (Heptabarbital) May decrease the serum concentration of Etoposide.¤ (Hexobarbital) May decrease the serum concentration of Etoposide.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Methohexital) Barbiturates may decrease the serum concentration of Etoposide.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Pentobarbital) Barbiturates may decrease the serum concentration of Etoposide.¤ (Phenobarbital) Barbiturates may decrease the serum concentration of Etoposide.¤ (Phenytoin) Phenytoin may decrease the serum concentration of Etoposide.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Primidone) May decrease the serum concentration of Etoposide.¤ (Proguanil) Atovaquone may increase the serum concentration of Etoposide.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Secobarbital) Barbiturates may decrease the serum concentration of Etoposide.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.', 'yes', '¤ Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can decrease serum levels of this product.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(85, 'Etravirine ', ' B ', '¤ (Amiodarone) May decrease the serum concentration of Amiodarone.¤ (Aripiprazole) CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.¤ (Artemether) Etravirine may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically~ concentrations of dihydroartemisinin may be decreased. Artemether may increase the serum concentration of Etravirine. Etravirine may increase the serum concentration of Artemether.¤ (Atazanavir) Atazanavir may increase the serum concentration of Etravirine. Etravirine may decrease the serum concentration of Atazanavir.¤ (Atorvastatin) May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin~ lovastatin and simvastatin. Conversely~ levels of fluvastatin may be increased.¤ (Avanafil) May decrease the serum concentration of Phosphodiesterase 5 Inhibitors.¤ (Axitinib) CYP3A4 Inducers (Moderate) may decrease the serum concentration of Axitinib.¤ (Batimastat) Etravirine may increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir~ saquinavir~ and lopinavir (with low-dose ritonavir).¤ (Boceprevir) May decrease the serum concentration of Etravirine.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Bosutinib) CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib.¤ (Buprenorphine) May decrease the serum concentration of Buprenorphine.¤ (Carbamazepine) May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.¤ (Carvedilol) CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically~ concentrations of the S-carvedilol enantiomer may be increased.¤ (Cilostazol) CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.¤ (Citalopram) CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.¤ (Clarithromycin) CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.¤ (Clopidogrel) CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Darunavir) Darunavir may decrease the serum concentration of Etravirine.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Delavirdine) Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine.¤ (Diazepam) May decrease the serum concentration of Diazepam. Etravirine may increase the serum concentration of Diazepam.¤ (Digoxin) May increase the serum concentration of Digoxin.¤ (Disopyramide) May decrease the serum concentration of Disopyramide.¤ (Dolutegravir) Etravirine may decrease the serum concentration of Dolutegravir.¤ (Dronabinol) CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.¤ (Efavirenz) Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Efavirenz. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Efavirenz.¤ (Enzalutamide) CYP3A4 Inducers (Moderate) may decrease the serum concentration of Enzalutamide.¤ (Fentanyl) CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL.¤ (Flecainide) May decrease the serum concentration of Flecainide.¤ (Fluconazole) May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Fluvastatin) May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin~ lovastatin and simvastatin. Conversely~ levels of fluvastatin may be increased.¤ (Fosamprenavir) May increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically~ amprenavir concentrations may increase.¤ (Fosphenytoin) Fosphenytoin may decrease the serum concentration of Etravirine.¤ (Hydrocodone) CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hydrocodone.¤ (Ifosfamide) CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide.¤ (Indinavir) May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir~ saquinavir~ and lopinavir (with low-dose ritonavir).¤ (Isoflurophate) Etravirine may increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir~ saquinavir~ and lopinavir (with low-dose ritonavir).¤ (Itraconazole) May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Lopinavir) Ritonavir may decrease the serum concentration of Etravirine.¤ (Lovastatin) May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin~ lovastatin and simvastatin. Conversely~ levels of fluvastatin may be increased.¤ (Lumefantrine) May decrease serum concentrations of the active metabolite(s) of Artemether. Specifically~ concentrations of dihydroartemisinin may be decreased. Artemether may increase the serum concentration of Etravirine. Etravirine may increase the serum concentration of Artemether.¤ (Maraviroc) May decrease the serum concentration of Maraviroc. Of note~ this effect only applies in the absence of a strong CYP3A4 inhibitor¤ (Methadone) May decrease the serum concentration of Methadone.¤ (Mexiletine) May decrease the serum concentration of Mexiletine.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nelfinavir) May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir~ saquinavir~ and lopinavir (with low-dose ritonavir).¤ (Nevirapine) Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine.¤ (Nisoldipine) CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nisoldipine.¤ (Phenobarbital) PHENobarbital may decrease the serum concentration of Etravirine.¤ (Phenytoin) Phenytoin may decrease the serum concentration of Etravirine.¤ (Posaconazole) May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Primidone) Primidone may decrease the serum concentration of Etravirine.¤ (Propafenone) May decrease the serum concentration of Propafenone.¤ (Quinidine) May decrease the serum concentration of QuiNIDine.¤ (Rifabutin) May decrease the serum concentration of Etravirine.¤ (Rifampicin) Rifamycin Derivatives may decrease the serum concentration of Etravirine.¤ (Rifapentine) Rifamycin Derivatives may decrease the serum concentration of Etravirine.¤ (Rilpivirine) Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz~ etravirine~ and nevirapine.¤ (Ritonavir) Ritonavir may decrease the serum concentration of Etravirine.¤ (Saquinavir) May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir~ saquinavir~ and lopinavir (with low-dose ritonavir).¤ (Saxagliptin) CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.¤ (Sildenafil) May decrease the serum concentration of Phosphodiesterase 5 Inhibitors.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) Etravirine may increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir~ saquinavir~ and lopinavir (with low-dose ritonavir).¤ (Simvastatin) May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin~ lovastatin and simvastatin. Conversely~ levels of fluvastatin may be increased.¤ (Tadalafil) May decrease the serum concentration of Phosphodiesterase 5 Inhibitors.¤ (Telaprevir) May decrease the serum concentration of Telaprevir.¤ (Tipranavir) Tipranavir may decrease the serum concentration of Etravirine.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Vardenafil) May decrease the serum concentration of Phosphodiesterase 5 Inhibitors.¤ (Voriconazole) May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(86, 'Exemestane ', ' D ', '¤ (Aripiprazole) CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Carbamazepine) CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Desogestrel) Estrogen Derivatives may diminish the therapeutic effect of Exemestane.¤ (Drospirenone) Estrogen Derivatives may diminish the therapeutic effect of Exemestane.¤ (Enzalutamide) CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.¤ (Estropipate) Estrogen Derivatives may diminish the therapeutic effect of Exemestane.¤ (Ethinyl Estradiol) Estrogen Derivatives may diminish the therapeutic effect of Exemestane.¤ (Ethynodiol) Estrogen Derivatives may diminish the therapeutic effect of Exemestane.¤ (Fosphenytoin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.¤ (Hydrocodone) CYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.¤ (Mestranol) Estrogen Derivatives may diminish the therapeutic effect of Exemestane.¤ (Methadone) May increase the serum concentration of Methadone.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Norelgestromin) Estrogen Derivatives may diminish the therapeutic effect of Exemestane.¤ (Norgestimate) Estrogen Derivatives may diminish the therapeutic effect of Exemestane.¤ (Phenobarbital) CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.¤ (Phenytoin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.¤ (Piperazine) Estrogen Derivatives may diminish the therapeutic effect of Exemestane.¤ (Primidone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.¤ (Rifampicin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.¤ (Rifapentine) CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.¤ (Saxagliptin) CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.', 'yes', '¤ High-fat meals increase plasma exemestane concentrations by approximately 40%.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(87, 'Famotidine ', ' B ', '¤ (Atazanavir) H2-Antagonists may decrease the serum concentration of Atazanavir.¤ (Bosutinib) H2-Antagonists may decrease the serum concentration of Bosutinib.¤ (Bupropion) May increase the serum concentration of OCT2 Substrates.¤ (Cefditoren) H2-Antagonists may decrease the serum concentration of Cefditoren.¤ (Cefpodoxime) H2-Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours.¤ (Cefuroxime) H2-Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.¤ (Dabrafenib) H2-Antagonists may decrease the serum concentration of Dabrafenib.¤ (Dasatinib) H2-Antagonists may decrease the absorption of Dasatinib.¤ (Delavirdine) H2-Antagonists may decrease the serum concentration of Delavirdine.¤ (Dexmethylphenidate) H2-Antagonists may increase the absorption of Dexmethylphenidate. Specifically~ H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand)~ which could result in both increased absorption (early) and decreased delayed absorption.¤ (Erlotinib) H2-Antagonists may decrease the serum concentration of Erlotinib.¤ (Fosamprenavir) H2-Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir~ making its effects on fosamprenavir/amprenavir concentrations difficult to predict.¤ (Gefitinib) H2-Antagonists may decrease the serum concentration of Gefitinib.¤ (Indinavir) H2-Antagonists may decrease the serum concentration of Indinavir.¤ (Itraconazole) H2-Antagonists may decrease the serum concentration of Itraconazole.¤ (Ledipasvir) H2-Antagonists may decrease the serum concentration of Ledipasvir.¤ (Methylphenidate) H2-Antagonists may increase the absorption of Methylphenidate. Specifically~ H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand)~ which could result in both increased absorption (early) and decreased delayed absorption.¤ (Mifepristone) May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).¤ (Nelfinavir) H2-Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced.¤ (Nilotinib) H2-Antagonists may decrease the serum concentration of Nilotinib.¤ (Pazopanib) H2-Antagonists may decrease the serum concentration of PAZOPanib.¤ (Posaconazole) H2-Antagonists may decrease the serum concentration of Posaconazole.¤ (Rilpivirine) H2-Antagonists may decrease the serum concentration of Rilpivirine.¤ (Risedronate) H2-Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.¤ (Saquinavir) H2-Antagonists may increase the serum concentration of Saquinavir.¤ (Varenicline) H2-Antagonists may increase the serum concentration of Varenicline.¤ (Vismodegib) H2-Antagonists may decrease the serum concentration of Vismodegib.', 'yes', '¤ Avoid alcohol.\n¤ Limit caffeine intake.\n¤ Take without regard to meals, food may slightly increase the product\'s bioavailability.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(88, 'Fentanyl ', ' B ', '¤ (Abiraterone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Acepromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Acetazolamide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Acetophenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Alvimopan) Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e.~ more than 7 days) opiates prior to alvimopan initiation.¤ (Amiloride) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Amisulpride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ammonium chloride) May increase the excretion of Analgesics (Opioid).¤ (Amphetamine) May enhance the analgesic effect of Analgesics (Opioid).¤ (Aprepitant) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Aripiprazole) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Atazanavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Bendroflumethiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Benzquinamide) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Bicalutamide) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Biotin) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Boceprevir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Bosentan) CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL.¤ (Bumetanide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Carbamazepine) CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.¤ (Carphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Cathinone) May enhance the analgesic effect of Analgesics (Opioid).¤ (Chlormezanone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Chlorothiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Chlorpromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Chlorprothixene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Chlorthalidone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Cimetidine) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Clarithromycin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Clotrimazole) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Clozapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Crizotinib) May increase the serum concentration of FentaNYL.¤ (Cyclothiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Dabrafenib) CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL.¤ (Dapoxetine) May enhance the adverse/toxic effect of Serotonin Modulators.¤ (Darunavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Delavirdine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Desipramine) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Desmopressin) Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.¤ (Diltiazem) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronedarone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Droperidol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Enzalutamide) May decrease the serum concentration of FentaNYL.¤ (Ethacrynic acid) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Ethoxzolamide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Etravirine) CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL.¤ (Fencamfamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluconazole) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Flupentixol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluspirilene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fosamprenavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Fosaprepitant) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Fosphenytoin) CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.¤ (Furosemide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Haloperidol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Hydrochlorothiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroflumethiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Indapamide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Indinavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Ioflupane I 123) FentaNYL may diminish the diagnostic effect of Ioflupane I 123.¤ (Isavuconazonium) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Itraconazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Lopinavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Loxapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Mesoridazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Methotrimeprazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Metoclopramide) Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.¤ (Metolazone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mifepristone) May increase the serum concentration of FentaNYL.¤ (Modafinil) CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL.¤ (Molindone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Nafcillin) CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL.¤ (Naltrexone) May diminish the therapeutic effect of Analgesics (Opioid).¤ (Naphazoline) Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.¤ (Nefazodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Nelfinavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Nilotinib) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Norfloxacin) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Olanzapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ondansetron) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Oxymetazoline) Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.¤ (Paliperidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Pegvisomant) Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Perphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Phenobarbital) CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.¤ (Phenylephrine) Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.¤ (Phenytoin) CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.¤ (Pimozide) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Piperacetazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Posaconazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Pramipexole) CNS Depressants may enhance the sedative effect of Pramipexole.¤ (Primidone) CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.¤ (Prochlorperazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Promazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Propylhexedrine) Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.¤ (Pseudoephedrine) Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.¤ (Quetiapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Remoxipride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Reserpine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Rifampicin) CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.¤ (Rifapentine) CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.¤ (Risperidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ritonavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Ropinirole) CNS Depressants may enhance the sedative effect of ROPINIRole.¤ (Rotigotine) CNS Depressants may enhance the sedative effect of Rotigotine.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Saquinavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Sertindole) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Spironolactone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Succinylcholine) May enhance the bradycardic effect of Analgesics (Opioid).¤ (Sulfisoxazole) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Sulpiride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Telaprevir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Telithromycin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Tetracycline) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Thioridazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Thiothixene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ticrynafen) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Torasemide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Triamterene) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Trichlormethiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Trifluoperazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Triflupromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Triprolidine) Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.¤ (Voriconazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Ziprasidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.¤ (Zuclopenthixol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', 'yes', '¤ Avoid alcohol.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(89, 'Filgrastim ', ' C ', '¤ (Bleomycin) Filgrastim may enhance the adverse/toxic effect of Bleomycin. Specifically~ the risk for pulmonary toxicity may be increased.¤ (Cyclophosphamide) Filgrastim may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the risk of pulmonary toxicity may be enhanced.¤ (Topotecan) Filgrastim may enhance the adverse/toxic effect of Topotecan.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(90, 'Fluconazole ', ' C ', '¤ (Acenocoumarol) May increase the serum concentration of Vitamin K Antagonists.¤ (Alfentanil) Fluconazole may increase the serum concentration of Alfentanil.¤ (Amitriptyline) May enhance the QTc-prolonging effect of Fluconazole. Fluconazole may increase the serum concentration of Amitriptyline.¤ (Amlodipine) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Amphotericin B) Antifungal Agents (Azole Derivatives~ Systemic) may diminish the therapeutic effect of Amphotericin B.¤ (Amrinone) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Aripiprazole) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.¤ (Atorvastatin) Fluconazole may increase the serum concentration of AtorvaSTATin.¤ (Avanafil) Fluconazole may increase the serum concentration of Avanafil.¤ (Bepridil) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Bosentan) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosentan.¤ (Bosutinib) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.¤ (Buspirone) Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of BusPIRone. Isavuconazonium considerations are addressed in separate monographs.¤ (Busulfan) Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Busulfan. Isavuconazonium considerations are addressed in separate monographs.¤ (Carbamazepine) Fluconazole may increase the serum concentration of CarBAMazepine.¤ (Carvedilol) CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically~ concentrations of the S-carvedilol enantiomer may be increased.¤ (Chlorpropamide) May increase the serum concentration of Sulfonylureas.¤ (Cilostazol) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.¤ (Cisapride) Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Cisapride. Isavuconazonium considerations are addressed in separate monographs.¤ (Citalopram) Fluconazole may enhance the QTc-prolonging effect of Citalopram. Fluconazole may increase the serum concentration of Citalopram.¤ (Clopidogrel) CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.¤ (Colchicine) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.¤ (Dapoxetine) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.¤ (Didanosine) May decrease the absorption of Antifungal Agents (Azole Derivatives~ Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.¤ (Diltiazem) May increase the serum concentration of Calcium Channel Blockers.¤ (Domperidone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone.¤ (Dronabinol) CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.¤ (Eletriptan) Fluconazole may increase the serum concentration of Eletriptan.¤ (Eplerenone) Fluconazole may increase the serum concentration of Eplerenone.¤ (Esomeprazole) Fluconazole may increase the serum concentration of Proton Pump Inhibitors.¤ (Etravirine) May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Everolimus) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.¤ (Felodipine) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Fentanyl) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.¤ (Flunarizine) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Fluvastatin) Fluconazole may increase the serum concentration of Fluvastatin.¤ (Fosphenytoin) Fluconazole may increase the serum concentration of Fosphenytoin.¤ (Gabapentin) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Gliclazide) May increase the serum concentration of Sulfonylureas.¤ (Glimepiride) May increase the serum concentration of Sulfonylureas.¤ (Glipizide) May increase the serum concentration of Sulfonylureas.¤ (Glyburide) May increase the serum concentration of Sulfonylureas.¤ (Hydrocodone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.¤ (Ifosfamide) CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.¤ (Imatinib) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Imatinib.¤ (Isradipine) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Ivacaftor) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.¤ (Lamotrigine) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Lansoprazole) Fluconazole may increase the serum concentration of Proton Pump Inhibitors.¤ (Lercanidipine) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Lomitapide) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.¤ (Losartan) Fluconazole may decrease the serum concentration of Losartan. Specifically~ fluconazole may decrease the serum concentration of E3174~ the more potent active metabolite of losartan.¤ (Lovastatin) Fluconazole may increase the serum concentration of Lovastatin.¤ (Lurasidone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.¤ (Magnesium Sulfate) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Methadone) Fluconazole may increase the serum concentration of Methadone.¤ (Mifepristone) May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.¤ (Nevirapine) Fluconazole may increase the serum concentration of Nevirapine.¤ (Nicardipine) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Nifedipine) May increase the serum concentration of Calcium Channel Blockers.¤ (Nimodipine) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Nisoldipine) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Nitrendipine) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Omeprazole) Fluconazole may increase the serum concentration of Proton Pump Inhibitors.¤ (Ospemifene) Fluconazole may increase the serum concentration of Ospemifene.¤ (Oxycodone) CYP3A4 Inhibitors (Moderate) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased.¤ (Pantoprazole) Fluconazole may increase the serum concentration of Proton Pump Inhibitors.¤ (Perhexiline) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Phenytoin) Fluconazole may increase the serum concentration of Phenytoin.¤ (Pimecrolimus) CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.¤ (Pimozide) Antifungal Agents (Azole Derivatives~ Systemic) may enhance the arrhythmogenic effect of Pimozide. Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Pimozide. This increase in serum concentrations may lead to QTc interval prolongation and ventricular arrhythmias. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Prednisone) Fluconazole may increase the serum concentration of PredniSONE.¤ (Prenylamine) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Quinidine) Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Rabeprazole) May increase the serum concentration of Proton Pump Inhibitors.¤ (Ramelteon) Fluconazole may increase the serum concentration of Ramelteon.¤ (Ranolazine) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.¤ (Risedronate) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Rivaroxaban) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rivaroxaban. This warning is more specifically for drugs that are inhibitors of both CYP3A4 and P-glycoprotein. For erythromycin~ refer to more specific erythromycin-rivaroxaban monograph recommendations.¤ (Ruxolitinib) Fluconazole may increase the serum concentration of Ruxolitinib.¤ (Salmeterol) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.¤ (Saxagliptin) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.¤ (Sildenafil) Fluconazole may increase the serum concentration of Sildenafil.¤ (Simeprevir) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir.¤ (Simvastatin) Fluconazole may increase the serum concentration of Simvastatin.¤ (Sirolimus) Fluconazole may increase the serum concentration of Sirolimus.¤ (Solifenacin) Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Solifenacin. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Sulfisoxazole) May enhance the QTc-prolonging effect of Erythromycin (Systemic). Fluconazole may increase the serum concentration of Erythromycin (Systemic).¤ (Sunitinib) Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of SUNItinib. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Suvorexant) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant.¤ (Tadalafil) Fluconazole may increase the serum concentration of Tadalafil.¤ (Temsirolimus) Fluconazole may increase serum concentrations of the active metabolite(s) of Temsirolimus.¤ (Tipranavir) Fluconazole may increase the serum concentration of Tipranavir.¤ (Tofacitinib) Fluconazole may increase the serum concentration of Tofacitinib.¤ (Tolazamide) May increase the serum concentration of Sulfonylureas.¤ (Tolbutamide) May increase the serum concentration of Sulfonylureas.¤ (Tolvaptan) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.¤ (Trabectedin) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin.¤ (Ulipristal) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal.¤ (Vardenafil) Fluconazole may increase the serum concentration of Vardenafil.¤ (Verapamil) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Vilazodone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.¤ (Voriconazole) Fluconazole may increase the serum concentration of Voriconazole.¤ (Zidovudine) Fluconazole may decrease the metabolism of Zidovudine.¤ (Zolpidem) Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Zolpidem. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Zopiclone) CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone.', 'yes', '¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(91, 'Fluorouracil ', ' D ', '', 'yes', '¤ Vitamin B1 needs increased with long term use.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(92, 'Fluoxetine ', ' C ', '¤ (Abciximab) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Acenocoumarol) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Acepromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Acetophenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Acetylsalicylic acid) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.¤ (Alteplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Amisulpride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Amitriptyline) May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.¤ (Amoxapine) May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.¤ (Anistreplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Apixaban) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically~ the risk for bleeding may be increased.¤ (Aripiprazole) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Atomoxetine) CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.¤ (Benzquinamide) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Bupropion) May enhance the adverse/toxic effect of FLUoxetine. BuPROPion may increase the serum concentration of FLUoxetine.¤ (Buspirone) May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.¤ (Carbamazepine) May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.¤ (Carphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Chlormezanone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Chlorpromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Chlorprothixene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Cilostazol) CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.¤ (Cimetidine) May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.¤ (Citric Acid) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Clomipramine) May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.¤ (Clopidogrel) CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.¤ (Clozapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Codeine) CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.¤ (Cyproheptadine) May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.¤ (Dabigatran etexilate) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.¤ (Dabrafenib) May decrease the serum concentration of CYP2C9 Substrates.¤ (Dalteparin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Dapoxetine) May enhance the adverse/toxic effect of Serotonin Modulators.¤ (Darunavir) May increase the serum concentration of CYP2D6 Substrates.¤ (Deoxycholic Acid) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically~ the risk for bleeding or bruising in the treatment area may be increased.¤ (Desipramine) May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.¤ (Desmopressin) Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.¤ (Dextromethorphan) Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.¤ (Dicoumarol) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Droperidol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Edetic Acid) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Enoxaparin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Ethyl biscoumacetate) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Fencamfamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fesoterodine) CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.¤ (Flupentixol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluspirilene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fondaparinux sodium) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Fosphenytoin) May enhance the QTc-prolonging effect of FLUoxetine. FLUoxetine may increase the serum concentration of Fosphenytoin.¤ (Glucosamine) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Haloperidol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Heparin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Hydrocodone) CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Hydrocodone. Specifically~ concentrations of hydromorphone may be decreased.¤ (Ibritumomab) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.¤ (Imipramine) May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.¤ (Ioflupane I 123) Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.¤ (Linezolid) May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.¤ (Lithium) May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.¤ (Loxapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Mequitazine) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine.¤ (Mesoridazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Methotrimeprazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Metoclopramide) May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.¤ (Metoprolol) CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.¤ (Metyrosine) May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.¤ (Mexiletine) Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine.¤ (Mifepristone) May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.¤ (Molindone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Nebivolol) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.¤ (Nifedipine) FLUoxetine may enhance the adverse/toxic effect of NIFEdipine.¤ (Nimodipine) May increase the serum concentration of NiMODipine.¤ (Nortriptyline) May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.¤ (Obinutuzumab) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically~ the risk of serious bleeding-related events may be increased.¤ (Olanzapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ondansetron) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Paliperidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Peginterferon alfa-2b) Peginterferon Alfa-2b may decrease the serum concentration of FLUoxetine.¤ (Pentoxifylline) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Perphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Phenindione) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Phenprocoumon) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Phenytoin) May increase the serum concentration of Phenytoin.¤ (Pimozide) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Piperacetazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Prochlorperazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Promazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Propafenone) May enhance the QTc-prolonging effect of FLUoxetine. FLUoxetine may increase the serum concentration of Propafenone.¤ (Protriptyline) May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.¤ (Quetiapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Remoxipride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Reserpine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Reteplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Ridogrel) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Risperidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Rivaroxaban) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.¤ (Salicylate-sodium) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.¤ (Sertindole) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Streptokinase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Sulodexide) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Sulpiride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Tamoxifen) CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.¤ (Tamsulosin) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.¤ (Tenecteplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Thioridazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Thiothixene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Tramadol) Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.¤ (Treprostinil) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Trifluoperazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Triflupromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Trimipramine) May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.¤ (Urokinase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Vitamin E) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Warfarin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Ziprasidone) May enhance the QTc-prolonging effect of Ziprasidone. Ziprasidone may enhance the serotonergic effect of FLUoxetine. This could result in serotonin syndrome.¤ (Zuclopenthixol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', 'yes', '¤ Avoid alcohol.\n¤ Take with food to reduce irritation and nausea.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(93, 'Fluphenazine Decanoate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(94, 'Formoterol Fumarate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(95, 'Furosemide ', ' C ', '¤ (Acetohexamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Acetylsalicylic acid) May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.¤ (Alfentanil) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Alfuzosin) May enhance the hypotensive effect of Antihypertensives.¤ (Aliskiren) May decrease the serum concentration of Furosemide.¤ (Allopurinol) Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically~ Loop Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Alogliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Amifostine) Antihypertensives may enhance the hypotensive effect of Amifostine.¤ (Amikacin) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Arbekacin) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Buprenorphine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Butabarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Butethal) May enhance the hypotensive effect of Hypotensive Agents.¤ (Butorphanol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Canagliflozin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Chloral hydrate) Furosemide may enhance the adverse/toxic effect of Chloral Hydrate.¤ (Chlorpropamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Cisplatin) Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.¤ (Codeine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Colesevelam) May decrease the absorption of Loop Diuretics.¤ (Diazoxide) May enhance the hypotensive effect of Antihypertensives.¤ (Dihydrocodeine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Dofetilide) Loop Diuretics may enhance the QTc-prolonging effect of Dofetilide.¤ (Duloxetine) Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.¤ (Ethacrynic acid) Furosemide may enhance the ototoxic effect of Ethacrynic Acid.¤ (Fentanyl) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Foscarnet) Loop Diuretics may increase the serum concentration of Foscarnet.¤ (Fosphenytoin) May diminish the diuretic effect of Loop Diuretics.¤ (Framycetin) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Gentamicin) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Gliclazide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glimepiride) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Gliquidone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glyburide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Heptabarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Hexobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Hydrocodone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Hydromorphone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Insulin Aspart) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Detemir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glargine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glulisine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Lispro) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Regular) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin~ isophane) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Kanamycin) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Levorphanol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Linagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Lithium) Loop Diuretics may decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium.¤ (Metformin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Methadone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Methohexital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Methotrexate) May diminish the therapeutic effect of Loop Diuretics. Methotrexate may increase the serum concentration of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate.¤ (Methylphenidate) May diminish the antihypertensive effect of Antihypertensives.¤ (Morphine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Nalbuphine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Neomycin) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Netilmicin) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Obinutuzumab) Antihypertensives may enhance the hypotensive effect of Obinutuzumab.¤ (Oxycodone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Oxymorphone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Pentobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Pentoxifylline) May enhance the hypotensive effect of Antihypertensives.¤ (Pethidine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Phenytoin) May diminish the diuretic effect of Loop Diuretics.¤ (Primidone) May enhance the hypotensive effect of Hypotensive Agents.¤ (Probenecid) May enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics.¤ (Remifentanil) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Repaglinide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Ribostamycin) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Risperidone) Loop Diuretics may enhance the adverse/toxic effect of RisperiDONE.¤ (Rituximab) Antihypertensives may enhance the hypotensive effect of RiTUXimab.¤ (Salicylate-sodium) May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.¤ (Saxagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Secobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Spectinomycin) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Streptomycin) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Sucralfate) Sucralfate may decrease the serum concentration of Furosemide. Sucralfate may impair the absorption of furosemide.¤ (Sufentanil) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Tadalafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Tapentadol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Teriflunomide) May increase the serum concentration of OAT3 Substrates.¤ (Tobramycin) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Tolbutamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Topiramate) Loop Diuretics may enhance the hypokalemic effect of Topiramate.¤ (Tramadol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Vardenafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Vildagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Yohimbine) May diminish the antihypertensive effect of Antihypertensives.', 'yes', '¤ Avoid alcohol.\n¤ Avoid excess salt/sodium unless otherwise instructed by your physician.\n¤ Increase potassium intake; add a banana or orange juice; unless instructed otherwise.\n¤ Take with food to reduce irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(96, 'Gentamycin Sulfate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(97, 'Glimepiride ', ' C ', '¤ (Acarbose) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Acetohexamide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Acetylsalicylic acid) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.¤ (Albiglutide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Alogliptin) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Aripiprazole) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Arsenic trioxide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Articaine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Asenapine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Atazanavir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Azilsartan medoxomil) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Bendroflumethiazide) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Bromocriptine) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Buformin) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Bumetanide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Buserelin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Canagliflozin) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Chloramphenicol) May decrease the metabolism of Sulfonylureas.¤ (Chlorothiazide) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Chlorpropamide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Chlorthalidone) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Cimetidine) May increase the serum concentration of Sulfonylureas.¤ (Clozapine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Colesevelam) May decrease the serum concentration of Glimepiride.¤ (Corticotropin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Cortisone acetate) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Cyproterone acetate) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Dabrafenib) May decrease the serum concentration of CYP2C9 Substrates.¤ (Danazol) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Dapagliflozin) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Darunavir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Desogestrel) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Diazoxide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Dihydrotestosterone) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.¤ (Disopyramide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Drospirenone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Dulaglutide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Empagliflozin) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Estropipate) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Ethacrynic acid) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Ethinyl Estradiol) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Ethynodiol) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Etonogestrel) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Everolimus) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Exenatide) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Fluconazole) May increase the serum concentration of Sulfonylureas.¤ (Fludrocortisone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Fosamprenavir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Furosemide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Gliclazide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Glipizide) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Gliquidone) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Glucagon recombinant) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Glyburide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Goserelin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Histrelin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Homoharringtonine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Hydrochlorothiazide) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Iloperidone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Indapamide) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Indinavir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (inhaled insulin) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin Aspart) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin Detemir) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin Glargine) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin Glulisine) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin Lispro) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin Regular) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin~ isophane) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin~ porcine) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Lanreotide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Leuprolide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Levonorgestrel) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Linagliptin) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Liraglutide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Lopinavir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Lurasidone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Mecasermin) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Medroxyprogesterone Acetate) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Megestrol acetate) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Mestranol) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Metformin) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Methotrimeprazine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Methyclothiazide) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Methylprednisolone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Metolazone) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Metreleptin) May enhance the hypoglycemic effect of Sulfonylureas.¤ (Mifepristone) May increase the serum concentration of CYP2C9 Substrates.¤ (Miglitol) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Mitiglinide) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Nateglinide) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Nelfinavir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Nilotinib) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Norelgestromin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Norethindrone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Norgestimate) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Octreotide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Olanzapine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Oxandrolone) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.¤ (Paliperidone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Pasireotide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Pegvisomant) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.¤ (Pentamidine) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Phenformin) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Pioglitazone) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Piperazine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Pipotiazine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Porfimer) Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.¤ (Pramlintide) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Prednisone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Probenecid) May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.¤ (Progesterone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Quetiapine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Quinine) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Ranitidine) May increase the serum concentration of Sulfonylureas.¤ (Repaglinide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Risperidone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Ritonavir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Rosiglitazone) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Salicylate-sodium) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.¤ (Saquinavir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Saxagliptin) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Sirolimus) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Sitagliptin) Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Sulfadiazine) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Sulfamethoxazole) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Sulfisoxazole) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Sulodexide) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Sunitinib) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Temsirolimus) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Testosterone) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.¤ (Tipranavir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Tolazamide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Tolbutamide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Torasemide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Triptorelin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Verteporfin) Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.¤ (Vildagliptin) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Voriconazole) May increase the serum concentration of Sulfonylureas.¤ (Vorinostat) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Ziprasidone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', 'yes', '¤ Avoid alcohol.\n¤ Even though food reduces product absorption, the manufacturer recommends taking the product with the first meal of the day.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(98, 'Griseofulvin ', ' C ', '¤ (Acenocoumarol) May decrease the serum concentration of Vitamin K Antagonists.¤ (Amobarbital) Barbiturates may decrease the serum concentration of Griseofulvin.¤ (Aripiprazole) CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.¤ (Butabarbital) Barbiturates may decrease the serum concentration of Griseofulvin.¤ (Butalbital) Barbiturates may decrease the serum concentration of Griseofulvin.¤ (Butethal) May decrease the serum concentration of Griseofulvin. Exceptions: Methohexital; Thiopental.¤ (Desogestrel) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Drospirenone) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Ethanol) May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.¤ (Ethinyl Estradiol) May increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible.¤ (Ethynodiol) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Etonogestrel) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Heptabarbital) May decrease the serum concentration of Griseofulvin. Exceptions: Methohexital; Thiopental.¤ (Hexobarbital) May decrease the serum concentration of Griseofulvin. Exceptions: Methohexital; Thiopental.¤ (Hydrocodone) CYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.¤ (Levonorgestrel) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Medroxyprogesterone Acetate) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Mestranol) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Methohexital) May decrease the serum concentration of Griseofulvin. Exceptions: Methohexital; Thiopental.¤ (Norelgestromin) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Norethindrone) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Norgestimate) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Pentobarbital) Barbiturates may decrease the serum concentration of Griseofulvin.¤ (Phenobarbital) Barbiturates may decrease the serum concentration of Griseofulvin.¤ (Porfimer) Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.¤ (Primidone) May decrease the serum concentration of Griseofulvin. Exceptions: Methohexital; Thiopental.¤ (Saxagliptin) CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.¤ (Secobarbital) May decrease the serum concentration of Griseofulvin. Exceptions: Methohexital; Thiopental.¤ (Ulipristal) Griseofulvin may decrease the serum concentration of Ulipristal.¤ (Verteporfin) Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.', 'yes', '¤  Avoid alcohol.\n¤ Take this medication with a high fat meal, fatty foods increase bioavailability.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(99, 'Haloperidol ', 'C ', '¤ (Aclidinium) May enhance the anticholinergic effect of Anticholinergic Agents.¤ (Almotriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Amisulpride) Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride.¤ (Amitriptyline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Amoxapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Amphetamine) May diminish the stimulatory effect of Amphetamines.¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) May enhance the QTc-prolonging effect of Haloperidol. ARIPiprazole may diminish the therapeutic effect of Haloperidol. Haloperidol may increase the serum concentration of ARIPiprazole.¤ (Benzphetamine) May diminish the stimulatory effect of Amphetamines.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Buprenorphine) CNS Depressants may enhance the CNS depressant effect of Buprenorphine.¤ (Buspirone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Cabergoline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Carbamazepine) May increase the metabolism of Haloperidol.¤ (Cathinone) Antipsychotic Agents may diminish the stimulatory effect of Amphetamines.¤ (Celecoxib) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Chlorpromazine) ChlorproMAZINE may enhance the QTc-prolonging effect of Haloperidol. ChlorproMAZINE may increase the serum concentration of Haloperidol. Haloperidol may increase the serum concentration of ChlorproMAZINE.¤ (Citalopram) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Clomipramine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Codeine) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Cyclobenzaprine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Desipramine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Desvenlafaxine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Dextroamphetamine) May diminish the stimulatory effect of Amphetamines.¤ (Dextromethorphan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Diflunisal) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Dihydroergotamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Donepezil) Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Droperidol) May enhance the CNS depressant effect of CNS Depressants.¤ (Duloxetine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Eletriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ergoloid mesylate) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ergonovine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ergotamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Escitalopram) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Etodolac) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Fenoprofen) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Fentanyl) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fesoterodine) CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.¤ (Floctafenine) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Fluoxetine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluvoxamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Frovatriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Galantamine) Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.¤ (Glycerol Phenylbutyrate) May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically~ Haloperidol may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range.¤ (Glycopyrrolate) May decrease the serum concentration of Haloperidol.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Ibuprofen) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Imipramine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Indomethacin) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Isocarboxazid) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Itopride) Anticholinergic Agents may diminish the therapeutic effect of Itopride.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Ketoprofen) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Ketorolac) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Levomilnacipran) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Linezolid) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Lisdexamfetamine) May diminish the stimulatory effect of Amphetamines.¤ (Lithium) May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.¤ (Lorcaserin) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Maprotiline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Mefenamic acid) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Meloxicam) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Mequitazine) Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.¤ (Methadone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Methamphetamine) May diminish the stimulatory effect of Amphetamines.¤ (Methotrimeprazine) CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.¤ (Methylergometrine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Methylphenidate) May enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents.¤ (Metoclopramide) May enhance the adverse/toxic effect of Antipsychotic Agents.¤ (Metoprolol) CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mifepristone) May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.¤ (Milnacipran) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Mirabegron) Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.¤ (Mirtazapine) CNS Depressants may enhance the CNS depressant effect of Mirtazapine.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Moclobemide) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Nabumetone) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Naproxen) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Naratriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Nebivolol) CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.¤ (Nefazodone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Nortriptyline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Oxaprozin) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Panobinostat) May increase the serum concentration of CYP2D6 Substrates.¤ (Paroxetine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Peginterferon alfa-2b) May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Pethidine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Phendimetrazine) May diminish the stimulatory effect of Amphetamines.¤ (Phenelzine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Phentermine) May diminish the stimulatory effect of Amphetamines.¤ (Piroxicam) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Potassium Chloride) Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.¤ (Pramlintide) May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.¤ (Procarbazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Promazine) ChlorproMAZINE may enhance the QTc-prolonging effect of Haloperidol. ChlorproMAZINE may increase the serum concentration of Haloperidol. Haloperidol may increase the serum concentration of ChlorproMAZINE.¤ (Promethazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Protriptyline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Quinidine) Haloperidol may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Haloperidol.¤ (Rasagiline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Rivastigmine) Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.¤ (Rizatriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Secretin) Anticholinergic Agents may diminish the therapeutic effect of Secretin.¤ (Selegiline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Sertraline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Sodium phenylbutyrate) May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically~ Haloperidol may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range.¤ (Sulindac) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Sulpiride) Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride.¤ (Sumatriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tamoxifen) CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Tedizolid Phosphate) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Tetrabenazine) Tetrabenazine may enhance the adverse/toxic effect of Antipsychotic Agents.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Thioridazine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Tiaprofenic acid) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Tiotropium) Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tolmetin) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Topiramate) Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.¤ (Tramadol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Tranylcypromine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Trimipramine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Venlafaxine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Vilazodone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Zolmitriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.', 'yes', '¤ Take with food to reduce irritation, limit caffeine intake. Avoid alcohol.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(100, 'Hydralazine Hydrochloride ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(101, 'Hydrochlorothiazide ', ' B ', '¤ (Acetohexamide) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Alfentanil) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Alfuzosin) May enhance the hypotensive effect of Antihypertensives.¤ (Allopurinol) Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.¤ (Alogliptin) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Amifostine) Antihypertensives may enhance the hypotensive effect of Amifostine.¤ (Benazepril) May enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.¤ (Buprenorphine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Butabarbital) May enhance the orthostatic hypotensive effect of Thiazide Diuretics.¤ (Butethal) May enhance the orthostatic hypotensive effect of Thiazide Diuretics.¤ (Butorphanol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Canagliflozin) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Carbamazepine) Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.¤ (Chlorpropamide) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Codeine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Colesevelam) May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.¤ (Cyclophosphamide) Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.¤ (Diazoxide) Thiazide Diuretics may enhance the adverse/toxic effect of Diazoxide.¤ (Dihydrocodeine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Dofetilide) Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.¤ (Duloxetine) Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.¤ (Fentanyl) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Gliclazide) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glimepiride) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Gliquidone) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glyburide) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Heptabarbital) May enhance the orthostatic hypotensive effect of Thiazide Diuretics.¤ (Hexobarbital) May enhance the orthostatic hypotensive effect of Thiazide Diuretics.¤ (Hydrocodone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Hydromorphone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Insulin Aspart) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Detemir) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glargine) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glulisine) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Lispro) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Regular) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin~ isophane) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Levorphanol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Linagliptin) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Lithium) Thiazide Diuretics may decrease the excretion of Lithium.¤ (Metformin) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Methadone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Methohexital) May enhance the orthostatic hypotensive effect of Thiazide Diuretics.¤ (Methylphenidate) May diminish the antihypertensive effect of Antihypertensives.¤ (Morphine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Nalbuphine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Obinutuzumab) Antihypertensives may enhance the hypotensive effect of Obinutuzumab.¤ (Oxcarbazepine) Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically~ there may be an increased risk for hyponatremia.¤ (Oxycodone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Oxymorphone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Pentobarbital) May enhance the orthostatic hypotensive effect of Thiazide Diuretics.¤ (Pentoxifylline) May enhance the hypotensive effect of Antihypertensives.¤ (Pethidine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Porfimer) Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.¤ (Primidone) May enhance the orthostatic hypotensive effect of Thiazide Diuretics.¤ (Remifentanil) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Repaglinide) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Risperidone) Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.¤ (Rituximab) Antihypertensives may enhance the hypotensive effect of RiTUXimab.¤ (Saxagliptin) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Secobarbital) May enhance the orthostatic hypotensive effect of Thiazide Diuretics.¤ (Sufentanil) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Tadalafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Tapentadol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Tolbutamide) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Topiramate) Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.¤ (Toremifene) Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.¤ (Tramadol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Valsartan) May enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.¤ (Vardenafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Verteporfin) Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.¤ (Vildagliptin) Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.¤ (Yohimbine) May diminish the antihypertensive effect of Antihypertensives.', 'yes', '¤ Avoid alcohol.\n¤ Avoid excess salt/sodium unless otherwise instructed by your physician.\n¤ Avoid natural licorice.\n¤ Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.\n¤ Increase potassium intake; add a banana or orange juice; unless instructed otherwise.\n¤ Take with food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(102, 'Hydrocortisone ', ' C ', '', 'yes', '¤ Take with food to reduce irritation. Calcium, phosphorous, potassium, Vitamin A, C, D and zinc needs increased with long term use.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(103, 'Hydroxyurea ', ' D ', '¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Didanosine) May enhance the adverse/toxic effect of Didanosine. An increased risk of pancreatitis~ hepatotoxicity and/or neuropathy may exist. Didanosine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis~ hepatotoxicity and/or neuropathy may exist.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Stavudine) Hydroxyurea may enhance the adverse/toxic effect of Stavudine. An increased risk of pancreatitis~ hepatotoxicity and/or neuropathy may exist. Stavudine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis~ hepatotoxicity and/or neuropathy may exist.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.', 'yes', '¤ Take without regard to meals. Drink liberally.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(104, 'Hyoscine Hydrobromide ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(105, 'Ibuprofen ', ' B ', '¤ (Abciximab) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Acenocoumarol) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Acetylsalicylic acid) NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.¤ (Aliskiren) Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.¤ (Alteplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Amikacin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Anistreplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Apixaban) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically~ the risk for bleeding may be increased.¤ (Arbekacin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Citric Acid) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Colesevelam) May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.¤ (Dabigatran etexilate) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.¤ (Dalteparin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Dasatinib) May enhance the anticoagulant effect of Agents with Antiplatelet Properties.¤ (Deferasirox) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically~ the risk for GI ulceration/irritation or GI bleeding may be increased.¤ (Deoxycholic Acid) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically~ the risk for bleeding or bruising in the treatment area may be increased.¤ (Desmopressin) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.¤ (Dicoumarol) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Digoxin) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Edetic Acid) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Enoxaparin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Eplerenone) Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.¤ (Ethyl biscoumacetate) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Floctafenine) May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.¤ (Fondaparinux sodium) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Framycetin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Gentamicin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Glucosamine) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Haloperidol) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Heparin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Hydralazine) Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.¤ (Ibritumomab) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.¤ (Imatinib) Ibuprofen may decrease the serum concentration of Imatinib. Specifically~ ibuprofen may decrease intracellular concentrations of imatinib~ leading to decreased clinical response.¤ (Kanamycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Lithium) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.¤ (Methotrexate) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.¤ (Neomycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Netilmicin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Obinutuzumab) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically~ the risk of serious bleeding-related events may be increased.¤ (Pemetrexed) NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.¤ (Pentoxifylline) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Phenindione) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Phenprocoumon) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Porfimer) Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.¤ (Pralatrexate) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically~ NSAIDS may decrease the renal excretion of pralatrexate.¤ (Probenecid) May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.¤ (Reteplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Ribostamycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Ridogrel) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Rivaroxaban) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.¤ (Salicylate-sodium) NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.¤ (Spectinomycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Streptokinase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Streptomycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Sulodexide) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Tenecteplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Tenofovir) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Tipranavir) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Tobramycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Treprostinil) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Urokinase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Vancomycin) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.¤ (Verteporfin) Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.¤ (Vitamin E) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Voriconazole) Voriconazole may increase the serum concentration of Ibuprofen. Specifically~ concentrations of the S-(+)-ibuprofen enantiomer may be increased.¤ (Warfarin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', 'yes', '¤ Avoid alcohol\n¤ Food delays the time to reach peak plasma concentrations by 30-60 minutes and reduces peak plasma concentrations by 30-50%. Extent of absorption is unaffected.\n¤ Take with food to reduce gastric irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(106, 'Imatinib Mesylate ', ' D ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(107, 'Indomethacin ', 'B first and second trimester; D third trimester ', '¤ (Abciximab) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Acenocoumarol) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Acetylsalicylic acid) NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.¤ (Aliskiren) Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.¤ (Alteplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Amikacin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Anistreplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Apixaban) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically~ the risk for bleeding may be increased.¤ (Arbekacin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Citric Acid) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Colesevelam) May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.¤ (Dabigatran etexilate) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.¤ (Dalteparin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Dasatinib) May enhance the anticoagulant effect of Agents with Antiplatelet Properties.¤ (Deferasirox) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically~ the risk for GI ulceration/irritation or GI bleeding may be increased.¤ (Deoxycholic Acid) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically~ the risk for bleeding or bruising in the treatment area may be increased.¤ (Desmopressin) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.¤ (Dicoumarol) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Digoxin) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Edetic Acid) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Enoxaparin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Eplerenone) Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.¤ (Ethyl biscoumacetate) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Floctafenine) May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.¤ (Fondaparinux sodium) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Framycetin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Gentamicin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Glucosamine) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Haloperidol) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Heparin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Hydralazine) Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.¤ (Ibritumomab) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.¤ (Kanamycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Lithium) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.¤ (Methotrexate) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.¤ (Neomycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Netilmicin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Obinutuzumab) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically~ the risk of serious bleeding-related events may be increased.¤ (Pemetrexed) NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.¤ (Pentoxifylline) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Phenindione) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Phenprocoumon) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Porfimer) Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.¤ (Pralatrexate) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically~ NSAIDS may decrease the renal excretion of pralatrexate.¤ (Probenecid) May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.¤ (Reteplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Ribostamycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Ridogrel) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Rivaroxaban) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.¤ (Salicylate-sodium) NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.¤ (Spectinomycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Streptokinase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Streptomycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Sulodexide) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Tenecteplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Tenofovir) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Tiludronate) Indomethacin may increase the serum concentration of Tiludronate.¤ (Tipranavir) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Tobramycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Treprostinil) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Triamterene) Indomethacin may enhance the nephrotoxic effect of Triamterene.¤ (Urokinase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Vancomycin) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.¤ (Verteporfin) Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.¤ (Vitamin E) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Warfarin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', 'yes', '¤ Avoid alcohol.\n¤ Take with food or antacids to reduce irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(108, 'Isoniazid ', ' C ', '¤ (Acetaminophen) May enhance the adverse/toxic effect of Acetaminophen.¤ (Aluminum hydroxide) May decrease the absorption of Isoniazid.¤ (Aminophylline) May increase the serum concentration of Theophylline Derivatives.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Butalbital) May enhance the adverse/toxic effect of Acetaminophen.¤ (Calcium carbonate) May decrease the absorption of Isoniazid.¤ (Carbamazepine) May decrease the metabolism of CarBAMazepine.¤ (Chlorzoxazone) May decrease the metabolism of Chlorzoxazone.¤ (Cilostazol) CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.¤ (Citalopram) CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.¤ (Clopidogrel) CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.¤ (Codeine) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.¤ (Corticotropin) Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.¤ (Cortisone acetate) Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.¤ (Cycloserine) May enhance the adverse/toxic effect of CycloSERINE. Specifically~ CNS toxicity may be enhanced.¤ (Dihydrocodeine) May enhance the adverse/toxic effect of Acetaminophen.¤ (Disulfiram) Disulfiram may enhance the adverse/toxic effect of Isoniazid. Disulfiram may increase the serum concentration of Isoniazid.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Eliglustat) CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.¤ (Ethionamide) Ethionamide may increase the serum concentration of Isoniazid.¤ (Fesoterodine) CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.¤ (Fludrocortisone) Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.¤ (Fosphenytoin) Isoniazid may increase the serum concentration of Fosphenytoin.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Isometheptene) May enhance the adverse/toxic effect of Acetaminophen.¤ (Itraconazole) Isoniazid may decrease the serum concentration of Itraconazole.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Magnesium oxide) May decrease the absorption of Isoniazid.¤ (Methylprednisolone) Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.¤ (Metoprolol) CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.¤ (Nebivolol) CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.¤ (Phenytoin) May increase the serum concentration of Phenytoin.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Prednisone) Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.¤ (Propafenone) May increase the serum concentration of CYP2D6 Inhibitors (Moderate).¤ (Rifampicin) Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so~ this is a frequently employed combination regimen.¤ (Rifapentine) Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so~ this is a frequently employed combination regimen.¤ (Sodium bicarbonate) Antacids may decrease the absorption of Isoniazid.¤ (Tamoxifen) CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.¤ (Theophylline) May increase the serum concentration of Theophylline Derivatives.¤ (Thioridazine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Tramadol) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', 'yes', '¤ Avoid aged foods (cheese, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.\n¤ Avoid alcohol.\n¤ Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.\n¤ Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.\n¤ Take on empty stomach: 1 hour before or 2 hours after meals.\n¤ Take with a full glass of water.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(109, 'Kanamycin Sulphate ', ' D ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(110, 'Ketoconazole ', ' C ', '', 'yes', '¤ Avoid alcohol.\n¤ Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.\n¤ Take with food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(111, 'Labetalol ', 'B first and second trimester; D third trimester ', '¤ (Acetylcholine) Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.¤ (Amifostine) Antihypertensives may enhance the hypotensive effect of Amifostine.¤ (Aminophylline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Amiodarone) May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.¤ (Amphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Arformoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (armodafinil) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Articaine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Atomoxetine) AtoMOXetine may enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.¤ (Benzphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Bretylium) May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.¤ (Bupivacaine) Beta-Blockers may increase the serum concentration of Bupivacaine.¤ (Butabarbital) May decrease the serum concentration of Beta-Blockers.¤ (Butethal) May decrease the serum concentration of Beta-Blockers.¤ (Caffeine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Carbachol) Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.¤ (Cocaine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dexmethylphenidate) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dextroamphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Diazoxide) May enhance the hypotensive effect of Antihypertensives.¤ (Diethylpropion) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dihydrocodeine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dipivefrin) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dipyridamole) May enhance the bradycardic effect of Beta-Blockers.¤ (Disopyramide) May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.¤ (Dobutamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dopamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Doxapram) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dronabinol) Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.¤ (Dronedarone) May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6.¤ (Duloxetine) Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.¤ (Fenoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Fingolimod) Beta-Blockers may enhance the bradycardic effect of Fingolimod.¤ (Floctafenine) May enhance the adverse/toxic effect of Beta-Blockers.¤ (Fluticasone furoate) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Formoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Heptabarbital) May decrease the serum concentration of Beta-Blockers.¤ (Hexobarbital) May decrease the serum concentration of Beta-Blockers.¤ (Indacaterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Iobenguane) May diminish the therapeutic effect of Iobenguane I 123.¤ (Ipratropium bromide) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Isometheptene) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Lacosamide) Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.¤ (Levonordefrin) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Linezolid) Linezolid may enhance the hypertensive effect of Sympathomimetics.¤ (Lisdexamfetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Mepivacaine) Beta-Blockers may increase the serum concentration of Mepivacaine.¤ (Methacholine) Beta-Blockers may enhance the adverse/toxic effect of Methacholine.¤ (Methamphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Methohexital) May decrease the serum concentration of Beta-Blockers.¤ (Methylphenidate) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Midodrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Modafinil) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Nabilone) Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.¤ (Naphazoline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Norepinephrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Obinutuzumab) Antihypertensives may enhance the hypotensive effect of Obinutuzumab.¤ (Orciprenaline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Oxymetazoline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Pentobarbital) May decrease the serum concentration of Beta-Blockers.¤ (Pentoxifylline) May enhance the hypotensive effect of Antihypertensives.¤ (Phendimetrazine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Pheniramine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phentermine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phenylephrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Pirbuterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Primidone) May decrease the serum concentration of Beta-Blockers.¤ (Propafenone) May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.¤ (Propylhexedrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Pseudoephedrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Regorafenib) May enhance the bradycardic effect of Beta-Blockers.¤ (Reserpine) May enhance the hypotensive effect of Beta-Blockers.¤ (Risperidone) Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.¤ (Rituximab) Antihypertensives may enhance the hypotensive effect of RiTUXimab.¤ (Rivastigmine) May enhance the bradycardic effect of Beta-Blockers.¤ (Ruxolitinib) May enhance the bradycardic effect of Bradycardia-Causing Agents.¤ (Salbutamol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Salmeterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Secobarbital) May decrease the serum concentration of Beta-Blockers.¤ (Tadalafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Tedizolid Phosphate) Tedizolid may enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.¤ (Terbutaline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Theophylline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Tofacitinib) May enhance the bradycardic effect of Bradycardia-Causing Agents.¤ (Triprolidine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Vardenafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Yohimbine) May diminish the antihypertensive effect of Antihypertensives.', 'yes', '¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(112, 'Lamivudine ', 'C ', '¤ (Emtricitabine) LamiVUDine may enhance the adverse/toxic effect of Emtricitabine.¤ (Ribavirin) May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.¤ (Sulfamethoxazole) Trimethoprim may decrease the excretion of LamiVUDine.¤ (Trimethoprim) Trimethoprim may decrease the excretion of LamiVUDine.', 'yes', '¤ Take without regard to meals. Food does not decrease the extent of absorption, but it decreases the Cmax by slowing the rate of absorption.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(113, 'Levodopa ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(114, 'Levofloxacin ', ' C ', '', 'yes', '¤ Take without regard to meals. Take with water, drink lliberally. Taking this product with orange juice can result in reduced quinolone plasma levels. ', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(115, 'Levothyroxine Sodium ', ' A ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(116, 'Lidocaine Hydrochloride ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(117, 'Lithium Carbonate ', ' C first trimester; D second and third trimester ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(118, 'Loperamide ', ' C ', '', 'yes', '¤ Take without regard to meals. Increase liquid intake.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(119, 'Lopinavir ', ' C ', '¤ (Abacavir) Protease Inhibitors may decrease the serum concentration of Abacavir.¤ (Acetohexamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (ado-trastuzumab emtansine) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically~ strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.¤ (Afatinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.¤ (Alfuzosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.¤ (Almotriptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.¤ (Alogliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Alosetron) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.¤ (Alprazolam) Protease Inhibitors may increase the serum concentration of ALPRAZolam.¤ (Amiodarone) May enhance the QTc-prolonging effect of Amiodarone. Lopinavir may increase the serum concentration of Amiodarone. More specifically~ Lopinavir/Ritonavir may increase the serum concentration of Amiodarone.¤ (Apixaban) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.¤ (Aripiprazole) May enhance the adverse/toxic effect of Ritonavir. The risk of metabolic disturbances (e.g. hyperglycemia~ weight gain~ hyperlipidemia) may be increased. Ritonavir may increase the serum concentration of ARIPiprazole.¤ (Astemizole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole.¤ (Atomoxetine) CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.¤ (Atorvastatin) Protease Inhibitors may increase the serum concentration of AtorvaSTATin.¤ (Atovaquone) Ritonavir may decrease the serum concentration of Atovaquone.¤ (Avanafil) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.¤ (Axitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.¤ (Batimastat) May increase the serum concentration of other Protease Inhibitors.¤ (Boceprevir) May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir.¤ (Bosentan) Bosentan may decrease the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Bosentan.¤ (Bosutinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.¤ (Brentuximab vedotin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.¤ (Brinzolamide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.¤ (Bupropion) May decrease the serum concentration of BuPROPion. Concentrations of the active metabolite~ hydroxybupropion~ may also be decreased.¤ (Cabazitaxel) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.¤ (Cabozantinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.¤ (Canagliflozin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Carbamazepine) CarBAMazepine may decrease the serum concentration of Lopinavir.¤ (Chlorpropamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Cilostazol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.¤ (Cisapride) Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.¤ (Clarithromycin) Clarithromycin may enhance the QTc-prolonging effect of Lopinavir. Lopinavir may diminish the therapeutic effect of Clarithromycin. Specifically~ lopinavir may decrease the formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness. Clarithromycin may increase the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Clarithromycin.¤ (Codeine) CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.¤ (Colchicine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Conivaptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.¤ (Crizotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.¤ (Cyclophosphamide) Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Dabigatran etexilate) P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dapoxetine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine.¤ (Darunavir) May decrease the serum concentration of Darunavir. Darunavir may increase the serum concentration of lopinavir¤ (Dasatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.¤ (Deferasirox) Ritonavir may decrease the serum concentration of Deferasirox.¤ (Delavirdine) May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.¤ (Desogestrel) May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).¤ (Didanosine) May decrease the serum concentration of Didanosine. This interaction refers only to lopinavir/ritonavir oral solution~ which must be taken with food~ and is principally the result of a food-didanosine interaction.¤ (Digoxin) Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Disulfiram) May enhance the adverse/toxic effect of Disulfiram. Specifically~ the combination of lopinavir/ritonavir solution~ which contains 42% alcohol~ may result in a disulfiram-alcohol reaction if combined.¤ (Domperidone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone.¤ (Dronabinol) Ritonavir may increase the serum concentration of Dronabinol.¤ (Dronedarone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.¤ (Drospirenone) May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).¤ (Dutasteride) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.¤ (Efavirenz) May decrease the serum concentration of Lopinavir.¤ (Enfuvirtide) May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.¤ (Enzalutamide) CYP2C8 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.¤ (Eplerenone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.¤ (Erlotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.¤ (Estazolam) Ritonavir may increase the serum concentration of Estazolam.¤ (Ethynodiol) May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).¤ (Etonogestrel) May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).¤ (Etravirine) Ritonavir may decrease the serum concentration of Etravirine.¤ (Everolimus) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.¤ (Fentanyl) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Fesoterodine) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.¤ (Flecainide) Ritonavir may increase the serum concentration of Flecainide.¤ (Fosamprenavir) Fosamprenavir may decrease the serum concentration of Lopinavir. Specifically~ amprenavir (the active metabolite of fosamprenavir) may decrease the serum concentration of lopinavir. Lopinavir may decrease the serum concentration of Fosamprenavir. Specifically~ lopinavir/ritonavir may decrease the serum concentration of amprenavir (the active metabolite of fosamprenavir)¤ (Fosphenytoin) Fosphenytoin may decrease the serum concentration of Lopinavir. Lopinavir may decrease the serum concentration of Fosphenytoin.¤ (Gliclazide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glimepiride) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Gliquidone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glyburide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Guanfacine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.¤ (Halofantrine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.¤ (Hydrocodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.¤ (Ifosfamide) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.¤ (Imatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib.¤ (Insulin Aspart) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Detemir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glargine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glulisine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Lispro) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Regular) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin~ isophane) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Irinotecan) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan.¤ (Isoflurophate) May increase the serum concentration of other Protease Inhibitors.¤ (Itraconazole) May increase the serum concentration of Itraconazole.¤ (Ivacaftor) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.¤ (Ixabepilone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.¤ (Lacosamide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide.¤ (Lamotrigine) Ritonavir may decrease the serum concentration of LamoTRIgine.¤ (Lapatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.¤ (Ledipasvir) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.¤ (Lercanidipine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine.¤ (Levobupivacaine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine.¤ (Levomilnacipran) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.¤ (Levonorgestrel) May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).¤ (Linagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Lomitapide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.¤ (Lovastatin) Protease Inhibitors may increase the serum concentration of Lovastatin.¤ (Lurasidone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.¤ (MACITENTAN) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan.¤ (Maraviroc) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.¤ (Medroxyprogesterone Acetate) May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).¤ (Mequitazine) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine.¤ (Mestranol) May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).¤ (Metformin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Methadone) Methadone may enhance the QTc-prolonging effect of Lopinavir. Lopinavir may decrease the serum concentration of Methadone. More specifically~ the combination of Lopinavir and Ritonavir may decrease Methadone serum concentrations.¤ (Methylprednisolone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Metoprolol) CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.¤ (Midazolam) Protease Inhibitors may increase the serum concentration of Midazolam.¤ (Mifepristone) May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nebivolol) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.¤ (Nefazodone) Protease Inhibitors may increase the serum concentration of Nefazodone.¤ (Nelfinavir) May increase the serum concentration of Nelfinavir. Concentrations of the nelfinavir M8 metabolite may also be increased. Nelfinavir may decrease the serum concentration of Lopinavir.¤ (Nevirapine) Nevirapine may decrease the serum concentration of Lopinavir.¤ (Nilotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.¤ (Nisoldipine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.¤ (Norelgestromin) May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).¤ (Norethindrone) May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).¤ (Norgestimate) May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).¤ (Ospemifene) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.¤ (Oxybutynin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin.¤ (Oxycodone) CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased.¤ (Paricalcitol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.¤ (Pazopanib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.¤ (Phenobarbital) PHENobarbital may decrease the serum concentration of Lopinavir.¤ (Phenytoin) May decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Lopinavir.¤ (Pimecrolimus) CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.¤ (Pimozide) Protease Inhibitors may increase the serum concentration of Pimozide.¤ (Pioglitazone) CYP2C8 Inhibitors (Strong) may increase the serum concentration of Pioglitazone.¤ (Ponatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.¤ (Pranlukast) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast.¤ (Prasugrel) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.¤ (Prednisone) Ritonavir may increase the serum concentration of PredniSONE.¤ (Proguanil) Ritonavir may decrease the serum concentration of Proguanil.¤ (Propafenone) Ritonavir may increase the serum concentration of Propafenone.¤ (prucalopride) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.¤ (Quinidine) May enhance the QTc-prolonging effect of QuiNIDine. Lopinavir may increase the serum concentration of QuiNIDine. Specifically~ lopinavir/ritonavir may increase the serum concentration of quinidine.¤ (Quinine) May decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir. The individual contributions of lopinavir and ritonavir to this effect are unclear.¤ (Ranolazine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.¤ (Regorafenib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.¤ (Repaglinide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Retapamulin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.¤ (Rifabutin) Lopinavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Lopinavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Lopinavir.¤ (Rifampicin) Rifampin may enhance the adverse/toxic effect of Lopinavir. Specifically~ the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Lopinavir.¤ (Rifaximin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.¤ (Rilpivirine) Ritonavir may increase the serum concentration of Rilpivirine.¤ (Riociguat) Protease Inhibitors may increase the serum concentration of Riociguat.¤ (Rivaroxaban) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. For clarithromycin~ refer to more specific clarithromycin-rivaroxaban monograph recommendations.¤ (Rosuvastatin) Protease Inhibitors may increase the serum concentration of Rosuvastatin.¤ (Ruxolitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.¤ (Salmeterol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.¤ (Saquinavir) Saquinavir may enhance the QTc-prolonging effect of Lopinavir.¤ (Saxagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Sildenafil) Protease Inhibitors may increase the serum concentration of Sildenafil.¤ (Silodosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of other Protease Inhibitors.¤ (Simvastatin) Protease Inhibitors may increase the serum concentration of Simvastatin.¤ (Suvorexant) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant.¤ (Tadalafil) Ritonavir may increase the serum concentration of Tadalafil.¤ (Tamoxifen) CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.¤ (Tamsulosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.¤ (Telaprevir) Lopinavir may decrease the serum concentration of Telaprevir.¤ (Temsirolimus) Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus~ the active metabolite~ may be increased~ likely due to inhibition of CYP-mediated metabolism.¤ (Tenofovir) May enhance the nephrotoxic effect of Tenofovir. Lopinavir may increase the serum concentration of Tenofovir.¤ (Terfenadine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Terfenadine.¤ (Thioridazine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Ticagrelor) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.¤ (Tipranavir) May decrease the serum concentration of Protease Inhibitors.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tofacitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.¤ (Tolbutamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Tolterodine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.¤ (Tolvaptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.¤ (Topotecan) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.¤ (Toremifene) CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.¤ (Trabectedin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin.¤ (Trazodone) Lopinavir may enhance the QTc-prolonging effect of TraZODone. Lopinavir may increase the serum concentration of TraZODone.¤ (Treprostinil) CYP2C8 Inhibitors (Strong) may increase the serum concentration of Treprostinil.¤ (Triazolam) Protease Inhibitors may increase the serum concentration of Triazolam.¤ (Ulipristal) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.¤ (Vardenafil) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.¤ (Vemurafenib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.¤ (Vilazodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.¤ (Vildagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Vinblastine) May increase the serum concentration of VinBLAStine.¤ (Vincristine) May increase the serum concentration of VinCRIStine.¤ (Vorapaxar) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar.¤ (Voriconazole) May decrease the serum concentration of Voriconazole.¤ (Warfarin) Lopinavir may decrease the serum concentration of Warfarin.¤ (Zidovudine) Protease Inhibitors may decrease the serum concentration of Zidovudine.¤ (Zopiclone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.', 'yes', '¤ Avoid St.John\'s Wort.\n¤ Take with food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(120, 'Lorazepam ', ' D ', '¤ (Aminophylline) Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.¤ (Buprenorphine) CNS Depressants may enhance the CNS depressant effect of Buprenorphine.¤ (Clozapine) Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Droperidol) May enhance the CNS depressant effect of CNS Depressants.¤ (Fosphenytoin) Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.¤ (Gamma Hydroxybutyric Acid) May enhance the CNS depressant effect of Sodium Oxybate.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Loxapine) May enhance the adverse/toxic effect of LORazepam. Specifically~ prolonged stupor~ respiratory depression~ and/or hypotension.¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Methadone) Benzodiazepines may enhance the CNS depressant effect of Methadone.¤ (Methotrimeprazine) CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mirtazapine) CNS Depressants may enhance the CNS depressant effect of Mirtazapine.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Olanzapine) May enhance the adverse/toxic effect of Benzodiazepines.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Phenytoin) Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.¤ (Pramipexole) CNS Depressants may enhance the sedative effect of Pramipexole.¤ (Probenecid) May increase the serum concentration of LORazepam.¤ (Ropinirole) CNS Depressants may enhance the sedative effect of ROPINIRole.¤ (Rotigotine) CNS Depressants may enhance the sedative effect of Rotigotine.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Teduglutide) May increase the serum concentration of Benzodiazepines.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Theophylline) Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.¤ (Valproic Acid) Valproic Acid and Derivatives may increase the serum concentration of LORazepam.¤ (Yohimbine) May diminish the therapeutic effect of Antianxiety Agents.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.', 'yes', '¤ Avoid alcohol.\n¤ Avoid excessive quantities of coffee or tea (Caffeine).\n¤ Take with food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(121, 'Mebendazole ', ' C ', '¤ (Carbamazepine) CarBAMazepine may decrease the serum concentration of Mebendazole.¤ (Cimetidine) Cimetidine may increase the serum concentration of Mebendazole.¤ (Fosphenytoin) May decrease the serum concentration of Mebendazole.¤ (Phenytoin) Phenytoin may decrease the serum concentration of Mebendazole.', 'yes', '¤ Lipid rich meals may improve absorption.\n¤ Take with food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(122, 'Meclizine Hydrochloride ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(123, 'Mefloquine Hydrochloride ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(124, 'Melphalan ', ' D ', '¤ (Carmustine) May enhance the adverse/toxic effect of Carmustine. Specifically~ melphalan may sensitize patients to carmustine lung toxicity.¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Nalidixic Acid) May enhance the adverse/toxic effect of Melphalan. Necrotic enterocolitis has been reported in pediatric patients.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.', 'yes', '¤ Take on an empty stomach. Food decreases bioavailabilty by approximately 30%. Increase liquid intake.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(125, 'Mercaptopurine ', ' D ', '¤ (Acenocoumarol) May diminish the anticoagulant effect of Vitamin K Antagonists.¤ (Allopurinol) Allopurinol may increase the serum concentration of Mercaptopurine. Allopurinol may also promote formation of active thioguanine nucleotides.¤ (Azathioprine) AzaTHIOprine may enhance the myelosuppressive effect of Mercaptopurine.¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Febuxostat) May increase the serum concentration of Mercaptopurine.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Sulfamethoxazole) Sulfamethoxazole may enhance the myelosuppressive effect of Mercaptopurine.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.¤ (Trimethoprim) Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine.', 'yes', '¤ Preferably on an empty stomach, drink plenty of liquids, avoid alcohol.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(126, 'Metformin Hydrochloride ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(127, 'Methotrexate Sodium ', 'x ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(128, 'Methyldopa ', ' B ', '¤ (Alfuzosin) May enhance the hypotensive effect of Antihypertensives.¤ (Amifostine) Antihypertensives may enhance the hypotensive effect of Amifostine.¤ (Bretylium) May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.¤ (Butabarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Butethal) May enhance the hypotensive effect of Hypotensive Agents.¤ (Diazoxide) May enhance the hypotensive effect of Antihypertensives.¤ (Duloxetine) Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.¤ (Heptabarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Hexobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Iobenguane) May diminish the therapeutic effect of Iobenguane I 123.¤ (Isocarboxazid) MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.¤ (Lacosamide) Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.¤ (Linezolid) MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.¤ (Lithium) Methyldopa may enhance the adverse/toxic effect of Lithium. This may occur without notable changes in serum lithium concentrations.¤ (Methohexital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Methylphenidate) May diminish the antihypertensive effect of Antihypertensives.¤ (Mirtazapine) May diminish the antihypertensive effect of Alpha2-Agonists.¤ (Moclobemide) MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.¤ (Obinutuzumab) Antihypertensives may enhance the hypotensive effect of Obinutuzumab.¤ (Pentobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Pentoxifylline) May enhance the hypotensive effect of Antihypertensives.¤ (Phenelzine) MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.¤ (Primidone) May enhance the hypotensive effect of Hypotensive Agents.¤ (Procarbazine) MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.¤ (Rasagiline) MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.¤ (Risperidone) Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.¤ (Rituximab) Antihypertensives may enhance the hypotensive effect of RiTUXimab.¤ (Ruxolitinib) May enhance the bradycardic effect of Bradycardia-Causing Agents.¤ (Secobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Selegiline) MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.¤ (Tadalafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Tedizolid Phosphate) MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.¤ (Tofacitinib) May enhance the bradycardic effect of Bradycardia-Causing Agents.¤ (Tranylcypromine) MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.¤ (Vardenafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Yohimbine) May diminish the antihypertensive effect of Antihypertensives.', 'yes', '¤ Avoid alcohol.\n¤ Avoid natural licorice.\n¤ Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.\n¤ May take Vitamin D.\n¤ No iron, zinc or fluoride within 2 hours of taking this medication.\n¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(129, 'Methylprednisolone ', ' C ', '¤ (Acetohexamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Acetylsalicylic acid) May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.¤ (Aldesleukin) Corticosteroids may diminish the antineoplastic effect of Aldesleukin.¤ (Alogliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Aluminum hydroxide) May decrease the bioavailability of Corticosteroids (Oral).¤ (Aminoglutethimide) May increase the metabolism of Corticosteroids (Systemic).¤ (Amphotericin B) Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.¤ (Aprepitant) May increase the serum concentration of Corticosteroids (Systemic).¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Atazanavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Boceprevir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Calcitriol) Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.¤ (Calcium carbonate) May decrease the bioavailability of Corticosteroids (Oral).¤ (Canagliflozin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Carbamazepine) CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.¤ (Chlorpropamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Clarithromycin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Colesevelam) May decrease the absorption of Corticosteroids (Oral).¤ (Conivaptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Darunavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Deferasirox) Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically~ the risk for GI ulceration/irritation or GI bleeding may be increased.¤ (Delavirdine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Dihydrotestosterone) Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Enzalutamide) CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.¤ (Fosamprenavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Fosaprepitant) May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.¤ (Fosphenytoin) CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.¤ (Gliclazide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glimepiride) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Gliquidone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glyburide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Hyaluronidase) Corticosteroids may diminish the therapeutic effect of Hyaluronidase.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Indacaterol) May enhance the hypokalemic effect of Corticosteroids (Systemic).¤ (Indinavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Insulin Aspart) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Detemir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glargine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glulisine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Lispro) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Regular) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin~ isophane) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Isoniazid) Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.¤ (Itraconazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Linagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Lopinavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Magnesium oxide) May decrease the bioavailability of Corticosteroids (Oral).¤ (Metformin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Mifepristone) May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic).¤ (Mitotane) May decrease the serum concentration of Corticosteroids (Systemic).¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Nefazodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Nelfinavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Oxandrolone) Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens.¤ (Phenobarbital) CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.¤ (Phenytoin) CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Posaconazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Primidone) CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.¤ (Repaglinide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Rifampicin) CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.¤ (Rifapentine) CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.¤ (Ritonavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Salicylate-sodium) May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.¤ (Saquinavir) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Saxagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Telaprevir) May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir.¤ (Telithromycin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Testosterone) Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Tolbutamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.¤ (Vildagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Voriconazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Warfarin) Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(130, 'Metoclopramide Hydrochloride ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(131, 'Metronidazole ', ' B ', '', 'yes', '¤ Avoid alcohol.\n¤ Take with food to reduce irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(132, 'Midazolam ', ' D ', '¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Atazanavir) Protease Inhibitors may increase the serum concentration of Midazolam.¤ (Atorvastatin) May increase the serum concentration of Midazolam.¤ (Batimastat) May increase the serum concentration of Midazolam.¤ (Boceprevir) May increase the serum concentration of Midazolam.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Buprenorphine) CNS Depressants may enhance the CNS depressant effect of Buprenorphine.¤ (Clarithromycin) Macrolide Antibiotics may increase the serum concentration of Midazolam.¤ (Clozapine) Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Darunavir) Protease Inhibitors may increase the serum concentration of Midazolam.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Droperidol) May enhance the CNS depressant effect of CNS Depressants.¤ (Fosamprenavir) Protease Inhibitors may increase the serum concentration of Midazolam.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Ginkgo biloba) May decrease the serum concentration of Midazolam.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Indinavir) Protease Inhibitors may increase the serum concentration of Midazolam.¤ (Isoflurophate) May increase the serum concentration of Midazolam.¤ (Itraconazole) May increase the serum concentration of Midazolam.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Lopinavir) Protease Inhibitors may increase the serum concentration of Midazolam.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Methadone) Benzodiazepines may enhance the CNS depressant effect of Methadone.¤ (Methotrimeprazine) CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Mirtazapine) CNS Depressants may enhance the CNS depressant effect of Mirtazapine.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Nelfinavir) Protease Inhibitors may increase the serum concentration of Midazolam.¤ (Olanzapine) May enhance the adverse/toxic effect of Benzodiazepines.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Pramipexole) CNS Depressants may enhance the sedative effect of Pramipexole.¤ (Propofol) Midazolam may increase the serum concentration of Propofol. Propofol may increase the serum concentration of Midazolam.¤ (Ritonavir) Protease Inhibitors may increase the serum concentration of Midazolam.¤ (Ropinirole) CNS Depressants may enhance the sedative effect of ROPINIRole.¤ (Rotigotine) CNS Depressants may enhance the sedative effect of Rotigotine.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Saquinavir) Protease Inhibitors may increase the serum concentration of Midazolam.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of Midazolam.¤ (Sulfisoxazole) Macrolide Antibiotics may increase the serum concentration of Midazolam.¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Teduglutide) May increase the serum concentration of Benzodiazepines.¤ (Telaprevir) May increase the serum concentration of Midazolam.¤ (Telithromycin) Macrolide Antibiotics may increase the serum concentration of Midazolam.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Tipranavir) Protease Inhibitors may increase the serum concentration of Midazolam.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Yohimbine) May diminish the therapeutic effect of Antianxiety Agents.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.', 'yes', '¤ Grapefruit juice slows the product\'s absorption and significantly increases its bioavailability.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(133, 'Morphine ', 'C (D in long&minus;term use or high dose, or close to term) ', '¤ (Acetazolamide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Alvimopan) Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e.~ more than 7 days) opiates prior to alvimopan initiation.¤ (Amiloride) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Ammonium chloride) May increase the excretion of Analgesics (Opioid).¤ (Amphetamine) May enhance the analgesic effect of Analgesics (Opioid).¤ (Bendroflumethiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Bumetanide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Cathinone) May enhance the analgesic effect of Analgesics (Opioid).¤ (Chlorothiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Chlorthalidone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Clopidogrel) Morphine (Liposomal) may diminish the antiplatelet effect of Clopidogrel. Morphine (Liposomal) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.¤ (Cyclothiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Desmopressin) Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Droperidol) May enhance the CNS depressant effect of CNS Depressants.¤ (Ethacrynic acid) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Ethoxzolamide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Furosemide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Hydrochlorothiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroflumethiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Indapamide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Methotrimeprazine) CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.¤ (Metolazone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mirtazapine) CNS Depressants may enhance the CNS depressant effect of Mirtazapine.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Naltrexone) May diminish the therapeutic effect of Analgesics (Opioid).¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Pegvisomant) Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Pramipexole) CNS Depressants may enhance the sedative effect of Pramipexole.¤ (Ropinirole) CNS Depressants may enhance the sedative effect of ROPINIRole.¤ (Rotigotine) CNS Depressants may enhance the sedative effect of Rotigotine.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Spironolactone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Succinylcholine) May enhance the bradycardic effect of Analgesics (Opioid).¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Ticrynafen) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Torasemide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Triamterene) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Trichlormethiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.', 'yes', '¤ Avoid alcohol.\n¤ Take with food.\n¤ To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(134, 'Nalidixic acid ', ' B second and third trimester ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(135, 'Naloxone ', ' C ', '¤ (Methylnaltrexone) May enhance the adverse/toxic effect of Opioid Antagonists. Specifically~ the risk for opioid withdrawal may be increased.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(136, 'Naproxen ', ' B ', '¤ (Abciximab) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Acenocoumarol) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Acetylsalicylic acid) NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.¤ (Aliskiren) Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.¤ (Alteplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Amikacin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Anistreplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Apixaban) Naproxen may enhance the adverse/toxic effect of Apixaban. Specifically~ the risk for bleeding may be increased. Naproxen may increase the serum concentration of Apixaban.¤ (Arbekacin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Citric Acid) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Colesevelam) May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.¤ (Dabigatran etexilate) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.¤ (Dalteparin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Dasatinib) May enhance the anticoagulant effect of Agents with Antiplatelet Properties.¤ (Deferasirox) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically~ the risk for GI ulceration/irritation or GI bleeding may be increased.¤ (Deoxycholic Acid) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically~ the risk for bleeding or bruising in the treatment area may be increased.¤ (Desmopressin) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.¤ (Dicoumarol) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Digoxin) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.¤ (Edetic Acid) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Enoxaparin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Eplerenone) Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.¤ (Ethyl biscoumacetate) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Floctafenine) May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.¤ (Fondaparinux sodium) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Framycetin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Gentamicin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Glucosamine) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Haloperidol) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.¤ (Heparin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Hydralazine) Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.¤ (Ibritumomab) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.¤ (Kanamycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Lithium) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.¤ (Methotrexate) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.¤ (Neomycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Netilmicin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Obinutuzumab) Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically~ the risk of serious bleeding-related events may be increased.¤ (Pemetrexed) NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.¤ (Pentoxifylline) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Phenindione) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Phenprocoumon) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Porfimer) Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.¤ (Pralatrexate) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically~ NSAIDS may decrease the renal excretion of pralatrexate.¤ (Probenecid) May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.¤ (Reteplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Ribostamycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Ridogrel) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Rivaroxaban) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.¤ (Salicylate-sodium) NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.¤ (Spectinomycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Streptokinase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Streptomycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Sulodexide) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Tenecteplase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Tenofovir) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Tipranavir) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Tobramycin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Treprostinil) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Urokinase) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.¤ (Vancomycin) Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.¤ (Verteporfin) Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.¤ (Vitamin E) May enhance the antiplatelet effect of Agents with Antiplatelet Properties.¤ (Warfarin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', 'yes', '¤ Avoid alcohol.\n¤ Take with a full glass of water.\n¤ Take with food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(137, 'Natamycin ', ' ', '', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(138, 'Neomycin ', ' C ', '¤ (Acarbose) May enhance the adverse/toxic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.¤ (Acenocoumarol) May enhance the anticoagulant effect of Vitamin K Antagonists.¤ (Amdinocillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Amoxicillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Amphotericin B) Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides.¤ (Ampicillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Atracurium) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Azidocillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Azlocillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Bacampicillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Benzylpenicillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Botulinum Toxin Type A) May enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.¤ (Botulinum Toxin Type B) May enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.¤ (Bumetanide) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Capreomycin) Capreomycin may enhance the neuromuscular-blocking effect of Aminoglycosides.¤ (Carbenicillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Carboplatin) May enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.¤ (Cefaclor) Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Cefdinir) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Cefepime) Cephalosporins (4th Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Cefixime) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Cefotaxime) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Cefotetan) Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Cefoxitin) Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Cefpodoxime) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Cefprozil) Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Ceftazidime) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Ceftibuten) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Ceftriaxone) Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Cefuroxime) Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.¤ (Celecoxib) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Cisatracurium Besylate) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Cisplatin) CISplatin may enhance the nephrotoxic effect of Aminoglycosides.¤ (Clodronate) May enhance the hypocalcemic effect of Bisphosphonate Derivatives.¤ (Cloxacillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Colistimethate) Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.¤ (Colistin) May enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.¤ (Cyclacillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Dicloxacillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Diflunisal) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Digoxin) May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).¤ (Ethacrynic acid) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Etodolac) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Fenoprofen) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Floctafenine) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Flucloxacillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Foscarnet) Foscarnet may enhance the nephrotoxic effect of Aminoglycosides.¤ (Furosemide) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Hetacillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Ibandronate) May enhance the hypocalcemic effect of Bisphosphonate Derivatives.¤ (Ibuprofen) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Indomethacin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Ketoprofen) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Ketorolac) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Mannitol) Mannitol may enhance the nephrotoxic effect of Aminoglycosides.¤ (Mefenamic acid) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Meloxicam) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Meticillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Mezlocillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Nabumetone) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Nafcillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Naproxen) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Oxacillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Oxaprozin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Pamidronate) May enhance the hypocalcemic effect of Bisphosphonate Derivatives.¤ (Pancuronium) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Penicillin V) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Piperacillin) Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction.¤ (Piroxicam) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Pivampicillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Pivmecillinam) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Risedronate) May enhance the hypocalcemic effect of Bisphosphonate Derivatives.¤ (Rocuronium) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Sorafenib) May decrease the serum concentration of SORAfenib.¤ (Succinylcholine) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Sulindac) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Tenofovir) Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.¤ (Tiaprofenic acid) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Ticarcillin) May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.¤ (Tiludronate) May enhance the hypocalcemic effect of Bisphosphonate Derivatives.¤ (Tolmetin) Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.¤ (Torasemide) Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.¤ (Vancomycin) Vancomycin may enhance the nephrotoxic effect of Aminoglycosides.¤ (Vecuronium) May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.¤ (Zoledronate) May enhance the hypocalcemic effect of Bisphosphonate Derivatives.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(139, 'Neostigmine ', ' C ', '¤ (Acetylcholine) Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.¤ (Carbachol) Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.¤ (Dipyridamole) May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.¤ (Succinylcholine) Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(140, 'Nevirapine (NVP) ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(141, 'Nifedipine ', ' C ', '¤ (Alfuzosin) May enhance the hypotensive effect of Antihypertensives.¤ (Amifostine) Antihypertensives may enhance the hypotensive effect of Amifostine.¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Batimastat) May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Butabarbital) May increase the metabolism of Calcium Channel Blockers.¤ (Butethal) May increase the metabolism of Calcium Channel Blockers.¤ (Carbamazepine) CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.¤ (Cimetidine) May increase the serum concentration of Calcium Channel Blockers.¤ (Cisapride) Cisapride may increase the serum concentration of NIFEdipine. Reported with sustained release nifedipine product.¤ (Clopidogrel) Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dapoxetine) May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Diazoxide) May enhance the hypotensive effect of Antihypertensives.¤ (Digoxin) May increase the serum concentration of Digoxin.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Duloxetine) Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.¤ (Efavirenz) May decrease the serum concentration of Calcium Channel Blockers.¤ (Enzalutamide) CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.¤ (Ethanol) Alcohol (Ethyl) may increase the serum concentration of NIFEdipine.¤ (Fluconazole) May increase the serum concentration of Calcium Channel Blockers.¤ (Fluoxetine) FLUoxetine may enhance the adverse/toxic effect of NIFEdipine.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Fosphenytoin) CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.¤ (Heptabarbital) May increase the metabolism of Calcium Channel Blockers.¤ (Hexobarbital) May increase the metabolism of Calcium Channel Blockers.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Isoflurophate) May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Melatonin) May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).¤ (Methohexital) May increase the metabolism of Calcium Channel Blockers.¤ (Methylphenidate) May diminish the antihypertensive effect of Antihypertensives.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Nafcillin) May increase the metabolism of Calcium Channel Blockers.¤ (Nitroprusside) Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.¤ (Obinutuzumab) Antihypertensives may enhance the hypotensive effect of Obinutuzumab.¤ (Pentobarbital) May increase the metabolism of Calcium Channel Blockers.¤ (Pentoxifylline) May enhance the hypotensive effect of Antihypertensives.¤ (Phenobarbital) CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.¤ (Phenytoin) CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Primidone) CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.¤ (Quinidine) May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.¤ (Rifampicin) CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.¤ (Rifapentine) CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.¤ (Risperidone) Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.¤ (Rituximab) Antihypertensives may enhance the hypotensive effect of RiTUXimab.¤ (Secobarbital) May increase the metabolism of Calcium Channel Blockers.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).¤ (Tadalafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Vardenafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Vincristine) May increase the serum concentration of VinCRIStine.¤ (Yohimbine) May diminish the antihypertensive effect of Antihypertensives.', 'yes', '¤ Avoid alcohol.\n¤ Avoid natural licorice.\n¤ Grapefruit down-regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nifedipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nifedipine and may cause toxicity. Avoid grapefruit products while on this medication. \n¤ Take with low fat meal.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(142, 'Nitrofurantoin ', ' B ', '¤ (Eplerenone) Nitrofurantoin may enhance the hyperkalemic effect of Eplerenone.¤ (Nitric Oxide) May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.¤ (Norfloxacin) Nitrofurantoin may diminish the therapeutic effect of Norfloxacin.¤ (Prilocaine) Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.¤ (Probenecid) May increase the serum concentration of Nitrofurantoin.¤ (Spironolactone) May enhance the hyperkalemic effect of Spironolactone.', 'yes', '¤ Do not take magnesium at the same time.\n¤ Take with food since it increases bioavailability and reduces irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(143, 'Nitroprusside Sodium ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(144, 'Nystatin ', ' C ', '', 'yes', '¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(145, 'Ofloxacin ', ' C ', '', 'yes', '¤ Avoid high doses of caffeine.\n¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(146, 'Omeprazole ', ' C ', '¤ (Acenocoumarol) May increase the serum concentration of Vitamin K Antagonists.¤ (Amphetamine) May increase the absorption of Amphetamine.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Atazanavir) Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.¤ (Bosentan) CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan.¤ (Bosutinib) Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.¤ (Carvedilol) CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically~ concentrations of the S-carvedilol enantiomer may be increased.¤ (Cefditoren) Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.¤ (Cilostazol) CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.¤ (Citalopram) CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.¤ (Clodronate) May diminish the therapeutic effect of Bisphosphonate Derivatives.¤ (Clopidogrel) Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.¤ (Clozapine) Omeprazole may decrease the serum concentration of CloZAPine. Omeprazole may increase the serum concentration of CloZAPine.¤ (Dabigatran etexilate) Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.¤ (Dabrafenib) May decrease the serum concentration of CYP2C19 Substrates.¤ (Dasatinib) Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.¤ (Delavirdine) Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.¤ (Dexmethylphenidate) Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically~ proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand)~ which could result in both increased absorption (early) and decreased delayed absorption.¤ (Dextroamphetamine) Proton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically~ the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Dronabinol) CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.¤ (Erlotinib) Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.¤ (Escitalopram) Omeprazole may increase the serum concentration of Escitalopram.¤ (Fluconazole) Fluconazole may increase the serum concentration of Proton Pump Inhibitors.¤ (Fosphenytoin) May decrease the serum concentration of Omeprazole. Omeprazole may increase the serum concentration of Fosphenytoin.¤ (Gefitinib) May decrease the serum concentration of Gefitinib.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Ibandronate) May diminish the therapeutic effect of Bisphosphonate Derivatives.¤ (Indinavir) May decrease the serum concentration of Indinavir.¤ (Itraconazole) Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.¤ (Ledipasvir) Proton Pump Inhibitors may decrease the serum concentration of Ledipasvir.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Mesalazine) May diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.¤ (Methotrexate) Proton Pump Inhibitors may increase the serum concentration of Methotrexate.¤ (Methylphenidate) Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically~ proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand)~ which could result in both increased absorption (early) and decreased delayed absorption.¤ (Mycophenolate mofetil) May decrease the serum concentration of Mycophenolate. Specifically~ concentrations of the active mycophenolic acid may be reduced.¤ (Mycophenolic acid) May decrease the serum concentration of Mycophenolate. Specifically~ concentrations of the active mycophenolic acid may be reduced.¤ (Nelfinavir) May decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.¤ (Nilotinib) Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.¤ (Pamidronate) May diminish the therapeutic effect of Bisphosphonate Derivatives.¤ (Pazopanib) Proton Pump Inhibitors may decrease the serum concentration of PAZOPanib.¤ (Phenytoin) May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Omeprazole.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Posaconazole) Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.¤ (Raltegravir) Proton Pump Inhibitors may increase the serum concentration of Raltegravir.¤ (Rifampicin) Rifampin may decrease the serum concentration of Omeprazole.¤ (Rilpivirine) Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.¤ (Riociguat) Proton Pump Inhibitors may decrease the serum concentration of Riociguat.¤ (Risedronate) Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.¤ (Saquinavir) Proton Pump Inhibitors may increase the serum concentration of Saquinavir.¤ (Tiludronate) May diminish the therapeutic effect of Bisphosphonate Derivatives.¤ (Tipranavir) May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.¤ (Vismodegib) Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.¤ (Voriconazole) Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.¤ (Zoledronate) May diminish the therapeutic effect of Bisphosphonate Derivatives.', 'yes', '¤ Avoid alcohol.\n¤ Take 30-60 minutes before meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(147, 'Ondansetron Hydrochloride ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(148, 'Oxycodone Chloride ', 'B (D for prolonged use or use of high doses at term) ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(149, 'Oxytocin ', ' ', '¤ (Carboprost Tromethamine) May enhance the adverse/toxic effect of Oxytocic Agents. Specifically~ oxytocic effects may be enhanced.¤ (Dinoprostone) May enhance the adverse/toxic effect of Oxytocin. Specifically~oxytocic effects may be enhanced.¤ (Mifepristone) May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).¤ (Misoprostol) May enhance the adverse/toxic effect of Oxytocin. Specifically~ oxytocic effects may be enhanced.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(150, 'Para&minus;aminosalicylic acid ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(151, 'Paracetamol ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(152, 'Paromomycin Sulfate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(153, 'Pencillamine ', ' D ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(154, 'Pentamidine Isethionate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(155, 'Permethrin ', ' B ', '', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(156, 'Pethidine / Meperdine ', 'B (D at term) ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(157, 'Phenobarbitone ', ' D ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(158, 'Phenylephrine ', ' ', '¤ (Acebutolol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Aminophylline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Amphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Arformoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (armodafinil) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Articaine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Atomoxetine) AtoMOXetine may enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.¤ (Benzphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Caffeine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Chlorphentermine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Clenbuterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Cocaine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dexmethylphenidate) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dextroamphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Diethylpropion) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dihydrocodeine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dipivefrin) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dobutamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dopamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Doxapram) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dronabinol) Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.¤ (Epinephrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Fenoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Fentanyl) Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.¤ (Fluticasone furoate) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Formoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Indacaterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Iobenguane) May diminish the therapeutic effect of Iobenguane I 123.¤ (Ipratropium bromide) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Isometheptene) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Isoprenaline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Labetalol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Levonordefrin) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Linezolid) May enhance the hypertensive effect of Sympathomimetics.¤ (Lisdexamfetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Mephentermine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Metaraminol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Methamphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Methoxamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Methylphenidate) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Midodrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Modafinil) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Nabilone) Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.¤ (Naphazoline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Norepinephrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Orciprenaline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Oxymetazoline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phendimetrazine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Pheniramine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phenmetrazine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phentermine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phenylpropanolamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Pirbuterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Propylhexedrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Pseudoephedrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Ritodrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Salbutamol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Salmeterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Tedizolid Phosphate) Tedizolid may enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.¤ (Terbutaline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Theophylline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Triprolidine) May enhance the adverse/toxic effect of other Sympathomimetics.', 'yes', '¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(159, 'Phenytoin ', ' ', '¤ (Acenocoumarol) May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Phenytoin.¤ (Acetaminophen) Fosphenytoin-Phenytoin may decrease the serum concentration of Acetaminophen. Specifically~ serum concentrations of acetaminophen may be decreased (leading to decreased efficacy)~ but the formation of the toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity).¤ (Acetazolamide) May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically~ the risk for osteomalacia or rickets may be increased. Exceptions: Brinzolamide; Dorzolamide.¤ (Afatinib) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.¤ (Albendazole) Phenytoin may decrease serum concentrations of the active metabolite(s) of Albendazole.¤ (Alprazolam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Aminophylline) Theophylline Derivatives may decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Theophylline Derivatives.¤ (Amiodarone) May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Amiodarone.¤ (Amlodipine) May increase the serum concentration of Phenytoin.¤ (Amphetamine) Amphetamines may decrease the serum concentration of Phenytoin.¤ (Amrinone) May increase the serum concentration of Phenytoin.¤ (Apixaban) CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.¤ (Apremilast) CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast.¤ (Aripiprazole) CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.¤ (Artemether) CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically~ dihydroartemisinin concentrations may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether.¤ (Atorvastatin) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Axitinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.¤ (bazedoxifene) Phenytoin may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or~ if bazedoxifene is combined with estrogen therapy~ an increased risk of endometrial hyperplasia.¤ (Bedaquiline) CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.¤ (Bepridil) May increase the serum concentration of Phenytoin.¤ (Bleomycin) May decrease the serum concentration of Phenytoin.¤ (Boceprevir) Phenytoin may decrease the serum concentration of Boceprevir.¤ (Bortezomib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.¤ (Bosutinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.¤ (Brentuximab vedotin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.¤ (Bromazepam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Bumetanide) May diminish the diuretic effect of Loop Diuretics.¤ (Buprenorphine) CNS Depressants may enhance the CNS depressant effect of Buprenorphine.¤ (Busulfan) Phenytoin may decrease the serum concentration of Busulfan.¤ (Cabozantinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.¤ (Camazepam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Canagliflozin) Phenytoin may decrease the serum concentration of Canagliflozin.¤ (Capecitabine) May increase the serum concentration of Phenytoin.¤ (Carbamazepine) May decrease the serum concentration of Phenytoin. CarBAMazepine may increase the serum concentration of Phenytoin. Possibly by competitive inhibition at sites of metabolism. Phenytoin may decrease the serum concentration of CarBAMazepine.¤ (Caspofungin) Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.¤ (Cathinone) May decrease the serum concentration of Phenytoin.¤ (Cefazolin) May decrease the protein binding of Phenytoin.¤ (Chlordiazepoxide) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Chlormezanone) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Cimetidine) May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Cimetidine may increase the serum concentration of Fosphenytoin-Phenytoin.¤ (Cinolazepam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Clarithromycin) CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.¤ (Clobazam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Clonazepam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Clotiazepam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Cloxazolam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Clozapine) CYP3A4 Inducers (Strong) may decrease the serum concentration of CloZAPine.¤ (Colesevelam) May decrease the serum concentration of Phenytoin.¤ (Cosyntropin) May enhance the hepatotoxic effect of Phenytoin.¤ (Crizotinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.¤ (Dabigatran etexilate) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.¤ (Dabrafenib) May decrease the serum concentration of CYP2C9 Substrates.¤ (Darunavir) May decrease the serum concentration of Phenytoin.¤ (Dasatinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.¤ (Deferasirox) Phenytoin may decrease the serum concentration of Deferasirox.¤ (Delavirdine) May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Delavirdine.¤ (Desogestrel) May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.¤ (Dexmethylphenidate) May increase the serum concentration of Phenytoin.¤ (Dextroamphetamine) Amphetamines may decrease the serum concentration of Phenytoin.¤ (Diazoxide) May decrease the serum concentration of Phenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations.¤ (Diclofenamide) May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically~ the risk for osteomalacia or rickets may be increased. Exceptions: Brinzolamide; Dorzolamide.¤ (Diltiazem) Calcium Channel Blockers may increase the serum concentration of Phenytoin.¤ (Disopyramide) Phenytoin may decrease the serum concentration of Disopyramide.¤ (Disulfiram) May increase the serum concentration of Phenytoin.¤ (Dolutegravir) Fosphenytoin-Phenytoin may decrease the serum concentration of Dolutegravir.¤ (Doxycycline) Phenytoin may decrease the serum concentration of Doxycycline.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronabinol.¤ (Dronedarone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.¤ (Droperidol) May enhance the CNS depressant effect of CNS Depressants.¤ (Drospirenone) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Efavirenz) May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Efavirenz.¤ (Eliglustat) CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat.¤ (Enzalutamide) CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.¤ (Erlotinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Erlotinib.¤ (Estazolam) Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.¤ (Ethacrynic acid) May diminish the diuretic effect of Loop Diuretics.¤ (Ethanol) Alcohol (Ethyl) may enhance the CNS depressant effect of Phenytoin. Alcohol (Ethyl) may increase the serum concentration of Phenytoin. This may be particularly applicable with acute~ heavy alcohol consumption. Alcohol (Ethyl) may decrease the serum concentration of Phenytoin. This may be particularly applicable with chronic~ heavy alcohol consumption.¤ (Ethinyl Estradiol) May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.¤ (Ethosuximide) May enhance the CNS depressant effect of Phenytoin. Ethosuximide may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Ethosuximide.¤ (Ethoxzolamide) May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically~ the risk for osteomalacia or rickets may be increased. Exceptions: Brinzolamide; Dorzolamide.¤ (Ethynodiol) May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.¤ (Etonogestrel) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Etoposide) Phenytoin may decrease the serum concentration of Etoposide.¤ (Etravirine) Phenytoin may decrease the serum concentration of Etravirine.¤ (Everolimus) CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.¤ (Exemestane) CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.¤ (Ezogabine) Phenytoin may decrease the serum concentration of Ezogabine.¤ (Felbamate) May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Felbamate.¤ (Felodipine) May increase the serum concentration of Phenytoin.¤ (Fentanyl) CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.¤ (Floxuridine) May increase the serum concentration of Phenytoin.¤ (Fluconazole) Fluconazole may increase the serum concentration of Phenytoin.¤ (Fludiazepam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Flunarizine) May increase the serum concentration of Phenytoin.¤ (Flunitrazepam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Fluoxetine) May increase the serum concentration of Phenytoin.¤ (Fluvastatin) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Fluvoxamine) FluvoxaMINE may increase the serum concentration of Phenytoin.¤ (Folic Acid) Folic Acid may decrease the serum concentration of Phenytoin.¤ (Fosamprenavir) May decrease the serum concentration of Phenytoin. The active amprenavir metabolite is likely responsible for this effect. Phenytoin may increase the serum concentration of Fosamprenavir. Specifically~ phenytoin may increase the concentration of the active metabolite amprenavir.¤ (Furosemide) May diminish the diuretic effect of Loop Diuretics.¤ (Gabapentin) May increase the serum concentration of Phenytoin.¤ (Gefitinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.¤ (Guanfacine) CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.¤ (Halazepam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Halothane) May increase the serum concentration of Phenytoin.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Imatinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.¤ (Irinotecan) CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan.¤ (Isoniazid) May increase the serum concentration of Phenytoin.¤ (Isradipine) May increase the serum concentration of Phenytoin.¤ (Itraconazole) CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.¤ (Ivacaftor) CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.¤ (Ixabepilone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.¤ (Ketazolam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Lacosamide) Phenytoin may decrease the serum concentration of Lacosamide.¤ (Lamotrigine) May increase the serum concentration of Phenytoin.¤ (Lapatinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.¤ (Ledipasvir) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir.¤ (Lercanidipine) May increase the serum concentration of Phenytoin.¤ (Levonorgestrel) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Levothyroxine) May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.¤ (Linagliptin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.¤ (Liothyronine) May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.¤ (Liotrix) May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.¤ (Lisdexamfetamine) Amphetamines may decrease the serum concentration of Phenytoin.¤ (Lithium) Phenytoin may enhance the adverse/toxic effect of Lithium.¤ (Lopinavir) May decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Lopinavir.¤ (Lorazepam) Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.¤ (Lovastatin) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (LULICONAZOLE) May increase the serum concentration of CYP2C19 Substrates.¤ (Lumefantrine) CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumefantrine.¤ (Lurasidone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.¤ (MACITENTAN) CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan.¤ (Magnesium Sulfate) May increase the serum concentration of Phenytoin.¤ (Maraviroc) CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.¤ (Mebendazole) Phenytoin may decrease the serum concentration of Mebendazole.¤ (Medroxyprogesterone Acetate) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Mefloquine) May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.¤ (Mestranol) May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.¤ (Methadone) Phenytoin may decrease the serum concentration of Methadone.¤ (Methamphetamine) Amphetamines may decrease the serum concentration of Phenytoin.¤ (Methotrexate) May decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may increase the serum concentration of Methotrexate. Specifically~ fosphenytoin-phenytoin may displace methotrexate from serum proteins~ increasing the concentration of free~ unbound drug.¤ (Methotrimeprazine) CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.¤ (Methylphenidate) May increase the serum concentration of Phenytoin.¤ (Methylprednisolone) CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.¤ (Metyrapone) Phenytoin may decrease the serum concentration of Metyrapone. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g.~ 750 mg every 2 hours).¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mexiletine) Phenytoin may decrease the serum concentration of Mexiletine.¤ (Mianserin) May diminish the therapeutic effect of Phenytoin. Phenytoin may decrease the serum concentration of Mianserin.¤ (Miconazole) Miconazole (Oral) may increase the serum concentration of Phenytoin.¤ (Mifepristone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Nelfinavir) Nelfinavir may decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Nelfinavir.¤ (Nicardipine) May increase the serum concentration of Phenytoin.¤ (Nifedipine) CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.¤ (Nilotinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.¤ (Nimodipine) May increase the serum concentration of Phenytoin.¤ (Nisoldipine) May increase the serum concentration of Phenytoin.¤ (Nitrazepam) Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.¤ (Nitrendipine) May increase the serum concentration of Phenytoin.¤ (Nitric Oxide) May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.¤ (Norelgestromin) May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.¤ (Norethindrone) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Norgestimate) May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.¤ (Omeprazole) May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Omeprazole.¤ (Orlistat) May decrease the serum concentration of Anticonvulsants.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Oxazepam) Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.¤ (Oxcarbazepine) Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically~ concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin.¤ (Paliperidone) Inducers of CYP3A4 and P-glycoprotein may decrease the serum concentration of Paliperidone.¤ (Panobinostat) CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat.¤ (Pazopanib) CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib.¤ (Perampanel) Phenytoin may decrease the serum concentration of Perampanel.¤ (Perhexiline) May increase the serum concentration of Phenytoin.¤ (Pethidine) May decrease the serum concentration of Meperidine.¤ (Phendimetrazine) Amphetamines may decrease the serum concentration of Phenytoin.¤ (Phenobarbital) Phenytoin may enhance the CNS depressant effect of PHENobarbital. PHENobarbital may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of PHENobarbital.¤ (Phentermine) Amphetamines may decrease the serum concentration of Phenytoin.¤ (Ponatinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib.¤ (Posaconazole) May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Phenytoin. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Pramipexole) CNS Depressants may enhance the sedative effect of Pramipexole.¤ (Pravastatin) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Praziquantel) CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.¤ (Prednisone) CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE.¤ (Prenylamine) May increase the serum concentration of Phenytoin.¤ (Prilocaine) Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.¤ (Primidone) Phenytoin may increase the metabolism of Primidone. The ratio of primidone:phenobarbital is thus changed.¤ (Pyridoxine) Pyridoxine may increase the metabolism of Phenytoin. This is most apparent in high pyridoxine doses (e.g.~ 80 mg to 200 mg daily)¤ (Quazepam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Quetiapine) CYP3A4 Inducers (Strong) may decrease the serum concentration of QUEtiapine.¤ (Quinidine) Phenytoin may decrease the serum concentration of QuiNIDine.¤ (Quinine) Phenytoin may decrease the serum concentration of QuiNINE.¤ (Ranolazine) CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.¤ (Regorafenib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.¤ (Rifampicin) Rifampin may decrease the serum concentration of Phenytoin.¤ (Rilpivirine) Phenytoin may decrease the serum concentration of Rilpivirine.¤ (Risedronate) May increase the serum concentration of Phenytoin.¤ (Ritonavir) Phenytoin may decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Phenytoin.¤ (Rivaroxaban) CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.¤ (Roflumilast) CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.¤ (Romidepsin) CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.¤ (Ropinirole) CNS Depressants may enhance the sedative effect of ROPINIRole.¤ (Rotigotine) CNS Depressants may enhance the sedative effect of Rotigotine.¤ (Rufinamide) Phenytoin may decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Phenytoin.¤ (Saxagliptin) CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.¤ (Sertraline) Phenytoin may decrease the serum concentration of Sertraline. Sertraline may increase the serum concentration of Phenytoin.¤ (Simeprevir) CYP3A4 Inducers (Strong) may decrease the serum concentration of Simeprevir.¤ (Simvastatin) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Sirolimus) Phenytoin may decrease the serum concentration of Sirolimus.¤ (Sofosbuvir) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir.¤ (Sorafenib) CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.¤ (Sulfamethoxazole) May increase the serum concentration of Phenytoin.¤ (Sunitinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.¤ (Suvorexant) CYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant.¤ (Tadalafil) CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Telaprevir) Phenytoin may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Phenytoin.¤ (Temazepam) Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.¤ (Temsirolimus) Phenytoin may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite~ sirolimus~ are also likely to be decreased (and maybe to an even greater degree).¤ (Teniposide) Phenytoin may decrease the serum concentration of Teniposide.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Theophylline) Theophylline Derivatives may decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Theophylline Derivatives.¤ (Ticagrelor) CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.¤ (Ticlopidine) Ticlopidine may increase the serum concentration of Phenytoin.¤ (Tipranavir) Phenytoin may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Phenytoin.¤ (Tofacitinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.¤ (Tofisopam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Tolvaptan) CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.¤ (Topiramate) Phenytoin may decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Phenytoin.¤ (Topotecan) Fosphenytoin-Phenytoin may decrease the serum concentration of Topotecan.¤ (Toremifene) CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.¤ (Trabectedin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin.¤ (Trazodone) Phenytoin may decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Phenytoin.¤ (Treprostinil) CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.¤ (Triazolam) May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.¤ (Trimethoprim) Phenytoin may decrease the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Phenytoin.¤ (Ulipristal) CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.¤ (Vandetanib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.¤ (Vemurafenib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.¤ (Verapamil) May increase the serum concentration of Phenytoin.¤ (Vigabatrin) May decrease the serum concentration of Phenytoin.¤ (Vilazodone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.¤ (Vincristine) Phenytoin may decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Phenytoin.¤ (Vorapaxar) CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar.¤ (Voriconazole) May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Phenytoin. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.¤ (Zonisamide) Phenytoin may decrease the serum concentration of Zonisamide.¤ (Zuclopenthixol) CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.', 'yes', '¤ Avoid alcohol.\n¤ Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.\n¤ Take with food to increase bioavailability and reduce irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(160, 'Pilocarpine ', ' ', '¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(161, 'Piperacillin Sodium ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(162, 'Praziquantel ', ' B ', '¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Carbamazepine) CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.¤ (Cimetidine) Cimetidine may increase the serum concentration of Praziquantel.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Enzalutamide) CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Fosphenytoin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Phenobarbital) CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.¤ (Phenytoin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.¤ (Primidone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.¤ (Rifampicin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.¤ (Rifapentine) CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.', 'yes', '¤ Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.\n¤ Take with food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(163, 'Prednisolone ', ' ', '', 'yes', '¤ Avoid alcohol. Avoid caffeine.\n¤ Take with food to reduce gastric irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(164, 'Primaquine Diphosphate ', ' CC ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(165, 'Procainamide ', ' C ', '¤ (Amiodarone) May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).¤ (Atracurium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Cimetidine) Cimetidine may decrease the excretion of Procainamide.¤ (Cisatracurium Besylate) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Darunavir) May increase the serum concentration of CYP2D6 Substrates.¤ (Fingolimod) May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).¤ (Lamotrigine) LamoTRIgine may increase the serum concentration of Procainamide.¤ (Lurasidone) May enhance the QTc-prolonging effect of Procainamide.¤ (Mifepristone) May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.¤ (Pancuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Peginterferon alfa-2b) May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.¤ (Propafenone) May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).¤ (Ranitidine) Ranitidine may increase the serum concentration of Procainamide. Ranitidine may also increase the concentration of the active N-acetyl-procainamide (NAPA) metabolite.¤ (Rocuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Succinylcholine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Sulfamethoxazole) Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.¤ (Trimethoprim) Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.¤ (Vecuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', 'yes', '¤ Avoid alcohol.\n¤ Take with food to reduce irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(166, 'Procarbazine ', ' D ', '¤ (Acepromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Acetophenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Altretamine) May enhance the orthostatic hypotensive effect of MAO Inhibitors.¤ (Amisulpride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Amphetamine) MAO Inhibitors may enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism~ management recommendations differ from other monoamine oxidase inhibitors. Refer to monographs specific to those agents for details.¤ (Apraclonidine) MAO Inhibitors may enhance the adverse/toxic effect of Apraclonidine. MAO Inhibitors may increase the serum concentration of Apraclonidine.¤ (Aripiprazole) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Atomoxetine) MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.¤ (Benzquinamide) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Betahistine) MAO Inhibitors may increase the serum concentration of Betahistine.¤ (Bezafibrate) MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.¤ (Buprenorphine) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Bupropion) MAO Inhibitors may enhance the hypertensive effect of BuPROPion.¤ (Buspirone) May enhance the adverse/toxic effect of MAO Inhibitors. Specifically~ blood pressure elevations been reported.¤ (Carbamazepine) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Carphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Cathinone) MAO Inhibitors may enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism~ management recommendations differ from other monoamine oxidase inhibitors. Refer to monographs specific to those agents for details.¤ (Chlormezanone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Chlorpromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Chlorprothixene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Clozapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Cyclobenzaprine) May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.¤ (Cyproheptadine) MAO Inhibitors may enhance the anticholinergic effect of Cyproheptadine. Cyproheptadine may diminish the serotonergic effect of MAO Inhibitors.¤ (Dapoxetine) May enhance the adverse/toxic effect of Serotonin Modulators.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Dexmethylphenidate) MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.¤ (Dextromethorphan) MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.¤ (Diethylpropion) MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.¤ (Domperidone) MAO Inhibitors may enhance the adverse/toxic effect of Domperidone. MAO Inhibitors may diminish the therapeutic effect of Domperidone. Domperidone may diminish the therapeutic effect of MAO Inhibitors.¤ (Doxapram) MAO Inhibitors may enhance the hypertensive effect of Doxapram.¤ (Doxylamine) MAO Inhibitors may enhance the anticholinergic effect of Doxylamine.¤ (Droperidol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fencamfamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Flupentixol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluspirilene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Haloperidol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Hydrocodone) MAO Inhibitors may enhance the adverse/toxic effect of Hydrocodone.¤ (Hydromorphone) MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.¤ (Isometheptene) MAO Inhibitors may enhance the adverse/toxic effect of Isometheptene.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Levonordefrin) MAO Inhibitors may enhance the hypertensive effect of Levonordefrin.¤ (Linezolid) MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.¤ (Lithium) MAO Inhibitors may enhance the adverse/toxic effect of Lithium.¤ (Loxapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Maprotiline) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Mequitazine) MAO Inhibitors may enhance the anticholinergic effect of Mequitazine.¤ (Mesoridazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Methadone) MAO Inhibitors may enhance the adverse/toxic effect of Methadone.¤ (Methotrimeprazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Methyldopa) MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.¤ (Methylphenidate) MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.¤ (Metoclopramide) Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.¤ (Mianserin) MAO Inhibitors may enhance the neurotoxic effect of Mianserin.¤ (Mirtazapine) MAO Inhibitors may enhance the neurotoxic (central) effect of Mirtazapine. While methylene blue and linezolid are expected to interact~ specific recommendations for their use differ from other monoamine oxidase inhibitors. Refer to monographs specific to those agents for details.¤ (Molindone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Norepinephrine) MAO Inhibitors may enhance the hypertensive effect of Norepinephrine.¤ (Olanzapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ondansetron) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Oxycodone) MAO Inhibitors may enhance the adverse/toxic effect of OxyCODONE.¤ (Oxymorphone) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Paliperidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Perphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Pimozide) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Piperacetazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Pizotifen) MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.¤ (Prochlorperazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Promazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Quetiapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Remoxipride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Reserpine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Risperidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Sertindole) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Sulpiride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Tapentadol) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Tetrabenazine) May enhance the adverse/toxic effect of MAO Inhibitors.¤ (Thioridazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Thiothixene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Tramadol) May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.¤ (Trifluoperazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Triflupromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ziprasidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Zuclopenthixol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(167, 'Promethazine Hydrochloride ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(168, 'Propofol ', ' B ', '¤ (Alfentanil) Alfentanil may enhance the adverse/toxic effect of Propofol. Specifically the development of opisthotonus (severe hyperextension and spasticity resulting in arching or bridging position) and/or grand mal seizures.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Buprenorphine) CNS Depressants may enhance the CNS depressant effect of Buprenorphine.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Droperidol) May enhance the CNS depressant effect of CNS Depressants.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Methotrimeprazine) CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Midazolam) Midazolam may increase the serum concentration of Propofol. Propofol may increase the serum concentration of Midazolam.¤ (Mifepristone) May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).¤ (Mirtazapine) CNS Depressants may enhance the CNS depressant effect of Mirtazapine.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Pramipexole) CNS Depressants may enhance the sedative effect of Pramipexole.¤ (Quazepam) May increase the serum concentration of CYP2B6 Substrates.¤ (Rifampicin) Rifampin may enhance the hypotensive effect of Propofol.¤ (Ropinirole) CNS Depressants may enhance the sedative effect of ROPINIRole.¤ (Ropivacaine) May increase the serum concentration of Ropivacaine.¤ (Rotigotine) CNS Depressants may enhance the sedative effect of Rotigotine.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(169, 'Propranolol Hydrochloride ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(170, 'Propylthiouracil ', ' D ', '¤ (Acenocoumarol) May diminish the anticoagulant effect of Vitamin K Antagonists.¤ (Aminophylline) May increase the serum concentration of Theophylline Derivatives.¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Digoxin) May increase the serum concentration of Cardiac Glycosides.¤ (Theophylline) May increase the serum concentration of Theophylline Derivatives.', 'yes', '¤ Take at the same time everyday.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(171, 'Protamine Sulfate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(172, 'Pyrazinamide ', ' C ', '¤ (Rifampicin) May enhance the hepatotoxic effect of Rifampin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection.', 'yes', '¤ Take without regard to meals.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(173, 'Quinidine ', ' C ', '¤ (Acenocoumarol) May enhance the anticoagulant effect of Vitamin K Antagonists. Note that the INR/PT might be unchanged in the face of increased bleeding.¤ (Acetazolamide) Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.¤ (Afatinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.¤ (Aluminum hydroxide) May decrease the excretion of QuiNIDine. Exceptions: Aluminum Hydroxide.¤ (Amiloride) Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.¤ (Amiodarone) May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).¤ (Amitriptyline) Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.¤ (Amlodipine) May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.¤ (Amoxapine) Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.¤ (Atazanavir) May increase the serum concentration of QuiNIDine.¤ (Atomoxetine) CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.¤ (Atracurium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Boceprevir) May increase the serum concentration of QuiNIDine.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Bosutinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.¤ (Brentuximab vedotin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.¤ (Calcium carbonate) May decrease the excretion of QuiNIDine. Exceptions: Aluminum Hydroxide.¤ (Cimetidine) Cimetidine may increase the serum concentration of QuiNIDine.¤ (Cisatracurium Besylate) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Clarithromycin) Macrolide Antibiotics may enhance the QTc-prolonging effect of QuiNIDine. Macrolide Antibiotics may increase the serum concentration of QuiNIDine.¤ (Clevidipine) May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.¤ (Clomipramine) Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.¤ (Codeine) CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.¤ (Colchicine) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Crizotinib) May enhance the QTc-prolonging effect of QuiNIDine. Crizotinib may increase the serum concentration of QuiNIDine.¤ (Dabigatran etexilate) QuiNIDine may increase the serum concentration of Dabigatran Etexilate.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dalfampridine) QuiNIDine may increase the serum concentration of Dalfampridine.¤ (Darunavir) May increase the serum concentration of QuiNIDine.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Desipramine) Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.¤ (Dextromethorphan) May increase the serum concentration of Dextromethorphan.¤ (Diclofenamide) May decrease the excretion of QuiNIDine. Exceptions: Brinzolamide; Dorzolamide.¤ (Digoxin) May increase the serum concentration of Cardiac Glycosides.¤ (Dihydrocodeine) QuiNIDine may diminish the analgesic effect of Dihydrocodeine.¤ (Diltiazem) Diltiazem may increase the serum concentration of QuiNIDine.¤ (Drospirenone) Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.¤ (Enzalutamide) May decrease the serum concentration of QuiNIDine.¤ (Eplerenone) Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.¤ (Ethoxzolamide) May decrease the excretion of QuiNIDine. Exceptions: Brinzolamide; Dorzolamide.¤ (Etravirine) May decrease the serum concentration of QuiNIDine.¤ (Everolimus) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.¤ (Fesoterodine) CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.¤ (Fingolimod) May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).¤ (Fluconazole) Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Fluvoxamine) FluvoxaMINE may increase the serum concentration of QuiNIDine. QuiNIDine may increase the serum concentration of FluvoxaMINE.¤ (Fosamprenavir) May increase the serum concentration of QuiNIDine.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Fosphenytoin) May enhance the QTc-prolonging effect of QuiNIDine. Fosphenytoin may decrease the serum concentration of QuiNIDine.¤ (Haloperidol) Haloperidol may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Haloperidol.¤ (Hydrocodone) QuiNIDine may decrease serum concentrations of the active metabolite(s) of Hydrocodone.¤ (Imipramine) Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.¤ (Indinavir) Indinavir may increase the serum concentration of QuiNIDine.¤ (Itraconazole) Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Kaolin) May decrease the serum concentration of QuiNIDine.¤ (Ledipasvir) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Lopinavir) May enhance the QTc-prolonging effect of QuiNIDine. Lopinavir may increase the serum concentration of QuiNIDine. Specifically~ lopinavir/ritonavir may increase the serum concentration of quinidine.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Lurasidone) May enhance the QTc-prolonging effect of QuiNIDine.¤ (Magnesium oxide) May decrease the excretion of QuiNIDine. Exceptions: Aluminum Hydroxide.¤ (Mefloquine) May enhance the adverse/toxic effect of Mefloquine. Specifically~ the risk for QTc-prolongation and the risk for convulsions may be increased.¤ (Mequitazine) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine.¤ (Methazolamide) Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.¤ (Metoprolol) CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.¤ (Mifepristone) Mifepristone may enhance the QTc-prolonging effect of QuiNIDine. Mifepristone may increase the serum concentration of QuiNIDine.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nebivolol) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.¤ (Nelfinavir) Nelfinavir may increase the serum concentration of QuiNIDine.¤ (Nifedipine) May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.¤ (Nimodipine) May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.¤ (Nortriptyline) Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.¤ (Pancuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Pazopanib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.¤ (Phenobarbital) May enhance the hepatotoxic effect of QuiNIDine. PHENobarbital may decrease the serum concentration of QuiNIDine.¤ (Phenytoin) Phenytoin may decrease the serum concentration of QuiNIDine.¤ (Pimozide) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide.¤ (Posaconazole) Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Primidone) Primidone may decrease the serum concentration of QuiNIDine.¤ (Propafenone) QuiNIDine may enhance the QTc-prolonging effect of Propafenone. QuiNIDine may increase the serum concentration of Propafenone.¤ (Propranolol) May increase the serum concentration of Propranolol.¤ (Protriptyline) Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.¤ (prucalopride) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.¤ (Reserpine) Reserpine may enhance the adverse/toxic effect of QuiNIDine.¤ (Rifampicin) Rifamycin Derivatives may decrease the serum concentration of QuiNIDine.¤ (Rifapentine) Rifamycin Derivatives may decrease the serum concentration of QuiNIDine.¤ (Rifaximin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.¤ (Ritonavir) Ritonavir may increase the serum concentration of QuiNIDine.¤ (Rivaroxaban) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.¤ (Rocuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Saquinavir) May enhance the QTc-prolonging effect of QuiNIDine. Saquinavir may increase the serum concentration of QuiNIDine.¤ (Silodosin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Sodium bicarbonate) Antacids may decrease the excretion of QuiNIDine.¤ (Spironolactone) Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.¤ (Succinylcholine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Sucralfate) Sucralfate may decrease the serum concentration of QuiNIDine. Specifically~ sucralfate may decrease the absorption of quinidine.¤ (Sulfisoxazole) Macrolide Antibiotics may enhance the QTc-prolonging effect of QuiNIDine. Macrolide Antibiotics may increase the serum concentration of QuiNIDine.¤ (Tamoxifen) CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.¤ (Tamsulosin) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.¤ (Telaprevir) May enhance the adverse/toxic effect of QuiNIDine. Telaprevir may increase the serum concentration of QuiNIDine.¤ (Telithromycin) Macrolide Antibiotics may enhance the QTc-prolonging effect of QuiNIDine. Macrolide Antibiotics may increase the serum concentration of QuiNIDine.¤ (Thioridazine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Tipranavir) May increase the serum concentration of QuiNIDine.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Topiramate) Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.¤ (Topotecan) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.¤ (Tramadol) CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Triamterene) Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.¤ (Trimipramine) Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.¤ (Vecuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Verapamil) QuiNIDine may enhance the hypotensive effect of Verapamil. Verapamil may increase the serum concentration of QuiNIDine.¤ (Voriconazole) Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs.¤ (Zonisamide) Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.', 'yes', '¤ Preferably take on an ampty stomach.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(174, 'Quinine ', ' x ', '¤ (Acenocoumarol) May enhance the anticoagulant effect of Vitamin K Antagonists.¤ (Acetohexamide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Acetylsalicylic acid) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.¤ (Afatinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.¤ (Alogliptin) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Aluminum hydroxide) May decrease the serum concentration of QuiNINE. Exceptions: Calcium Carbonate; Sodium Bicarbonate.¤ (Aminophylline) May increase the serum concentration of Theophylline Derivatives.¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Artemether) May enhance the adverse/toxic effect of Antimalarial Agents.¤ (Atorvastatin) May increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Atracurium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Biotin) Tetracycline may increase the serum concentration of QuiNINE.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Bosutinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.¤ (Brentuximab vedotin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.¤ (Buformin) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Calcium carbonate) May decrease the serum concentration of QuiNINE. Exceptions: Calcium Carbonate; Sodium Bicarbonate.¤ (Canagliflozin) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Carbamazepine) May decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of CarBAMazepine.¤ (Carvedilol) CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically~ concentrations of the S-carvedilol enantiomer may be increased.¤ (Chlorpropamide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Cimetidine) May increase the serum concentration of QuiNINE.¤ (Cisatracurium Besylate) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Clarithromycin) Macrolide Antibiotics may increase the serum concentration of QuiNINE.¤ (Codeine) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.¤ (Colchicine) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dabigatran etexilate) P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Digoxin) May increase the serum concentration of Digoxin.¤ (Dihydrotestosterone) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.¤ (Dronabinol) CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.¤ (Everolimus) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.¤ (Exenatide) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Fesoterodine) CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Fosphenytoin) May decrease the serum concentration of QuiNINE.¤ (Gliclazide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Glimepiride) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Glipizide) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Gliquidone) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Glucagon recombinant) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Glyburide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Halofantrine) QuiNINE may enhance the adverse/toxic effect of Halofantrine. QuiNINE may increase the serum concentration of Halofantrine.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Insulin Aspart) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin Detemir) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin Glargine) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin Glulisine) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin Lispro) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin Regular) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin~ isophane) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Insulin~ porcine) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Ledipasvir) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.¤ (Linagliptin) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Lopinavir) May decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir. The individual contributions of lopinavir and ritonavir to this effect are unclear.¤ (Lovastatin) May increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Lumefantrine) Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.¤ (Magnesium oxide) May decrease the serum concentration of QuiNINE. Exceptions: Calcium Carbonate; Sodium Bicarbonate.¤ (Mefloquine) May enhance the adverse/toxic effect of Mefloquine. Specifically~ the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of QuiNINE.¤ (Metformin) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Metoprolol) CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.¤ (Mifepristone) May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.¤ (Mitiglinide) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nateglinide) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Nebivolol) CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.¤ (Nitric Oxide) May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.¤ (Oxandrolone) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.¤ (Pancuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Pazopanib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.¤ (Pegvisomant) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.¤ (Phenformin) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Phenobarbital) May decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of PHENobarbital.¤ (Phenytoin) Phenytoin may decrease the serum concentration of QuiNINE.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Pioglitazone) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Prilocaine) Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.¤ (prucalopride) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.¤ (Repaglinide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Rifampicin) Rifampin may decrease the serum concentration of QuiNINE.¤ (Rifaximin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.¤ (Ritonavir) QuiNINE may increase the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir. The individual contributions of lopinavir and ritonavir to this effect are unclear. Ritonavir may increase the serum concentration of QuiNINE.¤ (Rivaroxaban) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.¤ (Rocuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Salicylate-sodium) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.¤ (Saxagliptin) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Silodosin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Simvastatin) May increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Sodium bicarbonate) Alkalinizing Agents may increase the serum concentration of QuiNINE.¤ (Spiramycin) Macrolide Antibiotics may increase the serum concentration of QuiNINE.¤ (Succinylcholine) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Sulfisoxazole) Macrolide Antibiotics may increase the serum concentration of QuiNINE.¤ (Sulodexide) May enhance the hypoglycemic effect of other Hypoglycemic Agents.¤ (Tamoxifen) CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.¤ (Telithromycin) Macrolide Antibiotics may increase the serum concentration of QuiNINE.¤ (Testosterone) May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.¤ (Tetracycline) May increase the serum concentration of QuiNINE.¤ (Theophylline) May increase the serum concentration of Theophylline Derivatives.¤ (Thioridazine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tolbutamide) May enhance the hypoglycemic effect of Hypoglycemic Agents.¤ (Topotecan) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.¤ (Tramadol) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Vecuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.¤ (Vildagliptin) May enhance the hypoglycemic effect of Hypoglycemic Agents.', 'yes', '¤ Take with food to reduce irritation.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(175, 'Ranitidine Hydrochloride ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(176, 'Rifampicin ', ' C ', '¤ (Afatinib) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.¤ (Alfentanil) Rifamycin Derivatives may decrease the serum concentration of Alfentanil.¤ (Amiodarone) Rifampin may decrease serum concentrations of the active metabolite(s) of Amiodarone. Specifically~ desethylamiodarone concentrations may decrease. Rifampin may decrease the serum concentration of Amiodarone.¤ (Amlodipine) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Amrinone) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Apixaban) CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.¤ (Apremilast) CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast.¤ (Aprepitant) Rifampin may decrease the serum concentration of Aprepitant.¤ (Aripiprazole) CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.¤ (Artemether) CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically~ dihydroartemisinin concentrations may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether.¤ (Atazanavir) Rifampin may decrease the serum concentration of Atazanavir.¤ (Atovaquone) Rifamycin Derivatives may decrease the serum concentration of Atovaquone.¤ (Axitinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.¤ (bazedoxifene) Rifampin may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or~ if bazedoxifene is combined with estrogen therapy~ an increased risk of endometrial hyperplasia.¤ (Bedaquiline) CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.¤ (Bendamustine) CYP1A2 Inducers (Strong) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.¤ (Bepridil) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Boceprevir) Rifampin may decrease the serum concentration of Boceprevir.¤ (Bortezomib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.¤ (Bosentan) Rifampin may decrease the serum concentration of Bosentan. Following the initial several weeks of concurrent rifampin~ this effect is most likely. Rifampin may increase the serum concentration of Bosentan. This effect is most likely to be observed within the initial few weeks of concurrent therapy (and may be greatest immediately following initiation of the combination).¤ (Bosutinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.¤ (Brentuximab vedotin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.¤ (Buspirone) Rifamycin Derivatives may decrease the serum concentration of BusPIRone.¤ (Butabarbital) Rifamycin Derivatives may increase the metabolism of Barbiturates.¤ (Butethal) Rifamycin Derivatives may increase the metabolism of Barbiturates.¤ (Cabozantinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.¤ (Canagliflozin) Rifampin may decrease the serum concentration of Canagliflozin.¤ (Caspofungin) Rifampin may decrease the serum concentration of Caspofungin.¤ (Chloramphenicol) Rifampin may increase the metabolism of Chloramphenicol.¤ (Citalopram) Rifampin may decrease the serum concentration of Citalopram.¤ (Clarithromycin) CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.¤ (Clopidogrel) Rifamycin Derivatives may enhance the adverse/toxic effect of Clopidogrel. Specifically~clopidogrel antiplatelet effects may be enhanced.¤ (Clozapine) CYP3A4 Inducers (Strong) may decrease the serum concentration of CloZAPine.¤ (Crizotinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.¤ (Dabigatran etexilate) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.¤ (Darunavir) Rifampin may decrease the serum concentration of Darunavir.¤ (Dasatinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.¤ (Deferasirox) Rifampin may decrease the serum concentration of Deferasirox.¤ (Delavirdine) Rifamycin Derivatives may increase the metabolism of Delavirdine. Delavirdine may increase the serum concentration of Rifamycin Derivatives. Specifically~ Rifabutin serum concentration may be increased.¤ (Diltiazem) Rifampin may decrease the serum concentration of Diltiazem.¤ (Disopyramide) Rifampin may decrease the serum concentration of Disopyramide.¤ (Dolutegravir) Rifampin may decrease the serum concentration of Dolutegravir.¤ (Doxycycline) Rifampin may decrease the serum concentration of Doxycycline.¤ (Dronabinol) CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronabinol.¤ (Dronedarone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.¤ (Efavirenz) Rifampin may decrease the serum concentration of Efavirenz.¤ (Eliglustat) CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat.¤ (Eltrombopag) May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.¤ (Enzalutamide) CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.¤ (Erlotinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Erlotinib.¤ (Esomeprazole) Rifampin may decrease the serum concentration of Esomeprazole.¤ (Etravirine) Rifamycin Derivatives may decrease the serum concentration of Etravirine.¤ (Everolimus) CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.¤ (Exemestane) CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.¤ (Felodipine) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Fentanyl) CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.¤ (Fexofenadine) Rifampin may decrease the serum concentration of Fexofenadine. Rifampin may increase the serum concentration of Fexofenadine.¤ (Flunarizine) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Fosamprenavir) Rifampin may decrease the serum concentration of Fosamprenavir. Specifically~ concentrations of amprenavir (active metabolite) may be decreased.¤ (Fosaprepitant) Rifampin may decrease the serum concentration of Fosaprepitant. More specifically~ rifampin may decrease concentrations of the active metabolite aprepitant.¤ (Fosphenytoin) Rifampin may decrease the serum concentration of Fosphenytoin.¤ (Gabapentin) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Gefitinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.¤ (Guanfacine) CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.¤ (Heptabarbital) Rifamycin Derivatives may increase the metabolism of Barbiturates.¤ (Hexobarbital) Rifamycin Derivatives may increase the metabolism of Barbiturates.¤ (Hydrocodone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocodone.¤ (Imatinib) Rifamycin Derivatives may decrease the serum concentration of Imatinib.¤ (Indinavir) Rifampin may decrease the serum concentration of Indinavir.¤ (Irinotecan) CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan.¤ (Isoniazid) Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so~ this is a frequently employed combination regimen.¤ (Isradipine) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Itraconazole) CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.¤ (Ivacaftor) CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.¤ (Ixabepilone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.¤ (Lamotrigine) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Lapatinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.¤ (Ledipasvir) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir.¤ (Leflunomide) Rifampin may increase serum concentrations of the active metabolite(s) of Leflunomide.¤ (Lercanidipine) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Linagliptin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.¤ (Lopinavir) Rifampin may enhance the adverse/toxic effect of Lopinavir. Specifically~ the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Lopinavir.¤ (Losartan) Rifampin may decrease the serum concentration of Losartan.¤ (Lumefantrine) CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumefantrine.¤ (Lurasidone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.¤ (MACITENTAN) CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan.¤ (Magnesium Sulfate) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Maraviroc) CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.¤ (Methadone) Rifamycin Derivatives may decrease the serum concentration of Methadone.¤ (Methohexital) Rifamycin Derivatives may increase the metabolism of Barbiturates.¤ (Methylprednisolone) CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.¤ (Mifepristone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.¤ (Mirabegron) Rifampin may decrease the serum concentration of Mirabegron.¤ (Nelfinavir) Rifampin may decrease the serum concentration of Nelfinavir.¤ (Nevirapine) Rifampin may decrease the serum concentration of Nevirapine.¤ (Nicardipine) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Nifedipine) CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.¤ (Nilotinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.¤ (Nimodipine) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Nisoldipine) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Nitrazepam) Rifampin may decrease the serum concentration of Nitrazepam.¤ (Nitrendipine) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Omeprazole) Rifampin may decrease the serum concentration of Omeprazole.¤ (Oxycodone) Rifampin may decrease the serum concentration of OxyCODONE.¤ (Paliperidone) Inducers of CYP3A4 and P-glycoprotein may decrease the serum concentration of Paliperidone.¤ (Panobinostat) CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat.¤ (Pazopanib) CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib.¤ (Pentobarbital) Rifamycin Derivatives may increase the metabolism of Barbiturates.¤ (Perampanel) CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.¤ (Perhexiline) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Phenytoin) Rifampin may decrease the serum concentration of Phenytoin.¤ (Pirfenidone) CYP1A2 Inducers (Strong) may decrease the serum concentration of Pirfenidone.¤ (Pitavastatin) Rifamycin Derivatives may increase the serum concentration of Pitavastatin.¤ (Pomalidomide) CYP1A2 Inducers (Strong) may decrease the serum concentration of Pomalidomide.¤ (Ponatinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib.¤ (Prasugrel) Rifampin may diminish the antiplatelet effect of Prasugrel.¤ (Praziquantel) CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.¤ (Prednisone) CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE.¤ (Prenylamine) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Primidone) Rifamycin Derivatives may increase the metabolism of Barbiturates.¤ (Propafenone) Rifamycin Derivatives may decrease the serum concentration of Propafenone.¤ (Propofol) Rifampin may enhance the hypotensive effect of Propofol.¤ (Pyrazinamide) May enhance the hepatotoxic effect of Rifampin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection.¤ (Quetiapine) CYP3A4 Inducers (Strong) may decrease the serum concentration of QUEtiapine.¤ (Quinidine) Rifamycin Derivatives may decrease the serum concentration of QuiNIDine.¤ (Quinine) Rifampin may decrease the serum concentration of QuiNINE.¤ (Raltegravir) Rifampin may decrease the serum concentration of Raltegravir.¤ (Ramelteon) Rifamycin Derivatives may increase the metabolism of Ramelteon.¤ (Ranolazine) Rifampin may decrease the serum concentration of Ranolazine.¤ (Regorafenib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.¤ (Repaglinide) Rifampin may decrease the serum concentration of Repaglinide.¤ (Rilpivirine) Rifamycin Derivatives may decrease the serum concentration of Rilpivirine.¤ (Risedronate) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Ritonavir) Rifampin may decrease the serum concentration of Ritonavir.¤ (Rivaroxaban) CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.¤ (Roflumilast) Rifampin may decrease the serum concentration of Roflumilast.¤ (Romidepsin) Rifampin may increase the serum concentration of RomiDEPsin.¤ (Saquinavir) Rifampin may enhance the adverse/toxic effect of Saquinavir. Specifically~ the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Saquinavir.¤ (Saxagliptin) CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.¤ (Secobarbital) Rifamycin Derivatives may increase the metabolism of Barbiturates.¤ (Simeprevir) CYP3A4 Inducers (Strong) may decrease the serum concentration of Simeprevir.¤ (Sirolimus) Rifampin may increase the metabolism of Sirolimus.¤ (Sofosbuvir) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir.¤ (Sorafenib) CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.¤ (Sunitinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.¤ (Suvorexant) CYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant.¤ (Tadalafil) CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.¤ (Tamoxifen) Rifamycin Derivatives may increase the metabolism of Tamoxifen.¤ (Telaprevir) Rifampin may decrease the serum concentration of Telaprevir.¤ (Temsirolimus) Rifamycin Derivatives may decrease the serum concentration of Temsirolimus. Rifamycins will likely cause an even greater decrease in the concentration of the active metabolite sirolimus.¤ (Teriflunomide) May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.¤ (Ticagrelor) CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.¤ (Tipranavir) Rifampin may decrease the serum concentration of Tipranavir.¤ (Tofacitinib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.¤ (Tolvaptan) CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.¤ (Toremifene) CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.¤ (Trabectedin) CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin.¤ (Treprostinil) CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.¤ (Ulipristal) CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.¤ (Vandetanib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.¤ (Vemurafenib) CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.¤ (Verapamil) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Vilazodone) CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.¤ (Vorapaxar) CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar.¤ (Voriconazole) May increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole.¤ (Zaleplon) Rifamycin Derivatives may increase the metabolism of Zaleplon.¤ (Zidovudine) Rifamycin Derivatives may decrease the serum concentration of Zidovudine.¤ (Zolpidem) Rifamycin Derivatives may decrease the serum concentration of Zolpidem.¤ (Zuclopenthixol) CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.', 'yes', '¤ Avoid alcohol.\n¤ Take on empty stomach: 1 hour before or 2 hours after meals.\n¤ Take with a full glass of water.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(177, 'Ritonavir ', ' B ', '¤ (Abacavir) Protease Inhibitors may decrease the serum concentration of Abacavir.¤ (Acetohexamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (ado-trastuzumab emtansine) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically~ strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.¤ (Afatinib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.¤ (Alfuzosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.¤ (Almotriptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.¤ (Alogliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Alosetron) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.¤ (Alprazolam) Protease Inhibitors may increase the serum concentration of ALPRAZolam.¤ (Amiodarone) Ritonavir may increase the serum concentration of Amiodarone.¤ (Apixaban) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.¤ (Aripiprazole) May enhance the adverse/toxic effect of Ritonavir. The risk of metabolic disturbances (e.g. hyperglycemia~ weight gain~ hyperlipidemia) may be increased. Ritonavir may increase the serum concentration of ARIPiprazole.¤ (Astemizole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole.¤ (Atomoxetine) CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.¤ (Atorvastatin) Protease Inhibitors may increase the serum concentration of AtorvaSTATin.¤ (Atovaquone) Ritonavir may decrease the serum concentration of Atovaquone.¤ (Avanafil) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.¤ (Axitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.¤ (Batimastat) May increase the serum concentration of other Protease Inhibitors.¤ (Bedaquiline) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.¤ (Boceprevir) May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Boceprevir.¤ (Bortezomib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.¤ (Bosentan) Ritonavir may increase the serum concentration of Bosentan.¤ (Bosutinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.¤ (Brentuximab vedotin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.¤ (Brinzolamide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.¤ (Bupropion) Ritonavir may decrease the serum concentration of BuPROPion. Mixed effects on concentrations of the active hydroxybupropion metabolite have been reported.¤ (Cabazitaxel) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.¤ (Cabozantinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.¤ (Canagliflozin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Carbamazepine) May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.¤ (Chlorpropamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Cilostazol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.¤ (Cisapride) Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.¤ (Clarithromycin) Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.¤ (Clorazepate) Ritonavir may increase the serum concentration of Clorazepate.¤ (Codeine) CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.¤ (Colchicine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.¤ (Conivaptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.¤ (Crizotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.¤ (Cyclophosphamide) Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.¤ (Dabigatran etexilate) P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dapoxetine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine.¤ (Dasatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.¤ (Deferasirox) Ritonavir may decrease the serum concentration of Deferasirox.¤ (Delavirdine) May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.¤ (Diazepam) Ritonavir may increase the serum concentration of Diazepam.¤ (Digoxin) Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.¤ (Disulfiram) Ritonavir may enhance the adverse/toxic effect of Disulfiram. Specifically~ the combination of ritonavir oral solution~ which contains 43% alcohol~ may result in a disulfiram-alcohol reaction if combined.¤ (Domperidone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone.¤ (Dronabinol) May increase the serum concentration of Dronabinol.¤ (Dronedarone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.¤ (Dutasteride) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.¤ (Efavirenz) May enhance the adverse/toxic effect of Ritonavir. Efavirenz may increase the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of Efavirenz.¤ (Eliglustat) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Eliglustat.¤ (Enfuvirtide) May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.¤ (Enzalutamide) CYP2C8 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.¤ (Eplerenone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.¤ (Erlotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.¤ (Estazolam) Ritonavir may increase the serum concentration of Estazolam.¤ (Etravirine) Ritonavir may decrease the serum concentration of Etravirine.¤ (Everolimus) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.¤ (Fentanyl) CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.¤ (Fesoterodine) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.¤ (Flecainide) Ritonavir may increase the serum concentration of Flecainide.¤ (Flurazepam) Ritonavir may increase the serum concentration of Flurazepam.¤ (Fluticasone Propionate) May increase the serum concentration of Fluticasone (Nasal).¤ (Fosphenytoin) May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Fosphenytoin.¤ (Gliclazide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glimepiride) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Gliquidone) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Glyburide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Guanfacine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.¤ (Halofantrine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.¤ (Hydrocodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.¤ (Ifosfamide) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.¤ (Iloperidone) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically~ concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.¤ (Imatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib.¤ (Insulin Aspart) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Detemir) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glargine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Glulisine) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Lispro) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin Regular) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Insulin~ isophane) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Irinotecan) CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan.¤ (Isoflurophate) May increase the serum concentration of other Protease Inhibitors.¤ (Itraconazole) Ritonavir may increase the serum concentration of Itraconazole.¤ (Ivacaftor) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.¤ (Ixabepilone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.¤ (Lacosamide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide.¤ (Lamotrigine) Ritonavir may decrease the serum concentration of LamoTRIgine.¤ (Lapatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.¤ (Ledipasvir) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.¤ (Lercanidipine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine.¤ (Levobupivacaine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine.¤ (Levomilnacipran) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.¤ (Linagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Lomitapide) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.¤ (Lovastatin) Protease Inhibitors may increase the serum concentration of Lovastatin.¤ (Lurasidone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.¤ (MACITENTAN) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan.¤ (Maraviroc) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.¤ (Mequitazine) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine.¤ (Metformin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Methadone) May decrease the serum concentration of Methadone.¤ (Methylprednisolone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.¤ (Metoprolol) CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.¤ (Midazolam) Protease Inhibitors may increase the serum concentration of Midazolam.¤ (Mifepristone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nebivolol) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.¤ (Nefazodone) Protease Inhibitors may increase the serum concentration of Nefazodone.¤ (Nilotinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.¤ (Nisoldipine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.¤ (Ospemifene) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.¤ (Oxybutynin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin.¤ (Oxycodone) CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased.¤ (Panobinostat) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.¤ (Paricalcitol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.¤ (Pazopanib) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.¤ (Phenytoin) Phenytoin may decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Phenytoin.¤ (Pimecrolimus) CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.¤ (Pimozide) Protease Inhibitors may increase the serum concentration of Pimozide.¤ (Pioglitazone) CYP2C8 Inhibitors (Strong) may increase the serum concentration of Pioglitazone.¤ (Ponatinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.¤ (Posaconazole) May increase the serum concentration of Ritonavir.¤ (Pranlukast) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast.¤ (Prasugrel) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.¤ (Prednisone) Ritonavir may increase the serum concentration of PredniSONE.¤ (Proguanil) Ritonavir may decrease the serum concentration of Proguanil.¤ (Propafenone) Ritonavir may increase the serum concentration of Propafenone.¤ (prucalopride) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.¤ (Quetiapine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of QUEtiapine.¤ (Quinidine) Ritonavir may increase the serum concentration of QuiNIDine.¤ (Quinine) QuiNINE may increase the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir. The individual contributions of lopinavir and ritonavir to this effect are unclear. Ritonavir may increase the serum concentration of QuiNINE.¤ (Ranolazine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.¤ (Regorafenib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.¤ (Repaglinide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Retapamulin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.¤ (Rifabutin) Ritonavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Ritonavir may increase the serum concentration of Rifabutin.¤ (Rifampicin) Rifampin may decrease the serum concentration of Ritonavir.¤ (Rifaximin) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.¤ (Rilpivirine) Ritonavir may increase the serum concentration of Rilpivirine.¤ (Riociguat) Protease Inhibitors may increase the serum concentration of Riociguat.¤ (Rivaroxaban) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. For clarithromycin~ refer to more specific clarithromycin-rivaroxaban monograph recommendations.¤ (Romidepsin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.¤ (Rosuvastatin) Protease Inhibitors may increase the serum concentration of Rosuvastatin.¤ (Ruxolitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.¤ (Salmeterol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.¤ (Saxagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Sildenafil) Protease Inhibitors may increase the serum concentration of Sildenafil.¤ (Silodosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of other Protease Inhibitors.¤ (Simvastatin) Protease Inhibitors may increase the serum concentration of Simvastatin.¤ (Sorafenib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.¤ (Suvorexant) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant.¤ (Tadalafil) Ritonavir may increase the serum concentration of Tadalafil.¤ (Tamoxifen) CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.¤ (Tamsulosin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.¤ (Telaprevir) Ritonavir may decrease the serum concentration of Telaprevir. Ritonavir may increase the serum concentration of Telaprevir.¤ (Temsirolimus) Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus~ the active metabolite~ may be increased~ likely due to inhibition of CYP-mediated metabolism.¤ (Terfenadine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Terfenadine.¤ (Tetrabenazine) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically~ concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.¤ (Thioridazine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Ticagrelor) CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tofacitinib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.¤ (Tolbutamide) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Tolterodine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.¤ (Tolvaptan) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.¤ (Topotecan) P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.¤ (Toremifene) CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.¤ (Trabectedin) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin.¤ (Trazodone) Ritonavir may increase the serum concentration of TraZODone.¤ (Treprostinil) CYP2C8 Inhibitors (Strong) may increase the serum concentration of Treprostinil.¤ (Triazolam) Protease Inhibitors may increase the serum concentration of Triazolam.¤ (Ulipristal) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.¤ (Vardenafil) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.¤ (Vemurafenib) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.¤ (Vilazodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.¤ (Vildagliptin) Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.¤ (Vinblastine) Ritonavir may increase the serum concentration of VinBLAStine.¤ (Vincristine) Ritonavir may increase the serum concentration of VinCRIStine.¤ (Vorapaxar) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar.¤ (Voriconazole) Ritonavir may decrease the serum concentration of Voriconazole.¤ (Warfarin) Ritonavir may decrease the serum concentration of Warfarin.¤ (Zidovudine) Protease Inhibitors may decrease the serum concentration of Zidovudine.¤ (Zopiclone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.¤ (Zuclopenthixol) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.', 'yes', '¤ Avoid St.John\'s Wort.\n¤ Take with food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(178, 'Salbutamol ', ' C ', '¤ (Acebutolol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Aclidinium) May enhance the anticholinergic effect of Anticholinergic Agents.¤ (Amphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Atomoxetine) May enhance the tachycardic effect of Beta2-Agonists.¤ (Benzphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Betahistine) May diminish the therapeutic effect of Beta2-Agonists.¤ (Chlorphentermine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Clenbuterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dobutamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dopamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Epinephrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Fenoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Formoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Isoprenaline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Itopride) Anticholinergic Agents may diminish the therapeutic effect of Itopride.¤ (Labetalol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Linezolid) May enhance the hypertensive effect of Sympathomimetics.¤ (Loxapine) Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically~ the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.¤ (Mephentermine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Metaraminol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Methamphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Methoxamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Metoclopramide) Anticholinergic Agents may diminish the therapeutic effect of Metoclopramide.¤ (Mianserin) May enhance the anticholinergic effect of Anticholinergic Agents.¤ (Midodrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Mirabegron) Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.¤ (Naphazoline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Norepinephrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Orciprenaline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Oxymetazoline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phenmetrazine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phentermine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phenylephrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phenylpropanolamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Potassium Chloride) Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.¤ (Pramlintide) May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.¤ (Ritodrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Salmeterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Secretin) Anticholinergic Agents may diminish the therapeutic effect of Secretin.¤ (Terbutaline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Tiotropium) Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.¤ (Topiramate) Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(179, 'Sildenafil Citrate ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(180, 'Silver Sulfadiazine ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(181, 'Simvastatin ', ' x ', '¤ (Aluminum hydroxide) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Amiodarone) May decrease the metabolism of HMG-CoA Reductase Inhibitors.¤ (Amlodipine) AmLODIPine may increase the serum concentration of Simvastatin.¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Atazanavir) Protease Inhibitors may increase the serum concentration of Simvastatin.¤ (Batimastat) May increase the serum concentration of Simvastatin.¤ (Bezafibrate) May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically~ bezafibrate may increase the serum concentration of fluvastatin¤ (Boceprevir) May increase the serum concentration of Simvastatin.¤ (Bosentan) May increase the metabolism of HMG-CoA Reductase Inhibitors.¤ (Calcium carbonate) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Clarithromycin) May increase the serum concentration of Simvastatin.¤ (Colchicine) May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Danazol) May increase the serum concentration of Simvastatin.¤ (Daptomycin) HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically~ the risk of skeletal muscle toxicity may be increased.¤ (Darunavir) Protease Inhibitors may increase the serum concentration of Simvastatin.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Delavirdine) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.¤ (Diltiazem) Diltiazem may increase the serum concentration of Simvastatin. Simvastatin may increase the serum concentration of Diltiazem.¤ (Dronedarone) May increase the serum concentration of Simvastatin.¤ (Efavirenz) May decrease the serum concentration of Simvastatin.¤ (Eltrombopag) May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.¤ (Etravirine) May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin~ lovastatin and simvastatin. Conversely~ levels of fluvastatin may be increased.¤ (Fluconazole) Fluconazole may increase the serum concentration of Simvastatin.¤ (Fosamprenavir) Protease Inhibitors may increase the serum concentration of Simvastatin.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Fosphenytoin) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Gemfibrozil) May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Gemfibrozil may increase the serum concentration of Simvastatin. Concentrations of the active simvastatin acid metabolite may also be increased by gemfibrozil.¤ (Imatinib) May decrease the metabolism of Simvastatin.¤ (Indinavir) Protease Inhibitors may increase the serum concentration of Simvastatin.¤ (Isoflurophate) May increase the serum concentration of Simvastatin.¤ (Itraconazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Lercanidipine) May increase the serum concentration of Simvastatin.¤ (Lomitapide) May increase the serum concentration of Simvastatin.¤ (Lopinavir) Protease Inhibitors may increase the serum concentration of Simvastatin.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Magnesium oxide) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Mifepristone) May increase the serum concentration of Simvastatin.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Nefazodone) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.¤ (Nelfinavir) Protease Inhibitors may increase the serum concentration of Simvastatin.¤ (Niacin) May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.¤ (Pazopanib) HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of PAZOPanib. Specifically~ the risk for increased serum transaminase concentrations may be increased.¤ (Phenytoin) May decrease the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Posaconazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.¤ (Quinine) May increase the serum concentration of HMG-CoA Reductase Inhibitors.¤ (Raltegravir) May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors.¤ (Ranolazine) Ranolazine may increase the serum concentration of Simvastatin.¤ (Ritonavir) Protease Inhibitors may increase the serum concentration of Simvastatin.¤ (Saquinavir) Protease Inhibitors may increase the serum concentration of Simvastatin.¤ (Sildenafil) May decrease the metabolism of HMG-CoA Reductase Inhibitors.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of Simvastatin.¤ (Sulfisoxazole) Erythromycin (Systemic) may increase the serum concentration of Simvastatin.¤ (Telaprevir) May increase the serum concentration of Simvastatin.¤ (Telithromycin) May increase the serum concentration of Simvastatin.¤ (Teriflunomide) May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.¤ (Ticagrelor) May increase the serum concentration of Simvastatin.¤ (Tipranavir) Protease Inhibitors may increase the serum concentration of Simvastatin.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Trabectedin) HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.¤ (Verapamil) May increase the serum concentration of Simvastatin.¤ (Voriconazole) CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.', 'yes', '¤ Avoid alcohol.\n¤ Avoid drastic changes in dietary habit.\n¤ Avoid taking with grapefruit juice.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(182, 'Spectinomycin Hydrochloride ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(183, 'Spironolactone ', ' D ', '¤ (Abiraterone) May diminish the therapeutic effect of Abiraterone Acetate.¤ (Alfentanil) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Alfuzosin) May enhance the hypotensive effect of Antihypertensives.¤ (Amifostine) Antihypertensives may enhance the hypotensive effect of Amifostine.¤ (Amiloride) May enhance the hyperkalemic effect of Spironolactone.¤ (Ammonium chloride) Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.¤ (Articaine) May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.¤ (Atorvastatin) May enhance the adverse/toxic effect of Spironolactone. Specifically~ there is a theoretical potential for enhanced effects on reducing endogenous steroid activity.¤ (Atracurium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Buprenorphine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Butabarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Butethal) May enhance the hypotensive effect of Hypotensive Agents.¤ (Butorphanol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Canagliflozin) May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics.¤ (Cholestyramine) Cholestyramine Resin may enhance the adverse/toxic effect of Spironolactone. Specifically~ the risks of developing metabolic acidosis and hyperkalemia may be elevated with this combination.¤ (Cisatracurium Besylate) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Codeine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Diazoxide) May enhance the hypotensive effect of Antihypertensives.¤ (Digoxin) May increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations~ falsely increasing or decreasing Digoxin concentrations.¤ (Dihydrocodeine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Dipivefrin) May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.¤ (Dopamine) May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.¤ (Drospirenone) May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.¤ (Duloxetine) Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.¤ (Eplerenone) May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.¤ (Fentanyl) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Heparin) May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.¤ (Heptabarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Hexobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Hydrocodone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Hydromorphone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Levonordefrin) May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.¤ (Levorphanol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Methadone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Methohexital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Methylphenidate) May diminish the antihypertensive effect of Antihypertensives.¤ (Mitotane) Spironolactone may diminish the therapeutic effect of Mitotane.¤ (Morphine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Nalbuphine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Nitrofurantoin) May enhance the hyperkalemic effect of Spironolactone.¤ (Norepinephrine) May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.¤ (Obinutuzumab) Antihypertensives may enhance the hypotensive effect of Obinutuzumab.¤ (Oxycodone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Oxymorphone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Pancuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Pentobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Pentoxifylline) May enhance the hypotensive effect of Antihypertensives.¤ (Pethidine) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Primidone) May enhance the hypotensive effect of Hypotensive Agents.¤ (Pseudoephedrine) May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.¤ (Quinidine) Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.¤ (Remifentanil) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Risperidone) Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.¤ (Rituximab) Antihypertensives may enhance the hypotensive effect of RiTUXimab.¤ (Rocuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Secobarbital) May enhance the hypotensive effect of Hypotensive Agents.¤ (Sufentanil) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Sulfamethoxazole) Trimethoprim may enhance the hyperkalemic effect of Spironolactone.¤ (Tadalafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Tapentadol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Tolvaptan) May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.¤ (Tramadol) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Triamterene) Triamterene may enhance the hyperkalemic effect of Spironolactone.¤ (Trimethoprim) May enhance the hyperkalemic effect of Spironolactone.¤ (Triprolidine) May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.¤ (Vardenafil) May enhance the antihypertensive effect of Antihypertensives.¤ (Vecuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Yohimbine) May diminish the antihypertensive effect of Antihypertensives.', 'yes', '¤ Avoid alcohol.\n¤ Food increases the bioavailability of spironolactone by almost 100%. \n¤ Spironolactone may decrease the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(184, 'Streptomycin sulfate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(185, 'Sulfasalazine ', ' B ', '¤ (Folic Acid) May decrease the serum concentration of Folic Acid.¤ (Heparin) 5-ASA Derivatives may enhance the adverse/toxic effect of Heparin. Specifically~ the risk for bleeding/bruising may be increased.¤ (Methotrexate) May enhance the hepatotoxic effect of Methotrexate.¤ (Nitric Oxide) May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.¤ (Prilocaine) Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.', 'yes', '¤ May take Vitamin D.\n¤ Take with a full glass of water No iron, zinc or fluoride within 2 hours of taking this medication.\n¤ Take with food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(186, 'Sumatriptan Succinate ', ' ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(187, 'Tamoxifen Citrate ', ' ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(188, 'Tamsulosin Hydrochloride ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(189, 'Tenofovir ', ' B ', '¤ (Aciclovir) Acyclovir-Valacyclovir may decrease the excretion of Tenofovir.¤ (Adefovir Dipivoxil) Adefovir may diminish the therapeutic effect of Tenofovir. Specifically~ adefovir-associated mutations in Hepatitis B viral reverse transcriptase may decrease viral susceptibility to tenofovir. Adefovir may increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Adefovir.¤ (Amikacin) Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.¤ (Arbekacin) Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.¤ (Atazanavir) May increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Atazanavir.¤ (Celecoxib) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Cidofovir) May decrease the excretion of Tenofovir.¤ (Darunavir) May increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Darunavir.¤ (Didanosine) Tenofovir may diminish the therapeutic effect of Didanosine. Tenofovir may increase the serum concentration of Didanosine.¤ (Diflunisal) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Etodolac) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Fenoprofen) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Floctafenine) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Framycetin) Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.¤ (Gentamicin) Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.¤ (Ibuprofen) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Indomethacin) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Kanamycin) Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.¤ (Ketoprofen) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Ketorolac) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Ledipasvir) May increase the serum concentration of Tenofovir.¤ (Lopinavir) May enhance the nephrotoxic effect of Tenofovir. Lopinavir may increase the serum concentration of Tenofovir.¤ (Mefenamic acid) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Meloxicam) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Nabumetone) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Naproxen) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Neomycin) Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.¤ (Netilmicin) Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.¤ (Oxaprozin) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Piroxicam) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Ribostamycin) Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.¤ (Simeprevir) May increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Simeprevir.¤ (Spectinomycin) Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.¤ (Streptomycin) Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.¤ (Sulindac) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Telaprevir) May increase the serum concentration of Tenofovir.¤ (Tiaprofenic acid) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Tipranavir) Tenofovir may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Tenofovir.¤ (Tobramycin) Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.¤ (Tolmetin) Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.¤ (Valganciclovir) May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir.', 'yes', '¤ When given with a high-fat meal, the oral bioavailability, AUC, and Cmax increased. ', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(190, 'Terbinafine Hydrochloride ', ' B ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(191, 'Terbutaline ', ' B ', '¤ (Acebutolol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Aminophylline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Amphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Arformoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (armodafinil) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Articaine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Atomoxetine) AtoMOXetine may enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.¤ (Benzphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Betahistine) May diminish the therapeutic effect of Beta2-Agonists.¤ (Caffeine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Chlorphentermine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Clenbuterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Cocaine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dexmethylphenidate) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dextroamphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Diethylpropion) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dihydrocodeine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dipivefrin) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dobutamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dopamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Doxapram) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Dronabinol) Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.¤ (Epinephrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Fenoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Fluticasone furoate) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Formoterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Indacaterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Iobenguane) May diminish the therapeutic effect of Iobenguane I 123.¤ (Ipratropium bromide) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Isometheptene) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Isoprenaline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Labetalol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Levonordefrin) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Linezolid) Linezolid may enhance the hypertensive effect of Sympathomimetics.¤ (Lisdexamfetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Loxapine) Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically~ the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.¤ (Mephentermine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Metaraminol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Methamphetamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Methoxamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Methylphenidate) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Midodrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Modafinil) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Nabilone) Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.¤ (Naphazoline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Norepinephrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Orciprenaline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Oxymetazoline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phendimetrazine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Pheniramine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phenmetrazine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phentermine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phenylephrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Phenylpropanolamine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Pirbuterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Propylhexedrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Pseudoephedrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Ritodrine) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Salbutamol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Salmeterol) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Tedizolid Phosphate) Tedizolid may enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.¤ (Theophylline) May enhance the adverse/toxic effect of other Sympathomimetics.¤ (Triprolidine) May enhance the adverse/toxic effect of other Sympathomimetics.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(192, 'Tetracaine Hydrochloride ', ' ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(193, 'Thioguanil ', ' D ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(194, 'Thiopental ', ' C ', '¤ (Aminophylline) Aminophylline may diminish the therapeutic effect of Thiopental.¤ (Chlorpromazine) Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.¤ (Diazoxide) May enhance the hypotensive effect of Diazoxide.¤ (Ketamine) Ketamine may enhance the adverse/toxic effect of Thiopental.¤ (Mefloquine) Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.¤ (Orlistat) Orlistat may decrease the serum concentration of Anticonvulsants. Exceptions: Fosphenytoin; PENTobarbital; Thiopental.¤ (Perphenazine) Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.¤ (Pipotiazine) Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.¤ (Prochlorperazine) Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.¤ (Promazine) Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.¤ (Sulfisoxazole) SulfiSOXAZOLE may enhance the therapeutic effect of Thiopental.¤ (Thioridazine) Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.¤ (Trifluoperazine) Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(195, 'Thioridazine ', ' C ', '¤ (Abiraterone) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Aclidinium) May enhance the anticholinergic effect of Anticholinergic Agents.¤ (Almotriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Aluminum hydroxide) May decrease the absorption of Antipsychotic Agents (Phenothiazines).¤ (Amiodarone) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Amisulpride) Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride.¤ (Amitriptyline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Amoxapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Amphetamine) May diminish the stimulatory effect of Amphetamines.¤ (Aripiprazole) CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.¤ (Artemether) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Atomoxetine) CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.¤ (Benzphetamine) May diminish the stimulatory effect of Amphetamines.¤ (Buprenorphine) CNS Depressants may enhance the CNS depressant effect of Buprenorphine.¤ (Bupropion) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Buspirone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Cabergoline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Calcium carbonate) May decrease the absorption of Antipsychotic Agents (Phenothiazines).¤ (Cathinone) Antipsychotic Agents may diminish the stimulatory effect of Amphetamines.¤ (Celecoxib) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Chloroquine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Chlorphenamine) Chlorpheniramine may enhance the arrhythmogenic effect of Thioridazine. Thioridazine may increase the serum concentration of Chlorpheniramine.¤ (Chlorpromazine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Cimetidine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Cinacalcet) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Citalopram) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Clobazam) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Clomipramine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Clozapine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Cocaine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Codeine) CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.¤ (Cyclobenzaprine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Dapoxetine) May enhance the arrhythmogenic effect of Thioridazine. Dapoxetine may increase the serum concentration of Thioridazine.¤ (Darifenacin) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Darunavir) May increase the serum concentration of CYP2D6 Substrates.¤ (Delavirdine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Desipramine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Desvenlafaxine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Dextroamphetamine) May diminish the stimulatory effect of Amphetamines.¤ (Dextromethorphan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Dihydroergotamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Donepezil) Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronedarone) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Duloxetine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Eletriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Eliglustat) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Ergoloid mesylate) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ergonovine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ergotamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Escitalopram) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fentanyl) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fesoterodine) CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.¤ (Fluoxetine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluvoxamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Frovatriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Galantamine) Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.¤ (Haloperidol) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Imipramine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Isocarboxazid) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Isoniazid) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Itopride) Anticholinergic Agents may diminish the therapeutic effect of Itopride.¤ (Levomilnacipran) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Linezolid) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Lisdexamfetamine) May diminish the stimulatory effect of Amphetamines.¤ (Lithium) Lithium may enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.¤ (Lopinavir) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Lorcaserin) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Lumefantrine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Magnesium oxide) May decrease the absorption of Antipsychotic Agents (Phenothiazines).¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Maprotiline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Mequitazine) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine.¤ (Methadone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Methamphetamine) May diminish the stimulatory effect of Amphetamines.¤ (Methotrimeprazine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Methylergometrine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Methylphenidate) May enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents.¤ (Metoclopramide) May enhance the adverse/toxic effect of Antipsychotic Agents.¤ (Metoprolol) CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mifepristone) May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.¤ (Milnacipran) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Mirabegron) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Moclobemide) May increase the serum concentration of Thioridazine.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Naratriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Nebivolol) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.¤ (Nefazodone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Nilotinib) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Nortriptyline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Panobinostat) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Paroxetine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Peginterferon alfa-2b) May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Pethidine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Phendimetrazine) May diminish the stimulatory effect of Amphetamines.¤ (Phenelzine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Phentermine) May diminish the stimulatory effect of Amphetamines.¤ (Pimozide) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide.¤ (Porfimer) Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.¤ (Potassium Chloride) Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.¤ (Pramlintide) May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.¤ (Procarbazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Promazine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Promethazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Protriptyline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Quinidine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Quinine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Rasagiline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ritonavir) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Rivastigmine) Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.¤ (Rizatriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Secretin) Anticholinergic Agents may diminish the therapeutic effect of Secretin.¤ (Selegiline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Sertraline) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Sulpiride) Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride.¤ (Sumatriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tamoxifen) CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.¤ (Tamsulosin) CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Tedizolid Phosphate) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Tetrabenazine) Tetrabenazine may enhance the adverse/toxic effect of Antipsychotic Agents.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Thiopental) Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.¤ (Ticlopidine) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Tiotropium) Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.¤ (Tipranavir) CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.¤ (Topiramate) Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.¤ (Tramadol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Tranylcypromine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Trimipramine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Venlafaxine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Verteporfin) Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.¤ (Vilazodone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Zolmitriptan) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(196, 'Timolol Maleate ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(197, 'Tinidazole ', 'D first trimester; C second and third trimester ', '¤ (Disulfiram) May enhance the adverse/toxic effect of Disulfiram.¤ (Ethanol) May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(198, 'Tramadol ', ' C ', '¤ (Abiraterone) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Acenocoumarol) May enhance the anticoagulant effect of Vitamin K Antagonists.¤ (Acepromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Acetazolamide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Acetophenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Alosetron) Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.¤ (Alvimopan) Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e.~ more than 7 days) opiates prior to alvimopan initiation.¤ (Amiloride) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Amiodarone) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Amisulpride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Amitriptyline) Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.¤ (Ammonium chloride) May increase the excretion of Analgesics (Opioid).¤ (Amoxapine) Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.¤ (Amphetamine) May enhance the analgesic effect of Analgesics (Opioid).¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Artemether) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Bendroflumethiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Benzquinamide) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Bumetanide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Bupropion) CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Carbamazepine) TraMADol may enhance the CNS depressant effect of CarBAMazepine. TraMADol may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of TraMADol.¤ (Carphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Cathinone) May enhance the analgesic effect of Analgesics (Opioid).¤ (Celecoxib) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Chlormezanone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Chloroquine) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Chlorothiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Chlorpromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Chlorprothixene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Chlorthalidone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Cimetidine) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Cinacalcet) CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Citalopram) Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.¤ (Clobazam) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Clomipramine) Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.¤ (Clozapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Cocaine) CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Cyclobenzaprine) May enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. Cyclobenzaprine may enhance the serotonergic effect of TraMADol. This could result in serotonin syndrome.¤ (Cyclothiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dapoxetine) May enhance the adverse/toxic effect of Serotonin Modulators.¤ (Darifenacin) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Desipramine) Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.¤ (Desmopressin) Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.¤ (Dolasetron) Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.¤ (Doxylamine) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronabinol) May enhance the CNS depressant effect of CNS Depressants.¤ (Dronedarone) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Droperidol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Eliglustat) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Escitalopram) Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.¤ (Ethacrynic acid) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Ethoxzolamide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Fencamfamine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluoxetine) Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.¤ (Flupentixol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluspirilene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Fluvoxamine) Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Furosemide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Granisetron) Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.¤ (Haloperidol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Hydrochlorothiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Hydrocodone) CNS Depressants may enhance the CNS depressant effect of Hydrocodone.¤ (Hydroflumethiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Hydroxyzine) May enhance the CNS depressant effect of CNS Depressants.¤ (Imipramine) Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.¤ (Indapamide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Isocarboxazid) May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.¤ (Isoniazid) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Linezolid) May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.¤ (Loxapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Lumefantrine) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Magnesium Sulfate) May enhance the CNS depressant effect of CNS Depressants.¤ (Mesoridazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Methotrimeprazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Metoclopramide) Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.¤ (Metolazone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Metyrosine) CNS Depressants may enhance the sedative effect of Metyrosine.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Mirabegron) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Moclobemide) May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.¤ (Molindone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Nabilone) May enhance the CNS depressant effect of CNS Depressants.¤ (Naltrexone) May diminish the therapeutic effect of Analgesics (Opioid).¤ (Nilotinib) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Nortriptyline) Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.¤ (Olanzapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ondansetron) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Orphenadrine) CNS Depressants may enhance the CNS depressant effect of Orphenadrine.¤ (Paliperidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Palonosetron) Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.¤ (Panobinostat) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Paroxetine) Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.¤ (Pegvisomant) Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.¤ (Perampanel) May enhance the CNS depressant effect of CNS Depressants.¤ (Perphenazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Phenelzine) May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.¤ (Pimozide) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Piperacetazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Pramipexole) CNS Depressants may enhance the sedative effect of Pramipexole.¤ (Procarbazine) May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.¤ (Prochlorperazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Promazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Protriptyline) Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.¤ (Quetiapine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Quinidine) CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Quinine) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Rasagiline) May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.¤ (Remoxipride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Reserpine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Risperidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ropinirole) CNS Depressants may enhance the sedative effect of ROPINIRole.¤ (Rotigotine) CNS Depressants may enhance the sedative effect of Rotigotine.¤ (Rufinamide) May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.¤ (Selegiline) May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.¤ (Sertindole) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Sertraline) Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Spironolactone) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Succinylcholine) May enhance the bradycardic effect of Analgesics (Opioid).¤ (Sulpiride) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Suvorexant) CNS Depressants may enhance the CNS depressant effect of Suvorexant.¤ (Tapentadol) May enhance the CNS depressant effect of CNS Depressants.¤ (Tedizolid Phosphate) May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.¤ (Thalidomide) CNS Depressants may enhance the CNS depressant effect of Thalidomide.¤ (Thioridazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Thiothixene) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Ticlopidine) CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Ticrynafen) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Tipranavir) CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Torasemide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Tranylcypromine) May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.¤ (Triamterene) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Trichlormethiazide) Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.¤ (Trifluoperazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Triflupromazine) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Trimipramine) Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.¤ (Vilazodone) Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.¤ (Ziprasidone) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.¤ (Zolpidem) CNS Depressants may enhance the CNS depressant effect of Zolpidem.¤ (Zuclopenthixol) Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', 'yes', '¤ Oral administration of tramadol hydrochloride with food does not significantly affect its rate or extent of absorption, therefore, tramadol hydrochloride can be administered without regard to food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(199, 'Trifluridine ', ' C ', '', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(200, 'Valproic acid ', ' D ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(201, 'Vecuronium Bromide ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(202, 'Verapamil ', ' C ', '¤ (Aliskiren) May increase the serum concentration of Aliskiren.¤ (Amobarbital) Barbiturates may increase the metabolism of Calcium Channel Blockers.¤ (Atorvastatin) AtorvaSTATin may increase the serum concentration of Verapamil. Verapamil may increase the serum concentration of AtorvaSTATin.¤ (Atracurium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Butabarbital) Barbiturates may increase the metabolism of Calcium Channel Blockers.¤ (Butalbital) Barbiturates may increase the metabolism of Calcium Channel Blockers.¤ (Calcium Acetate) Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.¤ (Calcium carbonate) Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.¤ (Calcium Chloride) Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.¤ (Cimetidine) Cimetidine may increase the serum concentration of Calcium Channel Blockers.¤ (Cisatracurium Besylate) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Clarithromycin) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Clopidogrel) May diminish the therapeutic effect of Clopidogrel. Exceptions: Clevidipine.¤ (Dabigatran etexilate) May increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.¤ (Disopyramide) May enhance the adverse/toxic effect of Disopyramide. Of particular concern is the potential for profound depression of myocardial contractility.¤ (Dofetilide) May increase the serum concentration of Dofetilide.¤ (Doxazosin) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Ethanol) May increase the serum concentration of Alcohol (Ethyl).¤ (Fexofenadine) May increase the bioavailability of Fexofenadine.¤ (Fingolimod) May enhance the bradycardic effect of Fingolimod.¤ (Flecainide) May enhance the adverse/toxic effect of Flecainide. In particular~ this combination may significantly impair myocardial contractility and AV nodal conduction.¤ (Fluconazole) Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Fosphenytoin) May increase the serum concentration of Fosphenytoin.¤ (Itraconazole) Antifungal Agents (Azole Derivatives~ Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically~ itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.¤ (Lovastatin) May increase the serum concentration of Lovastatin.¤ (Magnesium oxide) May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Magnesium salicylate) May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Metformin) May diminish the therapeutic effect of MetFORMIN.¤ (Methohexital) Barbiturates may increase the metabolism of Calcium Channel Blockers.¤ (Nafcillin) Nafcillin may increase the metabolism of Calcium Channel Blockers. Exceptions: Clevidipine.¤ (Nitroprusside) May enhance the hypotensive effect of Nitroprusside.¤ (Pancuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Pentobarbital) Barbiturates may increase the metabolism of Calcium Channel Blockers.¤ (Phenobarbital) Barbiturates may increase the metabolism of Calcium Channel Blockers.¤ (Phenoxybenzamine) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Phentolamine) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Phenytoin) May increase the serum concentration of Phenytoin.¤ (Posaconazole) Antifungal Agents (Azole Derivatives~ Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically~ itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.¤ (Prazosin) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Quinidine) QuiNIDine may enhance the hypotensive effect of Verapamil. Verapamil may increase the serum concentration of QuiNIDine.¤ (Rifampicin) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Rifapentine) Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.¤ (Risperidone) May increase the serum concentration of RisperiDONE.¤ (Rocuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Secobarbital) Barbiturates may increase the metabolism of Calcium Channel Blockers.¤ (Silodosin) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Simvastatin) May increase the serum concentration of Simvastatin.¤ (Sulfisoxazole) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Tamsulosin) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Telithromycin) Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.¤ (Terazosin) Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.¤ (Vecuronium) May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).¤ (Voriconazole) Antifungal Agents (Azole Derivatives~ Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically~ itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.', 'yes', '¤ Avoid alcohol.\n¤ Avoid excessive quantities of coffee or tea (Caffeine).\n¤ Avoid natural licorice.\n¤ Avoid taking with grapefruit juice.\n¤ Take with food.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(203, 'Vinblastine ', ' D ', '¤ (Afatinib) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Brentuximab vedotin) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dabigatran etexilate) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Itraconazole) May increase the serum concentration of VinBLAStine.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Ledipasvir) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Linagliptin) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Lopinavir) May increase the serum concentration of VinBLAStine.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Posaconazole) May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).¤ (Ritonavir) Ritonavir may increase the serum concentration of VinBLAStine.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Sofosbuvir) P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Tolterodine) VinBLAStine may increase the serum concentration of Tolterodine.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.¤ (Voriconazole) May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(204, 'Vincristine ', ' D ', '¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Fosphenytoin) May decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Fosphenytoin.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Itraconazole) May enhance the adverse/toxic effect of VinCRIStine. Itraconazole may increase the serum concentration of VinCRIStine.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (Lopinavir) May increase the serum concentration of VinCRIStine.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Nifedipine) May increase the serum concentration of VinCRIStine.¤ (Phenytoin) Phenytoin may decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Phenytoin.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Posaconazole) May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).¤ (Ritonavir) Ritonavir may increase the serum concentration of VinCRIStine.¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Teniposide) Teniposide may enhance the neurotoxic effect of VinCRIStine.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.¤ (Voriconazole) May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);
INSERT INTO `items` (`id`, `item_name`, `PregnancyRiskCategory`, `drug_interaction`, `affected`, `food_interaction`, `category`, `min_qty`, `unit_cost`, `unit_price`, `current_amount`, `valuation`, `barcode_main`, `barcode_generation`, `description`, `image`, `income_account`, `expense_account`, `inventory_account`, `created_at`, `updated_at`, `national_drug_code`, `item_name_tig`, `item_code`, `qty_shop`, `qty_store`, `item_order`, `company`, `owner`, `variants`, `package_tracking`, `active`, `other_attrib`, `remark`) VALUES
(205, 'Vinorelbine ', ' D ', '¤ (Aprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Aripiprazole) CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.¤ (Bosentan) May decrease the serum concentration of CYP3A4 Substrates.¤ (Cisplatin) May enhance the adverse/toxic effect of Vinorelbine. Specifically~ the combination may be associated with a higher risk of granulocytopenia.¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Conivaptan) May increase the serum concentration of CYP3A4 Substrates.¤ (Dabrafenib) May decrease the serum concentration of CYP3A4 Substrates.¤ (Dasatinib) May increase the serum concentration of CYP3A4 Substrates.¤ (Deferasirox) May decrease the serum concentration of CYP3A4 Substrates.¤ (Denosumab) May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.¤ (Dofetilide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.¤ (Fosaprepitant) May increase the serum concentration of CYP3A4 Substrates.¤ (Gefitinib) Gefitinib may enhance the neutropenic effect of Vinorelbine.¤ (Hydrocodone) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.¤ (Itraconazole) May enhance the adverse/toxic effect of Vinorelbine. Itraconazole may increase the serum concentration of Vinorelbine.¤ (Ivacaftor) May increase the serum concentration of CYP3A4 Substrates.¤ (Leflunomide) Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.¤ (Lomitapide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.¤ (LULICONAZOLE) May increase the serum concentration of CYP3A4 Substrates.¤ (Mifepristone) May increase the serum concentration of CYP3A4 Substrates.¤ (Mitotane) May decrease the serum concentration of CYP3A4 Substrates.¤ (Natalizumab) Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.¤ (Pimecrolimus) May enhance the adverse/toxic effect of Immunosuppressants.¤ (Pimozide) CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.¤ (Posaconazole) May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).¤ (Roflumilast) May enhance the immunosuppressive effect of Immunosuppressants.¤ (Siltuximab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Simeprevir) May increase the serum concentration of CYP3A4 Substrates.¤ (Sipuleucel-T) Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.¤ (Tocilizumab) May decrease the serum concentration of CYP3A4 Substrates.¤ (Tofacitinib) Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.¤ (Trastuzumab) May enhance the neutropenic effect of Immunosuppressants.¤ (Voriconazole) May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(206, 'Warfarin ', ' x ', '¤ (Abciximab) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Acenocoumarol) May enhance the anticoagulant effect of other Anticoagulants.¤ (Acetylsalicylic acid) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Adalimumab) Adalimumab may decrease the serum concentration of Warfarin.¤ (Alteplase) Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.¤ (Aminosalicylic Acid) Salicylates may enhance the anticoagulant effect of Anticoagulants.¤ (Anagrelide) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Apixaban) Apixaban may enhance the anticoagulant effect of Anticoagulants.¤ (Aprepitant) Aprepitant may decrease the serum concentration of Warfarin.¤ (Argatroban) May enhance the anticoagulant effect of other Anticoagulants.¤ (Atazanavir) Atazanavir may increase the serum concentration of Warfarin.¤ (Bismuth Subsalicylate) Salicylates may enhance the anticoagulant effect of Anticoagulants.¤ (Bivalirudin) May enhance the anticoagulant effect of other Anticoagulants.¤ (Boceprevir) Boceprevir may decrease the serum concentration of Warfarin. Boceprevir may increase the serum concentration of Warfarin.¤ (Celecoxib) Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.¤ (Choline) Fenofibrate and Derivatives may enhance the anticoagulant effect of Warfarin. Fenofibrate and Derivatives may increase the serum concentration of Warfarin.¤ (Cilostazol) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Citalopram) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Clopidogrel) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Corticotropin) Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.¤ (Cortisone acetate) Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.¤ (Cyproterone acetate) Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Dabigatran etexilate) Dabigatran Etexilate may enhance the anticoagulant effect of Anticoagulants.¤ (Dalteparin) May enhance the anticoagulant effect of other Anticoagulants.¤ (Danaparoid) May enhance the anticoagulant effect of other Anticoagulants.¤ (Darunavir) Darunavir may decrease the serum concentration of Warfarin.¤ (Dasatinib) Dasatinib may enhance the anticoagulant effect of Anticoagulants.¤ (Deferasirox) May enhance the adverse/toxic effect of Deferasirox. Specifically~ the risk for GI ulceration/irritation or GI bleeding may be increased.¤ (Desogestrel) Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Desvenlafaxine) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Diflunisal) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Dipyridamole) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Drospirenone) Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Duloxetine) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Enoxaparin) May enhance the anticoagulant effect of other Anticoagulants.¤ (Enzalutamide) Enzalutamide may decrease the serum concentration of Warfarin. More specifically~ enzalutamide may decrease concentrations of the S-warfarin enantiomer.¤ (Epoprostenol) Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically~ the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.¤ (Eptifibatide) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Erlotinib) Erlotinib may increase the serum concentration of Warfarin.¤ (Escitalopram) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Estropipate) Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Ethinyl Estradiol) Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Ethynodiol) Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Etodolac) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Etonogestrel) Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Fenofibrate) Fenofibrate and Derivatives may enhance the anticoagulant effect of Warfarin. Fenofibrate and Derivatives may increase the serum concentration of Warfarin.¤ (Fenoprofen) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Floctafenine) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Fludrocortisone) Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.¤ (Fluoxetine) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Fluvoxamine) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Fondaparinux sodium) May enhance the anticoagulant effect of other Anticoagulants.¤ (Fosamprenavir) Fosamprenavir may increase the serum concentration of Warfarin.¤ (Fosaprepitant) Fosaprepitant may decrease the serum concentration of Warfarin. The active metabolite aprepitant is likely responsible for this effect.¤ (Gemcitabine) Gemcitabine may enhance the anticoagulant effect of Warfarin.¤ (Heparin) May enhance the anticoagulant effect of other Anticoagulants.¤ (Homoharringtonine) May enhance the adverse/toxic effect of Omacetaxine. Specifically~ the risk for bleeding-related events may be increased.¤ (Ibritumomab) May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.¤ (Ibuprofen) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Icosapent) Omega-3 Fatty Acids may enhance the anticoagulant effect of Anticoagulants.¤ (Icosapent ethyl) Omega-3 Fatty Acids may enhance the anticoagulant effect of Anticoagulants.¤ (Iloprost) Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically~ the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.¤ (Indomethacin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Ketoprofen) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Ketorolac) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Levomilnacipran) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Levonorgestrel) Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Lomitapide) Lomitapide may increase the serum concentration of Warfarin.¤ (Lopinavir) Lopinavir may decrease the serum concentration of Warfarin.¤ (Magnesium salicylate) Salicylates may enhance the anticoagulant effect of Anticoagulants.¤ (Medroxyprogesterone Acetate) Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Mefenamic acid) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Megestrol acetate) Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Meloxicam) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Mestranol) Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Methylprednisolone) Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.¤ (Metreleptin) Metreleptin may decrease the serum concentration of Warfarin. Metreleptin may increase the serum concentration of Warfarin.¤ (Miconazole) Miconazole (Oral) may increase the serum concentration of Warfarin.¤ (Milnacipran) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Mirtazapine) Mirtazapine may enhance the anticoagulant effect of Warfarin.¤ (Nabumetone) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Nadroparin) May enhance the anticoagulant effect of other Anticoagulants.¤ (Naproxen) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Nelfinavir) Nelfinavir may decrease the serum concentration of Warfarin. Nelfinavir may increase the serum concentration of Warfarin.¤ (Norelgestromin) Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Norethindrone) Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Norgestimate) Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Obinutuzumab) May enhance the adverse/toxic effect of Obinutuzumab. Specifically~ the risk of serious bleeding-related events may be increased.¤ (Orlistat) Orlistat may enhance the anticoagulant effect of Warfarin.¤ (Oxaprozin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Paroxetine) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Pentosan Polysulfate) Pentosan Polysulfate Sodium may enhance the anticoagulant effect of Anticoagulants.¤ (Piperazine) Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Piroxicam) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Prasugrel) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Prednisone) Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.¤ (Progesterone) Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.¤ (Proguanil) Proguanil may enhance the anticoagulant effect of Warfarin.¤ (Ranitidine) Ranitidine may increase the serum concentration of Warfarin.¤ (Regorafenib) May enhance the adverse/toxic effect of Regorafenib. Specifically~ the risk for bleeding may be increased.¤ (Reteplase) Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.¤ (Ritonavir) Ritonavir may decrease the serum concentration of Warfarin.¤ (Rivaroxaban) May enhance the anticoagulant effect of Rivaroxaban.¤ (Salsalate) Salicylates may enhance the anticoagulant effect of Anticoagulants.¤ (Saquinavir) Saquinavir may increase the serum concentration of Warfarin.¤ (Sertraline) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Sorafenib) SORAfenib may enhance the anticoagulant effect of Warfarin. SORAfenib may increase the serum concentration of Warfarin.¤ (Sulindac) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Telaprevir) Telaprevir may decrease the serum concentration of Warfarin. Telaprevir may increase the serum concentration of Warfarin.¤ (Tenecteplase) Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.¤ (Teriflunomide) Teriflunomide may decrease the serum concentration of Warfarin.¤ (Tiaprofenic acid) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Ticagrelor) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Ticlopidine) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Tigecycline) Tigecycline may increase the serum concentration of Warfarin.¤ (Tinzaparin) May enhance the anticoagulant effect of other Anticoagulants.¤ (Tipranavir) Tipranavir may enhance the anticoagulant effect of Anticoagulants.¤ (Tirofiban) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Tolmetin) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Tolterodine) Tolterodine may enhance the anticoagulant effect of Warfarin.¤ (Torasemide) Torsemide may increase the serum concentration of Warfarin.¤ (Tositumomab) May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically~ the risk of bleeding-related adverse effects may be increased.¤ (Treprostinil) Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically~ the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.¤ (Vemurafenib) Vemurafenib may increase the serum concentration of Warfarin.¤ (Venlafaxine) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Vilazodone) Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.¤ (Vitamin E) Vitamin E may enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.¤ (Vorapaxar) Vorapaxar may enhance the adverse/toxic effect of Anticoagulants. More specifically~ this combination is expected to increase the risk of bleeding.¤ (Zileuton) Zileuton may increase the serum concentration of Warfarin.', 'yes', '¤ Avoid alcohol.\n¤ Avoid drastic changes in dietary habit.\n¤ Avoid St. John\'s Wort.\n¤ Consult your doctor before ingesting large amounts of dietary Vitamin K (e.g. from green leafy vegetables).\n¤ Limit garlic, ginger, gingko, and horse chestnut.', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(207, 'xylometazoline ', ' C ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(208, 'Zelodronic acid ', ' D ', '', '', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL),
(209, 'Zidovudine ', ' C ', '¤ (Aciclovir) Acyclovir-Valacyclovir may enhance the CNS depressant effect of Zidovudine.¤ (Atazanavir) Protease Inhibitors may decrease the serum concentration of Zidovudine.¤ (Batimastat) May decrease the serum concentration of Zidovudine.¤ (Clarithromycin) May enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine.¤ (Clozapine) Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.¤ (Darunavir) Protease Inhibitors may decrease the serum concentration of Zidovudine.¤ (Fluconazole) Fluconazole may decrease the metabolism of Zidovudine.¤ (Fosamprenavir) Protease Inhibitors may decrease the serum concentration of Zidovudine.¤ (Indinavir) Protease Inhibitors may decrease the serum concentration of Zidovudine.¤ (Interferon alfa-n3) Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.¤ (Interferon alfacon-1) Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.¤ (Interferon beta-1a) Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.¤ (Interferon beta-1b) Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.¤ (Interferon gamma-1b) Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.¤ (Isoflurophate) May decrease the serum concentration of Zidovudine.¤ (Lopinavir) Protease Inhibitors may decrease the serum concentration of Zidovudine.¤ (Methadone) Methadone may increase the serum concentration of Zidovudine.¤ (Nelfinavir) Protease Inhibitors may decrease the serum concentration of Zidovudine.¤ (Peginterferon alfa-2a) Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.¤ (Peginterferon alfa-2b) Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.¤ (Probenecid) May decrease the metabolism of Zidovudine.¤ (Raltegravir) May enhance the myopathic (rhabdomyolysis) effect of Zidovudine.¤ (Ribavirin) Zidovudine may enhance the adverse/toxic effect of Ribavirin. Specifically~ the risk/severity of anemia may be increased.¤ (Rifampicin) Rifamycin Derivatives may decrease the serum concentration of Zidovudine.¤ (Rifapentine) Rifamycin Derivatives may decrease the serum concentration of Zidovudine.¤ (Ritonavir) Protease Inhibitors may decrease the serum concentration of Zidovudine.¤ (Saquinavir) Protease Inhibitors may decrease the serum concentration of Zidovudine.¤ (Simeprevir) May decrease the serum concentration of Zidovudine.¤ (Stavudine) Zidovudine may diminish the therapeutic effect of Stavudine.¤ (Teriflunomide) May increase the serum concentration of OAT3 Substrates.¤ (Tipranavir) Protease Inhibitors may decrease the serum concentration of Zidovudine.¤ (Valproic Acid) Valproic Acid and Derivatives may decrease the metabolism of Zidovudine.', 'yes', '', 0, '0.00', '0.00', '0.00', '0.00', '0.00', '1111', NULL, NULL, '', 0, 0, 0, NULL, NULL, NULL, NULL, NULL, '0.00', '0.00', NULL, NULL, NULL, 'false', 0, 1, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `item_barcodes`
--

DROP TABLE IF EXISTS `item_barcodes`;
CREATE TABLE IF NOT EXISTS `item_barcodes` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `color` varchar(50) NOT NULL DEFAULT '0',
  `size` varchar(50) NOT NULL DEFAULT '0',
  `active` tinyint(4) NOT NULL DEFAULT '0',
  `item` int(11) NOT NULL,
  `barcode` varchar(150) NOT NULL,
  `is_main` int(4) NOT NULL,
  `current_qty` decimal(10,2) NOT NULL DEFAULT '0.00',
  `expire_date` date DEFAULT NULL,
  `location` int(5) NOT NULL DEFAULT '1',
  `available` varchar(10) NOT NULL DEFAULT 'true',
  `package_id` int(11) NOT NULL DEFAULT '1',
  `shop` decimal(10,2) NOT NULL DEFAULT '0.00',
  `store` decimal(10,2) NOT NULL DEFAULT '0.00',
  `unit_cost` decimal(10,2) NOT NULL DEFAULT '0.00',
  `unit_price` decimal(10,2) NOT NULL DEFAULT '0.00',
  `package` varchar(100) DEFAULT NULL,
  `other_attrib` varchar(150) DEFAULT NULL,
  `min_qty` decimal(10,2) NOT NULL DEFAULT '0.00',
  `dosage` varchar(50) DEFAULT NULL,
  `route` varchar(50) DEFAULT NULL,
  `uom` varchar(50) DEFAULT NULL,
  `uod` varchar(50) DEFAULT NULL,
  `min_qty_var` decimal(10,2) NOT NULL DEFAULT '0.00',
  `current_qty_var` decimal(10,2) NOT NULL DEFAULT '0.00',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=306 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `item_barcodes`
--

INSERT INTO `item_barcodes` (`id`, `color`, `size`, `active`, `item`, `barcode`, `is_main`, `current_qty`, `expire_date`, `location`, `available`, `package_id`, `shop`, `store`, `unit_cost`, `unit_price`, `package`, `other_attrib`, `min_qty`, `dosage`, `route`, `uom`, `uod`, `min_qty_var`, `current_qty_var`) VALUES
(283, 'Blackqq', 'Big', 1, 1, '1110018559', 1, '400.00', NULL, 1, 'true', 1, '20.00', '348.00', '13.50', '20.00', NULL, 'other', '50.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(284, 'Red', 'Medium', 1, 559, '1110018559', 1, '128.00', NULL, 1, 'true', 1, '38.00', '90.00', '17.22', '22.00', NULL, NULL, '25.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(285, 'Blue', 'Big', 1, 563, '1020563', 1, '-41.00', NULL, 1, 'true', 1, '-56.00', '15.00', '12.00', '13.00', NULL, 'test', '15.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(286, 'Red', 'Big', 0, 563, '111111', 1, '0.00', NULL, 1, 'true', 1, '15.00', '15.00', '13.00', '15.00', NULL, 'test', '10.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(287, 'Red', 'Medium', 1, 561, '1110018561', 1, '10.00', NULL, 1, 'true', 1, '-5.00', '15.00', '10.00', '15.00', NULL, 'test update', '15.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(288, 'Black', 'Big', 1, 567, '1110020567', 1, '681.00', NULL, 1, 'true', 1, '281.00', '400.00', '100.00', '200.00', NULL, '100', '500.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(289, 'Red', 'Medium', 0, 567, '1110020567', 1, '0.00', NULL, 1, 'true', 1, '851.00', '411.00', '321.00', '251.00', NULL, '45555', '651.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(290, 'Blue', 'Small', 1, 567, '1110020567', 1, '502.00', NULL, 1, 'true', 1, '330.00', '172.00', '178.97', '300.00', NULL, '700', '100.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(291, 'Blue', 'Medium', 1, 568, '1110018568', 1, '249.00', NULL, 1, 'true', 1, '69.00', '180.00', '40.00', '30.00', NULL, '14', '50.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(292, 'Black', 'Small', 1, 570, '111018-570-292', 1, '3.00', NULL, 1, 'true', 1, '-5.00', '8.00', '15.00', '10.00', NULL, 'italy', '7.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(293, 'Blue', 'Big', 1, 570, '111018-570-293', 1, '45.00', NULL, 1, 'true', 1, '18.00', '27.00', '20.00', '30.00', NULL, 'japan', '5.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(294, 'Red', 'Medium', 1, 571, '1019-571-294', 1, '57.00', NULL, 1, 'true', 1, '-7.00', '34.00', '11.23', '20.00', NULL, 'Men', '10.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(295, 'Red', 'Medium', 1, 571, '1019-571-295', 1, '154.00', NULL, 1, 'true', 1, '80.00', '74.00', '43.38', '30.00', NULL, 'Women', '20.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(296, 'Black', 'Small', 1, 572, '1018-572-296', 1, '0.00', NULL, 1, 'true', 1, '130.00', '150.00', '100.00', '120.00', NULL, 'hh', '20.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(297, 'Blue', 'Big', 1, 572, '1018-572-297', 1, '180.00', NULL, 1, 'true', 1, '83.00', '97.00', '48.33', '60.00', NULL, 'nn', '15.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(298, 'Blue', 'Big', 1, 573, '1018-573-298', 1, '44.00', NULL, 1, 'true', 1, '23.00', '21.00', '12.89', '15.00', NULL, '20', '10.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(299, 'Black', 'Big', 1, 574, '1012-15-01', 1, '160.00', NULL, 1, 'true', 1, '73.00', '87.00', '10.32', '20.00', NULL, NULL, '20.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(300, 'Black', 'Small', 1, 579, '1018-579-300', 1, '189.00', NULL, 1, 'true', 1, '69.00', '120.00', '60.70', '150.00', NULL, 'ccc', '40.00', NULL, NULL, NULL, '', '0.00', '0.00'),
(303, '', '', 0, 1, '1011-1-303', 1, '0.00', NULL, 1, 'true', 1, '140.00', '140.00', '10.00', '10.00', NULL, '', '100.00', NULL, NULL, NULL, NULL, '0.00', '0.00'),
(304, '', '', 0, 1, '1011-1-304', 1, '0.00', NULL, 1, 'true', 1, '19.00', '19.00', '15.00', '15.00', NULL, '', '20.00', NULL, NULL, NULL, NULL, '0.00', '0.00'),
(305, '', '', 0, 1, '1011-1-305', 1, '0.00', NULL, 1, 'true', 1, '80.00', '80.00', '60.00', '60.00', NULL, '', '90.00', '40', 'Wrap', 'mg', 'Box', '90.00', '80.00');

-- --------------------------------------------------------

--
-- Table structure for table `item_categories`
--

DROP TABLE IF EXISTS `item_categories`;
CREATE TABLE IF NOT EXISTS `item_categories` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `category_name` varchar(250) NOT NULL,
  `itemCategory_code` varchar(30) DEFAULT NULL,
  `parent_category` int(6) DEFAULT NULL,
  `main_category` varchar(150) DEFAULT NULL,
  `description` varchar(150) NOT NULL,
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=20 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `item_categories`
--

INSERT INTO `item_categories` (`id`, `category_name`, `itemCategory_code`, `parent_category`, `main_category`, `description`, `updated_at`, `created_at`) VALUES
(0, 'Uncategorized', '0', NULL, NULL, 'de', NULL, NULL),
(18, 'Food staff', NULL, NULL, NULL, 'Edible', NULL, NULL),
(19, 'Category 1333585', 'code12333385555', NULL, NULL, 'description3333855555555', '2019-05-01', '2019-04-21');

-- --------------------------------------------------------

--
-- Table structure for table `item_list`
--

DROP TABLE IF EXISTS `item_list`;
CREATE TABLE IF NOT EXISTS `item_list` (
  `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT,
  `product_name` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `product_code` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `min_amount` decimal(10,2) NOT NULL,
  `cost` decimal(10,2) NOT NULL,
  `selling_price` decimal(10,2) NOT NULL,
  `image` varchar(150) COLLATE utf8mb4_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `item_package`
--

DROP TABLE IF EXISTS `item_package`;
CREATE TABLE IF NOT EXISTS `item_package` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `item` int(11) DEFAULT '0',
  `package_name` varchar(50) DEFAULT '0',
  `purchase_date` date NOT NULL DEFAULT '2020-01-01',
  `description` varchar(250) DEFAULT NULL,
  `expire_date` date DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT CURRENT_TIMESTAMP,
  `updated_at` timestamp NULL DEFAULT CURRENT_TIMESTAMP,
  `variant` int(11) DEFAULT '0',
  `qty_total` decimal(10,2) DEFAULT '0.00',
  `qty_shop` decimal(10,2) DEFAULT '0.00',
  `qty_store` decimal(10,2) DEFAULT '0.00',
  `barcode` varchar(50) DEFAULT NULL,
  `unit_cost` decimal(10,2) NOT NULL DEFAULT '0.00',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=91 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `item_package`
--

INSERT INTO `item_package` (`id`, `item`, `package_name`, `purchase_date`, `description`, `expire_date`, `created_at`, `updated_at`, `variant`, `qty_total`, `qty_shop`, `qty_store`, `barcode`, `unit_cost`) VALUES
(81, 1, 'qruey', '2020-01-01', NULL, '2020-05-28', '2020-05-28 20:15:30', '2020-05-28 20:15:30', 317, '10.00', '7.00', '3.00', '0101811400823-317-81', '20.00'),
(82, 4, 'qruey', '2020-01-01', NULL, '2020-05-28', '2020-05-29 04:26:22', '2020-05-29 04:26:22', 0, '10.00', '7.00', '3.00', NULL, '20.00'),
(83, 1, 'qruey', '2020-01-01', NULL, '2020-05-28', '2020-05-29 07:30:16', '2020-05-29 07:30:16', 318, '10.00', '7.00', '3.00', '0101811400823-318-83', '20.00'),
(84, 1, 'qruey', '2020-01-01', NULL, '2020-05-28', '2020-05-29 07:31:01', '2020-05-29 07:31:01', 318, '10.00', '7.00', '3.00', '0101811400823-318-84', '40.00'),
(85, 1, 'qruey', '2020-01-01', NULL, '2020-05-28', '2020-05-29 07:34:51', '2020-05-29 07:34:51', 317, '10.00', '7.00', '3.00', '0101811400823-317-85', '40.00'),
(86, 1, 'qruey', '2020-01-01', NULL, '2020-05-28', '2020-05-29 07:39:54', '2020-05-29 07:39:54', 317, '10.00', '7.00', '3.00', '0101811400823-317-86', '40.00'),
(87, 1, 'qruey', '2020-01-01', NULL, '2020-05-28', '2020-05-29 07:44:37', '2020-05-29 07:44:37', 317, '10.00', '7.00', '3.00', '0101811400823-317-87', '40.00'),
(88, 1, 'qruey', '2020-01-01', NULL, '2020-05-28', '2020-05-29 07:47:58', '2020-05-29 07:47:58', 317, '10.00', '7.00', '3.00', '0101811400823-317-88', '40.00'),
(89, 1, 'qruey', '2020-01-01', NULL, '2020-05-28', '2020-05-29 07:49:33', '2020-05-29 07:49:33', 318, '10.00', '7.00', '3.00', '0101811400823-318-89', '40.00'),
(90, 1, 'jj', '2020-01-01', NULL, '2020-05-29', '2020-05-29 14:45:36', '2020-05-29 14:45:36', 317, '20.00', '12.00', '8.00', '0101811400823-317-90', '20.00');

-- --------------------------------------------------------

--
-- Table structure for table `item_package_transactions`
--

DROP TABLE IF EXISTS `item_package_transactions`;
CREATE TABLE IF NOT EXISTS `item_package_transactions` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `item` int(11) NOT NULL DEFAULT '0',
  `package_id` int(11) NOT NULL DEFAULT '0',
  `transaction_type` varchar(250) NOT NULL DEFAULT '0',
  `created_at` datetime NOT NULL DEFAULT CURRENT_TIMESTAMP,
  `updated_at` datetime NOT NULL DEFAULT CURRENT_TIMESTAMP,
  `variant` int(11) NOT NULL DEFAULT '0',
  `amount_change` decimal(10,2) NOT NULL DEFAULT '0.00',
  `qty_shop` decimal(10,2) NOT NULL DEFAULT '0.00',
  `qty_store` decimal(10,2) NOT NULL DEFAULT '0.00',
  `qty_total` decimal(10,2) NOT NULL DEFAULT '0.00',
  `balance` decimal(10,2) NOT NULL DEFAULT '0.00',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=85 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `item_package_transactions`
--

INSERT INTO `item_package_transactions` (`id`, `item`, `package_id`, `transaction_type`, `created_at`, `updated_at`, `variant`, `amount_change`, `qty_shop`, `qty_store`, `qty_total`, `balance`) VALUES
(69, 1, 75, 'Purchase', '2020-05-24 19:57:11', '2020-05-24 19:57:11', 0, '10.00', '4.00', '6.00', '10.00', '10.00'),
(70, 1, 76, 'Purchase', '2020-05-24 19:58:13', '2020-05-24 19:58:13', 0, '10.00', '4.00', '6.00', '10.00', '10.00'),
(71, 1, 77, 'Purchase', '2020-05-24 20:02:18', '2020-05-24 20:02:18', 0, '10.00', '4.00', '6.00', '10.00', '10.00'),
(72, 1, 78, 'Purchase', '2020-05-24 20:27:47', '2020-05-24 20:27:47', 0, '10.00', '4.00', '6.00', '10.00', '10.00'),
(73, 1, 79, 'Purchase', '2020-05-24 20:57:25', '2020-05-24 20:57:25', 0, '20.00', '14.00', '6.00', '20.00', '20.00'),
(74, 1, 80, 'Purchase', '2020-05-28 23:13:26', '2020-05-28 23:13:26', 0, '10.00', '7.00', '3.00', '10.00', '10.00'),
(75, 1, 81, 'Purchase', '2020-05-28 23:15:30', '2020-05-28 23:15:30', 0, '10.00', '7.00', '3.00', '10.00', '10.00'),
(76, 4, 82, 'Purchase', '2020-05-29 07:26:22', '2020-05-29 07:26:22', 0, '10.00', '7.00', '3.00', '10.00', '10.00'),
(77, 1, 83, 'Purchase', '2020-05-29 10:30:16', '2020-05-29 10:30:16', 318, '10.00', '7.00', '3.00', '10.00', '10.00'),
(78, 1, 84, 'Purchase', '2020-05-29 10:31:01', '2020-05-29 10:31:01', 318, '10.00', '7.00', '3.00', '10.00', '10.00'),
(79, 1, 85, 'Purchase', '2020-05-29 10:34:51', '2020-05-29 10:34:51', 317, '10.00', '7.00', '3.00', '10.00', '10.00'),
(80, 1, 86, 'Purchase', '2020-05-29 10:39:54', '2020-05-29 10:39:54', 317, '10.00', '7.00', '3.00', '10.00', '10.00'),
(81, 1, 87, 'Purchase', '2020-05-29 10:44:37', '2020-05-29 10:44:37', 317, '10.00', '7.00', '3.00', '10.00', '10.00'),
(82, 1, 88, 'Purchase', '2020-05-29 10:47:58', '2020-05-29 10:47:58', 317, '10.00', '7.00', '3.00', '10.00', '10.00'),
(83, 1, 89, 'Purchase', '2020-05-29 10:49:33', '2020-05-29 10:49:33', 318, '10.00', '7.00', '3.00', '10.00', '10.00'),
(84, 1, 90, 'Purchase', '2020-05-29 17:45:36', '2020-05-29 17:45:36', 317, '20.00', '10.00', '10.00', '20.00', '20.00');

-- --------------------------------------------------------

--
-- Table structure for table `item_variants`
--

DROP TABLE IF EXISTS `item_variants`;
CREATE TABLE IF NOT EXISTS `item_variants` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `color` varchar(50) NOT NULL DEFAULT '0',
  `size` varchar(50) NOT NULL DEFAULT '0',
  `active` tinyint(4) NOT NULL DEFAULT '1',
  `item` int(11) NOT NULL,
  `barcode` varchar(150) DEFAULT NULL,
  `is_main` int(4) NOT NULL DEFAULT '1',
  `current_qty` decimal(10,2) NOT NULL DEFAULT '0.00',
  `available` varchar(10) NOT NULL DEFAULT 'true',
  `shop` decimal(10,2) NOT NULL DEFAULT '0.00',
  `store` decimal(10,2) NOT NULL DEFAULT '0.00',
  `unit_cost` decimal(10,2) NOT NULL DEFAULT '0.00',
  `unit_price` decimal(10,2) NOT NULL DEFAULT '0.00',
  `other_attrib` varchar(150) DEFAULT NULL,
  `min_qty` decimal(10,2) NOT NULL DEFAULT '0.00',
  `dosage` varchar(50) DEFAULT NULL,
  `route` varchar(50) DEFAULT NULL,
  `uom` varchar(50) DEFAULT NULL,
  `uod` varchar(50) DEFAULT NULL,
  `min_qty_var` decimal(10,2) NOT NULL DEFAULT '0.00',
  `current_qty_var` decimal(10,2) NOT NULL DEFAULT '0.00',
  `location` int(10) NOT NULL DEFAULT '1',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=320 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `item_variants`
--

INSERT INTO `item_variants` (`id`, `color`, `size`, `active`, `item`, `barcode`, `is_main`, `current_qty`, `available`, `shop`, `store`, `unit_cost`, `unit_price`, `other_attrib`, `min_qty`, `dosage`, `route`, `uom`, `uod`, `min_qty_var`, `current_qty_var`, `location`) VALUES
(317, '', '', 1, 1, '1011-1-317', 1, '382.00', 'true', '180.00', '202.00', '15.38', '20.00', '', '20.00', '100', 'Tablet', 'mg', 'box', '20.00', '150.00', 1),
(318, '', '', 1, 1, '1011-1-318', 1, '30.00', 'true', '21.00', '9.00', '23.33', '30.00', '', '50.00', '50', 'Syrup', 'ml', 'Bottle', '50.00', '40.00', 1),
(319, '', '', 1, 1, '1011-1-319', 1, '0.00', 'true', '50.00', '50.00', '30.00', '40.00', '', '60.00', '80', 'Injectable', 'mg', 'Strip', '60.00', '50.00', 1);

-- --------------------------------------------------------

--
-- Table structure for table `item_varieties`
--

DROP TABLE IF EXISTS `item_varieties`;
CREATE TABLE IF NOT EXISTS `item_varieties` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `name` varchar(150) NOT NULL DEFAULT '0',
  `item` int(11) NOT NULL DEFAULT '0',
  `attribute1` varchar(150) NOT NULL DEFAULT '0',
  `attribute2` varchar(150) NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=3 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `item_varieties`
--

INSERT INTO `item_varieties` (`id`, `name`, `item`, `attribute1`, `attribute2`) VALUES
(1, 'wonderful', 1, 'red', 'big'),
(2, 'cool', 1, 'green', 'small');

-- --------------------------------------------------------

--
-- Table structure for table `journal`
--

DROP TABLE IF EXISTS `journal`;
CREATE TABLE IF NOT EXISTS `journal` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `partner` int(11) DEFAULT NULL,
  `date` date NOT NULL,
  `total_debit` decimal(10,2) NOT NULL DEFAULT '0.00',
  `total_credit` decimal(10,2) NOT NULL DEFAULT '0.00',
  `ref` varchar(100) NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `journals`
--

DROP TABLE IF EXISTS `journals`;
CREATE TABLE IF NOT EXISTS `journals` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `partner` int(11) DEFAULT NULL,
  `date` date NOT NULL,
  `amount` decimal(10,2) NOT NULL DEFAULT '0.00',
  `ref` varchar(100) DEFAULT NULL,
  `ref_id` int(11) NOT NULL,
  `activity` varchar(30) DEFAULT NULL,
  `status` varchar(10) NOT NULL DEFAULT 'active',
  `updated_at` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP,
  `created_at` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=173 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `journals`
--

INSERT INTO `journals` (`id`, `partner`, `date`, `amount`, `ref`, `ref_id`, `activity`, `status`, `updated_at`, `created_at`) VALUES
(162, 8, '2019-04-20', '0.00', 'jkldsjfkls89080', 0, NULL, 'active', '2019-04-20 12:00:31', '2019-04-20 12:00:30'),
(163, 8, '2019-04-20', '0.00', 'jskdlf', 0, NULL, 'active', '2019-04-20 12:08:21', '2019-04-20 12:08:21'),
(166, 1, '2019-04-26', '80.00', '', 710, NULL, 'active', '2019-04-26 08:23:28', '2019-04-26 08:23:28'),
(167, 1, '2019-04-26', '50.00', '', 711, NULL, 'active', '2019-04-26 08:26:48', '2019-04-26 08:26:48'),
(168, 1, '2019-04-26', '40.00', '', 712, NULL, 'active', '2019-04-26 08:28:19', '2019-04-26 08:28:19'),
(169, 1, '2019-04-26', '250.00', '', 713, NULL, 'active', '2019-04-26 08:39:18', '2019-04-26 08:39:18'),
(171, 1, '2019-04-26', '195.00', '', 715, 'Sale', 'active', '2019-04-26 08:54:24', '2019-04-26 08:54:24'),
(172, 1, '2019-04-26', '560.00', '', 716, 'Sale', 'void', '2019-04-26 13:06:49', '2019-04-26 08:54:40');

-- --------------------------------------------------------

--
-- Table structure for table `journal_items`
--

DROP TABLE IF EXISTS `journal_items`;
CREATE TABLE IF NOT EXISTS `journal_items` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `journal_id` int(11) NOT NULL,
  `date` date NOT NULL,
  `account_id` int(11) NOT NULL,
  `total_debit` decimal(10,2) NOT NULL DEFAULT '0.00',
  `total_credit` decimal(10,2) NOT NULL DEFAULT '0.00',
  `ref_id` int(20) DEFAULT NULL,
  `activity` varchar(30) DEFAULT NULL,
  `status` varchar(40) NOT NULL DEFAULT 'active',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=211 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `journal_items`
--

INSERT INTO `journal_items` (`id`, `journal_id`, `date`, `account_id`, `total_debit`, `total_credit`, `ref_id`, `activity`, `status`) VALUES
(196, 162, '2019-04-20', 0, '600.00', '0.00', NULL, NULL, 'active'),
(197, 162, '2019-04-20', 0, '0.00', '600.00', NULL, NULL, 'active'),
(198, 163, '2019-04-20', 0, '600.00', '0.00', NULL, NULL, 'active'),
(199, 163, '2019-04-20', 0, '0.00', '600.00', NULL, NULL, 'active'),
(200, 166, '2019-04-26', 0, '0.00', '80.00', NULL, NULL, 'active'),
(201, 167, '2019-04-26', 0, '0.00', '50.00', NULL, NULL, 'active'),
(202, 167, '2019-04-26', 1, '0.00', '50.00', NULL, NULL, 'active'),
(203, 168, '2019-04-26', 0, '0.00', '40.00', NULL, NULL, 'active'),
(204, 168, '2019-04-26', 1, '40.00', '0.00', NULL, NULL, 'active'),
(205, 169, '2019-04-26', 2, '0.00', '250.00', NULL, NULL, 'active'),
(206, 169, '2019-04-26', 1, '250.00', '0.00', NULL, NULL, 'active'),
(207, 171, '2019-04-26', 2, '0.00', '195.00', 715, NULL, 'active'),
(208, 171, '2019-04-26', 1, '195.00', '0.00', 715, NULL, 'active'),
(209, 172, '2019-04-26', 2, '0.00', '560.00', 716, NULL, 'active'),
(210, 172, '2019-04-26', 1, '560.00', '0.00', 716, 'Sale', 'void');

-- --------------------------------------------------------

--
-- Table structure for table `locations`
--

DROP TABLE IF EXISTS `locations`;
CREATE TABLE IF NOT EXISTS `locations` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `location_name` varchar(150) NOT NULL,
  `address` varchar(150) DEFAULT NULL,
  `description` varchar(150) DEFAULT NULL,
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=3 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `locations`
--

INSERT INTO `locations` (`id`, `location_name`, `address`, `description`, `updated_at`, `created_at`) VALUES
(1, 'shop', 'Asmara', '1', '2019-04-22', NULL),
(2, 'store', NULL, NULL, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `migrations`
--

DROP TABLE IF EXISTS `migrations`;
CREATE TABLE IF NOT EXISTS `migrations` (
  `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT,
  `migration` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `batch` int(11) NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `password_resets`
--

DROP TABLE IF EXISTS `password_resets`;
CREATE TABLE IF NOT EXISTS `password_resets` (
  `email` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `token` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  KEY `password_resets_email_index` (`email`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `patient_diagnosis`
--

DROP TABLE IF EXISTS `patient_diagnosis`;
CREATE TABLE IF NOT EXISTS `patient_diagnosis` (
  `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT,
  `customer` int(10) UNSIGNED DEFAULT NULL,
  `diagnosis` varchar(50) DEFAULT NULL,
  `date` date DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  `description` varchar(150) DEFAULT NULL,
  `status` varchar(45) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=21 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `patient_diagnosis`
--

INSERT INTO `patient_diagnosis` (`id`, `customer`, `diagnosis`, `date`, `created_at`, `updated_at`, `description`, `status`) VALUES
(1, 24, 'tb', '2019-05-27', NULL, NULL, 'TB', 'Bad'),
(2, 24, 'tb', '2019-05-27', NULL, NULL, 'TB', 'Bad'),
(3, 24, 'tb', '2019-05-27', NULL, NULL, 'TB', 'Bad'),
(4, 24, 'hib', '2019-05-27', NULL, NULL, 'stds', 'death'),
(5, 24, 'psycic', '2019-05-24', NULL, NULL, 'nerud', 'death'),
(6, 24, 'hiv', '2019-05-30', NULL, NULL, 'has not started medication', 'beginning'),
(7, 24, 'normal', '2019-05-29', NULL, NULL, 'normal', 'normal'),
(8, 24, 'simon', '2019-05-24', NULL, NULL, 'simon', 'simon'),
(9, 24, 'HIV', '2019-05-17', NULL, NULL, 'Will die young', 'top two month'),
(10, 25, 'ok', '2019-05-17', NULL, NULL, 'ok', 'ok'),
(11, 25, 'ok', '2019-05-17', NULL, NULL, 'ok', 'ok'),
(12, 25, 'test', '2019-05-18', NULL, NULL, 'test', 'test'),
(13, 26, 'simon', '2019-05-28', NULL, NULL, 'simon', 'simon'),
(14, 26, 'merhawi', '2019-05-30', NULL, NULL, 'merhawi', 'MAERHAWI'),
(17, 28, 'test', '2019-06-24', NULL, NULL, 'test', 'test'),
(18, 24, 'Diabetis', '2020-02-25', NULL, NULL, 'Diabetes type A', 'Active'),
(19, 18, 'sjdfkl', '2020-02-25', NULL, NULL, 'jklsdjfl', 'jklsdfjl'),
(20, 26, 'diabetic', '2020-02-25', NULL, NULL, 'dessss', 'cured');

-- --------------------------------------------------------

--
-- Table structure for table `payments`
--

DROP TABLE IF EXISTS `payments`;
CREATE TABLE IF NOT EXISTS `payments` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `customer` int(11) NOT NULL,
  `sales_id` int(11) NOT NULL DEFAULT '0',
  `date` date DEFAULT NULL,
  `amount` decimal(10,2) NOT NULL,
  `ref` varchar(50) DEFAULT NULL,
  `type` varchar(10) NOT NULL DEFAULT 'in',
  `activity` varchar(100) DEFAULT NULL,
  `status` varchar(20) NOT NULL DEFAULT 'active',
  `updated_at` date NOT NULL,
  `created_at` date NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=622 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `payments`
--

INSERT INTO `payments` (`id`, `customer`, `sales_id`, `date`, `amount`, `ref`, `type`, `activity`, `status`, `updated_at`, `created_at`) VALUES
(459, 18, 648, '2019-01-02', '70.00', NULL, 'in', 'Sale', 'void', '2019-04-20', '2019-04-20'),
(460, 18, 649, '2019-01-02', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-20', '2019-04-20'),
(461, 18, 650, '2019-01-02', '80.00', NULL, 'in', 'Sale', 'active', '2019-04-20', '2019-04-20'),
(462, 18, 652, '2019-01-02', '200.00', NULL, 'in', 'Sale', 'active', '2019-04-20', '2019-04-20'),
(463, 18, 0, '2019-04-20', '20.00', NULL, 'in', NULL, 'active', '2019-04-20', '2019-04-20'),
(464, 18, 0, '2019-04-19', '10.00', NULL, 'in', NULL, 'active', '2019-04-20', '2019-04-20'),
(465, 1, 0, '2019-04-20', '300.00', NULL, 'out', NULL, 'active', '2019-04-20', '2019-04-20'),
(466, 8, 0, '2019-04-20', '200.00', NULL, 'out', NULL, 'void', '2019-04-21', '2019-04-20'),
(467, 18, 654, '2019-04-20', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-20', '2019-04-20'),
(468, 18, 655, '2019-04-20', '30.00', NULL, 'in', 'Sale', 'active', '2019-04-20', '2019-04-20'),
(469, 18, 656, '2019-04-20', '30.00', NULL, 'in', 'Sale', 'active', '2019-04-20', '2019-04-20'),
(470, 18, 657, '2019-04-20', '120.00', NULL, 'in', 'Sale', 'active', '2019-04-20', '2019-04-20'),
(471, 18, 658, '2019-04-20', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-20', '2019-04-20'),
(472, 18, 0, '2019-04-20', '200.00', NULL, 'in', NULL, 'active', '2019-04-20', '2019-04-20'),
(473, 18, 0, '2019-04-20', '200.00', NULL, 'in', NULL, 'active', '2019-04-20', '2019-04-20'),
(474, 18, 0, '2019-04-20', '200.00', NULL, 'in', NULL, 'active', '2019-04-20', '2019-04-20'),
(475, 18, 0, '2019-04-20', '200.00', NULL, 'in', NULL, 'active', '2019-04-20', '2019-04-20'),
(476, 18, 0, '2019-04-20', '200.00', NULL, 'in', NULL, 'active', '2019-04-20', '2019-04-20'),
(477, 18, 0, '2019-04-20', '200.00', NULL, 'in', NULL, 'active', '2019-04-20', '2019-04-20'),
(478, 18, 0, '2019-04-20', '200.00', NULL, 'in', NULL, 'active', '2019-04-20', '2019-04-20'),
(479, 18, 659, '2019-04-21', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-21', '2019-04-21'),
(480, 18, 660, '2019-04-21', '30.00', NULL, 'in', 'Sale', 'void', '2019-04-21', '2019-04-21'),
(481, 18, 661, '2019-04-21', '30.00', NULL, 'in', 'Sale', 'void', '2019-04-21', '2019-04-21'),
(482, 18, 662, '2019-04-21', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-21', '2019-04-21'),
(483, 18, 663, '2019-05-25', '560.00', NULL, 'in', 'Sale', 'active', '2019-04-21', '2019-04-21'),
(484, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'void', '2019-04-21', '2019-04-21'),
(485, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'void', '2019-04-21', '2019-04-21'),
(486, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'void', '2019-06-01', '2019-04-21'),
(487, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(488, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'void', '2019-04-21', '2019-04-21'),
(489, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'void', '2019-04-21', '2019-04-21'),
(490, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(491, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(492, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(493, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(494, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(495, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(496, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(497, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(498, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(499, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(500, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'void', '2019-04-21', '2019-04-21'),
(501, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(502, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(503, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(504, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(505, 8, 0, '2019-04-22', '500.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(506, 8, 0, '2019-05-24', '1000.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(507, 8, 0, '2019-05-24', '1000.00', NULL, 'out', NULL, 'active', '2019-04-21', '2019-04-21'),
(508, 18, 664, '2019-04-22', '80.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(509, 18, 666, '2019-04-22', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(510, 18, 667, '2019-04-22', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(511, 18, 668, '2019-04-22', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(512, 18, 669, '2019-04-22', '40.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(513, 18, 670, '2019-04-22', '20.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(514, 18, 671, '2019-04-22', '20.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(515, 18, 672, '2019-04-22', '70.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(516, 18, 673, '2019-04-22', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(517, 18, 674, '2019-04-22', '40.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(518, 18, 675, '2019-04-22', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(519, 18, 676, '2019-04-22', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(520, 18, 677, '2019-04-22', '80.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(521, 18, 678, '2019-04-22', '40.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(522, 18, 679, '2019-04-22', '80.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(523, 18, 680, '2019-04-22', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(524, 18, 681, '2019-04-22', '80.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(525, 18, 682, '2019-04-22', '80.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(526, 18, 683, '2019-04-22', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(527, 18, 684, '2019-04-22', '40.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(528, 18, 687, '2019-04-22', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(529, 18, 688, '2019-04-22', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(530, 18, 689, '2019-04-22', '40.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(531, 18, 690, '2019-04-22', '40.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(532, 18, 691, '2019-04-22', '40.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(533, 18, 692, '2019-04-22', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(534, 18, 693, '2019-04-22', '140.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(535, 18, 694, '2019-04-22', '100.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(536, 18, 695, '2019-04-22', '140.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(537, 18, 696, '2019-04-22', '160.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(538, 18, 697, '2019-04-22', '570.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(539, 18, 698, '2019-04-22', '450.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(540, 18, 700, '2019-04-22', '40.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(541, 18, 701, '2019-04-22', '40.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(542, 18, 702, '2019-04-22', '100.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(543, 18, 704, '2019-04-22', '150.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(544, 18, 705, '2019-04-22', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(545, 18, 706, '2019-04-22', '200.00', NULL, 'in', 'Sale', 'active', '2019-04-22', '2019-04-22'),
(546, 18, 0, '2019-04-22', '500.00', NULL, 'in', NULL, 'active', '2019-04-22', '2019-04-22'),
(547, 18, 0, '2019-04-22', '500.00', NULL, 'in', NULL, 'active', '2019-04-22', '2019-04-22'),
(548, 8, 0, NULL, '500.00', NULL, 'out', NULL, 'active', '2019-04-22', '2019-04-22'),
(549, 8, 0, '2019-04-22', '100.00', NULL, 'out', NULL, 'active', '2019-04-22', '2019-04-22'),
(550, 18, 710, '2019-04-26', '80.00', NULL, 'in', 'Sale', 'active', '2019-04-26', '2019-04-26'),
(551, 18, 711, '2019-04-26', '50.00', NULL, 'in', 'Sale', 'active', '2019-04-26', '2019-04-26'),
(552, 18, 712, '2019-04-26', '40.00', NULL, 'in', 'Sale', 'active', '2019-04-26', '2019-04-26'),
(553, 18, 713, '2019-04-26', '250.00', NULL, 'in', 'Sale', 'active', '2019-04-26', '2019-04-26'),
(554, 18, 715, '2019-04-26', '195.00', NULL, 'in', 'Sale', 'active', '2019-04-26', '2019-04-26'),
(555, 18, 716, '2019-04-26', '560.00', NULL, 'in', 'Sale', 'void', '2019-04-26', '2019-04-26'),
(556, 18, 717, '2019-04-26', '100.00', NULL, 'in', 'Sale', 'active', '2019-04-26', '2019-04-26'),
(557, 18, 718, '2019-04-26', '60.00', NULL, 'in', 'Sale', 'active', '2019-04-26', '2019-04-26'),
(558, 18, 722, '2019-05-01', '36.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(559, 18, 723, '2019-05-01', '36.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(560, 18, 724, '2019-05-01', '192.00', NULL, 'in', 'Sale', 'void', '2019-05-01', '2019-05-01'),
(561, 18, 725, '2019-05-01', '120.00', NULL, 'in', 'Sale', 'void', '2019-05-01', '2019-05-01'),
(562, 18, 726, '2019-05-01', '120.00', NULL, 'in', 'Sale', 'void', '2019-05-01', '2019-05-01'),
(563, 18, 727, '2019-05-01', '180.00', NULL, 'in', 'Sale', 'void', '2019-05-01', '2019-05-01'),
(564, 18, 730, '2019-05-02', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(565, 18, 732, '2019-05-15', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(566, 18, 734, '2019-05-15', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(567, 18, 736, '2019-05-15', '36.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(568, 18, 737, '2019-05-15', '36.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(569, 18, 739, '2019-05-01', '36.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(570, 18, 740, '2019-05-01', '36.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(571, 18, 741, '2019-05-01', '36.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(572, 18, 742, '2019-05-01', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(573, 18, 743, '2019-05-01', '72.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(574, 18, 745, '2019-05-01', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(575, 18, 747, '2019-05-01', '36.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(576, 18, 748, '2019-05-01', '36.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(577, 18, 749, '2019-05-01', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(578, 18, 752, '2019-05-01', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(579, 18, 755, '2019-05-01', '54.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(580, 18, 757, '2019-05-01', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(581, 18, 758, '2019-05-01', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(582, 18, 759, '2019-05-01', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(583, 18, 760, '2019-05-01', '54.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(584, 18, 762, '2019-05-01', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(585, 18, 763, '2019-05-01', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(586, 18, 764, '2019-05-01', '36.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(587, 18, 765, '2019-05-01', '36.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(588, 18, 766, '2019-05-01', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(589, 18, 767, '2019-05-01', '114.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(590, 18, 768, '2019-05-01', '130.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(591, 18, 769, '2019-05-01', '18.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(592, 18, 770, '2019-05-01', '60.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(593, 18, 0, NULL, '10.00', NULL, 'in', NULL, 'active', '2019-05-01', '2019-05-01'),
(594, 18, 0, NULL, '10.00', NULL, 'in', NULL, 'active', '2019-05-01', '2019-05-01'),
(595, 18, 0, NULL, '10.00', NULL, 'in', NULL, 'active', '2019-05-01', '2019-05-01'),
(596, 18, 0, NULL, '10.00', NULL, 'in', NULL, 'active', '2019-05-01', '2019-05-01'),
(597, 18, 0, NULL, '10.00', NULL, 'in', NULL, 'active', '2019-05-01', '2019-05-01'),
(598, 18, 0, NULL, '10.00', NULL, 'in', NULL, 'active', '2019-05-01', '2019-05-01'),
(599, 18, 0, NULL, '10.00', NULL, 'in', NULL, 'active', '2019-05-01', '2019-05-01'),
(600, 18, 0, NULL, '10.00', NULL, 'in', NULL, 'active', '2019-05-01', '2019-05-01'),
(601, 18, 0, NULL, '10.00', NULL, 'in', NULL, 'active', '2019-05-01', '2019-05-01'),
(602, 18, 0, NULL, '10.00', NULL, 'in', NULL, 'active', '2019-05-01', '2019-05-01'),
(603, 18, 0, NULL, '10.00', NULL, 'in', NULL, 'active', '2019-05-01', '2019-05-01'),
(604, 18, 772, '2019-05-01', '84.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(605, 18, 773, '2019-05-01', '114.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(606, 18, 774, '2019-05-01', '180.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(607, 18, 775, '2019-05-01', '108.00', NULL, 'in', 'Sale', 'active', '2019-05-01', '2019-05-01'),
(608, 18, 776, '2019-05-02', '280.00', NULL, 'in', 'Sale', 'active', '2019-05-02', '2019-05-02'),
(609, 18, 777, '2019-05-02', '114.00', NULL, 'in', 'Sale', 'active', '2019-05-02', '2019-05-02'),
(610, 18, 0, '2019-05-05', '30.00', NULL, 'in', NULL, 'active', '2019-05-05', '2019-05-05'),
(611, 18, 0, '2019-05-05', '30.00', NULL, 'in', NULL, 'active', '2019-05-05', '2019-05-05'),
(612, 19, 779, '2019-05-05', '120.00', NULL, 'in', 'Sale', 'active', '2019-05-05', '2019-05-05'),
(613, 18, 780, '2019-05-06', '160.00', NULL, 'in', 'Sale', 'active', '2019-05-05', '2019-05-05'),
(614, 18, 0, '2019-05-09', '20.00', NULL, 'in', NULL, 'active', '2019-05-09', '2019-05-09'),
(615, 18, 0, '2019-05-09', '22.00', NULL, 'in', NULL, 'active', '2019-05-09', '2019-05-09'),
(616, 18, 0, '2019-05-09', '22.00', NULL, 'in', NULL, 'active', '2019-05-09', '2019-05-09'),
(617, 18, 0, '2019-05-09', '22.00', NULL, 'in', NULL, 'active', '2019-05-09', '2019-05-09'),
(618, 18, 0, '2019-05-09', '22.00', NULL, 'in', NULL, 'active', '2019-05-09', '2019-05-09'),
(619, 18, 0, '2019-05-10', '10.00', NULL, 'in', NULL, 'active', '2019-05-09', '2019-05-09'),
(620, 18, 0, '2019-05-10', '2.00', NULL, 'in', NULL, 'active', '2019-05-09', '2019-05-09'),
(621, 18, 785, '2019-05-11', '80.00', NULL, 'in', 'Sale', 'active', '2019-05-11', '2019-05-11');

-- --------------------------------------------------------

--
-- Table structure for table `payment_items`
--

DROP TABLE IF EXISTS `payment_items`;
CREATE TABLE IF NOT EXISTS `payment_items` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `payment_id` int(11) NOT NULL,
  `sales_id` int(11) NOT NULL,
  `amount` decimal(10,2) NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=54 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `payment_items`
--

INSERT INTO `payment_items` (`id`, `payment_id`, `sales_id`, `amount`) VALUES
(31, 463, 651, '20.00'),
(32, 464, 651, '10.00'),
(33, 465, 212, '300.00'),
(34, 466, 212, '200.00'),
(35, 593, 651, '10.00'),
(36, 594, 651, '10.00'),
(37, 595, 651, '10.00'),
(38, 596, 651, '10.00'),
(39, 597, 651, '10.00'),
(40, 598, 651, '10.00'),
(41, 599, 651, '10.00'),
(42, 600, 651, '10.00'),
(43, 601, 651, '10.00'),
(44, 602, 651, '10.00'),
(45, 603, 651, '10.00'),
(46, 611, 778, '30.00'),
(47, 614, 778, '20.00'),
(48, 615, 778, '22.00'),
(49, 616, 778, '22.00'),
(50, 617, 778, '22.00'),
(51, 618, 778, '22.00'),
(52, 619, 772, '10.00'),
(53, 620, 772, '2.00');

-- --------------------------------------------------------

--
-- Table structure for table `periods`
--

DROP TABLE IF EXISTS `periods`;
CREATE TABLE IF NOT EXISTS `periods` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `period_name` varchar(150) NOT NULL,
  `start_date` date NOT NULL,
  `end_date` date NOT NULL,
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `period_data`
--

DROP TABLE IF EXISTS `period_data`;
CREATE TABLE IF NOT EXISTS `period_data` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `period_id` int(11) NOT NULL,
  `item` int(11) NOT NULL,
  `beginning_balance` decimal(10,2) NOT NULL DEFAULT '0.00',
  `ending_balance` decimal(10,2) NOT NULL DEFAULT '0.00',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `products`
--

DROP TABLE IF EXISTS `products`;
CREATE TABLE IF NOT EXISTS `products` (
  `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT,
  `product_name` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `product_code` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `min_amount` decimal(10,2) NOT NULL,
  `cost` decimal(10,2) NOT NULL,
  `selling_price` decimal(10,2) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `purchases`
--

DROP TABLE IF EXISTS `purchases`;
CREATE TABLE IF NOT EXISTS `purchases` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `supplier` int(11) NOT NULL,
  `date` date NOT NULL,
  `total_amount` decimal(10,2) NOT NULL,
  `amount_paid` decimal(10,2) NOT NULL DEFAULT '0.00',
  `status` varchar(50) DEFAULT 'unpaid',
  `ref` varchar(50) DEFAULT NULL,
  `user` int(11) NOT NULL DEFAULT '1',
  `payment_mode` varchar(50) DEFAULT '1',
  `payment_status` varchar(100) DEFAULT NULL,
  `updated_at` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP,
  `created_at` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=364 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `purchases`
--

INSERT INTO `purchases` (`id`, `supplier`, `date`, `total_amount`, `amount_paid`, `status`, `ref`, `user`, `payment_mode`, `payment_status`, `updated_at`, `created_at`) VALUES
(352, 8, '2020-05-28', '200.00', '0.00', 'Paid', 'refff78', 6, 'Cash', 'Paid', '2020-05-28 17:15:30', '2020-05-28 17:15:30'),
(353, 8, '2020-05-28', '0.00', '0.00', 'unpaid', 'refff78', 6, 'Cash', NULL, '2020-05-29 01:22:11', '2020-05-29 01:22:11'),
(354, 8, '2020-05-28', '0.00', '0.00', 'unpaid', 'refff78', 6, 'Cash', NULL, '2020-05-29 01:25:56', '2020-05-29 01:25:56'),
(355, 8, '2020-05-28', '200.00', '200.00', 'Paid', 'refff78', 6, 'Cash', 'Paid', '2020-05-29 01:26:22', '2020-05-29 01:26:22'),
(356, 8, '2020-05-28', '200.00', '200.00', 'Paid', 'refff78', 6, 'Cash', 'Paid', '2020-05-29 04:30:17', '2020-05-29 04:30:16'),
(357, 8, '2020-05-28', '400.00', '400.00', 'Paid', 'refff78', 6, 'Cash', 'Paid', '2020-05-29 04:31:01', '2020-05-29 04:31:01'),
(358, 8, '2020-05-28', '400.00', '400.00', 'Paid', 'refff78', 6, 'Cash', 'Paid', '2020-05-29 04:34:51', '2020-05-29 04:34:51'),
(359, 8, '2020-05-28', '400.00', '400.00', 'Paid', 'refff78', 6, 'Cash', 'Paid', '2020-05-29 04:39:55', '2020-05-29 04:39:54'),
(360, 8, '2020-05-28', '400.00', '400.00', 'Paid', 'refff78', 6, 'Cash', 'Paid', '2020-05-29 04:44:38', '2020-05-29 04:44:37'),
(361, 8, '2020-05-28', '400.00', '400.00', 'Paid', 'refff78', 6, 'Cash', 'Paid', '2020-05-29 04:47:58', '2020-05-29 04:47:58'),
(362, 8, '2020-05-28', '400.00', '400.00', 'Paid', 'refff78', 6, 'Cash', 'Paid', '2020-05-29 04:49:33', '2020-05-29 04:49:32'),
(363, 8, '2020-05-28', '400.00', '400.00', 'Paid', 'yuuu', 6, 'Cash', 'Paid', '2020-05-29 11:45:37', '2020-05-29 11:45:36');

-- --------------------------------------------------------

--
-- Table structure for table `purchases_items_barcode`
--

DROP TABLE IF EXISTS `purchases_items_barcode`;
CREATE TABLE IF NOT EXISTS `purchases_items_barcode` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `item` int(11) NOT NULL,
  `purchase_id` int(11) NOT NULL,
  `purchases_items_barcode_id` int(11) NOT NULL,
  `qty` decimal(10,2) NOT NULL DEFAULT '0.00',
  `location` int(11) DEFAULT NULL,
  `shop` decimal(10,2) NOT NULL DEFAULT '0.00',
  `store` decimal(10,2) NOT NULL DEFAULT '0.00',
  `supplier` int(11) DEFAULT NULL,
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=109 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `purchases_items_barcode`
--

INSERT INTO `purchases_items_barcode` (`id`, `item`, `purchase_id`, `purchases_items_barcode_id`, `qty`, `location`, `shop`, `store`, `supplier`, `updated_at`, `created_at`) VALUES
(100, 1, 352, 317, '0.00', NULL, '7.00', '3.00', NULL, NULL, NULL),
(101, 1, 356, 318, '0.00', NULL, '7.00', '3.00', NULL, NULL, NULL),
(102, 1, 357, 318, '0.00', NULL, '7.00', '3.00', NULL, NULL, NULL),
(103, 1, 358, 317, '0.00', NULL, '7.00', '3.00', NULL, NULL, NULL),
(104, 1, 359, 317, '0.00', NULL, '7.00', '3.00', NULL, NULL, NULL),
(105, 1, 360, 317, '0.00', NULL, '7.00', '3.00', NULL, NULL, NULL),
(106, 1, 361, 317, '0.00', NULL, '7.00', '3.00', NULL, NULL, NULL),
(107, 1, 362, 318, '0.00', NULL, '7.00', '3.00', NULL, NULL, NULL),
(108, 1, 363, 317, '0.00', NULL, '10.00', '10.00', NULL, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `purchase_items`
--

DROP TABLE IF EXISTS `purchase_items`;
CREATE TABLE IF NOT EXISTS `purchase_items` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `item` int(11) NOT NULL,
  `purchase_id` int(11) NOT NULL,
  `qty` int(11) NOT NULL,
  `unit_price` decimal(10,2) NOT NULL,
  `tax` decimal(10,2) NOT NULL DEFAULT '0.00',
  `expire_date` date DEFAULT NULL,
  `barcode` varchar(150) DEFAULT NULL,
  `shop` decimal(10,2) NOT NULL DEFAULT '0.00',
  `variant` int(11) NOT NULL DEFAULT '0',
  `store` decimal(10,2) NOT NULL DEFAULT '0.00',
  `status` varchar(20) NOT NULL DEFAULT 'active',
  `updated_at` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP,
  `created_at` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP,
  `sub_total` decimal(10,2) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=333 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `purchase_items`
--

INSERT INTO `purchase_items` (`id`, `item`, `purchase_id`, `qty`, `unit_price`, `tax`, `expire_date`, `barcode`, `shop`, `variant`, `store`, `status`, `updated_at`, `created_at`, `sub_total`) VALUES
(321, 1, 352, 10, '20.00', '0.00', NULL, NULL, '7.00', 317, '3.00', 'active', '2020-05-28 17:15:30', '2020-05-28 17:15:30', '200.00'),
(322, 4, 353, 10, '20.00', '0.00', '2020-05-28', NULL, '7.00', 0, '3.00', 'active', '2020-05-29 01:22:11', '2020-05-29 01:22:11', '200.00'),
(323, 4, 354, 10, '20.00', '0.00', '2020-05-28', NULL, '7.00', 0, '3.00', 'active', '2020-05-29 01:25:56', '2020-05-29 01:25:56', '200.00'),
(324, 4, 355, 10, '20.00', '0.00', '2020-05-28', NULL, '7.00', 0, '3.00', 'active', '2020-05-29 01:26:22', '2020-05-29 01:26:22', '200.00'),
(325, 1, 356, 10, '20.00', '0.00', '2020-05-28', NULL, '7.00', 318, '3.00', 'active', '2020-05-29 04:30:16', '2020-05-29 04:30:16', '200.00'),
(326, 1, 357, 10, '40.00', '0.00', '2020-05-28', NULL, '7.00', 318, '3.00', 'active', '2020-05-29 04:31:01', '2020-05-29 04:31:01', '400.00'),
(327, 1, 358, 10, '40.00', '0.00', '2020-05-28', NULL, '7.00', 317, '3.00', 'active', '2020-05-29 04:34:51', '2020-05-29 04:34:51', '400.00'),
(328, 1, 359, 10, '40.00', '0.00', '2020-05-28', NULL, '7.00', 317, '3.00', 'active', '2020-05-29 04:39:54', '2020-05-29 04:39:54', '400.00'),
(329, 1, 360, 10, '40.00', '0.00', '2020-05-28', NULL, '7.00', 317, '3.00', 'active', '2020-05-29 04:44:37', '2020-05-29 04:44:37', '400.00'),
(330, 1, 361, 10, '40.00', '0.00', '2020-05-28', NULL, '7.00', 317, '3.00', 'active', '2020-05-29 04:47:58', '2020-05-29 04:47:58', '400.00'),
(331, 1, 362, 10, '40.00', '0.00', '2020-05-28', NULL, '7.00', 318, '3.00', 'active', '2020-05-29 04:49:32', '2020-05-29 04:49:32', '400.00'),
(332, 1, 363, 20, '20.00', '0.00', '2020-05-29', NULL, '10.00', 317, '10.00', 'active', '2020-05-29 11:45:36', '2020-05-29 11:45:36', '400.00');

-- --------------------------------------------------------

--
-- Table structure for table `receipts`
--

DROP TABLE IF EXISTS `receipts`;
CREATE TABLE IF NOT EXISTS `receipts` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `customer` int(11) NOT NULL,
  `sales_id` int(11) NOT NULL DEFAULT '0',
  `date` date DEFAULT NULL,
  `amount` decimal(10,2) NOT NULL,
  `ref` varchar(50) DEFAULT NULL,
  `type` varchar(10) NOT NULL DEFAULT 'in',
  `activity` varchar(100) DEFAULT NULL,
  `status` varchar(20) NOT NULL DEFAULT 'active',
  `updated_at` date NOT NULL,
  `created_at` date NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=28 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `receipts`
--

INSERT INTO `receipts` (`id`, `customer`, `sales_id`, `date`, `amount`, `ref`, `type`, `activity`, `status`, `updated_at`, `created_at`) VALUES
(14, 1, 987, '2020-05-24', '40.00', NULL, 'in', 'Sale', 'active', '2020-05-24', '2020-05-24'),
(15, 1, 988, '2020-05-24', '40.00', NULL, 'in', 'Sale', 'active', '2020-05-24', '2020-05-24'),
(16, 1, 989, '2020-05-24', '20.00', NULL, 'in', 'Sale', 'active', '2020-05-24', '2020-05-24'),
(17, 1, 990, '2020-05-24', '40.00', NULL, 'in', 'Sale', 'active', '2020-05-24', '2020-05-24'),
(18, 1, 991, '2020-05-24', '40.00', NULL, 'in', 'Sale', 'active', '2020-05-24', '2020-05-24'),
(19, 1, 992, '2020-05-24', '40.00', NULL, 'in', 'Sale', 'active', '2020-05-24', '2020-05-24'),
(20, 1, 993, '2020-05-24', '20.00', NULL, 'in', 'Sale', 'active', '2020-05-24', '2020-05-24'),
(21, 1, 994, '2020-05-24', '40.00', NULL, 'in', 'Sale', 'active', '2020-05-24', '2020-05-24'),
(22, 1, 995, '2020-05-24', '20.00', NULL, 'in', 'Sale', 'active', '2020-05-24', '2020-05-24'),
(23, 1, 996, '2020-05-28', '40.00', NULL, 'in', 'Sale', 'active', '2020-05-28', '2020-05-28'),
(24, 1, 997, '2020-05-28', '20.00', NULL, 'in', 'Sale', 'active', '2020-05-28', '2020-05-28'),
(25, 1, 998, '2020-05-28', '20.00', NULL, 'in', 'Sale', 'active', '2020-05-28', '2020-05-28'),
(26, 1, 999, '2020-05-28', '20.00', NULL, 'in', 'Sale', 'active', '2020-05-28', '2020-05-28'),
(27, 1, 1000, '2020-05-28', '20.00', NULL, 'in', 'Sale', 'active', '2020-05-28', '2020-05-28');

-- --------------------------------------------------------

--
-- Table structure for table `receipt_items`
--

DROP TABLE IF EXISTS `receipt_items`;
CREATE TABLE IF NOT EXISTS `receipt_items` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `receipt_id` int(11) NOT NULL,
  `sales_id` int(11) NOT NULL,
  `amount` decimal(10,2) NOT NULL,
  `status` varchar(20) NOT NULL DEFAULT 'active',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=14 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `receipt_items`
--

INSERT INTO `receipt_items` (`id`, `receipt_id`, `sales_id`, `amount`, `status`) VALUES
(1, 1, 772, '12.00', 'active'),
(2, 2, 772, '3.00', 'active'),
(3, 3, 772, '3.00', 'active'),
(4, 4, 772, '3.00', 'active'),
(5, 5, 772, '150.00', 'active'),
(6, 8, 782, '17.00', 'active'),
(7, 10, 782, '28.00', 'void'),
(8, 10, 783, '30.00', 'void'),
(9, 11, 782, '30.00', 'active'),
(10, 11, 783, '30.00', 'active'),
(11, 12, 782, '16.00', 'void'),
(12, 13, 782, '16.00', 'void'),
(13, 13, 783, '60.00', 'void');

-- --------------------------------------------------------

--
-- Table structure for table `returned`
--

DROP TABLE IF EXISTS `returned`;
CREATE TABLE IF NOT EXISTS `returned` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `customer_id` int(11) NOT NULL,
  `date` date NOT NULL,
  `why` text NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `returned_items`
--

DROP TABLE IF EXISTS `returned_items`;
CREATE TABLE IF NOT EXISTS `returned_items` (
  `return_id` int(11) NOT NULL,
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `item` int(50) NOT NULL,
  `amount` int(11) NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `sales`
--

DROP TABLE IF EXISTS `sales`;
CREATE TABLE IF NOT EXISTS `sales` (
  `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT,
  `customer` int(11) NOT NULL,
  `date` date DEFAULT NULL,
  `ref` varchar(150) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `total_amount` decimal(10,2) NOT NULL DEFAULT '0.00',
  `amount_paid` decimal(10,2) NOT NULL DEFAULT '0.00',
  `status` varchar(20) COLLATE utf8mb4_unicode_ci NOT NULL DEFAULT 'unpaid',
  `user` int(11) DEFAULT NULL,
  `location` int(11) NOT NULL DEFAULT '1',
  `period` int(11) NOT NULL DEFAULT '1',
  `user_name` varchar(150) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `payment_mode` varchar(20) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=1001 DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `sales`
--

INSERT INTO `sales` (`id`, `customer`, `date`, `ref`, `total_amount`, `amount_paid`, `status`, `user`, `location`, `period`, `user_name`, `payment_mode`, `created_at`, `updated_at`) VALUES
(973, 1, '2018-01-02', '', '0.00', '0.00', 'unpaid', 6, 1, 1, 'merhawi', NULL, '2020-05-24 13:58:34', '2020-05-24 13:58:34'),
(974, 1, '2018-01-02', '', '0.00', '0.00', 'unpaid', 6, 1, 1, 'merhawi', NULL, '2020-05-24 13:58:43', '2020-05-24 13:58:43'),
(975, 1, '2018-01-02', '', '0.00', '0.00', 'unpaid', 6, 1, 1, 'merhawi', NULL, '2020-05-24 14:00:48', '2020-05-24 14:00:48'),
(976, 1, '2018-01-02', '', '0.00', '0.00', 'unpaid', 6, 1, 1, 'merhawi', NULL, '2020-05-24 14:01:17', '2020-05-24 14:01:17'),
(977, 1, '2018-01-02', '', '0.00', '0.00', 'unpaid', 6, 1, 1, 'merhawi', NULL, '2020-05-24 14:03:46', '2020-05-24 14:03:46'),
(978, 1, '2018-01-02', '', '0.00', '0.00', 'unpaid', 6, 1, 1, 'merhawi', NULL, '2020-05-24 14:11:39', '2020-05-24 14:11:39'),
(979, 1, '2020-05-24', '', '0.00', '0.00', 'unpaid', 6, 1, 1, 'merhawi', NULL, '2020-05-24 14:18:30', '2020-05-24 14:18:30'),
(980, 20, '2020-05-24', '', '0.00', '0.00', 'unpaid', 6, 1, 1, 'merhawi', NULL, '2020-05-24 14:19:13', '2020-05-24 14:19:13'),
(981, 20, '2020-05-24', '', '0.00', '0.00', 'unpaid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 14:20:54', '2020-05-24 14:20:54'),
(982, 20, '2020-05-24', '', '0.00', '0.00', 'unpaid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 14:20:59', '2020-05-24 14:20:59'),
(983, 20, '2020-05-24', '', '0.00', '0.00', 'unpaid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 14:25:18', '2020-05-24 14:25:18'),
(984, 20, '2020-05-24', '', '40.00', '0.00', 'unpaid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 14:27:28', '2020-05-24 14:27:28'),
(985, 1, '2020-05-24', '', '40.00', '0.00', 'unpaid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 14:28:15', '2020-05-24 14:28:15'),
(986, 1, '2020-05-24', '', '20.00', '20.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 14:31:38', '2020-05-24 14:31:38'),
(987, 1, '2020-05-24', '', '40.00', '40.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 14:33:57', '2020-05-24 14:33:57'),
(988, 1, '2020-05-24', '', '40.00', '40.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 14:35:39', '2020-05-24 14:35:40'),
(989, 1, '2020-05-24', '', '20.00', '20.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 14:38:25', '2020-05-24 14:38:26'),
(990, 1, '2020-05-24', '', '40.00', '40.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 14:39:20', '2020-05-24 14:39:21'),
(991, 1, '2020-05-24', '', '40.00', '40.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 14:57:41', '2020-05-24 14:57:42'),
(992, 1, '2020-05-24', '', '40.00', '40.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 15:47:14', '2020-05-24 15:47:14'),
(993, 1, '2020-05-24', '', '20.00', '20.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 15:48:28', '2020-05-24 15:48:29'),
(994, 1, '2020-05-24', '', '40.00', '40.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 15:49:40', '2020-05-24 15:49:41'),
(995, 1, '2020-05-24', '', '20.00', '20.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-24 15:50:13', '2020-05-24 15:50:14'),
(996, 1, '2020-05-28', '', '40.00', '40.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-28 13:29:51', '2020-05-28 13:29:52'),
(997, 1, '2020-05-28', '', '20.00', '20.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-28 13:31:17', '2020-05-28 13:31:17'),
(998, 1, '2020-05-28', '', '20.00', '20.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-28 13:35:32', '2020-05-28 13:35:32'),
(999, 1, '2020-05-28', '', '20.00', '20.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-28 13:39:40', '2020-05-28 13:39:41'),
(1000, 1, '2020-05-28', '', '20.00', '20.00', 'paid', 6, 1, 1, 'merhawi', 'Cash', '2020-05-28 13:41:49', '2020-05-28 13:41:49');

-- --------------------------------------------------------

--
-- Table structure for table `sales_items_barcode`
--

DROP TABLE IF EXISTS `sales_items_barcode`;
CREATE TABLE IF NOT EXISTS `sales_items_barcode` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `item` int(11) NOT NULL,
  `sales_id` int(11) NOT NULL,
  `sales_items_barcode_id` int(11) NOT NULL,
  `qty` decimal(10,2) NOT NULL,
  `shop` decimal(10,2) NOT NULL DEFAULT '0.00',
  `store` decimal(10,2) NOT NULL DEFAULT '0.00',
  `status` varchar(20) NOT NULL DEFAULT 'active',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=23 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `sales_items_barcode`
--

INSERT INTO `sales_items_barcode` (`id`, `item`, `sales_id`, `sales_items_barcode_id`, `qty`, `shop`, `store`, `status`) VALUES
(1, 413, 772, 202, '3.00', '3.00', '0.00', 'active'),
(2, 414, 772, 207, '1.00', '1.00', '0.00', 'active'),
(3, 413, 773, 202, '3.00', '3.00', '0.00', 'active'),
(4, 414, 773, 207, '2.00', '2.00', '0.00', 'active'),
(5, 427, 774, 213, '6.00', '6.00', '0.00', 'active'),
(6, 413, 775, 202, '6.00', '6.00', '0.00', 'active'),
(7, 413, 776, 202, '5.00', '5.00', '0.00', 'active'),
(8, 414, 776, 207, '3.00', '3.00', '0.00', 'active'),
(9, 413, 777, 202, '3.00', '3.00', '0.00', 'active'),
(10, 413, 778, 202, '3.00', '3.00', '0.00', 'active'),
(11, 413, 779, 202, '3.00', '3.00', '0.00', 'active'),
(12, 413, 780, 202, '4.00', '4.00', '0.00', 'active'),
(16, 413, 782, 202, '1.00', '1.00', '0.00', 'active'),
(17, 414, 782, 207, '1.00', '1.00', '0.00', 'active'),
(18, 415, 782, 211, '1.00', '1.00', '0.00', 'active'),
(19, 425, 782, 177, '1.00', '1.00', '0.00', 'active'),
(20, 413, 783, 202, '4.00', '4.00', '0.00', 'active'),
(21, 413, 785, 202, '2.00', '2.00', '0.00', 'active'),
(22, 413, 786, 202, '3.00', '3.00', '0.00', 'active');

-- --------------------------------------------------------

--
-- Table structure for table `sales_orders`
--

DROP TABLE IF EXISTS `sales_orders`;
CREATE TABLE IF NOT EXISTS `sales_orders` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `customer` int(11) NOT NULL,
  `date` date NOT NULL,
  `ref` varchar(80) DEFAULT NULL,
  `total_amount` decimal(10,2) NOT NULL DEFAULT '0.00',
  `amount_paid` decimal(10,2) NOT NULL DEFAULT '0.00',
  `status` varchar(30) NOT NULL DEFAULT 'unpaid',
  `user` int(11) NOT NULL,
  `payment_mode` varchar(50) DEFAULT NULL,
  `remark` varchar(150) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `sale_items`
--

DROP TABLE IF EXISTS `sale_items`;
CREATE TABLE IF NOT EXISTS `sale_items` (
  `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT,
  `item` int(10) NOT NULL,
  `date` date DEFAULT NULL,
  `ref` varchar(191) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `qty` int(10) UNSIGNED NOT NULL,
  `unit_price` decimal(10,2) NOT NULL,
  `unit_cost` decimal(10,2) NOT NULL DEFAULT '0.00',
  `sale_id` int(10) UNSIGNED NOT NULL,
  `tax` decimal(8,2) DEFAULT '0.00',
  `discount_percent` decimal(5,2) NOT NULL DEFAULT '0.00',
  `discount` decimal(10,2) NOT NULL DEFAULT '0.00',
  `location` int(11) NOT NULL DEFAULT '1',
  `sub_total` decimal(10,2) NOT NULL DEFAULT '0.00',
  `status` varchar(20) COLLATE utf8mb4_unicode_ci NOT NULL DEFAULT 'active',
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  `barcode` varchar(100) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `variant` int(11) DEFAULT NULL,
  `package` int(11) DEFAULT NULL,
  `freq` varchar(150) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `dosage` decimal(10,2) NOT NULL DEFAULT '0.00',
  `uom` varchar(5) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `duration` int(11) NOT NULL DEFAULT '0',
  `uod` varchar(100) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `route` varchar(100) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  PRIMARY KEY (`id`),
  KEY `sale_items_sale_id_foreign` (`sale_id`)
) ENGINE=InnoDB AUTO_INCREMENT=236 DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `sale_items`
--

INSERT INTO `sale_items` (`id`, `item`, `date`, `ref`, `qty`, `unit_price`, `unit_cost`, `sale_id`, `tax`, `discount_percent`, `discount`, `location`, `sub_total`, `status`, `created_at`, `updated_at`, `barcode`, `variant`, `package`, `freq`, `dosage`, `uom`, `duration`, `uod`, `route`) VALUES
(223, 1, NULL, NULL, 2, '20.00', '20.00', 988, '0.00', '0.00', '0.00', 1, '0.00', 'active', '2020-05-24 14:35:39', '2020-05-24 14:35:39', '317', 317, NULL, '10', '10.00', 'mg', 20, 'days', 'tablet'),
(224, 1, NULL, NULL, 1, '20.00', '20.00', 989, '0.00', '0.00', '0.00', 1, '20.00', 'active', '2020-05-24 14:38:25', '2020-05-24 14:38:25', '317', 317, NULL, '10', '10.00', 'mg', 20, 'days', 'tablet'),
(225, 1, '2020-05-24', NULL, 2, '20.00', '20.00', 990, '0.00', '0.00', '0.00', 1, '40.00', 'active', '2020-05-24 14:39:21', '2020-05-24 14:39:21', '317', 317, NULL, '10', '4.00', 'mg', 5, 'days', 'tablet'),
(226, 1, '2020-05-24', NULL, 2, '20.00', '20.00', 991, '0.00', '0.00', '0.00', 1, '40.00', 'active', '2020-05-24 14:57:41', '2020-05-24 14:57:41', '317', 317, NULL, '10', '1.00', 'mg', 2, 'days', 'tablet'),
(227, 1, '2020-05-24', NULL, 2, '20.00', '20.00', 992, '0.00', '0.00', '0.00', 1, '40.00', 'active', '2020-05-24 15:47:14', '2020-05-24 15:47:14', '317', 317, NULL, '10', '5.00', 'mg', 8, 'days', 'tablet'),
(228, 1, '2020-05-24', NULL, 1, '20.00', '20.00', 993, '0.00', '0.00', '0.00', 1, '20.00', 'active', '2020-05-24 15:48:28', '2020-05-24 15:48:28', '317', 317, NULL, '10', '1.00', 'mg', 2, 'days', 'tablet'),
(229, 1, '2020-05-24', NULL, 2, '20.00', '20.00', 994, '0.00', '0.00', '0.00', 1, '40.00', 'active', '2020-05-24 15:49:41', '2020-05-24 15:49:41', '317', 317, NULL, '10', '2.00', 'mg', 3, 'days', 'tablet'),
(230, 1, '2020-05-24', NULL, 1, '20.00', '20.00', 995, '0.00', '0.00', '0.00', 1, '20.00', 'active', '2020-05-24 15:50:13', '2020-05-24 15:50:13', '317', 317, NULL, '10', '1.00', 'mg', 1, 'days', 'tablet'),
(231, 1, '2020-05-28', NULL, 2, '20.00', '0.00', 996, '0.00', '0.00', '0.00', 1, '40.00', 'active', '2020-05-28 13:29:51', '2020-05-28 13:29:51', '317', 317, NULL, '10', '10.00', 'mg', 20, 'days', 'tablet'),
(232, 1, '2020-05-28', NULL, 1, '20.00', '0.00', 997, '0.00', '0.00', '0.00', 1, '20.00', 'active', '2020-05-28 13:31:17', '2020-05-28 13:31:17', '317', 317, NULL, '10', '10.00', 'mg', 20, 'days', 'tablet'),
(233, 1, '2020-05-28', NULL, 1, '20.00', '0.00', 998, '0.00', '0.00', '0.00', 1, '20.00', 'active', '2020-05-28 13:35:32', '2020-05-28 13:35:32', '317', 317, NULL, '10', '10.00', 'mg', 20, 'days', 'tablet'),
(234, 1, '2020-05-28', NULL, 1, '20.00', '0.00', 999, '0.00', '0.00', '0.00', 1, '20.00', 'active', '2020-05-28 13:39:40', '2020-05-28 13:39:40', '317', 317, NULL, '10', '10.00', 'mg', 20, 'days', 'tablet'),
(235, 1, '2020-05-28', NULL, 1, '20.00', '0.00', 1000, '0.00', '0.00', '0.00', 1, '20.00', 'active', '2020-05-28 13:41:49', '2020-05-28 13:41:49', '317', 317, NULL, '10', '15.00', 'mg', 16, 'days', 'tablet');

-- --------------------------------------------------------

--
-- Table structure for table `sale_order_items`
--

DROP TABLE IF EXISTS `sale_order_items`;
CREATE TABLE IF NOT EXISTS `sale_order_items` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `item` int(11) NOT NULL,
  `date` date NOT NULL,
  `ref` varchar(100) DEFAULT NULL,
  `qty` decimal(6,2) DEFAULT NULL,
  `unit_cost` decimal(10,2) NOT NULL DEFAULT '0.00',
  `unit_price` decimal(10,2) NOT NULL DEFAULT '0.00',
  `sale_order_id` int(11) NOT NULL,
  `discount` decimal(10,2) NOT NULL DEFAULT '0.00',
  `subtotal` decimal(10,2) DEFAULT '0.00',
  `variant` int(11) DEFAULT NULL,
  `package` int(11) DEFAULT NULL,
  `barcode` varchar(100) DEFAULT NULL,
  `created_at` datetime DEFAULT NULL,
  `updated_at` datetime DEFAULT NULL,
  `deleted_at` datetime DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `soap`
--

DROP TABLE IF EXISTS `soap`;
CREATE TABLE IF NOT EXISTS `soap` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `customer` int(11) NOT NULL,
  `subjective` varchar(150) DEFAULT NULL,
  `objective` varchar(150) DEFAULT NULL,
  `assessment` varchar(150) DEFAULT NULL,
  `plan` varchar(150) DEFAULT NULL,
  `date` date DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=8 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `soap`
--

INSERT INTO `soap` (`id`, `customer`, `subjective`, `objective`, `assessment`, `plan`, `date`) VALUES
(1, 24, 'Subjectivessss', 'Obbbbb', 'Assssseeee', 'Plllllllaaannnn', NULL),
(2, 24, 'Subjectivessss2', 'Obbbbb3', 'Assssseeee2', 'Plllllllaaannnn2', NULL),
(3, 26, 'lksdjfslkqklj', 'jklsjdfkls', 'jklsdjfklsd', 'lksdjfl', NULL),
(4, 18, 'slkdjf', 'jkldsjlj', 'lksdjklj', 'ljdsljfl', NULL),
(5, 26, 'subject', 'objjj', 'ass', 'plnalksdjfkl', NULL),
(6, 26, 'hsdysdkyf', 'olllllllll', 'asssss', 'pllllllll', '2020-02-25'),
(7, 26, 'skdjfksjl', 'kkkkk', 'ljksdfl', 'pppp', '2020-02-25');

-- --------------------------------------------------------

--
-- Table structure for table `suppliers`
--

DROP TABLE IF EXISTS `suppliers`;
CREATE TABLE IF NOT EXISTS `suppliers` (
  `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT,
  `supplier_name` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `account_number` varchar(191) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `mobile` varchar(191) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `telephone` varchar(50) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `address` varchar(191) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `remark` varchar(100) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `account_receivable` int(11) NOT NULL DEFAULT '0',
  `account_payable` int(11) NOT NULL DEFAULT '0',
  `balance` decimal(10,2) NOT NULL DEFAULT '0.00',
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  `active` int(4) NOT NULL DEFAULT '1',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=11 DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `suppliers`
--

INSERT INTO `suppliers` (`id`, `supplier_name`, `account_number`, `mobile`, `telephone`, `address`, `remark`, `account_receivable`, `account_payable`, `balance`, `created_at`, `updated_at`, `active`) VALUES
(8, 'sigmen', '111111111', '07506234', '07172670', 'asmara', 'good programmer', 0, 0, '500.00', NULL, '2020-05-12 16:55:49', 1),
(9, 'Supplier namesss', 'ee', 'rr', 'ww', 'qq', 'ttt', 0, 0, '600.00', NULL, '2019-05-01 09:49:42', 1),
(10, 'aman', '0', '0', '0745', 'a', 'g', 0, 0, '-500.00', NULL, NULL, 1);

-- --------------------------------------------------------

--
-- Table structure for table `test_drug_interations`
--

DROP TABLE IF EXISTS `test_drug_interations`;
CREATE TABLE IF NOT EXISTS `test_drug_interations` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `drug_id` int(11) DEFAULT NULL,
  `drug_name` varchar(150) DEFAULT NULL,
  `drug_interacting_name` varchar(150) DEFAULT NULL,
  `interaction` text,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  `deleted_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=6676 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `test_drug_interations`
--

INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(2, 1, 'Abacavir ', 'Atazanavir', ' Protease Inhibitors may decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(3, 1, 'Abacavir ', 'Batimastat', ' May decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(4, 1, 'Abacavir ', 'Darunavir', ' Protease Inhibitors may decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(5, 1, 'Abacavir ', 'Fosamprenavir', ' Protease Inhibitors may decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(6, 1, 'Abacavir ', 'Indinavir', ' Protease Inhibitors may decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(7, 1, 'Abacavir ', 'Isoflurophate', ' May decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(8, 1, 'Abacavir ', 'Lopinavir', ' Protease Inhibitors may decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(9, 1, 'Abacavir ', 'Methadone', ' Methadone may diminish the therapeutic effect of Abacavir. Abacavir may decrease the serum concentration of Methadone.', NULL, NULL, NULL),
(10, 1, 'Abacavir ', 'Nelfinavir', ' Protease Inhibitors may decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(11, 1, 'Abacavir ', 'Ribavirin', ' May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.', NULL, NULL, NULL),
(12, 1, 'Abacavir ', 'Ritonavir', ' Protease Inhibitors may decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(13, 1, 'Abacavir ', 'Saquinavir', ' Protease Inhibitors may decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(14, 1, 'Abacavir ', 'Simeprevir', ' May decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(15, 1, 'Abacavir ', 'Tipranavir', ' Protease Inhibitors may decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(16, 2, 'Acetazolamide ', '0', '0', NULL, NULL, NULL),
(17, 2, 'Acetazolamide ', 'Acetylsalicylic acid', ' May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.', NULL, NULL, NULL),
(18, 2, 'Acetazolamide ', 'Alfentanil', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(19, 2, 'Acetazolamide ', 'Aminosalicylic Acid', ' Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(20, 2, 'Acetazolamide ', 'Amphetamine', ' May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(21, 2, 'Acetazolamide ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(22, 2, 'Acetazolamide ', 'Benzphetamine', ' May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(23, 2, 'Acetazolamide ', 'Bismuth Subsalicylate', ' Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(24, 2, 'Acetazolamide ', 'Brinzolamide', ' May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.', NULL, NULL, NULL),
(25, 2, 'Acetazolamide ', 'Buprenorphine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(26, 2, 'Acetazolamide ', 'Butabarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(27, 2, 'Acetazolamide ', 'Butethal', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(28, 2, 'Acetazolamide ', 'Butorphanol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(29, 2, 'Acetazolamide ', 'Carbamazepine', ' May increase the serum concentration of CarBAMazepine. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(30, 2, 'Acetazolamide ', 'Cathinone', ' Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines.', NULL, NULL, NULL),
(31, 2, 'Acetazolamide ', 'Codeine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(32, 2, 'Acetazolamide ', 'Dextroamphetamine', ' May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(33, 2, 'Acetazolamide ', 'Diclofenamide', ' May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.', NULL, NULL, NULL),
(34, 2, 'Acetazolamide ', 'Dihydrocodeine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(35, 2, 'Acetazolamide ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(36, 2, 'Acetazolamide ', 'Dorzolamide', ' May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.', NULL, NULL, NULL),
(37, 2, 'Acetazolamide ', 'Duloxetine', ' Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.', NULL, NULL, NULL),
(38, 2, 'Acetazolamide ', 'Ethoxzolamide', ' May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.', NULL, NULL, NULL),
(39, 2, 'Acetazolamide ', 'Fentanyl', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(40, 2, 'Acetazolamide ', 'Flecainide', ' Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide.', NULL, NULL, NULL),
(41, 2, 'Acetazolamide ', 'Fosphenytoin', ' May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically~ the risk for osteomalacia or rickets may be increased. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(42, 2, 'Acetazolamide ', 'Heptabarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(43, 2, 'Acetazolamide ', 'Hexobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(44, 2, 'Acetazolamide ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(45, 2, 'Acetazolamide ', 'Hydromorphone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(46, 2, 'Acetazolamide ', 'Levorphanol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(47, 2, 'Acetazolamide ', 'Lisdexamfetamine', ' May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(48, 2, 'Acetazolamide ', 'Lithium', ' Carbonic Anhydrase Inhibitors may decrease the serum concentration of Lithium.', NULL, NULL, NULL),
(49, 2, 'Acetazolamide ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(50, 2, 'Acetazolamide ', 'Magnesium salicylate', ' Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(51, 2, 'Acetazolamide ', 'Mefloquine', ' Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.', NULL, NULL, NULL),
(52, 2, 'Acetazolamide ', 'Memantine', ' Carbonic Anhydrase Inhibitors may decrease the excretion of Memantine.', NULL, NULL, NULL),
(53, 2, 'Acetazolamide ', 'Metformin', ' May enhance the adverse/toxic effect of MetFORMIN. Specifically~ the risk of developing lactic acidosis may be increased. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(54, 2, 'Acetazolamide ', 'Methadone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(55, 2, 'Acetazolamide ', 'Methamphetamine', ' May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(56, 2, 'Acetazolamide ', 'Methazolamide', ' May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.', NULL, NULL, NULL),
(57, 2, 'Acetazolamide ', 'Methenamine hippurate', ' May diminish the therapeutic effect of Methenamine.', NULL, NULL, NULL),
(58, 2, 'Acetazolamide ', 'Methenamine mandelate', ' May diminish the therapeutic effect of Methenamine.', NULL, NULL, NULL),
(59, 2, 'Acetazolamide ', 'Methohexital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(60, 2, 'Acetazolamide ', 'Mianserin', ' May diminish the therapeutic effect of Anticonvulsants.', NULL, NULL, NULL),
(61, 2, 'Acetazolamide ', 'Morphine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(62, 2, 'Acetazolamide ', 'Nalbuphine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(63, 2, 'Acetazolamide ', 'Orlistat', ' May decrease the serum concentration of Anticonvulsants.', NULL, NULL, NULL),
(64, 2, 'Acetazolamide ', 'Oxycodone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(65, 2, 'Acetazolamide ', 'Oxymorphone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(66, 2, 'Acetazolamide ', 'Pentobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(67, 2, 'Acetazolamide ', 'Pethidine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(68, 2, 'Acetazolamide ', 'Phendimetrazine', ' May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(69, 2, 'Acetazolamide ', 'Phentermine', ' May decrease the excretion of Amphetamines. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(70, 2, 'Acetazolamide ', 'Phenytoin', ' May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically~ the risk for osteomalacia or rickets may be increased. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(71, 2, 'Acetazolamide ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(72, 2, 'Acetazolamide ', 'Primidone', ' May enhance the adverse/toxic effect of Primidone. Specifically~ osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(73, 2, 'Acetazolamide ', 'Pseudoephedrine', ' May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).', NULL, NULL, NULL),
(74, 2, 'Acetazolamide ', 'Quinidine', ' Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.', NULL, NULL, NULL),
(75, 2, 'Acetazolamide ', 'Remifentanil', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(76, 2, 'Acetazolamide ', 'Risperidone', ' Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.', NULL, NULL, NULL),
(77, 2, 'Acetazolamide ', 'Salicylate-sodium', ' May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.', NULL, NULL, NULL),
(78, 2, 'Acetazolamide ', 'Salsalate', ' Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(79, 2, 'Acetazolamide ', 'Secobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(80, 2, 'Acetazolamide ', 'Sodium bicarbonate', ' AcetaZOLAMIDE may enhance the adverse/toxic effect of Sodium Bicarbonate. Specifically~ the risk of renal calculus formation may be increased.', NULL, NULL, NULL),
(81, 2, 'Acetazolamide ', 'Sufentanil', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(82, 2, 'Acetazolamide ', 'Tapentadol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(83, 2, 'Acetazolamide ', 'Topiramate', ' May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.', NULL, NULL, NULL),
(84, 2, 'Acetazolamide ', 'Tramadol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(85, 2, 'Acetazolamide ', 'Triprolidine', ' May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).', NULL, NULL, NULL),
(86, 2, 'Acetazolamide ', 'Zonisamide', ' May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.', NULL, NULL, NULL),
(87, 3, 'Acetylcysteine ', '0', '0', NULL, NULL, NULL),
(88, 4, 'Acyclovir ', '0', '0', NULL, NULL, NULL),
(89, 5, 'Albendazole ', '0', '0', NULL, NULL, NULL),
(90, 5, 'Albendazole ', 'Carbamazepine', ' May decrease serum concentrations of the active metabolite(s) of Albendazole.', NULL, NULL, NULL),
(91, 5, 'Albendazole ', 'Phenobarbital', ' May decrease serum concentrations of the active metabolite(s) of Albendazole.', NULL, NULL, NULL),
(92, 5, 'Albendazole ', 'Phenytoin', ' Phenytoin may decrease serum concentrations of the active metabolite(s) of Albendazole.', NULL, NULL, NULL),
(93, 6, 'Allopurinol ', '0', '0', NULL, NULL, NULL),
(94, 6, 'Allopurinol ', 'Acenocoumarol', ' May enhance the anticoagulant effect of Vitamin K Antagonists.', NULL, NULL, NULL),
(95, 6, 'Allopurinol ', 'Aluminum hydroxide', ' May decrease the absorption of Allopurinol. Exceptions: Sodium Bicarbonate.', NULL, NULL, NULL),
(96, 6, 'Allopurinol ', 'Aminophylline', ' May increase the serum concentration of Theophylline Derivatives.', NULL, NULL, NULL),
(97, 6, 'Allopurinol ', 'Amoxicillin', ' Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.', NULL, NULL, NULL),
(98, 6, 'Allopurinol ', 'Ampicillin', ' May enhance the potential for allergic or hypersensitivity reactions to Ampicillin.', NULL, NULL, NULL),
(99, 6, 'Allopurinol ', 'Azathioprine', ' Allopurinol may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. More specifically~ allopurinol may increase mercaptopurine serum concentrations and promote formation of active thioguanine nucleotides.', NULL, NULL, NULL),
(100, 6, 'Allopurinol ', 'Azilsartan medoxomil', ' Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(101, 6, 'Allopurinol ', 'Benazepril', ' ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.', NULL, NULL, NULL),
(102, 6, 'Allopurinol ', 'Bendamustine', ' Allopurinol may enhance the adverse/toxic effect of Bendamustine. Specifically~ the risk of severe skin reactions may be enhanced.', NULL, NULL, NULL),
(103, 6, 'Allopurinol ', 'Bendroflumethiazide', ' Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(104, 6, 'Allopurinol ', 'Bumetanide', ' Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically~ Loop Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(105, 6, 'Allopurinol ', 'Calcium carbonate', ' May decrease the absorption of Allopurinol. Exceptions: Sodium Bicarbonate.', NULL, NULL, NULL),
(106, 6, 'Allopurinol ', 'Captopril', ' ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.', NULL, NULL, NULL),
(107, 6, 'Allopurinol ', 'Carbamazepine', ' Allopurinol may increase the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(108, 6, 'Allopurinol ', 'Chlorothiazide', ' Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(109, 6, 'Allopurinol ', 'Chlorpropamide', ' Allopurinol may increase the serum concentration of ChlorproPAMIDE.', NULL, NULL, NULL),
(110, 6, 'Allopurinol ', 'Chlorthalidone', ' Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(111, 6, 'Allopurinol ', 'Cilazapril', ' ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.', NULL, NULL, NULL),
(112, 6, 'Allopurinol ', 'Cyclophosphamide', ' Allopurinol may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ bone marrow suppression.', NULL, NULL, NULL),
(113, 6, 'Allopurinol ', 'Didanosine', ' Allopurinol may increase the serum concentration of Didanosine.', NULL, NULL, NULL),
(114, 6, 'Allopurinol ', 'Enalapril', ' ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.', NULL, NULL, NULL),
(115, 6, 'Allopurinol ', 'Ethacrynic acid', ' Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically~ Loop Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(116, 6, 'Allopurinol ', 'Fosinopril', ' ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.', NULL, NULL, NULL),
(117, 6, 'Allopurinol ', 'Furosemide', ' Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically~ Loop Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(118, 6, 'Allopurinol ', 'Hydrochlorothiazide', ' Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(119, 6, 'Allopurinol ', 'Indapamide', ' Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(120, 6, 'Allopurinol ', 'Lisinopril', ' ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.', NULL, NULL, NULL),
(121, 6, 'Allopurinol ', 'Magnesium oxide', ' May decrease the absorption of Allopurinol. Exceptions: Sodium Bicarbonate.', NULL, NULL, NULL),
(122, 6, 'Allopurinol ', 'Mercaptopurine', ' Allopurinol may increase the serum concentration of Mercaptopurine. Allopurinol may also promote formation of active thioguanine nucleotides.', NULL, NULL, NULL),
(123, 6, 'Allopurinol ', 'Methyclothiazide', ' Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(124, 6, 'Allopurinol ', 'Metolazone', ' Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(125, 6, 'Allopurinol ', 'Moexipril', ' ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.', NULL, NULL, NULL),
(126, 6, 'Allopurinol ', 'Perindopril', ' ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.', NULL, NULL, NULL),
(127, 6, 'Allopurinol ', 'Quinapril', ' ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.', NULL, NULL, NULL),
(128, 6, 'Allopurinol ', 'Ramipril', ' ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.', NULL, NULL, NULL),
(129, 6, 'Allopurinol ', 'Theophylline', ' May increase the serum concentration of Theophylline Derivatives.', NULL, NULL, NULL),
(130, 6, 'Allopurinol ', 'Torasemide', ' Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically~ Loop Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(131, 6, 'Allopurinol ', 'Trandolapril', ' ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.', NULL, NULL, NULL),
(132, 7, 'Aluminium + Magnesium Hydroxide ', '0', '0', NULL, NULL, NULL),
(133, 8, 'Aminophylline / Theophylline Ethylenediamine ', '0', '0', NULL, NULL, NULL),
(134, 9, 'Amiodarone ', '0', '0', NULL, NULL, NULL),
(135, 9, 'Amiodarone ', 'Acebutolol', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(136, 9, 'Amiodarone ', 'Acenocoumarol', ' May enhance the anticoagulant effect of Vitamin K Antagonists. Amiodarone may increase the serum concentration of Vitamin K Antagonists.', NULL, NULL, NULL),
(137, 9, 'Amiodarone ', 'Afatinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.', NULL, NULL, NULL),
(138, 9, 'Amiodarone ', 'Agalsidase beta', ' May diminish the therapeutic effect of Agalsidase Beta.', NULL, NULL, NULL),
(139, 9, 'Amiodarone ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(140, 9, 'Amiodarone ', 'Atazanavir', ' Atazanavir may increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(141, 9, 'Amiodarone ', 'Atenolol', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(142, 9, 'Amiodarone ', 'Atorvastatin', ' May decrease the metabolism of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(143, 9, 'Amiodarone ', 'Bendroflumethiazide', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(144, 9, 'Amiodarone ', 'Betaxolol', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(145, 9, 'Amiodarone ', 'Bisoprolol', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(146, 9, 'Amiodarone ', 'Boceprevir', ' May increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(147, 9, 'Amiodarone ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(148, 9, 'Amiodarone ', 'Bosutinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.', NULL, NULL, NULL),
(149, 9, 'Amiodarone ', 'Brentuximab vedotin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.', NULL, NULL, NULL),
(150, 9, 'Amiodarone ', 'Bretylium', ' May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.', NULL, NULL, NULL),
(151, 9, 'Amiodarone ', 'Carteolol', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(152, 9, 'Amiodarone ', 'Carvedilol', ' CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically~ concentrations of the S-carvedilol enantiomer may be increased.', NULL, NULL, NULL),
(153, 9, 'Amiodarone ', 'Cholestyramine', ' Bile Acid Sequestrants may decrease the bioavailability of Amiodarone.', NULL, NULL, NULL),
(154, 9, 'Amiodarone ', 'Cimetidine', ' Cimetidine may increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(155, 9, 'Amiodarone ', 'Clopidogrel', ' May decrease serum concentrations of the active metabolite(s) of Clopidogrel.', NULL, NULL, NULL),
(156, 9, 'Amiodarone ', 'Codeine', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.', NULL, NULL, NULL),
(157, 9, 'Amiodarone ', 'Colchicine', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(158, 9, 'Amiodarone ', 'Colesevelam', ' Bile Acid Sequestrants may decrease the bioavailability of Amiodarone.', NULL, NULL, NULL),
(159, 9, 'Amiodarone ', 'Colestipol', ' Bile Acid Sequestrants may decrease the bioavailability of Amiodarone.', NULL, NULL, NULL),
(160, 9, 'Amiodarone ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(161, 9, 'Amiodarone ', 'Cyclophosphamide', ' Cyclophosphamide may enhance the adverse/toxic effect of Amiodarone. Specifically~ the risk of pulmonary toxicity may be enhanced.', NULL, NULL, NULL),
(162, 9, 'Amiodarone ', 'Dabigatran etexilate', ' Amiodarone may increase the serum concentration of Dabigatran Etexilate.', NULL, NULL, NULL),
(163, 9, 'Amiodarone ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(164, 9, 'Amiodarone ', 'Darunavir', ' May increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(165, 9, 'Amiodarone ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(166, 9, 'Amiodarone ', 'Digoxin', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(167, 9, 'Amiodarone ', 'Diltiazem', ' Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported.', NULL, NULL, NULL),
(168, 9, 'Amiodarone ', 'Disopyramide', ' May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).', NULL, NULL, NULL),
(169, 9, 'Amiodarone ', 'Dronabinol', ' CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.', NULL, NULL, NULL),
(170, 9, 'Amiodarone ', 'Esmolol', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(171, 9, 'Amiodarone ', 'Etravirine', ' May decrease the serum concentration of Amiodarone.', NULL, NULL, NULL),
(172, 9, 'Amiodarone ', 'Everolimus', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.', NULL, NULL, NULL),
(173, 9, 'Amiodarone ', 'Fesoterodine', ' CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.', NULL, NULL, NULL),
(174, 9, 'Amiodarone ', 'Fingolimod', ' May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).', NULL, NULL, NULL),
(175, 9, 'Amiodarone ', 'Flecainide', ' Amiodarone may enhance the QTc-prolonging effect of Flecainide. Amiodarone may increase the serum concentration of Flecainide.', NULL, NULL, NULL),
(176, 9, 'Amiodarone ', 'Fluvastatin', ' May decrease the metabolism of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(177, 9, 'Amiodarone ', 'Fosamprenavir', ' May increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(178, 9, 'Amiodarone ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(179, 9, 'Amiodarone ', 'Fosphenytoin', ' May enhance the QTc-prolonging effect of Amiodarone. Amiodarone may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Amiodarone.', NULL, NULL, NULL),
(180, 9, 'Amiodarone ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(181, 9, 'Amiodarone ', 'Indinavir', ' Indinavir may increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(182, 9, 'Amiodarone ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(183, 9, 'Amiodarone ', 'Labetalol', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(184, 9, 'Amiodarone ', 'Lacosamide', ' Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.', NULL, NULL, NULL),
(185, 9, 'Amiodarone ', 'Ledipasvir', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(186, 9, 'Amiodarone ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(187, 9, 'Amiodarone ', 'Lopinavir', ' May enhance the QTc-prolonging effect of Amiodarone. Lopinavir may increase the serum concentration of Amiodarone. More specifically~ Lopinavir/Ritonavir may increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(188, 9, 'Amiodarone ', 'Loratadine', ' May increase the serum concentration of Loratadine.', NULL, NULL, NULL),
(189, 9, 'Amiodarone ', 'Lovastatin', ' May decrease the metabolism of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(190, 9, 'Amiodarone ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(191, 9, 'Amiodarone ', 'Metoprolol', ' CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.', NULL, NULL, NULL),
(192, 9, 'Amiodarone ', 'Mifepristone', ' May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.', NULL, NULL, NULL),
(193, 9, 'Amiodarone ', 'Mipomersen', ' Amiodarone may enhance the hepatotoxic effect of Mipomersen.', NULL, NULL, NULL),
(194, 9, 'Amiodarone ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(195, 9, 'Amiodarone ', 'Nadolol', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(196, 9, 'Amiodarone ', 'Nebivolol', ' CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.', NULL, NULL, NULL),
(197, 9, 'Amiodarone ', 'Nelfinavir', ' Nelfinavir may increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(198, 9, 'Amiodarone ', 'Orlistat', ' Orlistat may decrease the absorption of Amiodarone.', NULL, NULL, NULL),
(199, 9, 'Amiodarone ', 'Pazopanib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(200, 9, 'Amiodarone ', 'Penbutolol', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(201, 9, 'Amiodarone ', 'Phenytoin', ' May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Amiodarone.', NULL, NULL, NULL),
(202, 9, 'Amiodarone ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(203, 9, 'Amiodarone ', 'Pindolol', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(204, 9, 'Amiodarone ', 'Porfimer', ' Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.', NULL, NULL, NULL),
(205, 9, 'Amiodarone ', 'Procainamide', ' May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).', NULL, NULL, NULL),
(206, 9, 'Amiodarone ', 'Procaine', ' May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).', NULL, NULL, NULL),
(207, 9, 'Amiodarone ', 'Propafenone', ' Amiodarone may enhance the adverse/toxic effect of Propafenone. Specifically~ the combination may result in altered cardiac conduction and repolarization. Amiodarone may increase the serum concentration of Propafenone.', NULL, NULL, NULL),
(208, 9, 'Amiodarone ', 'Propranolol', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(209, 9, 'Amiodarone ', 'prucalopride', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.', NULL, NULL, NULL),
(210, 9, 'Amiodarone ', 'Quinidine', ' May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).', NULL, NULL, NULL),
(211, 9, 'Amiodarone ', 'Rifampicin', ' Rifampin may decrease serum concentrations of the active metabolite(s) of Amiodarone. Specifically~ desethylamiodarone concentrations may decrease. Rifampin may decrease the serum concentration of Amiodarone.', NULL, NULL, NULL),
(212, 9, 'Amiodarone ', 'Rifaximin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.', NULL, NULL, NULL),
(213, 9, 'Amiodarone ', 'Ritonavir', ' Ritonavir may increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(214, 9, 'Amiodarone ', 'Rivaroxaban', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.', NULL, NULL, NULL),
(215, 9, 'Amiodarone ', 'Rosuvastatin', ' May decrease the metabolism of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(216, 9, 'Amiodarone ', 'Ruxolitinib', ' May enhance the bradycardic effect of Bradycardia-Causing Agents.', NULL, NULL, NULL),
(217, 9, 'Amiodarone ', 'Saquinavir', ' May enhance the QTc-prolonging effect of Amiodarone. Saquinavir may increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(218, 9, 'Amiodarone ', 'Silodosin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.', NULL, NULL, NULL),
(219, 9, 'Amiodarone ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(220, 9, 'Amiodarone ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(221, 9, 'Amiodarone ', 'Simvastatin', ' May decrease the metabolism of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(222, 9, 'Amiodarone ', 'Sofosbuvir', ' May enhance the bradycardic effect of Amiodarone.', NULL, NULL, NULL),
(223, 9, 'Amiodarone ', 'Tamoxifen', ' CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.', NULL, NULL, NULL),
(224, 9, 'Amiodarone ', 'Telaprevir', ' May enhance the adverse/toxic effect of Amiodarone. Telaprevir may increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(225, 9, 'Amiodarone ', 'Thioridazine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(226, 9, 'Amiodarone ', 'Timolol', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(227, 9, 'Amiodarone ', 'Tipranavir', ' Tipranavir may increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(228, 9, 'Amiodarone ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(229, 9, 'Amiodarone ', 'Tofacitinib', ' May enhance the bradycardic effect of Bradycardia-Causing Agents.', NULL, NULL, NULL),
(230, 9, 'Amiodarone ', 'Topotecan', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.', NULL, NULL, NULL),
(231, 9, 'Amiodarone ', 'Tramadol', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(232, 9, 'Amiodarone ', 'Verteporfin', ' Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.', NULL, NULL, NULL),
(233, 10, 'Amitriptyline ', '0', '0', NULL, NULL, NULL),
(234, 10, 'Amitriptyline ', 'Acepromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(235, 10, 'Amitriptyline ', 'Acetophenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(236, 10, 'Amitriptyline ', 'Aclidinium', ' May enhance the anticholinergic effect of Anticholinergic Agents.', NULL, NULL, NULL),
(237, 10, 'Amitriptyline ', 'Altretamine', ' May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.', NULL, NULL, NULL),
(238, 10, 'Amitriptyline ', 'Amisulpride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(239, 10, 'Amitriptyline ', 'Amphetamine', ' Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.', NULL, NULL, NULL),
(240, 10, 'Amitriptyline ', 'Aripiprazole', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(241, 10, 'Amitriptyline ', 'Batimastat', ' May increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(242, 10, 'Amitriptyline ', 'Benzquinamide', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(243, 10, 'Amitriptyline ', 'Buprenorphine', ' CNS Depressants may enhance the CNS depressant effect of Buprenorphine.', NULL, NULL, NULL),
(244, 10, 'Amitriptyline ', 'Bupropion', ' May decrease the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(245, 10, 'Amitriptyline ', 'Butabarbital', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(246, 10, 'Amitriptyline ', 'Butethal', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(247, 10, 'Amitriptyline ', 'Carbamazepine', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(248, 10, 'Amitriptyline ', 'Carphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(249, 10, 'Amitriptyline ', 'Cathinone', ' Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.', NULL, NULL, NULL),
(250, 10, 'Amitriptyline ', 'Chlormezanone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(251, 10, 'Amitriptyline ', 'Chlorpromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(252, 10, 'Amitriptyline ', 'Chlorprothixene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(253, 10, 'Amitriptyline ', 'Cimetidine', ' May decrease the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(254, 10, 'Amitriptyline ', 'Cinacalcet', ' May increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(255, 10, 'Amitriptyline ', 'Cisapride', ' Amitriptyline may enhance the arrhythmogenic effect of Cisapride.', NULL, NULL, NULL),
(256, 10, 'Amitriptyline ', 'Citalopram', ' Tricyclic Antidepressants may enhance the adverse/toxic effect of Citalopram. Tricyclic Antidepressants may increase the serum concentration of Citalopram. Citalopram may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(257, 10, 'Amitriptyline ', 'Clozapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(258, 10, 'Amitriptyline ', 'Dapoxetine', ' May enhance the adverse/toxic effect of Serotonin Modulators.', NULL, NULL, NULL),
(259, 10, 'Amitriptyline ', 'Darunavir', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(260, 10, 'Amitriptyline ', 'Desmopressin', ' Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.', NULL, NULL, NULL),
(261, 10, 'Amitriptyline ', 'Dexmethylphenidate', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(262, 10, 'Amitriptyline ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(263, 10, 'Amitriptyline ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(264, 10, 'Amitriptyline ', 'Droperidol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(265, 10, 'Amitriptyline ', 'Duloxetine', ' May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. DULoxetine may decrease the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(266, 10, 'Amitriptyline ', 'Escitalopram', ' Tricyclic Antidepressants may enhance the adverse/toxic effect of Escitalopram. Escitalopram may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(267, 10, 'Amitriptyline ', 'Fencamfamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(268, 10, 'Amitriptyline ', 'Fluconazole', ' May enhance the QTc-prolonging effect of Fluconazole. Fluconazole may increase the serum concentration of Amitriptyline.', NULL, NULL, NULL),
(269, 10, 'Amitriptyline ', 'Fluoxetine', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(270, 10, 'Amitriptyline ', 'Flupentixol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(271, 10, 'Amitriptyline ', 'Fluphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(272, 10, 'Amitriptyline ', 'Fluspirilene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(273, 10, 'Amitriptyline ', 'Fluvoxamine', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. FluvoxaMINE may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(274, 10, 'Amitriptyline ', 'Haloperidol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(275, 10, 'Amitriptyline ', 'Heptabarbital', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(276, 10, 'Amitriptyline ', 'Hexobarbital', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(277, 10, 'Amitriptyline ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(278, 10, 'Amitriptyline ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(279, 10, 'Amitriptyline ', 'Isoflurophate', ' May increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(280, 10, 'Amitriptyline ', 'Itopride', ' Anticholinergic Agents may diminish the therapeutic effect of Itopride.', NULL, NULL, NULL),
(281, 10, 'Amitriptyline ', 'Linezolid', ' May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.', NULL, NULL, NULL),
(282, 10, 'Amitriptyline ', 'Lithium', ' May enhance the neurotoxic effect of Tricyclic Antidepressants.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(283, 10, 'Amitriptyline ', 'Loxapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(284, 10, 'Amitriptyline ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(285, 10, 'Amitriptyline ', 'Mesoridazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(286, 10, 'Amitriptyline ', 'Methohexital', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(287, 10, 'Amitriptyline ', 'Methotrimeprazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(288, 10, 'Amitriptyline ', 'Methylphenidate', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(289, 10, 'Amitriptyline ', 'Metoclopramide', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants.', NULL, NULL, NULL),
(290, 10, 'Amitriptyline ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(291, 10, 'Amitriptyline ', 'Mianserin', ' May enhance the anticholinergic effect of Anticholinergic Agents.', NULL, NULL, NULL),
(292, 10, 'Amitriptyline ', 'Mifepristone', ' May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).', NULL, NULL, NULL),
(293, 10, 'Amitriptyline ', 'Mirabegron', ' Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.', NULL, NULL, NULL),
(294, 10, 'Amitriptyline ', 'Molindone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(295, 10, 'Amitriptyline ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(296, 10, 'Amitriptyline ', 'Olanzapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(297, 10, 'Amitriptyline ', 'Ondansetron', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(298, 10, 'Amitriptyline ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(299, 10, 'Amitriptyline ', 'Paliperidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(300, 10, 'Amitriptyline ', 'Panobinostat', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(301, 10, 'Amitriptyline ', 'Paroxetine', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. PARoxetine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(302, 10, 'Amitriptyline ', 'Peginterferon alfa-2b', ' May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(303, 10, 'Amitriptyline ', 'Pentobarbital', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(304, 10, 'Amitriptyline ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(305, 10, 'Amitriptyline ', 'Perphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(306, 10, 'Amitriptyline ', 'Pimozide', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(307, 10, 'Amitriptyline ', 'Piperacetazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(308, 10, 'Amitriptyline ', 'Potassium Chloride', ' Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.', NULL, NULL, NULL),
(309, 10, 'Amitriptyline ', 'Pramipexole', ' CNS Depressants may enhance the sedative effect of Pramipexole.', NULL, NULL, NULL),
(310, 10, 'Amitriptyline ', 'Pramlintide', ' May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.', NULL, NULL, NULL),
(311, 10, 'Amitriptyline ', 'Primidone', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(312, 10, 'Amitriptyline ', 'Prochlorperazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(313, 10, 'Amitriptyline ', 'Promazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(314, 10, 'Amitriptyline ', 'Quetiapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(315, 10, 'Amitriptyline ', 'Quinidine', ' Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(316, 10, 'Amitriptyline ', 'Remoxipride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(317, 10, 'Amitriptyline ', 'Reserpine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(318, 10, 'Amitriptyline ', 'Risperidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(319, 10, 'Amitriptyline ', 'Ropinirole', ' CNS Depressants may enhance the sedative effect of ROPINIRole.', NULL, NULL, NULL),
(320, 10, 'Amitriptyline ', 'Rotigotine', ' CNS Depressants may enhance the sedative effect of Rotigotine.', NULL, NULL, NULL),
(321, 10, 'Amitriptyline ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(322, 10, 'Amitriptyline ', 'Secobarbital', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(323, 10, 'Amitriptyline ', 'Secretin', ' Anticholinergic Agents may diminish the therapeutic effect of Secretin.', NULL, NULL, NULL),
(324, 10, 'Amitriptyline ', 'Sertindole', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(325, 10, 'Amitriptyline ', 'Sertraline', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(326, 10, 'Amitriptyline ', 'Simeprevir', ' May increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(327, 10, 'Amitriptyline ', 'Sulpiride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(328, 10, 'Amitriptyline ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(329, 10, 'Amitriptyline ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(330, 10, 'Amitriptyline ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(331, 10, 'Amitriptyline ', 'Thioridazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(332, 10, 'Amitriptyline ', 'Thiothixene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(333, 10, 'Amitriptyline ', 'Tiotropium', ' Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.', NULL, NULL, NULL),
(334, 10, 'Amitriptyline ', 'Topiramate', ' Topiramate may enhance the CNS depressant effect of Amitriptyline. Topiramate may increase serum concentrations of the active metabolite(s) of Amitriptyline. Topiramate may increase the serum concentration of Amitriptyline.', NULL, NULL, NULL),
(335, 10, 'Amitriptyline ', 'Tramadol', ' Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.', NULL, NULL, NULL),
(336, 10, 'Amitriptyline ', 'Trifluoperazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(337, 10, 'Amitriptyline ', 'Triflupromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(338, 10, 'Amitriptyline ', 'Yohimbine', ' Tricyclic Antidepressants may increase the serum concentration of Yohimbine.', NULL, NULL, NULL),
(339, 10, 'Amitriptyline ', 'Ziprasidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(340, 10, 'Amitriptyline ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(341, 10, 'Amitriptyline ', 'Zuclopenthixol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(342, 11, 'Amlodipine ', '0', '0', NULL, NULL, NULL),
(343, 11, 'Amlodipine ', 'Alfuzosin', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(344, 11, 'Amlodipine ', 'Amifostine', ' Antihypertensives may enhance the hypotensive effect of Amifostine.', NULL, NULL, NULL),
(345, 11, 'Amlodipine ', 'Amobarbital', ' Barbiturates may increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(346, 11, 'Amlodipine ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(347, 11, 'Amlodipine ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(348, 11, 'Amlodipine ', 'Atracurium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(349, 11, 'Amlodipine ', 'Batimastat', ' May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).', NULL, NULL, NULL),
(350, 11, 'Amlodipine ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(351, 11, 'Amlodipine ', 'Butabarbital', ' Barbiturates may increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(352, 11, 'Amlodipine ', 'Butalbital', ' Barbiturates may increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(353, 11, 'Amlodipine ', 'Butethal', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(354, 11, 'Amlodipine ', 'Calcium Acetate', ' Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(355, 11, 'Amlodipine ', 'Calcium carbonate', ' Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(356, 11, 'Amlodipine ', 'Calcium Chloride', ' Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(357, 11, 'Amlodipine ', 'Carbamazepine', ' May increase the metabolism of Calcium Channel Blockers (Dihydropyridine).', NULL, NULL, NULL),
(358, 11, 'Amlodipine ', 'Cimetidine', ' Cimetidine may increase the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(359, 11, 'Amlodipine ', 'Cisatracurium Besylate', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(360, 11, 'Amlodipine ', 'Clarithromycin', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(361, 11, 'Amlodipine ', 'Clopidogrel', ' Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.', NULL, NULL, NULL),
(362, 11, 'Amlodipine ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(363, 11, 'Amlodipine ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(364, 11, 'Amlodipine ', 'Dapoxetine', ' May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(365, 11, 'Amlodipine ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(366, 11, 'Amlodipine ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(367, 11, 'Amlodipine ', 'Diazoxide', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(368, 11, 'Amlodipine ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(369, 11, 'Amlodipine ', 'Doxazosin', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(370, 11, 'Amlodipine ', 'Duloxetine', ' Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.', NULL, NULL, NULL),
(371, 11, 'Amlodipine ', 'Efavirenz', ' May decrease the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(372, 11, 'Amlodipine ', 'Fluconazole', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(373, 11, 'Amlodipine ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(374, 11, 'Amlodipine ', 'Fosphenytoin', ' Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.', NULL, NULL, NULL),
(375, 11, 'Amlodipine ', 'Heptabarbital', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(376, 11, 'Amlodipine ', 'Hexobarbital', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(377, 11, 'Amlodipine ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(378, 11, 'Amlodipine ', 'Isoflurophate', ' May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).', NULL, NULL, NULL),
(379, 11, 'Amlodipine ', 'Itraconazole', ' Antifungal Agents (Azole Derivatives~ Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically~ itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.', NULL, NULL, NULL),
(380, 11, 'Amlodipine ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(381, 11, 'Amlodipine ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(382, 11, 'Amlodipine ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(383, 11, 'Amlodipine ', 'Magnesium oxide', ' May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(384, 11, 'Amlodipine ', 'Magnesium salicylate', ' May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(385, 11, 'Amlodipine ', 'Melatonin', ' May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).', NULL, NULL, NULL),
(386, 11, 'Amlodipine ', 'Methohexital', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(387, 11, 'Amlodipine ', 'Methylphenidate', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(388, 11, 'Amlodipine ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(389, 11, 'Amlodipine ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(390, 11, 'Amlodipine ', 'Nafcillin', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(391, 11, 'Amlodipine ', 'Nitroprusside', ' May enhance the hypotensive effect of Nitroprusside.', NULL, NULL, NULL),
(392, 11, 'Amlodipine ', 'Obinutuzumab', ' Antihypertensives may enhance the hypotensive effect of Obinutuzumab.', NULL, NULL, NULL),
(393, 11, 'Amlodipine ', 'Pancuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(394, 11, 'Amlodipine ', 'Pentobarbital', ' Barbiturates may increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(395, 11, 'Amlodipine ', 'Pentoxifylline', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(396, 11, 'Amlodipine ', 'Phenobarbital', ' Barbiturates may increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(397, 11, 'Amlodipine ', 'Phenoxybenzamine', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(398, 11, 'Amlodipine ', 'Phentolamine', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(399, 11, 'Amlodipine ', 'Phenytoin', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(400, 11, 'Amlodipine ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(401, 11, 'Amlodipine ', 'Posaconazole', ' Antifungal Agents (Azole Derivatives~ Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically~ itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.', NULL, NULL, NULL),
(402, 11, 'Amlodipine ', 'Prazosin', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(403, 11, 'Amlodipine ', 'Primidone', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(404, 11, 'Amlodipine ', 'Quinidine', ' May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(405, 11, 'Amlodipine ', 'Rifampicin', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(406, 11, 'Amlodipine ', 'Rifapentine', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(407, 11, 'Amlodipine ', 'Risperidone', ' Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.', NULL, NULL, NULL),
(408, 11, 'Amlodipine ', 'Rituximab', ' Antihypertensives may enhance the hypotensive effect of RiTUXimab.', NULL, NULL, NULL),
(409, 11, 'Amlodipine ', 'Rocuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(410, 11, 'Amlodipine ', 'Secobarbital', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(411, 11, 'Amlodipine ', 'Silodosin', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(412, 11, 'Amlodipine ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(413, 11, 'Amlodipine ', 'Simeprevir', ' May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).', NULL, NULL, NULL),
(414, 11, 'Amlodipine ', 'Simvastatin', ' AmLODIPine may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(415, 11, 'Amlodipine ', 'Sulfisoxazole', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(416, 11, 'Amlodipine ', 'Tadalafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(417, 11, 'Amlodipine ', 'Tamsulosin', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(418, 11, 'Amlodipine ', 'Telithromycin', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(419, 11, 'Amlodipine ', 'Terazosin', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(420, 11, 'Amlodipine ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(421, 11, 'Amlodipine ', 'Vardenafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(422, 11, 'Amlodipine ', 'Vecuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(423, 11, 'Amlodipine ', 'Voriconazole', ' Antifungal Agents (Azole Derivatives~ Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically~ itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.', NULL, NULL, NULL),
(424, 11, 'Amlodipine ', 'Yohimbine', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(425, 12, 'Amoxicillin ', '0', '0', NULL, NULL, NULL),
(426, 12, 'Amoxicillin ', 'Acenocoumarol', ' May enhance the anticoagulant effect of Vitamin K Antagonists.', NULL, NULL, NULL),
(427, 12, 'Amoxicillin ', 'Allopurinol', ' Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.', NULL, NULL, NULL),
(428, 12, 'Amoxicillin ', 'Amikacin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(429, 12, 'Amoxicillin ', 'Biotin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(430, 12, 'Amoxicillin ', 'Doxycycline', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(431, 12, 'Amoxicillin ', 'Kanamycin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(432, 12, 'Amoxicillin ', 'Methotrexate', ' May increase the serum concentration of Methotrexate.', NULL, NULL, NULL),
(433, 12, 'Amoxicillin ', 'Minocycline', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(434, 12, 'Amoxicillin ', 'Mycophenolate mofetil', ' May decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.', NULL, NULL, NULL),
(435, 12, 'Amoxicillin ', 'Mycophenolic acid', ' May decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.', NULL, NULL, NULL),
(436, 12, 'Amoxicillin ', 'Neomycin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(437, 12, 'Amoxicillin ', 'Probenecid', ' Probenecid may increase the serum concentration of Penicillins.', NULL, NULL, NULL),
(438, 12, 'Amoxicillin ', 'Streptomycin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(439, 12, 'Amoxicillin ', 'Tetracycline', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(440, 13, 'Ampicillin Sodium ', '0', '0', NULL, NULL, NULL),
(441, 14, 'Asparaginase ', '0', '0', NULL, NULL, NULL),
(442, 15, 'Aspirin ', '0', '0', NULL, NULL, NULL),
(443, 16, 'Atazanavir ', '0', '0', NULL, NULL, NULL),
(444, 16, 'Atazanavir ', 'Abacavir', ' Protease Inhibitors may decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(445, 16, 'Atazanavir ', 'Acetohexamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(446, 16, 'Atazanavir ', 'ado-trastuzumab emtansine', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically~ strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.', NULL, NULL, NULL),
(447, 16, 'Atazanavir ', 'Alfuzosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.', NULL, NULL, NULL),
(448, 16, 'Atazanavir ', 'Almotriptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.', NULL, NULL, NULL),
(449, 16, 'Atazanavir ', 'Alogliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(450, 16, 'Atazanavir ', 'Alosetron', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.', NULL, NULL, NULL),
(451, 16, 'Atazanavir ', 'Alprazolam', ' Protease Inhibitors may increase the serum concentration of ALPRAZolam.', NULL, NULL, NULL),
(452, 16, 'Atazanavir ', 'Aluminum hydroxide', ' May decrease the absorption of Atazanavir.', NULL, NULL, NULL),
(453, 16, 'Atazanavir ', 'Amiodarone', ' Atazanavir may increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(454, 16, 'Atazanavir ', 'Apixaban', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.', NULL, NULL, NULL),
(455, 16, 'Atazanavir ', 'Aripiprazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(456, 16, 'Atazanavir ', 'Astemizole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole.', NULL, NULL, NULL),
(457, 16, 'Atazanavir ', 'Atorvastatin', ' Protease Inhibitors may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(458, 16, 'Atazanavir ', 'Avanafil', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.', NULL, NULL, NULL),
(459, 16, 'Atazanavir ', 'Axitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.', NULL, NULL, NULL),
(460, 16, 'Atazanavir ', 'Batimastat', ' May increase the serum concentration of other Protease Inhibitors.', NULL, NULL, NULL),
(461, 16, 'Atazanavir ', 'Bedaquiline', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.', NULL, NULL, NULL),
(462, 16, 'Atazanavir ', 'Belinostat', ' Atazanavir may increase the serum concentration of Belinostat.', NULL, NULL, NULL),
(463, 16, 'Atazanavir ', 'Boceprevir', ' May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir.', NULL, NULL, NULL),
(464, 16, 'Atazanavir ', 'Bortezomib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.', NULL, NULL, NULL),
(465, 16, 'Atazanavir ', 'Bosentan', ' May increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(466, 16, 'Atazanavir ', 'Bosutinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.', NULL, NULL, NULL),
(467, 16, 'Atazanavir ', 'Brentuximab vedotin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.', NULL, NULL, NULL),
(468, 16, 'Atazanavir ', 'Brinzolamide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.', NULL, NULL, NULL),
(469, 16, 'Atazanavir ', 'Buprenorphine', ' May increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(470, 16, 'Atazanavir ', 'Cabazitaxel', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.', NULL, NULL, NULL),
(471, 16, 'Atazanavir ', 'Cabozantinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.', NULL, NULL, NULL),
(472, 16, 'Atazanavir ', 'Calcium carbonate', ' May decrease the absorption of Atazanavir.', NULL, NULL, NULL),
(473, 16, 'Atazanavir ', 'Canagliflozin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(474, 16, 'Atazanavir ', 'Carbamazepine', ' May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(475, 16, 'Atazanavir ', 'Chlorpropamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(476, 16, 'Atazanavir ', 'Cilostazol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.', NULL, NULL, NULL),
(477, 16, 'Atazanavir ', 'Cimetidine', ' H2-Antagonists may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(478, 16, 'Atazanavir ', 'Cisapride', ' Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.', NULL, NULL, NULL),
(479, 16, 'Atazanavir ', 'Clarithromycin', ' Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(480, 16, 'Atazanavir ', 'Colchicine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(481, 16, 'Atazanavir ', 'Conivaptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.', NULL, NULL, NULL),
(482, 16, 'Atazanavir ', 'Crizotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.', NULL, NULL, NULL),
(483, 16, 'Atazanavir ', 'Cyclophosphamide', ' Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(484, 16, 'Atazanavir ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(485, 16, 'Atazanavir ', 'Dapoxetine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine.', NULL, NULL, NULL),
(486, 16, 'Atazanavir ', 'Dasatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.', NULL, NULL, NULL),
(487, 16, 'Atazanavir ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(488, 16, 'Atazanavir ', 'Delavirdine', ' May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.', NULL, NULL, NULL),
(489, 16, 'Atazanavir ', 'Desogestrel', ' May increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(490, 16, 'Atazanavir ', 'Didanosine', ' May decrease the serum concentration of Didanosine. Reported with enteric coated didanosine capsules. Didanosine may decrease the serum concentration of Atazanavir. Specifically~ the buffered formulation of didanosine may decrease atazanavir absorption.', NULL, NULL, NULL),
(491, 16, 'Atazanavir ', 'Digoxin', ' Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(492, 16, 'Atazanavir ', 'Disulfiram', ' May diminish the therapeutic effect of Disulfiram.', NULL, NULL, NULL),
(493, 16, 'Atazanavir ', 'Domperidone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone.', NULL, NULL, NULL),
(494, 16, 'Atazanavir ', 'Dronabinol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronabinol.', NULL, NULL, NULL),
(495, 16, 'Atazanavir ', 'Dronedarone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.', NULL, NULL, NULL),
(496, 16, 'Atazanavir ', 'Drospirenone', ' May increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(497, 16, 'Atazanavir ', 'Dutasteride', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.', NULL, NULL, NULL),
(498, 16, 'Atazanavir ', 'Efavirenz', ' May decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(499, 16, 'Atazanavir ', 'Eliglustat', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eliglustat.', NULL, NULL, NULL),
(500, 16, 'Atazanavir ', 'Enfuvirtide', ' May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.', NULL, NULL, NULL),
(501, 16, 'Atazanavir ', 'Eplerenone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.', NULL, NULL, NULL),
(502, 16, 'Atazanavir ', 'Erlotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.', NULL, NULL, NULL),
(503, 16, 'Atazanavir ', 'Esomeprazole', ' Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(504, 16, 'Atazanavir ', 'Ethynodiol', ' May increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(505, 16, 'Atazanavir ', 'Etonogestrel', ' May increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(506, 16, 'Atazanavir ', 'Etravirine', ' Atazanavir may increase the serum concentration of Etravirine. Etravirine may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(507, 16, 'Atazanavir ', 'Everolimus', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.', NULL, NULL, NULL),
(508, 16, 'Atazanavir ', 'Famotidine', ' H2-Antagonists may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(509, 16, 'Atazanavir ', 'Fentanyl', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(510, 16, 'Atazanavir ', 'Fesoterodine', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.', NULL, NULL, NULL),
(511, 16, 'Atazanavir ', 'Fluvastatin', ' Atazanavir may increase the serum concentration of Fluvastatin.', NULL, NULL, NULL),
(512, 16, 'Atazanavir ', 'Gliclazide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(513, 16, 'Atazanavir ', 'Glimepiride', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(514, 16, 'Atazanavir ', 'Gliquidone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(515, 16, 'Atazanavir ', 'Glyburide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(516, 16, 'Atazanavir ', 'Guanfacine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.', NULL, NULL, NULL),
(517, 16, 'Atazanavir ', 'Halofantrine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.', NULL, NULL, NULL),
(518, 16, 'Atazanavir ', 'Hydrocodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(519, 16, 'Atazanavir ', 'Ifosfamide', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.', NULL, NULL, NULL),
(520, 16, 'Atazanavir ', 'Iloperidone', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically~ concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.', NULL, NULL, NULL),
(521, 16, 'Atazanavir ', 'Imatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib.', NULL, NULL, NULL),
(522, 16, 'Atazanavir ', 'Indinavir', ' May enhance the adverse/toxic effect of Indinavir. Indinavir may enhance the adverse/toxic effect of Atazanavir.', NULL, NULL, NULL),
(523, 16, 'Atazanavir ', 'Insulin Aspart', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(524, 16, 'Atazanavir ', 'Insulin Detemir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(525, 16, 'Atazanavir ', 'Insulin Glargine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(526, 16, 'Atazanavir ', 'Insulin Glulisine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(527, 16, 'Atazanavir ', 'Insulin Lispro', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(528, 16, 'Atazanavir ', 'Insulin Regular', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(529, 16, 'Atazanavir ', 'Insulin~ isophane', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(530, 16, 'Atazanavir ', 'Irinotecan', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan.', NULL, NULL, NULL),
(531, 16, 'Atazanavir ', 'Isoflurophate', ' May increase the serum concentration of other Protease Inhibitors.', NULL, NULL, NULL),
(532, 16, 'Atazanavir ', 'Ivacaftor', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.', NULL, NULL, NULL),
(533, 16, 'Atazanavir ', 'Ixabepilone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.', NULL, NULL, NULL),
(534, 16, 'Atazanavir ', 'Lacosamide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide.', NULL, NULL, NULL),
(535, 16, 'Atazanavir ', 'Lamotrigine', ' May decrease the serum concentration of LamoTRIgine.', NULL, NULL, NULL),
(536, 16, 'Atazanavir ', 'Lansoprazole', ' Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(537, 16, 'Atazanavir ', 'Lapatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.', NULL, NULL, NULL),
(538, 16, 'Atazanavir ', 'Lercanidipine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine.', NULL, NULL, NULL),
(539, 16, 'Atazanavir ', 'Levobupivacaine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine.', NULL, NULL, NULL),
(540, 16, 'Atazanavir ', 'Levomilnacipran', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.', NULL, NULL, NULL),
(541, 16, 'Atazanavir ', 'Levonorgestrel', ' May increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(542, 16, 'Atazanavir ', 'Linagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(543, 16, 'Atazanavir ', 'Lomitapide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(544, 16, 'Atazanavir ', 'Lovastatin', ' Protease Inhibitors may increase the serum concentration of Lovastatin.', NULL, NULL, NULL),
(545, 16, 'Atazanavir ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(546, 16, 'Atazanavir ', 'Lurasidone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.', NULL, NULL, NULL),
(547, 16, 'Atazanavir ', 'MACITENTAN', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan.', NULL, NULL, NULL),
(548, 16, 'Atazanavir ', 'Magnesium oxide', ' May decrease the absorption of Atazanavir.', NULL, NULL, NULL),
(549, 16, 'Atazanavir ', 'Maraviroc', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.', NULL, NULL, NULL),
(550, 16, 'Atazanavir ', 'Medroxyprogesterone Acetate', ' May increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(551, 16, 'Atazanavir ', 'Mestranol', ' May increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(552, 16, 'Atazanavir ', 'Metformin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(553, 16, 'Atazanavir ', 'Methylprednisolone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(554, 16, 'Atazanavir ', 'Midazolam', ' Protease Inhibitors may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(555, 16, 'Atazanavir ', 'Mifepristone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.', NULL, NULL, NULL),
(556, 16, 'Atazanavir ', 'Minocycline', ' Minocycline may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(557, 16, 'Atazanavir ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(558, 16, 'Atazanavir ', 'Nefazodone', ' Protease Inhibitors may increase the serum concentration of Nefazodone.', NULL, NULL, NULL),
(559, 16, 'Atazanavir ', 'Nevirapine', ' May increase the serum concentration of Nevirapine. Nevirapine may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(560, 16, 'Atazanavir ', 'Nilotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.', NULL, NULL, NULL),
(561, 16, 'Atazanavir ', 'Nisoldipine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.', NULL, NULL, NULL),
(562, 16, 'Atazanavir ', 'Nizatidine', ' H2-Antagonists may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(563, 16, 'Atazanavir ', 'Norelgestromin', ' May increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(564, 16, 'Atazanavir ', 'Norethindrone', ' May increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(565, 16, 'Atazanavir ', 'Norgestimate', ' May increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(566, 16, 'Atazanavir ', 'Omeprazole', ' Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(567, 16, 'Atazanavir ', 'Ospemifene', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.', NULL, NULL, NULL),
(568, 16, 'Atazanavir ', 'Oxybutynin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin.', NULL, NULL, NULL),
(569, 16, 'Atazanavir ', 'Oxycodone', ' CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased.', NULL, NULL, NULL),
(570, 16, 'Atazanavir ', 'Panobinostat', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.', NULL, NULL, NULL),
(571, 16, 'Atazanavir ', 'Pantoprazole', ' Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(572, 16, 'Atazanavir ', 'Paricalcitol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.', NULL, NULL, NULL),
(573, 16, 'Atazanavir ', 'Pazopanib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(574, 16, 'Atazanavir ', 'Pimecrolimus', ' CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.', NULL, NULL, NULL),
(575, 16, 'Atazanavir ', 'Pimozide', ' Protease Inhibitors may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(576, 16, 'Atazanavir ', 'Pitavastatin', ' Atazanavir may increase the serum concentration of Pitavastatin.', NULL, NULL, NULL),
(577, 16, 'Atazanavir ', 'Ponatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.', NULL, NULL, NULL),
(578, 16, 'Atazanavir ', 'Posaconazole', ' May increase the serum concentration of Atazanavir.', NULL, NULL, NULL),
(579, 16, 'Atazanavir ', 'Pranlukast', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast.', NULL, NULL, NULL),
(580, 16, 'Atazanavir ', 'Prasugrel', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.', NULL, NULL, NULL),
(581, 16, 'Atazanavir ', 'Prednisone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE.', NULL, NULL, NULL),
(582, 16, 'Atazanavir ', 'Propafenone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.', NULL, NULL, NULL),
(583, 16, 'Atazanavir ', 'Quetiapine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of QUEtiapine.', NULL, NULL, NULL),
(584, 16, 'Atazanavir ', 'Quinidine', ' May increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(585, 16, 'Atazanavir ', 'Rabeprazole', ' Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(586, 16, 'Atazanavir ', 'Ranitidine', ' H2-Antagonists may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(587, 16, 'Atazanavir ', 'Ranolazine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.', NULL, NULL, NULL),
(588, 16, 'Atazanavir ', 'Regorafenib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.', NULL, NULL, NULL),
(589, 16, 'Atazanavir ', 'Repaglinide', ' May increase the serum concentration of Repaglinide.', NULL, NULL, NULL),
(590, 16, 'Atazanavir ', 'Retapamulin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.', NULL, NULL, NULL),
(591, 16, 'Atazanavir ', 'Rifabutin', ' Atazanavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Atazanavir may increase the serum concentration of Rifabutin.', NULL, NULL, NULL),
(592, 16, 'Atazanavir ', 'Rifampicin', ' Rifampin may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(593, 16, 'Atazanavir ', 'Rilpivirine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rilpivirine.', NULL, NULL, NULL),
(594, 16, 'Atazanavir ', 'Riociguat', ' Protease Inhibitors may increase the serum concentration of Riociguat.', NULL, NULL, NULL),
(595, 16, 'Atazanavir ', 'Rivaroxaban', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. For clarithromycin~ refer to more specific clarithromycin-rivaroxaban monograph recommendations.', NULL, NULL, NULL),
(596, 16, 'Atazanavir ', 'Romidepsin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.', NULL, NULL, NULL),
(597, 16, 'Atazanavir ', 'Rosiglitazone', ' May increase the serum concentration of Rosiglitazone.', NULL, NULL, NULL),
(598, 16, 'Atazanavir ', 'Rosuvastatin', ' Protease Inhibitors may increase the serum concentration of Rosuvastatin.', NULL, NULL, NULL),
(599, 16, 'Atazanavir ', 'Ruxolitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.', NULL, NULL, NULL),
(600, 16, 'Atazanavir ', 'Salmeterol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.', NULL, NULL, NULL),
(601, 16, 'Atazanavir ', 'Saxagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(602, 16, 'Atazanavir ', 'Sildenafil', ' Protease Inhibitors may increase the serum concentration of Sildenafil.', NULL, NULL, NULL),
(603, 16, 'Atazanavir ', 'Silodosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.', NULL, NULL, NULL),
(604, 16, 'Atazanavir ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(605, 16, 'Atazanavir ', 'Simeprevir', ' May increase the serum concentration of other Protease Inhibitors.', NULL, NULL, NULL),
(606, 16, 'Atazanavir ', 'Simvastatin', ' Protease Inhibitors may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(607, 16, 'Atazanavir ', 'Sodium bicarbonate', ' Antacids may decrease the absorption of Atazanavir.', NULL, NULL, NULL),
(608, 16, 'Atazanavir ', 'Sorafenib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.', NULL, NULL, NULL),
(609, 16, 'Atazanavir ', 'Suvorexant', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant.', NULL, NULL, NULL),
(610, 16, 'Atazanavir ', 'Tadalafil', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.', NULL, NULL, NULL),
(611, 16, 'Atazanavir ', 'Tamsulosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.', NULL, NULL, NULL),
(612, 16, 'Atazanavir ', 'Telaprevir', ' Atazanavir may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Atazanavir.', NULL, NULL, NULL),
(613, 16, 'Atazanavir ', 'Temsirolimus', ' Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus~ the active metabolite~ may be increased~ likely due to inhibition of CYP-mediated metabolism.', NULL, NULL, NULL),
(614, 16, 'Atazanavir ', 'Tenofovir', ' May increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(615, 16, 'Atazanavir ', 'Terfenadine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Terfenadine.', NULL, NULL, NULL),
(616, 16, 'Atazanavir ', 'Ticagrelor', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.', NULL, NULL, NULL),
(617, 16, 'Atazanavir ', 'Tipranavir', ' May decrease the serum concentration of Protease Inhibitors.', NULL, NULL, NULL),
(618, 16, 'Atazanavir ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(619, 16, 'Atazanavir ', 'Tofacitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.', NULL, NULL, NULL),
(620, 16, 'Atazanavir ', 'Tolbutamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(621, 16, 'Atazanavir ', 'Tolterodine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.', NULL, NULL, NULL),
(622, 16, 'Atazanavir ', 'Tolvaptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.', NULL, NULL, NULL),
(623, 16, 'Atazanavir ', 'Toremifene', ' CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.', NULL, NULL, NULL),
(624, 16, 'Atazanavir ', 'Trabectedin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin.', NULL, NULL, NULL),
(625, 16, 'Atazanavir ', 'Trazodone', ' Atazanavir may increase the serum concentration of TraZODone.', NULL, NULL, NULL),
(626, 16, 'Atazanavir ', 'Triazolam', ' Protease Inhibitors may increase the serum concentration of Triazolam.', NULL, NULL, NULL),
(627, 16, 'Atazanavir ', 'Ulipristal', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.', NULL, NULL, NULL),
(628, 16, 'Atazanavir ', 'Vardenafil', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.', NULL, NULL, NULL),
(629, 16, 'Atazanavir ', 'Vemurafenib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.', NULL, NULL, NULL),
(630, 16, 'Atazanavir ', 'Vilazodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.', NULL, NULL, NULL),
(631, 16, 'Atazanavir ', 'Vildagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(632, 16, 'Atazanavir ', 'Vorapaxar', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar.', NULL, NULL, NULL),
(633, 16, 'Atazanavir ', 'Voriconazole', ' May decrease the serum concentration of Voriconazole. Atazanavir may increase the serum concentration of Voriconazole. Voriconazole may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(634, 16, 'Atazanavir ', 'Warfarin', ' Atazanavir may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(635, 16, 'Atazanavir ', 'Zidovudine', ' Protease Inhibitors may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(636, 16, 'Atazanavir ', 'Zopiclone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.', NULL, NULL, NULL),
(637, 16, 'Atazanavir ', 'Zuclopenthixol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.', NULL, NULL, NULL),
(638, 17, 'Atenolol ', '0', '0', NULL, NULL, NULL),
(639, 17, 'Atenolol ', 'Acetylcholine', ' Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.', NULL, NULL, NULL),
(640, 17, 'Atenolol ', 'Amifostine', ' Antihypertensives may enhance the hypotensive effect of Amifostine.', NULL, NULL, NULL),
(641, 17, 'Atenolol ', 'Amiodarone', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(642, 17, 'Atenolol ', 'Ampicillin', ' May decrease the bioavailability of Atenolol.', NULL, NULL, NULL),
(643, 17, 'Atenolol ', 'Bretylium', ' May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.', NULL, NULL, NULL),
(644, 17, 'Atenolol ', 'Bupivacaine', ' Beta-Blockers may increase the serum concentration of Bupivacaine.', NULL, NULL, NULL),
(645, 17, 'Atenolol ', 'Butabarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(646, 17, 'Atenolol ', 'Butethal', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(647, 17, 'Atenolol ', 'Carbachol', ' Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.', NULL, NULL, NULL),
(648, 17, 'Atenolol ', 'Diazoxide', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(649, 17, 'Atenolol ', 'Dipyridamole', ' May enhance the bradycardic effect of Beta-Blockers.', NULL, NULL, NULL),
(650, 17, 'Atenolol ', 'Disopyramide', ' May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.', NULL, NULL, NULL),
(651, 17, 'Atenolol ', 'Dronedarone', ' May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6.', NULL, NULL, NULL),
(652, 17, 'Atenolol ', 'Duloxetine', ' Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.', NULL, NULL, NULL),
(653, 17, 'Atenolol ', 'Fingolimod', ' Beta-Blockers may enhance the bradycardic effect of Fingolimod.', NULL, NULL, NULL),
(654, 17, 'Atenolol ', 'Floctafenine', ' May enhance the adverse/toxic effect of Beta-Blockers.', NULL, NULL, NULL),
(655, 17, 'Atenolol ', 'Glycopyrrolate', ' May increase the serum concentration of Atenolol.', NULL, NULL, NULL),
(656, 17, 'Atenolol ', 'Heptabarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(657, 17, 'Atenolol ', 'Hexobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(658, 17, 'Atenolol ', 'Lacosamide', ' Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.', NULL, NULL, NULL),
(659, 17, 'Atenolol ', 'Mepivacaine', ' Beta-Blockers may increase the serum concentration of Mepivacaine.', NULL, NULL, NULL),
(660, 17, 'Atenolol ', 'Methacholine', ' Beta-Blockers may enhance the adverse/toxic effect of Methacholine.', NULL, NULL, NULL),
(661, 17, 'Atenolol ', 'Methohexital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(662, 17, 'Atenolol ', 'Methylphenidate', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(663, 17, 'Atenolol ', 'Midodrine', ' Beta-Blockers may enhance the bradycardic effect of Midodrine.', NULL, NULL, NULL),
(664, 17, 'Atenolol ', 'Obinutuzumab', ' Antihypertensives may enhance the hypotensive effect of Obinutuzumab.', NULL, NULL, NULL),
(665, 17, 'Atenolol ', 'Pentobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(666, 17, 'Atenolol ', 'Pentoxifylline', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(667, 17, 'Atenolol ', 'Primidone', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(668, 17, 'Atenolol ', 'Regorafenib', ' May enhance the bradycardic effect of Beta-Blockers.', NULL, NULL, NULL),
(669, 17, 'Atenolol ', 'Reserpine', ' May enhance the hypotensive effect of Beta-Blockers.', NULL, NULL, NULL),
(670, 17, 'Atenolol ', 'Risperidone', ' Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.', NULL, NULL, NULL),
(671, 17, 'Atenolol ', 'Rituximab', ' Antihypertensives may enhance the hypotensive effect of RiTUXimab.', NULL, NULL, NULL),
(672, 17, 'Atenolol ', 'Rivastigmine', ' May enhance the bradycardic effect of Beta-Blockers.', NULL, NULL, NULL),
(673, 17, 'Atenolol ', 'Ruxolitinib', ' May enhance the bradycardic effect of Bradycardia-Causing Agents.', NULL, NULL, NULL),
(674, 17, 'Atenolol ', 'Secobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(675, 17, 'Atenolol ', 'Tadalafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(676, 17, 'Atenolol ', 'Tofacitinib', ' May enhance the bradycardic effect of Bradycardia-Causing Agents.', NULL, NULL, NULL),
(677, 17, 'Atenolol ', 'Vardenafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(678, 17, 'Atenolol ', 'Yohimbine', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(679, 18, 'Atorvastatin ', '0', '0', NULL, NULL, NULL),
(680, 18, 'Atorvastatin ', 'Afatinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.', NULL, NULL, NULL),
(681, 18, 'Atorvastatin ', 'Aliskiren', ' AtorvaSTATin may increase the serum concentration of Aliskiren.', NULL, NULL, NULL),
(682, 18, 'Atorvastatin ', 'Aluminum hydroxide', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(683, 18, 'Atorvastatin ', 'Amiodarone', ' May decrease the metabolism of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(684, 18, 'Atorvastatin ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(685, 18, 'Atorvastatin ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(686, 18, 'Atorvastatin ', 'Atazanavir', ' Protease Inhibitors may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(687, 18, 'Atorvastatin ', 'Batimastat', ' May increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(688, 18, 'Atorvastatin ', 'Bezafibrate', ' May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically~ bezafibrate may increase the serum concentration of fluvastatin', NULL, NULL, NULL),
(689, 18, 'Atorvastatin ', 'Boceprevir', ' May increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(690, 18, 'Atorvastatin ', 'Bosentan', ' May increase the metabolism of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(691, 18, 'Atorvastatin ', 'Bosutinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.', NULL, NULL, NULL),
(692, 18, 'Atorvastatin ', 'Brentuximab vedotin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.', NULL, NULL, NULL),
(693, 18, 'Atorvastatin ', 'Calcium carbonate', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(694, 18, 'Atorvastatin ', 'Cholestyramine', ' Bile Acid Sequestrants may decrease the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(695, 18, 'Atorvastatin ', 'Cimetidine', ' May enhance the adverse/toxic effect of Cimetidine. Specifically~ there is a theoretical potential for enhanced effects on reducing endogenous steroid activity.', NULL, NULL, NULL),
(696, 18, 'Atorvastatin ', 'Clarithromycin', ' May increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(697, 18, 'Atorvastatin ', 'Colchicine', ' May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(698, 18, 'Atorvastatin ', 'Colesevelam', ' Bile Acid Sequestrants may decrease the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(699, 18, 'Atorvastatin ', 'Colestipol', ' Bile Acid Sequestrants may decrease the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(700, 18, 'Atorvastatin ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(701, 18, 'Atorvastatin ', 'Dabigatran etexilate', ' AtorvaSTATin may decrease the serum concentration of Dabigatran Etexilate.', NULL, NULL, NULL),
(702, 18, 'Atorvastatin ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(703, 18, 'Atorvastatin ', 'Danazol', ' May increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(704, 18, 'Atorvastatin ', 'Daptomycin', ' HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically~ the risk of skeletal muscle toxicity may be increased.', NULL, NULL, NULL),
(705, 18, 'Atorvastatin ', 'Darunavir', ' Protease Inhibitors may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(706, 18, 'Atorvastatin ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(707, 18, 'Atorvastatin ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(708, 18, 'Atorvastatin ', 'Digoxin', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(709, 18, 'Atorvastatin ', 'Diltiazem', ' May increase the serum concentration of Diltiazem. Diltiazem may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(710, 18, 'Atorvastatin ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(711, 18, 'Atorvastatin ', 'Dronedarone', ' May increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(712, 18, 'Atorvastatin ', 'Efavirenz', ' May decrease the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(713, 18, 'Atorvastatin ', 'Eltrombopag', ' May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.', NULL, NULL, NULL),
(714, 18, 'Atorvastatin ', 'Etravirine', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin~ lovastatin and simvastatin. Conversely~ levels of fluvastatin may be increased.', NULL, NULL, NULL),
(715, 18, 'Atorvastatin ', 'Everolimus', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.', NULL, NULL, NULL),
(716, 18, 'Atorvastatin ', 'Fluconazole', ' Fluconazole may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(717, 18, 'Atorvastatin ', 'Fosamprenavir', ' Protease Inhibitors may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(718, 18, 'Atorvastatin ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(719, 18, 'Atorvastatin ', 'Fosphenytoin', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(720, 18, 'Atorvastatin ', 'Gemfibrozil', ' May enhance the myopathic (rhabdomyolysis) effect of AtorvaSTATin. Gemfibrozil may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(721, 18, 'Atorvastatin ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(722, 18, 'Atorvastatin ', 'Indinavir', ' Protease Inhibitors may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(723, 18, 'Atorvastatin ', 'Isoflurophate', ' May increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(724, 18, 'Atorvastatin ', 'Itraconazole', ' May increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(725, 18, 'Atorvastatin ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(726, 18, 'Atorvastatin ', 'Ledipasvir', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(727, 18, 'Atorvastatin ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(728, 18, 'Atorvastatin ', 'Lopinavir', ' Protease Inhibitors may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(729, 18, 'Atorvastatin ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(730, 18, 'Atorvastatin ', 'Magnesium oxide', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(731, 18, 'Atorvastatin ', 'Midazolam', ' May increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(732, 18, 'Atorvastatin ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(733, 18, 'Atorvastatin ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(734, 18, 'Atorvastatin ', 'Nelfinavir', ' Protease Inhibitors may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(735, 18, 'Atorvastatin ', 'Niacin', ' May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(736, 18, 'Atorvastatin ', 'Pazopanib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(737, 18, 'Atorvastatin ', 'Phenytoin', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(738, 18, 'Atorvastatin ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(739, 18, 'Atorvastatin ', 'Posaconazole', ' May increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(740, 18, 'Atorvastatin ', 'prucalopride', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.', NULL, NULL, NULL),
(741, 18, 'Atorvastatin ', 'Quinine', ' May increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(742, 18, 'Atorvastatin ', 'Raltegravir', ' May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(743, 18, 'Atorvastatin ', 'Ranolazine', ' Ranolazine may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(744, 18, 'Atorvastatin ', 'Rifaximin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.', NULL, NULL, NULL),
(745, 18, 'Atorvastatin ', 'Ritonavir', ' Protease Inhibitors may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(746, 18, 'Atorvastatin ', 'Rivaroxaban', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.', NULL, NULL, NULL),
(747, 18, 'Atorvastatin ', 'Saquinavir', ' Protease Inhibitors may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(748, 18, 'Atorvastatin ', 'Sildenafil', ' May decrease the metabolism of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(749, 18, 'Atorvastatin ', 'Silodosin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.', NULL, NULL, NULL),
(750, 18, 'Atorvastatin ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(751, 18, 'Atorvastatin ', 'Simeprevir', ' May increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(752, 18, 'Atorvastatin ', 'Spironolactone', ' May enhance the adverse/toxic effect of Spironolactone. Specifically~ there is a theoretical potential for enhanced effects on reducing endogenous steroid activity.', NULL, NULL, NULL),
(753, 18, 'Atorvastatin ', 'Sulfisoxazole', ' Erythromycin (Systemic) may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(754, 18, 'Atorvastatin ', 'Telaprevir', ' May increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(755, 18, 'Atorvastatin ', 'Telithromycin', ' Telithromycin may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(756, 18, 'Atorvastatin ', 'Teriflunomide', ' May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.', NULL, NULL, NULL),
(757, 18, 'Atorvastatin ', 'Tipranavir', ' Tipranavir may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(758, 18, 'Atorvastatin ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(759, 18, 'Atorvastatin ', 'Topotecan', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.', NULL, NULL, NULL),
(760, 18, 'Atorvastatin ', 'Trabectedin', ' HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.', NULL, NULL, NULL),
(761, 18, 'Atorvastatin ', 'Verapamil', ' AtorvaSTATin may increase the serum concentration of Verapamil. Verapamil may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(762, 18, 'Atorvastatin ', 'Voriconazole', ' Voriconazole may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(763, 19, 'Atracurium ', '0', '0', NULL, NULL, NULL),
(764, 19, 'Atracurium ', 'Amikacin', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(765, 19, 'Atracurium ', 'Amlodipine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(766, 19, 'Atracurium ', 'Amrinone', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(767, 19, 'Atracurium ', 'Arbekacin', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(768, 19, 'Atracurium ', 'Bepridil', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(769, 19, 'Atracurium ', 'Capreomycin', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(770, 19, 'Atracurium ', 'Colistimethate', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(771, 19, 'Atracurium ', 'Felodipine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(772, 19, 'Atracurium ', 'Flunarizine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(773, 19, 'Atracurium ', 'Framycetin', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(774, 19, 'Atracurium ', 'Gabapentin', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(775, 19, 'Atracurium ', 'Gentamicin', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(776, 19, 'Atracurium ', 'Isradipine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(777, 19, 'Atracurium ', 'Kanamycin', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(778, 19, 'Atracurium ', 'Lamotrigine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(779, 19, 'Atracurium ', 'Lercanidipine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(780, 19, 'Atracurium ', 'Lithium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(781, 19, 'Atracurium ', 'Magnesium Sulfate', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(782, 19, 'Atracurium ', 'Neomycin', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(783, 19, 'Atracurium ', 'Netilmicin', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(784, 19, 'Atracurium ', 'Nicardipine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(785, 19, 'Atracurium ', 'Nimodipine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(786, 19, 'Atracurium ', 'Nisoldipine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(787, 19, 'Atracurium ', 'Nitrendipine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(788, 19, 'Atracurium ', 'Perhexiline', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(789, 19, 'Atracurium ', 'Prenylamine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(790, 19, 'Atracurium ', 'Procainamide', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(791, 19, 'Atracurium ', 'Quinidine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(792, 19, 'Atracurium ', 'Quinine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(793, 19, 'Atracurium ', 'Ribostamycin', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(794, 19, 'Atracurium ', 'Risedronate', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(795, 19, 'Atracurium ', 'Spectinomycin', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(796, 19, 'Atracurium ', 'Spironolactone', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(797, 19, 'Atracurium ', 'Streptomycin', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(798, 19, 'Atracurium ', 'Tobramycin', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(799, 19, 'Atracurium ', 'Vancomycin', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(800, 19, 'Atracurium ', 'Verapamil', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(801, 20, 'Atropine Sulfate ', '0', '0', NULL, NULL, NULL),
(802, 21, 'Azathioprine Sodium ', '0', '0', NULL, NULL, NULL),
(803, 22, 'Azithromycin ', '0', '0', NULL, NULL, NULL),
(804, 23, 'Beclomethasone Dipropionate ', '0', '0', NULL, NULL, NULL),
(805, 24, 'Beractant ', '0', '0', NULL, NULL, NULL),
(806, 25, 'Betamethasone Valerate ', '0', '0', NULL, NULL, NULL),
(807, 26, 'Betaxolol Hydrochloride ', '0', '0', NULL, NULL, NULL),
(808, 27, 'Biclutomide ', '0', '0', NULL, NULL, NULL),
(809, 28, 'Biperiden Hydrochloride ', '0', '0', NULL, NULL, NULL),
(810, 29, 'Bisacodyl ', '0', '0', NULL, NULL, NULL),
(811, 29, 'Bisacodyl ', 'Aluminum hydroxide', ' Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine. Gastric irritation and/or cramps may occur.', NULL, NULL, NULL),
(812, 29, 'Bisacodyl ', 'Calcium carbonate', ' Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine. Gastric irritation and/or cramps may occur.', NULL, NULL, NULL),
(813, 29, 'Bisacodyl ', 'Magnesium oxide', ' May diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine. Gastric irritation and/or cramps may occur.', NULL, NULL, NULL),
(814, 29, 'Bisacodyl ', 'Sodium bicarbonate', ' Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine. Gastric irritation and/or cramps may occur.', NULL, NULL, NULL),
(815, 30, 'Bleomycin Sulfate ', '0', '0', NULL, NULL, NULL),
(816, 31, 'Brimonidine Tartrate ', '0', '0', NULL, NULL, NULL),
(817, 32, 'Bromocriptine ', '0', '0', NULL, NULL, NULL),
(818, 32, 'Bromocriptine ', 'Acetohexamide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(819, 32, 'Bromocriptine ', 'Acetylsalicylic acid', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.', NULL, NULL, NULL),
(820, 32, 'Bromocriptine ', 'Amisulpride', ' Anti-Parkinson\'s Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride. Amisulpride may diminish the therapeutic effect of Anti-Parkinson\'s Agents (Dopamine Agonist).', NULL, NULL, NULL),
(821, 32, 'Bromocriptine ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(822, 32, 'Bromocriptine ', 'Batimastat', ' May increase the serum concentration of Ergot Derivatives.', NULL, NULL, NULL),
(823, 32, 'Bromocriptine ', 'Buformin', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(824, 32, 'Bromocriptine ', 'Bupropion', ' Anti-Parkinson\'s Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion.', NULL, NULL, NULL),
(825, 32, 'Bromocriptine ', 'Chlorpropamide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(826, 32, 'Bromocriptine ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(827, 32, 'Bromocriptine ', 'Dapoxetine', ' May enhance the adverse/toxic effect of Serotonin Modulators.', NULL, NULL, NULL),
(828, 32, 'Bromocriptine ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(829, 32, 'Bromocriptine ', 'Dihydrotestosterone', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.', NULL, NULL, NULL),
(830, 32, 'Bromocriptine ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(831, 32, 'Bromocriptine ', 'Ethanol', ' Alcohol (Ethyl) may enhance the adverse/toxic effect of Bromocriptine. Bromocriptine may enhance the adverse/toxic effect of Alcohol (Ethyl).', NULL, NULL, NULL),
(832, 32, 'Bromocriptine ', 'Exenatide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(833, 32, 'Bromocriptine ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(834, 32, 'Bromocriptine ', 'Gliclazide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(835, 32, 'Bromocriptine ', 'Glimepiride', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(836, 32, 'Bromocriptine ', 'Glipizide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(837, 32, 'Bromocriptine ', 'Glucagon recombinant', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(838, 32, 'Bromocriptine ', 'Glyburide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(839, 32, 'Bromocriptine ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(840, 32, 'Bromocriptine ', 'Insulin Aspart', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(841, 32, 'Bromocriptine ', 'Insulin Glargine', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(842, 32, 'Bromocriptine ', 'Insulin Lispro', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(843, 32, 'Bromocriptine ', 'Insulin~ isophane', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(844, 32, 'Bromocriptine ', 'Insulin~ porcine', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(845, 32, 'Bromocriptine ', 'Isoflurophate', ' May increase the serum concentration of Ergot Derivatives.', NULL, NULL, NULL),
(846, 32, 'Bromocriptine ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(847, 32, 'Bromocriptine ', 'Lanreotide', ' Somatostatin Analogs may increase the serum concentration of Bromocriptine. Somatostatin Analogs may also delay bromocriptine absorption and time to maximum plasma concentrations.', NULL, NULL, NULL),
(848, 32, 'Bromocriptine ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(849, 32, 'Bromocriptine ', 'Lorcaserin', ' May enhance the adverse/toxic effect of Ergot Derivatives. Specifically~ use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.', NULL, NULL, NULL),
(850, 32, 'Bromocriptine ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(851, 32, 'Bromocriptine ', 'Methylphenidate', ' May enhance the adverse/toxic effect of Anti-Parkinson\'s Agents (Dopamine Agonist).', NULL, NULL, NULL),
(852, 32, 'Bromocriptine ', 'Metoclopramide', ' May diminish the therapeutic effect of Anti-Parkinson\'s Agents (Dopamine Agonist).', NULL, NULL, NULL),
(853, 32, 'Bromocriptine ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(854, 32, 'Bromocriptine ', 'Mitiglinide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(855, 32, 'Bromocriptine ', 'Nateglinide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(856, 32, 'Bromocriptine ', 'Nitroglycerin', ' Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.', NULL, NULL, NULL),
(857, 32, 'Bromocriptine ', 'Octreotide', ' Somatostatin Analogs may increase the serum concentration of Bromocriptine. Somatostatin Analogs may also delay bromocriptine absorption and time to maximum plasma concentrations.', NULL, NULL, NULL),
(858, 32, 'Bromocriptine ', 'Oxandrolone', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.', NULL, NULL, NULL),
(859, 32, 'Bromocriptine ', 'Pasireotide', ' Somatostatin Analogs may increase the serum concentration of Bromocriptine. Somatostatin Analogs may also delay bromocriptine absorption and time to maximum plasma concentrations.', NULL, NULL, NULL),
(860, 32, 'Bromocriptine ', 'Pegvisomant', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.', NULL, NULL, NULL),
(861, 32, 'Bromocriptine ', 'Phenformin', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(862, 32, 'Bromocriptine ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(863, 32, 'Bromocriptine ', 'Pioglitazone', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(864, 32, 'Bromocriptine ', 'Repaglinide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(865, 32, 'Bromocriptine ', 'Salicylate-sodium', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.', NULL, NULL, NULL),
(866, 32, 'Bromocriptine ', 'Simeprevir', ' May increase the serum concentration of Ergot Derivatives.', NULL, NULL, NULL),
(867, 32, 'Bromocriptine ', 'Sulodexide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(868, 32, 'Bromocriptine ', 'Testosterone', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.', NULL, NULL, NULL),
(869, 32, 'Bromocriptine ', 'Tolbutamide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(870, 33, 'Bupivacaine Hydrochloride ', '0', '0', NULL, NULL, NULL),
(871, 34, 'Caffeine Citrate ', '0', '0', NULL, NULL, NULL),
(872, 35, 'Capecitabine ', '0', '0', NULL, NULL, NULL),
(873, 35, 'Capecitabine ', 'Acenocoumarol', ' May increase the serum concentration of Vitamin K Antagonists.', NULL, NULL, NULL),
(874, 35, 'Capecitabine ', 'Bosentan', ' CYP2C9 Inhibitors (Strong) may increase the serum concentration of Bosentan.', NULL, NULL, NULL),
(875, 35, 'Capecitabine ', 'Carvedilol', ' CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically~ concentrations of the S-carvedilol enantiomer may be increased.', NULL, NULL, NULL),
(876, 35, 'Capecitabine ', 'Cimetidine', ' Cimetidine may increase serum concentrations of the active metabolite(s) of Capecitabine. Specifically~ concentrations of fluorouracil may be increased.', NULL, NULL, NULL),
(877, 35, 'Capecitabine ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(878, 35, 'Capecitabine ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(879, 35, 'Capecitabine ', 'Dronabinol', ' CYP2C9 Inhibitors (Strong) may increase the serum concentration of Dronabinol.', NULL, NULL, NULL),
(880, 35, 'Capecitabine ', 'Fosphenytoin', ' Capecitabine may increase the serum concentration of Fosphenytoin.', NULL, NULL, NULL),
(881, 35, 'Capecitabine ', 'Lacosamide', ' CYP2C9 Inhibitors (Strong) may increase the serum concentration of Lacosamide.', NULL, NULL, NULL),
(882, 35, 'Capecitabine ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(883, 35, 'Capecitabine ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(884, 35, 'Capecitabine ', 'Ospemifene', ' CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ospemifene.', NULL, NULL, NULL),
(885, 35, 'Capecitabine ', 'Phenytoin', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(886, 35, 'Capecitabine ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(887, 35, 'Capecitabine ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(888, 35, 'Capecitabine ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(889, 35, 'Capecitabine ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(890, 35, 'Capecitabine ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(891, 36, 'Capreomycin Sulfate ', '0', '0', NULL, NULL, NULL),
(892, 37, 'Captopril ', '0', '0', NULL, NULL, NULL),
(893, 37, 'Captopril ', 'Acetylsalicylic acid', ' May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems~ whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.', NULL, NULL, NULL),
(894, 37, 'Captopril ', 'Alfuzosin', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(895, 37, 'Captopril ', 'Aliskiren', ' May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors.', NULL, NULL, NULL),
(896, 37, 'Captopril ', 'Allopurinol', ' ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.', NULL, NULL, NULL),
(897, 37, 'Captopril ', 'Aluminum hydroxide', ' May decrease the serum concentration of Captopril.', NULL, NULL, NULL),
(898, 37, 'Captopril ', 'Amifostine', ' Antihypertensives may enhance the hypotensive effect of Amifostine.', NULL, NULL, NULL),
(899, 37, 'Captopril ', 'Aprotinin', ' May diminish the antihypertensive effect of ACE Inhibitors.', NULL, NULL, NULL),
(900, 37, 'Captopril ', 'Azathioprine', ' ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.', NULL, NULL, NULL),
(901, 37, 'Captopril ', 'Butabarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(902, 37, 'Captopril ', 'Butethal', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(903, 37, 'Captopril ', 'Calcium carbonate', ' May decrease the serum concentration of Captopril.', NULL, NULL, NULL),
(904, 37, 'Captopril ', 'Canagliflozin', ' May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.', NULL, NULL, NULL),
(905, 37, 'Captopril ', 'Dapoxetine', ' May enhance the orthostatic hypotensive effect of ACE Inhibitors.', NULL, NULL, NULL),
(906, 37, 'Captopril ', 'Darunavir', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(907, 37, 'Captopril ', 'Diazoxide', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(908, 37, 'Captopril ', 'Duloxetine', ' Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.', NULL, NULL, NULL),
(909, 37, 'Captopril ', 'Eplerenone', ' May enhance the hyperkalemic effect of ACE Inhibitors.', NULL, NULL, NULL),
(910, 37, 'Captopril ', 'Everolimus', ' May enhance the adverse/toxic effect of ACE Inhibitors. Specifically~ the risk of angioedema may be increased.', NULL, NULL, NULL),
(911, 37, 'Captopril ', 'Heparin', ' May enhance the hyperkalemic effect of ACE Inhibitors.', NULL, NULL, NULL),
(912, 37, 'Captopril ', 'Heptabarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(913, 37, 'Captopril ', 'Hexobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(914, 37, 'Captopril ', 'Icatibant', ' May diminish the antihypertensive effect of ACE Inhibitors.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(915, 37, 'Captopril ', 'Lithium', ' ACE Inhibitors may increase the serum concentration of Lithium.', NULL, NULL, NULL),
(916, 37, 'Captopril ', 'Magnesium oxide', ' May decrease the serum concentration of Captopril.', NULL, NULL, NULL),
(917, 37, 'Captopril ', 'Methohexital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(918, 37, 'Captopril ', 'Methylphenidate', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(919, 37, 'Captopril ', 'Obinutuzumab', ' Antihypertensives may enhance the hypotensive effect of Obinutuzumab.', NULL, NULL, NULL),
(920, 37, 'Captopril ', 'Panobinostat', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(921, 37, 'Captopril ', 'Peginterferon alfa-2b', ' May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(922, 37, 'Captopril ', 'Pentobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(923, 37, 'Captopril ', 'Pentoxifylline', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(924, 37, 'Captopril ', 'Primidone', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(925, 37, 'Captopril ', 'Risperidone', ' Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.', NULL, NULL, NULL),
(926, 37, 'Captopril ', 'Rituximab', ' Antihypertensives may enhance the hypotensive effect of RiTUXimab.', NULL, NULL, NULL),
(927, 37, 'Captopril ', 'Salicylate-sodium', ' May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems~ whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.', NULL, NULL, NULL),
(928, 37, 'Captopril ', 'Secobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(929, 37, 'Captopril ', 'Sirolimus', ' May enhance the adverse/toxic effect of ACE Inhibitors.', NULL, NULL, NULL),
(930, 37, 'Captopril ', 'Sodium bicarbonate', ' Antacids may decrease the serum concentration of Captopril.', NULL, NULL, NULL),
(931, 37, 'Captopril ', 'Tadalafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(932, 37, 'Captopril ', 'Temsirolimus', ' May enhance the adverse/toxic effect of ACE Inhibitors.', NULL, NULL, NULL),
(933, 37, 'Captopril ', 'Tizanidine', ' May enhance the hypotensive effect of ACE Inhibitors.', NULL, NULL, NULL),
(934, 37, 'Captopril ', 'Tolvaptan', ' May enhance the hyperkalemic effect of ACE Inhibitors.', NULL, NULL, NULL),
(935, 37, 'Captopril ', 'Trimethoprim', ' May enhance the hyperkalemic effect of ACE Inhibitors.', NULL, NULL, NULL),
(936, 37, 'Captopril ', 'Vardenafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(937, 37, 'Captopril ', 'Yohimbine', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(938, 38, 'Carbamazepine ', '0', '0', NULL, NULL, NULL),
(939, 38, 'Carbamazepine ', 'Acenocoumarol', ' May decrease the serum concentration of Vitamin K Antagonists.', NULL, NULL, NULL),
(940, 38, 'Carbamazepine ', 'Acetaminophen', ' May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.', NULL, NULL, NULL),
(941, 38, 'Carbamazepine ', 'Acetazolamide', ' May increase the serum concentration of CarBAMazepine. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(942, 38, 'Carbamazepine ', 'Adenosine', ' CarBAMazepine may enhance the adverse/toxic effect of Adenosine. Specifically~ the risk of higher degree heart block may be increased.', NULL, NULL, NULL),
(943, 38, 'Carbamazepine ', 'Afatinib', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.', NULL, NULL, NULL),
(944, 38, 'Carbamazepine ', 'Albendazole', ' May decrease serum concentrations of the active metabolite(s) of Albendazole.', NULL, NULL, NULL),
(945, 38, 'Carbamazepine ', 'Allopurinol', ' Allopurinol may increase the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(946, 38, 'Carbamazepine ', 'Aminophylline', ' Theophylline Derivatives may decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Theophylline Derivatives.', NULL, NULL, NULL),
(947, 38, 'Carbamazepine ', 'Amitriptyline', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(948, 38, 'Carbamazepine ', 'Amlodipine', ' May increase the metabolism of Calcium Channel Blockers (Dihydropyridine).', NULL, NULL, NULL),
(949, 38, 'Carbamazepine ', 'Amoxapine', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(950, 38, 'Carbamazepine ', 'Apixaban', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.', NULL, NULL, NULL),
(951, 38, 'Carbamazepine ', 'Apremilast', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast.', NULL, NULL, NULL),
(952, 38, 'Carbamazepine ', 'Aripiprazole', ' CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(953, 38, 'Carbamazepine ', 'Artemether', ' CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically~ dihydroartemisinin concentrations may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether.', NULL, NULL, NULL),
(954, 38, 'Carbamazepine ', 'Atazanavir', ' May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(955, 38, 'Carbamazepine ', 'Axitinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.', NULL, NULL, NULL),
(956, 38, 'Carbamazepine ', 'Azilsartan medoxomil', ' Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.', NULL, NULL, NULL),
(957, 38, 'Carbamazepine ', 'Batimastat', ' CarBAMazepine may increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(958, 38, 'Carbamazepine ', 'bazedoxifene', ' CarBAMazepine may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or~ if bazedoxifene is combined with estrogen therapy~ an increased risk of endometrial hyperplasia.', NULL, NULL, NULL),
(959, 38, 'Carbamazepine ', 'Bedaquiline', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.', NULL, NULL, NULL),
(960, 38, 'Carbamazepine ', 'Bendamustine', ' CYP1A2 Inducers (Strong) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.', NULL, NULL, NULL),
(961, 38, 'Carbamazepine ', 'Bendroflumethiazide', ' Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.', NULL, NULL, NULL),
(962, 38, 'Carbamazepine ', 'Boceprevir', ' CarBAMazepine may decrease the serum concentration of Boceprevir.', NULL, NULL, NULL),
(963, 38, 'Carbamazepine ', 'Bortezomib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.', NULL, NULL, NULL),
(964, 38, 'Carbamazepine ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(965, 38, 'Carbamazepine ', 'Bosutinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.', NULL, NULL, NULL),
(966, 38, 'Carbamazepine ', 'Brentuximab vedotin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.', NULL, NULL, NULL),
(967, 38, 'Carbamazepine ', 'Buprenorphine', ' CNS Depressants may enhance the CNS depressant effect of Buprenorphine.', NULL, NULL, NULL),
(968, 38, 'Carbamazepine ', 'Butalbital', ' May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.', NULL, NULL, NULL),
(969, 38, 'Carbamazepine ', 'Cabozantinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.', NULL, NULL, NULL),
(970, 38, 'Carbamazepine ', 'Canagliflozin', ' CarBAMazepine may decrease the serum concentration of Canagliflozin.', NULL, NULL, NULL),
(971, 38, 'Carbamazepine ', 'Caspofungin', ' Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.', NULL, NULL, NULL),
(972, 38, 'Carbamazepine ', 'Chlorothiazide', ' Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.', NULL, NULL, NULL),
(973, 38, 'Carbamazepine ', 'Chlorthalidone', ' Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.', NULL, NULL, NULL),
(974, 38, 'Carbamazepine ', 'Cimetidine', ' Cimetidine may increase the serum concentration of CarBAMazepine. The serum carbamazepine concentration might return to normal within one week of starting cimetidine.', NULL, NULL, NULL),
(975, 38, 'Carbamazepine ', 'Citalopram', ' May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.', NULL, NULL, NULL),
(976, 38, 'Carbamazepine ', 'Clarithromycin', ' CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(977, 38, 'Carbamazepine ', 'Clomipramine', ' CarBAMazepine may increase the serum concentration of ClomiPRAMINE.', NULL, NULL, NULL),
(978, 38, 'Carbamazepine ', 'Clozapine', ' May enhance the myelosuppressive effect of CloZAPine. CarBAMazepine may decrease the serum concentration of CloZAPine.', NULL, NULL, NULL),
(979, 38, 'Carbamazepine ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(980, 38, 'Carbamazepine ', 'Crizotinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.', NULL, NULL, NULL),
(981, 38, 'Carbamazepine ', 'Dabigatran etexilate', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.', NULL, NULL, NULL),
(982, 38, 'Carbamazepine ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(983, 38, 'Carbamazepine ', 'Danazol', ' May decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(984, 38, 'Carbamazepine ', 'Darunavir', ' May increase the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(985, 38, 'Carbamazepine ', 'Dasatinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.', NULL, NULL, NULL),
(986, 38, 'Carbamazepine ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(987, 38, 'Carbamazepine ', 'Delavirdine', ' May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.', NULL, NULL, NULL),
(988, 38, 'Carbamazepine ', 'Desipramine', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(989, 38, 'Carbamazepine ', 'Desmopressin', ' May enhance the adverse/toxic effect of Desmopressin.', NULL, NULL, NULL),
(990, 38, 'Carbamazepine ', 'Desogestrel', ' May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.', NULL, NULL, NULL),
(991, 38, 'Carbamazepine ', 'Diclofenamide', ' May increase the serum concentration of CarBAMazepine. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(992, 38, 'Carbamazepine ', 'Dihydrocodeine', ' May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.', NULL, NULL, NULL),
(993, 38, 'Carbamazepine ', 'Diltiazem', ' May decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(994, 38, 'Carbamazepine ', 'Dolutegravir', ' CarBAMazepine may decrease the serum concentration of Dolutegravir.', NULL, NULL, NULL),
(995, 38, 'Carbamazepine ', 'Doxycycline', ' May decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(996, 38, 'Carbamazepine ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(997, 38, 'Carbamazepine ', 'Dronabinol', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronabinol.', NULL, NULL, NULL),
(998, 38, 'Carbamazepine ', 'Dronedarone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.', NULL, NULL, NULL),
(999, 38, 'Carbamazepine ', 'Droperidol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1000, 38, 'Carbamazepine ', 'Drospirenone', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(1001, 38, 'Carbamazepine ', 'Eliglustat', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat.', NULL, NULL, NULL),
(1002, 38, 'Carbamazepine ', 'Enzalutamide', ' CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.', NULL, NULL, NULL),
(1003, 38, 'Carbamazepine ', 'Erlotinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Erlotinib.', NULL, NULL, NULL),
(1004, 38, 'Carbamazepine ', 'Escitalopram', ' May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.', NULL, NULL, NULL),
(1005, 38, 'Carbamazepine ', 'Ethinyl Estradiol', ' May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.', NULL, NULL, NULL),
(1006, 38, 'Carbamazepine ', 'Ethoxzolamide', ' May increase the serum concentration of CarBAMazepine. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(1007, 38, 'Carbamazepine ', 'Ethynodiol', ' May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.', NULL, NULL, NULL),
(1008, 38, 'Carbamazepine ', 'Etonogestrel', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(1009, 38, 'Carbamazepine ', 'Etravirine', ' May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.', NULL, NULL, NULL),
(1010, 38, 'Carbamazepine ', 'Everolimus', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.', NULL, NULL, NULL),
(1011, 38, 'Carbamazepine ', 'Exemestane', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.', NULL, NULL, NULL),
(1012, 38, 'Carbamazepine ', 'Ezogabine', ' CarBAMazepine may decrease the serum concentration of Ezogabine.', NULL, NULL, NULL),
(1013, 38, 'Carbamazepine ', 'Felbamate', ' CarBAMazepine may decrease the serum concentration of Felbamate. Felbamate may decrease the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(1014, 38, 'Carbamazepine ', 'Felodipine', ' May increase the metabolism of Calcium Channel Blockers (Dihydropyridine).', NULL, NULL, NULL),
(1015, 38, 'Carbamazepine ', 'Fentanyl', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(1016, 38, 'Carbamazepine ', 'Fingolimod', ' CarBAMazepine may decrease the serum concentration of Fingolimod.', NULL, NULL, NULL),
(1017, 38, 'Carbamazepine ', 'Fluconazole', ' Fluconazole may increase the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(1018, 38, 'Carbamazepine ', 'Flunarizine', ' CarBAMazepine may decrease the serum concentration of Flunarizine.', NULL, NULL, NULL),
(1019, 38, 'Carbamazepine ', 'Fluoxetine', ' May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.', NULL, NULL, NULL),
(1020, 38, 'Carbamazepine ', 'Fluvoxamine', ' May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.', NULL, NULL, NULL),
(1021, 38, 'Carbamazepine ', 'Fosamprenavir', ' May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(1022, 38, 'Carbamazepine ', 'Fosphenytoin', ' CarBAMazepine may decrease the serum concentration of Fosphenytoin. CarBAMazepine may increase the serum concentration of Fosphenytoin. Possibly by competitive inhibition at sites of metabolism. Fosphenytoin may decrease the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(1023, 38, 'Carbamazepine ', 'Gefitinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.', NULL, NULL, NULL),
(1024, 38, 'Carbamazepine ', 'Guanfacine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.', NULL, NULL, NULL),
(1025, 38, 'Carbamazepine ', 'Haloperidol', ' May increase the metabolism of Haloperidol.', NULL, NULL, NULL),
(1026, 38, 'Carbamazepine ', 'Hydrochlorothiazide', ' Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.', NULL, NULL, NULL),
(1027, 38, 'Carbamazepine ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(1028, 38, 'Carbamazepine ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1029, 38, 'Carbamazepine ', 'Imatinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.', NULL, NULL, NULL),
(1030, 38, 'Carbamazepine ', 'Indapamide', ' Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.', NULL, NULL, NULL),
(1031, 38, 'Carbamazepine ', 'Indinavir', ' May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(1032, 38, 'Carbamazepine ', 'Irinotecan', ' CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan.', NULL, NULL, NULL),
(1033, 38, 'Carbamazepine ', 'Isocarboxazid', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(1034, 38, 'Carbamazepine ', 'Isoflurophate', ' CarBAMazepine may increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(1035, 38, 'Carbamazepine ', 'Isometheptene', ' May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.', NULL, NULL, NULL),
(1036, 38, 'Carbamazepine ', 'Isoniazid', ' May decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(1037, 38, 'Carbamazepine ', 'Isradipine', ' May increase the metabolism of Calcium Channel Blockers (Dihydropyridine).', NULL, NULL, NULL),
(1038, 38, 'Carbamazepine ', 'Itraconazole', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.', NULL, NULL, NULL),
(1039, 38, 'Carbamazepine ', 'Ivacaftor', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.', NULL, NULL, NULL),
(1040, 38, 'Carbamazepine ', 'Ixabepilone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.', NULL, NULL, NULL),
(1041, 38, 'Carbamazepine ', 'Lacosamide', ' CarBAMazepine may enhance the AV-blocking effect of Lacosamide. CarBAMazepine may decrease the serum concentration of Lacosamide.', NULL, NULL, NULL),
(1042, 38, 'Carbamazepine ', 'Lamotrigine', ' LamoTRIgine may enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may increase the metabolism of LamoTRIgine.', NULL, NULL, NULL),
(1043, 38, 'Carbamazepine ', 'Lapatinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.', NULL, NULL, NULL),
(1044, 38, 'Carbamazepine ', 'Ledipasvir', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(1045, 38, 'Carbamazepine ', 'Levonorgestrel', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(1046, 38, 'Carbamazepine ', 'Levothyroxine', ' May decrease the serum concentration of Thyroid Products.', NULL, NULL, NULL),
(1047, 38, 'Carbamazepine ', 'Linagliptin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.', NULL, NULL, NULL),
(1048, 38, 'Carbamazepine ', 'Linezolid', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(1049, 38, 'Carbamazepine ', 'Liothyronine', ' May decrease the serum concentration of Thyroid Products.', NULL, NULL, NULL),
(1050, 38, 'Carbamazepine ', 'Liotrix', ' May decrease the serum concentration of Thyroid Products.', NULL, NULL, NULL),
(1051, 38, 'Carbamazepine ', 'Lithium', ' CarBAMazepine may enhance the adverse/toxic effect of Lithium.', NULL, NULL, NULL),
(1052, 38, 'Carbamazepine ', 'Lopinavir', ' CarBAMazepine may decrease the serum concentration of Lopinavir.', NULL, NULL, NULL),
(1053, 38, 'Carbamazepine ', 'Loxapine', ' Loxapine may increase serum concentrations of the active metabolite(s) of CarBAMazepine.', NULL, NULL, NULL),
(1054, 38, 'Carbamazepine ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1055, 38, 'Carbamazepine ', 'Lumefantrine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumefantrine.', NULL, NULL, NULL),
(1056, 38, 'Carbamazepine ', 'Lurasidone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.', NULL, NULL, NULL),
(1057, 38, 'Carbamazepine ', 'MACITENTAN', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan.', NULL, NULL, NULL),
(1058, 38, 'Carbamazepine ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1059, 38, 'Carbamazepine ', 'Maraviroc', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.', NULL, NULL, NULL),
(1060, 38, 'Carbamazepine ', 'Mebendazole', ' CarBAMazepine may decrease the serum concentration of Mebendazole.', NULL, NULL, NULL),
(1061, 38, 'Carbamazepine ', 'Medroxyprogesterone Acetate', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(1062, 38, 'Carbamazepine ', 'Mefloquine', ' Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.', NULL, NULL, NULL),
(1063, 38, 'Carbamazepine ', 'Mestranol', ' May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.', NULL, NULL, NULL),
(1064, 38, 'Carbamazepine ', 'Methadone', ' May increase the metabolism of Methadone.', NULL, NULL, NULL),
(1065, 38, 'Carbamazepine ', 'Methazolamide', ' Carbonic Anhydrase Inhibitors may increase the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(1066, 38, 'Carbamazepine ', 'Methotrimeprazine', ' CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1067, 38, 'Carbamazepine ', 'Methyclothiazide', ' Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.', NULL, NULL, NULL),
(1068, 38, 'Carbamazepine ', 'Methylprednisolone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(1069, 38, 'Carbamazepine ', 'Metolazone', ' Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.', NULL, NULL, NULL),
(1070, 38, 'Carbamazepine ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(1071, 38, 'Carbamazepine ', 'Mianserin', ' May diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Mianserin.', NULL, NULL, NULL),
(1072, 38, 'Carbamazepine ', 'Mifepristone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.', NULL, NULL, NULL),
(1073, 38, 'Carbamazepine ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1074, 38, 'Carbamazepine ', 'Moclobemide', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(1075, 38, 'Carbamazepine ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1076, 38, 'Carbamazepine ', 'Nefazodone', ' CarBAMazepine may decrease the serum concentration of Nefazodone. Concentrations of active Nefazodone metabolites may also be reduced. Nefazodone may increase the serum concentration of CarBAMazepine. Also~ concentrations of the active CarBAMazepine epoxide metabolite may be reduced.', NULL, NULL, NULL),
(1077, 38, 'Carbamazepine ', 'Nelfinavir', ' May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(1078, 38, 'Carbamazepine ', 'Nevirapine', ' May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.', NULL, NULL, NULL),
(1079, 38, 'Carbamazepine ', 'Nifedipine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.', NULL, NULL, NULL),
(1080, 38, 'Carbamazepine ', 'Nilotinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.', NULL, NULL, NULL),
(1081, 38, 'Carbamazepine ', 'Nimodipine', ' May increase the metabolism of Calcium Channel Blockers (Dihydropyridine).', NULL, NULL, NULL),
(1082, 38, 'Carbamazepine ', 'Nisoldipine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.', NULL, NULL, NULL),
(1083, 38, 'Carbamazepine ', 'Norelgestromin', ' May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.', NULL, NULL, NULL),
(1084, 38, 'Carbamazepine ', 'Norethindrone', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(1085, 38, 'Carbamazepine ', 'Norgestimate', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(1086, 38, 'Carbamazepine ', 'Nortriptyline', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(1087, 38, 'Carbamazepine ', 'Orlistat', ' May decrease the serum concentration of Anticonvulsants.', NULL, NULL, NULL),
(1088, 38, 'Carbamazepine ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(1089, 38, 'Carbamazepine ', 'Oxcarbazepine', ' CarBAMazepine may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically~ concentrations of the major active 10-monohydroxy metabolite may be reduced.', NULL, NULL, NULL),
(1090, 38, 'Carbamazepine ', 'Paliperidone', ' CarBAMazepine may decrease the serum concentration of Paliperidone.', NULL, NULL, NULL),
(1091, 38, 'Carbamazepine ', 'Panobinostat', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat.', NULL, NULL, NULL),
(1092, 38, 'Carbamazepine ', 'Paroxetine', ' May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.', NULL, NULL, NULL),
(1093, 38, 'Carbamazepine ', 'Pazopanib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(1094, 38, 'Carbamazepine ', 'Perampanel', ' CarBAMazepine may decrease the serum concentration of Perampanel.', NULL, NULL, NULL),
(1095, 38, 'Carbamazepine ', 'Phenelzine', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(1096, 38, 'Carbamazepine ', 'Phenytoin', ' May decrease the serum concentration of Phenytoin. CarBAMazepine may increase the serum concentration of Phenytoin. Possibly by competitive inhibition at sites of metabolism. Phenytoin may decrease the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(1097, 38, 'Carbamazepine ', 'Pirfenidone', ' CYP1A2 Inducers (Strong) may decrease the serum concentration of Pirfenidone.', NULL, NULL, NULL),
(1098, 38, 'Carbamazepine ', 'Pomalidomide', ' CYP1A2 Inducers (Strong) may decrease the serum concentration of Pomalidomide.', NULL, NULL, NULL),
(1099, 38, 'Carbamazepine ', 'Ponatinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib.', NULL, NULL, NULL),
(1100, 38, 'Carbamazepine ', 'Pramipexole', ' CNS Depressants may enhance the sedative effect of Pramipexole.', NULL, NULL, NULL),
(1101, 38, 'Carbamazepine ', 'Praziquantel', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.', NULL, NULL, NULL),
(1102, 38, 'Carbamazepine ', 'Prednisone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE.', NULL, NULL, NULL),
(1103, 38, 'Carbamazepine ', 'Procarbazine', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(1104, 38, 'Carbamazepine ', 'Protriptyline', ' May increase the metabolism of Tricyclic Antidepressants.', NULL, NULL, NULL),
(1105, 38, 'Carbamazepine ', 'Quetiapine', ' May increase serum concentrations of the active metabolite(s) of CarBAMazepine. CarBAMazepine may decrease the serum concentration of QUEtiapine.', NULL, NULL, NULL),
(1106, 38, 'Carbamazepine ', 'Quinine', ' May decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(1107, 38, 'Carbamazepine ', 'Ranolazine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.', NULL, NULL, NULL),
(1108, 38, 'Carbamazepine ', 'Rasagiline', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(1109, 38, 'Carbamazepine ', 'Regorafenib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.', NULL, NULL, NULL),
(1110, 38, 'Carbamazepine ', 'Rilpivirine', ' May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.', NULL, NULL, NULL),
(1111, 38, 'Carbamazepine ', 'Risperidone', ' CarBAMazepine may decrease the serum concentration of RisperiDONE.', NULL, NULL, NULL),
(1112, 38, 'Carbamazepine ', 'Ritonavir', ' May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(1113, 38, 'Carbamazepine ', 'Rivaroxaban', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.', NULL, NULL, NULL),
(1114, 38, 'Carbamazepine ', 'Roflumilast', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.', NULL, NULL, NULL),
(1115, 38, 'Carbamazepine ', 'Romidepsin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.', NULL, NULL, NULL),
(1116, 38, 'Carbamazepine ', 'Rotigotine', ' CNS Depressants may enhance the sedative effect of Rotigotine.', NULL, NULL, NULL),
(1117, 38, 'Carbamazepine ', 'Rufinamide', ' CarBAMazepine may decrease the serum concentration of Rufinamide. Rufinamide may decrease the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(1118, 38, 'Carbamazepine ', 'Saquinavir', ' May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(1119, 38, 'Carbamazepine ', 'Saxagliptin', ' CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.', NULL, NULL, NULL),
(1120, 38, 'Carbamazepine ', 'Selegiline', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(1121, 38, 'Carbamazepine ', 'Sertraline', ' May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.', NULL, NULL, NULL),
(1122, 38, 'Carbamazepine ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1123, 38, 'Carbamazepine ', 'Simeprevir', ' CarBAMazepine may increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(1124, 38, 'Carbamazepine ', 'Sofosbuvir', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir.', NULL, NULL, NULL),
(1125, 38, 'Carbamazepine ', 'Sorafenib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.', NULL, NULL, NULL),
(1126, 38, 'Carbamazepine ', 'Sulfisoxazole', ' Macrolide Antibiotics may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(1127, 38, 'Carbamazepine ', 'Sunitinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.', NULL, NULL, NULL),
(1128, 38, 'Carbamazepine ', 'Suvorexant', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant.', NULL, NULL, NULL),
(1129, 38, 'Carbamazepine ', 'Tadalafil', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.', NULL, NULL, NULL),
(1130, 38, 'Carbamazepine ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1131, 38, 'Carbamazepine ', 'Tedizolid Phosphate', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(1132, 38, 'Carbamazepine ', 'Telaprevir', ' CarBAMazepine may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(1133, 38, 'Carbamazepine ', 'Telithromycin', ' Macrolide Antibiotics may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(1134, 38, 'Carbamazepine ', 'Temsirolimus', ' CarBAMazepine may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite~ sirolimus~ are also likely to be decreased (and maybe to an even greater degree).', NULL, NULL, NULL),
(1135, 38, 'Carbamazepine ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(1136, 38, 'Carbamazepine ', 'Theophylline', ' Theophylline Derivatives may decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Theophylline Derivatives.', NULL, NULL, NULL),
(1137, 38, 'Carbamazepine ', 'Ticagrelor', ' CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.', NULL, NULL, NULL),
(1138, 38, 'Carbamazepine ', 'Tipranavir', ' May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(1139, 38, 'Carbamazepine ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1140, 38, 'Carbamazepine ', 'Tofacitinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.', NULL, NULL, NULL),
(1141, 38, 'Carbamazepine ', 'Tolvaptan', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.', NULL, NULL, NULL),
(1142, 38, 'Carbamazepine ', 'Topiramate', ' May decrease the serum concentration of Topiramate.', NULL, NULL, NULL),
(1143, 38, 'Carbamazepine ', 'Toremifene', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.', NULL, NULL, NULL),
(1144, 38, 'Carbamazepine ', 'Trabectedin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin.', NULL, NULL, NULL),
(1145, 38, 'Carbamazepine ', 'Tramadol', ' TraMADol may enhance the CNS depressant effect of CarBAMazepine. TraMADol may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of TraMADol.', NULL, NULL, NULL),
(1146, 38, 'Carbamazepine ', 'Tranylcypromine', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(1147, 38, 'Carbamazepine ', 'Treprostinil', ' CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.', NULL, NULL, NULL),
(1148, 38, 'Carbamazepine ', 'Ulipristal', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.', NULL, NULL, NULL),
(1149, 38, 'Carbamazepine ', 'Valproic Acid', ' Valproic Acid and Derivatives may increase serum concentrations of the active metabolite(s) of CarBAMazepine. Parent carbamazepine concentrations may be increased~ decreased~ or unchanged. CarBAMazepine may decrease the serum concentration of Valproic Acid and Derivatives.', NULL, NULL, NULL),
(1150, 38, 'Carbamazepine ', 'Vandetanib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.', NULL, NULL, NULL),
(1151, 38, 'Carbamazepine ', 'Vecuronium', ' CarBAMazepine may decrease the serum concentration of Vecuronium.', NULL, NULL, NULL),
(1152, 38, 'Carbamazepine ', 'Vemurafenib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.', NULL, NULL, NULL),
(1153, 38, 'Carbamazepine ', 'Vilazodone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.', NULL, NULL, NULL),
(1154, 38, 'Carbamazepine ', 'Vorapaxar', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar.', NULL, NULL, NULL),
(1155, 38, 'Carbamazepine ', 'Voriconazole', ' CarBAMazepine may decrease the serum concentration of Voriconazole.', NULL, NULL, NULL),
(1156, 38, 'Carbamazepine ', 'Ziprasidone', ' May decrease the serum concentration of Ziprasidone.', NULL, NULL, NULL),
(1157, 38, 'Carbamazepine ', 'Zolpidem', ' Zolpidem may enhance the CNS depressant effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Zolpidem.', NULL, NULL, NULL),
(1158, 38, 'Carbamazepine ', 'Zuclopenthixol', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.', NULL, NULL, NULL),
(1159, 39, 'Carmustine ', '0', '0', NULL, NULL, NULL),
(1160, 39, 'Carmustine ', 'Cimetidine', ' May enhance the myelosuppressive effect of Carmustine.', NULL, NULL, NULL),
(1161, 39, 'Carmustine ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(1162, 39, 'Carmustine ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(1163, 39, 'Carmustine ', 'L-Phenylalanine', ' Melphalan may enhance the adverse/toxic effect of Carmustine. Specifically~ melphalan may sensitize patients to carmustine lung toxicity.', NULL, NULL, NULL),
(1164, 39, 'Carmustine ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(1165, 39, 'Carmustine ', 'Melphalan', ' May enhance the adverse/toxic effect of Carmustine. Specifically~ melphalan may sensitize patients to carmustine lung toxicity.', NULL, NULL, NULL),
(1166, 39, 'Carmustine ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(1167, 39, 'Carmustine ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(1168, 39, 'Carmustine ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(1169, 39, 'Carmustine ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(1170, 39, 'Carmustine ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(1171, 39, 'Carmustine ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(1172, 40, 'Ceftazidime ', '0', '0', NULL, NULL, NULL),
(1173, 40, 'Ceftazidime ', 'Acenocoumarol', ' May enhance the anticoagulant effect of Vitamin K Antagonists.', NULL, NULL, NULL),
(1174, 40, 'Ceftazidime ', 'Amikacin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1175, 40, 'Ceftazidime ', 'Arbekacin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1176, 40, 'Ceftazidime ', 'Framycetin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1177, 40, 'Ceftazidime ', 'Gentamicin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1178, 40, 'Ceftazidime ', 'Kanamycin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1179, 40, 'Ceftazidime ', 'Neomycin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1180, 40, 'Ceftazidime ', 'Netilmicin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1181, 40, 'Ceftazidime ', 'Probenecid', ' May increase the serum concentration of Cephalosporins.', NULL, NULL, NULL),
(1182, 40, 'Ceftazidime ', 'Ribostamycin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1183, 40, 'Ceftazidime ', 'Spectinomycin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1184, 40, 'Ceftazidime ', 'Streptomycin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1185, 40, 'Ceftazidime ', 'Tobramycin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1186, 41, 'Ceftriaxone ', '0', '0', NULL, NULL, NULL),
(1187, 41, 'Ceftriaxone ', 'Acenocoumarol', ' May enhance the anticoagulant effect of Vitamin K Antagonists.', NULL, NULL, NULL),
(1188, 41, 'Ceftriaxone ', 'Amikacin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1189, 41, 'Ceftriaxone ', 'Arbekacin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1190, 41, 'Ceftriaxone ', 'Calcium Acetate', ' Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.', NULL, NULL, NULL),
(1191, 41, 'Ceftriaxone ', 'Calcium Chloride', ' Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.', NULL, NULL, NULL),
(1192, 41, 'Ceftriaxone ', 'Framycetin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1193, 41, 'Ceftriaxone ', 'Gentamicin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1194, 41, 'Ceftriaxone ', 'Kanamycin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1195, 41, 'Ceftriaxone ', 'Neomycin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1196, 41, 'Ceftriaxone ', 'Netilmicin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1197, 41, 'Ceftriaxone ', 'Probenecid', ' Probenecid may increase the serum concentration of Cephalosporins.', NULL, NULL, NULL),
(1198, 41, 'Ceftriaxone ', 'Ribostamycin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1199, 41, 'Ceftriaxone ', 'Spectinomycin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1200, 41, 'Ceftriaxone ', 'Streptomycin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1201, 41, 'Ceftriaxone ', 'Tobramycin', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1202, 42, 'Cetirizine ', '0', '0', NULL, NULL, NULL),
(1203, 42, 'Cetirizine ', 'Aclidinium', ' May enhance the anticholinergic effect of Anticholinergic Agents.', NULL, NULL, NULL),
(1204, 42, 'Cetirizine ', 'Amphetamine', ' May diminish the sedative effect of Antihistamines.', NULL, NULL, NULL),
(1205, 42, 'Cetirizine ', 'Benzylpenicilloyl Polylysine', ' Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.', NULL, NULL, NULL),
(1206, 42, 'Cetirizine ', 'Betahistine', ' Antihistamines may diminish the therapeutic effect of Betahistine.', NULL, NULL, NULL),
(1207, 42, 'Cetirizine ', 'Buprenorphine', ' CNS Depressants may enhance the CNS depressant effect of Buprenorphine.', NULL, NULL, NULL),
(1208, 42, 'Cetirizine ', 'Cathinone', ' May diminish the sedative effect of Antihistamines.', NULL, NULL, NULL),
(1209, 42, 'Cetirizine ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1210, 42, 'Cetirizine ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1211, 42, 'Cetirizine ', 'Droperidol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1212, 42, 'Cetirizine ', 'Hyaluronidase', ' Antihistamines may diminish the therapeutic effect of Hyaluronidase.', NULL, NULL, NULL),
(1213, 42, 'Cetirizine ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(1214, 42, 'Cetirizine ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1215, 42, 'Cetirizine ', 'Itopride', ' Anticholinergic Agents may diminish the therapeutic effect of Itopride.', NULL, NULL, NULL),
(1216, 42, 'Cetirizine ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1217, 42, 'Cetirizine ', 'Methotrimeprazine', ' CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1218, 42, 'Cetirizine ', 'Metoclopramide', ' Anticholinergic Agents may diminish the therapeutic effect of Metoclopramide.', NULL, NULL, NULL),
(1219, 42, 'Cetirizine ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(1220, 42, 'Cetirizine ', 'Mianserin', ' May enhance the anticholinergic effect of Anticholinergic Agents.', NULL, NULL, NULL),
(1221, 42, 'Cetirizine ', 'Mirabegron', ' Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.', NULL, NULL, NULL),
(1222, 42, 'Cetirizine ', 'Mirtazapine', ' CNS Depressants may enhance the CNS depressant effect of Mirtazapine.', NULL, NULL, NULL),
(1223, 42, 'Cetirizine ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1224, 42, 'Cetirizine ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(1225, 42, 'Cetirizine ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1226, 42, 'Cetirizine ', 'Potassium Chloride', ' Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.', NULL, NULL, NULL),
(1227, 42, 'Cetirizine ', 'Pramipexole', ' CNS Depressants may enhance the sedative effect of Pramipexole.', NULL, NULL, NULL),
(1228, 42, 'Cetirizine ', 'Pramlintide', ' May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.', NULL, NULL, NULL),
(1229, 42, 'Cetirizine ', 'Ropinirole', ' CNS Depressants may enhance the sedative effect of ROPINIRole.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(1230, 42, 'Cetirizine ', 'Rotigotine', ' CNS Depressants may enhance the sedative effect of Rotigotine.', NULL, NULL, NULL),
(1231, 42, 'Cetirizine ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(1232, 42, 'Cetirizine ', 'Secretin', ' Anticholinergic Agents may diminish the therapeutic effect of Secretin.', NULL, NULL, NULL),
(1233, 42, 'Cetirizine ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(1234, 42, 'Cetirizine ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1235, 42, 'Cetirizine ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(1236, 42, 'Cetirizine ', 'Tiotropium', ' Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.', NULL, NULL, NULL),
(1237, 42, 'Cetirizine ', 'Topiramate', ' Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.', NULL, NULL, NULL),
(1238, 42, 'Cetirizine ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(1239, 43, 'Chlorambucil ', '0', '0', NULL, NULL, NULL),
(1240, 43, 'Chlorambucil ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(1241, 43, 'Chlorambucil ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(1242, 43, 'Chlorambucil ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(1243, 43, 'Chlorambucil ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(1244, 43, 'Chlorambucil ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(1245, 43, 'Chlorambucil ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(1246, 43, 'Chlorambucil ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(1247, 43, 'Chlorambucil ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(1248, 43, 'Chlorambucil ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(1249, 44, 'Chloramphenicol ', '0', '0', NULL, NULL, NULL),
(1250, 44, 'Chloramphenicol ', 'Acenocoumarol', ' May enhance the anticoagulant effect of Vitamin K Antagonists. Chloramphenicol may increase the serum concentration of Vitamin K Antagonists.', NULL, NULL, NULL),
(1251, 44, 'Chloramphenicol ', 'Amobarbital', ' Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.', NULL, NULL, NULL),
(1252, 44, 'Chloramphenicol ', 'Butabarbital', ' Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.', NULL, NULL, NULL),
(1253, 44, 'Chloramphenicol ', 'Butalbital', ' Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.', NULL, NULL, NULL),
(1254, 44, 'Chloramphenicol ', 'Butethal', ' May increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.', NULL, NULL, NULL),
(1255, 44, 'Chloramphenicol ', 'Chlorpropamide', ' May decrease the metabolism of Sulfonylureas.', NULL, NULL, NULL),
(1256, 44, 'Chloramphenicol ', 'Cilostazol', ' CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.', NULL, NULL, NULL),
(1257, 44, 'Chloramphenicol ', 'Citalopram', ' CYP2C19 Inhibitors (Strong) may increase the serum concentration of Citalopram.', NULL, NULL, NULL),
(1258, 44, 'Chloramphenicol ', 'Clopidogrel', ' CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.', NULL, NULL, NULL),
(1259, 44, 'Chloramphenicol ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(1260, 44, 'Chloramphenicol ', 'Cyanocobalamin', ' May diminish the therapeutic effect of Vitamin B12.', NULL, NULL, NULL),
(1261, 44, 'Chloramphenicol ', 'Ethanol', ' May enhance the adverse/toxic effect of Alcohol (Ethyl).', NULL, NULL, NULL),
(1262, 44, 'Chloramphenicol ', 'Gliclazide', ' May decrease the metabolism of Sulfonylureas.', NULL, NULL, NULL),
(1263, 44, 'Chloramphenicol ', 'Glimepiride', ' May decrease the metabolism of Sulfonylureas.', NULL, NULL, NULL),
(1264, 44, 'Chloramphenicol ', 'Glipizide', ' May decrease the metabolism of Sulfonylureas.', NULL, NULL, NULL),
(1265, 44, 'Chloramphenicol ', 'Glyburide', ' May decrease the metabolism of Sulfonylureas.', NULL, NULL, NULL),
(1266, 44, 'Chloramphenicol ', 'Heptabarbital', ' May increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.', NULL, NULL, NULL),
(1267, 44, 'Chloramphenicol ', 'Hexobarbital', ' May increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.', NULL, NULL, NULL),
(1268, 44, 'Chloramphenicol ', 'Hydroxocobalamin', ' May diminish the therapeutic effect of Vitamin B12.', NULL, NULL, NULL),
(1269, 44, 'Chloramphenicol ', 'Methohexital', ' May increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.', NULL, NULL, NULL),
(1270, 44, 'Chloramphenicol ', 'Pentobarbital', ' Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.', NULL, NULL, NULL),
(1271, 44, 'Chloramphenicol ', 'Phenobarbital', ' Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.', NULL, NULL, NULL),
(1272, 44, 'Chloramphenicol ', 'Primidone', ' May increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.', NULL, NULL, NULL),
(1273, 44, 'Chloramphenicol ', 'Rifampicin', ' Rifampin may increase the metabolism of Chloramphenicol.', NULL, NULL, NULL),
(1274, 44, 'Chloramphenicol ', 'Secobarbital', ' Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.', NULL, NULL, NULL),
(1275, 44, 'Chloramphenicol ', 'Tolazamide', ' May decrease the metabolism of Sulfonylureas.', NULL, NULL, NULL),
(1276, 44, 'Chloramphenicol ', 'Tolbutamide', ' May decrease the metabolism of Sulfonylureas.', NULL, NULL, NULL),
(1277, 44, 'Chloramphenicol ', 'Voriconazole', ' Chloramphenicol may increase the serum concentration of Voriconazole.', NULL, NULL, NULL),
(1278, 45, 'Chlorpheniramine ', '0', '0', NULL, NULL, NULL),
(1279, 46, 'Chlorpromazine ', '0', '0', NULL, NULL, NULL),
(1280, 46, 'Chlorpromazine ', 'Aclidinium', ' May enhance the anticholinergic effect of Anticholinergic Agents.', NULL, NULL, NULL),
(1281, 46, 'Chlorpromazine ', 'Almotriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1282, 46, 'Chlorpromazine ', 'Aluminum hydroxide', ' May decrease the absorption of Antipsychotic Agents (Phenothiazines).', NULL, NULL, NULL),
(1283, 46, 'Chlorpromazine ', 'Amisulpride', ' Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride.', NULL, NULL, NULL),
(1284, 46, 'Chlorpromazine ', 'Amitriptyline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1285, 46, 'Chlorpromazine ', 'Amoxapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1286, 46, 'Chlorpromazine ', 'Amphetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(1287, 46, 'Chlorpromazine ', 'Aripiprazole', ' CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(1288, 46, 'Chlorpromazine ', 'Benzphetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(1289, 46, 'Chlorpromazine ', 'Buprenorphine', ' CNS Depressants may enhance the CNS depressant effect of Buprenorphine.', NULL, NULL, NULL),
(1290, 46, 'Chlorpromazine ', 'Buspirone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1291, 46, 'Chlorpromazine ', 'Cabergoline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1292, 46, 'Chlorpromazine ', 'Calcium carbonate', ' May decrease the absorption of Antipsychotic Agents (Phenothiazines).', NULL, NULL, NULL),
(1293, 46, 'Chlorpromazine ', 'Cathinone', ' Antipsychotic Agents may diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(1294, 46, 'Chlorpromazine ', 'Citalopram', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1295, 46, 'Chlorpromazine ', 'Clomipramine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1296, 46, 'Chlorpromazine ', 'Codeine', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.', NULL, NULL, NULL),
(1297, 46, 'Chlorpromazine ', 'Cyclobenzaprine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1298, 46, 'Chlorpromazine ', 'Darunavir', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1299, 46, 'Chlorpromazine ', 'Desipramine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1300, 46, 'Chlorpromazine ', 'Desmopressin', ' May enhance the adverse/toxic effect of Desmopressin.', NULL, NULL, NULL),
(1301, 46, 'Chlorpromazine ', 'Desvenlafaxine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1302, 46, 'Chlorpromazine ', 'Dextroamphetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(1303, 46, 'Chlorpromazine ', 'Dextromethorphan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1304, 46, 'Chlorpromazine ', 'Dihydroergotamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1305, 46, 'Chlorpromazine ', 'Donepezil', ' Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.', NULL, NULL, NULL),
(1306, 46, 'Chlorpromazine ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1307, 46, 'Chlorpromazine ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1308, 46, 'Chlorpromazine ', 'Droperidol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1309, 46, 'Chlorpromazine ', 'Duloxetine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1310, 46, 'Chlorpromazine ', 'Eletriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1311, 46, 'Chlorpromazine ', 'Ergoloid mesylate', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1312, 46, 'Chlorpromazine ', 'Ergonovine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1313, 46, 'Chlorpromazine ', 'Ergotamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1314, 46, 'Chlorpromazine ', 'Escitalopram', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1315, 46, 'Chlorpromazine ', 'Fentanyl', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1316, 46, 'Chlorpromazine ', 'Fesoterodine', ' CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.', NULL, NULL, NULL),
(1317, 46, 'Chlorpromazine ', 'Fluoxetine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1318, 46, 'Chlorpromazine ', 'Fluvoxamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1319, 46, 'Chlorpromazine ', 'Frovatriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1320, 46, 'Chlorpromazine ', 'Galantamine', ' Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.', NULL, NULL, NULL),
(1321, 46, 'Chlorpromazine ', 'Haloperidol', ' ChlorproMAZINE may enhance the QTc-prolonging effect of Haloperidol. ChlorproMAZINE may increase the serum concentration of Haloperidol. Haloperidol may increase the serum concentration of ChlorproMAZINE.', NULL, NULL, NULL),
(1322, 46, 'Chlorpromazine ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(1323, 46, 'Chlorpromazine ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1324, 46, 'Chlorpromazine ', 'Imipramine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1325, 46, 'Chlorpromazine ', 'Isocarboxazid', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1326, 46, 'Chlorpromazine ', 'Itopride', ' Anticholinergic Agents may diminish the therapeutic effect of Itopride.', NULL, NULL, NULL),
(1327, 46, 'Chlorpromazine ', 'Levomilnacipran', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1328, 46, 'Chlorpromazine ', 'Linezolid', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1329, 46, 'Chlorpromazine ', 'Lisdexamfetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(1330, 46, 'Chlorpromazine ', 'Lithium', ' May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.', NULL, NULL, NULL),
(1331, 46, 'Chlorpromazine ', 'Lorcaserin', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1332, 46, 'Chlorpromazine ', 'Magnesium oxide', ' May decrease the absorption of Antipsychotic Agents (Phenothiazines).', NULL, NULL, NULL),
(1333, 46, 'Chlorpromazine ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1334, 46, 'Chlorpromazine ', 'Maprotiline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1335, 46, 'Chlorpromazine ', 'Mequitazine', ' Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.', NULL, NULL, NULL),
(1336, 46, 'Chlorpromazine ', 'Methadone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1337, 46, 'Chlorpromazine ', 'Methamphetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(1338, 46, 'Chlorpromazine ', 'Methotrimeprazine', ' CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1339, 46, 'Chlorpromazine ', 'Methylergometrine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1340, 46, 'Chlorpromazine ', 'Methylphenidate', ' May enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents.', NULL, NULL, NULL),
(1341, 46, 'Chlorpromazine ', 'Metoclopramide', ' May enhance the adverse/toxic effect of Antipsychotic Agents.', NULL, NULL, NULL),
(1342, 46, 'Chlorpromazine ', 'Metoprolol', ' CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.', NULL, NULL, NULL),
(1343, 46, 'Chlorpromazine ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(1344, 46, 'Chlorpromazine ', 'Mifepristone', ' May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.', NULL, NULL, NULL),
(1345, 46, 'Chlorpromazine ', 'Milnacipran', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1346, 46, 'Chlorpromazine ', 'Mirabegron', ' Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.', NULL, NULL, NULL),
(1347, 46, 'Chlorpromazine ', 'Mirtazapine', ' CNS Depressants may enhance the CNS depressant effect of Mirtazapine.', NULL, NULL, NULL),
(1348, 46, 'Chlorpromazine ', 'Moclobemide', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1349, 46, 'Chlorpromazine ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1350, 46, 'Chlorpromazine ', 'Naratriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1351, 46, 'Chlorpromazine ', 'Nebivolol', ' CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.', NULL, NULL, NULL),
(1352, 46, 'Chlorpromazine ', 'Nefazodone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1353, 46, 'Chlorpromazine ', 'Nortriptyline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1354, 46, 'Chlorpromazine ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(1355, 46, 'Chlorpromazine ', 'Panobinostat', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1356, 46, 'Chlorpromazine ', 'Paroxetine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1357, 46, 'Chlorpromazine ', 'Peginterferon alfa-2b', ' May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1358, 46, 'Chlorpromazine ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1359, 46, 'Chlorpromazine ', 'Pethidine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1360, 46, 'Chlorpromazine ', 'Phendimetrazine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(1361, 46, 'Chlorpromazine ', 'Phenelzine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1362, 46, 'Chlorpromazine ', 'Phentermine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(1363, 46, 'Chlorpromazine ', 'Porfimer', ' Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.', NULL, NULL, NULL),
(1364, 46, 'Chlorpromazine ', 'Potassium Chloride', ' Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.', NULL, NULL, NULL),
(1365, 46, 'Chlorpromazine ', 'Pramlintide', ' May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.', NULL, NULL, NULL),
(1366, 46, 'Chlorpromazine ', 'Procarbazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1367, 46, 'Chlorpromazine ', 'Promethazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1368, 46, 'Chlorpromazine ', 'Protriptyline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1369, 46, 'Chlorpromazine ', 'Rasagiline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1370, 46, 'Chlorpromazine ', 'Rivastigmine', ' Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.', NULL, NULL, NULL),
(1371, 46, 'Chlorpromazine ', 'Rizatriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1372, 46, 'Chlorpromazine ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(1373, 46, 'Chlorpromazine ', 'Secretin', ' Anticholinergic Agents may diminish the therapeutic effect of Secretin.', NULL, NULL, NULL),
(1374, 46, 'Chlorpromazine ', 'Selegiline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1375, 46, 'Chlorpromazine ', 'Sertraline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1376, 46, 'Chlorpromazine ', 'Sulpiride', ' Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride.', NULL, NULL, NULL),
(1377, 46, 'Chlorpromazine ', 'Sumatriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1378, 46, 'Chlorpromazine ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(1379, 46, 'Chlorpromazine ', 'Tamoxifen', ' CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.', NULL, NULL, NULL),
(1380, 46, 'Chlorpromazine ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1381, 46, 'Chlorpromazine ', 'Tedizolid Phosphate', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1382, 46, 'Chlorpromazine ', 'Tetrabenazine', ' Tetrabenazine may enhance the adverse/toxic effect of Antipsychotic Agents.', NULL, NULL, NULL),
(1383, 46, 'Chlorpromazine ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(1384, 46, 'Chlorpromazine ', 'Thiopental', ' Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.', NULL, NULL, NULL),
(1385, 46, 'Chlorpromazine ', 'Thioridazine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(1386, 46, 'Chlorpromazine ', 'Tiotropium', ' Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.', NULL, NULL, NULL),
(1387, 46, 'Chlorpromazine ', 'Topiramate', ' Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.', NULL, NULL, NULL),
(1388, 46, 'Chlorpromazine ', 'Tramadol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1389, 46, 'Chlorpromazine ', 'Tranylcypromine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1390, 46, 'Chlorpromazine ', 'Trimipramine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1391, 46, 'Chlorpromazine ', 'Valproic Acid', ' May increase the serum concentration of Valproic Acid and Derivatives.', NULL, NULL, NULL),
(1392, 46, 'Chlorpromazine ', 'Venlafaxine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1393, 46, 'Chlorpromazine ', 'Verteporfin', ' Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.', NULL, NULL, NULL),
(1394, 46, 'Chlorpromazine ', 'Vilazodone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1395, 46, 'Chlorpromazine ', 'Zolmitriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(1396, 46, 'Chlorpromazine ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(1397, 47, 'Ciprofloxacin ', '0', '0', NULL, NULL, NULL),
(1398, 48, 'Cisplatin ', '0', '0', NULL, NULL, NULL),
(1399, 48, 'Cisplatin ', 'Amikacin', ' May enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1400, 48, 'Cisplatin ', 'Arbekacin', ' CISplatin may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1401, 48, 'Cisplatin ', 'Bumetanide', ' Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.', NULL, NULL, NULL),
(1402, 48, 'Cisplatin ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(1403, 48, 'Cisplatin ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(1404, 48, 'Cisplatin ', 'Ethacrynic acid', ' Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.', NULL, NULL, NULL),
(1405, 48, 'Cisplatin ', 'Framycetin', ' CISplatin may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1406, 48, 'Cisplatin ', 'Furosemide', ' Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.', NULL, NULL, NULL),
(1407, 48, 'Cisplatin ', 'Gentamicin', ' CISplatin may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1408, 48, 'Cisplatin ', 'Kanamycin', ' CISplatin may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1409, 48, 'Cisplatin ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(1410, 48, 'Cisplatin ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(1411, 48, 'Cisplatin ', 'Neomycin', ' CISplatin may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1412, 48, 'Cisplatin ', 'Netilmicin', ' CISplatin may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1413, 48, 'Cisplatin ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(1414, 48, 'Cisplatin ', 'Ribostamycin', ' CISplatin may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1415, 48, 'Cisplatin ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(1416, 48, 'Cisplatin ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(1417, 48, 'Cisplatin ', 'Spectinomycin', ' CISplatin may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1418, 48, 'Cisplatin ', 'Streptomycin', ' CISplatin may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1419, 48, 'Cisplatin ', 'Tobramycin', ' CISplatin may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(1420, 48, 'Cisplatin ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(1421, 48, 'Cisplatin ', 'Topotecan', ' Platinum Derivatives may enhance the adverse/toxic effect of Topotecan.', NULL, NULL, NULL),
(1422, 48, 'Cisplatin ', 'Torasemide', ' Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.', NULL, NULL, NULL),
(1423, 48, 'Cisplatin ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(1424, 48, 'Cisplatin ', 'Vinorelbine', ' May enhance the adverse/toxic effect of Vinorelbine. Specifically~ the combination may be associated with a higher risk of granulocytopenia.', NULL, NULL, NULL),
(1425, 49, 'Clarithromycin ', '0', '0', NULL, NULL, NULL),
(1426, 49, 'Clarithromycin ', 'ado-trastuzumab emtansine', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically~ strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.', NULL, NULL, NULL),
(1427, 49, 'Clarithromycin ', 'Afatinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.', NULL, NULL, NULL),
(1428, 49, 'Clarithromycin ', 'Alfentanil', ' Macrolide Antibiotics may increase the serum concentration of Alfentanil.', NULL, NULL, NULL),
(1429, 49, 'Clarithromycin ', 'Alfuzosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.', NULL, NULL, NULL),
(1430, 49, 'Clarithromycin ', 'Almotriptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.', NULL, NULL, NULL),
(1431, 49, 'Clarithromycin ', 'Alosetron', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.', NULL, NULL, NULL),
(1432, 49, 'Clarithromycin ', 'Alprazolam', ' Macrolide Antibiotics may increase the serum concentration of ALPRAZolam.', NULL, NULL, NULL),
(1433, 49, 'Clarithromycin ', 'Amlodipine', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1434, 49, 'Clarithromycin ', 'Amrinone', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1435, 49, 'Clarithromycin ', 'Apixaban', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.', NULL, NULL, NULL),
(1436, 49, 'Clarithromycin ', 'Aripiprazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(1437, 49, 'Clarithromycin ', 'Astemizole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole.', NULL, NULL, NULL),
(1438, 49, 'Clarithromycin ', 'Atazanavir', ' Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(1439, 49, 'Clarithromycin ', 'Atorvastatin', ' May increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(1440, 49, 'Clarithromycin ', 'Avanafil', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.', NULL, NULL, NULL),
(1441, 49, 'Clarithromycin ', 'Axitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.', NULL, NULL, NULL),
(1442, 49, 'Clarithromycin ', 'Batimastat', ' May diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(1443, 49, 'Clarithromycin ', 'Bedaquiline', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.', NULL, NULL, NULL),
(1444, 49, 'Clarithromycin ', 'Bepridil', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1445, 49, 'Clarithromycin ', 'Boceprevir', ' May increase the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Boceprevir.', NULL, NULL, NULL),
(1446, 49, 'Clarithromycin ', 'Bortezomib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.', NULL, NULL, NULL),
(1447, 49, 'Clarithromycin ', 'Bosentan', ' CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1448, 49, 'Clarithromycin ', 'Bosutinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.', NULL, NULL, NULL),
(1449, 49, 'Clarithromycin ', 'Brentuximab vedotin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.', NULL, NULL, NULL),
(1450, 49, 'Clarithromycin ', 'Brinzolamide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.', NULL, NULL, NULL),
(1451, 49, 'Clarithromycin ', 'Buspirone', ' Macrolide Antibiotics may decrease the metabolism of BusPIRone.', NULL, NULL, NULL),
(1452, 49, 'Clarithromycin ', 'Cabazitaxel', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.', NULL, NULL, NULL),
(1453, 49, 'Clarithromycin ', 'Cabergoline', ' May increase the serum concentration of Cabergoline.', NULL, NULL, NULL),
(1454, 49, 'Clarithromycin ', 'Cabozantinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.', NULL, NULL, NULL),
(1455, 49, 'Clarithromycin ', 'Carbamazepine', ' CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1456, 49, 'Clarithromycin ', 'Cilostazol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.', NULL, NULL, NULL),
(1457, 49, 'Clarithromycin ', 'Cisapride', ' Macrolide Antibiotics may decrease the metabolism of Cisapride.', NULL, NULL, NULL),
(1458, 49, 'Clarithromycin ', 'Clopidogrel', ' Macrolide Antibiotics may diminish the therapeutic effect of Clopidogrel.', NULL, NULL, NULL),
(1459, 49, 'Clarithromycin ', 'Clozapine', ' Macrolide Antibiotics may decrease the metabolism of CloZAPine.', NULL, NULL, NULL),
(1460, 49, 'Clarithromycin ', 'Colchicine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1461, 49, 'Clarithromycin ', 'Conivaptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.', NULL, NULL, NULL),
(1462, 49, 'Clarithromycin ', 'Crizotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.', NULL, NULL, NULL),
(1463, 49, 'Clarithromycin ', 'Dabigatran etexilate', ' Clarithromycin may increase the serum concentration of Dabigatran Etexilate.', NULL, NULL, NULL),
(1464, 49, 'Clarithromycin ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1465, 49, 'Clarithromycin ', 'Dapoxetine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(1466, 49, 'Clarithromycin ', 'Darunavir', ' Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(1467, 49, 'Clarithromycin ', 'Dasatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.', NULL, NULL, NULL),
(1468, 49, 'Clarithromycin ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1469, 49, 'Clarithromycin ', 'Dihydroergotamine', ' May increase the serum concentration of Dihydroergotamine.', NULL, NULL, NULL),
(1470, 49, 'Clarithromycin ', 'Disopyramide', ' Macrolide Antibiotics may enhance the QTc-prolonging effect of Disopyramide. Macrolide Antibiotics may decrease the metabolism of Disopyramide.', NULL, NULL, NULL),
(1471, 49, 'Clarithromycin ', 'Domperidone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone.', NULL, NULL, NULL),
(1472, 49, 'Clarithromycin ', 'Dronabinol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronabinol.', NULL, NULL, NULL),
(1473, 49, 'Clarithromycin ', 'Dronedarone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.', NULL, NULL, NULL),
(1474, 49, 'Clarithromycin ', 'Dutasteride', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.', NULL, NULL, NULL),
(1475, 49, 'Clarithromycin ', 'Efavirenz', ' May decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1476, 49, 'Clarithromycin ', 'Eletriptan', ' Macrolide Antibiotics may decrease the metabolism of Eletriptan.', NULL, NULL, NULL),
(1477, 49, 'Clarithromycin ', 'Enzalutamide', ' CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1478, 49, 'Clarithromycin ', 'Eplerenone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.', NULL, NULL, NULL),
(1479, 49, 'Clarithromycin ', 'Ergotamine', ' May increase the serum concentration of Ergotamine.', NULL, NULL, NULL),
(1480, 49, 'Clarithromycin ', 'Erlotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.', NULL, NULL, NULL),
(1481, 49, 'Clarithromycin ', 'Estazolam', ' Macrolide Antibiotics may increase the serum concentration of Estazolam.', NULL, NULL, NULL),
(1482, 49, 'Clarithromycin ', 'Etravirine', ' CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1483, 49, 'Clarithromycin ', 'Everolimus', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.', NULL, NULL, NULL),
(1484, 49, 'Clarithromycin ', 'Felodipine', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1485, 49, 'Clarithromycin ', 'Fentanyl', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(1486, 49, 'Clarithromycin ', 'Fesoterodine', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.', NULL, NULL, NULL),
(1487, 49, 'Clarithromycin ', 'Flunarizine', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1488, 49, 'Clarithromycin ', 'Fosamprenavir', ' Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(1489, 49, 'Clarithromycin ', 'Fosphenytoin', ' CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1490, 49, 'Clarithromycin ', 'Gabapentin', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1491, 49, 'Clarithromycin ', 'Glipizide', ' May increase the serum concentration of GlipiZIDE.', NULL, NULL, NULL),
(1492, 49, 'Clarithromycin ', 'Glyburide', ' May increase the serum concentration of GlyBURIDE.', NULL, NULL, NULL),
(1493, 49, 'Clarithromycin ', 'Guanfacine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.', NULL, NULL, NULL),
(1494, 49, 'Clarithromycin ', 'Halofantrine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.', NULL, NULL, NULL),
(1495, 49, 'Clarithromycin ', 'Hydrocodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(1496, 49, 'Clarithromycin ', 'Ifosfamide', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.', NULL, NULL, NULL),
(1497, 49, 'Clarithromycin ', 'Imatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib.', NULL, NULL, NULL),
(1498, 49, 'Clarithromycin ', 'Indinavir', ' Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(1499, 49, 'Clarithromycin ', 'Irinotecan', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan.', NULL, NULL, NULL),
(1500, 49, 'Clarithromycin ', 'Isoflurophate', ' May diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(1501, 49, 'Clarithromycin ', 'Isradipine', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1502, 49, 'Clarithromycin ', 'Ivacaftor', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.', NULL, NULL, NULL),
(1503, 49, 'Clarithromycin ', 'Ixabepilone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.', NULL, NULL, NULL),
(1504, 49, 'Clarithromycin ', 'Lacosamide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide.', NULL, NULL, NULL),
(1505, 49, 'Clarithromycin ', 'Lamotrigine', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1506, 49, 'Clarithromycin ', 'Lapatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.', NULL, NULL, NULL),
(1507, 49, 'Clarithromycin ', 'Ledipasvir', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(1508, 49, 'Clarithromycin ', 'Lercanidipine', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1509, 49, 'Clarithromycin ', 'Levobupivacaine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine.', NULL, NULL, NULL),
(1510, 49, 'Clarithromycin ', 'Levomilnacipran', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.', NULL, NULL, NULL),
(1511, 49, 'Clarithromycin ', 'Lomitapide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(1512, 49, 'Clarithromycin ', 'Lopinavir', ' Clarithromycin may enhance the QTc-prolonging effect of Lopinavir. Lopinavir may diminish the therapeutic effect of Clarithromycin. Specifically~ lopinavir may decrease the formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness. Clarithromycin may increase the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1513, 49, 'Clarithromycin ', 'Lovastatin', ' May increase the serum concentration of Lovastatin.', NULL, NULL, NULL),
(1514, 49, 'Clarithromycin ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1515, 49, 'Clarithromycin ', 'Lurasidone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.', NULL, NULL, NULL),
(1516, 49, 'Clarithromycin ', 'MACITENTAN', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan.', NULL, NULL, NULL),
(1517, 49, 'Clarithromycin ', 'Magnesium Sulfate', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1518, 49, 'Clarithromycin ', 'Maraviroc', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.', NULL, NULL, NULL),
(1519, 49, 'Clarithromycin ', 'Methylprednisolone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(1520, 49, 'Clarithromycin ', 'Midazolam', ' Macrolide Antibiotics may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(1521, 49, 'Clarithromycin ', 'Mifepristone', ' May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.', NULL, NULL, NULL),
(1522, 49, 'Clarithromycin ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1523, 49, 'Clarithromycin ', 'Modafinil', ' CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1524, 49, 'Clarithromycin ', 'Nafcillin', ' CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1525, 49, 'Clarithromycin ', 'Nelfinavir', ' Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(1526, 49, 'Clarithromycin ', 'Nicardipine', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1527, 49, 'Clarithromycin ', 'Nilotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.', NULL, NULL, NULL),
(1528, 49, 'Clarithromycin ', 'Nimodipine', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1529, 49, 'Clarithromycin ', 'Nisoldipine', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1530, 49, 'Clarithromycin ', 'Nitrendipine', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1531, 49, 'Clarithromycin ', 'Ospemifene', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.', NULL, NULL, NULL),
(1532, 49, 'Clarithromycin ', 'Oxybutynin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin.', NULL, NULL, NULL),
(1533, 49, 'Clarithromycin ', 'Oxycodone', ' CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased.', NULL, NULL, NULL),
(1534, 49, 'Clarithromycin ', 'Panobinostat', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.', NULL, NULL, NULL),
(1535, 49, 'Clarithromycin ', 'Paricalcitol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.', NULL, NULL, NULL),
(1536, 49, 'Clarithromycin ', 'Pazopanib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(1537, 49, 'Clarithromycin ', 'Perhexiline', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1538, 49, 'Clarithromycin ', 'Phenobarbital', ' CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1539, 49, 'Clarithromycin ', 'Phenytoin', ' CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1540, 49, 'Clarithromycin ', 'Pimecrolimus', ' CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.', NULL, NULL, NULL),
(1541, 49, 'Clarithromycin ', 'Pimozide', ' Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin.', NULL, NULL, NULL),
(1542, 49, 'Clarithromycin ', 'Pitavastatin', ' Clarithromycin may increase the serum concentration of Pitavastatin.', NULL, NULL, NULL),
(1543, 49, 'Clarithromycin ', 'Ponatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.', NULL, NULL, NULL),
(1544, 49, 'Clarithromycin ', 'Pranlukast', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast.', NULL, NULL, NULL),
(1545, 49, 'Clarithromycin ', 'Prasugrel', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.', NULL, NULL, NULL),
(1546, 49, 'Clarithromycin ', 'Pravastatin', ' May increase the serum concentration of Pravastatin.', NULL, NULL, NULL),
(1547, 49, 'Clarithromycin ', 'Prednisone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE.', NULL, NULL, NULL),
(1548, 49, 'Clarithromycin ', 'Prenylamine', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1549, 49, 'Clarithromycin ', 'Primidone', ' CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1550, 49, 'Clarithromycin ', 'prucalopride', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.', NULL, NULL, NULL),
(1551, 49, 'Clarithromycin ', 'Quinidine', ' Macrolide Antibiotics may enhance the QTc-prolonging effect of QuiNIDine. Macrolide Antibiotics may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(1552, 49, 'Clarithromycin ', 'Quinine', ' Macrolide Antibiotics may increase the serum concentration of QuiNINE.', NULL, NULL, NULL),
(1553, 49, 'Clarithromycin ', 'Ranolazine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.', NULL, NULL, NULL),
(1554, 49, 'Clarithromycin ', 'Regorafenib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.', NULL, NULL, NULL),
(1555, 49, 'Clarithromycin ', 'Repaglinide', ' Macrolide Antibiotics may increase the serum concentration of Repaglinide.', NULL, NULL, NULL),
(1556, 49, 'Clarithromycin ', 'Retapamulin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.', NULL, NULL, NULL),
(1557, 49, 'Clarithromycin ', 'Rifampicin', ' CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1558, 49, 'Clarithromycin ', 'Rifapentine', ' CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1559, 49, 'Clarithromycin ', 'Rifaximin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.', NULL, NULL, NULL),
(1560, 49, 'Clarithromycin ', 'Rilpivirine', ' Macrolide Antibiotics may increase the serum concentration of Rilpivirine.', NULL, NULL, NULL),
(1561, 49, 'Clarithromycin ', 'Risedronate', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1562, 49, 'Clarithromycin ', 'Ritonavir', ' Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(1563, 49, 'Clarithromycin ', 'Rivaroxaban', ' Clarithromycin may increase the serum concentration of Rivaroxaban.', NULL, NULL, NULL),
(1564, 49, 'Clarithromycin ', 'Ruxolitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.', NULL, NULL, NULL),
(1565, 49, 'Clarithromycin ', 'Salmeterol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.', NULL, NULL, NULL),
(1566, 49, 'Clarithromycin ', 'Saquinavir', ' Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(1567, 49, 'Clarithromycin ', 'Saxagliptin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.', NULL, NULL, NULL),
(1568, 49, 'Clarithromycin ', 'Sildenafil', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.', NULL, NULL, NULL),
(1569, 49, 'Clarithromycin ', 'Silodosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.', NULL, NULL, NULL),
(1570, 49, 'Clarithromycin ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1571, 49, 'Clarithromycin ', 'Simeprevir', ' May diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(1572, 49, 'Clarithromycin ', 'Simvastatin', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(1573, 49, 'Clarithromycin ', 'Sirolimus', ' Macrolide Antibiotics may decrease the metabolism of Sirolimus.', NULL, NULL, NULL),
(1574, 49, 'Clarithromycin ', 'Suvorexant', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant.', NULL, NULL, NULL),
(1575, 49, 'Clarithromycin ', 'Tadalafil', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.', NULL, NULL, NULL),
(1576, 49, 'Clarithromycin ', 'Tamsulosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.', NULL, NULL, NULL),
(1577, 49, 'Clarithromycin ', 'Telaprevir', ' Clarithromycin may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(1578, 49, 'Clarithromycin ', 'Temsirolimus', ' Macrolide Antibiotics may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus~ the active metabolite~ may be increased~ likely due to inhibition of CYP-mediated metabolism.', NULL, NULL, NULL),
(1579, 49, 'Clarithromycin ', 'Terfenadine', ' Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine.', NULL, NULL, NULL),
(1580, 49, 'Clarithromycin ', 'Ticagrelor', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.', NULL, NULL, NULL),
(1581, 49, 'Clarithromycin ', 'Tipranavir', ' Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(1582, 49, 'Clarithromycin ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1583, 49, 'Clarithromycin ', 'Tofacitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.', NULL, NULL, NULL),
(1584, 49, 'Clarithromycin ', 'Tolterodine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.', NULL, NULL, NULL),
(1585, 49, 'Clarithromycin ', 'Tolvaptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.', NULL, NULL, NULL),
(1586, 49, 'Clarithromycin ', 'Topotecan', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.', NULL, NULL, NULL),
(1587, 49, 'Clarithromycin ', 'Toremifene', ' CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.', NULL, NULL, NULL),
(1588, 49, 'Clarithromycin ', 'Trabectedin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin.', NULL, NULL, NULL),
(1589, 49, 'Clarithromycin ', 'Triazolam', ' Macrolide Antibiotics may increase the serum concentration of Triazolam.', NULL, NULL, NULL),
(1590, 49, 'Clarithromycin ', 'Ulipristal', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.', NULL, NULL, NULL),
(1591, 49, 'Clarithromycin ', 'Vardenafil', ' May increase the serum concentration of Vardenafil.', NULL, NULL, NULL),
(1592, 49, 'Clarithromycin ', 'Vemurafenib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.', NULL, NULL, NULL),
(1593, 49, 'Clarithromycin ', 'Verapamil', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(1594, 49, 'Clarithromycin ', 'Vilazodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.', NULL, NULL, NULL),
(1595, 49, 'Clarithromycin ', 'Vorapaxar', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar.', NULL, NULL, NULL),
(1596, 49, 'Clarithromycin ', 'Zidovudine', ' May enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(1597, 49, 'Clarithromycin ', 'Zopiclone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.', NULL, NULL, NULL),
(1598, 50, 'Clindamycin Phosphate ', '0', '0', NULL, NULL, NULL),
(1599, 51, 'Clomifene citrate ', '0', '0', NULL, NULL, NULL),
(1600, 52, 'Clonazepam ', '0', '0', NULL, NULL, NULL),
(1601, 52, 'Clonazepam ', 'Aminophylline', ' Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.', NULL, NULL, NULL),
(1602, 52, 'Clonazepam ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1603, 52, 'Clonazepam ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1604, 52, 'Clonazepam ', 'Buprenorphine', ' CNS Depressants may enhance the CNS depressant effect of Buprenorphine.', NULL, NULL, NULL),
(1605, 52, 'Clonazepam ', 'Clozapine', ' May enhance the adverse/toxic effect of CloZAPine.', NULL, NULL, NULL),
(1606, 52, 'Clonazepam ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1607, 52, 'Clonazepam ', 'Cosyntropin', ' May enhance the hepatotoxic effect of ClonazePAM.', NULL, NULL, NULL),
(1608, 52, 'Clonazepam ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1609, 52, 'Clonazepam ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1610, 52, 'Clonazepam ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1611, 52, 'Clonazepam ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1612, 52, 'Clonazepam ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1613, 52, 'Clonazepam ', 'Droperidol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1614, 52, 'Clonazepam ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1615, 52, 'Clonazepam ', 'Fosphenytoin', ' May increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(1616, 52, 'Clonazepam ', 'Gamma Hydroxybutyric Acid', ' May enhance the CNS depressant effect of Sodium Oxybate.', NULL, NULL, NULL),
(1617, 52, 'Clonazepam ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(1618, 52, 'Clonazepam ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1619, 52, 'Clonazepam ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1620, 52, 'Clonazepam ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1621, 52, 'Clonazepam ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1622, 52, 'Clonazepam ', 'Mefloquine', ' Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.', NULL, NULL, NULL),
(1623, 52, 'Clonazepam ', 'Methadone', ' May enhance the CNS depressant effect of Methadone.', NULL, NULL, NULL),
(1624, 52, 'Clonazepam ', 'Methotrimeprazine', ' CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1625, 52, 'Clonazepam ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(1626, 52, 'Clonazepam ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1627, 52, 'Clonazepam ', 'Mirtazapine', ' CNS Depressants may enhance the CNS depressant effect of Mirtazapine.', NULL, NULL, NULL),
(1628, 52, 'Clonazepam ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1629, 52, 'Clonazepam ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1630, 52, 'Clonazepam ', 'Olanzapine', ' OLANZapine may enhance the adverse/toxic effect of Benzodiazepines.', NULL, NULL, NULL),
(1631, 52, 'Clonazepam ', 'Orlistat', ' Orlistat may decrease the serum concentration of Anticonvulsants. Exceptions: Fosphenytoin; PENTobarbital; Thiopental.', NULL, NULL, NULL),
(1632, 52, 'Clonazepam ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(1633, 52, 'Clonazepam ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1634, 52, 'Clonazepam ', 'Phenytoin', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(1635, 52, 'Clonazepam ', 'Pramipexole', ' CNS Depressants may enhance the sedative effect of Pramipexole.', NULL, NULL, NULL),
(1636, 52, 'Clonazepam ', 'Ropinirole', ' CNS Depressants may enhance the sedative effect of ROPINIRole.', NULL, NULL, NULL),
(1637, 52, 'Clonazepam ', 'Rotigotine', ' CNS Depressants may enhance the sedative effect of Rotigotine.', NULL, NULL, NULL),
(1638, 52, 'Clonazepam ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(1639, 52, 'Clonazepam ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1640, 52, 'Clonazepam ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1641, 52, 'Clonazepam ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(1642, 52, 'Clonazepam ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(1643, 52, 'Clonazepam ', 'Teduglutide', ' May increase the serum concentration of Benzodiazepines.', NULL, NULL, NULL),
(1644, 52, 'Clonazepam ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(1645, 52, 'Clonazepam ', 'Theophylline', ' Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.', NULL, NULL, NULL),
(1646, 52, 'Clonazepam ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1647, 52, 'Clonazepam ', 'Vigabatrin', ' May enhance the CNS depressant effect of ClonazePAM. Vigabatrin may increase the serum concentration of ClonazePAM.', NULL, NULL, NULL),
(1648, 52, 'Clonazepam ', 'Yohimbine', ' May diminish the therapeutic effect of Antianxiety Agents.', NULL, NULL, NULL),
(1649, 52, 'Clonazepam ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(1650, 53, 'Clotrimazole ', '0', '0', NULL, NULL, NULL),
(1651, 53, 'Clotrimazole ', 'Aripiprazole', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(1652, 53, 'Clotrimazole ', 'Avanafil', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.', NULL, NULL, NULL),
(1653, 53, 'Clotrimazole ', 'Bosentan', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosentan.', NULL, NULL, NULL),
(1654, 53, 'Clotrimazole ', 'Bosutinib', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.', NULL, NULL, NULL),
(1655, 53, 'Clotrimazole ', 'Cilostazol', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.', NULL, NULL, NULL),
(1656, 53, 'Clotrimazole ', 'Colchicine', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1657, 53, 'Clotrimazole ', 'Dapoxetine', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.', NULL, NULL, NULL),
(1658, 53, 'Clotrimazole ', 'Dofetilide', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(1659, 53, 'Clotrimazole ', 'Domperidone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone.', NULL, NULL, NULL),
(1660, 53, 'Clotrimazole ', 'Dronabinol', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.', NULL, NULL, NULL),
(1661, 53, 'Clotrimazole ', 'Eliglustat', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.', NULL, NULL, NULL),
(1662, 53, 'Clotrimazole ', 'Eplerenone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.', NULL, NULL, NULL),
(1663, 53, 'Clotrimazole ', 'Everolimus', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.', NULL, NULL, NULL),
(1664, 53, 'Clotrimazole ', 'Fentanyl', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(1665, 53, 'Clotrimazole ', 'Halofantrine', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.', NULL, NULL, NULL),
(1666, 53, 'Clotrimazole ', 'Hydrocodone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(1667, 53, 'Clotrimazole ', 'Ifosfamide', ' CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.', NULL, NULL, NULL),
(1668, 53, 'Clotrimazole ', 'Imatinib', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Imatinib.', NULL, NULL, NULL),
(1669, 53, 'Clotrimazole ', 'Ivacaftor', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.', NULL, NULL, NULL),
(1670, 53, 'Clotrimazole ', 'Lomitapide', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(1671, 53, 'Clotrimazole ', 'Lurasidone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.', NULL, NULL, NULL),
(1672, 53, 'Clotrimazole ', 'Oxycodone', ' CYP3A4 Inhibitors (Moderate) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased.', NULL, NULL, NULL),
(1673, 53, 'Clotrimazole ', 'Pimecrolimus', ' CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.', NULL, NULL, NULL),
(1674, 53, 'Clotrimazole ', 'Pimozide', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(1675, 53, 'Clotrimazole ', 'Propafenone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.', NULL, NULL, NULL),
(1676, 53, 'Clotrimazole ', 'Ranolazine', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.', NULL, NULL, NULL),
(1677, 53, 'Clotrimazole ', 'Rivaroxaban', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rivaroxaban. This warning is more specifically for drugs that are inhibitors of both CYP3A4 and P-glycoprotein. For erythromycin~ refer to more specific erythromycin-rivaroxaban monograph recommendations.', NULL, NULL, NULL),
(1678, 53, 'Clotrimazole ', 'Salmeterol', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.', NULL, NULL, NULL),
(1679, 53, 'Clotrimazole ', 'Saxagliptin', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.', NULL, NULL, NULL),
(1680, 53, 'Clotrimazole ', 'Simeprevir', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir.', NULL, NULL, NULL),
(1681, 53, 'Clotrimazole ', 'Suvorexant', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant.', NULL, NULL, NULL),
(1682, 53, 'Clotrimazole ', 'Tolvaptan', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.', NULL, NULL, NULL),
(1683, 53, 'Clotrimazole ', 'Trabectedin', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin.', NULL, NULL, NULL),
(1684, 53, 'Clotrimazole ', 'Ulipristal', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal.', NULL, NULL, NULL),
(1685, 53, 'Clotrimazole ', 'Vilazodone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.', NULL, NULL, NULL),
(1686, 53, 'Clotrimazole ', 'Zopiclone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone.', NULL, NULL, NULL),
(1687, 53, 'Clotrimazole ', 'Zuclopenthixol', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.', NULL, NULL, NULL),
(1688, 54, 'Cloxacillin Sodium ', '0', '0', NULL, NULL, NULL),
(1689, 55, 'Codeine Phosphate ', '0', '0', NULL, NULL, NULL),
(1690, 56, 'Colchicine ', '0', '0', NULL, NULL, NULL),
(1691, 56, 'Colchicine ', 'Abiraterone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1692, 56, 'Colchicine ', 'Amiodarone', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1693, 56, 'Colchicine ', 'Aprepitant', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1694, 56, 'Colchicine ', 'Atazanavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1695, 56, 'Colchicine ', 'Atorvastatin', ' May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(1696, 56, 'Colchicine ', 'Bezafibrate', ' Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine.', NULL, NULL, NULL),
(1697, 56, 'Colchicine ', 'Bicalutamide', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1698, 56, 'Colchicine ', 'Biotin', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1699, 56, 'Colchicine ', 'Boceprevir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1700, 56, 'Colchicine ', 'Carvedilol', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1701, 56, 'Colchicine ', 'Choline', ' Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine.', NULL, NULL, NULL),
(1702, 56, 'Colchicine ', 'Cimetidine', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1703, 56, 'Colchicine ', 'Clarithromycin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1704, 56, 'Colchicine ', 'Clotrimazole', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1705, 56, 'Colchicine ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1706, 56, 'Colchicine ', 'Crizotinib', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1707, 56, 'Colchicine ', 'Cyanocobalamin', ' May decrease the serum concentration of Cyanocobalamin.', NULL, NULL, NULL),
(1708, 56, 'Colchicine ', 'Darunavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1709, 56, 'Colchicine ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1710, 56, 'Colchicine ', 'Delavirdine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1711, 56, 'Colchicine ', 'Desipramine', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1712, 56, 'Colchicine ', 'Digoxin', ' Digoxin may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1713, 56, 'Colchicine ', 'Diltiazem', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1714, 56, 'Colchicine ', 'Dipyridamole', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1715, 56, 'Colchicine ', 'Dronedarone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1716, 56, 'Colchicine ', 'Eliglustat', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1717, 56, 'Colchicine ', 'Fenofibrate', ' Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine.', NULL, NULL, NULL),
(1718, 56, 'Colchicine ', 'Fluconazole', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1719, 56, 'Colchicine ', 'Fluvastatin', ' May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(1720, 56, 'Colchicine ', 'Fosamprenavir', ' Fosamprenavir may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1721, 56, 'Colchicine ', 'Fosaprepitant', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1722, 56, 'Colchicine ', 'Gemfibrozil', ' Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine.', NULL, NULL, NULL),
(1723, 56, 'Colchicine ', 'Indinavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1724, 56, 'Colchicine ', 'Isavuconazonium', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1725, 56, 'Colchicine ', 'Itraconazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1726, 56, 'Colchicine ', 'Ivacaftor', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1727, 56, 'Colchicine ', 'Lapatinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1728, 56, 'Colchicine ', 'Ledipasvir', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1729, 56, 'Colchicine ', 'Lomitapide', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1730, 56, 'Colchicine ', 'Lopinavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1731, 56, 'Colchicine ', 'Lovastatin', ' May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(1732, 56, 'Colchicine ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1733, 56, 'Colchicine ', 'Mefloquine', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1734, 56, 'Colchicine ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1735, 56, 'Colchicine ', 'Nefazodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1736, 56, 'Colchicine ', 'Nelfinavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1737, 56, 'Colchicine ', 'Nilotinib', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1738, 56, 'Colchicine ', 'Norfloxacin', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1739, 56, 'Colchicine ', 'Pitavastatin', ' May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(1740, 56, 'Colchicine ', 'Posaconazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1741, 56, 'Colchicine ', 'Pravastatin', ' May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(1742, 56, 'Colchicine ', 'Progesterone', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1743, 56, 'Colchicine ', 'Propranolol', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1744, 56, 'Colchicine ', 'Quinidine', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1745, 56, 'Colchicine ', 'Quinine', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1746, 56, 'Colchicine ', 'Ranolazine', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1747, 56, 'Colchicine ', 'Reserpine', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1748, 56, 'Colchicine ', 'Ritonavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1749, 56, 'Colchicine ', 'Rosuvastatin', ' May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(1750, 56, 'Colchicine ', 'Saquinavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1751, 56, 'Colchicine ', 'Simeprevir', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1752, 56, 'Colchicine ', 'Simvastatin', ' May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(1753, 56, 'Colchicine ', 'Sulfisoxazole', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1754, 56, 'Colchicine ', 'Sunitinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1755, 56, 'Colchicine ', 'Tamoxifen', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1756, 56, 'Colchicine ', 'Telaprevir', ' May increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1757, 56, 'Colchicine ', 'Telithromycin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(1758, 56, 'Colchicine ', 'Tetracycline', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1759, 56, 'Colchicine ', 'Tipranavir', ' Tipranavir may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1760, 56, 'Colchicine ', 'Vandetanib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1761, 56, 'Colchicine ', 'Vemurafenib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(1762, 56, 'Colchicine ', 'Voriconazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1763, 57, 'Cyclophosphamide ', '0', '0', NULL, NULL, NULL),
(1764, 57, 'Cyclophosphamide ', 'Allopurinol', ' Allopurinol may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ bone marrow suppression.', NULL, NULL, NULL),
(1765, 57, 'Cyclophosphamide ', 'Amiodarone', ' Cyclophosphamide may enhance the adverse/toxic effect of Amiodarone. Specifically~ the risk of pulmonary toxicity may be enhanced.', NULL, NULL, NULL),
(1766, 57, 'Cyclophosphamide ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(1767, 57, 'Cyclophosphamide ', 'Atazanavir', ' Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(1768, 57, 'Cyclophosphamide ', 'Azathioprine', ' May enhance the hepatotoxic effect of Cyclophosphamide.', NULL, NULL, NULL),
(1769, 57, 'Cyclophosphamide ', 'Azilsartan medoxomil', ' Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.', NULL, NULL, NULL),
(1770, 57, 'Cyclophosphamide ', 'Batimastat', ' May enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(1771, 57, 'Cyclophosphamide ', 'Belimumab', ' May enhance the adverse/toxic effect of Cyclophosphamide.', NULL, NULL, NULL),
(1772, 57, 'Cyclophosphamide ', 'Bendroflumethiazide', ' Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.', NULL, NULL, NULL),
(1773, 57, 'Cyclophosphamide ', 'Chlorothiazide', ' Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.', NULL, NULL, NULL),
(1774, 57, 'Cyclophosphamide ', 'Chlorthalidone', ' Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.', NULL, NULL, NULL),
(1775, 57, 'Cyclophosphamide ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(1776, 57, 'Cyclophosphamide ', 'Dabrafenib', ' May decrease the serum concentration of CYP2B6 Substrates.', NULL, NULL, NULL),
(1777, 57, 'Cyclophosphamide ', 'Darunavir', ' Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(1778, 57, 'Cyclophosphamide ', 'Daunorubicin', ' May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline~ Systemic).', NULL, NULL, NULL),
(1779, 57, 'Cyclophosphamide ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(1780, 57, 'Cyclophosphamide ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(1781, 57, 'Cyclophosphamide ', 'Epirubicin', ' May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline~ Systemic).', NULL, NULL, NULL),
(1782, 57, 'Cyclophosphamide ', 'Etanercept', ' Etanercept may enhance the adverse/toxic effect of Cyclophosphamide. An increased risk of solid cancer development may be present.', NULL, NULL, NULL),
(1783, 57, 'Cyclophosphamide ', 'Filgrastim', ' Filgrastim may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the risk of pulmonary toxicity may be enhanced.', NULL, NULL, NULL),
(1784, 57, 'Cyclophosphamide ', 'Fosamprenavir', ' Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(1785, 57, 'Cyclophosphamide ', 'Hydrochlorothiazide', ' Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.', NULL, NULL, NULL),
(1786, 57, 'Cyclophosphamide ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(1787, 57, 'Cyclophosphamide ', 'Idarubicin', ' May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline~ Systemic).', NULL, NULL, NULL),
(1788, 57, 'Cyclophosphamide ', 'Indapamide', ' Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.', NULL, NULL, NULL),
(1789, 57, 'Cyclophosphamide ', 'Indinavir', ' Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(1790, 57, 'Cyclophosphamide ', 'Isoflurophate', ' May enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(1791, 57, 'Cyclophosphamide ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(1792, 57, 'Cyclophosphamide ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(1793, 57, 'Cyclophosphamide ', 'Lopinavir', ' Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(1794, 57, 'Cyclophosphamide ', 'Methyclothiazide', ' Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.', NULL, NULL, NULL),
(1795, 57, 'Cyclophosphamide ', 'Metolazone', ' Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.', NULL, NULL, NULL),
(1796, 57, 'Cyclophosphamide ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(1797, 57, 'Cyclophosphamide ', 'Nelfinavir', ' Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(1798, 57, 'Cyclophosphamide ', 'Pentostatin', ' May enhance the cardiotoxic effect of Cyclophosphamide.', NULL, NULL, NULL),
(1799, 57, 'Cyclophosphamide ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(1800, 57, 'Cyclophosphamide ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(1801, 57, 'Cyclophosphamide ', 'Quazepam', ' May increase the serum concentration of CYP2B6 Substrates.', NULL, NULL, NULL),
(1802, 57, 'Cyclophosphamide ', 'Ritonavir', ' Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(1803, 57, 'Cyclophosphamide ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(1804, 57, 'Cyclophosphamide ', 'Saquinavir', ' Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(1805, 57, 'Cyclophosphamide ', 'Sargramostim', ' May enhance the adverse/toxic effect of Sargramostim. Specifically~ the risk of pulmonary toxicity may be enhanced.', NULL, NULL, NULL),
(1806, 57, 'Cyclophosphamide ', 'Simeprevir', ' May enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(1807, 57, 'Cyclophosphamide ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(1808, 57, 'Cyclophosphamide ', 'Succinylcholine', ' May increase the serum concentration of Succinylcholine.', NULL, NULL, NULL),
(1809, 57, 'Cyclophosphamide ', 'Tipranavir', ' Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(1810, 57, 'Cyclophosphamide ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(1811, 57, 'Cyclophosphamide ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(1812, 58, 'Cycloserine ', '0', '0', NULL, NULL, NULL),
(1813, 58, 'Cycloserine ', 'Ethanol', ' Alcohol (Ethyl) may enhance the neurotoxic effect of CycloSERINE. Specifically~ the risk for seizures may be increased.', NULL, NULL, NULL),
(1814, 58, 'Cycloserine ', 'Ethionamide', ' May enhance the adverse/toxic effect of CycloSERINE.', NULL, NULL, NULL),
(1815, 58, 'Cycloserine ', 'Isoniazid', ' May enhance the adverse/toxic effect of CycloSERINE. Specifically~ CNS toxicity may be enhanced.', NULL, NULL, NULL),
(1816, 59, 'Cytarabine ', '0', '0', NULL, NULL, NULL),
(1817, 59, 'Cytarabine ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(1818, 59, 'Cytarabine ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(1819, 59, 'Cytarabine ', 'Flucytosine', ' Cytarabine (Conventional) may diminish the therapeutic effect of Flucytosine.', NULL, NULL, NULL),
(1820, 59, 'Cytarabine ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(1821, 59, 'Cytarabine ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(1822, 59, 'Cytarabine ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(1823, 59, 'Cytarabine ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(1824, 59, 'Cytarabine ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(1825, 59, 'Cytarabine ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(1826, 59, 'Cytarabine ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(1827, 60, 'Dactinomycine ', '0', '0', NULL, NULL, NULL),
(1828, 61, 'Dapsone ', '0', '0', NULL, NULL, NULL),
(1829, 62, 'Darunavir ', '0', '0', NULL, NULL, NULL),
(1830, 62, 'Darunavir ', 'Abacavir', ' Protease Inhibitors may decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(1831, 62, 'Darunavir ', 'Acetohexamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1832, 62, 'Darunavir ', 'ado-trastuzumab emtansine', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically~ strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.', NULL, NULL, NULL),
(1833, 62, 'Darunavir ', 'Afatinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.', NULL, NULL, NULL),
(1834, 62, 'Darunavir ', 'Alfuzosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.', NULL, NULL, NULL),
(1835, 62, 'Darunavir ', 'Almotriptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.', NULL, NULL, NULL),
(1836, 62, 'Darunavir ', 'Alogliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1837, 62, 'Darunavir ', 'Alosetron', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.', NULL, NULL, NULL),
(1838, 62, 'Darunavir ', 'Alprazolam', ' Protease Inhibitors may increase the serum concentration of ALPRAZolam.', NULL, NULL, NULL),
(1839, 62, 'Darunavir ', 'Amiodarone', ' May increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(1840, 62, 'Darunavir ', 'Amitriptyline', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1841, 62, 'Darunavir ', 'Amoxapine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1842, 62, 'Darunavir ', 'Apixaban', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.', NULL, NULL, NULL),
(1843, 62, 'Darunavir ', 'Aripiprazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(1844, 62, 'Darunavir ', 'Astemizole', ' Darunavir may increase the serum concentration of Astemizole.', NULL, NULL, NULL),
(1845, 62, 'Darunavir ', 'Atomoxetine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1846, 62, 'Darunavir ', 'Atorvastatin', ' Protease Inhibitors may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(1847, 62, 'Darunavir ', 'Avanafil', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.', NULL, NULL, NULL),
(1848, 62, 'Darunavir ', 'Axitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.', NULL, NULL, NULL),
(1849, 62, 'Darunavir ', 'Batimastat', ' May increase the serum concentration of other Protease Inhibitors.', NULL, NULL, NULL),
(1850, 62, 'Darunavir ', 'Bedaquiline', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.', NULL, NULL, NULL),
(1851, 62, 'Darunavir ', 'Boceprevir', ' May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir.', NULL, NULL, NULL),
(1852, 62, 'Darunavir ', 'Bortezomib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.', NULL, NULL, NULL),
(1853, 62, 'Darunavir ', 'Bosentan', ' Bosentan may decrease the serum concentration of Darunavir. Darunavir may increase the serum concentration of Bosentan.', NULL, NULL, NULL),
(1854, 62, 'Darunavir ', 'Bosutinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.', NULL, NULL, NULL),
(1855, 62, 'Darunavir ', 'Brentuximab vedotin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.', NULL, NULL, NULL),
(1856, 62, 'Darunavir ', 'Brinzolamide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.', NULL, NULL, NULL),
(1857, 62, 'Darunavir ', 'Cabazitaxel', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.', NULL, NULL, NULL),
(1858, 62, 'Darunavir ', 'Cabozantinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.', NULL, NULL, NULL),
(1859, 62, 'Darunavir ', 'Canagliflozin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1860, 62, 'Darunavir ', 'Captopril', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1861, 62, 'Darunavir ', 'Carbamazepine', ' May increase the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(1862, 62, 'Darunavir ', 'Carvedilol', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1863, 62, 'Darunavir ', 'Chlorphenamine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1864, 62, 'Darunavir ', 'Chlorpromazine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1865, 62, 'Darunavir ', 'Chlorpropamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1866, 62, 'Darunavir ', 'Cilostazol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.', NULL, NULL, NULL),
(1867, 62, 'Darunavir ', 'Cisapride', ' Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.', NULL, NULL, NULL),
(1868, 62, 'Darunavir ', 'Clarithromycin', ' Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(1869, 62, 'Darunavir ', 'Clomipramine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1870, 62, 'Darunavir ', 'Colchicine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(1871, 62, 'Darunavir ', 'Conivaptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.', NULL, NULL, NULL),
(1872, 62, 'Darunavir ', 'Crizotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.', NULL, NULL, NULL),
(1873, 62, 'Darunavir ', 'Cyclophosphamide', ' Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(1874, 62, 'Darunavir ', 'Dabigatran etexilate', ' P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.', NULL, NULL, NULL),
(1875, 62, 'Darunavir ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1876, 62, 'Darunavir ', 'Dapoxetine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine.', NULL, NULL, NULL),
(1877, 62, 'Darunavir ', 'Dasatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.', NULL, NULL, NULL),
(1878, 62, 'Darunavir ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1879, 62, 'Darunavir ', 'Delavirdine', ' May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.', NULL, NULL, NULL),
(1880, 62, 'Darunavir ', 'Desipramine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1881, 62, 'Darunavir ', 'Desogestrel', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(1882, 62, 'Darunavir ', 'Dextromethorphan', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1883, 62, 'Darunavir ', 'Didanosine', ' May decrease the serum concentration of Didanosine. More specifically~ this interaction is likely due to the effects of food (with which darunavir/ritonavir are taken) on didanosine~ which is supposed to be given on an empty stomach.', NULL, NULL, NULL),
(1884, 62, 'Darunavir ', 'Digoxin', ' Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(1885, 62, 'Darunavir ', 'Dofetilide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(1886, 62, 'Darunavir ', 'Domperidone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone.', NULL, NULL, NULL),
(1887, 62, 'Darunavir ', 'Dronabinol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronabinol.', NULL, NULL, NULL),
(1888, 62, 'Darunavir ', 'Dronedarone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.', NULL, NULL, NULL),
(1889, 62, 'Darunavir ', 'Drospirenone', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(1890, 62, 'Darunavir ', 'Duloxetine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1891, 62, 'Darunavir ', 'Dutasteride', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.', NULL, NULL, NULL),
(1892, 62, 'Darunavir ', 'Efavirenz', ' Darunavir may increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Darunavir.', NULL, NULL, NULL),
(1893, 62, 'Darunavir ', 'Eliglustat', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eliglustat.', NULL, NULL, NULL),
(1894, 62, 'Darunavir ', 'Enfuvirtide', ' May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.', NULL, NULL, NULL),
(1895, 62, 'Darunavir ', 'Eplerenone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.', NULL, NULL, NULL),
(1896, 62, 'Darunavir ', 'Erlotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.', NULL, NULL, NULL),
(1897, 62, 'Darunavir ', 'Ethynodiol', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(1898, 62, 'Darunavir ', 'Etonogestrel', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(1899, 62, 'Darunavir ', 'Etravirine', ' Darunavir may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(1900, 62, 'Darunavir ', 'Everolimus', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.', NULL, NULL, NULL),
(1901, 62, 'Darunavir ', 'Fentanyl', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(1902, 62, 'Darunavir ', 'Fesoterodine', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.', NULL, NULL, NULL),
(1903, 62, 'Darunavir ', 'Flecainide', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1904, 62, 'Darunavir ', 'Fluoxetine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1905, 62, 'Darunavir ', 'Fluvoxamine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1906, 62, 'Darunavir ', 'Fosphenytoin', ' May decrease the serum concentration of Darunavir.', NULL, NULL, NULL),
(1907, 62, 'Darunavir ', 'Gliclazide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1908, 62, 'Darunavir ', 'Glimepiride', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1909, 62, 'Darunavir ', 'Gliquidone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1910, 62, 'Darunavir ', 'Glyburide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1911, 62, 'Darunavir ', 'Guanfacine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.', NULL, NULL, NULL),
(1912, 62, 'Darunavir ', 'Halofantrine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.', NULL, NULL, NULL),
(1913, 62, 'Darunavir ', 'Hydrocodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(1914, 62, 'Darunavir ', 'Ifosfamide', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.', NULL, NULL, NULL),
(1915, 62, 'Darunavir ', 'Iloperidone', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically~ concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.', NULL, NULL, NULL),
(1916, 62, 'Darunavir ', 'Imatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib.', NULL, NULL, NULL),
(1917, 62, 'Darunavir ', 'Imipramine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1918, 62, 'Darunavir ', 'Insulin Aspart', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1919, 62, 'Darunavir ', 'Insulin Detemir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1920, 62, 'Darunavir ', 'Insulin Glargine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1921, 62, 'Darunavir ', 'Insulin Glulisine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1922, 62, 'Darunavir ', 'Insulin Lispro', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1923, 62, 'Darunavir ', 'Insulin Regular', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1924, 62, 'Darunavir ', 'Insulin~ isophane', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1925, 62, 'Darunavir ', 'Irinotecan', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan.', NULL, NULL, NULL),
(1926, 62, 'Darunavir ', 'Isoflurophate', ' May increase the serum concentration of other Protease Inhibitors.', NULL, NULL, NULL),
(1927, 62, 'Darunavir ', 'Itraconazole', ' May increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Darunavir.', NULL, NULL, NULL),
(1928, 62, 'Darunavir ', 'Ivacaftor', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.', NULL, NULL, NULL),
(1929, 62, 'Darunavir ', 'Ixabepilone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.', NULL, NULL, NULL),
(1930, 62, 'Darunavir ', 'Lacosamide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide.', NULL, NULL, NULL),
(1931, 62, 'Darunavir ', 'Lapatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.', NULL, NULL, NULL),
(1932, 62, 'Darunavir ', 'Ledipasvir', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(1933, 62, 'Darunavir ', 'Lercanidipine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine.', NULL, NULL, NULL),
(1934, 62, 'Darunavir ', 'Levobupivacaine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine.', NULL, NULL, NULL),
(1935, 62, 'Darunavir ', 'Levomilnacipran', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.', NULL, NULL, NULL),
(1936, 62, 'Darunavir ', 'Levonorgestrel', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(1937, 62, 'Darunavir ', 'Linagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1938, 62, 'Darunavir ', 'Lomitapide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(1939, 62, 'Darunavir ', 'Lopinavir', ' May decrease the serum concentration of Darunavir. Darunavir may increase the serum concentration of lopinavir', NULL, NULL, NULL),
(1940, 62, 'Darunavir ', 'Lovastatin', ' Protease Inhibitors may increase the serum concentration of Lovastatin.', NULL, NULL, NULL),
(1941, 62, 'Darunavir ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1942, 62, 'Darunavir ', 'Lumefantrine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.', NULL, NULL, NULL),
(1943, 62, 'Darunavir ', 'Lurasidone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.', NULL, NULL, NULL),
(1944, 62, 'Darunavir ', 'MACITENTAN', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan.', NULL, NULL, NULL),
(1945, 62, 'Darunavir ', 'Maprotiline', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1946, 62, 'Darunavir ', 'Maraviroc', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.', NULL, NULL, NULL),
(1947, 62, 'Darunavir ', 'Medroxyprogesterone Acetate', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(1948, 62, 'Darunavir ', 'Mestranol', ' May decrease the serum concentration of Norethindrone.', NULL, NULL, NULL),
(1949, 62, 'Darunavir ', 'Metformin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1950, 62, 'Darunavir ', 'Methadone', ' May decrease the serum concentration of Methadone. More specifically~ the combination of Darunavir and Ritonavir may decrease Methadone serum concentrations.', NULL, NULL, NULL),
(1951, 62, 'Darunavir ', 'Methamphetamine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1952, 62, 'Darunavir ', 'Methylprednisolone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(1953, 62, 'Darunavir ', 'Metoprolol', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1954, 62, 'Darunavir ', 'Mexiletine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1955, 62, 'Darunavir ', 'Midazolam', ' Protease Inhibitors may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(1956, 62, 'Darunavir ', 'Mifepristone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.', NULL, NULL, NULL),
(1957, 62, 'Darunavir ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(1958, 62, 'Darunavir ', 'Nefazodone', ' Protease Inhibitors may increase the serum concentration of Nefazodone.', NULL, NULL, NULL),
(1959, 62, 'Darunavir ', 'Nevirapine', ' May increase the serum concentration of Nevirapine. Nevirapine may increase the serum concentration of Darunavir.', NULL, NULL, NULL),
(1960, 62, 'Darunavir ', 'Nilotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.', NULL, NULL, NULL),
(1961, 62, 'Darunavir ', 'Nisoldipine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.', NULL, NULL, NULL),
(1962, 62, 'Darunavir ', 'Norelgestromin', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(1963, 62, 'Darunavir ', 'Norethindrone', ' May decrease the serum concentration of Norethindrone.', NULL, NULL, NULL),
(1964, 62, 'Darunavir ', 'Norgestimate', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(1965, 62, 'Darunavir ', 'Nortriptyline', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1966, 62, 'Darunavir ', 'Ospemifene', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.', NULL, NULL, NULL),
(1967, 62, 'Darunavir ', 'Oxybutynin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin.', NULL, NULL, NULL),
(1968, 62, 'Darunavir ', 'Oxycodone', ' CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased.', NULL, NULL, NULL),
(1969, 62, 'Darunavir ', 'Panobinostat', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.', NULL, NULL, NULL),
(1970, 62, 'Darunavir ', 'Paricalcitol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.', NULL, NULL, NULL),
(1971, 62, 'Darunavir ', 'Paroxetine', ' May decrease the serum concentration of PARoxetine.', NULL, NULL, NULL),
(1972, 62, 'Darunavir ', 'Pazopanib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(1973, 62, 'Darunavir ', 'Perphenazine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1974, 62, 'Darunavir ', 'Phenobarbital', ' May decrease the serum concentration of PHENobarbital.', NULL, NULL, NULL),
(1975, 62, 'Darunavir ', 'Phenytoin', ' May decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(1976, 62, 'Darunavir ', 'Pimecrolimus', ' CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.', NULL, NULL, NULL),
(1977, 62, 'Darunavir ', 'Pimozide', ' Protease Inhibitors may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(1978, 62, 'Darunavir ', 'Ponatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.', NULL, NULL, NULL),
(1979, 62, 'Darunavir ', 'Pranlukast', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast.', NULL, NULL, NULL),
(1980, 62, 'Darunavir ', 'Prasugrel', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.', NULL, NULL, NULL),
(1981, 62, 'Darunavir ', 'Pravastatin', ' May increase the serum concentration of Pravastatin. This effect has only been demonstrated with darunavir/ritonavir. The individual contributions of darunavir and ritonavir are unknown.', NULL, NULL, NULL),
(1982, 62, 'Darunavir ', 'Prednisone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE.', NULL, NULL, NULL),
(1983, 62, 'Darunavir ', 'Primaquine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1984, 62, 'Darunavir ', 'Procainamide', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1985, 62, 'Darunavir ', 'Procaine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1986, 62, 'Darunavir ', 'Promazine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1987, 62, 'Darunavir ', 'Promethazine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1988, 62, 'Darunavir ', 'Propafenone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.', NULL, NULL, NULL),
(1989, 62, 'Darunavir ', 'Propranolol', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1990, 62, 'Darunavir ', 'Protriptyline', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(1991, 62, 'Darunavir ', 'prucalopride', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.', NULL, NULL, NULL),
(1992, 62, 'Darunavir ', 'Quetiapine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of QUEtiapine.', NULL, NULL, NULL),
(1993, 62, 'Darunavir ', 'Quinidine', ' May increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(1994, 62, 'Darunavir ', 'Ranolazine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.', NULL, NULL, NULL),
(1995, 62, 'Darunavir ', 'Regorafenib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.', NULL, NULL, NULL),
(1996, 62, 'Darunavir ', 'Repaglinide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(1997, 62, 'Darunavir ', 'Retapamulin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.', NULL, NULL, NULL),
(1998, 62, 'Darunavir ', 'Rifabutin', ' Darunavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Darunavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Darunavir.', NULL, NULL, NULL),
(1999, 62, 'Darunavir ', 'Rifampicin', ' Rifampin may decrease the serum concentration of Darunavir.', NULL, NULL, NULL),
(2000, 62, 'Darunavir ', 'Rifaximin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.', NULL, NULL, NULL),
(2001, 62, 'Darunavir ', 'Rilpivirine', ' Darunavir may increase the serum concentration of Rilpivirine.', NULL, NULL, NULL),
(2002, 62, 'Darunavir ', 'Riociguat', ' Protease Inhibitors may increase the serum concentration of Riociguat.', NULL, NULL, NULL),
(2003, 62, 'Darunavir ', 'Risperidone', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(2004, 62, 'Darunavir ', 'Rivaroxaban', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. For clarithromycin~ refer to more specific clarithromycin-rivaroxaban monograph recommendations.', NULL, NULL, NULL),
(2005, 62, 'Darunavir ', 'Romidepsin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.', NULL, NULL, NULL),
(2006, 62, 'Darunavir ', 'Rosuvastatin', ' Protease Inhibitors may increase the serum concentration of Rosuvastatin.', NULL, NULL, NULL),
(2007, 62, 'Darunavir ', 'Ruxolitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.', NULL, NULL, NULL),
(2008, 62, 'Darunavir ', 'Salmeterol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.', NULL, NULL, NULL),
(2009, 62, 'Darunavir ', 'Saquinavir', ' Saquinavir may decrease the serum concentration of Darunavir.', NULL, NULL, NULL),
(2010, 62, 'Darunavir ', 'Saxagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(2011, 62, 'Darunavir ', 'Sertraline', ' May decrease the serum concentration of Sertraline.', NULL, NULL, NULL),
(2012, 62, 'Darunavir ', 'Sildenafil', ' Protease Inhibitors may increase the serum concentration of Sildenafil.', NULL, NULL, NULL),
(2013, 62, 'Darunavir ', 'Silodosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.', NULL, NULL, NULL),
(2014, 62, 'Darunavir ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2015, 62, 'Darunavir ', 'Simeprevir', ' May increase the serum concentration of other Protease Inhibitors.', NULL, NULL, NULL),
(2016, 62, 'Darunavir ', 'Simvastatin', ' Protease Inhibitors may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(2017, 62, 'Darunavir ', 'Sorafenib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.', NULL, NULL, NULL),
(2018, 62, 'Darunavir ', 'Suvorexant', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant.', NULL, NULL, NULL),
(2019, 62, 'Darunavir ', 'Tadalafil', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.', NULL, NULL, NULL),
(2020, 62, 'Darunavir ', 'Tamsulosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.', NULL, NULL, NULL),
(2021, 62, 'Darunavir ', 'Telaprevir', ' Darunavir may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Darunavir.', NULL, NULL, NULL),
(2022, 62, 'Darunavir ', 'Temsirolimus', ' Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus~ the active metabolite~ may be increased~ likely due to inhibition of CYP-mediated metabolism.', NULL, NULL, NULL),
(2023, 62, 'Darunavir ', 'Tenofovir', ' May increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Darunavir.', NULL, NULL, NULL),
(2024, 62, 'Darunavir ', 'Terfenadine', ' Darunavir may increase the serum concentration of Terfenadine.', NULL, NULL, NULL),
(2025, 62, 'Darunavir ', 'Tetrabenazine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(2026, 62, 'Darunavir ', 'Thioridazine', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(2027, 62, 'Darunavir ', 'Ticagrelor', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.', NULL, NULL, NULL),
(2028, 62, 'Darunavir ', 'Timolol', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(2029, 62, 'Darunavir ', 'Tipranavir', ' May decrease the serum concentration of Protease Inhibitors.', NULL, NULL, NULL),
(2030, 62, 'Darunavir ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2031, 62, 'Darunavir ', 'Tofacitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.', NULL, NULL, NULL),
(2032, 62, 'Darunavir ', 'Tolbutamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(2033, 62, 'Darunavir ', 'Tolterodine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.', NULL, NULL, NULL),
(2034, 62, 'Darunavir ', 'Tolvaptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.', NULL, NULL, NULL),
(2035, 62, 'Darunavir ', 'Topotecan', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.', NULL, NULL, NULL),
(2036, 62, 'Darunavir ', 'Toremifene', ' CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.', NULL, NULL, NULL),
(2037, 62, 'Darunavir ', 'Trabectedin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin.', NULL, NULL, NULL),
(2038, 62, 'Darunavir ', 'Trazodone', ' Darunavir may increase the serum concentration of TraZODone.', NULL, NULL, NULL),
(2039, 62, 'Darunavir ', 'Triazolam', ' Protease Inhibitors may increase the serum concentration of Triazolam.', NULL, NULL, NULL),
(2040, 62, 'Darunavir ', 'Ulipristal', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.', NULL, NULL, NULL),
(2041, 62, 'Darunavir ', 'Vardenafil', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.', NULL, NULL, NULL),
(2042, 62, 'Darunavir ', 'Vemurafenib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.', NULL, NULL, NULL),
(2043, 62, 'Darunavir ', 'Vilazodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.', NULL, NULL, NULL),
(2044, 62, 'Darunavir ', 'Vildagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(2045, 62, 'Darunavir ', 'Vorapaxar', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar.', NULL, NULL, NULL),
(2046, 62, 'Darunavir ', 'Voriconazole', ' May decrease the serum concentration of Voriconazole.', NULL, NULL, NULL),
(2047, 62, 'Darunavir ', 'Warfarin', ' Darunavir may decrease the serum concentration of Warfarin.', NULL, NULL, NULL),
(2048, 62, 'Darunavir ', 'Zidovudine', ' Protease Inhibitors may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(2049, 62, 'Darunavir ', 'Zopiclone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.', NULL, NULL, NULL),
(2050, 62, 'Darunavir ', 'Zuclopenthixol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.', NULL, NULL, NULL),
(2051, 63, 'Deferoxamine mesylate ', '0', '0', NULL, NULL, NULL),
(2052, 64, 'Dexamethasone Sodium ', '0', '0', NULL, NULL, NULL),
(2053, 65, 'Dextromethrophan ', '0', '0', NULL, NULL, NULL),
(2054, 66, 'Diazepam ', '0', '0', NULL, NULL, NULL),
(2055, 66, 'Diazepam ', 'Alfentanil', ' May enhance the CNS depressant effect of Alfentanil. Hypotension may also occur.', NULL, NULL, NULL),
(2056, 66, 'Diazepam ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2057, 66, 'Diazepam ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(2058, 66, 'Diazepam ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2059, 66, 'Diazepam ', 'Buprenorphine', ' CNS Depressants may enhance the CNS depressant effect of Buprenorphine.', NULL, NULL, NULL),
(2060, 66, 'Diazepam ', 'Clozapine', ' Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.', NULL, NULL, NULL),
(2061, 66, 'Diazepam ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2062, 66, 'Diazepam ', 'Cosyntropin', ' May enhance the hepatotoxic effect of Diazepam.', NULL, NULL, NULL),
(2063, 66, 'Diazepam ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2064, 66, 'Diazepam ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2065, 66, 'Diazepam ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2066, 66, 'Diazepam ', 'Disulfiram', ' Disulfiram may increase the serum concentration of Diazepam.', NULL, NULL, NULL),
(2067, 66, 'Diazepam ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(2068, 66, 'Diazepam ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2069, 66, 'Diazepam ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2070, 66, 'Diazepam ', 'Droperidol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2071, 66, 'Diazepam ', 'Etravirine', ' May decrease the serum concentration of Diazepam. Etravirine may increase the serum concentration of Diazepam.', NULL, NULL, NULL),
(2072, 66, 'Diazepam ', 'Fosamprenavir', ' May increase the serum concentration of Diazepam.', NULL, NULL, NULL),
(2073, 66, 'Diazepam ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2074, 66, 'Diazepam ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(2075, 66, 'Diazepam ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2076, 66, 'Diazepam ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2077, 66, 'Diazepam ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(2078, 66, 'Diazepam ', 'LULICONAZOLE', ' May increase the serum concentration of CYP2C19 Substrates.', NULL, NULL, NULL),
(2079, 66, 'Diazepam ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2080, 66, 'Diazepam ', 'Mefloquine', ' Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.', NULL, NULL, NULL),
(2081, 66, 'Diazepam ', 'Methadone', ' Benzodiazepines may enhance the CNS depressant effect of Methadone.', NULL, NULL, NULL),
(2082, 66, 'Diazepam ', 'Methotrimeprazine', ' CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2083, 66, 'Diazepam ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(2084, 66, 'Diazepam ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2085, 66, 'Diazepam ', 'Mirtazapine', ' CNS Depressants may enhance the CNS depressant effect of Mirtazapine.', NULL, NULL, NULL),
(2086, 66, 'Diazepam ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2087, 66, 'Diazepam ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2088, 66, 'Diazepam ', 'Olanzapine', ' May enhance the adverse/toxic effect of Benzodiazepines.', NULL, NULL, NULL),
(2089, 66, 'Diazepam ', 'Orlistat', ' Orlistat may decrease the serum concentration of Anticonvulsants. Exceptions: Fosphenytoin; PENTobarbital; Thiopental.', NULL, NULL, NULL),
(2090, 66, 'Diazepam ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(2091, 66, 'Diazepam ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(2092, 66, 'Diazepam ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(2093, 66, 'Diazepam ', 'Pramipexole', ' CNS Depressants may enhance the sedative effect of Pramipexole.', NULL, NULL, NULL),
(2094, 66, 'Diazepam ', 'Ritonavir', ' Ritonavir may increase the serum concentration of Diazepam.', NULL, NULL, NULL),
(2095, 66, 'Diazepam ', 'Ropinirole', ' CNS Depressants may enhance the sedative effect of ROPINIRole.', NULL, NULL, NULL),
(2096, 66, 'Diazepam ', 'Rotigotine', ' CNS Depressants may enhance the sedative effect of Rotigotine.', NULL, NULL, NULL),
(2097, 66, 'Diazepam ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(2098, 66, 'Diazepam ', 'Saquinavir', ' May increase the serum concentration of Diazepam.', NULL, NULL, NULL),
(2099, 66, 'Diazepam ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2100, 66, 'Diazepam ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2101, 66, 'Diazepam ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(2102, 66, 'Diazepam ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2103, 66, 'Diazepam ', 'Teduglutide', ' May increase the serum concentration of Benzodiazepines.', NULL, NULL, NULL),
(2104, 66, 'Diazepam ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(2105, 66, 'Diazepam ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2106, 66, 'Diazepam ', 'Yohimbine', ' May diminish the therapeutic effect of Antianxiety Agents.', NULL, NULL, NULL),
(2107, 66, 'Diazepam ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(2108, 67, 'Diclofenac Sodium ', '0', '0', NULL, NULL, NULL),
(2109, 68, 'Dicyclomine Hydrochloride ', '0', '0', NULL, NULL, NULL),
(2110, 69, 'Digoxin ', '0', '0', NULL, NULL, NULL),
(2111, 69, 'Digoxin ', 'Acarbose', ' Acarbose may decrease the serum concentration of Digoxin.', NULL, NULL, NULL),
(2112, 69, 'Digoxin ', 'Adenosine', ' Digoxin may enhance the adverse/toxic effect of Adenosine.', NULL, NULL, NULL),
(2113, 69, 'Digoxin ', 'Amikacin', ' May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).', NULL, NULL, NULL),
(2114, 69, 'Digoxin ', 'Amiodarone', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2115, 69, 'Digoxin ', 'Amphotericin B', ' May enhance the adverse/toxic effect of Cardiac Glycosides.', NULL, NULL, NULL),
(2116, 69, 'Digoxin ', 'Arbekacin', ' May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).', NULL, NULL, NULL),
(2117, 69, 'Digoxin ', 'Atazanavir', ' Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(2118, 69, 'Digoxin ', 'Atorvastatin', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2119, 69, 'Digoxin ', 'Batimastat', ' May increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(2120, 69, 'Digoxin ', 'Boceprevir', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2121, 69, 'Digoxin ', 'Bretylium', ' May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.', NULL, NULL, NULL),
(2122, 69, 'Digoxin ', 'Calcidiol', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2123, 69, 'Digoxin ', 'Calcitriol', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2124, 69, 'Digoxin ', 'Carbimazole', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2125, 69, 'Digoxin ', 'Carvedilol', ' Digoxin may enhance the bradycardic effect of Carvedilol. Carvedilol may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2126, 69, 'Digoxin ', 'Celecoxib', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2127, 69, 'Digoxin ', 'Cholecalciferol', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2128, 69, 'Digoxin ', 'Clonidine', ' May enhance the AV-blocking effect of Cardiac Glycosides. Sinus node dysfunction may also be enhanced.', NULL, NULL, NULL),
(2129, 69, 'Digoxin ', 'Colchicine', ' Digoxin may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(2130, 69, 'Digoxin ', 'Colesevelam', ' May decrease the absorption of Cardiac Glycosides. Exceptions: Colesevelam.', NULL, NULL, NULL),
(2131, 69, 'Digoxin ', 'Conivaptan', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2132, 69, 'Digoxin ', 'Darunavir', ' Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(2133, 69, 'Digoxin ', 'Diflunisal', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2134, 69, 'Digoxin ', 'Dihydrotachysterol', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2135, 69, 'Digoxin ', 'Dronedarone', ' Digoxin may enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2136, 69, 'Digoxin ', 'Eliglustat', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2137, 69, 'Digoxin ', 'Epoprostenol', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2138, 69, 'Digoxin ', 'Ergocalciferol', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2139, 69, 'Digoxin ', 'Etodolac', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2140, 69, 'Digoxin ', 'Etravirine', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2141, 69, 'Digoxin ', 'Ezogabine', ' May increase the serum concentration of Digoxin. More specifically~ the N-acetyl metabolite of ezogabine may increase digoxin concentrations.', NULL, NULL, NULL),
(2142, 69, 'Digoxin ', 'Fenoprofen', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2143, 69, 'Digoxin ', 'Flecainide', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2144, 69, 'Digoxin ', 'Floctafenine', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2145, 69, 'Digoxin ', 'Fosamprenavir', ' Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(2146, 69, 'Digoxin ', 'Framycetin', ' May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).', NULL, NULL, NULL),
(2147, 69, 'Digoxin ', 'Gentamicin', ' May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).', NULL, NULL, NULL),
(2148, 69, 'Digoxin ', 'Glycopyrrolate', ' May increase the serum concentration of Digoxin. This effect is specific to digoxin administered as slow dissolution oral tablets.', NULL, NULL, NULL),
(2149, 69, 'Digoxin ', 'Ibuprofen', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2150, 69, 'Digoxin ', 'Indinavir', ' Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(2151, 69, 'Digoxin ', 'Indomethacin', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2152, 69, 'Digoxin ', 'Isavuconazonium', ' Isavuconazonium Sulfate may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2153, 69, 'Digoxin ', 'Isoflurophate', ' May increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(2154, 69, 'Digoxin ', 'Itraconazole', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2155, 69, 'Digoxin ', 'Kanamycin', ' May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).', NULL, NULL, NULL),
(2156, 69, 'Digoxin ', 'Kaolin', ' May decrease the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2157, 69, 'Digoxin ', 'Ketoprofen', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2158, 69, 'Digoxin ', 'Ketorolac', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2159, 69, 'Digoxin ', 'Lacosamide', ' Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.', NULL, NULL, NULL),
(2160, 69, 'Digoxin ', 'Lenalidomide', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2161, 69, 'Digoxin ', 'Lopinavir', ' Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(2162, 69, 'Digoxin ', 'Mefenamic acid', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2163, 69, 'Digoxin ', 'Meloxicam', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2164, 69, 'Digoxin ', 'Methimazole', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2165, 69, 'Digoxin ', 'Midodrine', ' Cardiac Glycosides may enhance the bradycardic effect of Midodrine.', NULL, NULL, NULL),
(2166, 69, 'Digoxin ', 'Mifepristone', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2167, 69, 'Digoxin ', 'Milnacipran', ' May enhance the adverse/toxic effect of Digoxin. The risk of postural hypotension and tachycardia may be increased~ particularly with IV digoxin.', NULL, NULL, NULL),
(2168, 69, 'Digoxin ', 'Mirabegron', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2169, 69, 'Digoxin ', 'Nabumetone', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2170, 69, 'Digoxin ', 'Naproxen', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2171, 69, 'Digoxin ', 'Nefazodone', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2172, 69, 'Digoxin ', 'Nelfinavir', ' Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(2173, 69, 'Digoxin ', 'Neomycin', ' May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).', NULL, NULL, NULL),
(2174, 69, 'Digoxin ', 'Netilmicin', ' May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).', NULL, NULL, NULL),
(2175, 69, 'Digoxin ', 'Nifedipine', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2176, 69, 'Digoxin ', 'Oxaprozin', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2177, 69, 'Digoxin ', 'Paricalcitol', ' May enhance the adverse/toxic effect of Digoxin.', NULL, NULL, NULL),
(2178, 69, 'Digoxin ', 'Penicillamine', ' May decrease the serum concentration of Digoxin.', NULL, NULL, NULL),
(2179, 69, 'Digoxin ', 'Piroxicam', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2180, 69, 'Digoxin ', 'Posaconazole', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2181, 69, 'Digoxin ', 'Propafenone', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2182, 69, 'Digoxin ', 'Propylthiouracil', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2183, 69, 'Digoxin ', 'Quinidine', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2184, 69, 'Digoxin ', 'Quinine', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2185, 69, 'Digoxin ', 'Ranolazine', ' Ranolazine may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2186, 69, 'Digoxin ', 'Regorafenib', ' May enhance the bradycardic effect of Digoxin.', NULL, NULL, NULL),
(2187, 69, 'Digoxin ', 'Reserpine', ' May enhance the adverse/toxic effect of Cardiac Glycosides.', NULL, NULL, NULL),
(2188, 69, 'Digoxin ', 'Ribostamycin', ' May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).', NULL, NULL, NULL),
(2189, 69, 'Digoxin ', 'Ritonavir', ' Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(2190, 69, 'Digoxin ', 'Ruxolitinib', ' May enhance the bradycardic effect of Bradycardia-Causing Agents.', NULL, NULL, NULL),
(2191, 69, 'Digoxin ', 'Saquinavir', ' Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(2192, 69, 'Digoxin ', 'Simeprevir', ' May increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(2193, 69, 'Digoxin ', 'Sitagliptin', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2194, 69, 'Digoxin ', 'Spectinomycin', ' May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).', NULL, NULL, NULL),
(2195, 69, 'Digoxin ', 'Spironolactone', ' May increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations~ falsely increasing or decreasing Digoxin concentrations.', NULL, NULL, NULL),
(2196, 69, 'Digoxin ', 'Streptomycin', ' May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).', NULL, NULL, NULL),
(2197, 69, 'Digoxin ', 'Sucralfate', ' Sucralfate may decrease the serum concentration of Digoxin. Specifically~ sucralfate may decrease the absorption of digoxin.', NULL, NULL, NULL),
(2198, 69, 'Digoxin ', 'Sulfamethoxazole', ' Trimethoprim may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2199, 69, 'Digoxin ', 'Sulindac', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2200, 69, 'Digoxin ', 'Telaprevir', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2201, 69, 'Digoxin ', 'Telmisartan', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(2202, 69, 'Digoxin ', 'Tiaprofenic acid', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2203, 69, 'Digoxin ', 'Ticagrelor', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2204, 69, 'Digoxin ', 'Tipranavir', ' Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(2205, 69, 'Digoxin ', 'Tobramycin', ' May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).', NULL, NULL, NULL),
(2206, 69, 'Digoxin ', 'Tofacitinib', ' May enhance the bradycardic effect of Bradycardia-Causing Agents.', NULL, NULL, NULL),
(2207, 69, 'Digoxin ', 'Tolmetin', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2208, 69, 'Digoxin ', 'Tolvaptan', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2209, 69, 'Digoxin ', 'Trimethoprim', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2210, 69, 'Digoxin ', 'Vandetanib', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2211, 69, 'Digoxin ', 'Vilazodone', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2212, 70, 'Dimercaprol ', '0', '0', NULL, NULL, NULL),
(2213, 70, 'Dimercaprol ', 'Ferric Carboxymaltose', ' May enhance the nephrotoxic effect of Iron Salts.', NULL, NULL, NULL),
(2214, 70, 'Dimercaprol ', 'Iron', ' May enhance the nephrotoxic effect of Iron Salts.', NULL, NULL, NULL),
(2215, 70, 'Dimercaprol ', 'Iron Dextran', ' May enhance the nephrotoxic effect of Iron Salts.', NULL, NULL, NULL),
(2216, 70, 'Dimercaprol ', 'Iron sucrose', ' May enhance the nephrotoxic effect of Iron Salts.', NULL, NULL, NULL),
(2217, 71, 'Dobutamine ', '0', '0', NULL, NULL, NULL),
(2218, 71, 'Dobutamine ', 'Acebutolol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2219, 71, 'Dobutamine ', 'Aminophylline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2220, 71, 'Dobutamine ', 'Amphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2221, 71, 'Dobutamine ', 'Arformoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2222, 71, 'Dobutamine ', 'armodafinil', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2223, 71, 'Dobutamine ', 'Articaine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2224, 71, 'Dobutamine ', 'Atomoxetine', ' AtoMOXetine may enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(2225, 71, 'Dobutamine ', 'Benzphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2226, 71, 'Dobutamine ', 'Caffeine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2227, 71, 'Dobutamine ', 'Calcium Acetate', ' Calcium Salts may diminish the therapeutic effect of DOBUTamine.', NULL, NULL, NULL),
(2228, 71, 'Dobutamine ', 'Calcium carbonate', ' Calcium Salts may diminish the therapeutic effect of DOBUTamine.', NULL, NULL, NULL),
(2229, 71, 'Dobutamine ', 'Calcium Chloride', ' Calcium Salts may diminish the therapeutic effect of DOBUTamine.', NULL, NULL, NULL),
(2230, 71, 'Dobutamine ', 'Chlorphentermine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2231, 71, 'Dobutamine ', 'Clenbuterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2232, 71, 'Dobutamine ', 'Cocaine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2233, 71, 'Dobutamine ', 'Dexmethylphenidate', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2234, 71, 'Dobutamine ', 'Dextroamphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2235, 71, 'Dobutamine ', 'Diethylpropion', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2236, 71, 'Dobutamine ', 'Dihydrocodeine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2237, 71, 'Dobutamine ', 'Dipivefrin', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2238, 71, 'Dobutamine ', 'Dopamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2239, 71, 'Dobutamine ', 'Doxapram', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2240, 71, 'Dobutamine ', 'Dronabinol', ' Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(2241, 71, 'Dobutamine ', 'Epinephrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2242, 71, 'Dobutamine ', 'Fenoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2243, 71, 'Dobutamine ', 'Fluticasone furoate', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2244, 71, 'Dobutamine ', 'Formoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2245, 71, 'Dobutamine ', 'Indacaterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2246, 71, 'Dobutamine ', 'Iobenguane', ' May diminish the therapeutic effect of Iobenguane I 123.', NULL, NULL, NULL),
(2247, 71, 'Dobutamine ', 'Ipratropium bromide', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2248, 71, 'Dobutamine ', 'Isometheptene', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2249, 71, 'Dobutamine ', 'Isoprenaline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2250, 71, 'Dobutamine ', 'Labetalol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2251, 71, 'Dobutamine ', 'Levonordefrin', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2252, 71, 'Dobutamine ', 'Linezolid', ' Linezolid may enhance the hypertensive effect of Sympathomimetics.', NULL, NULL, NULL),
(2253, 71, 'Dobutamine ', 'Lisdexamfetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2254, 71, 'Dobutamine ', 'Mephentermine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2255, 71, 'Dobutamine ', 'Metaraminol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2256, 71, 'Dobutamine ', 'Methamphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2257, 71, 'Dobutamine ', 'Methoxamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2258, 71, 'Dobutamine ', 'Methylphenidate', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2259, 71, 'Dobutamine ', 'Midodrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2260, 71, 'Dobutamine ', 'Modafinil', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2261, 71, 'Dobutamine ', 'Nabilone', ' Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(2262, 71, 'Dobutamine ', 'Naphazoline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2263, 71, 'Dobutamine ', 'Norepinephrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2264, 71, 'Dobutamine ', 'Orciprenaline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2265, 71, 'Dobutamine ', 'Oxymetazoline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2266, 71, 'Dobutamine ', 'Phendimetrazine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2267, 71, 'Dobutamine ', 'Pheniramine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2268, 71, 'Dobutamine ', 'Phenmetrazine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2269, 71, 'Dobutamine ', 'Phentermine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2270, 71, 'Dobutamine ', 'Phenylephrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2271, 71, 'Dobutamine ', 'Phenylpropanolamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2272, 71, 'Dobutamine ', 'Pirbuterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2273, 71, 'Dobutamine ', 'Propylhexedrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2274, 71, 'Dobutamine ', 'Pseudoephedrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2275, 71, 'Dobutamine ', 'Ritodrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2276, 71, 'Dobutamine ', 'Salbutamol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2277, 71, 'Dobutamine ', 'Salmeterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2278, 71, 'Dobutamine ', 'Tedizolid Phosphate', ' Tedizolid may enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(2279, 71, 'Dobutamine ', 'Terbutaline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2280, 71, 'Dobutamine ', 'Theophylline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2281, 71, 'Dobutamine ', 'Triprolidine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(2282, 72, 'Docetaxel ', '0', '0', NULL, NULL, NULL),
(2283, 72, 'Docetaxel ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(2284, 72, 'Docetaxel ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2285, 72, 'Docetaxel ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(2286, 72, 'Docetaxel ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2287, 72, 'Docetaxel ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2288, 72, 'Docetaxel ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2289, 72, 'Docetaxel ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2290, 72, 'Docetaxel ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(2291, 72, 'Docetaxel ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(2292, 72, 'Docetaxel ', 'Dronedarone', ' May increase the serum concentration of DOCEtaxel.', NULL, NULL, NULL),
(2293, 72, 'Docetaxel ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(2294, 72, 'Docetaxel ', 'Itraconazole', ' Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of DOCEtaxel. Fluconazole and isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2295, 72, 'Docetaxel ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2296, 72, 'Docetaxel ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(2297, 72, 'Docetaxel ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(2298, 72, 'Docetaxel ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2299, 72, 'Docetaxel ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2300, 72, 'Docetaxel ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2301, 72, 'Docetaxel ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(2302, 72, 'Docetaxel ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(2303, 72, 'Docetaxel ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(2304, 72, 'Docetaxel ', 'Posaconazole', ' Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of DOCEtaxel. Fluconazole and isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2305, 72, 'Docetaxel ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(2306, 72, 'Docetaxel ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2307, 72, 'Docetaxel ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2308, 72, 'Docetaxel ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(2309, 72, 'Docetaxel ', 'Sorafenib', ' SORAfenib may increase the serum concentration of DOCEtaxel.', NULL, NULL, NULL),
(2310, 72, 'Docetaxel ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2311, 72, 'Docetaxel ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(2312, 72, 'Docetaxel ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(2313, 72, 'Docetaxel ', 'Voriconazole', ' Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of DOCEtaxel. Fluconazole and isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2314, 73, 'Dopamine Hydrochloride ', '0', '0', NULL, NULL, NULL),
(2315, 74, 'Dorzolamide ', '0', '0', NULL, NULL, NULL),
(2316, 74, 'Dorzolamide ', 'Acetazolamide', ' May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.', NULL, NULL, NULL),
(2317, 74, 'Dorzolamide ', 'Diclofenamide', ' May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.', NULL, NULL, NULL),
(2318, 74, 'Dorzolamide ', 'Ethoxzolamide', ' May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported.', NULL, NULL, NULL),
(2319, 75, 'Doxorubicin Hydrochloride ', '0', '0', NULL, NULL, NULL),
(2320, 76, 'Doxycycline ', '0', '0', NULL, NULL, NULL),
(2321, 76, 'Doxycycline ', 'Aluminum hydroxide', ' May decrease the absorption of Tetracycline Derivatives.', NULL, NULL, NULL),
(2322, 76, 'Doxycycline ', 'Amdinocillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2323, 76, 'Doxycycline ', 'Amobarbital', ' Barbiturates may decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2324, 76, 'Doxycycline ', 'Amoxicillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2325, 76, 'Doxycycline ', 'Ampicillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2326, 76, 'Doxycycline ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(2327, 76, 'Doxycycline ', 'Azidocillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2328, 76, 'Doxycycline ', 'Azlocillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2329, 76, 'Doxycycline ', 'Bacampicillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2330, 76, 'Doxycycline ', 'Benzylpenicillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2331, 76, 'Doxycycline ', 'Bismuth Subsalicylate', ' May decrease the serum concentration of Tetracycline Derivatives.', NULL, NULL, NULL),
(2332, 76, 'Doxycycline ', 'Butabarbital', ' Barbiturates may decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2333, 76, 'Doxycycline ', 'Butalbital', ' Barbiturates may decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2334, 76, 'Doxycycline ', 'Butethal', ' May decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2335, 76, 'Doxycycline ', 'Calcium carbonate', ' May decrease the absorption of Tetracycline Derivatives.', NULL, NULL, NULL),
(2336, 76, 'Doxycycline ', 'Carbamazepine', ' May decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2337, 76, 'Doxycycline ', 'Carbenicillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2338, 76, 'Doxycycline ', 'Cloxacillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2339, 76, 'Doxycycline ', 'Colesevelam', ' May decrease the absorption of Tetracycline Derivatives.', NULL, NULL, NULL),
(2340, 76, 'Doxycycline ', 'Cyclacillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2341, 76, 'Doxycycline ', 'Dicloxacillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2342, 76, 'Doxycycline ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(2343, 76, 'Doxycycline ', 'Flucloxacillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2344, 76, 'Doxycycline ', 'Fosphenytoin', ' May decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2345, 76, 'Doxycycline ', 'Heptabarbital', ' May decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2346, 76, 'Doxycycline ', 'Hetacillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2347, 76, 'Doxycycline ', 'Hexobarbital', ' May decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2348, 76, 'Doxycycline ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(2349, 76, 'Doxycycline ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(2350, 76, 'Doxycycline ', 'Magnesium oxide', ' May decrease the absorption of Tetracycline Derivatives.', NULL, NULL, NULL),
(2351, 76, 'Doxycycline ', 'Methohexital', ' May decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2352, 76, 'Doxycycline ', 'Meticillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2353, 76, 'Doxycycline ', 'Mezlocillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2354, 76, 'Doxycycline ', 'Mipomersen', ' Tetracycline Derivatives may enhance the hepatotoxic effect of Mipomersen.', NULL, NULL, NULL),
(2355, 76, 'Doxycycline ', 'Nafcillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2356, 76, 'Doxycycline ', 'Oxacillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2357, 76, 'Doxycycline ', 'Penicillin V', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2358, 76, 'Doxycycline ', 'Pentobarbital', ' May decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2359, 76, 'Doxycycline ', 'Phenobarbital', ' Barbiturates may decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2360, 76, 'Doxycycline ', 'Phenytoin', ' Phenytoin may decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2361, 76, 'Doxycycline ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(2362, 76, 'Doxycycline ', 'Piperacillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2363, 76, 'Doxycycline ', 'Pivampicillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2364, 76, 'Doxycycline ', 'Pivmecillinam', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2365, 76, 'Doxycycline ', 'Porfimer', ' Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.', NULL, NULL, NULL),
(2366, 76, 'Doxycycline ', 'Primidone', ' May decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2367, 76, 'Doxycycline ', 'Quinapril', ' May decrease the serum concentration of Tetracycline Derivatives.', NULL, NULL, NULL),
(2368, 76, 'Doxycycline ', 'Rifampicin', ' Rifampin may decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2369, 76, 'Doxycycline ', 'Secobarbital', ' May decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(2370, 76, 'Doxycycline ', 'Sucralfate', ' May decrease the absorption of Tetracycline Derivatives.', NULL, NULL, NULL),
(2371, 76, 'Doxycycline ', 'Ticarcillin', ' Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.', NULL, NULL, NULL),
(2372, 76, 'Doxycycline ', 'Verteporfin', ' Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.', NULL, NULL, NULL),
(2373, 77, 'Efavirenz ', '0', '0', NULL, NULL, NULL),
(2374, 77, 'Efavirenz ', 'Acenocoumarol', ' May decrease the serum concentration of Vitamin K Antagonists. Efavirenz may increase the serum concentration of Vitamin K Antagonists.', NULL, NULL, NULL),
(2375, 77, 'Efavirenz ', 'Amlodipine', ' May decrease the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(2376, 77, 'Efavirenz ', 'Artemether', ' May decrease the serum concentration of Artemether. Concentrations of dihydroartemisinin (active metabolite of artemether) may also be decreased by efavirenz', NULL, NULL, NULL),
(2377, 77, 'Efavirenz ', 'Atazanavir', ' May decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(2378, 77, 'Efavirenz ', 'Atorvastatin', ' May decrease the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(2379, 77, 'Efavirenz ', 'Atovaquone', ' May decrease the serum concentration of Atovaquone.', NULL, NULL, NULL),
(2380, 77, 'Efavirenz ', 'Boceprevir', ' Boceprevir may increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Boceprevir.', NULL, NULL, NULL),
(2381, 77, 'Efavirenz ', 'Buprenorphine', ' May decrease serum concentrations of the active metabolite(s) of Buprenorphine. Efavirenz may decrease the serum concentration of Buprenorphine.', NULL, NULL, NULL),
(2382, 77, 'Efavirenz ', 'Bupropion', ' May decrease the serum concentration of BuPROPion.', NULL, NULL, NULL),
(2383, 77, 'Efavirenz ', 'Canagliflozin', ' May decrease the serum concentration of Canagliflozin.', NULL, NULL, NULL),
(2384, 77, 'Efavirenz ', 'Clarithromycin', ' May decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(2385, 77, 'Efavirenz ', 'Clevidipine', ' May decrease the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(2386, 77, 'Efavirenz ', 'Darunavir', ' Darunavir may increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Darunavir.', NULL, NULL, NULL),
(2387, 77, 'Efavirenz ', 'Delavirdine', ' Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Efavirenz. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Efavirenz.', NULL, NULL, NULL),
(2388, 77, 'Efavirenz ', 'Desogestrel', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(2389, 77, 'Efavirenz ', 'Diltiazem', ' May decrease the serum concentration of Diltiazem.', NULL, NULL, NULL),
(2390, 77, 'Efavirenz ', 'Dolutegravir', ' May decrease the serum concentration of Dolutegravir.', NULL, NULL, NULL),
(2391, 77, 'Efavirenz ', 'Drospirenone', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(2392, 77, 'Efavirenz ', 'Ethanol', ' May enhance the adverse/toxic effect of Alcohol (Ethyl). Efavirenz may decrease the serum concentration of Alcohol (Ethyl).', NULL, NULL, NULL),
(2393, 77, 'Efavirenz ', 'Ethynodiol', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(2394, 77, 'Efavirenz ', 'Etonogestrel', ' May diminish the therapeutic effect of Etonogestrel.', NULL, NULL, NULL),
(2395, 77, 'Efavirenz ', 'Etravirine', ' Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Efavirenz. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Efavirenz.', NULL, NULL, NULL),
(2396, 77, 'Efavirenz ', 'Everolimus', ' May decrease the serum concentration of Everolimus.', NULL, NULL, NULL),
(2397, 77, 'Efavirenz ', 'Felodipine', ' May decrease the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(2398, 77, 'Efavirenz ', 'Fosamprenavir', ' May decrease serum concentrations of the active metabolite(s) of Fosamprenavir.', NULL, NULL, NULL),
(2399, 77, 'Efavirenz ', 'Fosphenytoin', ' May increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Efavirenz.', NULL, NULL, NULL),
(2400, 77, 'Efavirenz ', 'Indinavir', ' May decrease the serum concentration of Indinavir.', NULL, NULL, NULL),
(2401, 77, 'Efavirenz ', 'Isradipine', ' May decrease the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(2402, 77, 'Efavirenz ', 'Itraconazole', ' May decrease the serum concentration of Itraconazole.', NULL, NULL, NULL),
(2403, 77, 'Efavirenz ', 'Levonorgestrel', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(2404, 77, 'Efavirenz ', 'Lopinavir', ' May decrease the serum concentration of Lopinavir.', NULL, NULL, NULL),
(2405, 77, 'Efavirenz ', 'Lovastatin', ' May decrease the serum concentration of Lovastatin.', NULL, NULL, NULL),
(2406, 77, 'Efavirenz ', 'Lumefantrine', ' May decrease the serum concentration of Artemether. Concentrations of dihydroartemisinin (active metabolite of artemether) may also be decreased by efavirenz', NULL, NULL, NULL),
(2407, 77, 'Efavirenz ', 'Maraviroc', ' May decrease the serum concentration of Maraviroc. Of note~ this effect only applies in the absence of a strong CYP3A4 inhibitor', NULL, NULL, NULL),
(2408, 77, 'Efavirenz ', 'Medroxyprogesterone Acetate', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(2409, 77, 'Efavirenz ', 'Mestranol', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(2410, 77, 'Efavirenz ', 'Mifepristone', ' Mifepristone may increase the serum concentration of Efavirenz.', NULL, NULL, NULL),
(2411, 77, 'Efavirenz ', 'Nevirapine', ' May enhance the adverse/toxic effect of Nevirapine. Nevirapine may enhance the adverse/toxic effect of Efavirenz. Nevirapine may decrease the serum concentration of Efavirenz.', NULL, NULL, NULL),
(2412, 77, 'Efavirenz ', 'Nifedipine', ' May decrease the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(2413, 77, 'Efavirenz ', 'Nimodipine', ' May decrease the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(2414, 77, 'Efavirenz ', 'Norelgestromin', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(2415, 77, 'Efavirenz ', 'Norethindrone', ' May decrease the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(2416, 77, 'Efavirenz ', 'Norgestimate', ' May decrease serum concentrations of the active metabolite(s) of Norgestimate.', NULL, NULL, NULL),
(2417, 77, 'Efavirenz ', 'Phenytoin', ' May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Efavirenz.', NULL, NULL, NULL),
(2418, 77, 'Efavirenz ', 'Posaconazole', ' May decrease the serum concentration of Posaconazole.', NULL, NULL, NULL),
(2419, 77, 'Efavirenz ', 'Pravastatin', ' May decrease the serum concentration of Pravastatin.', NULL, NULL, NULL),
(2420, 77, 'Efavirenz ', 'Proguanil', ' May decrease the serum concentration of Atovaquone.', NULL, NULL, NULL),
(2421, 77, 'Efavirenz ', 'Rifampicin', ' Rifampin may decrease the serum concentration of Efavirenz.', NULL, NULL, NULL),
(2422, 77, 'Efavirenz ', 'Rilpivirine', ' Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Efavirenz. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Efavirenz.', NULL, NULL, NULL),
(2423, 77, 'Efavirenz ', 'Ritonavir', ' May enhance the adverse/toxic effect of Ritonavir. Efavirenz may increase the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of Efavirenz.', NULL, NULL, NULL),
(2424, 77, 'Efavirenz ', 'Saquinavir', ' Saquinavir may enhance the adverse/toxic effect of Efavirenz. Efavirenz may decrease the serum concentration of Saquinavir.', NULL, NULL, NULL),
(2425, 77, 'Efavirenz ', 'Sertraline', ' May decrease the serum concentration of Sertraline.', NULL, NULL, NULL),
(2426, 77, 'Efavirenz ', 'Simvastatin', ' May decrease the serum concentration of Simvastatin.', NULL, NULL, NULL),
(2427, 77, 'Efavirenz ', 'Sirolimus', ' May decrease the serum concentration of Sirolimus.', NULL, NULL, NULL),
(2428, 77, 'Efavirenz ', 'Telaprevir', ' May decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Efavirenz.', NULL, NULL, NULL),
(2429, 77, 'Efavirenz ', 'Ulipristal', ' May decrease the serum concentration of Ulipristal.', NULL, NULL, NULL),
(2430, 77, 'Efavirenz ', 'Voriconazole', ' May decrease the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Efavirenz.', NULL, NULL, NULL),
(2431, 78, 'Enalapril Maleate ', '0', '0', NULL, NULL, NULL),
(2432, 79, 'Epinephrine Hydrochloride ', '0', '0', NULL, NULL, NULL),
(2433, 80, 'Erythromycin Stearate / Succinate ', '0', '0', NULL, NULL, NULL),
(2434, 81, 'Ethambutol ', '0', '0', NULL, NULL, NULL),
(2435, 81, 'Ethambutol ', 'Aluminum hydroxide', ' May decrease the absorption of Ethambutol.', NULL, NULL, NULL),
(2436, 82, 'Ethionamide Hydrochloride ', '0', '0', NULL, NULL, NULL),
(2437, 83, 'Ethosuximide ', '0', '0', NULL, NULL, NULL),
(2438, 83, 'Ethosuximide ', 'Amphetamine', ' Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.', NULL, NULL, NULL),
(2439, 83, 'Ethosuximide ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2440, 83, 'Ethosuximide ', 'Benzphetamine', ' Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.', NULL, NULL, NULL),
(2441, 83, 'Ethosuximide ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2442, 83, 'Ethosuximide ', 'Buprenorphine', ' CNS Depressants may enhance the CNS depressant effect of Buprenorphine.', NULL, NULL, NULL),
(2443, 83, 'Ethosuximide ', 'Cathinone', ' May diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.', NULL, NULL, NULL),
(2444, 83, 'Ethosuximide ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(2445, 83, 'Ethosuximide ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2446, 83, 'Ethosuximide ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2447, 83, 'Ethosuximide ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2448, 83, 'Ethosuximide ', 'Dextroamphetamine', ' Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.', NULL, NULL, NULL),
(2449, 83, 'Ethosuximide ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2450, 83, 'Ethosuximide ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2451, 83, 'Ethosuximide ', 'Droperidol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2452, 83, 'Ethosuximide ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2453, 83, 'Ethosuximide ', 'Fosphenytoin', ' Ethosuximide may enhance the CNS depressant effect of Fosphenytoin. Ethosuximide may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Ethosuximide.', NULL, NULL, NULL),
(2454, 83, 'Ethosuximide ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(2455, 83, 'Ethosuximide ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2456, 83, 'Ethosuximide ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2457, 83, 'Ethosuximide ', 'Lisdexamfetamine', ' Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.', NULL, NULL, NULL),
(2458, 83, 'Ethosuximide ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2459, 83, 'Ethosuximide ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2460, 83, 'Ethosuximide ', 'Mefloquine', ' Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.', NULL, NULL, NULL),
(2461, 83, 'Ethosuximide ', 'Methamphetamine', ' Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.', NULL, NULL, NULL),
(2462, 83, 'Ethosuximide ', 'Methotrimeprazine', ' CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2463, 83, 'Ethosuximide ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(2464, 83, 'Ethosuximide ', 'Mianserin', ' May diminish the therapeutic effect of Anticonvulsants.', NULL, NULL, NULL),
(2465, 83, 'Ethosuximide ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2466, 83, 'Ethosuximide ', 'Mirtazapine', ' CNS Depressants may enhance the CNS depressant effect of Mirtazapine.', NULL, NULL, NULL),
(2467, 83, 'Ethosuximide ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2468, 83, 'Ethosuximide ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2469, 83, 'Ethosuximide ', 'Orlistat', ' May decrease the serum concentration of Anticonvulsants.', NULL, NULL, NULL),
(2470, 83, 'Ethosuximide ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(2471, 83, 'Ethosuximide ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2472, 83, 'Ethosuximide ', 'Phendimetrazine', ' Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.', NULL, NULL, NULL),
(2473, 83, 'Ethosuximide ', 'Phentermine', ' Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.', NULL, NULL, NULL),
(2474, 83, 'Ethosuximide ', 'Phenytoin', ' May enhance the CNS depressant effect of Phenytoin. Ethosuximide may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Ethosuximide.', NULL, NULL, NULL),
(2475, 83, 'Ethosuximide ', 'Pramipexole', ' CNS Depressants may enhance the sedative effect of Pramipexole.', NULL, NULL, NULL),
(2476, 83, 'Ethosuximide ', 'Ropinirole', ' CNS Depressants may enhance the sedative effect of ROPINIRole.', NULL, NULL, NULL),
(2477, 83, 'Ethosuximide ', 'Rotigotine', ' CNS Depressants may enhance the sedative effect of Rotigotine.', NULL, NULL, NULL),
(2478, 83, 'Ethosuximide ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(2479, 83, 'Ethosuximide ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2480, 83, 'Ethosuximide ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2481, 83, 'Ethosuximide ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(2482, 83, 'Ethosuximide ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2483, 83, 'Ethosuximide ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(2484, 83, 'Ethosuximide ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2485, 83, 'Ethosuximide ', 'Valproic Acid', ' May decrease the serum concentration of Valproic Acid and Derivatives. Valproic Acid and Derivatives may increase the serum concentration of Ethosuximide.', NULL, NULL, NULL),
(2486, 83, 'Ethosuximide ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(2487, 84, 'Etoposide ', '0', '0', NULL, NULL, NULL),
(2488, 84, 'Etoposide ', 'Acenocoumarol', ' May enhance the anticoagulant effect of Vitamin K Antagonists.', NULL, NULL, NULL),
(2489, 84, 'Etoposide ', 'Amobarbital', ' Barbiturates may decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(2490, 84, 'Etoposide ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2491, 84, 'Etoposide ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(2492, 84, 'Etoposide ', 'Atovaquone', ' May increase the serum concentration of Etoposide.', NULL, NULL, NULL),
(2493, 84, 'Etoposide ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2494, 84, 'Etoposide ', 'Butabarbital', ' Barbiturates may decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(2495, 84, 'Etoposide ', 'Butalbital', ' Barbiturates may decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(2496, 84, 'Etoposide ', 'Butethal', ' May decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(2497, 84, 'Etoposide ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(2498, 84, 'Etoposide ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2499, 84, 'Etoposide ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2500, 84, 'Etoposide ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2501, 84, 'Etoposide ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2502, 84, 'Etoposide ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(2503, 84, 'Etoposide ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(2504, 84, 'Etoposide ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2505, 84, 'Etoposide ', 'Fosphenytoin', ' May decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(2506, 84, 'Etoposide ', 'Heptabarbital', ' May decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(2507, 84, 'Etoposide ', 'Hexobarbital', ' May decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(2508, 84, 'Etoposide ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(2509, 84, 'Etoposide ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2510, 84, 'Etoposide ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(2511, 84, 'Etoposide ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(2512, 84, 'Etoposide ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2513, 84, 'Etoposide ', 'Methohexital', ' Barbiturates may decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(2514, 84, 'Etoposide ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2515, 84, 'Etoposide ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2516, 84, 'Etoposide ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(2517, 84, 'Etoposide ', 'Pentobarbital', ' Barbiturates may decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(2518, 84, 'Etoposide ', 'Phenobarbital', ' Barbiturates may decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(2519, 84, 'Etoposide ', 'Phenytoin', ' Phenytoin may decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(2520, 84, 'Etoposide ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(2521, 84, 'Etoposide ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(2522, 84, 'Etoposide ', 'Primidone', ' May decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(2523, 84, 'Etoposide ', 'Proguanil', ' Atovaquone may increase the serum concentration of Etoposide.', NULL, NULL, NULL),
(2524, 84, 'Etoposide ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(2525, 84, 'Etoposide ', 'Secobarbital', ' Barbiturates may decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(2526, 84, 'Etoposide ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2527, 84, 'Etoposide ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2528, 84, 'Etoposide ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(2529, 84, 'Etoposide ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2530, 84, 'Etoposide ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(2531, 84, 'Etoposide ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(2532, 85, 'Etravirine ', '0', '0', NULL, NULL, NULL),
(2533, 85, 'Etravirine ', 'Amiodarone', ' May decrease the serum concentration of Amiodarone.', NULL, NULL, NULL),
(2534, 85, 'Etravirine ', 'Aripiprazole', ' CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(2535, 85, 'Etravirine ', 'Artemether', ' Etravirine may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically~ concentrations of dihydroartemisinin may be decreased. Artemether may increase the serum concentration of Etravirine. Etravirine may increase the serum concentration of Artemether.', NULL, NULL, NULL),
(2536, 85, 'Etravirine ', 'Atazanavir', ' Atazanavir may increase the serum concentration of Etravirine. Etravirine may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(2537, 85, 'Etravirine ', 'Atorvastatin', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin~ lovastatin and simvastatin. Conversely~ levels of fluvastatin may be increased.', NULL, NULL, NULL),
(2538, 85, 'Etravirine ', 'Avanafil', ' May decrease the serum concentration of Phosphodiesterase 5 Inhibitors.', NULL, NULL, NULL),
(2539, 85, 'Etravirine ', 'Axitinib', ' CYP3A4 Inducers (Moderate) may decrease the serum concentration of Axitinib.', NULL, NULL, NULL),
(2540, 85, 'Etravirine ', 'Batimastat', ' Etravirine may increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir~ saquinavir~ and lopinavir (with low-dose ritonavir).', NULL, NULL, NULL),
(2541, 85, 'Etravirine ', 'Boceprevir', ' May decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(2542, 85, 'Etravirine ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2543, 85, 'Etravirine ', 'Bosutinib', ' CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib.', NULL, NULL, NULL),
(2544, 85, 'Etravirine ', 'Buprenorphine', ' May decrease the serum concentration of Buprenorphine.', NULL, NULL, NULL),
(2545, 85, 'Etravirine ', 'Carbamazepine', ' May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.', NULL, NULL, NULL),
(2546, 85, 'Etravirine ', 'Carvedilol', ' CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically~ concentrations of the S-carvedilol enantiomer may be increased.', NULL, NULL, NULL),
(2547, 85, 'Etravirine ', 'Cilostazol', ' CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.', NULL, NULL, NULL),
(2548, 85, 'Etravirine ', 'Citalopram', ' CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.', NULL, NULL, NULL),
(2549, 85, 'Etravirine ', 'Clarithromycin', ' CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(2550, 85, 'Etravirine ', 'Clopidogrel', ' CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.', NULL, NULL, NULL),
(2551, 85, 'Etravirine ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2552, 85, 'Etravirine ', 'Darunavir', ' Darunavir may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(2553, 85, 'Etravirine ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2554, 85, 'Etravirine ', 'Delavirdine', ' Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine.', NULL, NULL, NULL),
(2555, 85, 'Etravirine ', 'Diazepam', ' May decrease the serum concentration of Diazepam. Etravirine may increase the serum concentration of Diazepam.', NULL, NULL, NULL),
(2556, 85, 'Etravirine ', 'Digoxin', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(2557, 85, 'Etravirine ', 'Disopyramide', ' May decrease the serum concentration of Disopyramide.', NULL, NULL, NULL),
(2558, 85, 'Etravirine ', 'Dolutegravir', ' Etravirine may decrease the serum concentration of Dolutegravir.', NULL, NULL, NULL),
(2559, 85, 'Etravirine ', 'Dronabinol', ' CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.', NULL, NULL, NULL),
(2560, 85, 'Etravirine ', 'Efavirenz', ' Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Efavirenz. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Efavirenz.', NULL, NULL, NULL),
(2561, 85, 'Etravirine ', 'Enzalutamide', ' CYP3A4 Inducers (Moderate) may decrease the serum concentration of Enzalutamide.', NULL, NULL, NULL),
(2562, 85, 'Etravirine ', 'Fentanyl', ' CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2563, 85, 'Etravirine ', 'Flecainide', ' May decrease the serum concentration of Flecainide.', NULL, NULL, NULL),
(2564, 85, 'Etravirine ', 'Fluconazole', ' May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2565, 85, 'Etravirine ', 'Fluvastatin', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin~ lovastatin and simvastatin. Conversely~ levels of fluvastatin may be increased.', NULL, NULL, NULL),
(2566, 85, 'Etravirine ', 'Fosamprenavir', ' May increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically~ amprenavir concentrations may increase.', NULL, NULL, NULL),
(2567, 85, 'Etravirine ', 'Fosphenytoin', ' Fosphenytoin may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(2568, 85, 'Etravirine ', 'Hydrocodone', ' CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(2569, 85, 'Etravirine ', 'Ifosfamide', ' CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide.', NULL, NULL, NULL),
(2570, 85, 'Etravirine ', 'Indinavir', ' May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir~ saquinavir~ and lopinavir (with low-dose ritonavir).', NULL, NULL, NULL),
(2571, 85, 'Etravirine ', 'Isoflurophate', ' Etravirine may increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir~ saquinavir~ and lopinavir (with low-dose ritonavir).', NULL, NULL, NULL),
(2572, 85, 'Etravirine ', 'Itraconazole', ' May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2573, 85, 'Etravirine ', 'Lopinavir', ' Ritonavir may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(2574, 85, 'Etravirine ', 'Lovastatin', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin~ lovastatin and simvastatin. Conversely~ levels of fluvastatin may be increased.', NULL, NULL, NULL),
(2575, 85, 'Etravirine ', 'Lumefantrine', ' May decrease serum concentrations of the active metabolite(s) of Artemether. Specifically~ concentrations of dihydroartemisinin may be decreased. Artemether may increase the serum concentration of Etravirine. Etravirine may increase the serum concentration of Artemether.', NULL, NULL, NULL),
(2576, 85, 'Etravirine ', 'Maraviroc', ' May decrease the serum concentration of Maraviroc. Of note~ this effect only applies in the absence of a strong CYP3A4 inhibitor', NULL, NULL, NULL),
(2577, 85, 'Etravirine ', 'Methadone', ' May decrease the serum concentration of Methadone.', NULL, NULL, NULL),
(2578, 85, 'Etravirine ', 'Mexiletine', ' May decrease the serum concentration of Mexiletine.', NULL, NULL, NULL),
(2579, 85, 'Etravirine ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2580, 85, 'Etravirine ', 'Nelfinavir', ' May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir~ saquinavir~ and lopinavir (with low-dose ritonavir).', NULL, NULL, NULL),
(2581, 85, 'Etravirine ', 'Nevirapine', ' Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine.', NULL, NULL, NULL),
(2582, 85, 'Etravirine ', 'Nisoldipine', ' CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nisoldipine.', NULL, NULL, NULL),
(2583, 85, 'Etravirine ', 'Phenobarbital', ' PHENobarbital may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(2584, 85, 'Etravirine ', 'Phenytoin', ' Phenytoin may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(2585, 85, 'Etravirine ', 'Posaconazole', ' May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2586, 85, 'Etravirine ', 'Primidone', ' Primidone may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(2587, 85, 'Etravirine ', 'Propafenone', ' May decrease the serum concentration of Propafenone.', NULL, NULL, NULL),
(2588, 85, 'Etravirine ', 'Quinidine', ' May decrease the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(2589, 85, 'Etravirine ', 'Rifabutin', ' May decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(2590, 85, 'Etravirine ', 'Rifampicin', ' Rifamycin Derivatives may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(2591, 85, 'Etravirine ', 'Rifapentine', ' Rifamycin Derivatives may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(2592, 85, 'Etravirine ', 'Rilpivirine', ' Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz~ etravirine~ and nevirapine.', NULL, NULL, NULL),
(2593, 85, 'Etravirine ', 'Ritonavir', ' Ritonavir may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(2594, 85, 'Etravirine ', 'Saquinavir', ' May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir~ saquinavir~ and lopinavir (with low-dose ritonavir).', NULL, NULL, NULL),
(2595, 85, 'Etravirine ', 'Saxagliptin', ' CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.', NULL, NULL, NULL),
(2596, 85, 'Etravirine ', 'Sildenafil', ' May decrease the serum concentration of Phosphodiesterase 5 Inhibitors.', NULL, NULL, NULL),
(2597, 85, 'Etravirine ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2598, 85, 'Etravirine ', 'Simeprevir', ' Etravirine may increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir~ saquinavir~ and lopinavir (with low-dose ritonavir).', NULL, NULL, NULL),
(2599, 85, 'Etravirine ', 'Simvastatin', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin~ lovastatin and simvastatin. Conversely~ levels of fluvastatin may be increased.', NULL, NULL, NULL),
(2600, 85, 'Etravirine ', 'Tadalafil', ' May decrease the serum concentration of Phosphodiesterase 5 Inhibitors.', NULL, NULL, NULL),
(2601, 85, 'Etravirine ', 'Telaprevir', ' May decrease the serum concentration of Telaprevir.', NULL, NULL, NULL),
(2602, 85, 'Etravirine ', 'Tipranavir', ' Tipranavir may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(2603, 85, 'Etravirine ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2604, 85, 'Etravirine ', 'Vardenafil', ' May decrease the serum concentration of Phosphodiesterase 5 Inhibitors.', NULL, NULL, NULL),
(2605, 85, 'Etravirine ', 'Voriconazole', ' May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2606, 86, 'Exemestane ', '0', '0', NULL, NULL, NULL),
(2607, 86, 'Exemestane ', 'Aripiprazole', ' CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(2608, 86, 'Exemestane ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2609, 86, 'Exemestane ', 'Carbamazepine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.', NULL, NULL, NULL),
(2610, 86, 'Exemestane ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2611, 86, 'Exemestane ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2612, 86, 'Exemestane ', 'Desogestrel', ' Estrogen Derivatives may diminish the therapeutic effect of Exemestane.', NULL, NULL, NULL),
(2613, 86, 'Exemestane ', 'Drospirenone', ' Estrogen Derivatives may diminish the therapeutic effect of Exemestane.', NULL, NULL, NULL),
(2614, 86, 'Exemestane ', 'Enzalutamide', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.', NULL, NULL, NULL),
(2615, 86, 'Exemestane ', 'Estropipate', ' Estrogen Derivatives may diminish the therapeutic effect of Exemestane.', NULL, NULL, NULL),
(2616, 86, 'Exemestane ', 'Ethinyl Estradiol', ' Estrogen Derivatives may diminish the therapeutic effect of Exemestane.', NULL, NULL, NULL),
(2617, 86, 'Exemestane ', 'Ethynodiol', ' Estrogen Derivatives may diminish the therapeutic effect of Exemestane.', NULL, NULL, NULL),
(2618, 86, 'Exemestane ', 'Fosphenytoin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.', NULL, NULL, NULL),
(2619, 86, 'Exemestane ', 'Hydrocodone', ' CYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(2620, 86, 'Exemestane ', 'Mestranol', ' Estrogen Derivatives may diminish the therapeutic effect of Exemestane.', NULL, NULL, NULL),
(2621, 86, 'Exemestane ', 'Methadone', ' May increase the serum concentration of Methadone.', NULL, NULL, NULL),
(2622, 86, 'Exemestane ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2623, 86, 'Exemestane ', 'Norelgestromin', ' Estrogen Derivatives may diminish the therapeutic effect of Exemestane.', NULL, NULL, NULL),
(2624, 86, 'Exemestane ', 'Norgestimate', ' Estrogen Derivatives may diminish the therapeutic effect of Exemestane.', NULL, NULL, NULL),
(2625, 86, 'Exemestane ', 'Phenobarbital', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.', NULL, NULL, NULL),
(2626, 86, 'Exemestane ', 'Phenytoin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.', NULL, NULL, NULL),
(2627, 86, 'Exemestane ', 'Piperazine', ' Estrogen Derivatives may diminish the therapeutic effect of Exemestane.', NULL, NULL, NULL),
(2628, 86, 'Exemestane ', 'Primidone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.', NULL, NULL, NULL),
(2629, 86, 'Exemestane ', 'Rifampicin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.', NULL, NULL, NULL),
(2630, 86, 'Exemestane ', 'Rifapentine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.', NULL, NULL, NULL),
(2631, 86, 'Exemestane ', 'Saxagliptin', ' CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.', NULL, NULL, NULL),
(2632, 86, 'Exemestane ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2633, 86, 'Exemestane ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2634, 87, 'Famotidine ', '0', '0', NULL, NULL, NULL),
(2635, 87, 'Famotidine ', 'Atazanavir', ' H2-Antagonists may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(2636, 87, 'Famotidine ', 'Bosutinib', ' H2-Antagonists may decrease the serum concentration of Bosutinib.', NULL, NULL, NULL),
(2637, 87, 'Famotidine ', 'Bupropion', ' May increase the serum concentration of OCT2 Substrates.', NULL, NULL, NULL),
(2638, 87, 'Famotidine ', 'Cefditoren', ' H2-Antagonists may decrease the serum concentration of Cefditoren.', NULL, NULL, NULL),
(2639, 87, 'Famotidine ', 'Cefpodoxime', ' H2-Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours.', NULL, NULL, NULL),
(2640, 87, 'Famotidine ', 'Cefuroxime', ' H2-Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.', NULL, NULL, NULL),
(2641, 87, 'Famotidine ', 'Dabrafenib', ' H2-Antagonists may decrease the serum concentration of Dabrafenib.', NULL, NULL, NULL),
(2642, 87, 'Famotidine ', 'Dasatinib', ' H2-Antagonists may decrease the absorption of Dasatinib.', NULL, NULL, NULL),
(2643, 87, 'Famotidine ', 'Delavirdine', ' H2-Antagonists may decrease the serum concentration of Delavirdine.', NULL, NULL, NULL),
(2644, 87, 'Famotidine ', 'Dexmethylphenidate', ' H2-Antagonists may increase the absorption of Dexmethylphenidate. Specifically~ H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand)~ which could result in both increased absorption (early) and decreased delayed absorption.', NULL, NULL, NULL),
(2645, 87, 'Famotidine ', 'Erlotinib', ' H2-Antagonists may decrease the serum concentration of Erlotinib.', NULL, NULL, NULL),
(2646, 87, 'Famotidine ', 'Fosamprenavir', ' H2-Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir~ making its effects on fosamprenavir/amprenavir concentrations difficult to predict.', NULL, NULL, NULL),
(2647, 87, 'Famotidine ', 'Gefitinib', ' H2-Antagonists may decrease the serum concentration of Gefitinib.', NULL, NULL, NULL),
(2648, 87, 'Famotidine ', 'Indinavir', ' H2-Antagonists may decrease the serum concentration of Indinavir.', NULL, NULL, NULL),
(2649, 87, 'Famotidine ', 'Itraconazole', ' H2-Antagonists may decrease the serum concentration of Itraconazole.', NULL, NULL, NULL),
(2650, 87, 'Famotidine ', 'Ledipasvir', ' H2-Antagonists may decrease the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(2651, 87, 'Famotidine ', 'Methylphenidate', ' H2-Antagonists may increase the absorption of Methylphenidate. Specifically~ H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand)~ which could result in both increased absorption (early) and decreased delayed absorption.', NULL, NULL, NULL),
(2652, 87, 'Famotidine ', 'Mifepristone', ' May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).', NULL, NULL, NULL),
(2653, 87, 'Famotidine ', 'Nelfinavir', ' H2-Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced.', NULL, NULL, NULL),
(2654, 87, 'Famotidine ', 'Nilotinib', ' H2-Antagonists may decrease the serum concentration of Nilotinib.', NULL, NULL, NULL),
(2655, 87, 'Famotidine ', 'Pazopanib', ' H2-Antagonists may decrease the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(2656, 87, 'Famotidine ', 'Posaconazole', ' H2-Antagonists may decrease the serum concentration of Posaconazole.', NULL, NULL, NULL),
(2657, 87, 'Famotidine ', 'Rilpivirine', ' H2-Antagonists may decrease the serum concentration of Rilpivirine.', NULL, NULL, NULL),
(2658, 87, 'Famotidine ', 'Risedronate', ' H2-Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.', NULL, NULL, NULL),
(2659, 87, 'Famotidine ', 'Saquinavir', ' H2-Antagonists may increase the serum concentration of Saquinavir.', NULL, NULL, NULL),
(2660, 87, 'Famotidine ', 'Varenicline', ' H2-Antagonists may increase the serum concentration of Varenicline.', NULL, NULL, NULL),
(2661, 87, 'Famotidine ', 'Vismodegib', ' H2-Antagonists may decrease the serum concentration of Vismodegib.', NULL, NULL, NULL),
(2662, 88, 'Fentanyl ', '0', '0', NULL, NULL, NULL),
(2663, 88, 'Fentanyl ', 'Abiraterone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2664, 88, 'Fentanyl ', 'Acepromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2665, 88, 'Fentanyl ', 'Acetazolamide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2666, 88, 'Fentanyl ', 'Acetophenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2667, 88, 'Fentanyl ', 'Alvimopan', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e.~ more than 7 days) opiates prior to alvimopan initiation.', NULL, NULL, NULL),
(2668, 88, 'Fentanyl ', 'Amiloride', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2669, 88, 'Fentanyl ', 'Amisulpride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2670, 88, 'Fentanyl ', 'Ammonium chloride', ' May increase the excretion of Analgesics (Opioid).', NULL, NULL, NULL),
(2671, 88, 'Fentanyl ', 'Amphetamine', ' May enhance the analgesic effect of Analgesics (Opioid).', NULL, NULL, NULL),
(2672, 88, 'Fentanyl ', 'Aprepitant', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2673, 88, 'Fentanyl ', 'Aripiprazole', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2674, 88, 'Fentanyl ', 'Atazanavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2675, 88, 'Fentanyl ', 'Bendroflumethiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2676, 88, 'Fentanyl ', 'Benzquinamide', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2677, 88, 'Fentanyl ', 'Bicalutamide', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2678, 88, 'Fentanyl ', 'Biotin', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2679, 88, 'Fentanyl ', 'Boceprevir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2680, 88, 'Fentanyl ', 'Bosentan', ' CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2681, 88, 'Fentanyl ', 'Bumetanide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2682, 88, 'Fentanyl ', 'Carbamazepine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2683, 88, 'Fentanyl ', 'Carphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2684, 88, 'Fentanyl ', 'Cathinone', ' May enhance the analgesic effect of Analgesics (Opioid).', NULL, NULL, NULL),
(2685, 88, 'Fentanyl ', 'Chlormezanone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2686, 88, 'Fentanyl ', 'Chlorothiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2687, 88, 'Fentanyl ', 'Chlorpromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2688, 88, 'Fentanyl ', 'Chlorprothixene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2689, 88, 'Fentanyl ', 'Chlorthalidone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2690, 88, 'Fentanyl ', 'Cimetidine', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2691, 88, 'Fentanyl ', 'Clarithromycin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2692, 88, 'Fentanyl ', 'Clotrimazole', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2693, 88, 'Fentanyl ', 'Clozapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2694, 88, 'Fentanyl ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2695, 88, 'Fentanyl ', 'Crizotinib', ' May increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2696, 88, 'Fentanyl ', 'Cyclothiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2697, 88, 'Fentanyl ', 'Dabrafenib', ' CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2698, 88, 'Fentanyl ', 'Dapoxetine', ' May enhance the adverse/toxic effect of Serotonin Modulators.', NULL, NULL, NULL),
(2699, 88, 'Fentanyl ', 'Darunavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2700, 88, 'Fentanyl ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2701, 88, 'Fentanyl ', 'Delavirdine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2702, 88, 'Fentanyl ', 'Desipramine', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2703, 88, 'Fentanyl ', 'Desmopressin', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.', NULL, NULL, NULL),
(2704, 88, 'Fentanyl ', 'Diltiazem', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2705, 88, 'Fentanyl ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(2706, 88, 'Fentanyl ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2707, 88, 'Fentanyl ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2708, 88, 'Fentanyl ', 'Dronedarone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2709, 88, 'Fentanyl ', 'Droperidol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2710, 88, 'Fentanyl ', 'Enzalutamide', ' May decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2711, 88, 'Fentanyl ', 'Ethacrynic acid', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2712, 88, 'Fentanyl ', 'Ethoxzolamide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2713, 88, 'Fentanyl ', 'Etravirine', ' CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2714, 88, 'Fentanyl ', 'Fencamfamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2715, 88, 'Fentanyl ', 'Fluconazole', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2716, 88, 'Fentanyl ', 'Flupentixol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2717, 88, 'Fentanyl ', 'Fluphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2718, 88, 'Fentanyl ', 'Fluspirilene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2719, 88, 'Fentanyl ', 'Fosamprenavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2720, 88, 'Fentanyl ', 'Fosaprepitant', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2721, 88, 'Fentanyl ', 'Fosphenytoin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2722, 88, 'Fentanyl ', 'Furosemide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2723, 88, 'Fentanyl ', 'Haloperidol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2724, 88, 'Fentanyl ', 'Hydrochlorothiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2725, 88, 'Fentanyl ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(2726, 88, 'Fentanyl ', 'Hydroflumethiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2727, 88, 'Fentanyl ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2728, 88, 'Fentanyl ', 'Indapamide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2729, 88, 'Fentanyl ', 'Indinavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2730, 88, 'Fentanyl ', 'Ioflupane I 123', ' FentaNYL may diminish the diagnostic effect of Ioflupane I 123.', NULL, NULL, NULL),
(2731, 88, 'Fentanyl ', 'Isavuconazonium', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2732, 88, 'Fentanyl ', 'Itraconazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2733, 88, 'Fentanyl ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2734, 88, 'Fentanyl ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(2735, 88, 'Fentanyl ', 'Lopinavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2736, 88, 'Fentanyl ', 'Loxapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2737, 88, 'Fentanyl ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2738, 88, 'Fentanyl ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2739, 88, 'Fentanyl ', 'Mesoridazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(2740, 88, 'Fentanyl ', 'Methotrimeprazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2741, 88, 'Fentanyl ', 'Metoclopramide', ' Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.', NULL, NULL, NULL),
(2742, 88, 'Fentanyl ', 'Metolazone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2743, 88, 'Fentanyl ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(2744, 88, 'Fentanyl ', 'Mifepristone', ' May increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2745, 88, 'Fentanyl ', 'Modafinil', ' CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2746, 88, 'Fentanyl ', 'Molindone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2747, 88, 'Fentanyl ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2748, 88, 'Fentanyl ', 'Nafcillin', ' CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2749, 88, 'Fentanyl ', 'Naltrexone', ' May diminish the therapeutic effect of Analgesics (Opioid).', NULL, NULL, NULL),
(2750, 88, 'Fentanyl ', 'Naphazoline', ' Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.', NULL, NULL, NULL),
(2751, 88, 'Fentanyl ', 'Nefazodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2752, 88, 'Fentanyl ', 'Nelfinavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2753, 88, 'Fentanyl ', 'Nilotinib', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2754, 88, 'Fentanyl ', 'Norfloxacin', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2755, 88, 'Fentanyl ', 'Olanzapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2756, 88, 'Fentanyl ', 'Ondansetron', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2757, 88, 'Fentanyl ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(2758, 88, 'Fentanyl ', 'Oxymetazoline', ' Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.', NULL, NULL, NULL),
(2759, 88, 'Fentanyl ', 'Paliperidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2760, 88, 'Fentanyl ', 'Pegvisomant', ' Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.', NULL, NULL, NULL),
(2761, 88, 'Fentanyl ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2762, 88, 'Fentanyl ', 'Perphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2763, 88, 'Fentanyl ', 'Phenobarbital', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2764, 88, 'Fentanyl ', 'Phenylephrine', ' Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.', NULL, NULL, NULL),
(2765, 88, 'Fentanyl ', 'Phenytoin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2766, 88, 'Fentanyl ', 'Pimozide', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2767, 88, 'Fentanyl ', 'Piperacetazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2768, 88, 'Fentanyl ', 'Posaconazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2769, 88, 'Fentanyl ', 'Pramipexole', ' CNS Depressants may enhance the sedative effect of Pramipexole.', NULL, NULL, NULL),
(2770, 88, 'Fentanyl ', 'Primidone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2771, 88, 'Fentanyl ', 'Prochlorperazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2772, 88, 'Fentanyl ', 'Promazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2773, 88, 'Fentanyl ', 'Propylhexedrine', ' Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.', NULL, NULL, NULL),
(2774, 88, 'Fentanyl ', 'Pseudoephedrine', ' Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.', NULL, NULL, NULL),
(2775, 88, 'Fentanyl ', 'Quetiapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2776, 88, 'Fentanyl ', 'Remoxipride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2777, 88, 'Fentanyl ', 'Reserpine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2778, 88, 'Fentanyl ', 'Rifampicin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2779, 88, 'Fentanyl ', 'Rifapentine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2780, 88, 'Fentanyl ', 'Risperidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2781, 88, 'Fentanyl ', 'Ritonavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2782, 88, 'Fentanyl ', 'Ropinirole', ' CNS Depressants may enhance the sedative effect of ROPINIRole.', NULL, NULL, NULL),
(2783, 88, 'Fentanyl ', 'Rotigotine', ' CNS Depressants may enhance the sedative effect of Rotigotine.', NULL, NULL, NULL),
(2784, 88, 'Fentanyl ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(2785, 88, 'Fentanyl ', 'Saquinavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2786, 88, 'Fentanyl ', 'Sertindole', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2787, 88, 'Fentanyl ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(2788, 88, 'Fentanyl ', 'Spironolactone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2789, 88, 'Fentanyl ', 'Succinylcholine', ' May enhance the bradycardic effect of Analgesics (Opioid).', NULL, NULL, NULL),
(2790, 88, 'Fentanyl ', 'Sulfisoxazole', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2791, 88, 'Fentanyl ', 'Sulpiride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2792, 88, 'Fentanyl ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(2793, 88, 'Fentanyl ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(2794, 88, 'Fentanyl ', 'Telaprevir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2795, 88, 'Fentanyl ', 'Telithromycin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2796, 88, 'Fentanyl ', 'Tetracycline', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2797, 88, 'Fentanyl ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(2798, 88, 'Fentanyl ', 'Thioridazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2799, 88, 'Fentanyl ', 'Thiothixene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2800, 88, 'Fentanyl ', 'Ticrynafen', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2801, 88, 'Fentanyl ', 'Torasemide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2802, 88, 'Fentanyl ', 'Triamterene', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2803, 88, 'Fentanyl ', 'Trichlormethiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(2804, 88, 'Fentanyl ', 'Trifluoperazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2805, 88, 'Fentanyl ', 'Triflupromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2806, 88, 'Fentanyl ', 'Triprolidine', ' Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.', NULL, NULL, NULL),
(2807, 88, 'Fentanyl ', 'Voriconazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2808, 88, 'Fentanyl ', 'Ziprasidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2809, 88, 'Fentanyl ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(2810, 88, 'Fentanyl ', 'Zuclopenthixol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2811, 89, 'Filgrastim ', '0', '0', NULL, NULL, NULL),
(2812, 89, 'Filgrastim ', 'Bleomycin', ' Filgrastim may enhance the adverse/toxic effect of Bleomycin. Specifically~ the risk for pulmonary toxicity may be increased.', NULL, NULL, NULL),
(2813, 89, 'Filgrastim ', 'Cyclophosphamide', ' Filgrastim may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the risk of pulmonary toxicity may be enhanced.', NULL, NULL, NULL),
(2814, 89, 'Filgrastim ', 'Topotecan', ' Filgrastim may enhance the adverse/toxic effect of Topotecan.', NULL, NULL, NULL),
(2815, 90, 'Fluconazole ', '0', '0', NULL, NULL, NULL),
(2816, 90, 'Fluconazole ', 'Acenocoumarol', ' May increase the serum concentration of Vitamin K Antagonists.', NULL, NULL, NULL),
(2817, 90, 'Fluconazole ', 'Alfentanil', ' Fluconazole may increase the serum concentration of Alfentanil.', NULL, NULL, NULL),
(2818, 90, 'Fluconazole ', 'Amitriptyline', ' May enhance the QTc-prolonging effect of Fluconazole. Fluconazole may increase the serum concentration of Amitriptyline.', NULL, NULL, NULL),
(2819, 90, 'Fluconazole ', 'Amlodipine', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2820, 90, 'Fluconazole ', 'Amphotericin B', ' Antifungal Agents (Azole Derivatives~ Systemic) may diminish the therapeutic effect of Amphotericin B.', NULL, NULL, NULL),
(2821, 90, 'Fluconazole ', 'Amrinone', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2822, 90, 'Fluconazole ', 'Aripiprazole', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(2823, 90, 'Fluconazole ', 'Atorvastatin', ' Fluconazole may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(2824, 90, 'Fluconazole ', 'Avanafil', ' Fluconazole may increase the serum concentration of Avanafil.', NULL, NULL, NULL),
(2825, 90, 'Fluconazole ', 'Bepridil', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2826, 90, 'Fluconazole ', 'Bosentan', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosentan.', NULL, NULL, NULL),
(2827, 90, 'Fluconazole ', 'Bosutinib', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.', NULL, NULL, NULL),
(2828, 90, 'Fluconazole ', 'Buspirone', ' Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of BusPIRone. Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2829, 90, 'Fluconazole ', 'Busulfan', ' Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Busulfan. Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2830, 90, 'Fluconazole ', 'Carbamazepine', ' Fluconazole may increase the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(2831, 90, 'Fluconazole ', 'Carvedilol', ' CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically~ concentrations of the S-carvedilol enantiomer may be increased.', NULL, NULL, NULL),
(2832, 90, 'Fluconazole ', 'Chlorpropamide', ' May increase the serum concentration of Sulfonylureas.', NULL, NULL, NULL),
(2833, 90, 'Fluconazole ', 'Cilostazol', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.', NULL, NULL, NULL),
(2834, 90, 'Fluconazole ', 'Cisapride', ' Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Cisapride. Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2835, 90, 'Fluconazole ', 'Citalopram', ' Fluconazole may enhance the QTc-prolonging effect of Citalopram. Fluconazole may increase the serum concentration of Citalopram.', NULL, NULL, NULL),
(2836, 90, 'Fluconazole ', 'Clopidogrel', ' CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.', NULL, NULL, NULL),
(2837, 90, 'Fluconazole ', 'Colchicine', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(2838, 90, 'Fluconazole ', 'Dapoxetine', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.', NULL, NULL, NULL),
(2839, 90, 'Fluconazole ', 'Didanosine', ' May decrease the absorption of Antifungal Agents (Azole Derivatives~ Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.', NULL, NULL, NULL),
(2840, 90, 'Fluconazole ', 'Diltiazem', ' May increase the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(2841, 90, 'Fluconazole ', 'Domperidone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone.', NULL, NULL, NULL),
(2842, 90, 'Fluconazole ', 'Dronabinol', ' CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.', NULL, NULL, NULL),
(2843, 90, 'Fluconazole ', 'Eletriptan', ' Fluconazole may increase the serum concentration of Eletriptan.', NULL, NULL, NULL),
(2844, 90, 'Fluconazole ', 'Eplerenone', ' Fluconazole may increase the serum concentration of Eplerenone.', NULL, NULL, NULL),
(2845, 90, 'Fluconazole ', 'Esomeprazole', ' Fluconazole may increase the serum concentration of Proton Pump Inhibitors.', NULL, NULL, NULL),
(2846, 90, 'Fluconazole ', 'Etravirine', ' May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2847, 90, 'Fluconazole ', 'Everolimus', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.', NULL, NULL, NULL),
(2848, 90, 'Fluconazole ', 'Felodipine', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2849, 90, 'Fluconazole ', 'Fentanyl', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(2850, 90, 'Fluconazole ', 'Flunarizine', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2851, 90, 'Fluconazole ', 'Fluvastatin', ' Fluconazole may increase the serum concentration of Fluvastatin.', NULL, NULL, NULL),
(2852, 90, 'Fluconazole ', 'Fosphenytoin', ' Fluconazole may increase the serum concentration of Fosphenytoin.', NULL, NULL, NULL),
(2853, 90, 'Fluconazole ', 'Gabapentin', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2854, 90, 'Fluconazole ', 'Gliclazide', ' May increase the serum concentration of Sulfonylureas.', NULL, NULL, NULL),
(2855, 90, 'Fluconazole ', 'Glimepiride', ' May increase the serum concentration of Sulfonylureas.', NULL, NULL, NULL),
(2856, 90, 'Fluconazole ', 'Glipizide', ' May increase the serum concentration of Sulfonylureas.', NULL, NULL, NULL),
(2857, 90, 'Fluconazole ', 'Glyburide', ' May increase the serum concentration of Sulfonylureas.', NULL, NULL, NULL),
(2858, 90, 'Fluconazole ', 'Hydrocodone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(2859, 90, 'Fluconazole ', 'Ifosfamide', ' CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.', NULL, NULL, NULL),
(2860, 90, 'Fluconazole ', 'Imatinib', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Imatinib.', NULL, NULL, NULL),
(2861, 90, 'Fluconazole ', 'Isradipine', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2862, 90, 'Fluconazole ', 'Ivacaftor', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.', NULL, NULL, NULL),
(2863, 90, 'Fluconazole ', 'Lamotrigine', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2864, 90, 'Fluconazole ', 'Lansoprazole', ' Fluconazole may increase the serum concentration of Proton Pump Inhibitors.', NULL, NULL, NULL),
(2865, 90, 'Fluconazole ', 'Lercanidipine', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2866, 90, 'Fluconazole ', 'Lomitapide', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(2867, 90, 'Fluconazole ', 'Losartan', ' Fluconazole may decrease the serum concentration of Losartan. Specifically~ fluconazole may decrease the serum concentration of E3174~ the more potent active metabolite of losartan.', NULL, NULL, NULL),
(2868, 90, 'Fluconazole ', 'Lovastatin', ' Fluconazole may increase the serum concentration of Lovastatin.', NULL, NULL, NULL),
(2869, 90, 'Fluconazole ', 'Lurasidone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.', NULL, NULL, NULL),
(2870, 90, 'Fluconazole ', 'Magnesium Sulfate', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2871, 90, 'Fluconazole ', 'Methadone', ' Fluconazole may increase the serum concentration of Methadone.', NULL, NULL, NULL),
(2872, 90, 'Fluconazole ', 'Mifepristone', ' May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.', NULL, NULL, NULL),
(2873, 90, 'Fluconazole ', 'Nevirapine', ' Fluconazole may increase the serum concentration of Nevirapine.', NULL, NULL, NULL),
(2874, 90, 'Fluconazole ', 'Nicardipine', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2875, 90, 'Fluconazole ', 'Nifedipine', ' May increase the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(2876, 90, 'Fluconazole ', 'Nimodipine', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2877, 90, 'Fluconazole ', 'Nisoldipine', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2878, 90, 'Fluconazole ', 'Nitrendipine', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2879, 90, 'Fluconazole ', 'Omeprazole', ' Fluconazole may increase the serum concentration of Proton Pump Inhibitors.', NULL, NULL, NULL),
(2880, 90, 'Fluconazole ', 'Ospemifene', ' Fluconazole may increase the serum concentration of Ospemifene.', NULL, NULL, NULL),
(2881, 90, 'Fluconazole ', 'Oxycodone', ' CYP3A4 Inhibitors (Moderate) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased.', NULL, NULL, NULL),
(2882, 90, 'Fluconazole ', 'Pantoprazole', ' Fluconazole may increase the serum concentration of Proton Pump Inhibitors.', NULL, NULL, NULL),
(2883, 90, 'Fluconazole ', 'Perhexiline', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2884, 90, 'Fluconazole ', 'Phenytoin', ' Fluconazole may increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(2885, 90, 'Fluconazole ', 'Pimecrolimus', ' CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.', NULL, NULL, NULL),
(2886, 90, 'Fluconazole ', 'Pimozide', ' Antifungal Agents (Azole Derivatives~ Systemic) may enhance the arrhythmogenic effect of Pimozide. Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Pimozide. This increase in serum concentrations may lead to QTc interval prolongation and ventricular arrhythmias. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2887, 90, 'Fluconazole ', 'Prednisone', ' Fluconazole may increase the serum concentration of PredniSONE.', NULL, NULL, NULL),
(2888, 90, 'Fluconazole ', 'Prenylamine', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2889, 90, 'Fluconazole ', 'Quinidine', ' Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2890, 90, 'Fluconazole ', 'Rabeprazole', ' May increase the serum concentration of Proton Pump Inhibitors.', NULL, NULL, NULL),
(2891, 90, 'Fluconazole ', 'Ramelteon', ' Fluconazole may increase the serum concentration of Ramelteon.', NULL, NULL, NULL),
(2892, 90, 'Fluconazole ', 'Ranolazine', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.', NULL, NULL, NULL),
(2893, 90, 'Fluconazole ', 'Risedronate', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2894, 90, 'Fluconazole ', 'Rivaroxaban', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rivaroxaban. This warning is more specifically for drugs that are inhibitors of both CYP3A4 and P-glycoprotein. For erythromycin~ refer to more specific erythromycin-rivaroxaban monograph recommendations.', NULL, NULL, NULL),
(2895, 90, 'Fluconazole ', 'Ruxolitinib', ' Fluconazole may increase the serum concentration of Ruxolitinib.', NULL, NULL, NULL),
(2896, 90, 'Fluconazole ', 'Salmeterol', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.', NULL, NULL, NULL),
(2897, 90, 'Fluconazole ', 'Saxagliptin', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.', NULL, NULL, NULL),
(2898, 90, 'Fluconazole ', 'Sildenafil', ' Fluconazole may increase the serum concentration of Sildenafil.', NULL, NULL, NULL),
(2899, 90, 'Fluconazole ', 'Simeprevir', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir.', NULL, NULL, NULL),
(2900, 90, 'Fluconazole ', 'Simvastatin', ' Fluconazole may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(2901, 90, 'Fluconazole ', 'Sirolimus', ' Fluconazole may increase the serum concentration of Sirolimus.', NULL, NULL, NULL),
(2902, 90, 'Fluconazole ', 'Solifenacin', ' Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Solifenacin. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2903, 90, 'Fluconazole ', 'Sulfisoxazole', ' May enhance the QTc-prolonging effect of Erythromycin (Systemic). Fluconazole may increase the serum concentration of Erythromycin (Systemic).', NULL, NULL, NULL),
(2904, 90, 'Fluconazole ', 'Sunitinib', ' Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of SUNItinib. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2905, 90, 'Fluconazole ', 'Suvorexant', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant.', NULL, NULL, NULL),
(2906, 90, 'Fluconazole ', 'Tadalafil', ' Fluconazole may increase the serum concentration of Tadalafil.', NULL, NULL, NULL),
(2907, 90, 'Fluconazole ', 'Temsirolimus', ' Fluconazole may increase serum concentrations of the active metabolite(s) of Temsirolimus.', NULL, NULL, NULL),
(2908, 90, 'Fluconazole ', 'Tipranavir', ' Fluconazole may increase the serum concentration of Tipranavir.', NULL, NULL, NULL),
(2909, 90, 'Fluconazole ', 'Tofacitinib', ' Fluconazole may increase the serum concentration of Tofacitinib.', NULL, NULL, NULL),
(2910, 90, 'Fluconazole ', 'Tolazamide', ' May increase the serum concentration of Sulfonylureas.', NULL, NULL, NULL),
(2911, 90, 'Fluconazole ', 'Tolbutamide', ' May increase the serum concentration of Sulfonylureas.', NULL, NULL, NULL),
(2912, 90, 'Fluconazole ', 'Tolvaptan', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.', NULL, NULL, NULL),
(2913, 90, 'Fluconazole ', 'Trabectedin', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin.', NULL, NULL, NULL),
(2914, 90, 'Fluconazole ', 'Ulipristal', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal.', NULL, NULL, NULL),
(2915, 90, 'Fluconazole ', 'Vardenafil', ' Fluconazole may increase the serum concentration of Vardenafil.', NULL, NULL, NULL),
(2916, 90, 'Fluconazole ', 'Verapamil', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(2917, 90, 'Fluconazole ', 'Vilazodone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.', NULL, NULL, NULL),
(2918, 90, 'Fluconazole ', 'Voriconazole', ' Fluconazole may increase the serum concentration of Voriconazole.', NULL, NULL, NULL),
(2919, 90, 'Fluconazole ', 'Zidovudine', ' Fluconazole may decrease the metabolism of Zidovudine.', NULL, NULL, NULL),
(2920, 90, 'Fluconazole ', 'Zolpidem', ' Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Zolpidem. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(2921, 90, 'Fluconazole ', 'Zopiclone', ' CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone.', NULL, NULL, NULL),
(2922, 91, 'Fluorouracil ', '0', '0', NULL, NULL, NULL),
(2923, 92, 'Fluoxetine ', '0', '0', NULL, NULL, NULL),
(2924, 92, 'Fluoxetine ', 'Abciximab', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(2925, 92, 'Fluoxetine ', 'Acenocoumarol', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(2926, 92, 'Fluoxetine ', 'Acepromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2927, 92, 'Fluoxetine ', 'Acetophenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2928, 92, 'Fluoxetine ', 'Acetylsalicylic acid', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.', NULL, NULL, NULL),
(2929, 92, 'Fluoxetine ', 'Alteplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(2930, 92, 'Fluoxetine ', 'Amisulpride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2931, 92, 'Fluoxetine ', 'Amitriptyline', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(2932, 92, 'Fluoxetine ', 'Amoxapine', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(2933, 92, 'Fluoxetine ', 'Anistreplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(2934, 92, 'Fluoxetine ', 'Apixaban', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically~ the risk for bleeding may be increased.', NULL, NULL, NULL),
(2935, 92, 'Fluoxetine ', 'Aripiprazole', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2936, 92, 'Fluoxetine ', 'Atomoxetine', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.', NULL, NULL, NULL),
(2937, 92, 'Fluoxetine ', 'Benzquinamide', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2938, 92, 'Fluoxetine ', 'Bupropion', ' May enhance the adverse/toxic effect of FLUoxetine. BuPROPion may increase the serum concentration of FLUoxetine.', NULL, NULL, NULL),
(2939, 92, 'Fluoxetine ', 'Buspirone', ' May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.', NULL, NULL, NULL),
(2940, 92, 'Fluoxetine ', 'Carbamazepine', ' May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2~ 2C~ and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.', NULL, NULL, NULL),
(2941, 92, 'Fluoxetine ', 'Carphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2942, 92, 'Fluoxetine ', 'Chlormezanone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2943, 92, 'Fluoxetine ', 'Chlorpromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2944, 92, 'Fluoxetine ', 'Chlorprothixene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2945, 92, 'Fluoxetine ', 'Cilostazol', ' CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.', NULL, NULL, NULL),
(2946, 92, 'Fluoxetine ', 'Cimetidine', ' May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.', NULL, NULL, NULL),
(2947, 92, 'Fluoxetine ', 'Citric Acid', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(2948, 92, 'Fluoxetine ', 'Clomipramine', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(2949, 92, 'Fluoxetine ', 'Clopidogrel', ' CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.', NULL, NULL, NULL),
(2950, 92, 'Fluoxetine ', 'Clozapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2951, 92, 'Fluoxetine ', 'Codeine', ' CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.', NULL, NULL, NULL),
(2952, 92, 'Fluoxetine ', 'Cyproheptadine', ' May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.', NULL, NULL, NULL),
(2953, 92, 'Fluoxetine ', 'Dabigatran etexilate', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.', NULL, NULL, NULL),
(2954, 92, 'Fluoxetine ', 'Dabrafenib', ' May decrease the serum concentration of CYP2C9 Substrates.', NULL, NULL, NULL),
(2955, 92, 'Fluoxetine ', 'Dalteparin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(2956, 92, 'Fluoxetine ', 'Dapoxetine', ' May enhance the adverse/toxic effect of Serotonin Modulators.', NULL, NULL, NULL),
(2957, 92, 'Fluoxetine ', 'Darunavir', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(2958, 92, 'Fluoxetine ', 'Deoxycholic Acid', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically~ the risk for bleeding or bruising in the treatment area may be increased.', NULL, NULL, NULL),
(2959, 92, 'Fluoxetine ', 'Desipramine', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(2960, 92, 'Fluoxetine ', 'Desmopressin', ' Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.', NULL, NULL, NULL),
(2961, 92, 'Fluoxetine ', 'Dextromethorphan', ' Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.', NULL, NULL, NULL),
(2962, 92, 'Fluoxetine ', 'Dicoumarol', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(2963, 92, 'Fluoxetine ', 'Droperidol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2964, 92, 'Fluoxetine ', 'Edetic Acid', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(2965, 92, 'Fluoxetine ', 'Enoxaparin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(2966, 92, 'Fluoxetine ', 'Ethyl biscoumacetate', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(2967, 92, 'Fluoxetine ', 'Fencamfamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2968, 92, 'Fluoxetine ', 'Fesoterodine', ' CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.', NULL, NULL, NULL),
(2969, 92, 'Fluoxetine ', 'Flupentixol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2970, 92, 'Fluoxetine ', 'Fluphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2971, 92, 'Fluoxetine ', 'Fluspirilene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2972, 92, 'Fluoxetine ', 'Fondaparinux sodium', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(2973, 92, 'Fluoxetine ', 'Fosphenytoin', ' May enhance the QTc-prolonging effect of FLUoxetine. FLUoxetine may increase the serum concentration of Fosphenytoin.', NULL, NULL, NULL),
(2974, 92, 'Fluoxetine ', 'Glucosamine', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(2975, 92, 'Fluoxetine ', 'Haloperidol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2976, 92, 'Fluoxetine ', 'Heparin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(2977, 92, 'Fluoxetine ', 'Hydrocodone', ' CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Hydrocodone. Specifically~ concentrations of hydromorphone may be decreased.', NULL, NULL, NULL),
(2978, 92, 'Fluoxetine ', 'Ibritumomab', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.', NULL, NULL, NULL),
(2979, 92, 'Fluoxetine ', 'Imipramine', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(2980, 92, 'Fluoxetine ', 'Ioflupane I 123', ' Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.', NULL, NULL, NULL),
(2981, 92, 'Fluoxetine ', 'Linezolid', ' May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2982, 92, 'Fluoxetine ', 'Lithium', ' May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.', NULL, NULL, NULL),
(2983, 92, 'Fluoxetine ', 'Loxapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2984, 92, 'Fluoxetine ', 'Mequitazine', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine.', NULL, NULL, NULL),
(2985, 92, 'Fluoxetine ', 'Mesoridazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2986, 92, 'Fluoxetine ', 'Methotrimeprazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2987, 92, 'Fluoxetine ', 'Metoclopramide', ' May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.', NULL, NULL, NULL),
(2988, 92, 'Fluoxetine ', 'Metoprolol', ' CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.', NULL, NULL, NULL),
(2989, 92, 'Fluoxetine ', 'Metyrosine', ' May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(2990, 92, 'Fluoxetine ', 'Mexiletine', ' Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine.', NULL, NULL, NULL),
(2991, 92, 'Fluoxetine ', 'Mifepristone', ' May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.', NULL, NULL, NULL),
(2992, 92, 'Fluoxetine ', 'Molindone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2993, 92, 'Fluoxetine ', 'Nebivolol', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.', NULL, NULL, NULL),
(2994, 92, 'Fluoxetine ', 'Nifedipine', ' FLUoxetine may enhance the adverse/toxic effect of NIFEdipine.', NULL, NULL, NULL),
(2995, 92, 'Fluoxetine ', 'Nimodipine', ' May increase the serum concentration of NiMODipine.', NULL, NULL, NULL),
(2996, 92, 'Fluoxetine ', 'Nortriptyline', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(2997, 92, 'Fluoxetine ', 'Obinutuzumab', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically~ the risk of serious bleeding-related events may be increased.', NULL, NULL, NULL),
(2998, 92, 'Fluoxetine ', 'Olanzapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(2999, 92, 'Fluoxetine ', 'Ondansetron', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3000, 92, 'Fluoxetine ', 'Paliperidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3001, 92, 'Fluoxetine ', 'Peginterferon alfa-2b', ' Peginterferon Alfa-2b may decrease the serum concentration of FLUoxetine.', NULL, NULL, NULL),
(3002, 92, 'Fluoxetine ', 'Pentoxifylline', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(3003, 92, 'Fluoxetine ', 'Perphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3004, 92, 'Fluoxetine ', 'Phenindione', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3005, 92, 'Fluoxetine ', 'Phenprocoumon', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3006, 92, 'Fluoxetine ', 'Phenytoin', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(3007, 92, 'Fluoxetine ', 'Pimozide', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3008, 92, 'Fluoxetine ', 'Piperacetazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3009, 92, 'Fluoxetine ', 'Prochlorperazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3010, 92, 'Fluoxetine ', 'Promazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3011, 92, 'Fluoxetine ', 'Propafenone', ' May enhance the QTc-prolonging effect of FLUoxetine. FLUoxetine may increase the serum concentration of Propafenone.', NULL, NULL, NULL),
(3012, 92, 'Fluoxetine ', 'Protriptyline', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(3013, 92, 'Fluoxetine ', 'Quetiapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3014, 92, 'Fluoxetine ', 'Remoxipride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3015, 92, 'Fluoxetine ', 'Reserpine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3016, 92, 'Fluoxetine ', 'Reteplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3017, 92, 'Fluoxetine ', 'Ridogrel', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3018, 92, 'Fluoxetine ', 'Risperidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3019, 92, 'Fluoxetine ', 'Rivaroxaban', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.', NULL, NULL, NULL),
(3020, 92, 'Fluoxetine ', 'Salicylate-sodium', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.', NULL, NULL, NULL),
(3021, 92, 'Fluoxetine ', 'Sertindole', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3022, 92, 'Fluoxetine ', 'Streptokinase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3023, 92, 'Fluoxetine ', 'Sulodexide', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3024, 92, 'Fluoxetine ', 'Sulpiride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3025, 92, 'Fluoxetine ', 'Tamoxifen', ' CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.', NULL, NULL, NULL),
(3026, 92, 'Fluoxetine ', 'Tamsulosin', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.', NULL, NULL, NULL),
(3027, 92, 'Fluoxetine ', 'Tenecteplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3028, 92, 'Fluoxetine ', 'Thioridazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3029, 92, 'Fluoxetine ', 'Thiothixene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3030, 92, 'Fluoxetine ', 'Tramadol', ' Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.', NULL, NULL, NULL),
(3031, 92, 'Fluoxetine ', 'Treprostinil', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3032, 92, 'Fluoxetine ', 'Trifluoperazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3033, 92, 'Fluoxetine ', 'Triflupromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3034, 92, 'Fluoxetine ', 'Trimipramine', ' May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(3035, 92, 'Fluoxetine ', 'Urokinase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3036, 92, 'Fluoxetine ', 'Vitamin E', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(3037, 92, 'Fluoxetine ', 'Warfarin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3038, 92, 'Fluoxetine ', 'Ziprasidone', ' May enhance the QTc-prolonging effect of Ziprasidone. Ziprasidone may enhance the serotonergic effect of FLUoxetine. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3039, 92, 'Fluoxetine ', 'Zuclopenthixol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3040, 93, 'Fluphenazine Decanoate ', '0', '0', NULL, NULL, NULL),
(3041, 94, 'Formoterol Fumarate ', '0', '0', NULL, NULL, NULL),
(3042, 95, 'Furosemide ', '0', '0', NULL, NULL, NULL),
(3043, 95, 'Furosemide ', 'Acetohexamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3044, 95, 'Furosemide ', 'Acetylsalicylic acid', ' May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.', NULL, NULL, NULL),
(3045, 95, 'Furosemide ', 'Alfentanil', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3046, 95, 'Furosemide ', 'Alfuzosin', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(3047, 95, 'Furosemide ', 'Aliskiren', ' May decrease the serum concentration of Furosemide.', NULL, NULL, NULL),
(3048, 95, 'Furosemide ', 'Allopurinol', ' Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically~ Loop Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(3049, 95, 'Furosemide ', 'Alogliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3050, 95, 'Furosemide ', 'Amifostine', ' Antihypertensives may enhance the hypotensive effect of Amifostine.', NULL, NULL, NULL),
(3051, 95, 'Furosemide ', 'Amikacin', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(3052, 95, 'Furosemide ', 'Arbekacin', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(3053, 95, 'Furosemide ', 'Buprenorphine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3054, 95, 'Furosemide ', 'Butabarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(3055, 95, 'Furosemide ', 'Butethal', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(3056, 95, 'Furosemide ', 'Butorphanol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3057, 95, 'Furosemide ', 'Canagliflozin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3058, 95, 'Furosemide ', 'Chloral hydrate', ' Furosemide may enhance the adverse/toxic effect of Chloral Hydrate.', NULL, NULL, NULL),
(3059, 95, 'Furosemide ', 'Chlorpropamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3060, 95, 'Furosemide ', 'Cisplatin', ' Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.', NULL, NULL, NULL),
(3061, 95, 'Furosemide ', 'Codeine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3062, 95, 'Furosemide ', 'Colesevelam', ' May decrease the absorption of Loop Diuretics.', NULL, NULL, NULL),
(3063, 95, 'Furosemide ', 'Diazoxide', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(3064, 95, 'Furosemide ', 'Dihydrocodeine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3065, 95, 'Furosemide ', 'Dofetilide', ' Loop Diuretics may enhance the QTc-prolonging effect of Dofetilide.', NULL, NULL, NULL),
(3066, 95, 'Furosemide ', 'Duloxetine', ' Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.', NULL, NULL, NULL),
(3067, 95, 'Furosemide ', 'Ethacrynic acid', ' Furosemide may enhance the ototoxic effect of Ethacrynic Acid.', NULL, NULL, NULL),
(3068, 95, 'Furosemide ', 'Fentanyl', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3069, 95, 'Furosemide ', 'Foscarnet', ' Loop Diuretics may increase the serum concentration of Foscarnet.', NULL, NULL, NULL),
(3070, 95, 'Furosemide ', 'Fosphenytoin', ' May diminish the diuretic effect of Loop Diuretics.', NULL, NULL, NULL),
(3071, 95, 'Furosemide ', 'Framycetin', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(3072, 95, 'Furosemide ', 'Gentamicin', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(3073, 95, 'Furosemide ', 'Gliclazide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3074, 95, 'Furosemide ', 'Glimepiride', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3075, 95, 'Furosemide ', 'Gliquidone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3076, 95, 'Furosemide ', 'Glyburide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3077, 95, 'Furosemide ', 'Heptabarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(3078, 95, 'Furosemide ', 'Hexobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(3079, 95, 'Furosemide ', 'Hydrocodone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3080, 95, 'Furosemide ', 'Hydromorphone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3081, 95, 'Furosemide ', 'Insulin Aspart', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3082, 95, 'Furosemide ', 'Insulin Detemir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3083, 95, 'Furosemide ', 'Insulin Glargine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3084, 95, 'Furosemide ', 'Insulin Glulisine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3085, 95, 'Furosemide ', 'Insulin Lispro', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3086, 95, 'Furosemide ', 'Insulin Regular', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3087, 95, 'Furosemide ', 'Insulin~ isophane', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3088, 95, 'Furosemide ', 'Kanamycin', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(3089, 95, 'Furosemide ', 'Levorphanol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3090, 95, 'Furosemide ', 'Linagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3091, 95, 'Furosemide ', 'Lithium', ' Loop Diuretics may decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium.', NULL, NULL, NULL),
(3092, 95, 'Furosemide ', 'Metformin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3093, 95, 'Furosemide ', 'Methadone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3094, 95, 'Furosemide ', 'Methohexital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(3095, 95, 'Furosemide ', 'Methotrexate', ' May diminish the therapeutic effect of Loop Diuretics. Methotrexate may increase the serum concentration of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate.', NULL, NULL, NULL),
(3096, 95, 'Furosemide ', 'Methylphenidate', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(3097, 95, 'Furosemide ', 'Morphine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3098, 95, 'Furosemide ', 'Nalbuphine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3099, 95, 'Furosemide ', 'Neomycin', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(3100, 95, 'Furosemide ', 'Netilmicin', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(3101, 95, 'Furosemide ', 'Obinutuzumab', ' Antihypertensives may enhance the hypotensive effect of Obinutuzumab.', NULL, NULL, NULL),
(3102, 95, 'Furosemide ', 'Oxycodone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3103, 95, 'Furosemide ', 'Oxymorphone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3104, 95, 'Furosemide ', 'Pentobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(3105, 95, 'Furosemide ', 'Pentoxifylline', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(3106, 95, 'Furosemide ', 'Pethidine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3107, 95, 'Furosemide ', 'Phenytoin', ' May diminish the diuretic effect of Loop Diuretics.', NULL, NULL, NULL),
(3108, 95, 'Furosemide ', 'Primidone', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(3109, 95, 'Furosemide ', 'Probenecid', ' May enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics.', NULL, NULL, NULL),
(3110, 95, 'Furosemide ', 'Remifentanil', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3111, 95, 'Furosemide ', 'Repaglinide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3112, 95, 'Furosemide ', 'Ribostamycin', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(3113, 95, 'Furosemide ', 'Risperidone', ' Loop Diuretics may enhance the adverse/toxic effect of RisperiDONE.', NULL, NULL, NULL),
(3114, 95, 'Furosemide ', 'Rituximab', ' Antihypertensives may enhance the hypotensive effect of RiTUXimab.', NULL, NULL, NULL),
(3115, 95, 'Furosemide ', 'Salicylate-sodium', ' May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.', NULL, NULL, NULL),
(3116, 95, 'Furosemide ', 'Saxagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3117, 95, 'Furosemide ', 'Secobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(3118, 95, 'Furosemide ', 'Spectinomycin', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(3119, 95, 'Furosemide ', 'Streptomycin', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(3120, 95, 'Furosemide ', 'Sucralfate', ' Sucralfate may decrease the serum concentration of Furosemide. Sucralfate may impair the absorption of furosemide.', NULL, NULL, NULL),
(3121, 95, 'Furosemide ', 'Sufentanil', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3122, 95, 'Furosemide ', 'Tadalafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(3123, 95, 'Furosemide ', 'Tapentadol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3124, 95, 'Furosemide ', 'Teriflunomide', ' May increase the serum concentration of OAT3 Substrates.', NULL, NULL, NULL),
(3125, 95, 'Furosemide ', 'Tobramycin', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(3126, 95, 'Furosemide ', 'Tolbutamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3127, 95, 'Furosemide ', 'Topiramate', ' Loop Diuretics may enhance the hypokalemic effect of Topiramate.', NULL, NULL, NULL),
(3128, 95, 'Furosemide ', 'Tramadol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3129, 95, 'Furosemide ', 'Vardenafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(3130, 95, 'Furosemide ', 'Vildagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3131, 95, 'Furosemide ', 'Yohimbine', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(3132, 96, 'Gentamycin Sulfate ', '0', '0', NULL, NULL, NULL),
(3133, 97, 'Glimepiride ', '0', '0', NULL, NULL, NULL),
(3134, 97, 'Glimepiride ', 'Acarbose', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3135, 97, 'Glimepiride ', 'Acetohexamide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3136, 97, 'Glimepiride ', 'Acetylsalicylic acid', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.', NULL, NULL, NULL),
(3137, 97, 'Glimepiride ', 'Albiglutide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3138, 97, 'Glimepiride ', 'Alogliptin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3139, 97, 'Glimepiride ', 'Aripiprazole', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3140, 97, 'Glimepiride ', 'Arsenic trioxide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3141, 97, 'Glimepiride ', 'Articaine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3142, 97, 'Glimepiride ', 'Asenapine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3143, 97, 'Glimepiride ', 'Atazanavir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3144, 97, 'Glimepiride ', 'Azilsartan medoxomil', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3145, 97, 'Glimepiride ', 'Bendroflumethiazide', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3146, 97, 'Glimepiride ', 'Bromocriptine', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3147, 97, 'Glimepiride ', 'Buformin', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(3148, 97, 'Glimepiride ', 'Bumetanide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3149, 97, 'Glimepiride ', 'Buserelin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3150, 97, 'Glimepiride ', 'Canagliflozin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3151, 97, 'Glimepiride ', 'Chloramphenicol', ' May decrease the metabolism of Sulfonylureas.', NULL, NULL, NULL),
(3152, 97, 'Glimepiride ', 'Chlorothiazide', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3153, 97, 'Glimepiride ', 'Chlorpropamide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3154, 97, 'Glimepiride ', 'Chlorthalidone', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3155, 97, 'Glimepiride ', 'Cimetidine', ' May increase the serum concentration of Sulfonylureas.', NULL, NULL, NULL),
(3156, 97, 'Glimepiride ', 'Clozapine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3157, 97, 'Glimepiride ', 'Colesevelam', ' May decrease the serum concentration of Glimepiride.', NULL, NULL, NULL),
(3158, 97, 'Glimepiride ', 'Corticotropin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3159, 97, 'Glimepiride ', 'Cortisone acetate', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3160, 97, 'Glimepiride ', 'Cyproterone acetate', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3161, 97, 'Glimepiride ', 'Dabrafenib', ' May decrease the serum concentration of CYP2C9 Substrates.', NULL, NULL, NULL),
(3162, 97, 'Glimepiride ', 'Danazol', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3163, 97, 'Glimepiride ', 'Dapagliflozin', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3164, 97, 'Glimepiride ', 'Darunavir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3165, 97, 'Glimepiride ', 'Desogestrel', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3166, 97, 'Glimepiride ', 'Diazoxide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3167, 97, 'Glimepiride ', 'Dihydrotestosterone', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.', NULL, NULL, NULL),
(3168, 97, 'Glimepiride ', 'Disopyramide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3169, 97, 'Glimepiride ', 'Drospirenone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3170, 97, 'Glimepiride ', 'Dulaglutide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3171, 97, 'Glimepiride ', 'Empagliflozin', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3172, 97, 'Glimepiride ', 'Estropipate', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3173, 97, 'Glimepiride ', 'Ethacrynic acid', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3174, 97, 'Glimepiride ', 'Ethinyl Estradiol', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3175, 97, 'Glimepiride ', 'Ethynodiol', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3176, 97, 'Glimepiride ', 'Etonogestrel', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3177, 97, 'Glimepiride ', 'Everolimus', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3178, 97, 'Glimepiride ', 'Exenatide', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(3179, 97, 'Glimepiride ', 'Fluconazole', ' May increase the serum concentration of Sulfonylureas.', NULL, NULL, NULL),
(3180, 97, 'Glimepiride ', 'Fludrocortisone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3181, 97, 'Glimepiride ', 'Fosamprenavir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3182, 97, 'Glimepiride ', 'Furosemide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3183, 97, 'Glimepiride ', 'Gliclazide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3184, 97, 'Glimepiride ', 'Glipizide', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(3185, 97, 'Glimepiride ', 'Gliquidone', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3186, 97, 'Glimepiride ', 'Glucagon recombinant', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(3187, 97, 'Glimepiride ', 'Glyburide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3188, 97, 'Glimepiride ', 'Goserelin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3189, 97, 'Glimepiride ', 'Histrelin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3190, 97, 'Glimepiride ', 'Homoharringtonine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3191, 97, 'Glimepiride ', 'Hydrochlorothiazide', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3192, 97, 'Glimepiride ', 'Iloperidone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3193, 97, 'Glimepiride ', 'Indapamide', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3194, 97, 'Glimepiride ', 'Indinavir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3195, 97, 'Glimepiride ', 'inhaled insulin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3196, 97, 'Glimepiride ', 'Insulin Aspart', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3197, 97, 'Glimepiride ', 'Insulin Detemir', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3198, 97, 'Glimepiride ', 'Insulin Glargine', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3199, 97, 'Glimepiride ', 'Insulin Glulisine', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3200, 97, 'Glimepiride ', 'Insulin Lispro', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3201, 97, 'Glimepiride ', 'Insulin Regular', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3202, 97, 'Glimepiride ', 'Insulin~ isophane', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3203, 97, 'Glimepiride ', 'Insulin~ porcine', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(3204, 97, 'Glimepiride ', 'Lanreotide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3205, 97, 'Glimepiride ', 'Leuprolide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3206, 97, 'Glimepiride ', 'Levonorgestrel', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3207, 97, 'Glimepiride ', 'Linagliptin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3208, 97, 'Glimepiride ', 'Liraglutide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3209, 97, 'Glimepiride ', 'Lopinavir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3210, 97, 'Glimepiride ', 'Lurasidone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3211, 97, 'Glimepiride ', 'Mecasermin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3212, 97, 'Glimepiride ', 'Medroxyprogesterone Acetate', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3213, 97, 'Glimepiride ', 'Megestrol acetate', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3214, 97, 'Glimepiride ', 'Mestranol', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3215, 97, 'Glimepiride ', 'Metformin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3216, 97, 'Glimepiride ', 'Methotrimeprazine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3217, 97, 'Glimepiride ', 'Methyclothiazide', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3218, 97, 'Glimepiride ', 'Methylprednisolone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3219, 97, 'Glimepiride ', 'Metolazone', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3220, 97, 'Glimepiride ', 'Metreleptin', ' May enhance the hypoglycemic effect of Sulfonylureas.', NULL, NULL, NULL),
(3221, 97, 'Glimepiride ', 'Mifepristone', ' May increase the serum concentration of CYP2C9 Substrates.', NULL, NULL, NULL),
(3222, 97, 'Glimepiride ', 'Miglitol', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3223, 97, 'Glimepiride ', 'Mitiglinide', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(3224, 97, 'Glimepiride ', 'Nateglinide', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(3225, 97, 'Glimepiride ', 'Nelfinavir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3226, 97, 'Glimepiride ', 'Nilotinib', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3227, 97, 'Glimepiride ', 'Norelgestromin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3228, 97, 'Glimepiride ', 'Norethindrone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3229, 97, 'Glimepiride ', 'Norgestimate', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3230, 97, 'Glimepiride ', 'Octreotide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3231, 97, 'Glimepiride ', 'Olanzapine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3232, 97, 'Glimepiride ', 'Oxandrolone', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.', NULL, NULL, NULL),
(3233, 97, 'Glimepiride ', 'Paliperidone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3234, 97, 'Glimepiride ', 'Pasireotide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3235, 97, 'Glimepiride ', 'Pegvisomant', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.', NULL, NULL, NULL),
(3236, 97, 'Glimepiride ', 'Pentamidine', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3237, 97, 'Glimepiride ', 'Phenformin', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(3238, 97, 'Glimepiride ', 'Pioglitazone', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(3239, 97, 'Glimepiride ', 'Piperazine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3240, 97, 'Glimepiride ', 'Pipotiazine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3241, 97, 'Glimepiride ', 'Porfimer', ' Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.', NULL, NULL, NULL),
(3242, 97, 'Glimepiride ', 'Pramlintide', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3243, 97, 'Glimepiride ', 'Prednisone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3244, 97, 'Glimepiride ', 'Probenecid', ' May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.', NULL, NULL, NULL),
(3245, 97, 'Glimepiride ', 'Progesterone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3246, 97, 'Glimepiride ', 'Quetiapine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3247, 97, 'Glimepiride ', 'Quinine', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3248, 97, 'Glimepiride ', 'Ranitidine', ' May increase the serum concentration of Sulfonylureas.', NULL, NULL, NULL),
(3249, 97, 'Glimepiride ', 'Repaglinide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3250, 97, 'Glimepiride ', 'Risperidone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3251, 97, 'Glimepiride ', 'Ritonavir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3252, 97, 'Glimepiride ', 'Rosiglitazone', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3253, 97, 'Glimepiride ', 'Salicylate-sodium', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.', NULL, NULL, NULL),
(3254, 97, 'Glimepiride ', 'Saquinavir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3255, 97, 'Glimepiride ', 'Saxagliptin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3256, 97, 'Glimepiride ', 'Sirolimus', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3257, 97, 'Glimepiride ', 'Sitagliptin', ' Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3258, 97, 'Glimepiride ', 'Sulfadiazine', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3259, 97, 'Glimepiride ', 'Sulfamethoxazole', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3260, 97, 'Glimepiride ', 'Sulfisoxazole', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3261, 97, 'Glimepiride ', 'Sulodexide', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(3262, 97, 'Glimepiride ', 'Sunitinib', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3263, 97, 'Glimepiride ', 'Temsirolimus', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3264, 97, 'Glimepiride ', 'Testosterone', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.', NULL, NULL, NULL),
(3265, 97, 'Glimepiride ', 'Tipranavir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3266, 97, 'Glimepiride ', 'Tolazamide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3267, 97, 'Glimepiride ', 'Tolbutamide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3268, 97, 'Glimepiride ', 'Torasemide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3269, 97, 'Glimepiride ', 'Triptorelin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3270, 97, 'Glimepiride ', 'Verteporfin', ' Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.', NULL, NULL, NULL),
(3271, 97, 'Glimepiride ', 'Vildagliptin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(3272, 97, 'Glimepiride ', 'Voriconazole', ' May increase the serum concentration of Sulfonylureas.', NULL, NULL, NULL),
(3273, 97, 'Glimepiride ', 'Vorinostat', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3274, 97, 'Glimepiride ', 'Ziprasidone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3275, 98, 'Griseofulvin ', '0', '0', NULL, NULL, NULL),
(3276, 98, 'Griseofulvin ', 'Acenocoumarol', ' May decrease the serum concentration of Vitamin K Antagonists.', NULL, NULL, NULL),
(3277, 98, 'Griseofulvin ', 'Amobarbital', ' Barbiturates may decrease the serum concentration of Griseofulvin.', NULL, NULL, NULL),
(3278, 98, 'Griseofulvin ', 'Aripiprazole', ' CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(3279, 98, 'Griseofulvin ', 'Butabarbital', ' Barbiturates may decrease the serum concentration of Griseofulvin.', NULL, NULL, NULL),
(3280, 98, 'Griseofulvin ', 'Butalbital', ' Barbiturates may decrease the serum concentration of Griseofulvin.', NULL, NULL, NULL),
(3281, 98, 'Griseofulvin ', 'Butethal', ' May decrease the serum concentration of Griseofulvin. Exceptions: Methohexital; Thiopental.', NULL, NULL, NULL),
(3282, 98, 'Griseofulvin ', 'Desogestrel', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(3283, 98, 'Griseofulvin ', 'Drospirenone', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(3284, 98, 'Griseofulvin ', 'Ethanol', ' May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.', NULL, NULL, NULL),
(3285, 98, 'Griseofulvin ', 'Ethinyl Estradiol', ' May increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible.', NULL, NULL, NULL),
(3286, 98, 'Griseofulvin ', 'Ethynodiol', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(3287, 98, 'Griseofulvin ', 'Etonogestrel', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(3288, 98, 'Griseofulvin ', 'Heptabarbital', ' May decrease the serum concentration of Griseofulvin. Exceptions: Methohexital; Thiopental.', NULL, NULL, NULL),
(3289, 98, 'Griseofulvin ', 'Hexobarbital', ' May decrease the serum concentration of Griseofulvin. Exceptions: Methohexital; Thiopental.', NULL, NULL, NULL),
(3290, 98, 'Griseofulvin ', 'Hydrocodone', ' CYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(3291, 98, 'Griseofulvin ', 'Levonorgestrel', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(3292, 98, 'Griseofulvin ', 'Medroxyprogesterone Acetate', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(3293, 98, 'Griseofulvin ', 'Mestranol', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(3294, 98, 'Griseofulvin ', 'Methohexital', ' May decrease the serum concentration of Griseofulvin. Exceptions: Methohexital; Thiopental.', NULL, NULL, NULL),
(3295, 98, 'Griseofulvin ', 'Norelgestromin', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(3296, 98, 'Griseofulvin ', 'Norethindrone', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(3297, 98, 'Griseofulvin ', 'Norgestimate', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(3298, 98, 'Griseofulvin ', 'Pentobarbital', ' Barbiturates may decrease the serum concentration of Griseofulvin.', NULL, NULL, NULL),
(3299, 98, 'Griseofulvin ', 'Phenobarbital', ' Barbiturates may decrease the serum concentration of Griseofulvin.', NULL, NULL, NULL),
(3300, 98, 'Griseofulvin ', 'Porfimer', ' Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.', NULL, NULL, NULL),
(3301, 98, 'Griseofulvin ', 'Primidone', ' May decrease the serum concentration of Griseofulvin. Exceptions: Methohexital; Thiopental.', NULL, NULL, NULL),
(3302, 98, 'Griseofulvin ', 'Saxagliptin', ' CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.', NULL, NULL, NULL),
(3303, 98, 'Griseofulvin ', 'Secobarbital', ' May decrease the serum concentration of Griseofulvin. Exceptions: Methohexital; Thiopental.', NULL, NULL, NULL),
(3304, 98, 'Griseofulvin ', 'Ulipristal', ' Griseofulvin may decrease the serum concentration of Ulipristal.', NULL, NULL, NULL),
(3305, 98, 'Griseofulvin ', 'Verteporfin', ' Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.', NULL, NULL, NULL),
(3306, 99, 'Haloperidol ', '0', '0', NULL, NULL, NULL),
(3307, 99, 'Haloperidol ', 'Aclidinium', ' May enhance the anticholinergic effect of Anticholinergic Agents.', NULL, NULL, NULL),
(3308, 99, 'Haloperidol ', 'Almotriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3309, 99, 'Haloperidol ', 'Amisulpride', ' Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride.', NULL, NULL, NULL),
(3310, 99, 'Haloperidol ', 'Amitriptyline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3311, 99, 'Haloperidol ', 'Amoxapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3312, 99, 'Haloperidol ', 'Amphetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(3313, 99, 'Haloperidol ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3314, 99, 'Haloperidol ', 'Aripiprazole', ' May enhance the QTc-prolonging effect of Haloperidol. ARIPiprazole may diminish the therapeutic effect of Haloperidol. Haloperidol may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(3315, 99, 'Haloperidol ', 'Benzphetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(3316, 99, 'Haloperidol ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3317, 99, 'Haloperidol ', 'Buprenorphine', ' CNS Depressants may enhance the CNS depressant effect of Buprenorphine.', NULL, NULL, NULL),
(3318, 99, 'Haloperidol ', 'Buspirone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3319, 99, 'Haloperidol ', 'Cabergoline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3320, 99, 'Haloperidol ', 'Carbamazepine', ' May increase the metabolism of Haloperidol.', NULL, NULL, NULL),
(3321, 99, 'Haloperidol ', 'Cathinone', ' Antipsychotic Agents may diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(3322, 99, 'Haloperidol ', 'Celecoxib', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3323, 99, 'Haloperidol ', 'Chlorpromazine', ' ChlorproMAZINE may enhance the QTc-prolonging effect of Haloperidol. ChlorproMAZINE may increase the serum concentration of Haloperidol. Haloperidol may increase the serum concentration of ChlorproMAZINE.', NULL, NULL, NULL),
(3324, 99, 'Haloperidol ', 'Citalopram', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3325, 99, 'Haloperidol ', 'Clomipramine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3326, 99, 'Haloperidol ', 'Codeine', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.', NULL, NULL, NULL),
(3327, 99, 'Haloperidol ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3328, 99, 'Haloperidol ', 'Cyclobenzaprine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3329, 99, 'Haloperidol ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3330, 99, 'Haloperidol ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3331, 99, 'Haloperidol ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3332, 99, 'Haloperidol ', 'Desipramine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3333, 99, 'Haloperidol ', 'Desvenlafaxine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3334, 99, 'Haloperidol ', 'Dextroamphetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(3335, 99, 'Haloperidol ', 'Dextromethorphan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3336, 99, 'Haloperidol ', 'Diflunisal', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3337, 99, 'Haloperidol ', 'Dihydroergotamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3338, 99, 'Haloperidol ', 'Donepezil', ' Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.', NULL, NULL, NULL),
(3339, 99, 'Haloperidol ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(3340, 99, 'Haloperidol ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(3341, 99, 'Haloperidol ', 'Droperidol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(3342, 99, 'Haloperidol ', 'Duloxetine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3343, 99, 'Haloperidol ', 'Eletriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3344, 99, 'Haloperidol ', 'Ergoloid mesylate', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3345, 99, 'Haloperidol ', 'Ergonovine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3346, 99, 'Haloperidol ', 'Ergotamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3347, 99, 'Haloperidol ', 'Escitalopram', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3348, 99, 'Haloperidol ', 'Etodolac', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3349, 99, 'Haloperidol ', 'Fenoprofen', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3350, 99, 'Haloperidol ', 'Fentanyl', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3351, 99, 'Haloperidol ', 'Fesoterodine', ' CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.', NULL, NULL, NULL),
(3352, 99, 'Haloperidol ', 'Floctafenine', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3353, 99, 'Haloperidol ', 'Fluoxetine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3354, 99, 'Haloperidol ', 'Fluvoxamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3355, 99, 'Haloperidol ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3356, 99, 'Haloperidol ', 'Frovatriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3357, 99, 'Haloperidol ', 'Galantamine', ' Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.', NULL, NULL, NULL),
(3358, 99, 'Haloperidol ', 'Glycerol Phenylbutyrate', ' May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically~ Haloperidol may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range.', NULL, NULL, NULL),
(3359, 99, 'Haloperidol ', 'Glycopyrrolate', ' May decrease the serum concentration of Haloperidol.', NULL, NULL, NULL),
(3360, 99, 'Haloperidol ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(3361, 99, 'Haloperidol ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(3362, 99, 'Haloperidol ', 'Ibuprofen', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3363, 99, 'Haloperidol ', 'Imipramine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3364, 99, 'Haloperidol ', 'Indomethacin', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3365, 99, 'Haloperidol ', 'Isocarboxazid', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3366, 99, 'Haloperidol ', 'Itopride', ' Anticholinergic Agents may diminish the therapeutic effect of Itopride.', NULL, NULL, NULL),
(3367, 99, 'Haloperidol ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3368, 99, 'Haloperidol ', 'Ketoprofen', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3369, 99, 'Haloperidol ', 'Ketorolac', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3370, 99, 'Haloperidol ', 'Levomilnacipran', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3371, 99, 'Haloperidol ', 'Linezolid', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3372, 99, 'Haloperidol ', 'Lisdexamfetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(3373, 99, 'Haloperidol ', 'Lithium', ' May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.', NULL, NULL, NULL),
(3374, 99, 'Haloperidol ', 'Lorcaserin', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3375, 99, 'Haloperidol ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3376, 99, 'Haloperidol ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(3377, 99, 'Haloperidol ', 'Maprotiline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3378, 99, 'Haloperidol ', 'Mefenamic acid', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3379, 99, 'Haloperidol ', 'Meloxicam', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3380, 99, 'Haloperidol ', 'Mequitazine', ' Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.', NULL, NULL, NULL),
(3381, 99, 'Haloperidol ', 'Methadone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3382, 99, 'Haloperidol ', 'Methamphetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(3383, 99, 'Haloperidol ', 'Methotrimeprazine', ' CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(3384, 99, 'Haloperidol ', 'Methylergometrine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3385, 99, 'Haloperidol ', 'Methylphenidate', ' May enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents.', NULL, NULL, NULL),
(3386, 99, 'Haloperidol ', 'Metoclopramide', ' May enhance the adverse/toxic effect of Antipsychotic Agents.', NULL, NULL, NULL),
(3387, 99, 'Haloperidol ', 'Metoprolol', ' CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.', NULL, NULL, NULL),
(3388, 99, 'Haloperidol ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(3389, 99, 'Haloperidol ', 'Mifepristone', ' May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.', NULL, NULL, NULL),
(3390, 99, 'Haloperidol ', 'Milnacipran', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3391, 99, 'Haloperidol ', 'Mirabegron', ' Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.', NULL, NULL, NULL),
(3392, 99, 'Haloperidol ', 'Mirtazapine', ' CNS Depressants may enhance the CNS depressant effect of Mirtazapine.', NULL, NULL, NULL),
(3393, 99, 'Haloperidol ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3394, 99, 'Haloperidol ', 'Moclobemide', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3395, 99, 'Haloperidol ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(3396, 99, 'Haloperidol ', 'Nabumetone', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3397, 99, 'Haloperidol ', 'Naproxen', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3398, 99, 'Haloperidol ', 'Naratriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3399, 99, 'Haloperidol ', 'Nebivolol', ' CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.', NULL, NULL, NULL),
(3400, 99, 'Haloperidol ', 'Nefazodone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3401, 99, 'Haloperidol ', 'Nortriptyline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3402, 99, 'Haloperidol ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(3403, 99, 'Haloperidol ', 'Oxaprozin', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3404, 99, 'Haloperidol ', 'Panobinostat', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(3405, 99, 'Haloperidol ', 'Paroxetine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3406, 99, 'Haloperidol ', 'Peginterferon alfa-2b', ' May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(3407, 99, 'Haloperidol ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(3408, 99, 'Haloperidol ', 'Pethidine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3409, 99, 'Haloperidol ', 'Phendimetrazine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(3410, 99, 'Haloperidol ', 'Phenelzine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3411, 99, 'Haloperidol ', 'Phentermine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(3412, 99, 'Haloperidol ', 'Piroxicam', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3413, 99, 'Haloperidol ', 'Potassium Chloride', ' Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.', NULL, NULL, NULL),
(3414, 99, 'Haloperidol ', 'Pramlintide', ' May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.', NULL, NULL, NULL),
(3415, 99, 'Haloperidol ', 'Procarbazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3416, 99, 'Haloperidol ', 'Promazine', ' ChlorproMAZINE may enhance the QTc-prolonging effect of Haloperidol. ChlorproMAZINE may increase the serum concentration of Haloperidol. Haloperidol may increase the serum concentration of ChlorproMAZINE.', NULL, NULL, NULL),
(3417, 99, 'Haloperidol ', 'Promethazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3418, 99, 'Haloperidol ', 'Protriptyline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3419, 99, 'Haloperidol ', 'Quinidine', ' Haloperidol may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Haloperidol.', NULL, NULL, NULL),
(3420, 99, 'Haloperidol ', 'Rasagiline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3421, 99, 'Haloperidol ', 'Rivastigmine', ' Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.', NULL, NULL, NULL),
(3422, 99, 'Haloperidol ', 'Rizatriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3423, 99, 'Haloperidol ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(3424, 99, 'Haloperidol ', 'Secretin', ' Anticholinergic Agents may diminish the therapeutic effect of Secretin.', NULL, NULL, NULL),
(3425, 99, 'Haloperidol ', 'Selegiline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3426, 99, 'Haloperidol ', 'Sertraline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3427, 99, 'Haloperidol ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3428, 99, 'Haloperidol ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3429, 99, 'Haloperidol ', 'Sodium phenylbutyrate', ' May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically~ Haloperidol may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range.', NULL, NULL, NULL),
(3430, 99, 'Haloperidol ', 'Sulindac', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3431, 99, 'Haloperidol ', 'Sulpiride', ' Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride.', NULL, NULL, NULL),
(3432, 99, 'Haloperidol ', 'Sumatriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3433, 99, 'Haloperidol ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(3434, 99, 'Haloperidol ', 'Tamoxifen', ' CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.', NULL, NULL, NULL),
(3435, 99, 'Haloperidol ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(3436, 99, 'Haloperidol ', 'Tedizolid Phosphate', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3437, 99, 'Haloperidol ', 'Tetrabenazine', ' Tetrabenazine may enhance the adverse/toxic effect of Antipsychotic Agents.', NULL, NULL, NULL),
(3438, 99, 'Haloperidol ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(3439, 99, 'Haloperidol ', 'Thioridazine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(3440, 99, 'Haloperidol ', 'Tiaprofenic acid', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3441, 99, 'Haloperidol ', 'Tiotropium', ' Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.', NULL, NULL, NULL),
(3442, 99, 'Haloperidol ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3443, 99, 'Haloperidol ', 'Tolmetin', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3444, 99, 'Haloperidol ', 'Topiramate', ' Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.', NULL, NULL, NULL),
(3445, 99, 'Haloperidol ', 'Tramadol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3446, 99, 'Haloperidol ', 'Tranylcypromine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3447, 99, 'Haloperidol ', 'Trimipramine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3448, 99, 'Haloperidol ', 'Venlafaxine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3449, 99, 'Haloperidol ', 'Vilazodone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3450, 99, 'Haloperidol ', 'Zolmitriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(3451, 99, 'Haloperidol ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(3452, 100, 'Hydralazine Hydrochloride ', '0', '0', NULL, NULL, NULL),
(3453, 101, 'Hydrochlorothiazide ', '0', '0', NULL, NULL, NULL),
(3454, 101, 'Hydrochlorothiazide ', 'Acetohexamide', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3455, 101, 'Hydrochlorothiazide ', 'Alfentanil', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3456, 101, 'Hydrochlorothiazide ', 'Alfuzosin', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(3457, 101, 'Hydrochlorothiazide ', 'Allopurinol', ' Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically~ Thiazide Diuretics may increase the concentration of Oxypurinol~ an active metabolite of Allopurinol.', NULL, NULL, NULL),
(3458, 101, 'Hydrochlorothiazide ', 'Alogliptin', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3459, 101, 'Hydrochlorothiazide ', 'Amifostine', ' Antihypertensives may enhance the hypotensive effect of Amifostine.', NULL, NULL, NULL),
(3460, 101, 'Hydrochlorothiazide ', 'Benazepril', ' May enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.', NULL, NULL, NULL),
(3461, 101, 'Hydrochlorothiazide ', 'Buprenorphine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3462, 101, 'Hydrochlorothiazide ', 'Butabarbital', ' May enhance the orthostatic hypotensive effect of Thiazide Diuretics.', NULL, NULL, NULL),
(3463, 101, 'Hydrochlorothiazide ', 'Butethal', ' May enhance the orthostatic hypotensive effect of Thiazide Diuretics.', NULL, NULL, NULL),
(3464, 101, 'Hydrochlorothiazide ', 'Butorphanol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3465, 101, 'Hydrochlorothiazide ', 'Canagliflozin', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3466, 101, 'Hydrochlorothiazide ', 'Carbamazepine', ' Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically~ there may be an increased risk for hyponatremia.', NULL, NULL, NULL),
(3467, 101, 'Hydrochlorothiazide ', 'Chlorpropamide', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3468, 101, 'Hydrochlorothiazide ', 'Codeine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3469, 101, 'Hydrochlorothiazide ', 'Colesevelam', ' May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.', NULL, NULL, NULL),
(3470, 101, 'Hydrochlorothiazide ', 'Cyclophosphamide', ' Thiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ granulocytopenia may be enhanced.', NULL, NULL, NULL),
(3471, 101, 'Hydrochlorothiazide ', 'Diazoxide', ' Thiazide Diuretics may enhance the adverse/toxic effect of Diazoxide.', NULL, NULL, NULL),
(3472, 101, 'Hydrochlorothiazide ', 'Dihydrocodeine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3473, 101, 'Hydrochlorothiazide ', 'Dofetilide', ' Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(3474, 101, 'Hydrochlorothiazide ', 'Duloxetine', ' Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.', NULL, NULL, NULL),
(3475, 101, 'Hydrochlorothiazide ', 'Fentanyl', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3476, 101, 'Hydrochlorothiazide ', 'Gliclazide', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3477, 101, 'Hydrochlorothiazide ', 'Glimepiride', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3478, 101, 'Hydrochlorothiazide ', 'Gliquidone', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3479, 101, 'Hydrochlorothiazide ', 'Glyburide', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3480, 101, 'Hydrochlorothiazide ', 'Heptabarbital', ' May enhance the orthostatic hypotensive effect of Thiazide Diuretics.', NULL, NULL, NULL),
(3481, 101, 'Hydrochlorothiazide ', 'Hexobarbital', ' May enhance the orthostatic hypotensive effect of Thiazide Diuretics.', NULL, NULL, NULL),
(3482, 101, 'Hydrochlorothiazide ', 'Hydrocodone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3483, 101, 'Hydrochlorothiazide ', 'Hydromorphone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3484, 101, 'Hydrochlorothiazide ', 'Insulin Aspart', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3485, 101, 'Hydrochlorothiazide ', 'Insulin Detemir', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3486, 101, 'Hydrochlorothiazide ', 'Insulin Glargine', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3487, 101, 'Hydrochlorothiazide ', 'Insulin Glulisine', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3488, 101, 'Hydrochlorothiazide ', 'Insulin Lispro', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3489, 101, 'Hydrochlorothiazide ', 'Insulin Regular', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3490, 101, 'Hydrochlorothiazide ', 'Insulin~ isophane', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3491, 101, 'Hydrochlorothiazide ', 'Levorphanol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3492, 101, 'Hydrochlorothiazide ', 'Linagliptin', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3493, 101, 'Hydrochlorothiazide ', 'Lithium', ' Thiazide Diuretics may decrease the excretion of Lithium.', NULL, NULL, NULL),
(3494, 101, 'Hydrochlorothiazide ', 'Metformin', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3495, 101, 'Hydrochlorothiazide ', 'Methadone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3496, 101, 'Hydrochlorothiazide ', 'Methohexital', ' May enhance the orthostatic hypotensive effect of Thiazide Diuretics.', NULL, NULL, NULL),
(3497, 101, 'Hydrochlorothiazide ', 'Methylphenidate', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(3498, 101, 'Hydrochlorothiazide ', 'Morphine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3499, 101, 'Hydrochlorothiazide ', 'Nalbuphine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3500, 101, 'Hydrochlorothiazide ', 'Obinutuzumab', ' Antihypertensives may enhance the hypotensive effect of Obinutuzumab.', NULL, NULL, NULL),
(3501, 101, 'Hydrochlorothiazide ', 'Oxcarbazepine', ' Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically~ there may be an increased risk for hyponatremia.', NULL, NULL, NULL),
(3502, 101, 'Hydrochlorothiazide ', 'Oxycodone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3503, 101, 'Hydrochlorothiazide ', 'Oxymorphone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3504, 101, 'Hydrochlorothiazide ', 'Pentobarbital', ' May enhance the orthostatic hypotensive effect of Thiazide Diuretics.', NULL, NULL, NULL),
(3505, 101, 'Hydrochlorothiazide ', 'Pentoxifylline', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(3506, 101, 'Hydrochlorothiazide ', 'Pethidine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3507, 101, 'Hydrochlorothiazide ', 'Porfimer', ' Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.', NULL, NULL, NULL),
(3508, 101, 'Hydrochlorothiazide ', 'Primidone', ' May enhance the orthostatic hypotensive effect of Thiazide Diuretics.', NULL, NULL, NULL),
(3509, 101, 'Hydrochlorothiazide ', 'Remifentanil', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3510, 101, 'Hydrochlorothiazide ', 'Repaglinide', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3511, 101, 'Hydrochlorothiazide ', 'Risperidone', ' Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.', NULL, NULL, NULL),
(3512, 101, 'Hydrochlorothiazide ', 'Rituximab', ' Antihypertensives may enhance the hypotensive effect of RiTUXimab.', NULL, NULL, NULL),
(3513, 101, 'Hydrochlorothiazide ', 'Saxagliptin', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3514, 101, 'Hydrochlorothiazide ', 'Secobarbital', ' May enhance the orthostatic hypotensive effect of Thiazide Diuretics.', NULL, NULL, NULL),
(3515, 101, 'Hydrochlorothiazide ', 'Sufentanil', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3516, 101, 'Hydrochlorothiazide ', 'Tadalafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(3517, 101, 'Hydrochlorothiazide ', 'Tapentadol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3518, 101, 'Hydrochlorothiazide ', 'Tolbutamide', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3519, 101, 'Hydrochlorothiazide ', 'Topiramate', ' Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.', NULL, NULL, NULL),
(3520, 101, 'Hydrochlorothiazide ', 'Toremifene', ' Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.', NULL, NULL, NULL),
(3521, 101, 'Hydrochlorothiazide ', 'Tramadol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(3522, 101, 'Hydrochlorothiazide ', 'Valsartan', ' May enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.', NULL, NULL, NULL),
(3523, 101, 'Hydrochlorothiazide ', 'Vardenafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(3524, 101, 'Hydrochlorothiazide ', 'Verteporfin', ' Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.', NULL, NULL, NULL),
(3525, 101, 'Hydrochlorothiazide ', 'Vildagliptin', ' Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3526, 101, 'Hydrochlorothiazide ', 'Yohimbine', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(3527, 102, 'Hydrocortisone ', '0', '0', NULL, NULL, NULL),
(3528, 103, 'Hydroxyurea ', '0', '0', NULL, NULL, NULL),
(3529, 103, 'Hydroxyurea ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(3530, 103, 'Hydroxyurea ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(3531, 103, 'Hydroxyurea ', 'Didanosine', ' May enhance the adverse/toxic effect of Didanosine. An increased risk of pancreatitis~ hepatotoxicity and/or neuropathy may exist. Didanosine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis~ hepatotoxicity and/or neuropathy may exist.', NULL, NULL, NULL),
(3532, 103, 'Hydroxyurea ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(3533, 103, 'Hydroxyurea ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(3534, 103, 'Hydroxyurea ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(3535, 103, 'Hydroxyurea ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(3536, 103, 'Hydroxyurea ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(3537, 103, 'Hydroxyurea ', 'Stavudine', ' Hydroxyurea may enhance the adverse/toxic effect of Stavudine. An increased risk of pancreatitis~ hepatotoxicity and/or neuropathy may exist. Stavudine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis~ hepatotoxicity and/or neuropathy may exist.', NULL, NULL, NULL),
(3538, 103, 'Hydroxyurea ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(3539, 103, 'Hydroxyurea ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(3540, 104, 'Hyoscine Hydrobromide ', '0', '0', NULL, NULL, NULL),
(3541, 105, 'Ibuprofen ', '0', '0', NULL, NULL, NULL),
(3542, 105, 'Ibuprofen ', 'Abciximab', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3543, 105, 'Ibuprofen ', 'Acenocoumarol', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3544, 105, 'Ibuprofen ', 'Acetylsalicylic acid', ' NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.', NULL, NULL, NULL),
(3545, 105, 'Ibuprofen ', 'Aliskiren', ' Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.', NULL, NULL, NULL),
(3546, 105, 'Ibuprofen ', 'Alteplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3547, 105, 'Ibuprofen ', 'Amikacin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3548, 105, 'Ibuprofen ', 'Anistreplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3549, 105, 'Ibuprofen ', 'Apixaban', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically~ the risk for bleeding may be increased.', NULL, NULL, NULL),
(3550, 105, 'Ibuprofen ', 'Arbekacin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3551, 105, 'Ibuprofen ', 'Citric Acid', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3552, 105, 'Ibuprofen ', 'Colesevelam', ' May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.', NULL, NULL, NULL),
(3553, 105, 'Ibuprofen ', 'Dabigatran etexilate', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.', NULL, NULL, NULL),
(3554, 105, 'Ibuprofen ', 'Dalteparin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3555, 105, 'Ibuprofen ', 'Dasatinib', ' May enhance the anticoagulant effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(3556, 105, 'Ibuprofen ', 'Deferasirox', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically~ the risk for GI ulceration/irritation or GI bleeding may be increased.', NULL, NULL, NULL),
(3557, 105, 'Ibuprofen ', 'Deoxycholic Acid', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically~ the risk for bleeding or bruising in the treatment area may be increased.', NULL, NULL, NULL),
(3558, 105, 'Ibuprofen ', 'Desmopressin', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.', NULL, NULL, NULL),
(3559, 105, 'Ibuprofen ', 'Dicoumarol', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3560, 105, 'Ibuprofen ', 'Digoxin', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(3561, 105, 'Ibuprofen ', 'Edetic Acid', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3562, 105, 'Ibuprofen ', 'Enoxaparin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3563, 105, 'Ibuprofen ', 'Eplerenone', ' Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.', NULL, NULL, NULL),
(3564, 105, 'Ibuprofen ', 'Ethyl biscoumacetate', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3565, 105, 'Ibuprofen ', 'Floctafenine', ' May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.', NULL, NULL, NULL),
(3566, 105, 'Ibuprofen ', 'Fondaparinux sodium', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3567, 105, 'Ibuprofen ', 'Framycetin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3568, 105, 'Ibuprofen ', 'Gentamicin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3569, 105, 'Ibuprofen ', 'Glucosamine', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(3570, 105, 'Ibuprofen ', 'Haloperidol', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3571, 105, 'Ibuprofen ', 'Heparin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3572, 105, 'Ibuprofen ', 'Hydralazine', ' Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.', NULL, NULL, NULL),
(3573, 105, 'Ibuprofen ', 'Ibritumomab', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.', NULL, NULL, NULL),
(3574, 105, 'Ibuprofen ', 'Imatinib', ' Ibuprofen may decrease the serum concentration of Imatinib. Specifically~ ibuprofen may decrease intracellular concentrations of imatinib~ leading to decreased clinical response.', NULL, NULL, NULL),
(3575, 105, 'Ibuprofen ', 'Kanamycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3576, 105, 'Ibuprofen ', 'Lithium', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.', NULL, NULL, NULL),
(3577, 105, 'Ibuprofen ', 'Methotrexate', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.', NULL, NULL, NULL),
(3578, 105, 'Ibuprofen ', 'Neomycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3579, 105, 'Ibuprofen ', 'Netilmicin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3580, 105, 'Ibuprofen ', 'Obinutuzumab', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically~ the risk of serious bleeding-related events may be increased.', NULL, NULL, NULL),
(3581, 105, 'Ibuprofen ', 'Pemetrexed', ' NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.', NULL, NULL, NULL),
(3582, 105, 'Ibuprofen ', 'Pentoxifylline', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(3583, 105, 'Ibuprofen ', 'Phenindione', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3584, 105, 'Ibuprofen ', 'Phenprocoumon', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3585, 105, 'Ibuprofen ', 'Porfimer', ' Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.', NULL, NULL, NULL),
(3586, 105, 'Ibuprofen ', 'Pralatrexate', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically~ NSAIDS may decrease the renal excretion of pralatrexate.', NULL, NULL, NULL),
(3587, 105, 'Ibuprofen ', 'Probenecid', ' May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.', NULL, NULL, NULL),
(3588, 105, 'Ibuprofen ', 'Reteplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3589, 105, 'Ibuprofen ', 'Ribostamycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3590, 105, 'Ibuprofen ', 'Ridogrel', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3591, 105, 'Ibuprofen ', 'Rivaroxaban', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.', NULL, NULL, NULL),
(3592, 105, 'Ibuprofen ', 'Salicylate-sodium', ' NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.', NULL, NULL, NULL),
(3593, 105, 'Ibuprofen ', 'Spectinomycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3594, 105, 'Ibuprofen ', 'Streptokinase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3595, 105, 'Ibuprofen ', 'Streptomycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3596, 105, 'Ibuprofen ', 'Sulodexide', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3597, 105, 'Ibuprofen ', 'Tenecteplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3598, 105, 'Ibuprofen ', 'Tenofovir', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(3599, 105, 'Ibuprofen ', 'Tipranavir', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(3600, 105, 'Ibuprofen ', 'Tobramycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3601, 105, 'Ibuprofen ', 'Treprostinil', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3602, 105, 'Ibuprofen ', 'Urokinase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3603, 105, 'Ibuprofen ', 'Vancomycin', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.', NULL, NULL, NULL),
(3604, 105, 'Ibuprofen ', 'Verteporfin', ' Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.', NULL, NULL, NULL),
(3605, 105, 'Ibuprofen ', 'Vitamin E', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(3606, 105, 'Ibuprofen ', 'Voriconazole', ' Voriconazole may increase the serum concentration of Ibuprofen. Specifically~ concentrations of the S-(+)-ibuprofen enantiomer may be increased.', NULL, NULL, NULL),
(3607, 105, 'Ibuprofen ', 'Warfarin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3608, 106, 'Imatinib Mesylate ', '0', '0', NULL, NULL, NULL),
(3609, 107, 'Indomethacin ', '0', '0', NULL, NULL, NULL),
(3610, 107, 'Indomethacin ', 'Abciximab', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3611, 107, 'Indomethacin ', 'Acenocoumarol', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3612, 107, 'Indomethacin ', 'Acetylsalicylic acid', ' NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.', NULL, NULL, NULL),
(3613, 107, 'Indomethacin ', 'Aliskiren', ' Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.', NULL, NULL, NULL),
(3614, 107, 'Indomethacin ', 'Alteplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3615, 107, 'Indomethacin ', 'Amikacin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3616, 107, 'Indomethacin ', 'Anistreplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3617, 107, 'Indomethacin ', 'Apixaban', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically~ the risk for bleeding may be increased.', NULL, NULL, NULL),
(3618, 107, 'Indomethacin ', 'Arbekacin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3619, 107, 'Indomethacin ', 'Citric Acid', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3620, 107, 'Indomethacin ', 'Colesevelam', ' May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.', NULL, NULL, NULL),
(3621, 107, 'Indomethacin ', 'Dabigatran etexilate', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.', NULL, NULL, NULL),
(3622, 107, 'Indomethacin ', 'Dalteparin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3623, 107, 'Indomethacin ', 'Dasatinib', ' May enhance the anticoagulant effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(3624, 107, 'Indomethacin ', 'Deferasirox', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically~ the risk for GI ulceration/irritation or GI bleeding may be increased.', NULL, NULL, NULL),
(3625, 107, 'Indomethacin ', 'Deoxycholic Acid', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically~ the risk for bleeding or bruising in the treatment area may be increased.', NULL, NULL, NULL),
(3626, 107, 'Indomethacin ', 'Desmopressin', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.', NULL, NULL, NULL),
(3627, 107, 'Indomethacin ', 'Dicoumarol', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3628, 107, 'Indomethacin ', 'Digoxin', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(3629, 107, 'Indomethacin ', 'Edetic Acid', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3630, 107, 'Indomethacin ', 'Enoxaparin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3631, 107, 'Indomethacin ', 'Eplerenone', ' Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.', NULL, NULL, NULL),
(3632, 107, 'Indomethacin ', 'Ethyl biscoumacetate', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3633, 107, 'Indomethacin ', 'Floctafenine', ' May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.', NULL, NULL, NULL),
(3634, 107, 'Indomethacin ', 'Fondaparinux sodium', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3635, 107, 'Indomethacin ', 'Framycetin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3636, 107, 'Indomethacin ', 'Gentamicin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3637, 107, 'Indomethacin ', 'Glucosamine', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(3638, 107, 'Indomethacin ', 'Haloperidol', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(3639, 107, 'Indomethacin ', 'Heparin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3640, 107, 'Indomethacin ', 'Hydralazine', ' Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.', NULL, NULL, NULL),
(3641, 107, 'Indomethacin ', 'Ibritumomab', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.', NULL, NULL, NULL),
(3642, 107, 'Indomethacin ', 'Kanamycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3643, 107, 'Indomethacin ', 'Lithium', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.', NULL, NULL, NULL),
(3644, 107, 'Indomethacin ', 'Methotrexate', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.', NULL, NULL, NULL),
(3645, 107, 'Indomethacin ', 'Neomycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3646, 107, 'Indomethacin ', 'Netilmicin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3647, 107, 'Indomethacin ', 'Obinutuzumab', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically~ the risk of serious bleeding-related events may be increased.', NULL, NULL, NULL),
(3648, 107, 'Indomethacin ', 'Pemetrexed', ' NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.', NULL, NULL, NULL),
(3649, 107, 'Indomethacin ', 'Pentoxifylline', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(3650, 107, 'Indomethacin ', 'Phenindione', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3651, 107, 'Indomethacin ', 'Phenprocoumon', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3652, 107, 'Indomethacin ', 'Porfimer', ' Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.', NULL, NULL, NULL),
(3653, 107, 'Indomethacin ', 'Pralatrexate', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically~ NSAIDS may decrease the renal excretion of pralatrexate.', NULL, NULL, NULL),
(3654, 107, 'Indomethacin ', 'Probenecid', ' May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.', NULL, NULL, NULL),
(3655, 107, 'Indomethacin ', 'Reteplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3656, 107, 'Indomethacin ', 'Ribostamycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3657, 107, 'Indomethacin ', 'Ridogrel', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3658, 107, 'Indomethacin ', 'Rivaroxaban', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.', NULL, NULL, NULL),
(3659, 107, 'Indomethacin ', 'Salicylate-sodium', ' NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.', NULL, NULL, NULL),
(3660, 107, 'Indomethacin ', 'Spectinomycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3661, 107, 'Indomethacin ', 'Streptokinase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3662, 107, 'Indomethacin ', 'Streptomycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3663, 107, 'Indomethacin ', 'Sulodexide', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3664, 107, 'Indomethacin ', 'Tenecteplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3665, 107, 'Indomethacin ', 'Tenofovir', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(3666, 107, 'Indomethacin ', 'Tiludronate', ' Indomethacin may increase the serum concentration of Tiludronate.', NULL, NULL, NULL),
(3667, 107, 'Indomethacin ', 'Tipranavir', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(3668, 107, 'Indomethacin ', 'Tobramycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(3669, 107, 'Indomethacin ', 'Treprostinil', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3670, 107, 'Indomethacin ', 'Triamterene', ' Indomethacin may enhance the nephrotoxic effect of Triamterene.', NULL, NULL, NULL),
(3671, 107, 'Indomethacin ', 'Urokinase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(3672, 107, 'Indomethacin ', 'Vancomycin', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.', NULL, NULL, NULL),
(3673, 107, 'Indomethacin ', 'Verteporfin', ' Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.', NULL, NULL, NULL),
(3674, 107, 'Indomethacin ', 'Vitamin E', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(3675, 107, 'Indomethacin ', 'Warfarin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(3676, 108, 'Isoniazid ', '0', '0', NULL, NULL, NULL),
(3677, 108, 'Isoniazid ', 'Acetaminophen', ' May enhance the adverse/toxic effect of Acetaminophen.', NULL, NULL, NULL),
(3678, 108, 'Isoniazid ', 'Aluminum hydroxide', ' May decrease the absorption of Isoniazid.', NULL, NULL, NULL),
(3679, 108, 'Isoniazid ', 'Aminophylline', ' May increase the serum concentration of Theophylline Derivatives.', NULL, NULL, NULL),
(3680, 108, 'Isoniazid ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(3681, 108, 'Isoniazid ', 'Butalbital', ' May enhance the adverse/toxic effect of Acetaminophen.', NULL, NULL, NULL),
(3682, 108, 'Isoniazid ', 'Calcium carbonate', ' May decrease the absorption of Isoniazid.', NULL, NULL, NULL),
(3683, 108, 'Isoniazid ', 'Carbamazepine', ' May decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(3684, 108, 'Isoniazid ', 'Chlorzoxazone', ' May decrease the metabolism of Chlorzoxazone.', NULL, NULL, NULL),
(3685, 108, 'Isoniazid ', 'Cilostazol', ' CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.', NULL, NULL, NULL),
(3686, 108, 'Isoniazid ', 'Citalopram', ' CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.', NULL, NULL, NULL),
(3687, 108, 'Isoniazid ', 'Clopidogrel', ' CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.', NULL, NULL, NULL),
(3688, 108, 'Isoniazid ', 'Codeine', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.', NULL, NULL, NULL),
(3689, 108, 'Isoniazid ', 'Corticotropin', ' Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.', NULL, NULL, NULL),
(3690, 108, 'Isoniazid ', 'Cortisone acetate', ' Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.', NULL, NULL, NULL),
(3691, 108, 'Isoniazid ', 'Cycloserine', ' May enhance the adverse/toxic effect of CycloSERINE. Specifically~ CNS toxicity may be enhanced.', NULL, NULL, NULL),
(3692, 108, 'Isoniazid ', 'Dihydrocodeine', ' May enhance the adverse/toxic effect of Acetaminophen.', NULL, NULL, NULL),
(3693, 108, 'Isoniazid ', 'Disulfiram', ' Disulfiram may enhance the adverse/toxic effect of Isoniazid. Disulfiram may increase the serum concentration of Isoniazid.', NULL, NULL, NULL),
(3694, 108, 'Isoniazid ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(3695, 108, 'Isoniazid ', 'Eliglustat', ' CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.', NULL, NULL, NULL),
(3696, 108, 'Isoniazid ', 'Ethionamide', ' Ethionamide may increase the serum concentration of Isoniazid.', NULL, NULL, NULL),
(3697, 108, 'Isoniazid ', 'Fesoterodine', ' CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.', NULL, NULL, NULL),
(3698, 108, 'Isoniazid ', 'Fludrocortisone', ' Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.', NULL, NULL, NULL),
(3699, 108, 'Isoniazid ', 'Fosphenytoin', ' Isoniazid may increase the serum concentration of Fosphenytoin.', NULL, NULL, NULL),
(3700, 108, 'Isoniazid ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(3701, 108, 'Isoniazid ', 'Isometheptene', ' May enhance the adverse/toxic effect of Acetaminophen.', NULL, NULL, NULL),
(3702, 108, 'Isoniazid ', 'Itraconazole', ' Isoniazid may decrease the serum concentration of Itraconazole.', NULL, NULL, NULL),
(3703, 108, 'Isoniazid ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(3704, 108, 'Isoniazid ', 'Magnesium oxide', ' May decrease the absorption of Isoniazid.', NULL, NULL, NULL),
(3705, 108, 'Isoniazid ', 'Methylprednisolone', ' Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.', NULL, NULL, NULL),
(3706, 108, 'Isoniazid ', 'Metoprolol', ' CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.', NULL, NULL, NULL),
(3707, 108, 'Isoniazid ', 'Nebivolol', ' CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.', NULL, NULL, NULL),
(3708, 108, 'Isoniazid ', 'Phenytoin', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(3709, 108, 'Isoniazid ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(3710, 108, 'Isoniazid ', 'Prednisone', ' Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.', NULL, NULL, NULL),
(3711, 108, 'Isoniazid ', 'Propafenone', ' May increase the serum concentration of CYP2D6 Inhibitors (Moderate).', NULL, NULL, NULL),
(3712, 108, 'Isoniazid ', 'Rifampicin', ' Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so~ this is a frequently employed combination regimen.', NULL, NULL, NULL),
(3713, 108, 'Isoniazid ', 'Rifapentine', ' Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so~ this is a frequently employed combination regimen.', NULL, NULL, NULL),
(3714, 108, 'Isoniazid ', 'Sodium bicarbonate', ' Antacids may decrease the absorption of Isoniazid.', NULL, NULL, NULL),
(3715, 108, 'Isoniazid ', 'Tamoxifen', ' CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.', NULL, NULL, NULL),
(3716, 108, 'Isoniazid ', 'Theophylline', ' May increase the serum concentration of Theophylline Derivatives.', NULL, NULL, NULL),
(3717, 108, 'Isoniazid ', 'Thioridazine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(3718, 108, 'Isoniazid ', 'Tramadol', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(3719, 109, 'Kanamycin Sulphate ', '0', '0', NULL, NULL, NULL),
(3720, 110, 'Ketoconazole ', '0', '0', NULL, NULL, NULL),
(3721, 111, 'Labetalol ', '0', '0', NULL, NULL, NULL),
(3722, 111, 'Labetalol ', 'Acetylcholine', ' Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.', NULL, NULL, NULL),
(3723, 111, 'Labetalol ', 'Amifostine', ' Antihypertensives may enhance the hypotensive effect of Amifostine.', NULL, NULL, NULL),
(3724, 111, 'Labetalol ', 'Aminophylline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3725, 111, 'Labetalol ', 'Amiodarone', ' May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(3726, 111, 'Labetalol ', 'Amphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3727, 111, 'Labetalol ', 'Arformoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3728, 111, 'Labetalol ', 'armodafinil', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3729, 111, 'Labetalol ', 'Articaine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3730, 111, 'Labetalol ', 'Atomoxetine', ' AtoMOXetine may enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(3731, 111, 'Labetalol ', 'Benzphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3732, 111, 'Labetalol ', 'Bretylium', ' May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.', NULL, NULL, NULL),
(3733, 111, 'Labetalol ', 'Bupivacaine', ' Beta-Blockers may increase the serum concentration of Bupivacaine.', NULL, NULL, NULL),
(3734, 111, 'Labetalol ', 'Butabarbital', ' May decrease the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(3735, 111, 'Labetalol ', 'Butethal', ' May decrease the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(3736, 111, 'Labetalol ', 'Caffeine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3737, 111, 'Labetalol ', 'Carbachol', ' Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.', NULL, NULL, NULL),
(3738, 111, 'Labetalol ', 'Cocaine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3739, 111, 'Labetalol ', 'Dexmethylphenidate', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3740, 111, 'Labetalol ', 'Dextroamphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3741, 111, 'Labetalol ', 'Diazoxide', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(3742, 111, 'Labetalol ', 'Diethylpropion', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3743, 111, 'Labetalol ', 'Dihydrocodeine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3744, 111, 'Labetalol ', 'Dipivefrin', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3745, 111, 'Labetalol ', 'Dipyridamole', ' May enhance the bradycardic effect of Beta-Blockers.', NULL, NULL, NULL),
(3746, 111, 'Labetalol ', 'Disopyramide', ' May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.', NULL, NULL, NULL),
(3747, 111, 'Labetalol ', 'Dobutamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3748, 111, 'Labetalol ', 'Dopamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3749, 111, 'Labetalol ', 'Doxapram', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3750, 111, 'Labetalol ', 'Dronabinol', ' Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(3751, 111, 'Labetalol ', 'Dronedarone', ' May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6.', NULL, NULL, NULL),
(3752, 111, 'Labetalol ', 'Duloxetine', ' Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.', NULL, NULL, NULL),
(3753, 111, 'Labetalol ', 'Fenoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3754, 111, 'Labetalol ', 'Fingolimod', ' Beta-Blockers may enhance the bradycardic effect of Fingolimod.', NULL, NULL, NULL),
(3755, 111, 'Labetalol ', 'Floctafenine', ' May enhance the adverse/toxic effect of Beta-Blockers.', NULL, NULL, NULL),
(3756, 111, 'Labetalol ', 'Fluticasone furoate', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3757, 111, 'Labetalol ', 'Formoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3758, 111, 'Labetalol ', 'Heptabarbital', ' May decrease the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(3759, 111, 'Labetalol ', 'Hexobarbital', ' May decrease the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(3760, 111, 'Labetalol ', 'Indacaterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3761, 111, 'Labetalol ', 'Iobenguane', ' May diminish the therapeutic effect of Iobenguane I 123.', NULL, NULL, NULL),
(3762, 111, 'Labetalol ', 'Ipratropium bromide', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3763, 111, 'Labetalol ', 'Isometheptene', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3764, 111, 'Labetalol ', 'Lacosamide', ' Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.', NULL, NULL, NULL),
(3765, 111, 'Labetalol ', 'Levonordefrin', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3766, 111, 'Labetalol ', 'Linezolid', ' Linezolid may enhance the hypertensive effect of Sympathomimetics.', NULL, NULL, NULL),
(3767, 111, 'Labetalol ', 'Lisdexamfetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3768, 111, 'Labetalol ', 'Mepivacaine', ' Beta-Blockers may increase the serum concentration of Mepivacaine.', NULL, NULL, NULL),
(3769, 111, 'Labetalol ', 'Methacholine', ' Beta-Blockers may enhance the adverse/toxic effect of Methacholine.', NULL, NULL, NULL),
(3770, 111, 'Labetalol ', 'Methamphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3771, 111, 'Labetalol ', 'Methohexital', ' May decrease the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(3772, 111, 'Labetalol ', 'Methylphenidate', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3773, 111, 'Labetalol ', 'Midodrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3774, 111, 'Labetalol ', 'Modafinil', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3775, 111, 'Labetalol ', 'Nabilone', ' Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(3776, 111, 'Labetalol ', 'Naphazoline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3777, 111, 'Labetalol ', 'Norepinephrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3778, 111, 'Labetalol ', 'Obinutuzumab', ' Antihypertensives may enhance the hypotensive effect of Obinutuzumab.', NULL, NULL, NULL),
(3779, 111, 'Labetalol ', 'Orciprenaline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3780, 111, 'Labetalol ', 'Oxymetazoline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3781, 111, 'Labetalol ', 'Pentobarbital', ' May decrease the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(3782, 111, 'Labetalol ', 'Pentoxifylline', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(3783, 111, 'Labetalol ', 'Phendimetrazine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3784, 111, 'Labetalol ', 'Pheniramine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3785, 111, 'Labetalol ', 'Phentermine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3786, 111, 'Labetalol ', 'Phenylephrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3787, 111, 'Labetalol ', 'Pirbuterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3788, 111, 'Labetalol ', 'Primidone', ' May decrease the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(3789, 111, 'Labetalol ', 'Propafenone', ' May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.', NULL, NULL, NULL),
(3790, 111, 'Labetalol ', 'Propylhexedrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3791, 111, 'Labetalol ', 'Pseudoephedrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3792, 111, 'Labetalol ', 'Regorafenib', ' May enhance the bradycardic effect of Beta-Blockers.', NULL, NULL, NULL),
(3793, 111, 'Labetalol ', 'Reserpine', ' May enhance the hypotensive effect of Beta-Blockers.', NULL, NULL, NULL),
(3794, 111, 'Labetalol ', 'Risperidone', ' Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.', NULL, NULL, NULL),
(3795, 111, 'Labetalol ', 'Rituximab', ' Antihypertensives may enhance the hypotensive effect of RiTUXimab.', NULL, NULL, NULL),
(3796, 111, 'Labetalol ', 'Rivastigmine', ' May enhance the bradycardic effect of Beta-Blockers.', NULL, NULL, NULL),
(3797, 111, 'Labetalol ', 'Ruxolitinib', ' May enhance the bradycardic effect of Bradycardia-Causing Agents.', NULL, NULL, NULL),
(3798, 111, 'Labetalol ', 'Salbutamol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3799, 111, 'Labetalol ', 'Salmeterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3800, 111, 'Labetalol ', 'Secobarbital', ' May decrease the serum concentration of Beta-Blockers.', NULL, NULL, NULL),
(3801, 111, 'Labetalol ', 'Tadalafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(3802, 111, 'Labetalol ', 'Tedizolid Phosphate', ' Tedizolid may enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(3803, 111, 'Labetalol ', 'Terbutaline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3804, 111, 'Labetalol ', 'Theophylline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3805, 111, 'Labetalol ', 'Tofacitinib', ' May enhance the bradycardic effect of Bradycardia-Causing Agents.', NULL, NULL, NULL),
(3806, 111, 'Labetalol ', 'Triprolidine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(3807, 111, 'Labetalol ', 'Vardenafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(3808, 111, 'Labetalol ', 'Yohimbine', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(3809, 112, 'Lamivudine ', '0', '0', NULL, NULL, NULL),
(3810, 112, 'Lamivudine ', 'Emtricitabine', ' LamiVUDine may enhance the adverse/toxic effect of Emtricitabine.', NULL, NULL, NULL),
(3811, 112, 'Lamivudine ', 'Ribavirin', ' May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.', NULL, NULL, NULL),
(3812, 112, 'Lamivudine ', 'Sulfamethoxazole', ' Trimethoprim may decrease the excretion of LamiVUDine.', NULL, NULL, NULL),
(3813, 112, 'Lamivudine ', 'Trimethoprim', ' Trimethoprim may decrease the excretion of LamiVUDine.', NULL, NULL, NULL),
(3814, 113, 'Levodopa ', '0', '0', NULL, NULL, NULL),
(3815, 114, 'Levofloxacin ', '0', '0', NULL, NULL, NULL),
(3816, 115, 'Levothyroxine Sodium ', '0', '0', NULL, NULL, NULL),
(3817, 116, 'Lidocaine Hydrochloride ', '0', '0', NULL, NULL, NULL),
(3818, 117, 'Lithium Carbonate ', '0', '0', NULL, NULL, NULL),
(3819, 118, 'Loperamide ', '0', '0', NULL, NULL, NULL),
(3820, 119, 'Lopinavir ', '0', '0', NULL, NULL, NULL),
(3821, 119, 'Lopinavir ', 'Abacavir', ' Protease Inhibitors may decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(3822, 119, 'Lopinavir ', 'Acetohexamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3823, 119, 'Lopinavir ', 'ado-trastuzumab emtansine', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically~ strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.', NULL, NULL, NULL),
(3824, 119, 'Lopinavir ', 'Afatinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.', NULL, NULL, NULL),
(3825, 119, 'Lopinavir ', 'Alfuzosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.', NULL, NULL, NULL),
(3826, 119, 'Lopinavir ', 'Almotriptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.', NULL, NULL, NULL),
(3827, 119, 'Lopinavir ', 'Alogliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3828, 119, 'Lopinavir ', 'Alosetron', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.', NULL, NULL, NULL),
(3829, 119, 'Lopinavir ', 'Alprazolam', ' Protease Inhibitors may increase the serum concentration of ALPRAZolam.', NULL, NULL, NULL),
(3830, 119, 'Lopinavir ', 'Amiodarone', ' May enhance the QTc-prolonging effect of Amiodarone. Lopinavir may increase the serum concentration of Amiodarone. More specifically~ Lopinavir/Ritonavir may increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(3831, 119, 'Lopinavir ', 'Apixaban', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.', NULL, NULL, NULL),
(3832, 119, 'Lopinavir ', 'Aripiprazole', ' May enhance the adverse/toxic effect of Ritonavir. The risk of metabolic disturbances (e.g. hyperglycemia~ weight gain~ hyperlipidemia) may be increased. Ritonavir may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(3833, 119, 'Lopinavir ', 'Astemizole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole.', NULL, NULL, NULL),
(3834, 119, 'Lopinavir ', 'Atomoxetine', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.', NULL, NULL, NULL),
(3835, 119, 'Lopinavir ', 'Atorvastatin', ' Protease Inhibitors may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(3836, 119, 'Lopinavir ', 'Atovaquone', ' Ritonavir may decrease the serum concentration of Atovaquone.', NULL, NULL, NULL),
(3837, 119, 'Lopinavir ', 'Avanafil', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.', NULL, NULL, NULL),
(3838, 119, 'Lopinavir ', 'Axitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.', NULL, NULL, NULL),
(3839, 119, 'Lopinavir ', 'Batimastat', ' May increase the serum concentration of other Protease Inhibitors.', NULL, NULL, NULL),
(3840, 119, 'Lopinavir ', 'Boceprevir', ' May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir.', NULL, NULL, NULL),
(3841, 119, 'Lopinavir ', 'Bosentan', ' Bosentan may decrease the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Bosentan.', NULL, NULL, NULL),
(3842, 119, 'Lopinavir ', 'Bosutinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.', NULL, NULL, NULL),
(3843, 119, 'Lopinavir ', 'Brentuximab vedotin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.', NULL, NULL, NULL),
(3844, 119, 'Lopinavir ', 'Brinzolamide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.', NULL, NULL, NULL),
(3845, 119, 'Lopinavir ', 'Bupropion', ' May decrease the serum concentration of BuPROPion. Concentrations of the active metabolite~ hydroxybupropion~ may also be decreased.', NULL, NULL, NULL),
(3846, 119, 'Lopinavir ', 'Cabazitaxel', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.', NULL, NULL, NULL),
(3847, 119, 'Lopinavir ', 'Cabozantinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.', NULL, NULL, NULL),
(3848, 119, 'Lopinavir ', 'Canagliflozin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3849, 119, 'Lopinavir ', 'Carbamazepine', ' CarBAMazepine may decrease the serum concentration of Lopinavir.', NULL, NULL, NULL),
(3850, 119, 'Lopinavir ', 'Chlorpropamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3851, 119, 'Lopinavir ', 'Cilostazol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(3852, 119, 'Lopinavir ', 'Cisapride', ' Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.', NULL, NULL, NULL),
(3853, 119, 'Lopinavir ', 'Clarithromycin', ' Clarithromycin may enhance the QTc-prolonging effect of Lopinavir. Lopinavir may diminish the therapeutic effect of Clarithromycin. Specifically~ lopinavir may decrease the formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness. Clarithromycin may increase the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(3854, 119, 'Lopinavir ', 'Codeine', ' CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.', NULL, NULL, NULL),
(3855, 119, 'Lopinavir ', 'Colchicine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(3856, 119, 'Lopinavir ', 'Conivaptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.', NULL, NULL, NULL),
(3857, 119, 'Lopinavir ', 'Crizotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.', NULL, NULL, NULL),
(3858, 119, 'Lopinavir ', 'Cyclophosphamide', ' Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(3859, 119, 'Lopinavir ', 'Dabigatran etexilate', ' P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.', NULL, NULL, NULL),
(3860, 119, 'Lopinavir ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3861, 119, 'Lopinavir ', 'Dapoxetine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine.', NULL, NULL, NULL),
(3862, 119, 'Lopinavir ', 'Darunavir', ' May decrease the serum concentration of Darunavir. Darunavir may increase the serum concentration of lopinavir', NULL, NULL, NULL),
(3863, 119, 'Lopinavir ', 'Dasatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.', NULL, NULL, NULL),
(3864, 119, 'Lopinavir ', 'Deferasirox', ' Ritonavir may decrease the serum concentration of Deferasirox.', NULL, NULL, NULL),
(3865, 119, 'Lopinavir ', 'Delavirdine', ' May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.', NULL, NULL, NULL),
(3866, 119, 'Lopinavir ', 'Desogestrel', ' May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(3867, 119, 'Lopinavir ', 'Didanosine', ' May decrease the serum concentration of Didanosine. This interaction refers only to lopinavir/ritonavir oral solution~ which must be taken with food~ and is principally the result of a food-didanosine interaction.', NULL, NULL, NULL),
(3868, 119, 'Lopinavir ', 'Digoxin', ' Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(3869, 119, 'Lopinavir ', 'Disulfiram', ' May enhance the adverse/toxic effect of Disulfiram. Specifically~ the combination of lopinavir/ritonavir solution~ which contains 42% alcohol~ may result in a disulfiram-alcohol reaction if combined.', NULL, NULL, NULL),
(3870, 119, 'Lopinavir ', 'Domperidone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone.', NULL, NULL, NULL),
(3871, 119, 'Lopinavir ', 'Dronabinol', ' Ritonavir may increase the serum concentration of Dronabinol.', NULL, NULL, NULL),
(3872, 119, 'Lopinavir ', 'Dronedarone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.', NULL, NULL, NULL),
(3873, 119, 'Lopinavir ', 'Drospirenone', ' May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(3874, 119, 'Lopinavir ', 'Dutasteride', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.', NULL, NULL, NULL),
(3875, 119, 'Lopinavir ', 'Efavirenz', ' May decrease the serum concentration of Lopinavir.', NULL, NULL, NULL),
(3876, 119, 'Lopinavir ', 'Enfuvirtide', ' May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.', NULL, NULL, NULL),
(3877, 119, 'Lopinavir ', 'Enzalutamide', ' CYP2C8 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.', NULL, NULL, NULL),
(3878, 119, 'Lopinavir ', 'Eplerenone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.', NULL, NULL, NULL),
(3879, 119, 'Lopinavir ', 'Erlotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.', NULL, NULL, NULL),
(3880, 119, 'Lopinavir ', 'Estazolam', ' Ritonavir may increase the serum concentration of Estazolam.', NULL, NULL, NULL),
(3881, 119, 'Lopinavir ', 'Ethynodiol', ' May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(3882, 119, 'Lopinavir ', 'Etonogestrel', ' May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(3883, 119, 'Lopinavir ', 'Etravirine', ' Ritonavir may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(3884, 119, 'Lopinavir ', 'Everolimus', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.', NULL, NULL, NULL),
(3885, 119, 'Lopinavir ', 'Fentanyl', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(3886, 119, 'Lopinavir ', 'Fesoterodine', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.', NULL, NULL, NULL),
(3887, 119, 'Lopinavir ', 'Flecainide', ' Ritonavir may increase the serum concentration of Flecainide.', NULL, NULL, NULL),
(3888, 119, 'Lopinavir ', 'Fosamprenavir', ' Fosamprenavir may decrease the serum concentration of Lopinavir. Specifically~ amprenavir (the active metabolite of fosamprenavir) may decrease the serum concentration of lopinavir. Lopinavir may decrease the serum concentration of Fosamprenavir. Specifically~ lopinavir/ritonavir may decrease the serum concentration of amprenavir (the active metabolite of fosamprenavir)', NULL, NULL, NULL),
(3889, 119, 'Lopinavir ', 'Fosphenytoin', ' Fosphenytoin may decrease the serum concentration of Lopinavir. Lopinavir may decrease the serum concentration of Fosphenytoin.', NULL, NULL, NULL),
(3890, 119, 'Lopinavir ', 'Gliclazide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3891, 119, 'Lopinavir ', 'Glimepiride', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3892, 119, 'Lopinavir ', 'Gliquidone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3893, 119, 'Lopinavir ', 'Glyburide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3894, 119, 'Lopinavir ', 'Guanfacine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.', NULL, NULL, NULL),
(3895, 119, 'Lopinavir ', 'Halofantrine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.', NULL, NULL, NULL),
(3896, 119, 'Lopinavir ', 'Hydrocodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(3897, 119, 'Lopinavir ', 'Ifosfamide', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.', NULL, NULL, NULL),
(3898, 119, 'Lopinavir ', 'Imatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib.', NULL, NULL, NULL),
(3899, 119, 'Lopinavir ', 'Insulin Aspart', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3900, 119, 'Lopinavir ', 'Insulin Detemir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3901, 119, 'Lopinavir ', 'Insulin Glargine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3902, 119, 'Lopinavir ', 'Insulin Glulisine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3903, 119, 'Lopinavir ', 'Insulin Lispro', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3904, 119, 'Lopinavir ', 'Insulin Regular', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3905, 119, 'Lopinavir ', 'Insulin~ isophane', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3906, 119, 'Lopinavir ', 'Irinotecan', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan.', NULL, NULL, NULL),
(3907, 119, 'Lopinavir ', 'Isoflurophate', ' May increase the serum concentration of other Protease Inhibitors.', NULL, NULL, NULL),
(3908, 119, 'Lopinavir ', 'Itraconazole', ' May increase the serum concentration of Itraconazole.', NULL, NULL, NULL),
(3909, 119, 'Lopinavir ', 'Ivacaftor', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.', NULL, NULL, NULL),
(3910, 119, 'Lopinavir ', 'Ixabepilone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.', NULL, NULL, NULL),
(3911, 119, 'Lopinavir ', 'Lacosamide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide.', NULL, NULL, NULL),
(3912, 119, 'Lopinavir ', 'Lamotrigine', ' Ritonavir may decrease the serum concentration of LamoTRIgine.', NULL, NULL, NULL),
(3913, 119, 'Lopinavir ', 'Lapatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.', NULL, NULL, NULL),
(3914, 119, 'Lopinavir ', 'Ledipasvir', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(3915, 119, 'Lopinavir ', 'Lercanidipine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine.', NULL, NULL, NULL),
(3916, 119, 'Lopinavir ', 'Levobupivacaine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine.', NULL, NULL, NULL),
(3917, 119, 'Lopinavir ', 'Levomilnacipran', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.', NULL, NULL, NULL),
(3918, 119, 'Lopinavir ', 'Levonorgestrel', ' May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(3919, 119, 'Lopinavir ', 'Linagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3920, 119, 'Lopinavir ', 'Lomitapide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(3921, 119, 'Lopinavir ', 'Lovastatin', ' Protease Inhibitors may increase the serum concentration of Lovastatin.', NULL, NULL, NULL),
(3922, 119, 'Lopinavir ', 'Lurasidone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.', NULL, NULL, NULL),
(3923, 119, 'Lopinavir ', 'MACITENTAN', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan.', NULL, NULL, NULL),
(3924, 119, 'Lopinavir ', 'Maraviroc', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.', NULL, NULL, NULL),
(3925, 119, 'Lopinavir ', 'Medroxyprogesterone Acetate', ' May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(3926, 119, 'Lopinavir ', 'Mequitazine', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine.', NULL, NULL, NULL),
(3927, 119, 'Lopinavir ', 'Mestranol', ' May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(3928, 119, 'Lopinavir ', 'Metformin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3929, 119, 'Lopinavir ', 'Methadone', ' Methadone may enhance the QTc-prolonging effect of Lopinavir. Lopinavir may decrease the serum concentration of Methadone. More specifically~ the combination of Lopinavir and Ritonavir may decrease Methadone serum concentrations.', NULL, NULL, NULL),
(3930, 119, 'Lopinavir ', 'Methylprednisolone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(3931, 119, 'Lopinavir ', 'Metoprolol', ' CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.', NULL, NULL, NULL),
(3932, 119, 'Lopinavir ', 'Midazolam', ' Protease Inhibitors may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(3933, 119, 'Lopinavir ', 'Mifepristone', ' May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.', NULL, NULL, NULL),
(3934, 119, 'Lopinavir ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3935, 119, 'Lopinavir ', 'Nebivolol', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.', NULL, NULL, NULL),
(3936, 119, 'Lopinavir ', 'Nefazodone', ' Protease Inhibitors may increase the serum concentration of Nefazodone.', NULL, NULL, NULL),
(3937, 119, 'Lopinavir ', 'Nelfinavir', ' May increase the serum concentration of Nelfinavir. Concentrations of the nelfinavir M8 metabolite may also be increased. Nelfinavir may decrease the serum concentration of Lopinavir.', NULL, NULL, NULL),
(3938, 119, 'Lopinavir ', 'Nevirapine', ' Nevirapine may decrease the serum concentration of Lopinavir.', NULL, NULL, NULL),
(3939, 119, 'Lopinavir ', 'Nilotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.', NULL, NULL, NULL),
(3940, 119, 'Lopinavir ', 'Nisoldipine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.', NULL, NULL, NULL),
(3941, 119, 'Lopinavir ', 'Norelgestromin', ' May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(3942, 119, 'Lopinavir ', 'Norethindrone', ' May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(3943, 119, 'Lopinavir ', 'Norgestimate', ' May decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).', NULL, NULL, NULL),
(3944, 119, 'Lopinavir ', 'Ospemifene', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.', NULL, NULL, NULL),
(3945, 119, 'Lopinavir ', 'Oxybutynin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin.', NULL, NULL, NULL),
(3946, 119, 'Lopinavir ', 'Oxycodone', ' CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased.', NULL, NULL, NULL),
(3947, 119, 'Lopinavir ', 'Paricalcitol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.', NULL, NULL, NULL),
(3948, 119, 'Lopinavir ', 'Pazopanib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(3949, 119, 'Lopinavir ', 'Phenobarbital', ' PHENobarbital may decrease the serum concentration of Lopinavir.', NULL, NULL, NULL),
(3950, 119, 'Lopinavir ', 'Phenytoin', ' May decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Lopinavir.', NULL, NULL, NULL),
(3951, 119, 'Lopinavir ', 'Pimecrolimus', ' CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.', NULL, NULL, NULL),
(3952, 119, 'Lopinavir ', 'Pimozide', ' Protease Inhibitors may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(3953, 119, 'Lopinavir ', 'Pioglitazone', ' CYP2C8 Inhibitors (Strong) may increase the serum concentration of Pioglitazone.', NULL, NULL, NULL),
(3954, 119, 'Lopinavir ', 'Ponatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.', NULL, NULL, NULL),
(3955, 119, 'Lopinavir ', 'Pranlukast', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast.', NULL, NULL, NULL),
(3956, 119, 'Lopinavir ', 'Prasugrel', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.', NULL, NULL, NULL),
(3957, 119, 'Lopinavir ', 'Prednisone', ' Ritonavir may increase the serum concentration of PredniSONE.', NULL, NULL, NULL),
(3958, 119, 'Lopinavir ', 'Proguanil', ' Ritonavir may decrease the serum concentration of Proguanil.', NULL, NULL, NULL),
(3959, 119, 'Lopinavir ', 'Propafenone', ' Ritonavir may increase the serum concentration of Propafenone.', NULL, NULL, NULL),
(3960, 119, 'Lopinavir ', 'prucalopride', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.', NULL, NULL, NULL),
(3961, 119, 'Lopinavir ', 'Quinidine', ' May enhance the QTc-prolonging effect of QuiNIDine. Lopinavir may increase the serum concentration of QuiNIDine. Specifically~ lopinavir/ritonavir may increase the serum concentration of quinidine.', NULL, NULL, NULL),
(3962, 119, 'Lopinavir ', 'Quinine', ' May decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir. The individual contributions of lopinavir and ritonavir to this effect are unclear.', NULL, NULL, NULL),
(3963, 119, 'Lopinavir ', 'Ranolazine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.', NULL, NULL, NULL),
(3964, 119, 'Lopinavir ', 'Regorafenib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.', NULL, NULL, NULL),
(3965, 119, 'Lopinavir ', 'Repaglinide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3966, 119, 'Lopinavir ', 'Retapamulin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.', NULL, NULL, NULL),
(3967, 119, 'Lopinavir ', 'Rifabutin', ' Lopinavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Lopinavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Lopinavir.', NULL, NULL, NULL),
(3968, 119, 'Lopinavir ', 'Rifampicin', ' Rifampin may enhance the adverse/toxic effect of Lopinavir. Specifically~ the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Lopinavir.', NULL, NULL, NULL),
(3969, 119, 'Lopinavir ', 'Rifaximin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.', NULL, NULL, NULL),
(3970, 119, 'Lopinavir ', 'Rilpivirine', ' Ritonavir may increase the serum concentration of Rilpivirine.', NULL, NULL, NULL),
(3971, 119, 'Lopinavir ', 'Riociguat', ' Protease Inhibitors may increase the serum concentration of Riociguat.', NULL, NULL, NULL),
(3972, 119, 'Lopinavir ', 'Rivaroxaban', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. For clarithromycin~ refer to more specific clarithromycin-rivaroxaban monograph recommendations.', NULL, NULL, NULL),
(3973, 119, 'Lopinavir ', 'Rosuvastatin', ' Protease Inhibitors may increase the serum concentration of Rosuvastatin.', NULL, NULL, NULL),
(3974, 119, 'Lopinavir ', 'Ruxolitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.', NULL, NULL, NULL),
(3975, 119, 'Lopinavir ', 'Salmeterol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.', NULL, NULL, NULL),
(3976, 119, 'Lopinavir ', 'Saquinavir', ' Saquinavir may enhance the QTc-prolonging effect of Lopinavir.', NULL, NULL, NULL),
(3977, 119, 'Lopinavir ', 'Saxagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3978, 119, 'Lopinavir ', 'Sildenafil', ' Protease Inhibitors may increase the serum concentration of Sildenafil.', NULL, NULL, NULL),
(3979, 119, 'Lopinavir ', 'Silodosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.', NULL, NULL, NULL),
(3980, 119, 'Lopinavir ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3981, 119, 'Lopinavir ', 'Simeprevir', ' May increase the serum concentration of other Protease Inhibitors.', NULL, NULL, NULL),
(3982, 119, 'Lopinavir ', 'Simvastatin', ' Protease Inhibitors may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(3983, 119, 'Lopinavir ', 'Suvorexant', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant.', NULL, NULL, NULL),
(3984, 119, 'Lopinavir ', 'Tadalafil', ' Ritonavir may increase the serum concentration of Tadalafil.', NULL, NULL, NULL),
(3985, 119, 'Lopinavir ', 'Tamoxifen', ' CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.', NULL, NULL, NULL),
(3986, 119, 'Lopinavir ', 'Tamsulosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.', NULL, NULL, NULL),
(3987, 119, 'Lopinavir ', 'Telaprevir', ' Lopinavir may decrease the serum concentration of Telaprevir.', NULL, NULL, NULL),
(3988, 119, 'Lopinavir ', 'Temsirolimus', ' Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus~ the active metabolite~ may be increased~ likely due to inhibition of CYP-mediated metabolism.', NULL, NULL, NULL),
(3989, 119, 'Lopinavir ', 'Tenofovir', ' May enhance the nephrotoxic effect of Tenofovir. Lopinavir may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(3990, 119, 'Lopinavir ', 'Terfenadine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Terfenadine.', NULL, NULL, NULL),
(3991, 119, 'Lopinavir ', 'Thioridazine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(3992, 119, 'Lopinavir ', 'Ticagrelor', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.', NULL, NULL, NULL),
(3993, 119, 'Lopinavir ', 'Tipranavir', ' May decrease the serum concentration of Protease Inhibitors.', NULL, NULL, NULL),
(3994, 119, 'Lopinavir ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(3995, 119, 'Lopinavir ', 'Tofacitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.', NULL, NULL, NULL),
(3996, 119, 'Lopinavir ', 'Tolbutamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(3997, 119, 'Lopinavir ', 'Tolterodine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.', NULL, NULL, NULL),
(3998, 119, 'Lopinavir ', 'Tolvaptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.', NULL, NULL, NULL),
(3999, 119, 'Lopinavir ', 'Topotecan', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.', NULL, NULL, NULL),
(4000, 119, 'Lopinavir ', 'Toremifene', ' CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.', NULL, NULL, NULL),
(4001, 119, 'Lopinavir ', 'Trabectedin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin.', NULL, NULL, NULL),
(4002, 119, 'Lopinavir ', 'Trazodone', ' Lopinavir may enhance the QTc-prolonging effect of TraZODone. Lopinavir may increase the serum concentration of TraZODone.', NULL, NULL, NULL),
(4003, 119, 'Lopinavir ', 'Treprostinil', ' CYP2C8 Inhibitors (Strong) may increase the serum concentration of Treprostinil.', NULL, NULL, NULL),
(4004, 119, 'Lopinavir ', 'Triazolam', ' Protease Inhibitors may increase the serum concentration of Triazolam.', NULL, NULL, NULL),
(4005, 119, 'Lopinavir ', 'Ulipristal', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.', NULL, NULL, NULL),
(4006, 119, 'Lopinavir ', 'Vardenafil', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.', NULL, NULL, NULL),
(4007, 119, 'Lopinavir ', 'Vemurafenib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.', NULL, NULL, NULL),
(4008, 119, 'Lopinavir ', 'Vilazodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.', NULL, NULL, NULL),
(4009, 119, 'Lopinavir ', 'Vildagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4010, 119, 'Lopinavir ', 'Vinblastine', ' May increase the serum concentration of VinBLAStine.', NULL, NULL, NULL),
(4011, 119, 'Lopinavir ', 'Vincristine', ' May increase the serum concentration of VinCRIStine.', NULL, NULL, NULL),
(4012, 119, 'Lopinavir ', 'Vorapaxar', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar.', NULL, NULL, NULL),
(4013, 119, 'Lopinavir ', 'Voriconazole', ' May decrease the serum concentration of Voriconazole.', NULL, NULL, NULL),
(4014, 119, 'Lopinavir ', 'Warfarin', ' Lopinavir may decrease the serum concentration of Warfarin.', NULL, NULL, NULL),
(4015, 119, 'Lopinavir ', 'Zidovudine', ' Protease Inhibitors may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(4016, 119, 'Lopinavir ', 'Zopiclone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.', NULL, NULL, NULL),
(4017, 120, 'Lorazepam ', '0', '0', NULL, NULL, NULL),
(4018, 120, 'Lorazepam ', 'Aminophylline', ' Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.', NULL, NULL, NULL),
(4019, 120, 'Lorazepam ', 'Buprenorphine', ' CNS Depressants may enhance the CNS depressant effect of Buprenorphine.', NULL, NULL, NULL),
(4020, 120, 'Lorazepam ', 'Clozapine', ' Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.', NULL, NULL, NULL),
(4021, 120, 'Lorazepam ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4022, 120, 'Lorazepam ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4023, 120, 'Lorazepam ', 'Droperidol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4024, 120, 'Lorazepam ', 'Fosphenytoin', ' Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.', NULL, NULL, NULL),
(4025, 120, 'Lorazepam ', 'Gamma Hydroxybutyric Acid', ' May enhance the CNS depressant effect of Sodium Oxybate.', NULL, NULL, NULL),
(4026, 120, 'Lorazepam ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(4027, 120, 'Lorazepam ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4028, 120, 'Lorazepam ', 'Loxapine', ' May enhance the adverse/toxic effect of LORazepam. Specifically~ prolonged stupor~ respiratory depression~ and/or hypotension.', NULL, NULL, NULL),
(4029, 120, 'Lorazepam ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4030, 120, 'Lorazepam ', 'Methadone', ' Benzodiazepines may enhance the CNS depressant effect of Methadone.', NULL, NULL, NULL),
(4031, 120, 'Lorazepam ', 'Methotrimeprazine', ' CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4032, 120, 'Lorazepam ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(4033, 120, 'Lorazepam ', 'Mirtazapine', ' CNS Depressants may enhance the CNS depressant effect of Mirtazapine.', NULL, NULL, NULL),
(4034, 120, 'Lorazepam ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4035, 120, 'Lorazepam ', 'Olanzapine', ' May enhance the adverse/toxic effect of Benzodiazepines.', NULL, NULL, NULL),
(4036, 120, 'Lorazepam ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(4037, 120, 'Lorazepam ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4038, 120, 'Lorazepam ', 'Phenytoin', ' Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.', NULL, NULL, NULL),
(4039, 120, 'Lorazepam ', 'Pramipexole', ' CNS Depressants may enhance the sedative effect of Pramipexole.', NULL, NULL, NULL),
(4040, 120, 'Lorazepam ', 'Probenecid', ' May increase the serum concentration of LORazepam.', NULL, NULL, NULL),
(4041, 120, 'Lorazepam ', 'Ropinirole', ' CNS Depressants may enhance the sedative effect of ROPINIRole.', NULL, NULL, NULL),
(4042, 120, 'Lorazepam ', 'Rotigotine', ' CNS Depressants may enhance the sedative effect of Rotigotine.', NULL, NULL, NULL),
(4043, 120, 'Lorazepam ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(4044, 120, 'Lorazepam ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(4045, 120, 'Lorazepam ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4046, 120, 'Lorazepam ', 'Teduglutide', ' May increase the serum concentration of Benzodiazepines.', NULL, NULL, NULL),
(4047, 120, 'Lorazepam ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(4048, 120, 'Lorazepam ', 'Theophylline', ' Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.', NULL, NULL, NULL),
(4049, 120, 'Lorazepam ', 'Valproic Acid', ' Valproic Acid and Derivatives may increase the serum concentration of LORazepam.', NULL, NULL, NULL),
(4050, 120, 'Lorazepam ', 'Yohimbine', ' May diminish the therapeutic effect of Antianxiety Agents.', NULL, NULL, NULL),
(4051, 120, 'Lorazepam ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(4052, 121, 'Mebendazole ', '0', '0', NULL, NULL, NULL),
(4053, 121, 'Mebendazole ', 'Carbamazepine', ' CarBAMazepine may decrease the serum concentration of Mebendazole.', NULL, NULL, NULL),
(4054, 121, 'Mebendazole ', 'Cimetidine', ' Cimetidine may increase the serum concentration of Mebendazole.', NULL, NULL, NULL),
(4055, 121, 'Mebendazole ', 'Fosphenytoin', ' May decrease the serum concentration of Mebendazole.', NULL, NULL, NULL),
(4056, 121, 'Mebendazole ', 'Phenytoin', ' Phenytoin may decrease the serum concentration of Mebendazole.', NULL, NULL, NULL),
(4057, 122, 'Meclizine Hydrochloride ', '0', '0', NULL, NULL, NULL),
(4058, 123, 'Mefloquine Hydrochloride ', '0', '0', NULL, NULL, NULL),
(4059, 124, 'Melphalan ', '0', '0', NULL, NULL, NULL),
(4060, 124, 'Melphalan ', 'Carmustine', ' May enhance the adverse/toxic effect of Carmustine. Specifically~ melphalan may sensitize patients to carmustine lung toxicity.', NULL, NULL, NULL),
(4061, 124, 'Melphalan ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(4062, 124, 'Melphalan ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(4063, 124, 'Melphalan ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(4064, 124, 'Melphalan ', 'Nalidixic Acid', ' May enhance the adverse/toxic effect of Melphalan. Necrotic enterocolitis has been reported in pediatric patients.', NULL, NULL, NULL),
(4065, 124, 'Melphalan ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(4066, 124, 'Melphalan ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(4067, 124, 'Melphalan ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(4068, 124, 'Melphalan ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(4069, 124, 'Melphalan ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(4070, 124, 'Melphalan ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(4071, 125, 'Mercaptopurine ', '0', '0', NULL, NULL, NULL),
(4072, 125, 'Mercaptopurine ', 'Acenocoumarol', ' May diminish the anticoagulant effect of Vitamin K Antagonists.', NULL, NULL, NULL),
(4073, 125, 'Mercaptopurine ', 'Allopurinol', ' Allopurinol may increase the serum concentration of Mercaptopurine. Allopurinol may also promote formation of active thioguanine nucleotides.', NULL, NULL, NULL),
(4074, 125, 'Mercaptopurine ', 'Azathioprine', ' AzaTHIOprine may enhance the myelosuppressive effect of Mercaptopurine.', NULL, NULL, NULL),
(4075, 125, 'Mercaptopurine ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(4076, 125, 'Mercaptopurine ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(4077, 125, 'Mercaptopurine ', 'Febuxostat', ' May increase the serum concentration of Mercaptopurine.', NULL, NULL, NULL),
(4078, 125, 'Mercaptopurine ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(4079, 125, 'Mercaptopurine ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(4080, 125, 'Mercaptopurine ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(4081, 125, 'Mercaptopurine ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(4082, 125, 'Mercaptopurine ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(4083, 125, 'Mercaptopurine ', 'Sulfamethoxazole', ' Sulfamethoxazole may enhance the myelosuppressive effect of Mercaptopurine.', NULL, NULL, NULL),
(4084, 125, 'Mercaptopurine ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(4085, 125, 'Mercaptopurine ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(4086, 125, 'Mercaptopurine ', 'Trimethoprim', ' Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine.', NULL, NULL, NULL),
(4087, 126, 'Metformin Hydrochloride ', '0', '0', NULL, NULL, NULL),
(4088, 127, 'Methotrexate Sodium ', '0', '0', NULL, NULL, NULL),
(4089, 128, 'Methyldopa ', '0', '0', NULL, NULL, NULL),
(4090, 128, 'Methyldopa ', 'Alfuzosin', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(4091, 128, 'Methyldopa ', 'Amifostine', ' Antihypertensives may enhance the hypotensive effect of Amifostine.', NULL, NULL, NULL),
(4092, 128, 'Methyldopa ', 'Bretylium', ' May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.', NULL, NULL, NULL),
(4093, 128, 'Methyldopa ', 'Butabarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(4094, 128, 'Methyldopa ', 'Butethal', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(4095, 128, 'Methyldopa ', 'Diazoxide', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(4096, 128, 'Methyldopa ', 'Duloxetine', ' Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.', NULL, NULL, NULL),
(4097, 128, 'Methyldopa ', 'Heptabarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(4098, 128, 'Methyldopa ', 'Hexobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(4099, 128, 'Methyldopa ', 'Iobenguane', ' May diminish the therapeutic effect of Iobenguane I 123.', NULL, NULL, NULL),
(4100, 128, 'Methyldopa ', 'Isocarboxazid', ' MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.', NULL, NULL, NULL),
(4101, 128, 'Methyldopa ', 'Lacosamide', ' Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.', NULL, NULL, NULL),
(4102, 128, 'Methyldopa ', 'Linezolid', ' MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.', NULL, NULL, NULL),
(4103, 128, 'Methyldopa ', 'Lithium', ' Methyldopa may enhance the adverse/toxic effect of Lithium. This may occur without notable changes in serum lithium concentrations.', NULL, NULL, NULL),
(4104, 128, 'Methyldopa ', 'Methohexital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(4105, 128, 'Methyldopa ', 'Methylphenidate', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(4106, 128, 'Methyldopa ', 'Mirtazapine', ' May diminish the antihypertensive effect of Alpha2-Agonists.', NULL, NULL, NULL),
(4107, 128, 'Methyldopa ', 'Moclobemide', ' MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.', NULL, NULL, NULL),
(4108, 128, 'Methyldopa ', 'Obinutuzumab', ' Antihypertensives may enhance the hypotensive effect of Obinutuzumab.', NULL, NULL, NULL),
(4109, 128, 'Methyldopa ', 'Pentobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(4110, 128, 'Methyldopa ', 'Pentoxifylline', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(4111, 128, 'Methyldopa ', 'Phenelzine', ' MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.', NULL, NULL, NULL),
(4112, 128, 'Methyldopa ', 'Primidone', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(4113, 128, 'Methyldopa ', 'Procarbazine', ' MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.', NULL, NULL, NULL),
(4114, 128, 'Methyldopa ', 'Rasagiline', ' MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.', NULL, NULL, NULL),
(4115, 128, 'Methyldopa ', 'Risperidone', ' Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.', NULL, NULL, NULL),
(4116, 128, 'Methyldopa ', 'Rituximab', ' Antihypertensives may enhance the hypotensive effect of RiTUXimab.', NULL, NULL, NULL),
(4117, 128, 'Methyldopa ', 'Ruxolitinib', ' May enhance the bradycardic effect of Bradycardia-Causing Agents.', NULL, NULL, NULL),
(4118, 128, 'Methyldopa ', 'Secobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(4119, 128, 'Methyldopa ', 'Selegiline', ' MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.', NULL, NULL, NULL),
(4120, 128, 'Methyldopa ', 'Tadalafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(4121, 128, 'Methyldopa ', 'Tedizolid Phosphate', ' MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.', NULL, NULL, NULL),
(4122, 128, 'Methyldopa ', 'Tofacitinib', ' May enhance the bradycardic effect of Bradycardia-Causing Agents.', NULL, NULL, NULL),
(4123, 128, 'Methyldopa ', 'Tranylcypromine', ' MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.', NULL, NULL, NULL),
(4124, 128, 'Methyldopa ', 'Vardenafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(4125, 128, 'Methyldopa ', 'Yohimbine', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(4126, 129, 'Methylprednisolone ', '0', '0', NULL, NULL, NULL),
(4127, 129, 'Methylprednisolone ', 'Acetohexamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4128, 129, 'Methylprednisolone ', 'Acetylsalicylic acid', ' May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.', NULL, NULL, NULL),
(4129, 129, 'Methylprednisolone ', 'Aldesleukin', ' Corticosteroids may diminish the antineoplastic effect of Aldesleukin.', NULL, NULL, NULL),
(4130, 129, 'Methylprednisolone ', 'Alogliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4131, 129, 'Methylprednisolone ', 'Aluminum hydroxide', ' May decrease the bioavailability of Corticosteroids (Oral).', NULL, NULL, NULL),
(4132, 129, 'Methylprednisolone ', 'Aminoglutethimide', ' May increase the metabolism of Corticosteroids (Systemic).', NULL, NULL, NULL),
(4133, 129, 'Methylprednisolone ', 'Amphotericin B', ' Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.', NULL, NULL, NULL),
(4134, 129, 'Methylprednisolone ', 'Aprepitant', ' May increase the serum concentration of Corticosteroids (Systemic).', NULL, NULL, NULL),
(4135, 129, 'Methylprednisolone ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(4136, 129, 'Methylprednisolone ', 'Atazanavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4137, 129, 'Methylprednisolone ', 'Boceprevir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4138, 129, 'Methylprednisolone ', 'Calcitriol', ' Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.', NULL, NULL, NULL),
(4139, 129, 'Methylprednisolone ', 'Calcium carbonate', ' May decrease the bioavailability of Corticosteroids (Oral).', NULL, NULL, NULL),
(4140, 129, 'Methylprednisolone ', 'Canagliflozin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4141, 129, 'Methylprednisolone ', 'Carbamazepine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4142, 129, 'Methylprednisolone ', 'Chlorpropamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4143, 129, 'Methylprednisolone ', 'Clarithromycin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4144, 129, 'Methylprednisolone ', 'Colesevelam', ' May decrease the absorption of Corticosteroids (Oral).', NULL, NULL, NULL),
(4145, 129, 'Methylprednisolone ', 'Conivaptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4146, 129, 'Methylprednisolone ', 'Darunavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4147, 129, 'Methylprednisolone ', 'Deferasirox', ' Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically~ the risk for GI ulceration/irritation or GI bleeding may be increased.', NULL, NULL, NULL),
(4148, 129, 'Methylprednisolone ', 'Delavirdine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4149, 129, 'Methylprednisolone ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(4150, 129, 'Methylprednisolone ', 'Dihydrotestosterone', ' Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens.', NULL, NULL, NULL),
(4151, 129, 'Methylprednisolone ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(4152, 129, 'Methylprednisolone ', 'Enzalutamide', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4153, 129, 'Methylprednisolone ', 'Fosamprenavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4154, 129, 'Methylprednisolone ', 'Fosaprepitant', ' May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.', NULL, NULL, NULL),
(4155, 129, 'Methylprednisolone ', 'Fosphenytoin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4156, 129, 'Methylprednisolone ', 'Gliclazide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4157, 129, 'Methylprednisolone ', 'Glimepiride', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4158, 129, 'Methylprednisolone ', 'Gliquidone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4159, 129, 'Methylprednisolone ', 'Glyburide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4160, 129, 'Methylprednisolone ', 'Hyaluronidase', ' Corticosteroids may diminish the therapeutic effect of Hyaluronidase.', NULL, NULL, NULL),
(4161, 129, 'Methylprednisolone ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(4162, 129, 'Methylprednisolone ', 'Indacaterol', ' May enhance the hypokalemic effect of Corticosteroids (Systemic).', NULL, NULL, NULL),
(4163, 129, 'Methylprednisolone ', 'Indinavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4164, 129, 'Methylprednisolone ', 'Insulin Aspart', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4165, 129, 'Methylprednisolone ', 'Insulin Detemir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4166, 129, 'Methylprednisolone ', 'Insulin Glargine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4167, 129, 'Methylprednisolone ', 'Insulin Glulisine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4168, 129, 'Methylprednisolone ', 'Insulin Lispro', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4169, 129, 'Methylprednisolone ', 'Insulin Regular', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4170, 129, 'Methylprednisolone ', 'Insulin~ isophane', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4171, 129, 'Methylprednisolone ', 'Isoniazid', ' Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.', NULL, NULL, NULL),
(4172, 129, 'Methylprednisolone ', 'Itraconazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4173, 129, 'Methylprednisolone ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(4174, 129, 'Methylprednisolone ', 'Linagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4175, 129, 'Methylprednisolone ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(4176, 129, 'Methylprednisolone ', 'Lopinavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4177, 129, 'Methylprednisolone ', 'Magnesium oxide', ' May decrease the bioavailability of Corticosteroids (Oral).', NULL, NULL, NULL),
(4178, 129, 'Methylprednisolone ', 'Metformin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4179, 129, 'Methylprednisolone ', 'Mifepristone', ' May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic).', NULL, NULL, NULL),
(4180, 129, 'Methylprednisolone ', 'Mitotane', ' May decrease the serum concentration of Corticosteroids (Systemic).', NULL, NULL, NULL),
(4181, 129, 'Methylprednisolone ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(4182, 129, 'Methylprednisolone ', 'Nefazodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4183, 129, 'Methylprednisolone ', 'Nelfinavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4184, 129, 'Methylprednisolone ', 'Oxandrolone', ' Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens.', NULL, NULL, NULL),
(4185, 129, 'Methylprednisolone ', 'Phenobarbital', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4186, 129, 'Methylprednisolone ', 'Phenytoin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4187, 129, 'Methylprednisolone ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(4188, 129, 'Methylprednisolone ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(4189, 129, 'Methylprednisolone ', 'Posaconazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4190, 129, 'Methylprednisolone ', 'Primidone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4191, 129, 'Methylprednisolone ', 'Repaglinide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4192, 129, 'Methylprednisolone ', 'Rifampicin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4193, 129, 'Methylprednisolone ', 'Rifapentine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4194, 129, 'Methylprednisolone ', 'Ritonavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4195, 129, 'Methylprednisolone ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(4196, 129, 'Methylprednisolone ', 'Salicylate-sodium', ' May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.', NULL, NULL, NULL),
(4197, 129, 'Methylprednisolone ', 'Saquinavir', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4198, 129, 'Methylprednisolone ', 'Saxagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4199, 129, 'Methylprednisolone ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(4200, 129, 'Methylprednisolone ', 'Telaprevir', ' May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir.', NULL, NULL, NULL),
(4201, 129, 'Methylprednisolone ', 'Telithromycin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4202, 129, 'Methylprednisolone ', 'Testosterone', ' Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens.', NULL, NULL, NULL),
(4203, 129, 'Methylprednisolone ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(4204, 129, 'Methylprednisolone ', 'Tolbutamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4205, 129, 'Methylprednisolone ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(4206, 129, 'Methylprednisolone ', 'Vildagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(4207, 129, 'Methylprednisolone ', 'Voriconazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4208, 129, 'Methylprednisolone ', 'Warfarin', ' Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.', NULL, NULL, NULL),
(4209, 130, 'Metoclopramide Hydrochloride ', '0', '0', NULL, NULL, NULL),
(4210, 131, 'Metronidazole ', '0', '0', NULL, NULL, NULL),
(4211, 132, 'Midazolam ', '0', '0', NULL, NULL, NULL),
(4212, 132, 'Midazolam ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4213, 132, 'Midazolam ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(4214, 132, 'Midazolam ', 'Atazanavir', ' Protease Inhibitors may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4215, 132, 'Midazolam ', 'Atorvastatin', ' May increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4216, 132, 'Midazolam ', 'Batimastat', ' May increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4217, 132, 'Midazolam ', 'Boceprevir', ' May increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4218, 132, 'Midazolam ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4219, 132, 'Midazolam ', 'Buprenorphine', ' CNS Depressants may enhance the CNS depressant effect of Buprenorphine.', NULL, NULL, NULL),
(4220, 132, 'Midazolam ', 'Clarithromycin', ' Macrolide Antibiotics may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4221, 132, 'Midazolam ', 'Clozapine', ' Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.', NULL, NULL, NULL),
(4222, 132, 'Midazolam ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4223, 132, 'Midazolam ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4224, 132, 'Midazolam ', 'Darunavir', ' Protease Inhibitors may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4225, 132, 'Midazolam ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4226, 132, 'Midazolam ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4227, 132, 'Midazolam ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(4228, 132, 'Midazolam ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4229, 132, 'Midazolam ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4230, 132, 'Midazolam ', 'Droperidol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4231, 132, 'Midazolam ', 'Fosamprenavir', ' Protease Inhibitors may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4232, 132, 'Midazolam ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4233, 132, 'Midazolam ', 'Ginkgo biloba', ' May decrease the serum concentration of Midazolam.', NULL, NULL, NULL),
(4234, 132, 'Midazolam ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(4235, 132, 'Midazolam ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4236, 132, 'Midazolam ', 'Indinavir', ' Protease Inhibitors may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4237, 132, 'Midazolam ', 'Isoflurophate', ' May increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4238, 132, 'Midazolam ', 'Itraconazole', ' May increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4239, 132, 'Midazolam ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4240, 132, 'Midazolam ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(4241, 132, 'Midazolam ', 'Lopinavir', ' Protease Inhibitors may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4242, 132, 'Midazolam ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4243, 132, 'Midazolam ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4244, 132, 'Midazolam ', 'Methadone', ' Benzodiazepines may enhance the CNS depressant effect of Methadone.', NULL, NULL, NULL),
(4245, 132, 'Midazolam ', 'Methotrimeprazine', ' CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4246, 132, 'Midazolam ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(4247, 132, 'Midazolam ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4248, 132, 'Midazolam ', 'Mirtazapine', ' CNS Depressants may enhance the CNS depressant effect of Mirtazapine.', NULL, NULL, NULL),
(4249, 132, 'Midazolam ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4250, 132, 'Midazolam ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4251, 132, 'Midazolam ', 'Nelfinavir', ' Protease Inhibitors may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4252, 132, 'Midazolam ', 'Olanzapine', ' May enhance the adverse/toxic effect of Benzodiazepines.', NULL, NULL, NULL),
(4253, 132, 'Midazolam ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(4254, 132, 'Midazolam ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4255, 132, 'Midazolam ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(4256, 132, 'Midazolam ', 'Pramipexole', ' CNS Depressants may enhance the sedative effect of Pramipexole.', NULL, NULL, NULL),
(4257, 132, 'Midazolam ', 'Propofol', ' Midazolam may increase the serum concentration of Propofol. Propofol may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4258, 132, 'Midazolam ', 'Ritonavir', ' Protease Inhibitors may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4259, 132, 'Midazolam ', 'Ropinirole', ' CNS Depressants may enhance the sedative effect of ROPINIRole.', NULL, NULL, NULL),
(4260, 132, 'Midazolam ', 'Rotigotine', ' CNS Depressants may enhance the sedative effect of Rotigotine.', NULL, NULL, NULL),
(4261, 132, 'Midazolam ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(4262, 132, 'Midazolam ', 'Saquinavir', ' Protease Inhibitors may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4263, 132, 'Midazolam ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4264, 132, 'Midazolam ', 'Simeprevir', ' May increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4265, 132, 'Midazolam ', 'Sulfisoxazole', ' Macrolide Antibiotics may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4266, 132, 'Midazolam ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(4267, 132, 'Midazolam ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4268, 132, 'Midazolam ', 'Teduglutide', ' May increase the serum concentration of Benzodiazepines.', NULL, NULL, NULL),
(4269, 132, 'Midazolam ', 'Telaprevir', ' May increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4270, 132, 'Midazolam ', 'Telithromycin', ' Macrolide Antibiotics may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4271, 132, 'Midazolam ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(4272, 132, 'Midazolam ', 'Tipranavir', ' Protease Inhibitors may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(4273, 132, 'Midazolam ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4274, 132, 'Midazolam ', 'Yohimbine', ' May diminish the therapeutic effect of Antianxiety Agents.', NULL, NULL, NULL),
(4275, 132, 'Midazolam ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(4276, 133, 'Morphine ', '0', '0', NULL, NULL, NULL),
(4277, 133, 'Morphine ', 'Acetazolamide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4278, 133, 'Morphine ', 'Alvimopan', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e.~ more than 7 days) opiates prior to alvimopan initiation.', NULL, NULL, NULL),
(4279, 133, 'Morphine ', 'Amiloride', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4280, 133, 'Morphine ', 'Ammonium chloride', ' May increase the excretion of Analgesics (Opioid).', NULL, NULL, NULL),
(4281, 133, 'Morphine ', 'Amphetamine', ' May enhance the analgesic effect of Analgesics (Opioid).', NULL, NULL, NULL),
(4282, 133, 'Morphine ', 'Bendroflumethiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4283, 133, 'Morphine ', 'Bumetanide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4284, 133, 'Morphine ', 'Cathinone', ' May enhance the analgesic effect of Analgesics (Opioid).', NULL, NULL, NULL),
(4285, 133, 'Morphine ', 'Chlorothiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4286, 133, 'Morphine ', 'Chlorthalidone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4287, 133, 'Morphine ', 'Clopidogrel', ' Morphine (Liposomal) may diminish the antiplatelet effect of Clopidogrel. Morphine (Liposomal) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.', NULL, NULL, NULL),
(4288, 133, 'Morphine ', 'Cyclothiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4289, 133, 'Morphine ', 'Desmopressin', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.', NULL, NULL, NULL),
(4290, 133, 'Morphine ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4291, 133, 'Morphine ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4292, 133, 'Morphine ', 'Droperidol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4293, 133, 'Morphine ', 'Ethacrynic acid', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4294, 133, 'Morphine ', 'Ethoxzolamide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4295, 133, 'Morphine ', 'Furosemide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4296, 133, 'Morphine ', 'Hydrochlorothiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4297, 133, 'Morphine ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(4298, 133, 'Morphine ', 'Hydroflumethiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4299, 133, 'Morphine ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4300, 133, 'Morphine ', 'Indapamide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4301, 133, 'Morphine ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4302, 133, 'Morphine ', 'Methotrimeprazine', ' CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4303, 133, 'Morphine ', 'Metolazone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4304, 133, 'Morphine ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(4305, 133, 'Morphine ', 'Mirtazapine', ' CNS Depressants may enhance the CNS depressant effect of Mirtazapine.', NULL, NULL, NULL),
(4306, 133, 'Morphine ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4307, 133, 'Morphine ', 'Naltrexone', ' May diminish the therapeutic effect of Analgesics (Opioid).', NULL, NULL, NULL),
(4308, 133, 'Morphine ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(4309, 133, 'Morphine ', 'Pegvisomant', ' Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.', NULL, NULL, NULL),
(4310, 133, 'Morphine ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4311, 133, 'Morphine ', 'Pramipexole', ' CNS Depressants may enhance the sedative effect of Pramipexole.', NULL, NULL, NULL),
(4312, 133, 'Morphine ', 'Ropinirole', ' CNS Depressants may enhance the sedative effect of ROPINIRole.', NULL, NULL, NULL),
(4313, 133, 'Morphine ', 'Rotigotine', ' CNS Depressants may enhance the sedative effect of Rotigotine.', NULL, NULL, NULL),
(4314, 133, 'Morphine ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(4315, 133, 'Morphine ', 'Spironolactone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4316, 133, 'Morphine ', 'Succinylcholine', ' May enhance the bradycardic effect of Analgesics (Opioid).', NULL, NULL, NULL),
(4317, 133, 'Morphine ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(4318, 133, 'Morphine ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4319, 133, 'Morphine ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(4320, 133, 'Morphine ', 'Ticrynafen', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4321, 133, 'Morphine ', 'Torasemide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4322, 133, 'Morphine ', 'Triamterene', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4323, 133, 'Morphine ', 'Trichlormethiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(4324, 133, 'Morphine ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(4325, 134, 'Nalidixic acid ', '0', '0', NULL, NULL, NULL),
(4326, 135, 'Naloxone ', '0', '0', NULL, NULL, NULL),
(4327, 135, 'Naloxone ', 'Methylnaltrexone', ' May enhance the adverse/toxic effect of Opioid Antagonists. Specifically~ the risk for opioid withdrawal may be increased.', NULL, NULL, NULL),
(4328, 136, 'Naproxen ', '0', '0', NULL, NULL, NULL),
(4329, 136, 'Naproxen ', 'Abciximab', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4330, 136, 'Naproxen ', 'Acenocoumarol', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4331, 136, 'Naproxen ', 'Acetylsalicylic acid', ' NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.', NULL, NULL, NULL),
(4332, 136, 'Naproxen ', 'Aliskiren', ' Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.', NULL, NULL, NULL),
(4333, 136, 'Naproxen ', 'Alteplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(4334, 136, 'Naproxen ', 'Amikacin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4335, 136, 'Naproxen ', 'Anistreplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(4336, 136, 'Naproxen ', 'Apixaban', ' Naproxen may enhance the adverse/toxic effect of Apixaban. Specifically~ the risk for bleeding may be increased. Naproxen may increase the serum concentration of Apixaban.', NULL, NULL, NULL),
(4337, 136, 'Naproxen ', 'Arbekacin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4338, 136, 'Naproxen ', 'Citric Acid', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4339, 136, 'Naproxen ', 'Colesevelam', ' May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.', NULL, NULL, NULL),
(4340, 136, 'Naproxen ', 'Dabigatran etexilate', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.', NULL, NULL, NULL),
(4341, 136, 'Naproxen ', 'Dalteparin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4342, 136, 'Naproxen ', 'Dasatinib', ' May enhance the anticoagulant effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(4343, 136, 'Naproxen ', 'Deferasirox', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically~ the risk for GI ulceration/irritation or GI bleeding may be increased.', NULL, NULL, NULL),
(4344, 136, 'Naproxen ', 'Deoxycholic Acid', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically~ the risk for bleeding or bruising in the treatment area may be increased.', NULL, NULL, NULL),
(4345, 136, 'Naproxen ', 'Desmopressin', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.', NULL, NULL, NULL),
(4346, 136, 'Naproxen ', 'Dicoumarol', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4347, 136, 'Naproxen ', 'Digoxin', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(4348, 136, 'Naproxen ', 'Edetic Acid', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4349, 136, 'Naproxen ', 'Enoxaparin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4350, 136, 'Naproxen ', 'Eplerenone', ' Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.', NULL, NULL, NULL),
(4351, 136, 'Naproxen ', 'Ethyl biscoumacetate', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4352, 136, 'Naproxen ', 'Floctafenine', ' May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.', NULL, NULL, NULL),
(4353, 136, 'Naproxen ', 'Fondaparinux sodium', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4354, 136, 'Naproxen ', 'Framycetin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4355, 136, 'Naproxen ', 'Gentamicin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4356, 136, 'Naproxen ', 'Glucosamine', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(4357, 136, 'Naproxen ', 'Haloperidol', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.', NULL, NULL, NULL),
(4358, 136, 'Naproxen ', 'Heparin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4359, 136, 'Naproxen ', 'Hydralazine', ' Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.', NULL, NULL, NULL),
(4360, 136, 'Naproxen ', 'Ibritumomab', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.', NULL, NULL, NULL),
(4361, 136, 'Naproxen ', 'Kanamycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4362, 136, 'Naproxen ', 'Lithium', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.', NULL, NULL, NULL),
(4363, 136, 'Naproxen ', 'Methotrexate', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.', NULL, NULL, NULL),
(4364, 136, 'Naproxen ', 'Neomycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4365, 136, 'Naproxen ', 'Netilmicin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4366, 136, 'Naproxen ', 'Obinutuzumab', ' Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically~ the risk of serious bleeding-related events may be increased.', NULL, NULL, NULL),
(4367, 136, 'Naproxen ', 'Pemetrexed', ' NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.', NULL, NULL, NULL),
(4368, 136, 'Naproxen ', 'Pentoxifylline', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(4369, 136, 'Naproxen ', 'Phenindione', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4370, 136, 'Naproxen ', 'Phenprocoumon', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4371, 136, 'Naproxen ', 'Porfimer', ' Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.', NULL, NULL, NULL),
(4372, 136, 'Naproxen ', 'Pralatrexate', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically~ NSAIDS may decrease the renal excretion of pralatrexate.', NULL, NULL, NULL),
(4373, 136, 'Naproxen ', 'Probenecid', ' May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.', NULL, NULL, NULL),
(4374, 136, 'Naproxen ', 'Reteplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(4375, 136, 'Naproxen ', 'Ribostamycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4376, 136, 'Naproxen ', 'Ridogrel', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(4377, 136, 'Naproxen ', 'Rivaroxaban', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.', NULL, NULL, NULL),
(4378, 136, 'Naproxen ', 'Salicylate-sodium', ' NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.', NULL, NULL, NULL),
(4379, 136, 'Naproxen ', 'Spectinomycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4380, 136, 'Naproxen ', 'Streptokinase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(4381, 136, 'Naproxen ', 'Streptomycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4382, 136, 'Naproxen ', 'Sulodexide', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4383, 136, 'Naproxen ', 'Tenecteplase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(4384, 136, 'Naproxen ', 'Tenofovir', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(4385, 136, 'Naproxen ', 'Tipranavir', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(4386, 136, 'Naproxen ', 'Tobramycin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4387, 136, 'Naproxen ', 'Treprostinil', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4388, 136, 'Naproxen ', 'Urokinase', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.', NULL, NULL, NULL),
(4389, 136, 'Naproxen ', 'Vancomycin', ' Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.', NULL, NULL, NULL),
(4390, 136, 'Naproxen ', 'Verteporfin', ' Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.', NULL, NULL, NULL),
(4391, 136, 'Naproxen ', 'Vitamin E', ' May enhance the antiplatelet effect of Agents with Antiplatelet Properties.', NULL, NULL, NULL),
(4392, 136, 'Naproxen ', 'Warfarin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(4393, 137, 'Natamycin ', '0', '0', NULL, NULL, NULL),
(4394, 138, 'Neomycin ', '0', '0', NULL, NULL, NULL),
(4395, 138, 'Neomycin ', 'Acarbose', ' May enhance the adverse/toxic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.', NULL, NULL, NULL),
(4396, 138, 'Neomycin ', 'Acenocoumarol', ' May enhance the anticoagulant effect of Vitamin K Antagonists.', NULL, NULL, NULL),
(4397, 138, 'Neomycin ', 'Amdinocillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4398, 138, 'Neomycin ', 'Amoxicillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4399, 138, 'Neomycin ', 'Amphotericin B', ' Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4400, 138, 'Neomycin ', 'Ampicillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4401, 138, 'Neomycin ', 'Atracurium', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(4402, 138, 'Neomycin ', 'Azidocillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4403, 138, 'Neomycin ', 'Azlocillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4404, 138, 'Neomycin ', 'Bacampicillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4405, 138, 'Neomycin ', 'Benzylpenicillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4406, 138, 'Neomycin ', 'Botulinum Toxin Type A', ' May enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.', NULL, NULL, NULL),
(4407, 138, 'Neomycin ', 'Botulinum Toxin Type B', ' May enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.', NULL, NULL, NULL),
(4408, 138, 'Neomycin ', 'Bumetanide', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(4409, 138, 'Neomycin ', 'Capreomycin', ' Capreomycin may enhance the neuromuscular-blocking effect of Aminoglycosides.', NULL, NULL, NULL),
(4410, 138, 'Neomycin ', 'Carbenicillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4411, 138, 'Neomycin ', 'Carboplatin', ' May enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.', NULL, NULL, NULL),
(4412, 138, 'Neomycin ', 'Cefaclor', ' Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4413, 138, 'Neomycin ', 'Cefdinir', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4414, 138, 'Neomycin ', 'Cefepime', ' Cephalosporins (4th Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4415, 138, 'Neomycin ', 'Cefixime', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4416, 138, 'Neomycin ', 'Cefotaxime', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4417, 138, 'Neomycin ', 'Cefotetan', ' Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4418, 138, 'Neomycin ', 'Cefoxitin', ' Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4419, 138, 'Neomycin ', 'Cefpodoxime', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4420, 138, 'Neomycin ', 'Cefprozil', ' Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4421, 138, 'Neomycin ', 'Ceftazidime', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4422, 138, 'Neomycin ', 'Ceftibuten', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4423, 138, 'Neomycin ', 'Ceftriaxone', ' Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4424, 138, 'Neomycin ', 'Cefuroxime', ' Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4425, 138, 'Neomycin ', 'Celecoxib', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4426, 138, 'Neomycin ', 'Cisatracurium Besylate', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(4427, 138, 'Neomycin ', 'Cisplatin', ' CISplatin may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4428, 138, 'Neomycin ', 'Clodronate', ' May enhance the hypocalcemic effect of Bisphosphonate Derivatives.', NULL, NULL, NULL),
(4429, 138, 'Neomycin ', 'Cloxacillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4430, 138, 'Neomycin ', 'Colistimethate', ' Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.', NULL, NULL, NULL),
(4431, 138, 'Neomycin ', 'Colistin', ' May enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.', NULL, NULL, NULL),
(4432, 138, 'Neomycin ', 'Cyclacillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4433, 138, 'Neomycin ', 'Dicloxacillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4434, 138, 'Neomycin ', 'Diflunisal', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4435, 138, 'Neomycin ', 'Digoxin', ' May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Gentamicin (Systemic); Streptomycin; Tobramycin (Systemic~ Oral Inhalation).', NULL, NULL, NULL),
(4436, 138, 'Neomycin ', 'Ethacrynic acid', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(4437, 138, 'Neomycin ', 'Etodolac', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4438, 138, 'Neomycin ', 'Fenoprofen', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4439, 138, 'Neomycin ', 'Floctafenine', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4440, 138, 'Neomycin ', 'Flucloxacillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4441, 138, 'Neomycin ', 'Foscarnet', ' Foscarnet may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4442, 138, 'Neomycin ', 'Furosemide', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(4443, 138, 'Neomycin ', 'Hetacillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4444, 138, 'Neomycin ', 'Ibandronate', ' May enhance the hypocalcemic effect of Bisphosphonate Derivatives.', NULL, NULL, NULL),
(4445, 138, 'Neomycin ', 'Ibuprofen', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4446, 138, 'Neomycin ', 'Indomethacin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4447, 138, 'Neomycin ', 'Ketoprofen', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4448, 138, 'Neomycin ', 'Ketorolac', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4449, 138, 'Neomycin ', 'Mannitol', ' Mannitol may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4450, 138, 'Neomycin ', 'Mefenamic acid', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4451, 138, 'Neomycin ', 'Meloxicam', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4452, 138, 'Neomycin ', 'Meticillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4453, 138, 'Neomycin ', 'Mezlocillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4454, 138, 'Neomycin ', 'Nabumetone', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4455, 138, 'Neomycin ', 'Nafcillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4456, 138, 'Neomycin ', 'Naproxen', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4457, 138, 'Neomycin ', 'Oxacillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4458, 138, 'Neomycin ', 'Oxaprozin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4459, 138, 'Neomycin ', 'Pamidronate', ' May enhance the hypocalcemic effect of Bisphosphonate Derivatives.', NULL, NULL, NULL),
(4460, 138, 'Neomycin ', 'Pancuronium', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(4461, 138, 'Neomycin ', 'Penicillin V', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4462, 138, 'Neomycin ', 'Piperacillin', ' Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction.', NULL, NULL, NULL),
(4463, 138, 'Neomycin ', 'Piroxicam', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4464, 138, 'Neomycin ', 'Pivampicillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4465, 138, 'Neomycin ', 'Pivmecillinam', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4466, 138, 'Neomycin ', 'Risedronate', ' May enhance the hypocalcemic effect of Bisphosphonate Derivatives.', NULL, NULL, NULL),
(4467, 138, 'Neomycin ', 'Rocuronium', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(4468, 138, 'Neomycin ', 'Sorafenib', ' May decrease the serum concentration of SORAfenib.', NULL, NULL, NULL),
(4469, 138, 'Neomycin ', 'Succinylcholine', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(4470, 138, 'Neomycin ', 'Sulindac', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4471, 138, 'Neomycin ', 'Tenofovir', ' Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(4472, 138, 'Neomycin ', 'Tiaprofenic acid', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(4473, 138, 'Neomycin ', 'Ticarcillin', ' May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins~ and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.', NULL, NULL, NULL),
(4474, 138, 'Neomycin ', 'Tiludronate', ' May enhance the hypocalcemic effect of Bisphosphonate Derivatives.', NULL, NULL, NULL),
(4475, 138, 'Neomycin ', 'Tolmetin', ' Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.', NULL, NULL, NULL),
(4476, 138, 'Neomycin ', 'Torasemide', ' Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically~ nephrotoxicity and ototoxicity.', NULL, NULL, NULL),
(4477, 138, 'Neomycin ', 'Vancomycin', ' Vancomycin may enhance the nephrotoxic effect of Aminoglycosides.', NULL, NULL, NULL),
(4478, 138, 'Neomycin ', 'Vecuronium', ' May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(4479, 138, 'Neomycin ', 'Zoledronate', ' May enhance the hypocalcemic effect of Bisphosphonate Derivatives.', NULL, NULL, NULL),
(4480, 139, 'Neostigmine ', '0', '0', NULL, NULL, NULL),
(4481, 139, 'Neostigmine ', 'Acetylcholine', ' Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.', NULL, NULL, NULL),
(4482, 139, 'Neostigmine ', 'Carbachol', ' Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.', NULL, NULL, NULL),
(4483, 139, 'Neostigmine ', 'Dipyridamole', ' May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.', NULL, NULL, NULL),
(4484, 139, 'Neostigmine ', 'Succinylcholine', ' Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.', NULL, NULL, NULL),
(4485, 140, 'Nevirapine (NVP) ', '0', '0', NULL, NULL, NULL),
(4486, 141, 'Nifedipine ', '0', '0', NULL, NULL, NULL),
(4487, 141, 'Nifedipine ', 'Alfuzosin', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(4488, 141, 'Nifedipine ', 'Amifostine', ' Antihypertensives may enhance the hypotensive effect of Amifostine.', NULL, NULL, NULL),
(4489, 141, 'Nifedipine ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4490, 141, 'Nifedipine ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(4491, 141, 'Nifedipine ', 'Batimastat', ' May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).', NULL, NULL, NULL),
(4492, 141, 'Nifedipine ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4493, 141, 'Nifedipine ', 'Butabarbital', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(4494, 141, 'Nifedipine ', 'Butethal', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(4495, 141, 'Nifedipine ', 'Carbamazepine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.', NULL, NULL, NULL),
(4496, 141, 'Nifedipine ', 'Cimetidine', ' May increase the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(4497, 141, 'Nifedipine ', 'Cisapride', ' Cisapride may increase the serum concentration of NIFEdipine. Reported with sustained release nifedipine product.', NULL, NULL, NULL),
(4498, 141, 'Nifedipine ', 'Clopidogrel', ' Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.', NULL, NULL, NULL),
(4499, 141, 'Nifedipine ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4500, 141, 'Nifedipine ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4501, 141, 'Nifedipine ', 'Dapoxetine', ' May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(4502, 141, 'Nifedipine ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4503, 141, 'Nifedipine ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4504, 141, 'Nifedipine ', 'Diazoxide', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(4505, 141, 'Nifedipine ', 'Digoxin', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(4506, 141, 'Nifedipine ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(4507, 141, 'Nifedipine ', 'Duloxetine', ' Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.', NULL, NULL, NULL),
(4508, 141, 'Nifedipine ', 'Efavirenz', ' May decrease the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(4509, 141, 'Nifedipine ', 'Enzalutamide', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.', NULL, NULL, NULL),
(4510, 141, 'Nifedipine ', 'Ethanol', ' Alcohol (Ethyl) may increase the serum concentration of NIFEdipine.', NULL, NULL, NULL),
(4511, 141, 'Nifedipine ', 'Fluconazole', ' May increase the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(4512, 141, 'Nifedipine ', 'Fluoxetine', ' FLUoxetine may enhance the adverse/toxic effect of NIFEdipine.', NULL, NULL, NULL),
(4513, 141, 'Nifedipine ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4514, 141, 'Nifedipine ', 'Fosphenytoin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.', NULL, NULL, NULL),
(4515, 141, 'Nifedipine ', 'Heptabarbital', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(4516, 141, 'Nifedipine ', 'Hexobarbital', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(4517, 141, 'Nifedipine ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(4518, 141, 'Nifedipine ', 'Isoflurophate', ' May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).', NULL, NULL, NULL),
(4519, 141, 'Nifedipine ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4520, 141, 'Nifedipine ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(4521, 141, 'Nifedipine ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4522, 141, 'Nifedipine ', 'Melatonin', ' May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).', NULL, NULL, NULL),
(4523, 141, 'Nifedipine ', 'Methohexital', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(4524, 141, 'Nifedipine ', 'Methylphenidate', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(4525, 141, 'Nifedipine ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4526, 141, 'Nifedipine ', 'Nafcillin', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(4527, 141, 'Nifedipine ', 'Nitroprusside', ' Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.', NULL, NULL, NULL),
(4528, 141, 'Nifedipine ', 'Obinutuzumab', ' Antihypertensives may enhance the hypotensive effect of Obinutuzumab.', NULL, NULL, NULL),
(4529, 141, 'Nifedipine ', 'Pentobarbital', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(4530, 141, 'Nifedipine ', 'Pentoxifylline', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(4531, 141, 'Nifedipine ', 'Phenobarbital', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.', NULL, NULL, NULL),
(4532, 141, 'Nifedipine ', 'Phenytoin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.', NULL, NULL, NULL),
(4533, 141, 'Nifedipine ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(4534, 141, 'Nifedipine ', 'Primidone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.', NULL, NULL, NULL),
(4535, 141, 'Nifedipine ', 'Quinidine', ' May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(4536, 141, 'Nifedipine ', 'Rifampicin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.', NULL, NULL, NULL),
(4537, 141, 'Nifedipine ', 'Rifapentine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.', NULL, NULL, NULL),
(4538, 141, 'Nifedipine ', 'Risperidone', ' Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.', NULL, NULL, NULL),
(4539, 141, 'Nifedipine ', 'Rituximab', ' Antihypertensives may enhance the hypotensive effect of RiTUXimab.', NULL, NULL, NULL),
(4540, 141, 'Nifedipine ', 'Secobarbital', ' May increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(4541, 141, 'Nifedipine ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4542, 141, 'Nifedipine ', 'Simeprevir', ' May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).', NULL, NULL, NULL),
(4543, 141, 'Nifedipine ', 'Tadalafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(4544, 141, 'Nifedipine ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4545, 141, 'Nifedipine ', 'Vardenafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(4546, 141, 'Nifedipine ', 'Vincristine', ' May increase the serum concentration of VinCRIStine.', NULL, NULL, NULL),
(4547, 141, 'Nifedipine ', 'Yohimbine', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(4548, 142, 'Nitrofurantoin ', '0', '0', NULL, NULL, NULL),
(4549, 142, 'Nitrofurantoin ', 'Eplerenone', ' Nitrofurantoin may enhance the hyperkalemic effect of Eplerenone.', NULL, NULL, NULL),
(4550, 142, 'Nitrofurantoin ', 'Nitric Oxide', ' May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.', NULL, NULL, NULL),
(4551, 142, 'Nitrofurantoin ', 'Norfloxacin', ' Nitrofurantoin may diminish the therapeutic effect of Norfloxacin.', NULL, NULL, NULL),
(4552, 142, 'Nitrofurantoin ', 'Prilocaine', ' Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.', NULL, NULL, NULL),
(4553, 142, 'Nitrofurantoin ', 'Probenecid', ' May increase the serum concentration of Nitrofurantoin.', NULL, NULL, NULL),
(4554, 142, 'Nitrofurantoin ', 'Spironolactone', ' May enhance the hyperkalemic effect of Spironolactone.', NULL, NULL, NULL),
(4555, 143, 'Nitroprusside Sodium ', '0', '0', NULL, NULL, NULL),
(4556, 144, 'Nystatin ', '0', '0', NULL, NULL, NULL),
(4557, 145, 'Ofloxacin ', '0', '0', NULL, NULL, NULL),
(4558, 146, 'Omeprazole ', '0', '0', NULL, NULL, NULL),
(4559, 146, 'Omeprazole ', 'Acenocoumarol', ' May increase the serum concentration of Vitamin K Antagonists.', NULL, NULL, NULL),
(4560, 146, 'Omeprazole ', 'Amphetamine', ' May increase the absorption of Amphetamine.', NULL, NULL, NULL),
(4561, 146, 'Omeprazole ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(4562, 146, 'Omeprazole ', 'Atazanavir', ' Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(4563, 146, 'Omeprazole ', 'Bosentan', ' CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan.', NULL, NULL, NULL),
(4564, 146, 'Omeprazole ', 'Bosutinib', ' Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.', NULL, NULL, NULL),
(4565, 146, 'Omeprazole ', 'Carvedilol', ' CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically~ concentrations of the S-carvedilol enantiomer may be increased.', NULL, NULL, NULL),
(4566, 146, 'Omeprazole ', 'Cefditoren', ' Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.', NULL, NULL, NULL),
(4567, 146, 'Omeprazole ', 'Cilostazol', ' CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.', NULL, NULL, NULL),
(4568, 146, 'Omeprazole ', 'Citalopram', ' CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.', NULL, NULL, NULL),
(4569, 146, 'Omeprazole ', 'Clodronate', ' May diminish the therapeutic effect of Bisphosphonate Derivatives.', NULL, NULL, NULL),
(4570, 146, 'Omeprazole ', 'Clopidogrel', ' Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.', NULL, NULL, NULL),
(4571, 146, 'Omeprazole ', 'Clozapine', ' Omeprazole may decrease the serum concentration of CloZAPine. Omeprazole may increase the serum concentration of CloZAPine.', NULL, NULL, NULL),
(4572, 146, 'Omeprazole ', 'Dabigatran etexilate', ' Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.', NULL, NULL, NULL),
(4573, 146, 'Omeprazole ', 'Dabrafenib', ' May decrease the serum concentration of CYP2C19 Substrates.', NULL, NULL, NULL),
(4574, 146, 'Omeprazole ', 'Dasatinib', ' Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.', NULL, NULL, NULL),
(4575, 146, 'Omeprazole ', 'Delavirdine', ' Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.', NULL, NULL, NULL),
(4576, 146, 'Omeprazole ', 'Dexmethylphenidate', ' Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically~ proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand)~ which could result in both increased absorption (early) and decreased delayed absorption.', NULL, NULL, NULL),
(4577, 146, 'Omeprazole ', 'Dextroamphetamine', ' Proton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically~ the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing.', NULL, NULL, NULL),
(4578, 146, 'Omeprazole ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(4579, 146, 'Omeprazole ', 'Dronabinol', ' CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.', NULL, NULL, NULL),
(4580, 146, 'Omeprazole ', 'Erlotinib', ' Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.', NULL, NULL, NULL),
(4581, 146, 'Omeprazole ', 'Escitalopram', ' Omeprazole may increase the serum concentration of Escitalopram.', NULL, NULL, NULL),
(4582, 146, 'Omeprazole ', 'Fluconazole', ' Fluconazole may increase the serum concentration of Proton Pump Inhibitors.', NULL, NULL, NULL),
(4583, 146, 'Omeprazole ', 'Fosphenytoin', ' May decrease the serum concentration of Omeprazole. Omeprazole may increase the serum concentration of Fosphenytoin.', NULL, NULL, NULL),
(4584, 146, 'Omeprazole ', 'Gefitinib', ' May decrease the serum concentration of Gefitinib.', NULL, NULL, NULL),
(4585, 146, 'Omeprazole ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(4586, 146, 'Omeprazole ', 'Ibandronate', ' May diminish the therapeutic effect of Bisphosphonate Derivatives.', NULL, NULL, NULL),
(4587, 146, 'Omeprazole ', 'Indinavir', ' May decrease the serum concentration of Indinavir.', NULL, NULL, NULL),
(4588, 146, 'Omeprazole ', 'Itraconazole', ' Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.', NULL, NULL, NULL),
(4589, 146, 'Omeprazole ', 'Ledipasvir', ' Proton Pump Inhibitors may decrease the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(4590, 146, 'Omeprazole ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(4591, 146, 'Omeprazole ', 'Mesalazine', ' May diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.', NULL, NULL, NULL),
(4592, 146, 'Omeprazole ', 'Methotrexate', ' Proton Pump Inhibitors may increase the serum concentration of Methotrexate.', NULL, NULL, NULL),
(4593, 146, 'Omeprazole ', 'Methylphenidate', ' Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically~ proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand)~ which could result in both increased absorption (early) and decreased delayed absorption.', NULL, NULL, NULL),
(4594, 146, 'Omeprazole ', 'Mycophenolate mofetil', ' May decrease the serum concentration of Mycophenolate. Specifically~ concentrations of the active mycophenolic acid may be reduced.', NULL, NULL, NULL),
(4595, 146, 'Omeprazole ', 'Mycophenolic acid', ' May decrease the serum concentration of Mycophenolate. Specifically~ concentrations of the active mycophenolic acid may be reduced.', NULL, NULL, NULL),
(4596, 146, 'Omeprazole ', 'Nelfinavir', ' May decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.', NULL, NULL, NULL),
(4597, 146, 'Omeprazole ', 'Nilotinib', ' Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.', NULL, NULL, NULL),
(4598, 146, 'Omeprazole ', 'Pamidronate', ' May diminish the therapeutic effect of Bisphosphonate Derivatives.', NULL, NULL, NULL),
(4599, 146, 'Omeprazole ', 'Pazopanib', ' Proton Pump Inhibitors may decrease the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(4600, 146, 'Omeprazole ', 'Phenytoin', ' May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Omeprazole.', NULL, NULL, NULL),
(4601, 146, 'Omeprazole ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(4602, 146, 'Omeprazole ', 'Posaconazole', ' Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.', NULL, NULL, NULL),
(4603, 146, 'Omeprazole ', 'Raltegravir', ' Proton Pump Inhibitors may increase the serum concentration of Raltegravir.', NULL, NULL, NULL),
(4604, 146, 'Omeprazole ', 'Rifampicin', ' Rifampin may decrease the serum concentration of Omeprazole.', NULL, NULL, NULL),
(4605, 146, 'Omeprazole ', 'Rilpivirine', ' Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.', NULL, NULL, NULL),
(4606, 146, 'Omeprazole ', 'Riociguat', ' Proton Pump Inhibitors may decrease the serum concentration of Riociguat.', NULL, NULL, NULL),
(4607, 146, 'Omeprazole ', 'Risedronate', ' Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.', NULL, NULL, NULL),
(4608, 146, 'Omeprazole ', 'Saquinavir', ' Proton Pump Inhibitors may increase the serum concentration of Saquinavir.', NULL, NULL, NULL),
(4609, 146, 'Omeprazole ', 'Tiludronate', ' May diminish the therapeutic effect of Bisphosphonate Derivatives.', NULL, NULL, NULL),
(4610, 146, 'Omeprazole ', 'Tipranavir', ' May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.', NULL, NULL, NULL),
(4611, 146, 'Omeprazole ', 'Vismodegib', ' Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.', NULL, NULL, NULL),
(4612, 146, 'Omeprazole ', 'Voriconazole', ' Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.', NULL, NULL, NULL),
(4613, 146, 'Omeprazole ', 'Zoledronate', ' May diminish the therapeutic effect of Bisphosphonate Derivatives.', NULL, NULL, NULL),
(4614, 147, 'Ondansetron Hydrochloride ', '0', '0', NULL, NULL, NULL),
(4615, 148, 'Oxycodone Chloride ', '0', '0', NULL, NULL, NULL),
(4616, 149, 'Oxytocin ', '0', '0', NULL, NULL, NULL),
(4617, 149, 'Oxytocin ', 'Carboprost Tromethamine', ' May enhance the adverse/toxic effect of Oxytocic Agents. Specifically~ oxytocic effects may be enhanced.', NULL, NULL, NULL),
(4618, 149, 'Oxytocin ', 'Dinoprostone', ' May enhance the adverse/toxic effect of Oxytocin. Specifically~oxytocic effects may be enhanced.', NULL, NULL, NULL),
(4619, 149, 'Oxytocin ', 'Mifepristone', ' May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).', NULL, NULL, NULL),
(4620, 149, 'Oxytocin ', 'Misoprostol', ' May enhance the adverse/toxic effect of Oxytocin. Specifically~ oxytocic effects may be enhanced.', NULL, NULL, NULL),
(4621, 150, 'Para&minus;aminosalicylic acid ', '0', '0', NULL, NULL, NULL),
(4622, 151, 'Paracetamol ', '0', '0', NULL, NULL, NULL),
(4623, 152, 'Paromomycin Sulfate ', '0', '0', NULL, NULL, NULL),
(4624, 153, 'Pencillamine ', '0', '0', NULL, NULL, NULL),
(4625, 154, 'Pentamidine Isethionate ', '0', '0', NULL, NULL, NULL),
(4626, 155, 'Permethrin ', '0', '0', NULL, NULL, NULL),
(4627, 156, 'Pethidine / Meperdine ', '0', '0', NULL, NULL, NULL),
(4628, 157, 'Phenobarbitone ', '0', '0', NULL, NULL, NULL),
(4629, 158, 'Phenylephrine ', '0', '0', NULL, NULL, NULL),
(4630, 158, 'Phenylephrine ', 'Acebutolol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4631, 158, 'Phenylephrine ', 'Aminophylline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4632, 158, 'Phenylephrine ', 'Amphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4633, 158, 'Phenylephrine ', 'Arformoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4634, 158, 'Phenylephrine ', 'armodafinil', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4635, 158, 'Phenylephrine ', 'Articaine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4636, 158, 'Phenylephrine ', 'Atomoxetine', ' AtoMOXetine may enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(4637, 158, 'Phenylephrine ', 'Benzphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4638, 158, 'Phenylephrine ', 'Caffeine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4639, 158, 'Phenylephrine ', 'Chlorphentermine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4640, 158, 'Phenylephrine ', 'Clenbuterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4641, 158, 'Phenylephrine ', 'Cocaine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4642, 158, 'Phenylephrine ', 'Dexmethylphenidate', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4643, 158, 'Phenylephrine ', 'Dextroamphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4644, 158, 'Phenylephrine ', 'Diethylpropion', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4645, 158, 'Phenylephrine ', 'Dihydrocodeine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4646, 158, 'Phenylephrine ', 'Dipivefrin', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4647, 158, 'Phenylephrine ', 'Dobutamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4648, 158, 'Phenylephrine ', 'Dopamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4649, 158, 'Phenylephrine ', 'Doxapram', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4650, 158, 'Phenylephrine ', 'Dronabinol', ' Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(4651, 158, 'Phenylephrine ', 'Epinephrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4652, 158, 'Phenylephrine ', 'Fenoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4653, 158, 'Phenylephrine ', 'Fentanyl', ' Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically~ fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.', NULL, NULL, NULL),
(4654, 158, 'Phenylephrine ', 'Fluticasone furoate', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4655, 158, 'Phenylephrine ', 'Formoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4656, 158, 'Phenylephrine ', 'Indacaterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4657, 158, 'Phenylephrine ', 'Iobenguane', ' May diminish the therapeutic effect of Iobenguane I 123.', NULL, NULL, NULL),
(4658, 158, 'Phenylephrine ', 'Ipratropium bromide', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4659, 158, 'Phenylephrine ', 'Isometheptene', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4660, 158, 'Phenylephrine ', 'Isoprenaline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4661, 158, 'Phenylephrine ', 'Labetalol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4662, 158, 'Phenylephrine ', 'Levonordefrin', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4663, 158, 'Phenylephrine ', 'Linezolid', ' May enhance the hypertensive effect of Sympathomimetics.', NULL, NULL, NULL),
(4664, 158, 'Phenylephrine ', 'Lisdexamfetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4665, 158, 'Phenylephrine ', 'Mephentermine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4666, 158, 'Phenylephrine ', 'Metaraminol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4667, 158, 'Phenylephrine ', 'Methamphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4668, 158, 'Phenylephrine ', 'Methoxamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4669, 158, 'Phenylephrine ', 'Methylphenidate', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4670, 158, 'Phenylephrine ', 'Midodrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4671, 158, 'Phenylephrine ', 'Modafinil', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4672, 158, 'Phenylephrine ', 'Nabilone', ' Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(4673, 158, 'Phenylephrine ', 'Naphazoline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4674, 158, 'Phenylephrine ', 'Norepinephrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4675, 158, 'Phenylephrine ', 'Orciprenaline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4676, 158, 'Phenylephrine ', 'Oxymetazoline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4677, 158, 'Phenylephrine ', 'Phendimetrazine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4678, 158, 'Phenylephrine ', 'Pheniramine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4679, 158, 'Phenylephrine ', 'Phenmetrazine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4680, 158, 'Phenylephrine ', 'Phentermine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4681, 158, 'Phenylephrine ', 'Phenylpropanolamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4682, 158, 'Phenylephrine ', 'Pirbuterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4683, 158, 'Phenylephrine ', 'Propylhexedrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4684, 158, 'Phenylephrine ', 'Pseudoephedrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4685, 158, 'Phenylephrine ', 'Ritodrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4686, 158, 'Phenylephrine ', 'Salbutamol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4687, 158, 'Phenylephrine ', 'Salmeterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4688, 158, 'Phenylephrine ', 'Tedizolid Phosphate', ' Tedizolid may enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(4689, 158, 'Phenylephrine ', 'Terbutaline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4690, 158, 'Phenylephrine ', 'Theophylline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4691, 158, 'Phenylephrine ', 'Triprolidine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(4692, 159, 'Phenytoin ', '0', '0', NULL, NULL, NULL),
(4693, 159, 'Phenytoin ', 'Acenocoumarol', ' May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4694, 159, 'Phenytoin ', 'Acetaminophen', ' Fosphenytoin-Phenytoin may decrease the serum concentration of Acetaminophen. Specifically~ serum concentrations of acetaminophen may be decreased (leading to decreased efficacy)~ but the formation of the toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity).', NULL, NULL, NULL),
(4695, 159, 'Phenytoin ', 'Acetazolamide', ' May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically~ the risk for osteomalacia or rickets may be increased. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(4696, 159, 'Phenytoin ', 'Afatinib', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.', NULL, NULL, NULL),
(4697, 159, 'Phenytoin ', 'Albendazole', ' Phenytoin may decrease serum concentrations of the active metabolite(s) of Albendazole.', NULL, NULL, NULL),
(4698, 159, 'Phenytoin ', 'Alprazolam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4699, 159, 'Phenytoin ', 'Aminophylline', ' Theophylline Derivatives may decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Theophylline Derivatives.', NULL, NULL, NULL),
(4700, 159, 'Phenytoin ', 'Amiodarone', ' May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Amiodarone.', NULL, NULL, NULL),
(4701, 159, 'Phenytoin ', 'Amlodipine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4702, 159, 'Phenytoin ', 'Amphetamine', ' Amphetamines may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4703, 159, 'Phenytoin ', 'Amrinone', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4704, 159, 'Phenytoin ', 'Apixaban', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.', NULL, NULL, NULL),
(4705, 159, 'Phenytoin ', 'Apremilast', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast.', NULL, NULL, NULL),
(4706, 159, 'Phenytoin ', 'Aripiprazole', ' CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(4707, 159, 'Phenytoin ', 'Artemether', ' CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically~ dihydroartemisinin concentrations may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether.', NULL, NULL, NULL),
(4708, 159, 'Phenytoin ', 'Atorvastatin', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(4709, 159, 'Phenytoin ', 'Axitinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.', NULL, NULL, NULL),
(4710, 159, 'Phenytoin ', 'bazedoxifene', ' Phenytoin may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or~ if bazedoxifene is combined with estrogen therapy~ an increased risk of endometrial hyperplasia.', NULL, NULL, NULL),
(4711, 159, 'Phenytoin ', 'Bedaquiline', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.', NULL, NULL, NULL),
(4712, 159, 'Phenytoin ', 'Bepridil', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4713, 159, 'Phenytoin ', 'Bleomycin', ' May decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4714, 159, 'Phenytoin ', 'Boceprevir', ' Phenytoin may decrease the serum concentration of Boceprevir.', NULL, NULL, NULL),
(4715, 159, 'Phenytoin ', 'Bortezomib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.', NULL, NULL, NULL),
(4716, 159, 'Phenytoin ', 'Bosutinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.', NULL, NULL, NULL),
(4717, 159, 'Phenytoin ', 'Brentuximab vedotin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.', NULL, NULL, NULL),
(4718, 159, 'Phenytoin ', 'Bromazepam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4719, 159, 'Phenytoin ', 'Bumetanide', ' May diminish the diuretic effect of Loop Diuretics.', NULL, NULL, NULL),
(4720, 159, 'Phenytoin ', 'Buprenorphine', ' CNS Depressants may enhance the CNS depressant effect of Buprenorphine.', NULL, NULL, NULL),
(4721, 159, 'Phenytoin ', 'Busulfan', ' Phenytoin may decrease the serum concentration of Busulfan.', NULL, NULL, NULL),
(4722, 159, 'Phenytoin ', 'Cabozantinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.', NULL, NULL, NULL),
(4723, 159, 'Phenytoin ', 'Camazepam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4724, 159, 'Phenytoin ', 'Canagliflozin', ' Phenytoin may decrease the serum concentration of Canagliflozin.', NULL, NULL, NULL),
(4725, 159, 'Phenytoin ', 'Capecitabine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4726, 159, 'Phenytoin ', 'Carbamazepine', ' May decrease the serum concentration of Phenytoin. CarBAMazepine may increase the serum concentration of Phenytoin. Possibly by competitive inhibition at sites of metabolism. Phenytoin may decrease the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(4727, 159, 'Phenytoin ', 'Caspofungin', ' Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.', NULL, NULL, NULL),
(4728, 159, 'Phenytoin ', 'Cathinone', ' May decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4729, 159, 'Phenytoin ', 'Cefazolin', ' May decrease the protein binding of Phenytoin.', NULL, NULL, NULL),
(4730, 159, 'Phenytoin ', 'Chlordiazepoxide', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4731, 159, 'Phenytoin ', 'Chlormezanone', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4732, 159, 'Phenytoin ', 'Cimetidine', ' May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Cimetidine may increase the serum concentration of Fosphenytoin-Phenytoin.', NULL, NULL, NULL),
(4733, 159, 'Phenytoin ', 'Cinolazepam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4734, 159, 'Phenytoin ', 'Clarithromycin', ' CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(4735, 159, 'Phenytoin ', 'Clobazam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4736, 159, 'Phenytoin ', 'Clonazepam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4737, 159, 'Phenytoin ', 'Clotiazepam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4738, 159, 'Phenytoin ', 'Cloxazolam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4739, 159, 'Phenytoin ', 'Clozapine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of CloZAPine.', NULL, NULL, NULL),
(4740, 159, 'Phenytoin ', 'Colesevelam', ' May decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4741, 159, 'Phenytoin ', 'Cosyntropin', ' May enhance the hepatotoxic effect of Phenytoin.', NULL, NULL, NULL),
(4742, 159, 'Phenytoin ', 'Crizotinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.', NULL, NULL, NULL),
(4743, 159, 'Phenytoin ', 'Dabigatran etexilate', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.', NULL, NULL, NULL),
(4744, 159, 'Phenytoin ', 'Dabrafenib', ' May decrease the serum concentration of CYP2C9 Substrates.', NULL, NULL, NULL),
(4745, 159, 'Phenytoin ', 'Darunavir', ' May decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4746, 159, 'Phenytoin ', 'Dasatinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.', NULL, NULL, NULL),
(4747, 159, 'Phenytoin ', 'Deferasirox', ' Phenytoin may decrease the serum concentration of Deferasirox.', NULL, NULL, NULL),
(4748, 159, 'Phenytoin ', 'Delavirdine', ' May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Delavirdine.', NULL, NULL, NULL),
(4749, 159, 'Phenytoin ', 'Desogestrel', ' May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.', NULL, NULL, NULL),
(4750, 159, 'Phenytoin ', 'Dexmethylphenidate', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4751, 159, 'Phenytoin ', 'Dextroamphetamine', ' Amphetamines may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4752, 159, 'Phenytoin ', 'Diazoxide', ' May decrease the serum concentration of Phenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations.', NULL, NULL, NULL),
(4753, 159, 'Phenytoin ', 'Diclofenamide', ' May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically~ the risk for osteomalacia or rickets may be increased. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(4754, 159, 'Phenytoin ', 'Diltiazem', ' Calcium Channel Blockers may increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4755, 159, 'Phenytoin ', 'Disopyramide', ' Phenytoin may decrease the serum concentration of Disopyramide.', NULL, NULL, NULL),
(4756, 159, 'Phenytoin ', 'Disulfiram', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4757, 159, 'Phenytoin ', 'Dolutegravir', ' Fosphenytoin-Phenytoin may decrease the serum concentration of Dolutegravir.', NULL, NULL, NULL),
(4758, 159, 'Phenytoin ', 'Doxycycline', ' Phenytoin may decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(4759, 159, 'Phenytoin ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4760, 159, 'Phenytoin ', 'Dronabinol', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronabinol.', NULL, NULL, NULL),
(4761, 159, 'Phenytoin ', 'Dronedarone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.', NULL, NULL, NULL),
(4762, 159, 'Phenytoin ', 'Droperidol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4763, 159, 'Phenytoin ', 'Drospirenone', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(4764, 159, 'Phenytoin ', 'Efavirenz', ' May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Efavirenz.', NULL, NULL, NULL),
(4765, 159, 'Phenytoin ', 'Eliglustat', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat.', NULL, NULL, NULL),
(4766, 159, 'Phenytoin ', 'Enzalutamide', ' CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.', NULL, NULL, NULL),
(4767, 159, 'Phenytoin ', 'Erlotinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Erlotinib.', NULL, NULL, NULL),
(4768, 159, 'Phenytoin ', 'Estazolam', ' Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.', NULL, NULL, NULL),
(4769, 159, 'Phenytoin ', 'Ethacrynic acid', ' May diminish the diuretic effect of Loop Diuretics.', NULL, NULL, NULL),
(4770, 159, 'Phenytoin ', 'Ethanol', ' Alcohol (Ethyl) may enhance the CNS depressant effect of Phenytoin. Alcohol (Ethyl) may increase the serum concentration of Phenytoin. This may be particularly applicable with acute~ heavy alcohol consumption. Alcohol (Ethyl) may decrease the serum concentration of Phenytoin. This may be particularly applicable with chronic~ heavy alcohol consumption.', NULL, NULL, NULL),
(4771, 159, 'Phenytoin ', 'Ethinyl Estradiol', ' May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.', NULL, NULL, NULL),
(4772, 159, 'Phenytoin ', 'Ethosuximide', ' May enhance the CNS depressant effect of Phenytoin. Ethosuximide may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Ethosuximide.', NULL, NULL, NULL),
(4773, 159, 'Phenytoin ', 'Ethoxzolamide', ' May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically~ the risk for osteomalacia or rickets may be increased. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(4774, 159, 'Phenytoin ', 'Ethynodiol', ' May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.', NULL, NULL, NULL),
(4775, 159, 'Phenytoin ', 'Etonogestrel', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(4776, 159, 'Phenytoin ', 'Etoposide', ' Phenytoin may decrease the serum concentration of Etoposide.', NULL, NULL, NULL),
(4777, 159, 'Phenytoin ', 'Etravirine', ' Phenytoin may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(4778, 159, 'Phenytoin ', 'Everolimus', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.', NULL, NULL, NULL),
(4779, 159, 'Phenytoin ', 'Exemestane', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.', NULL, NULL, NULL),
(4780, 159, 'Phenytoin ', 'Ezogabine', ' Phenytoin may decrease the serum concentration of Ezogabine.', NULL, NULL, NULL),
(4781, 159, 'Phenytoin ', 'Felbamate', ' May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Felbamate.', NULL, NULL, NULL),
(4782, 159, 'Phenytoin ', 'Felodipine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4783, 159, 'Phenytoin ', 'Fentanyl', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(4784, 159, 'Phenytoin ', 'Floxuridine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4785, 159, 'Phenytoin ', 'Fluconazole', ' Fluconazole may increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4786, 159, 'Phenytoin ', 'Fludiazepam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4787, 159, 'Phenytoin ', 'Flunarizine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4788, 159, 'Phenytoin ', 'Flunitrazepam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4789, 159, 'Phenytoin ', 'Fluoxetine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4790, 159, 'Phenytoin ', 'Fluvastatin', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(4791, 159, 'Phenytoin ', 'Fluvoxamine', ' FluvoxaMINE may increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4792, 159, 'Phenytoin ', 'Folic Acid', ' Folic Acid may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4793, 159, 'Phenytoin ', 'Fosamprenavir', ' May decrease the serum concentration of Phenytoin. The active amprenavir metabolite is likely responsible for this effect. Phenytoin may increase the serum concentration of Fosamprenavir. Specifically~ phenytoin may increase the concentration of the active metabolite amprenavir.', NULL, NULL, NULL),
(4794, 159, 'Phenytoin ', 'Furosemide', ' May diminish the diuretic effect of Loop Diuretics.', NULL, NULL, NULL),
(4795, 159, 'Phenytoin ', 'Gabapentin', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4796, 159, 'Phenytoin ', 'Gefitinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.', NULL, NULL, NULL),
(4797, 159, 'Phenytoin ', 'Guanfacine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.', NULL, NULL, NULL),
(4798, 159, 'Phenytoin ', 'Halazepam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4799, 159, 'Phenytoin ', 'Halothane', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4800, 159, 'Phenytoin ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(4801, 159, 'Phenytoin ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4802, 159, 'Phenytoin ', 'Imatinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.', NULL, NULL, NULL),
(4803, 159, 'Phenytoin ', 'Irinotecan', ' CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan.', NULL, NULL, NULL),
(4804, 159, 'Phenytoin ', 'Isoniazid', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4805, 159, 'Phenytoin ', 'Isradipine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4806, 159, 'Phenytoin ', 'Itraconazole', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.', NULL, NULL, NULL),
(4807, 159, 'Phenytoin ', 'Ivacaftor', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.', NULL, NULL, NULL),
(4808, 159, 'Phenytoin ', 'Ixabepilone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.', NULL, NULL, NULL),
(4809, 159, 'Phenytoin ', 'Ketazolam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4810, 159, 'Phenytoin ', 'Lacosamide', ' Phenytoin may decrease the serum concentration of Lacosamide.', NULL, NULL, NULL),
(4811, 159, 'Phenytoin ', 'Lamotrigine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(4812, 159, 'Phenytoin ', 'Lapatinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.', NULL, NULL, NULL),
(4813, 159, 'Phenytoin ', 'Ledipasvir', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(4814, 159, 'Phenytoin ', 'Lercanidipine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4815, 159, 'Phenytoin ', 'Levonorgestrel', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(4816, 159, 'Phenytoin ', 'Levothyroxine', ' May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.', NULL, NULL, NULL),
(4817, 159, 'Phenytoin ', 'Linagliptin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.', NULL, NULL, NULL),
(4818, 159, 'Phenytoin ', 'Liothyronine', ' May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.', NULL, NULL, NULL),
(4819, 159, 'Phenytoin ', 'Liotrix', ' May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.', NULL, NULL, NULL),
(4820, 159, 'Phenytoin ', 'Lisdexamfetamine', ' Amphetamines may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4821, 159, 'Phenytoin ', 'Lithium', ' Phenytoin may enhance the adverse/toxic effect of Lithium.', NULL, NULL, NULL),
(4822, 159, 'Phenytoin ', 'Lopinavir', ' May decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Lopinavir.', NULL, NULL, NULL),
(4823, 159, 'Phenytoin ', 'Lorazepam', ' Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.', NULL, NULL, NULL),
(4824, 159, 'Phenytoin ', 'Lovastatin', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(4825, 159, 'Phenytoin ', 'LULICONAZOLE', ' May increase the serum concentration of CYP2C19 Substrates.', NULL, NULL, NULL),
(4826, 159, 'Phenytoin ', 'Lumefantrine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumefantrine.', NULL, NULL, NULL),
(4827, 159, 'Phenytoin ', 'Lurasidone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.', NULL, NULL, NULL),
(4828, 159, 'Phenytoin ', 'MACITENTAN', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan.', NULL, NULL, NULL),
(4829, 159, 'Phenytoin ', 'Magnesium Sulfate', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4830, 159, 'Phenytoin ', 'Maraviroc', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.', NULL, NULL, NULL),
(4831, 159, 'Phenytoin ', 'Mebendazole', ' Phenytoin may decrease the serum concentration of Mebendazole.', NULL, NULL, NULL),
(4832, 159, 'Phenytoin ', 'Medroxyprogesterone Acetate', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(4833, 159, 'Phenytoin ', 'Mefloquine', ' May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.', NULL, NULL, NULL),
(4834, 159, 'Phenytoin ', 'Mestranol', ' May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.', NULL, NULL, NULL),
(4835, 159, 'Phenytoin ', 'Methadone', ' Phenytoin may decrease the serum concentration of Methadone.', NULL, NULL, NULL),
(4836, 159, 'Phenytoin ', 'Methamphetamine', ' Amphetamines may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4837, 159, 'Phenytoin ', 'Methotrexate', ' May decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may increase the serum concentration of Methotrexate. Specifically~ fosphenytoin-phenytoin may displace methotrexate from serum proteins~ increasing the concentration of free~ unbound drug.', NULL, NULL, NULL),
(4838, 159, 'Phenytoin ', 'Methotrimeprazine', ' CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4839, 159, 'Phenytoin ', 'Methylphenidate', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4840, 159, 'Phenytoin ', 'Methylprednisolone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(4841, 159, 'Phenytoin ', 'Metyrapone', ' Phenytoin may decrease the serum concentration of Metyrapone. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g.~ 750 mg every 2 hours).', NULL, NULL, NULL),
(4842, 159, 'Phenytoin ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(4843, 159, 'Phenytoin ', 'Mexiletine', ' Phenytoin may decrease the serum concentration of Mexiletine.', NULL, NULL, NULL),
(4844, 159, 'Phenytoin ', 'Mianserin', ' May diminish the therapeutic effect of Phenytoin. Phenytoin may decrease the serum concentration of Mianserin.', NULL, NULL, NULL),
(4845, 159, 'Phenytoin ', 'Miconazole', ' Miconazole (Oral) may increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4846, 159, 'Phenytoin ', 'Mifepristone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.', NULL, NULL, NULL),
(4847, 159, 'Phenytoin ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4848, 159, 'Phenytoin ', 'Nelfinavir', ' Nelfinavir may decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Nelfinavir.', NULL, NULL, NULL),
(4849, 159, 'Phenytoin ', 'Nicardipine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4850, 159, 'Phenytoin ', 'Nifedipine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.', NULL, NULL, NULL),
(4851, 159, 'Phenytoin ', 'Nilotinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.', NULL, NULL, NULL),
(4852, 159, 'Phenytoin ', 'Nimodipine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4853, 159, 'Phenytoin ', 'Nisoldipine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4854, 159, 'Phenytoin ', 'Nitrazepam', ' Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.', NULL, NULL, NULL),
(4855, 159, 'Phenytoin ', 'Nitrendipine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4856, 159, 'Phenytoin ', 'Nitric Oxide', ' May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.', NULL, NULL, NULL),
(4857, 159, 'Phenytoin ', 'Norelgestromin', ' May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.', NULL, NULL, NULL),
(4858, 159, 'Phenytoin ', 'Norethindrone', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(4859, 159, 'Phenytoin ', 'Norgestimate', ' May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.', NULL, NULL, NULL),
(4860, 159, 'Phenytoin ', 'Omeprazole', ' May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Omeprazole.', NULL, NULL, NULL),
(4861, 159, 'Phenytoin ', 'Orlistat', ' May decrease the serum concentration of Anticonvulsants.', NULL, NULL, NULL),
(4862, 159, 'Phenytoin ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(4863, 159, 'Phenytoin ', 'Oxazepam', ' Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.', NULL, NULL, NULL),
(4864, 159, 'Phenytoin ', 'Oxcarbazepine', ' Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically~ concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin.', NULL, NULL, NULL),
(4865, 159, 'Phenytoin ', 'Paliperidone', ' Inducers of CYP3A4 and P-glycoprotein may decrease the serum concentration of Paliperidone.', NULL, NULL, NULL),
(4866, 159, 'Phenytoin ', 'Panobinostat', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat.', NULL, NULL, NULL),
(4867, 159, 'Phenytoin ', 'Pazopanib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(4868, 159, 'Phenytoin ', 'Perampanel', ' Phenytoin may decrease the serum concentration of Perampanel.', NULL, NULL, NULL),
(4869, 159, 'Phenytoin ', 'Perhexiline', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4870, 159, 'Phenytoin ', 'Pethidine', ' May decrease the serum concentration of Meperidine.', NULL, NULL, NULL),
(4871, 159, 'Phenytoin ', 'Phendimetrazine', ' Amphetamines may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4872, 159, 'Phenytoin ', 'Phenobarbital', ' Phenytoin may enhance the CNS depressant effect of PHENobarbital. PHENobarbital may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of PHENobarbital.', NULL, NULL, NULL),
(4873, 159, 'Phenytoin ', 'Phentermine', ' Amphetamines may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4874, 159, 'Phenytoin ', 'Ponatinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib.', NULL, NULL, NULL),
(4875, 159, 'Phenytoin ', 'Posaconazole', ' May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Phenytoin. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(4876, 159, 'Phenytoin ', 'Pramipexole', ' CNS Depressants may enhance the sedative effect of Pramipexole.', NULL, NULL, NULL),
(4877, 159, 'Phenytoin ', 'Pravastatin', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(4878, 159, 'Phenytoin ', 'Praziquantel', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.', NULL, NULL, NULL),
(4879, 159, 'Phenytoin ', 'Prednisone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE.', NULL, NULL, NULL),
(4880, 159, 'Phenytoin ', 'Prenylamine', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4881, 159, 'Phenytoin ', 'Prilocaine', ' Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.', NULL, NULL, NULL),
(4882, 159, 'Phenytoin ', 'Primidone', ' Phenytoin may increase the metabolism of Primidone. The ratio of primidone:phenobarbital is thus changed.', NULL, NULL, NULL),
(4883, 159, 'Phenytoin ', 'Pyridoxine', ' Pyridoxine may increase the metabolism of Phenytoin. This is most apparent in high pyridoxine doses (e.g.~ 80 mg to 200 mg daily)', NULL, NULL, NULL),
(4884, 159, 'Phenytoin ', 'Quazepam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4885, 159, 'Phenytoin ', 'Quetiapine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of QUEtiapine.', NULL, NULL, NULL),
(4886, 159, 'Phenytoin ', 'Quinidine', ' Phenytoin may decrease the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(4887, 159, 'Phenytoin ', 'Quinine', ' Phenytoin may decrease the serum concentration of QuiNINE.', NULL, NULL, NULL),
(4888, 159, 'Phenytoin ', 'Ranolazine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.', NULL, NULL, NULL),
(4889, 159, 'Phenytoin ', 'Regorafenib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.', NULL, NULL, NULL),
(4890, 159, 'Phenytoin ', 'Rifampicin', ' Rifampin may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4891, 159, 'Phenytoin ', 'Rilpivirine', ' Phenytoin may decrease the serum concentration of Rilpivirine.', NULL, NULL, NULL),
(4892, 159, 'Phenytoin ', 'Risedronate', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4893, 159, 'Phenytoin ', 'Ritonavir', ' Phenytoin may decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4894, 159, 'Phenytoin ', 'Rivaroxaban', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.', NULL, NULL, NULL),
(4895, 159, 'Phenytoin ', 'Roflumilast', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.', NULL, NULL, NULL),
(4896, 159, 'Phenytoin ', 'Romidepsin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.', NULL, NULL, NULL),
(4897, 159, 'Phenytoin ', 'Ropinirole', ' CNS Depressants may enhance the sedative effect of ROPINIRole.', NULL, NULL, NULL),
(4898, 159, 'Phenytoin ', 'Rotigotine', ' CNS Depressants may enhance the sedative effect of Rotigotine.', NULL, NULL, NULL),
(4899, 159, 'Phenytoin ', 'Rufinamide', ' Phenytoin may decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4900, 159, 'Phenytoin ', 'Saxagliptin', ' CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.', NULL, NULL, NULL),
(4901, 159, 'Phenytoin ', 'Sertraline', ' Phenytoin may decrease the serum concentration of Sertraline. Sertraline may increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4902, 159, 'Phenytoin ', 'Simeprevir', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Simeprevir.', NULL, NULL, NULL),
(4903, 159, 'Phenytoin ', 'Simvastatin', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(4904, 159, 'Phenytoin ', 'Sirolimus', ' Phenytoin may decrease the serum concentration of Sirolimus.', NULL, NULL, NULL),
(4905, 159, 'Phenytoin ', 'Sofosbuvir', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir.', NULL, NULL, NULL),
(4906, 159, 'Phenytoin ', 'Sorafenib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.', NULL, NULL, NULL),
(4907, 159, 'Phenytoin ', 'Sulfamethoxazole', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4908, 159, 'Phenytoin ', 'Sunitinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.', NULL, NULL, NULL),
(4909, 159, 'Phenytoin ', 'Suvorexant', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant.', NULL, NULL, NULL),
(4910, 159, 'Phenytoin ', 'Tadalafil', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.', NULL, NULL, NULL),
(4911, 159, 'Phenytoin ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(4912, 159, 'Phenytoin ', 'Telaprevir', ' Phenytoin may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4913, 159, 'Phenytoin ', 'Temazepam', ' Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.', NULL, NULL, NULL),
(4914, 159, 'Phenytoin ', 'Temsirolimus', ' Phenytoin may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite~ sirolimus~ are also likely to be decreased (and maybe to an even greater degree).', NULL, NULL, NULL),
(4915, 159, 'Phenytoin ', 'Teniposide', ' Phenytoin may decrease the serum concentration of Teniposide.', NULL, NULL, NULL),
(4916, 159, 'Phenytoin ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(4917, 159, 'Phenytoin ', 'Theophylline', ' Theophylline Derivatives may decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Theophylline Derivatives.', NULL, NULL, NULL),
(4918, 159, 'Phenytoin ', 'Ticagrelor', ' CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.', NULL, NULL, NULL),
(4919, 159, 'Phenytoin ', 'Ticlopidine', ' Ticlopidine may increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4920, 159, 'Phenytoin ', 'Tipranavir', ' Phenytoin may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4921, 159, 'Phenytoin ', 'Tofacitinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.', NULL, NULL, NULL),
(4922, 159, 'Phenytoin ', 'Tofisopam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4923, 159, 'Phenytoin ', 'Tolvaptan', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.', NULL, NULL, NULL),
(4924, 159, 'Phenytoin ', 'Topiramate', ' Phenytoin may decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4925, 159, 'Phenytoin ', 'Topotecan', ' Fosphenytoin-Phenytoin may decrease the serum concentration of Topotecan.', NULL, NULL, NULL),
(4926, 159, 'Phenytoin ', 'Toremifene', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.', NULL, NULL, NULL),
(4927, 159, 'Phenytoin ', 'Trabectedin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin.', NULL, NULL, NULL),
(4928, 159, 'Phenytoin ', 'Trazodone', ' Phenytoin may decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4929, 159, 'Phenytoin ', 'Treprostinil', ' CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.', NULL, NULL, NULL),
(4930, 159, 'Phenytoin ', 'Triazolam', ' May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.', NULL, NULL, NULL),
(4931, 159, 'Phenytoin ', 'Trimethoprim', ' Phenytoin may decrease the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4932, 159, 'Phenytoin ', 'Ulipristal', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.', NULL, NULL, NULL),
(4933, 159, 'Phenytoin ', 'Vandetanib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.', NULL, NULL, NULL),
(4934, 159, 'Phenytoin ', 'Vemurafenib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.', NULL, NULL, NULL),
(4935, 159, 'Phenytoin ', 'Verapamil', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4936, 159, 'Phenytoin ', 'Vigabatrin', ' May decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4937, 159, 'Phenytoin ', 'Vilazodone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.', NULL, NULL, NULL),
(4938, 159, 'Phenytoin ', 'Vincristine', ' Phenytoin may decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(4939, 159, 'Phenytoin ', 'Vorapaxar', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar.', NULL, NULL, NULL),
(4940, 159, 'Phenytoin ', 'Voriconazole', ' May decrease the serum concentration of Antifungal Agents (Azole Derivatives~ Systemic). Antifungal Agents (Azole Derivatives~ Systemic) may increase the serum concentration of Phenytoin. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(4941, 159, 'Phenytoin ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(4942, 159, 'Phenytoin ', 'Zonisamide', ' Phenytoin may decrease the serum concentration of Zonisamide.', NULL, NULL, NULL),
(4943, 159, 'Phenytoin ', 'Zuclopenthixol', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.', NULL, NULL, NULL),
(4944, 160, 'Pilocarpine ', '0', '0', NULL, NULL, NULL),
(4945, 160, 'Pilocarpine ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(4946, 160, 'Pilocarpine ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(4947, 160, 'Pilocarpine ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(4948, 160, 'Pilocarpine ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(4949, 160, 'Pilocarpine ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(4950, 161, 'Piperacillin Sodium ', '0', '0', NULL, NULL, NULL),
(4951, 162, 'Praziquantel ', '0', '0', NULL, NULL, NULL),
(4952, 162, 'Praziquantel ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4953, 162, 'Praziquantel ', 'Aripiprazole', ' CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(4954, 162, 'Praziquantel ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4955, 162, 'Praziquantel ', 'Carbamazepine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.', NULL, NULL, NULL),
(4956, 162, 'Praziquantel ', 'Cimetidine', ' Cimetidine may increase the serum concentration of Praziquantel.', NULL, NULL, NULL),
(4957, 162, 'Praziquantel ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4958, 162, 'Praziquantel ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4959, 162, 'Praziquantel ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4960, 162, 'Praziquantel ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4961, 162, 'Praziquantel ', 'Enzalutamide', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.', NULL, NULL, NULL),
(4962, 162, 'Praziquantel ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4963, 162, 'Praziquantel ', 'Fosphenytoin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.', NULL, NULL, NULL),
(4964, 162, 'Praziquantel ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4965, 162, 'Praziquantel ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4966, 162, 'Praziquantel ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4967, 162, 'Praziquantel ', 'Phenobarbital', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.', NULL, NULL, NULL),
(4968, 162, 'Praziquantel ', 'Phenytoin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.', NULL, NULL, NULL),
(4969, 162, 'Praziquantel ', 'Primidone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.', NULL, NULL, NULL),
(4970, 162, 'Praziquantel ', 'Rifampicin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.', NULL, NULL, NULL),
(4971, 162, 'Praziquantel ', 'Rifapentine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.', NULL, NULL, NULL),
(4972, 162, 'Praziquantel ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4973, 162, 'Praziquantel ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4974, 162, 'Praziquantel ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(4975, 163, 'Prednisolone ', '0', '0', NULL, NULL, NULL),
(4976, 164, 'Primaquine Diphosphate ', '0', '0', NULL, NULL, NULL),
(4977, 165, 'Procainamide ', '0', '0', NULL, NULL, NULL),
(4978, 165, 'Procainamide ', 'Amiodarone', ' May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).', NULL, NULL, NULL),
(4979, 165, 'Procainamide ', 'Atracurium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(4980, 165, 'Procainamide ', 'Cimetidine', ' Cimetidine may decrease the excretion of Procainamide.', NULL, NULL, NULL),
(4981, 165, 'Procainamide ', 'Cisatracurium Besylate', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(4982, 165, 'Procainamide ', 'Darunavir', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(4983, 165, 'Procainamide ', 'Fingolimod', ' May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).', NULL, NULL, NULL),
(4984, 165, 'Procainamide ', 'Lamotrigine', ' LamoTRIgine may increase the serum concentration of Procainamide.', NULL, NULL, NULL),
(4985, 165, 'Procainamide ', 'Lurasidone', ' May enhance the QTc-prolonging effect of Procainamide.', NULL, NULL, NULL),
(4986, 165, 'Procainamide ', 'Mifepristone', ' May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.', NULL, NULL, NULL),
(4987, 165, 'Procainamide ', 'Pancuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(4988, 165, 'Procainamide ', 'Peginterferon alfa-2b', ' May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(4989, 165, 'Procainamide ', 'Propafenone', ' May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).', NULL, NULL, NULL),
(4990, 165, 'Procainamide ', 'Ranitidine', ' Ranitidine may increase the serum concentration of Procainamide. Ranitidine may also increase the concentration of the active N-acetyl-procainamide (NAPA) metabolite.', NULL, NULL, NULL),
(4991, 165, 'Procainamide ', 'Rocuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(4992, 165, 'Procainamide ', 'Succinylcholine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(4993, 165, 'Procainamide ', 'Sulfamethoxazole', ' Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.', NULL, NULL, NULL),
(4994, 165, 'Procainamide ', 'Trimethoprim', ' Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.', NULL, NULL, NULL),
(4995, 165, 'Procainamide ', 'Vecuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(4996, 166, 'Procarbazine ', '0', '0', NULL, NULL, NULL),
(4997, 166, 'Procarbazine ', 'Acepromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(4998, 166, 'Procarbazine ', 'Acetophenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(4999, 166, 'Procarbazine ', 'Altretamine', ' May enhance the orthostatic hypotensive effect of MAO Inhibitors.', NULL, NULL, NULL),
(5000, 166, 'Procarbazine ', 'Amisulpride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5001, 166, 'Procarbazine ', 'Amphetamine', ' MAO Inhibitors may enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism~ management recommendations differ from other monoamine oxidase inhibitors. Refer to monographs specific to those agents for details.', NULL, NULL, NULL),
(5002, 166, 'Procarbazine ', 'Apraclonidine', ' MAO Inhibitors may enhance the adverse/toxic effect of Apraclonidine. MAO Inhibitors may increase the serum concentration of Apraclonidine.', NULL, NULL, NULL),
(5003, 166, 'Procarbazine ', 'Aripiprazole', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5004, 166, 'Procarbazine ', 'Atomoxetine', ' MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.', NULL, NULL, NULL),
(5005, 166, 'Procarbazine ', 'Benzquinamide', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5006, 166, 'Procarbazine ', 'Betahistine', ' MAO Inhibitors may increase the serum concentration of Betahistine.', NULL, NULL, NULL),
(5007, 166, 'Procarbazine ', 'Bezafibrate', ' MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.', NULL, NULL, NULL),
(5008, 166, 'Procarbazine ', 'Buprenorphine', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(5009, 166, 'Procarbazine ', 'Bupropion', ' MAO Inhibitors may enhance the hypertensive effect of BuPROPion.', NULL, NULL, NULL),
(5010, 166, 'Procarbazine ', 'Buspirone', ' May enhance the adverse/toxic effect of MAO Inhibitors. Specifically~ blood pressure elevations been reported.', NULL, NULL, NULL),
(5011, 166, 'Procarbazine ', 'Carbamazepine', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(5012, 166, 'Procarbazine ', 'Carphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5013, 166, 'Procarbazine ', 'Cathinone', ' MAO Inhibitors may enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism~ management recommendations differ from other monoamine oxidase inhibitors. Refer to monographs specific to those agents for details.', NULL, NULL, NULL),
(5014, 166, 'Procarbazine ', 'Chlormezanone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5015, 166, 'Procarbazine ', 'Chlorpromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5016, 166, 'Procarbazine ', 'Chlorprothixene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5017, 166, 'Procarbazine ', 'Clozapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5018, 166, 'Procarbazine ', 'Cyclobenzaprine', ' May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5019, 166, 'Procarbazine ', 'Cyproheptadine', ' MAO Inhibitors may enhance the anticholinergic effect of Cyproheptadine. Cyproheptadine may diminish the serotonergic effect of MAO Inhibitors.', NULL, NULL, NULL),
(5020, 166, 'Procarbazine ', 'Dapoxetine', ' May enhance the adverse/toxic effect of Serotonin Modulators.', NULL, NULL, NULL),
(5021, 166, 'Procarbazine ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(5022, 166, 'Procarbazine ', 'Dexmethylphenidate', ' MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.', NULL, NULL, NULL),
(5023, 166, 'Procarbazine ', 'Dextromethorphan', ' MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.', NULL, NULL, NULL),
(5024, 166, 'Procarbazine ', 'Diethylpropion', ' MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.', NULL, NULL, NULL),
(5025, 166, 'Procarbazine ', 'Domperidone', ' MAO Inhibitors may enhance the adverse/toxic effect of Domperidone. MAO Inhibitors may diminish the therapeutic effect of Domperidone. Domperidone may diminish the therapeutic effect of MAO Inhibitors.', NULL, NULL, NULL),
(5026, 166, 'Procarbazine ', 'Doxapram', ' MAO Inhibitors may enhance the hypertensive effect of Doxapram.', NULL, NULL, NULL),
(5027, 166, 'Procarbazine ', 'Doxylamine', ' MAO Inhibitors may enhance the anticholinergic effect of Doxylamine.', NULL, NULL, NULL),
(5028, 166, 'Procarbazine ', 'Droperidol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5029, 166, 'Procarbazine ', 'Fencamfamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5030, 166, 'Procarbazine ', 'Flupentixol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5031, 166, 'Procarbazine ', 'Fluphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5032, 166, 'Procarbazine ', 'Fluspirilene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5033, 166, 'Procarbazine ', 'Haloperidol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5034, 166, 'Procarbazine ', 'Hydrocodone', ' MAO Inhibitors may enhance the adverse/toxic effect of Hydrocodone.', NULL, NULL, NULL),
(5035, 166, 'Procarbazine ', 'Hydromorphone', ' MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.', NULL, NULL, NULL),
(5036, 166, 'Procarbazine ', 'Isometheptene', ' MAO Inhibitors may enhance the adverse/toxic effect of Isometheptene.', NULL, NULL, NULL),
(5037, 166, 'Procarbazine ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(5038, 166, 'Procarbazine ', 'Levonordefrin', ' MAO Inhibitors may enhance the hypertensive effect of Levonordefrin.', NULL, NULL, NULL),
(5039, 166, 'Procarbazine ', 'Linezolid', ' MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.', NULL, NULL, NULL),
(5040, 166, 'Procarbazine ', 'Lithium', ' MAO Inhibitors may enhance the adverse/toxic effect of Lithium.', NULL, NULL, NULL),
(5041, 166, 'Procarbazine ', 'Loxapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5042, 166, 'Procarbazine ', 'Maprotiline', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(5043, 166, 'Procarbazine ', 'Mequitazine', ' MAO Inhibitors may enhance the anticholinergic effect of Mequitazine.', NULL, NULL, NULL),
(5044, 166, 'Procarbazine ', 'Mesoridazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5045, 166, 'Procarbazine ', 'Methadone', ' MAO Inhibitors may enhance the adverse/toxic effect of Methadone.', NULL, NULL, NULL),
(5046, 166, 'Procarbazine ', 'Methotrimeprazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5047, 166, 'Procarbazine ', 'Methyldopa', ' MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.', NULL, NULL, NULL),
(5048, 166, 'Procarbazine ', 'Methylphenidate', ' MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.', NULL, NULL, NULL),
(5049, 166, 'Procarbazine ', 'Metoclopramide', ' Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.', NULL, NULL, NULL),
(5050, 166, 'Procarbazine ', 'Mianserin', ' MAO Inhibitors may enhance the neurotoxic effect of Mianserin.', NULL, NULL, NULL),
(5051, 166, 'Procarbazine ', 'Mirtazapine', ' MAO Inhibitors may enhance the neurotoxic (central) effect of Mirtazapine. While methylene blue and linezolid are expected to interact~ specific recommendations for their use differ from other monoamine oxidase inhibitors. Refer to monographs specific to those agents for details.', NULL, NULL, NULL),
(5052, 166, 'Procarbazine ', 'Molindone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5053, 166, 'Procarbazine ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(5054, 166, 'Procarbazine ', 'Norepinephrine', ' MAO Inhibitors may enhance the hypertensive effect of Norepinephrine.', NULL, NULL, NULL),
(5055, 166, 'Procarbazine ', 'Olanzapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5056, 166, 'Procarbazine ', 'Ondansetron', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5057, 166, 'Procarbazine ', 'Oxycodone', ' MAO Inhibitors may enhance the adverse/toxic effect of OxyCODONE.', NULL, NULL, NULL),
(5058, 166, 'Procarbazine ', 'Oxymorphone', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(5059, 166, 'Procarbazine ', 'Paliperidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5060, 166, 'Procarbazine ', 'Perphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5061, 166, 'Procarbazine ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(5062, 166, 'Procarbazine ', 'Pimozide', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5063, 166, 'Procarbazine ', 'Piperacetazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5064, 166, 'Procarbazine ', 'Pizotifen', ' MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.', NULL, NULL, NULL),
(5065, 166, 'Procarbazine ', 'Prochlorperazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5066, 166, 'Procarbazine ', 'Promazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5067, 166, 'Procarbazine ', 'Quetiapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5068, 166, 'Procarbazine ', 'Remoxipride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5069, 166, 'Procarbazine ', 'Reserpine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5070, 166, 'Procarbazine ', 'Risperidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5071, 166, 'Procarbazine ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(5072, 166, 'Procarbazine ', 'Sertindole', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5073, 166, 'Procarbazine ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(5074, 166, 'Procarbazine ', 'Sulpiride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5075, 166, 'Procarbazine ', 'Tapentadol', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(5076, 166, 'Procarbazine ', 'Tetrabenazine', ' May enhance the adverse/toxic effect of MAO Inhibitors.', NULL, NULL, NULL),
(5077, 166, 'Procarbazine ', 'Thioridazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5078, 166, 'Procarbazine ', 'Thiothixene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5079, 166, 'Procarbazine ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(5080, 166, 'Procarbazine ', 'Tramadol', ' May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.', NULL, NULL, NULL),
(5081, 166, 'Procarbazine ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(5082, 166, 'Procarbazine ', 'Trifluoperazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5083, 166, 'Procarbazine ', 'Triflupromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5084, 166, 'Procarbazine ', 'Ziprasidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5085, 166, 'Procarbazine ', 'Zuclopenthixol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(5086, 167, 'Promethazine Hydrochloride ', '0', '0', NULL, NULL, NULL),
(5087, 168, 'Propofol ', '0', '0', NULL, NULL, NULL),
(5088, 168, 'Propofol ', 'Alfentanil', ' Alfentanil may enhance the adverse/toxic effect of Propofol. Specifically the development of opisthotonus (severe hyperextension and spasticity resulting in arching or bridging position) and/or grand mal seizures.', NULL, NULL, NULL),
(5089, 168, 'Propofol ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(5090, 168, 'Propofol ', 'Buprenorphine', ' CNS Depressants may enhance the CNS depressant effect of Buprenorphine.', NULL, NULL, NULL),
(5091, 168, 'Propofol ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(5092, 168, 'Propofol ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(5093, 168, 'Propofol ', 'Droperidol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(5094, 168, 'Propofol ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(5095, 168, 'Propofol ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(5096, 168, 'Propofol ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(5097, 168, 'Propofol ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(5098, 168, 'Propofol ', 'Methotrimeprazine', ' CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(5099, 168, 'Propofol ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(5100, 168, 'Propofol ', 'Midazolam', ' Midazolam may increase the serum concentration of Propofol. Propofol may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(5101, 168, 'Propofol ', 'Mifepristone', ' May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).', NULL, NULL, NULL),
(5102, 168, 'Propofol ', 'Mirtazapine', ' CNS Depressants may enhance the CNS depressant effect of Mirtazapine.', NULL, NULL, NULL),
(5103, 168, 'Propofol ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(5104, 168, 'Propofol ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(5105, 168, 'Propofol ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(5106, 168, 'Propofol ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(5107, 168, 'Propofol ', 'Pramipexole', ' CNS Depressants may enhance the sedative effect of Pramipexole.', NULL, NULL, NULL),
(5108, 168, 'Propofol ', 'Quazepam', ' May increase the serum concentration of CYP2B6 Substrates.', NULL, NULL, NULL),
(5109, 168, 'Propofol ', 'Rifampicin', ' Rifampin may enhance the hypotensive effect of Propofol.', NULL, NULL, NULL),
(5110, 168, 'Propofol ', 'Ropinirole', ' CNS Depressants may enhance the sedative effect of ROPINIRole.', NULL, NULL, NULL),
(5111, 168, 'Propofol ', 'Ropivacaine', ' May increase the serum concentration of Ropivacaine.', NULL, NULL, NULL),
(5112, 168, 'Propofol ', 'Rotigotine', ' CNS Depressants may enhance the sedative effect of Rotigotine.', NULL, NULL, NULL),
(5113, 168, 'Propofol ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(5114, 168, 'Propofol ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(5115, 168, 'Propofol ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(5116, 168, 'Propofol ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(5117, 168, 'Propofol ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(5118, 169, 'Propranolol Hydrochloride ', '0', '0', NULL, NULL, NULL),
(5119, 170, 'Propylthiouracil ', '0', '0', NULL, NULL, NULL),
(5120, 170, 'Propylthiouracil ', 'Acenocoumarol', ' May diminish the anticoagulant effect of Vitamin K Antagonists.', NULL, NULL, NULL),
(5121, 170, 'Propylthiouracil ', 'Aminophylline', ' May increase the serum concentration of Theophylline Derivatives.', NULL, NULL, NULL),
(5122, 170, 'Propylthiouracil ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(5123, 170, 'Propylthiouracil ', 'Digoxin', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(5124, 170, 'Propylthiouracil ', 'Theophylline', ' May increase the serum concentration of Theophylline Derivatives.', NULL, NULL, NULL),
(5125, 171, 'Protamine Sulfate ', '0', '0', NULL, NULL, NULL),
(5126, 172, 'Pyrazinamide ', '0', '0', NULL, NULL, NULL),
(5127, 172, 'Pyrazinamide ', 'Rifampicin', ' May enhance the hepatotoxic effect of Rifampin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection.', NULL, NULL, NULL),
(5128, 173, 'Quinidine ', '0', '0', NULL, NULL, NULL),
(5129, 173, 'Quinidine ', 'Acenocoumarol', ' May enhance the anticoagulant effect of Vitamin K Antagonists. Note that the INR/PT might be unchanged in the face of increased bleeding.', NULL, NULL, NULL),
(5130, 173, 'Quinidine ', 'Acetazolamide', ' Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.', NULL, NULL, NULL),
(5131, 173, 'Quinidine ', 'Afatinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.', NULL, NULL, NULL),
(5132, 173, 'Quinidine ', 'Aluminum hydroxide', ' May decrease the excretion of QuiNIDine. Exceptions: Aluminum Hydroxide.', NULL, NULL, NULL),
(5133, 173, 'Quinidine ', 'Amiloride', ' Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.', NULL, NULL, NULL),
(5134, 173, 'Quinidine ', 'Amiodarone', ' May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).', NULL, NULL, NULL),
(5135, 173, 'Quinidine ', 'Amitriptyline', ' Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(5136, 173, 'Quinidine ', 'Amlodipine', ' May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5137, 173, 'Quinidine ', 'Amoxapine', ' Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(5138, 173, 'Quinidine ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5139, 173, 'Quinidine ', 'Aripiprazole', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(5140, 173, 'Quinidine ', 'Atazanavir', ' May increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5141, 173, 'Quinidine ', 'Atomoxetine', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.', NULL, NULL, NULL),
(5142, 173, 'Quinidine ', 'Atracurium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(5143, 173, 'Quinidine ', 'Boceprevir', ' May increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5144, 173, 'Quinidine ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5145, 173, 'Quinidine ', 'Bosutinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.', NULL, NULL, NULL),
(5146, 173, 'Quinidine ', 'Brentuximab vedotin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.', NULL, NULL, NULL),
(5147, 173, 'Quinidine ', 'Calcium carbonate', ' May decrease the excretion of QuiNIDine. Exceptions: Aluminum Hydroxide.', NULL, NULL, NULL),
(5148, 173, 'Quinidine ', 'Cimetidine', ' Cimetidine may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5149, 173, 'Quinidine ', 'Cisatracurium Besylate', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(5150, 173, 'Quinidine ', 'Clarithromycin', ' Macrolide Antibiotics may enhance the QTc-prolonging effect of QuiNIDine. Macrolide Antibiotics may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5151, 173, 'Quinidine ', 'Clevidipine', ' May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5152, 173, 'Quinidine ', 'Clomipramine', ' Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(5153, 173, 'Quinidine ', 'Codeine', ' CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.', NULL, NULL, NULL),
(5154, 173, 'Quinidine ', 'Colchicine', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(5155, 173, 'Quinidine ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5156, 173, 'Quinidine ', 'Crizotinib', ' May enhance the QTc-prolonging effect of QuiNIDine. Crizotinib may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5157, 173, 'Quinidine ', 'Dabigatran etexilate', ' QuiNIDine may increase the serum concentration of Dabigatran Etexilate.', NULL, NULL, NULL),
(5158, 173, 'Quinidine ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5159, 173, 'Quinidine ', 'Dalfampridine', ' QuiNIDine may increase the serum concentration of Dalfampridine.', NULL, NULL, NULL),
(5160, 173, 'Quinidine ', 'Darunavir', ' May increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5161, 173, 'Quinidine ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5162, 173, 'Quinidine ', 'Desipramine', ' Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(5163, 173, 'Quinidine ', 'Dextromethorphan', ' May increase the serum concentration of Dextromethorphan.', NULL, NULL, NULL),
(5164, 173, 'Quinidine ', 'Diclofenamide', ' May decrease the excretion of QuiNIDine. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(5165, 173, 'Quinidine ', 'Digoxin', ' May increase the serum concentration of Cardiac Glycosides.', NULL, NULL, NULL),
(5166, 173, 'Quinidine ', 'Dihydrocodeine', ' QuiNIDine may diminish the analgesic effect of Dihydrocodeine.', NULL, NULL, NULL),
(5167, 173, 'Quinidine ', 'Diltiazem', ' Diltiazem may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5168, 173, 'Quinidine ', 'Drospirenone', ' Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.', NULL, NULL, NULL),
(5169, 173, 'Quinidine ', 'Enzalutamide', ' May decrease the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5170, 173, 'Quinidine ', 'Eplerenone', ' Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.', NULL, NULL, NULL),
(5171, 173, 'Quinidine ', 'Ethoxzolamide', ' May decrease the excretion of QuiNIDine. Exceptions: Brinzolamide; Dorzolamide.', NULL, NULL, NULL),
(5172, 173, 'Quinidine ', 'Etravirine', ' May decrease the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5173, 173, 'Quinidine ', 'Everolimus', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.', NULL, NULL, NULL),
(5174, 173, 'Quinidine ', 'Fesoterodine', ' CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.', NULL, NULL, NULL),
(5175, 173, 'Quinidine ', 'Fingolimod', ' May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).', NULL, NULL, NULL),
(5176, 173, 'Quinidine ', 'Fluconazole', ' Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(5177, 173, 'Quinidine ', 'Fluvoxamine', ' FluvoxaMINE may increase the serum concentration of QuiNIDine. QuiNIDine may increase the serum concentration of FluvoxaMINE.', NULL, NULL, NULL),
(5178, 173, 'Quinidine ', 'Fosamprenavir', ' May increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5179, 173, 'Quinidine ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5180, 173, 'Quinidine ', 'Fosphenytoin', ' May enhance the QTc-prolonging effect of QuiNIDine. Fosphenytoin may decrease the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5181, 173, 'Quinidine ', 'Haloperidol', ' Haloperidol may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Haloperidol.', NULL, NULL, NULL),
(5182, 173, 'Quinidine ', 'Hydrocodone', ' QuiNIDine may decrease serum concentrations of the active metabolite(s) of Hydrocodone.', NULL, NULL, NULL),
(5183, 173, 'Quinidine ', 'Imipramine', ' Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(5184, 173, 'Quinidine ', 'Indinavir', ' Indinavir may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5185, 173, 'Quinidine ', 'Itraconazole', ' Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(5186, 173, 'Quinidine ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5187, 173, 'Quinidine ', 'Kaolin', ' May decrease the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5188, 173, 'Quinidine ', 'Ledipasvir', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(5189, 173, 'Quinidine ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(5190, 173, 'Quinidine ', 'Lopinavir', ' May enhance the QTc-prolonging effect of QuiNIDine. Lopinavir may increase the serum concentration of QuiNIDine. Specifically~ lopinavir/ritonavir may increase the serum concentration of quinidine.', NULL, NULL, NULL),
(5191, 173, 'Quinidine ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5192, 173, 'Quinidine ', 'Lurasidone', ' May enhance the QTc-prolonging effect of QuiNIDine.', NULL, NULL, NULL),
(5193, 173, 'Quinidine ', 'Magnesium oxide', ' May decrease the excretion of QuiNIDine. Exceptions: Aluminum Hydroxide.', NULL, NULL, NULL),
(5194, 173, 'Quinidine ', 'Mefloquine', ' May enhance the adverse/toxic effect of Mefloquine. Specifically~ the risk for QTc-prolongation and the risk for convulsions may be increased.', NULL, NULL, NULL),
(5195, 173, 'Quinidine ', 'Mequitazine', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine.', NULL, NULL, NULL),
(5196, 173, 'Quinidine ', 'Methazolamide', ' Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.', NULL, NULL, NULL),
(5197, 173, 'Quinidine ', 'Metoprolol', ' CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.', NULL, NULL, NULL),
(5198, 173, 'Quinidine ', 'Mifepristone', ' Mifepristone may enhance the QTc-prolonging effect of QuiNIDine. Mifepristone may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5199, 173, 'Quinidine ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5200, 173, 'Quinidine ', 'Nebivolol', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.', NULL, NULL, NULL),
(5201, 173, 'Quinidine ', 'Nelfinavir', ' Nelfinavir may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5202, 173, 'Quinidine ', 'Nifedipine', ' May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5203, 173, 'Quinidine ', 'Nimodipine', ' May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5204, 173, 'Quinidine ', 'Nortriptyline', ' Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(5205, 173, 'Quinidine ', 'Pancuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(5206, 173, 'Quinidine ', 'Pazopanib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(5207, 173, 'Quinidine ', 'Phenobarbital', ' May enhance the hepatotoxic effect of QuiNIDine. PHENobarbital may decrease the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5208, 173, 'Quinidine ', 'Phenytoin', ' Phenytoin may decrease the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5209, 173, 'Quinidine ', 'Pimozide', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(5210, 173, 'Quinidine ', 'Posaconazole', ' Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(5211, 173, 'Quinidine ', 'Primidone', ' Primidone may decrease the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5212, 173, 'Quinidine ', 'Propafenone', ' QuiNIDine may enhance the QTc-prolonging effect of Propafenone. QuiNIDine may increase the serum concentration of Propafenone.', NULL, NULL, NULL),
(5213, 173, 'Quinidine ', 'Propranolol', ' May increase the serum concentration of Propranolol.', NULL, NULL, NULL),
(5214, 173, 'Quinidine ', 'Protriptyline', ' Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(5215, 173, 'Quinidine ', 'prucalopride', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.', NULL, NULL, NULL),
(5216, 173, 'Quinidine ', 'Reserpine', ' Reserpine may enhance the adverse/toxic effect of QuiNIDine.', NULL, NULL, NULL),
(5217, 173, 'Quinidine ', 'Rifampicin', ' Rifamycin Derivatives may decrease the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5218, 173, 'Quinidine ', 'Rifapentine', ' Rifamycin Derivatives may decrease the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5219, 173, 'Quinidine ', 'Rifaximin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.', NULL, NULL, NULL),
(5220, 173, 'Quinidine ', 'Ritonavir', ' Ritonavir may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5221, 173, 'Quinidine ', 'Rivaroxaban', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.', NULL, NULL, NULL),
(5222, 173, 'Quinidine ', 'Rocuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(5223, 173, 'Quinidine ', 'Saquinavir', ' May enhance the QTc-prolonging effect of QuiNIDine. Saquinavir may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5224, 173, 'Quinidine ', 'Silodosin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.', NULL, NULL, NULL),
(5225, 173, 'Quinidine ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5226, 173, 'Quinidine ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5227, 173, 'Quinidine ', 'Sodium bicarbonate', ' Antacids may decrease the excretion of QuiNIDine.', NULL, NULL, NULL),
(5228, 173, 'Quinidine ', 'Spironolactone', ' Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.', NULL, NULL, NULL),
(5229, 173, 'Quinidine ', 'Succinylcholine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(5230, 173, 'Quinidine ', 'Sucralfate', ' Sucralfate may decrease the serum concentration of QuiNIDine. Specifically~ sucralfate may decrease the absorption of quinidine.', NULL, NULL, NULL),
(5231, 173, 'Quinidine ', 'Sulfisoxazole', ' Macrolide Antibiotics may enhance the QTc-prolonging effect of QuiNIDine. Macrolide Antibiotics may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5232, 173, 'Quinidine ', 'Tamoxifen', ' CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.', NULL, NULL, NULL),
(5233, 173, 'Quinidine ', 'Tamsulosin', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.', NULL, NULL, NULL),
(5234, 173, 'Quinidine ', 'Telaprevir', ' May enhance the adverse/toxic effect of QuiNIDine. Telaprevir may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5235, 173, 'Quinidine ', 'Telithromycin', ' Macrolide Antibiotics may enhance the QTc-prolonging effect of QuiNIDine. Macrolide Antibiotics may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5236, 173, 'Quinidine ', 'Thioridazine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(5237, 173, 'Quinidine ', 'Tipranavir', ' May increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5238, 173, 'Quinidine ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5239, 173, 'Quinidine ', 'Topiramate', ' Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.', NULL, NULL, NULL),
(5240, 173, 'Quinidine ', 'Topotecan', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.', NULL, NULL, NULL),
(5241, 173, 'Quinidine ', 'Tramadol', ' CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(5242, 173, 'Quinidine ', 'Triamterene', ' Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.', NULL, NULL, NULL),
(5243, 173, 'Quinidine ', 'Trimipramine', ' Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.', NULL, NULL, NULL),
(5244, 173, 'Quinidine ', 'Vecuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(5245, 173, 'Quinidine ', 'Verapamil', ' QuiNIDine may enhance the hypotensive effect of Verapamil. Verapamil may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5246, 173, 'Quinidine ', 'Voriconazole', ' Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs.', NULL, NULL, NULL),
(5247, 173, 'Quinidine ', 'Zonisamide', ' Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.', NULL, NULL, NULL),
(5248, 174, 'Quinine ', '0', '0', NULL, NULL, NULL),
(5249, 174, 'Quinine ', 'Acenocoumarol', ' May enhance the anticoagulant effect of Vitamin K Antagonists.', NULL, NULL, NULL),
(5250, 174, 'Quinine ', 'Acetohexamide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5251, 174, 'Quinine ', 'Acetylsalicylic acid', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.', NULL, NULL, NULL),
(5252, 174, 'Quinine ', 'Afatinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.', NULL, NULL, NULL),
(5253, 174, 'Quinine ', 'Alogliptin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5254, 174, 'Quinine ', 'Aluminum hydroxide', ' May decrease the serum concentration of QuiNINE. Exceptions: Calcium Carbonate; Sodium Bicarbonate.', NULL, NULL, NULL),
(5255, 174, 'Quinine ', 'Aminophylline', ' May increase the serum concentration of Theophylline Derivatives.', NULL, NULL, NULL),
(5256, 174, 'Quinine ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5257, 174, 'Quinine ', 'Artemether', ' May enhance the adverse/toxic effect of Antimalarial Agents.', NULL, NULL, NULL),
(5258, 174, 'Quinine ', 'Atorvastatin', ' May increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5259, 174, 'Quinine ', 'Atracurium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(5260, 174, 'Quinine ', 'Biotin', ' Tetracycline may increase the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5261, 174, 'Quinine ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5262, 174, 'Quinine ', 'Bosutinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.', NULL, NULL, NULL),
(5263, 174, 'Quinine ', 'Brentuximab vedotin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.', NULL, NULL, NULL),
(5264, 174, 'Quinine ', 'Buformin', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(5265, 174, 'Quinine ', 'Calcium carbonate', ' May decrease the serum concentration of QuiNINE. Exceptions: Calcium Carbonate; Sodium Bicarbonate.', NULL, NULL, NULL),
(5266, 174, 'Quinine ', 'Canagliflozin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5267, 174, 'Quinine ', 'Carbamazepine', ' May decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of CarBAMazepine.', NULL, NULL, NULL),
(5268, 174, 'Quinine ', 'Carvedilol', ' CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically~ concentrations of the S-carvedilol enantiomer may be increased.', NULL, NULL, NULL),
(5269, 174, 'Quinine ', 'Chlorpropamide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5270, 174, 'Quinine ', 'Cimetidine', ' May increase the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5271, 174, 'Quinine ', 'Cisatracurium Besylate', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(5272, 174, 'Quinine ', 'Clarithromycin', ' Macrolide Antibiotics may increase the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5273, 174, 'Quinine ', 'Codeine', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.', NULL, NULL, NULL),
(5274, 174, 'Quinine ', 'Colchicine', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g.~ brain) may also be increased.', NULL, NULL, NULL),
(5275, 174, 'Quinine ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5276, 174, 'Quinine ', 'Dabigatran etexilate', ' P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.', NULL, NULL, NULL),
(5277, 174, 'Quinine ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5278, 174, 'Quinine ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5279, 174, 'Quinine ', 'Digoxin', ' May increase the serum concentration of Digoxin.', NULL, NULL, NULL),
(5280, 174, 'Quinine ', 'Dihydrotestosterone', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.', NULL, NULL, NULL),
(5281, 174, 'Quinine ', 'Dronabinol', ' CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.', NULL, NULL, NULL),
(5282, 174, 'Quinine ', 'Everolimus', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.', NULL, NULL, NULL),
(5283, 174, 'Quinine ', 'Exenatide', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(5284, 174, 'Quinine ', 'Fesoterodine', ' CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.', NULL, NULL, NULL),
(5285, 174, 'Quinine ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5286, 174, 'Quinine ', 'Fosphenytoin', ' May decrease the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5287, 174, 'Quinine ', 'Gliclazide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5288, 174, 'Quinine ', 'Glimepiride', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5289, 174, 'Quinine ', 'Glipizide', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(5290, 174, 'Quinine ', 'Gliquidone', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5291, 174, 'Quinine ', 'Glucagon recombinant', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(5292, 174, 'Quinine ', 'Glyburide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5293, 174, 'Quinine ', 'Halofantrine', ' QuiNINE may enhance the adverse/toxic effect of Halofantrine. QuiNINE may increase the serum concentration of Halofantrine.', NULL, NULL, NULL),
(5294, 174, 'Quinine ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(5295, 174, 'Quinine ', 'Insulin Aspart', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5296, 174, 'Quinine ', 'Insulin Detemir', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5297, 174, 'Quinine ', 'Insulin Glargine', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5298, 174, 'Quinine ', 'Insulin Glulisine', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5299, 174, 'Quinine ', 'Insulin Lispro', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5300, 174, 'Quinine ', 'Insulin Regular', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5301, 174, 'Quinine ', 'Insulin~ isophane', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5302, 174, 'Quinine ', 'Insulin~ porcine', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(5303, 174, 'Quinine ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5304, 174, 'Quinine ', 'Ledipasvir', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(5305, 174, 'Quinine ', 'Linagliptin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5306, 174, 'Quinine ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(5307, 174, 'Quinine ', 'Lopinavir', ' May decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir. The individual contributions of lopinavir and ritonavir to this effect are unclear.', NULL, NULL, NULL),
(5308, 174, 'Quinine ', 'Lovastatin', ' May increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5309, 174, 'Quinine ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5310, 174, 'Quinine ', 'Lumefantrine', ' Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.', NULL, NULL, NULL),
(5311, 174, 'Quinine ', 'Magnesium oxide', ' May decrease the serum concentration of QuiNINE. Exceptions: Calcium Carbonate; Sodium Bicarbonate.', NULL, NULL, NULL),
(5312, 174, 'Quinine ', 'Mefloquine', ' May enhance the adverse/toxic effect of Mefloquine. Specifically~ the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5313, 174, 'Quinine ', 'Metformin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5314, 174, 'Quinine ', 'Metoprolol', ' CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.', NULL, NULL, NULL),
(5315, 174, 'Quinine ', 'Mifepristone', ' May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.', NULL, NULL, NULL),
(5316, 174, 'Quinine ', 'Mitiglinide', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(5317, 174, 'Quinine ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5318, 174, 'Quinine ', 'Nateglinide', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(5319, 174, 'Quinine ', 'Nebivolol', ' CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.', NULL, NULL, NULL),
(5320, 174, 'Quinine ', 'Nitric Oxide', ' May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.', NULL, NULL, NULL),
(5321, 174, 'Quinine ', 'Oxandrolone', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.', NULL, NULL, NULL),
(5322, 174, 'Quinine ', 'Pancuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(5323, 174, 'Quinine ', 'Pazopanib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(5324, 174, 'Quinine ', 'Pegvisomant', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.', NULL, NULL, NULL),
(5325, 174, 'Quinine ', 'Phenformin', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(5326, 174, 'Quinine ', 'Phenobarbital', ' May decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of PHENobarbital.', NULL, NULL, NULL),
(5327, 174, 'Quinine ', 'Phenytoin', ' Phenytoin may decrease the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5328, 174, 'Quinine ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(5329, 174, 'Quinine ', 'Pioglitazone', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(5330, 174, 'Quinine ', 'Prilocaine', ' Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.', NULL, NULL, NULL),
(5331, 174, 'Quinine ', 'prucalopride', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.', NULL, NULL, NULL),
(5332, 174, 'Quinine ', 'Repaglinide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5333, 174, 'Quinine ', 'Rifampicin', ' Rifampin may decrease the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5334, 174, 'Quinine ', 'Rifaximin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.', NULL, NULL, NULL),
(5335, 174, 'Quinine ', 'Ritonavir', ' QuiNINE may increase the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir. The individual contributions of lopinavir and ritonavir to this effect are unclear. Ritonavir may increase the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5336, 174, 'Quinine ', 'Rivaroxaban', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.', NULL, NULL, NULL),
(5337, 174, 'Quinine ', 'Rocuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(5338, 174, 'Quinine ', 'Salicylate-sodium', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.', NULL, NULL, NULL),
(5339, 174, 'Quinine ', 'Saxagliptin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5340, 174, 'Quinine ', 'Silodosin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.', NULL, NULL, NULL),
(5341, 174, 'Quinine ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5342, 174, 'Quinine ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5343, 174, 'Quinine ', 'Simvastatin', ' May increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5344, 174, 'Quinine ', 'Sodium bicarbonate', ' Alkalinizing Agents may increase the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5345, 174, 'Quinine ', 'Spiramycin', ' Macrolide Antibiotics may increase the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5346, 174, 'Quinine ', 'Succinylcholine', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(5347, 174, 'Quinine ', 'Sulfisoxazole', ' Macrolide Antibiotics may increase the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5348, 174, 'Quinine ', 'Sulodexide', ' May enhance the hypoglycemic effect of other Hypoglycemic Agents.', NULL, NULL, NULL),
(5349, 174, 'Quinine ', 'Tamoxifen', ' CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.', NULL, NULL, NULL),
(5350, 174, 'Quinine ', 'Telithromycin', ' Macrolide Antibiotics may increase the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5351, 174, 'Quinine ', 'Testosterone', ' May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.', NULL, NULL, NULL),
(5352, 174, 'Quinine ', 'Tetracycline', ' May increase the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5353, 174, 'Quinine ', 'Theophylline', ' May increase the serum concentration of Theophylline Derivatives.', NULL, NULL, NULL),
(5354, 174, 'Quinine ', 'Thioridazine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(5355, 174, 'Quinine ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5356, 174, 'Quinine ', 'Tolbutamide', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5357, 174, 'Quinine ', 'Topotecan', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.', NULL, NULL, NULL),
(5358, 174, 'Quinine ', 'Tramadol', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(5359, 174, 'Quinine ', 'Vecuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.', NULL, NULL, NULL),
(5360, 174, 'Quinine ', 'Vildagliptin', ' May enhance the hypoglycemic effect of Hypoglycemic Agents.', NULL, NULL, NULL),
(5361, 175, 'Ranitidine Hydrochloride ', '0', '0', NULL, NULL, NULL),
(5362, 176, 'Rifampicin ', '0', '0', NULL, NULL, NULL),
(5363, 176, 'Rifampicin ', 'Afatinib', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.', NULL, NULL, NULL),
(5364, 176, 'Rifampicin ', 'Alfentanil', ' Rifamycin Derivatives may decrease the serum concentration of Alfentanil.', NULL, NULL, NULL),
(5365, 176, 'Rifampicin ', 'Amiodarone', ' Rifampin may decrease serum concentrations of the active metabolite(s) of Amiodarone. Specifically~ desethylamiodarone concentrations may decrease. Rifampin may decrease the serum concentration of Amiodarone.', NULL, NULL, NULL),
(5366, 176, 'Rifampicin ', 'Amlodipine', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5367, 176, 'Rifampicin ', 'Amrinone', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5368, 176, 'Rifampicin ', 'Apixaban', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.', NULL, NULL, NULL),
(5369, 176, 'Rifampicin ', 'Apremilast', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast.', NULL, NULL, NULL),
(5370, 176, 'Rifampicin ', 'Aprepitant', ' Rifampin may decrease the serum concentration of Aprepitant.', NULL, NULL, NULL),
(5371, 176, 'Rifampicin ', 'Aripiprazole', ' CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(5372, 176, 'Rifampicin ', 'Artemether', ' CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically~ dihydroartemisinin concentrations may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether.', NULL, NULL, NULL),
(5373, 176, 'Rifampicin ', 'Atazanavir', ' Rifampin may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(5374, 176, 'Rifampicin ', 'Atovaquone', ' Rifamycin Derivatives may decrease the serum concentration of Atovaquone.', NULL, NULL, NULL),
(5375, 176, 'Rifampicin ', 'Axitinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.', NULL, NULL, NULL),
(5376, 176, 'Rifampicin ', 'bazedoxifene', ' Rifampin may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or~ if bazedoxifene is combined with estrogen therapy~ an increased risk of endometrial hyperplasia.', NULL, NULL, NULL),
(5377, 176, 'Rifampicin ', 'Bedaquiline', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.', NULL, NULL, NULL),
(5378, 176, 'Rifampicin ', 'Bendamustine', ' CYP1A2 Inducers (Strong) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.', NULL, NULL, NULL),
(5379, 176, 'Rifampicin ', 'Bepridil', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5380, 176, 'Rifampicin ', 'Boceprevir', ' Rifampin may decrease the serum concentration of Boceprevir.', NULL, NULL, NULL),
(5381, 176, 'Rifampicin ', 'Bortezomib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.', NULL, NULL, NULL),
(5382, 176, 'Rifampicin ', 'Bosentan', ' Rifampin may decrease the serum concentration of Bosentan. Following the initial several weeks of concurrent rifampin~ this effect is most likely. Rifampin may increase the serum concentration of Bosentan. This effect is most likely to be observed within the initial few weeks of concurrent therapy (and may be greatest immediately following initiation of the combination).', NULL, NULL, NULL),
(5383, 176, 'Rifampicin ', 'Bosutinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.', NULL, NULL, NULL),
(5384, 176, 'Rifampicin ', 'Brentuximab vedotin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.', NULL, NULL, NULL),
(5385, 176, 'Rifampicin ', 'Buspirone', ' Rifamycin Derivatives may decrease the serum concentration of BusPIRone.', NULL, NULL, NULL),
(5386, 176, 'Rifampicin ', 'Butabarbital', ' Rifamycin Derivatives may increase the metabolism of Barbiturates.', NULL, NULL, NULL),
(5387, 176, 'Rifampicin ', 'Butethal', ' Rifamycin Derivatives may increase the metabolism of Barbiturates.', NULL, NULL, NULL),
(5388, 176, 'Rifampicin ', 'Cabozantinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.', NULL, NULL, NULL),
(5389, 176, 'Rifampicin ', 'Canagliflozin', ' Rifampin may decrease the serum concentration of Canagliflozin.', NULL, NULL, NULL),
(5390, 176, 'Rifampicin ', 'Caspofungin', ' Rifampin may decrease the serum concentration of Caspofungin.', NULL, NULL, NULL),
(5391, 176, 'Rifampicin ', 'Chloramphenicol', ' Rifampin may increase the metabolism of Chloramphenicol.', NULL, NULL, NULL),
(5392, 176, 'Rifampicin ', 'Citalopram', ' Rifampin may decrease the serum concentration of Citalopram.', NULL, NULL, NULL),
(5393, 176, 'Rifampicin ', 'Clarithromycin', ' CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.', NULL, NULL, NULL),
(5394, 176, 'Rifampicin ', 'Clopidogrel', ' Rifamycin Derivatives may enhance the adverse/toxic effect of Clopidogrel. Specifically~clopidogrel antiplatelet effects may be enhanced.', NULL, NULL, NULL),
(5395, 176, 'Rifampicin ', 'Clozapine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of CloZAPine.', NULL, NULL, NULL),
(5396, 176, 'Rifampicin ', 'Crizotinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.', NULL, NULL, NULL),
(5397, 176, 'Rifampicin ', 'Dabigatran etexilate', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.', NULL, NULL, NULL),
(5398, 176, 'Rifampicin ', 'Darunavir', ' Rifampin may decrease the serum concentration of Darunavir.', NULL, NULL, NULL),
(5399, 176, 'Rifampicin ', 'Dasatinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.', NULL, NULL, NULL),
(5400, 176, 'Rifampicin ', 'Deferasirox', ' Rifampin may decrease the serum concentration of Deferasirox.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(5401, 176, 'Rifampicin ', 'Delavirdine', ' Rifamycin Derivatives may increase the metabolism of Delavirdine. Delavirdine may increase the serum concentration of Rifamycin Derivatives. Specifically~ Rifabutin serum concentration may be increased.', NULL, NULL, NULL),
(5402, 176, 'Rifampicin ', 'Diltiazem', ' Rifampin may decrease the serum concentration of Diltiazem.', NULL, NULL, NULL),
(5403, 176, 'Rifampicin ', 'Disopyramide', ' Rifampin may decrease the serum concentration of Disopyramide.', NULL, NULL, NULL),
(5404, 176, 'Rifampicin ', 'Dolutegravir', ' Rifampin may decrease the serum concentration of Dolutegravir.', NULL, NULL, NULL),
(5405, 176, 'Rifampicin ', 'Doxycycline', ' Rifampin may decrease the serum concentration of Doxycycline.', NULL, NULL, NULL),
(5406, 176, 'Rifampicin ', 'Dronabinol', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronabinol.', NULL, NULL, NULL),
(5407, 176, 'Rifampicin ', 'Dronedarone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.', NULL, NULL, NULL),
(5408, 176, 'Rifampicin ', 'Efavirenz', ' Rifampin may decrease the serum concentration of Efavirenz.', NULL, NULL, NULL),
(5409, 176, 'Rifampicin ', 'Eliglustat', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat.', NULL, NULL, NULL),
(5410, 176, 'Rifampicin ', 'Eltrombopag', ' May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.', NULL, NULL, NULL),
(5411, 176, 'Rifampicin ', 'Enzalutamide', ' CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.', NULL, NULL, NULL),
(5412, 176, 'Rifampicin ', 'Erlotinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Erlotinib.', NULL, NULL, NULL),
(5413, 176, 'Rifampicin ', 'Esomeprazole', ' Rifampin may decrease the serum concentration of Esomeprazole.', NULL, NULL, NULL),
(5414, 176, 'Rifampicin ', 'Etravirine', ' Rifamycin Derivatives may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(5415, 176, 'Rifampicin ', 'Everolimus', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.', NULL, NULL, NULL),
(5416, 176, 'Rifampicin ', 'Exemestane', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.', NULL, NULL, NULL),
(5417, 176, 'Rifampicin ', 'Felodipine', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5418, 176, 'Rifampicin ', 'Fentanyl', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.', NULL, NULL, NULL),
(5419, 176, 'Rifampicin ', 'Fexofenadine', ' Rifampin may decrease the serum concentration of Fexofenadine. Rifampin may increase the serum concentration of Fexofenadine.', NULL, NULL, NULL),
(5420, 176, 'Rifampicin ', 'Flunarizine', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5421, 176, 'Rifampicin ', 'Fosamprenavir', ' Rifampin may decrease the serum concentration of Fosamprenavir. Specifically~ concentrations of amprenavir (active metabolite) may be decreased.', NULL, NULL, NULL),
(5422, 176, 'Rifampicin ', 'Fosaprepitant', ' Rifampin may decrease the serum concentration of Fosaprepitant. More specifically~ rifampin may decrease concentrations of the active metabolite aprepitant.', NULL, NULL, NULL),
(5423, 176, 'Rifampicin ', 'Fosphenytoin', ' Rifampin may decrease the serum concentration of Fosphenytoin.', NULL, NULL, NULL),
(5424, 176, 'Rifampicin ', 'Gabapentin', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5425, 176, 'Rifampicin ', 'Gefitinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.', NULL, NULL, NULL),
(5426, 176, 'Rifampicin ', 'Guanfacine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.', NULL, NULL, NULL),
(5427, 176, 'Rifampicin ', 'Heptabarbital', ' Rifamycin Derivatives may increase the metabolism of Barbiturates.', NULL, NULL, NULL),
(5428, 176, 'Rifampicin ', 'Hexobarbital', ' Rifamycin Derivatives may increase the metabolism of Barbiturates.', NULL, NULL, NULL),
(5429, 176, 'Rifampicin ', 'Hydrocodone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(5430, 176, 'Rifampicin ', 'Imatinib', ' Rifamycin Derivatives may decrease the serum concentration of Imatinib.', NULL, NULL, NULL),
(5431, 176, 'Rifampicin ', 'Indinavir', ' Rifampin may decrease the serum concentration of Indinavir.', NULL, NULL, NULL),
(5432, 176, 'Rifampicin ', 'Irinotecan', ' CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan.', NULL, NULL, NULL),
(5433, 176, 'Rifampicin ', 'Isoniazid', ' Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so~ this is a frequently employed combination regimen.', NULL, NULL, NULL),
(5434, 176, 'Rifampicin ', 'Isradipine', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5435, 176, 'Rifampicin ', 'Itraconazole', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.', NULL, NULL, NULL),
(5436, 176, 'Rifampicin ', 'Ivacaftor', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.', NULL, NULL, NULL),
(5437, 176, 'Rifampicin ', 'Ixabepilone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.', NULL, NULL, NULL),
(5438, 176, 'Rifampicin ', 'Lamotrigine', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5439, 176, 'Rifampicin ', 'Lapatinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.', NULL, NULL, NULL),
(5440, 176, 'Rifampicin ', 'Ledipasvir', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(5441, 176, 'Rifampicin ', 'Leflunomide', ' Rifampin may increase serum concentrations of the active metabolite(s) of Leflunomide.', NULL, NULL, NULL),
(5442, 176, 'Rifampicin ', 'Lercanidipine', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5443, 176, 'Rifampicin ', 'Linagliptin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.', NULL, NULL, NULL),
(5444, 176, 'Rifampicin ', 'Lopinavir', ' Rifampin may enhance the adverse/toxic effect of Lopinavir. Specifically~ the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Lopinavir.', NULL, NULL, NULL),
(5445, 176, 'Rifampicin ', 'Losartan', ' Rifampin may decrease the serum concentration of Losartan.', NULL, NULL, NULL),
(5446, 176, 'Rifampicin ', 'Lumefantrine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumefantrine.', NULL, NULL, NULL),
(5447, 176, 'Rifampicin ', 'Lurasidone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.', NULL, NULL, NULL),
(5448, 176, 'Rifampicin ', 'MACITENTAN', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan.', NULL, NULL, NULL),
(5449, 176, 'Rifampicin ', 'Magnesium Sulfate', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5450, 176, 'Rifampicin ', 'Maraviroc', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.', NULL, NULL, NULL),
(5451, 176, 'Rifampicin ', 'Methadone', ' Rifamycin Derivatives may decrease the serum concentration of Methadone.', NULL, NULL, NULL),
(5452, 176, 'Rifampicin ', 'Methohexital', ' Rifamycin Derivatives may increase the metabolism of Barbiturates.', NULL, NULL, NULL),
(5453, 176, 'Rifampicin ', 'Methylprednisolone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(5454, 176, 'Rifampicin ', 'Mifepristone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.', NULL, NULL, NULL),
(5455, 176, 'Rifampicin ', 'Mirabegron', ' Rifampin may decrease the serum concentration of Mirabegron.', NULL, NULL, NULL),
(5456, 176, 'Rifampicin ', 'Nelfinavir', ' Rifampin may decrease the serum concentration of Nelfinavir.', NULL, NULL, NULL),
(5457, 176, 'Rifampicin ', 'Nevirapine', ' Rifampin may decrease the serum concentration of Nevirapine.', NULL, NULL, NULL),
(5458, 176, 'Rifampicin ', 'Nicardipine', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5459, 176, 'Rifampicin ', 'Nifedipine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.', NULL, NULL, NULL),
(5460, 176, 'Rifampicin ', 'Nilotinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.', NULL, NULL, NULL),
(5461, 176, 'Rifampicin ', 'Nimodipine', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5462, 176, 'Rifampicin ', 'Nisoldipine', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5463, 176, 'Rifampicin ', 'Nitrazepam', ' Rifampin may decrease the serum concentration of Nitrazepam.', NULL, NULL, NULL),
(5464, 176, 'Rifampicin ', 'Nitrendipine', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5465, 176, 'Rifampicin ', 'Omeprazole', ' Rifampin may decrease the serum concentration of Omeprazole.', NULL, NULL, NULL),
(5466, 176, 'Rifampicin ', 'Oxycodone', ' Rifampin may decrease the serum concentration of OxyCODONE.', NULL, NULL, NULL),
(5467, 176, 'Rifampicin ', 'Paliperidone', ' Inducers of CYP3A4 and P-glycoprotein may decrease the serum concentration of Paliperidone.', NULL, NULL, NULL),
(5468, 176, 'Rifampicin ', 'Panobinostat', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat.', NULL, NULL, NULL),
(5469, 176, 'Rifampicin ', 'Pazopanib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(5470, 176, 'Rifampicin ', 'Pentobarbital', ' Rifamycin Derivatives may increase the metabolism of Barbiturates.', NULL, NULL, NULL),
(5471, 176, 'Rifampicin ', 'Perampanel', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.', NULL, NULL, NULL),
(5472, 176, 'Rifampicin ', 'Perhexiline', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5473, 176, 'Rifampicin ', 'Phenytoin', ' Rifampin may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(5474, 176, 'Rifampicin ', 'Pirfenidone', ' CYP1A2 Inducers (Strong) may decrease the serum concentration of Pirfenidone.', NULL, NULL, NULL),
(5475, 176, 'Rifampicin ', 'Pitavastatin', ' Rifamycin Derivatives may increase the serum concentration of Pitavastatin.', NULL, NULL, NULL),
(5476, 176, 'Rifampicin ', 'Pomalidomide', ' CYP1A2 Inducers (Strong) may decrease the serum concentration of Pomalidomide.', NULL, NULL, NULL),
(5477, 176, 'Rifampicin ', 'Ponatinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib.', NULL, NULL, NULL),
(5478, 176, 'Rifampicin ', 'Prasugrel', ' Rifampin may diminish the antiplatelet effect of Prasugrel.', NULL, NULL, NULL),
(5479, 176, 'Rifampicin ', 'Praziquantel', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.', NULL, NULL, NULL),
(5480, 176, 'Rifampicin ', 'Prednisone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE.', NULL, NULL, NULL),
(5481, 176, 'Rifampicin ', 'Prenylamine', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5482, 176, 'Rifampicin ', 'Primidone', ' Rifamycin Derivatives may increase the metabolism of Barbiturates.', NULL, NULL, NULL),
(5483, 176, 'Rifampicin ', 'Propafenone', ' Rifamycin Derivatives may decrease the serum concentration of Propafenone.', NULL, NULL, NULL),
(5484, 176, 'Rifampicin ', 'Propofol', ' Rifampin may enhance the hypotensive effect of Propofol.', NULL, NULL, NULL),
(5485, 176, 'Rifampicin ', 'Pyrazinamide', ' May enhance the hepatotoxic effect of Rifampin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection.', NULL, NULL, NULL),
(5486, 176, 'Rifampicin ', 'Quetiapine', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of QUEtiapine.', NULL, NULL, NULL),
(5487, 176, 'Rifampicin ', 'Quinidine', ' Rifamycin Derivatives may decrease the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5488, 176, 'Rifampicin ', 'Quinine', ' Rifampin may decrease the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5489, 176, 'Rifampicin ', 'Raltegravir', ' Rifampin may decrease the serum concentration of Raltegravir.', NULL, NULL, NULL),
(5490, 176, 'Rifampicin ', 'Ramelteon', ' Rifamycin Derivatives may increase the metabolism of Ramelteon.', NULL, NULL, NULL),
(5491, 176, 'Rifampicin ', 'Ranolazine', ' Rifampin may decrease the serum concentration of Ranolazine.', NULL, NULL, NULL),
(5492, 176, 'Rifampicin ', 'Regorafenib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.', NULL, NULL, NULL),
(5493, 176, 'Rifampicin ', 'Repaglinide', ' Rifampin may decrease the serum concentration of Repaglinide.', NULL, NULL, NULL),
(5494, 176, 'Rifampicin ', 'Rilpivirine', ' Rifamycin Derivatives may decrease the serum concentration of Rilpivirine.', NULL, NULL, NULL),
(5495, 176, 'Rifampicin ', 'Risedronate', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5496, 176, 'Rifampicin ', 'Ritonavir', ' Rifampin may decrease the serum concentration of Ritonavir.', NULL, NULL, NULL),
(5497, 176, 'Rifampicin ', 'Rivaroxaban', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.', NULL, NULL, NULL),
(5498, 176, 'Rifampicin ', 'Roflumilast', ' Rifampin may decrease the serum concentration of Roflumilast.', NULL, NULL, NULL),
(5499, 176, 'Rifampicin ', 'Romidepsin', ' Rifampin may increase the serum concentration of RomiDEPsin.', NULL, NULL, NULL),
(5500, 176, 'Rifampicin ', 'Saquinavir', ' Rifampin may enhance the adverse/toxic effect of Saquinavir. Specifically~ the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Saquinavir.', NULL, NULL, NULL),
(5501, 176, 'Rifampicin ', 'Saxagliptin', ' CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.', NULL, NULL, NULL),
(5502, 176, 'Rifampicin ', 'Secobarbital', ' Rifamycin Derivatives may increase the metabolism of Barbiturates.', NULL, NULL, NULL),
(5503, 176, 'Rifampicin ', 'Simeprevir', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Simeprevir.', NULL, NULL, NULL),
(5504, 176, 'Rifampicin ', 'Sirolimus', ' Rifampin may increase the metabolism of Sirolimus.', NULL, NULL, NULL),
(5505, 176, 'Rifampicin ', 'Sofosbuvir', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir.', NULL, NULL, NULL),
(5506, 176, 'Rifampicin ', 'Sorafenib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.', NULL, NULL, NULL),
(5507, 176, 'Rifampicin ', 'Sunitinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.', NULL, NULL, NULL),
(5508, 176, 'Rifampicin ', 'Suvorexant', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant.', NULL, NULL, NULL),
(5509, 176, 'Rifampicin ', 'Tadalafil', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.', NULL, NULL, NULL),
(5510, 176, 'Rifampicin ', 'Tamoxifen', ' Rifamycin Derivatives may increase the metabolism of Tamoxifen.', NULL, NULL, NULL),
(5511, 176, 'Rifampicin ', 'Telaprevir', ' Rifampin may decrease the serum concentration of Telaprevir.', NULL, NULL, NULL),
(5512, 176, 'Rifampicin ', 'Temsirolimus', ' Rifamycin Derivatives may decrease the serum concentration of Temsirolimus. Rifamycins will likely cause an even greater decrease in the concentration of the active metabolite sirolimus.', NULL, NULL, NULL),
(5513, 176, 'Rifampicin ', 'Teriflunomide', ' May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.', NULL, NULL, NULL),
(5514, 176, 'Rifampicin ', 'Ticagrelor', ' CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.', NULL, NULL, NULL),
(5515, 176, 'Rifampicin ', 'Tipranavir', ' Rifampin may decrease the serum concentration of Tipranavir.', NULL, NULL, NULL),
(5516, 176, 'Rifampicin ', 'Tofacitinib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.', NULL, NULL, NULL),
(5517, 176, 'Rifampicin ', 'Tolvaptan', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.', NULL, NULL, NULL),
(5518, 176, 'Rifampicin ', 'Toremifene', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.', NULL, NULL, NULL),
(5519, 176, 'Rifampicin ', 'Trabectedin', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin.', NULL, NULL, NULL),
(5520, 176, 'Rifampicin ', 'Treprostinil', ' CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.', NULL, NULL, NULL),
(5521, 176, 'Rifampicin ', 'Ulipristal', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.', NULL, NULL, NULL),
(5522, 176, 'Rifampicin ', 'Vandetanib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.', NULL, NULL, NULL),
(5523, 176, 'Rifampicin ', 'Vemurafenib', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.', NULL, NULL, NULL),
(5524, 176, 'Rifampicin ', 'Verapamil', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(5525, 176, 'Rifampicin ', 'Vilazodone', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.', NULL, NULL, NULL),
(5526, 176, 'Rifampicin ', 'Vorapaxar', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar.', NULL, NULL, NULL),
(5527, 176, 'Rifampicin ', 'Voriconazole', ' May increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole.', NULL, NULL, NULL),
(5528, 176, 'Rifampicin ', 'Zaleplon', ' Rifamycin Derivatives may increase the metabolism of Zaleplon.', NULL, NULL, NULL),
(5529, 176, 'Rifampicin ', 'Zidovudine', ' Rifamycin Derivatives may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(5530, 176, 'Rifampicin ', 'Zolpidem', ' Rifamycin Derivatives may decrease the serum concentration of Zolpidem.', NULL, NULL, NULL),
(5531, 176, 'Rifampicin ', 'Zuclopenthixol', ' CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.', NULL, NULL, NULL),
(5532, 177, 'Ritonavir ', '0', '0', NULL, NULL, NULL),
(5533, 177, 'Ritonavir ', 'Abacavir', ' Protease Inhibitors may decrease the serum concentration of Abacavir.', NULL, NULL, NULL),
(5534, 177, 'Ritonavir ', 'Acetohexamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5535, 177, 'Ritonavir ', 'ado-trastuzumab emtansine', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically~ strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.', NULL, NULL, NULL),
(5536, 177, 'Ritonavir ', 'Afatinib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.', NULL, NULL, NULL),
(5537, 177, 'Ritonavir ', 'Alfuzosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.', NULL, NULL, NULL),
(5538, 177, 'Ritonavir ', 'Almotriptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.', NULL, NULL, NULL),
(5539, 177, 'Ritonavir ', 'Alogliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5540, 177, 'Ritonavir ', 'Alosetron', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.', NULL, NULL, NULL),
(5541, 177, 'Ritonavir ', 'Alprazolam', ' Protease Inhibitors may increase the serum concentration of ALPRAZolam.', NULL, NULL, NULL),
(5542, 177, 'Ritonavir ', 'Amiodarone', ' Ritonavir may increase the serum concentration of Amiodarone.', NULL, NULL, NULL),
(5543, 177, 'Ritonavir ', 'Apixaban', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.', NULL, NULL, NULL),
(5544, 177, 'Ritonavir ', 'Aripiprazole', ' May enhance the adverse/toxic effect of Ritonavir. The risk of metabolic disturbances (e.g. hyperglycemia~ weight gain~ hyperlipidemia) may be increased. Ritonavir may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(5545, 177, 'Ritonavir ', 'Astemizole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole.', NULL, NULL, NULL),
(5546, 177, 'Ritonavir ', 'Atomoxetine', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.', NULL, NULL, NULL),
(5547, 177, 'Ritonavir ', 'Atorvastatin', ' Protease Inhibitors may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(5548, 177, 'Ritonavir ', 'Atovaquone', ' Ritonavir may decrease the serum concentration of Atovaquone.', NULL, NULL, NULL),
(5549, 177, 'Ritonavir ', 'Avanafil', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.', NULL, NULL, NULL),
(5550, 177, 'Ritonavir ', 'Axitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.', NULL, NULL, NULL),
(5551, 177, 'Ritonavir ', 'Batimastat', ' May increase the serum concentration of other Protease Inhibitors.', NULL, NULL, NULL),
(5552, 177, 'Ritonavir ', 'Bedaquiline', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.', NULL, NULL, NULL),
(5553, 177, 'Ritonavir ', 'Boceprevir', ' May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Boceprevir.', NULL, NULL, NULL),
(5554, 177, 'Ritonavir ', 'Bortezomib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.', NULL, NULL, NULL),
(5555, 177, 'Ritonavir ', 'Bosentan', ' Ritonavir may increase the serum concentration of Bosentan.', NULL, NULL, NULL),
(5556, 177, 'Ritonavir ', 'Bosutinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.', NULL, NULL, NULL),
(5557, 177, 'Ritonavir ', 'Brentuximab vedotin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be increased.', NULL, NULL, NULL),
(5558, 177, 'Ritonavir ', 'Brinzolamide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.', NULL, NULL, NULL),
(5559, 177, 'Ritonavir ', 'Bupropion', ' Ritonavir may decrease the serum concentration of BuPROPion. Mixed effects on concentrations of the active hydroxybupropion metabolite have been reported.', NULL, NULL, NULL),
(5560, 177, 'Ritonavir ', 'Cabazitaxel', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.', NULL, NULL, NULL),
(5561, 177, 'Ritonavir ', 'Cabozantinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.', NULL, NULL, NULL),
(5562, 177, 'Ritonavir ', 'Canagliflozin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5563, 177, 'Ritonavir ', 'Carbamazepine', ' May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.', NULL, NULL, NULL),
(5564, 177, 'Ritonavir ', 'Chlorpropamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5565, 177, 'Ritonavir ', 'Cilostazol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.', NULL, NULL, NULL),
(5566, 177, 'Ritonavir ', 'Cisapride', ' Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.', NULL, NULL, NULL),
(5567, 177, 'Ritonavir ', 'Clarithromycin', ' Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically~ certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite~ which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.', NULL, NULL, NULL),
(5568, 177, 'Ritonavir ', 'Clorazepate', ' Ritonavir may increase the serum concentration of Clorazepate.', NULL, NULL, NULL),
(5569, 177, 'Ritonavir ', 'Codeine', ' CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.', NULL, NULL, NULL),
(5570, 177, 'Ritonavir ', 'Colchicine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.', NULL, NULL, NULL),
(5571, 177, 'Ritonavir ', 'Conivaptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.', NULL, NULL, NULL),
(5572, 177, 'Ritonavir ', 'Crizotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.', NULL, NULL, NULL),
(5573, 177, 'Ritonavir ', 'Cyclophosphamide', ' Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically~ the incidences of neutropenia~ infection~ and mucositis may be increased.', NULL, NULL, NULL),
(5574, 177, 'Ritonavir ', 'Dabigatran etexilate', ' P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.', NULL, NULL, NULL),
(5575, 177, 'Ritonavir ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5576, 177, 'Ritonavir ', 'Dapoxetine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine.', NULL, NULL, NULL),
(5577, 177, 'Ritonavir ', 'Dasatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.', NULL, NULL, NULL),
(5578, 177, 'Ritonavir ', 'Deferasirox', ' Ritonavir may decrease the serum concentration of Deferasirox.', NULL, NULL, NULL),
(5579, 177, 'Ritonavir ', 'Delavirdine', ' May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.', NULL, NULL, NULL),
(5580, 177, 'Ritonavir ', 'Diazepam', ' Ritonavir may increase the serum concentration of Diazepam.', NULL, NULL, NULL),
(5581, 177, 'Ritonavir ', 'Digoxin', ' Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.', NULL, NULL, NULL),
(5582, 177, 'Ritonavir ', 'Disulfiram', ' Ritonavir may enhance the adverse/toxic effect of Disulfiram. Specifically~ the combination of ritonavir oral solution~ which contains 43% alcohol~ may result in a disulfiram-alcohol reaction if combined.', NULL, NULL, NULL),
(5583, 177, 'Ritonavir ', 'Domperidone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone.', NULL, NULL, NULL),
(5584, 177, 'Ritonavir ', 'Dronabinol', ' May increase the serum concentration of Dronabinol.', NULL, NULL, NULL),
(5585, 177, 'Ritonavir ', 'Dronedarone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.', NULL, NULL, NULL),
(5586, 177, 'Ritonavir ', 'Dutasteride', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.', NULL, NULL, NULL),
(5587, 177, 'Ritonavir ', 'Efavirenz', ' May enhance the adverse/toxic effect of Ritonavir. Efavirenz may increase the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of Efavirenz.', NULL, NULL, NULL),
(5588, 177, 'Ritonavir ', 'Eliglustat', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Eliglustat.', NULL, NULL, NULL),
(5589, 177, 'Ritonavir ', 'Enfuvirtide', ' May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.', NULL, NULL, NULL),
(5590, 177, 'Ritonavir ', 'Enzalutamide', ' CYP2C8 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.', NULL, NULL, NULL),
(5591, 177, 'Ritonavir ', 'Eplerenone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.', NULL, NULL, NULL),
(5592, 177, 'Ritonavir ', 'Erlotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.', NULL, NULL, NULL),
(5593, 177, 'Ritonavir ', 'Estazolam', ' Ritonavir may increase the serum concentration of Estazolam.', NULL, NULL, NULL),
(5594, 177, 'Ritonavir ', 'Etravirine', ' Ritonavir may decrease the serum concentration of Etravirine.', NULL, NULL, NULL),
(5595, 177, 'Ritonavir ', 'Everolimus', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.', NULL, NULL, NULL),
(5596, 177, 'Ritonavir ', 'Fentanyl', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.', NULL, NULL, NULL),
(5597, 177, 'Ritonavir ', 'Fesoterodine', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.', NULL, NULL, NULL),
(5598, 177, 'Ritonavir ', 'Flecainide', ' Ritonavir may increase the serum concentration of Flecainide.', NULL, NULL, NULL),
(5599, 177, 'Ritonavir ', 'Flurazepam', ' Ritonavir may increase the serum concentration of Flurazepam.', NULL, NULL, NULL),
(5600, 177, 'Ritonavir ', 'Fluticasone Propionate', ' May increase the serum concentration of Fluticasone (Nasal).', NULL, NULL, NULL),
(5601, 177, 'Ritonavir ', 'Fosphenytoin', ' May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Fosphenytoin.', NULL, NULL, NULL),
(5602, 177, 'Ritonavir ', 'Gliclazide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5603, 177, 'Ritonavir ', 'Glimepiride', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5604, 177, 'Ritonavir ', 'Gliquidone', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5605, 177, 'Ritonavir ', 'Glyburide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5606, 177, 'Ritonavir ', 'Guanfacine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.', NULL, NULL, NULL),
(5607, 177, 'Ritonavir ', 'Halofantrine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.', NULL, NULL, NULL),
(5608, 177, 'Ritonavir ', 'Hydrocodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(5609, 177, 'Ritonavir ', 'Ifosfamide', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.', NULL, NULL, NULL),
(5610, 177, 'Ritonavir ', 'Iloperidone', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically~ concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.', NULL, NULL, NULL),
(5611, 177, 'Ritonavir ', 'Imatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib.', NULL, NULL, NULL),
(5612, 177, 'Ritonavir ', 'Insulin Aspart', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5613, 177, 'Ritonavir ', 'Insulin Detemir', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5614, 177, 'Ritonavir ', 'Insulin Glargine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5615, 177, 'Ritonavir ', 'Insulin Glulisine', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5616, 177, 'Ritonavir ', 'Insulin Lispro', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5617, 177, 'Ritonavir ', 'Insulin Regular', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5618, 177, 'Ritonavir ', 'Insulin~ isophane', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5619, 177, 'Ritonavir ', 'Irinotecan', ' CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan. Specifically~ serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan.', NULL, NULL, NULL),
(5620, 177, 'Ritonavir ', 'Isoflurophate', ' May increase the serum concentration of other Protease Inhibitors.', NULL, NULL, NULL),
(5621, 177, 'Ritonavir ', 'Itraconazole', ' Ritonavir may increase the serum concentration of Itraconazole.', NULL, NULL, NULL),
(5622, 177, 'Ritonavir ', 'Ivacaftor', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.', NULL, NULL, NULL),
(5623, 177, 'Ritonavir ', 'Ixabepilone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.', NULL, NULL, NULL),
(5624, 177, 'Ritonavir ', 'Lacosamide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide.', NULL, NULL, NULL),
(5625, 177, 'Ritonavir ', 'Lamotrigine', ' Ritonavir may decrease the serum concentration of LamoTRIgine.', NULL, NULL, NULL),
(5626, 177, 'Ritonavir ', 'Lapatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.', NULL, NULL, NULL),
(5627, 177, 'Ritonavir ', 'Ledipasvir', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(5628, 177, 'Ritonavir ', 'Lercanidipine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine.', NULL, NULL, NULL),
(5629, 177, 'Ritonavir ', 'Levobupivacaine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine.', NULL, NULL, NULL),
(5630, 177, 'Ritonavir ', 'Levomilnacipran', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.', NULL, NULL, NULL),
(5631, 177, 'Ritonavir ', 'Linagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5632, 177, 'Ritonavir ', 'Lomitapide', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(5633, 177, 'Ritonavir ', 'Lovastatin', ' Protease Inhibitors may increase the serum concentration of Lovastatin.', NULL, NULL, NULL),
(5634, 177, 'Ritonavir ', 'Lurasidone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.', NULL, NULL, NULL),
(5635, 177, 'Ritonavir ', 'MACITENTAN', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan.', NULL, NULL, NULL),
(5636, 177, 'Ritonavir ', 'Maraviroc', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.', NULL, NULL, NULL),
(5637, 177, 'Ritonavir ', 'Mequitazine', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine.', NULL, NULL, NULL),
(5638, 177, 'Ritonavir ', 'Metformin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5639, 177, 'Ritonavir ', 'Methadone', ' May decrease the serum concentration of Methadone.', NULL, NULL, NULL),
(5640, 177, 'Ritonavir ', 'Methylprednisolone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.', NULL, NULL, NULL),
(5641, 177, 'Ritonavir ', 'Metoprolol', ' CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.', NULL, NULL, NULL),
(5642, 177, 'Ritonavir ', 'Midazolam', ' Protease Inhibitors may increase the serum concentration of Midazolam.', NULL, NULL, NULL),
(5643, 177, 'Ritonavir ', 'Mifepristone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.', NULL, NULL, NULL),
(5644, 177, 'Ritonavir ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5645, 177, 'Ritonavir ', 'Nebivolol', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.', NULL, NULL, NULL),
(5646, 177, 'Ritonavir ', 'Nefazodone', ' Protease Inhibitors may increase the serum concentration of Nefazodone.', NULL, NULL, NULL),
(5647, 177, 'Ritonavir ', 'Nilotinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.', NULL, NULL, NULL),
(5648, 177, 'Ritonavir ', 'Nisoldipine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.', NULL, NULL, NULL),
(5649, 177, 'Ritonavir ', 'Ospemifene', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.', NULL, NULL, NULL),
(5650, 177, 'Ritonavir ', 'Oxybutynin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin.', NULL, NULL, NULL),
(5651, 177, 'Ritonavir ', 'Oxycodone', ' CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased.', NULL, NULL, NULL),
(5652, 177, 'Ritonavir ', 'Panobinostat', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.', NULL, NULL, NULL),
(5653, 177, 'Ritonavir ', 'Paricalcitol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.', NULL, NULL, NULL),
(5654, 177, 'Ritonavir ', 'Pazopanib', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.', NULL, NULL, NULL),
(5655, 177, 'Ritonavir ', 'Phenytoin', ' Phenytoin may decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(5656, 177, 'Ritonavir ', 'Pimecrolimus', ' CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.', NULL, NULL, NULL),
(5657, 177, 'Ritonavir ', 'Pimozide', ' Protease Inhibitors may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(5658, 177, 'Ritonavir ', 'Pioglitazone', ' CYP2C8 Inhibitors (Strong) may increase the serum concentration of Pioglitazone.', NULL, NULL, NULL),
(5659, 177, 'Ritonavir ', 'Ponatinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.', NULL, NULL, NULL),
(5660, 177, 'Ritonavir ', 'Posaconazole', ' May increase the serum concentration of Ritonavir.', NULL, NULL, NULL),
(5661, 177, 'Ritonavir ', 'Pranlukast', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast.', NULL, NULL, NULL),
(5662, 177, 'Ritonavir ', 'Prasugrel', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.', NULL, NULL, NULL),
(5663, 177, 'Ritonavir ', 'Prednisone', ' Ritonavir may increase the serum concentration of PredniSONE.', NULL, NULL, NULL),
(5664, 177, 'Ritonavir ', 'Proguanil', ' Ritonavir may decrease the serum concentration of Proguanil.', NULL, NULL, NULL),
(5665, 177, 'Ritonavir ', 'Propafenone', ' Ritonavir may increase the serum concentration of Propafenone.', NULL, NULL, NULL),
(5666, 177, 'Ritonavir ', 'prucalopride', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.', NULL, NULL, NULL),
(5667, 177, 'Ritonavir ', 'Quetiapine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of QUEtiapine.', NULL, NULL, NULL),
(5668, 177, 'Ritonavir ', 'Quinidine', ' Ritonavir may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(5669, 177, 'Ritonavir ', 'Quinine', ' QuiNINE may increase the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir. The individual contributions of lopinavir and ritonavir to this effect are unclear. Ritonavir may increase the serum concentration of QuiNINE.', NULL, NULL, NULL),
(5670, 177, 'Ritonavir ', 'Ranolazine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.', NULL, NULL, NULL),
(5671, 177, 'Ritonavir ', 'Regorafenib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.', NULL, NULL, NULL),
(5672, 177, 'Ritonavir ', 'Repaglinide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5673, 177, 'Ritonavir ', 'Retapamulin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.', NULL, NULL, NULL),
(5674, 177, 'Ritonavir ', 'Rifabutin', ' Ritonavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Ritonavir may increase the serum concentration of Rifabutin.', NULL, NULL, NULL),
(5675, 177, 'Ritonavir ', 'Rifampicin', ' Rifampin may decrease the serum concentration of Ritonavir.', NULL, NULL, NULL),
(5676, 177, 'Ritonavir ', 'Rifaximin', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.', NULL, NULL, NULL),
(5677, 177, 'Ritonavir ', 'Rilpivirine', ' Ritonavir may increase the serum concentration of Rilpivirine.', NULL, NULL, NULL),
(5678, 177, 'Ritonavir ', 'Riociguat', ' Protease Inhibitors may increase the serum concentration of Riociguat.', NULL, NULL, NULL),
(5679, 177, 'Ritonavir ', 'Rivaroxaban', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. For clarithromycin~ refer to more specific clarithromycin-rivaroxaban monograph recommendations.', NULL, NULL, NULL),
(5680, 177, 'Ritonavir ', 'Romidepsin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.', NULL, NULL, NULL),
(5681, 177, 'Ritonavir ', 'Rosuvastatin', ' Protease Inhibitors may increase the serum concentration of Rosuvastatin.', NULL, NULL, NULL),
(5682, 177, 'Ritonavir ', 'Ruxolitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.', NULL, NULL, NULL),
(5683, 177, 'Ritonavir ', 'Salmeterol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.', NULL, NULL, NULL),
(5684, 177, 'Ritonavir ', 'Saxagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5685, 177, 'Ritonavir ', 'Sildenafil', ' Protease Inhibitors may increase the serum concentration of Sildenafil.', NULL, NULL, NULL),
(5686, 177, 'Ritonavir ', 'Silodosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.', NULL, NULL, NULL),
(5687, 177, 'Ritonavir ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5688, 177, 'Ritonavir ', 'Simeprevir', ' May increase the serum concentration of other Protease Inhibitors.', NULL, NULL, NULL),
(5689, 177, 'Ritonavir ', 'Simvastatin', ' Protease Inhibitors may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5690, 177, 'Ritonavir ', 'Sorafenib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.', NULL, NULL, NULL),
(5691, 177, 'Ritonavir ', 'Suvorexant', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant.', NULL, NULL, NULL),
(5692, 177, 'Ritonavir ', 'Tadalafil', ' Ritonavir may increase the serum concentration of Tadalafil.', NULL, NULL, NULL),
(5693, 177, 'Ritonavir ', 'Tamoxifen', ' CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.', NULL, NULL, NULL),
(5694, 177, 'Ritonavir ', 'Tamsulosin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.', NULL, NULL, NULL),
(5695, 177, 'Ritonavir ', 'Telaprevir', ' Ritonavir may decrease the serum concentration of Telaprevir. Ritonavir may increase the serum concentration of Telaprevir.', NULL, NULL, NULL),
(5696, 177, 'Ritonavir ', 'Temsirolimus', ' Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus~ the active metabolite~ may be increased~ likely due to inhibition of CYP-mediated metabolism.', NULL, NULL, NULL),
(5697, 177, 'Ritonavir ', 'Terfenadine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Terfenadine.', NULL, NULL, NULL),
(5698, 177, 'Ritonavir ', 'Tetrabenazine', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically~ concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.', NULL, NULL, NULL),
(5699, 177, 'Ritonavir ', 'Thioridazine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(5700, 177, 'Ritonavir ', 'Ticagrelor', ' CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.', NULL, NULL, NULL),
(5701, 177, 'Ritonavir ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5702, 177, 'Ritonavir ', 'Tofacitinib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.', NULL, NULL, NULL),
(5703, 177, 'Ritonavir ', 'Tolbutamide', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5704, 177, 'Ritonavir ', 'Tolterodine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.', NULL, NULL, NULL),
(5705, 177, 'Ritonavir ', 'Tolvaptan', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.', NULL, NULL, NULL),
(5706, 177, 'Ritonavir ', 'Topotecan', ' P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.', NULL, NULL, NULL),
(5707, 177, 'Ritonavir ', 'Toremifene', ' CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.', NULL, NULL, NULL),
(5708, 177, 'Ritonavir ', 'Trabectedin', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin.', NULL, NULL, NULL),
(5709, 177, 'Ritonavir ', 'Trazodone', ' Ritonavir may increase the serum concentration of TraZODone.', NULL, NULL, NULL),
(5710, 177, 'Ritonavir ', 'Treprostinil', ' CYP2C8 Inhibitors (Strong) may increase the serum concentration of Treprostinil.', NULL, NULL, NULL),
(5711, 177, 'Ritonavir ', 'Triazolam', ' Protease Inhibitors may increase the serum concentration of Triazolam.', NULL, NULL, NULL),
(5712, 177, 'Ritonavir ', 'Ulipristal', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.', NULL, NULL, NULL),
(5713, 177, 'Ritonavir ', 'Vardenafil', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.', NULL, NULL, NULL),
(5714, 177, 'Ritonavir ', 'Vemurafenib', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.', NULL, NULL, NULL),
(5715, 177, 'Ritonavir ', 'Vilazodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.', NULL, NULL, NULL),
(5716, 177, 'Ritonavir ', 'Vildagliptin', ' Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.', NULL, NULL, NULL),
(5717, 177, 'Ritonavir ', 'Vinblastine', ' Ritonavir may increase the serum concentration of VinBLAStine.', NULL, NULL, NULL),
(5718, 177, 'Ritonavir ', 'Vincristine', ' Ritonavir may increase the serum concentration of VinCRIStine.', NULL, NULL, NULL),
(5719, 177, 'Ritonavir ', 'Vorapaxar', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar.', NULL, NULL, NULL),
(5720, 177, 'Ritonavir ', 'Voriconazole', ' Ritonavir may decrease the serum concentration of Voriconazole.', NULL, NULL, NULL),
(5721, 177, 'Ritonavir ', 'Warfarin', ' Ritonavir may decrease the serum concentration of Warfarin.', NULL, NULL, NULL),
(5722, 177, 'Ritonavir ', 'Zidovudine', ' Protease Inhibitors may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(5723, 177, 'Ritonavir ', 'Zopiclone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(5724, 177, 'Ritonavir ', 'Zuclopenthixol', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.', NULL, NULL, NULL),
(5725, 178, 'Salbutamol ', '0', '0', NULL, NULL, NULL),
(5726, 178, 'Salbutamol ', 'Acebutolol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5727, 178, 'Salbutamol ', 'Aclidinium', ' May enhance the anticholinergic effect of Anticholinergic Agents.', NULL, NULL, NULL),
(5728, 178, 'Salbutamol ', 'Amphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5729, 178, 'Salbutamol ', 'Atomoxetine', ' May enhance the tachycardic effect of Beta2-Agonists.', NULL, NULL, NULL),
(5730, 178, 'Salbutamol ', 'Benzphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5731, 178, 'Salbutamol ', 'Betahistine', ' May diminish the therapeutic effect of Beta2-Agonists.', NULL, NULL, NULL),
(5732, 178, 'Salbutamol ', 'Chlorphentermine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5733, 178, 'Salbutamol ', 'Clenbuterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5734, 178, 'Salbutamol ', 'Dobutamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5735, 178, 'Salbutamol ', 'Dopamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5736, 178, 'Salbutamol ', 'Epinephrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5737, 178, 'Salbutamol ', 'Fenoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5738, 178, 'Salbutamol ', 'Formoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5739, 178, 'Salbutamol ', 'Isoprenaline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5740, 178, 'Salbutamol ', 'Itopride', ' Anticholinergic Agents may diminish the therapeutic effect of Itopride.', NULL, NULL, NULL),
(5741, 178, 'Salbutamol ', 'Labetalol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5742, 178, 'Salbutamol ', 'Linezolid', ' May enhance the hypertensive effect of Sympathomimetics.', NULL, NULL, NULL),
(5743, 178, 'Salbutamol ', 'Loxapine', ' Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically~ the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.', NULL, NULL, NULL),
(5744, 178, 'Salbutamol ', 'Mephentermine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5745, 178, 'Salbutamol ', 'Metaraminol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5746, 178, 'Salbutamol ', 'Methamphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5747, 178, 'Salbutamol ', 'Methoxamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5748, 178, 'Salbutamol ', 'Metoclopramide', ' Anticholinergic Agents may diminish the therapeutic effect of Metoclopramide.', NULL, NULL, NULL),
(5749, 178, 'Salbutamol ', 'Mianserin', ' May enhance the anticholinergic effect of Anticholinergic Agents.', NULL, NULL, NULL),
(5750, 178, 'Salbutamol ', 'Midodrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5751, 178, 'Salbutamol ', 'Mirabegron', ' Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.', NULL, NULL, NULL),
(5752, 178, 'Salbutamol ', 'Naphazoline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5753, 178, 'Salbutamol ', 'Norepinephrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5754, 178, 'Salbutamol ', 'Orciprenaline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5755, 178, 'Salbutamol ', 'Oxymetazoline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5756, 178, 'Salbutamol ', 'Phenmetrazine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5757, 178, 'Salbutamol ', 'Phentermine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5758, 178, 'Salbutamol ', 'Phenylephrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5759, 178, 'Salbutamol ', 'Phenylpropanolamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5760, 178, 'Salbutamol ', 'Potassium Chloride', ' Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.', NULL, NULL, NULL),
(5761, 178, 'Salbutamol ', 'Pramlintide', ' May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.', NULL, NULL, NULL),
(5762, 178, 'Salbutamol ', 'Ritodrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5763, 178, 'Salbutamol ', 'Salmeterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5764, 178, 'Salbutamol ', 'Secretin', ' Anticholinergic Agents may diminish the therapeutic effect of Secretin.', NULL, NULL, NULL),
(5765, 178, 'Salbutamol ', 'Terbutaline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5766, 178, 'Salbutamol ', 'Tiotropium', ' Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.', NULL, NULL, NULL),
(5767, 178, 'Salbutamol ', 'Topiramate', ' Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.', NULL, NULL, NULL),
(5768, 179, 'Sildenafil Citrate ', '0', '0', NULL, NULL, NULL),
(5769, 180, 'Silver Sulfadiazine ', '0', '0', NULL, NULL, NULL),
(5770, 181, 'Simvastatin ', '0', '0', NULL, NULL, NULL),
(5771, 181, 'Simvastatin ', 'Aluminum hydroxide', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5772, 181, 'Simvastatin ', 'Amiodarone', ' May decrease the metabolism of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5773, 181, 'Simvastatin ', 'Amlodipine', ' AmLODIPine may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5774, 181, 'Simvastatin ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5775, 181, 'Simvastatin ', 'Aripiprazole', ' CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(5776, 181, 'Simvastatin ', 'Atazanavir', ' Protease Inhibitors may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5777, 181, 'Simvastatin ', 'Batimastat', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5778, 181, 'Simvastatin ', 'Bezafibrate', ' May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically~ bezafibrate may increase the serum concentration of fluvastatin', NULL, NULL, NULL),
(5779, 181, 'Simvastatin ', 'Boceprevir', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5780, 181, 'Simvastatin ', 'Bosentan', ' May increase the metabolism of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5781, 181, 'Simvastatin ', 'Calcium carbonate', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5782, 181, 'Simvastatin ', 'Clarithromycin', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5783, 181, 'Simvastatin ', 'Colchicine', ' May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5784, 181, 'Simvastatin ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5785, 181, 'Simvastatin ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5786, 181, 'Simvastatin ', 'Danazol', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5787, 181, 'Simvastatin ', 'Daptomycin', ' HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically~ the risk of skeletal muscle toxicity may be increased.', NULL, NULL, NULL),
(5788, 181, 'Simvastatin ', 'Darunavir', ' Protease Inhibitors may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5789, 181, 'Simvastatin ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5790, 181, 'Simvastatin ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5791, 181, 'Simvastatin ', 'Delavirdine', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5792, 181, 'Simvastatin ', 'Diltiazem', ' Diltiazem may increase the serum concentration of Simvastatin. Simvastatin may increase the serum concentration of Diltiazem.', NULL, NULL, NULL),
(5793, 181, 'Simvastatin ', 'Dronedarone', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5794, 181, 'Simvastatin ', 'Efavirenz', ' May decrease the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5795, 181, 'Simvastatin ', 'Eltrombopag', ' May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.', NULL, NULL, NULL),
(5796, 181, 'Simvastatin ', 'Etravirine', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin~ lovastatin and simvastatin. Conversely~ levels of fluvastatin may be increased.', NULL, NULL, NULL),
(5797, 181, 'Simvastatin ', 'Fluconazole', ' Fluconazole may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5798, 181, 'Simvastatin ', 'Fosamprenavir', ' Protease Inhibitors may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5799, 181, 'Simvastatin ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5800, 181, 'Simvastatin ', 'Fosphenytoin', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5801, 181, 'Simvastatin ', 'Gemfibrozil', ' May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Gemfibrozil may increase the serum concentration of Simvastatin. Concentrations of the active simvastatin acid metabolite may also be increased by gemfibrozil.', NULL, NULL, NULL),
(5802, 181, 'Simvastatin ', 'Imatinib', ' May decrease the metabolism of Simvastatin.', NULL, NULL, NULL),
(5803, 181, 'Simvastatin ', 'Indinavir', ' Protease Inhibitors may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5804, 181, 'Simvastatin ', 'Isoflurophate', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5805, 181, 'Simvastatin ', 'Itraconazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5806, 181, 'Simvastatin ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5807, 181, 'Simvastatin ', 'Lercanidipine', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5808, 181, 'Simvastatin ', 'Lomitapide', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5809, 181, 'Simvastatin ', 'Lopinavir', ' Protease Inhibitors may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5810, 181, 'Simvastatin ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5811, 181, 'Simvastatin ', 'Magnesium oxide', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5812, 181, 'Simvastatin ', 'Mifepristone', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5813, 181, 'Simvastatin ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5814, 181, 'Simvastatin ', 'Nefazodone', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5815, 181, 'Simvastatin ', 'Nelfinavir', ' Protease Inhibitors may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5816, 181, 'Simvastatin ', 'Niacin', ' May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5817, 181, 'Simvastatin ', 'Pazopanib', ' HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of PAZOPanib. Specifically~ the risk for increased serum transaminase concentrations may be increased.', NULL, NULL, NULL),
(5818, 181, 'Simvastatin ', 'Phenytoin', ' May decrease the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5819, 181, 'Simvastatin ', 'Posaconazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5820, 181, 'Simvastatin ', 'Quinine', ' May increase the serum concentration of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5821, 181, 'Simvastatin ', 'Raltegravir', ' May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5822, 181, 'Simvastatin ', 'Ranolazine', ' Ranolazine may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5823, 181, 'Simvastatin ', 'Ritonavir', ' Protease Inhibitors may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5824, 181, 'Simvastatin ', 'Saquinavir', ' Protease Inhibitors may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5825, 181, 'Simvastatin ', 'Sildenafil', ' May decrease the metabolism of HMG-CoA Reductase Inhibitors.', NULL, NULL, NULL),
(5826, 181, 'Simvastatin ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5827, 181, 'Simvastatin ', 'Simeprevir', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5828, 181, 'Simvastatin ', 'Sulfisoxazole', ' Erythromycin (Systemic) may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5829, 181, 'Simvastatin ', 'Telaprevir', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5830, 181, 'Simvastatin ', 'Telithromycin', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5831, 181, 'Simvastatin ', 'Teriflunomide', ' May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.', NULL, NULL, NULL),
(5832, 181, 'Simvastatin ', 'Ticagrelor', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5833, 181, 'Simvastatin ', 'Tipranavir', ' Protease Inhibitors may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5834, 181, 'Simvastatin ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(5835, 181, 'Simvastatin ', 'Trabectedin', ' HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.', NULL, NULL, NULL),
(5836, 181, 'Simvastatin ', 'Verapamil', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5837, 181, 'Simvastatin ', 'Voriconazole', ' CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(5838, 182, 'Spectinomycin Hydrochloride ', '0', '0', NULL, NULL, NULL),
(5839, 183, 'Spironolactone ', '0', '0', NULL, NULL, NULL),
(5840, 183, 'Spironolactone ', 'Abiraterone', ' May diminish the therapeutic effect of Abiraterone Acetate.', NULL, NULL, NULL),
(5841, 183, 'Spironolactone ', 'Alfentanil', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5842, 183, 'Spironolactone ', 'Alfuzosin', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(5843, 183, 'Spironolactone ', 'Amifostine', ' Antihypertensives may enhance the hypotensive effect of Amifostine.', NULL, NULL, NULL),
(5844, 183, 'Spironolactone ', 'Amiloride', ' May enhance the hyperkalemic effect of Spironolactone.', NULL, NULL, NULL),
(5845, 183, 'Spironolactone ', 'Ammonium chloride', ' Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.', NULL, NULL, NULL),
(5846, 183, 'Spironolactone ', 'Articaine', ' May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.', NULL, NULL, NULL),
(5847, 183, 'Spironolactone ', 'Atorvastatin', ' May enhance the adverse/toxic effect of Spironolactone. Specifically~ there is a theoretical potential for enhanced effects on reducing endogenous steroid activity.', NULL, NULL, NULL),
(5848, 183, 'Spironolactone ', 'Atracurium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(5849, 183, 'Spironolactone ', 'Buprenorphine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5850, 183, 'Spironolactone ', 'Butabarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(5851, 183, 'Spironolactone ', 'Butethal', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(5852, 183, 'Spironolactone ', 'Butorphanol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5853, 183, 'Spironolactone ', 'Canagliflozin', ' May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics.', NULL, NULL, NULL),
(5854, 183, 'Spironolactone ', 'Cholestyramine', ' Cholestyramine Resin may enhance the adverse/toxic effect of Spironolactone. Specifically~ the risks of developing metabolic acidosis and hyperkalemia may be elevated with this combination.', NULL, NULL, NULL),
(5855, 183, 'Spironolactone ', 'Cisatracurium Besylate', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(5856, 183, 'Spironolactone ', 'Codeine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5857, 183, 'Spironolactone ', 'Diazoxide', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(5858, 183, 'Spironolactone ', 'Digoxin', ' May increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations~ falsely increasing or decreasing Digoxin concentrations.', NULL, NULL, NULL),
(5859, 183, 'Spironolactone ', 'Dihydrocodeine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5860, 183, 'Spironolactone ', 'Dipivefrin', ' May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.', NULL, NULL, NULL),
(5861, 183, 'Spironolactone ', 'Dopamine', ' May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.', NULL, NULL, NULL),
(5862, 183, 'Spironolactone ', 'Drospirenone', ' May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.', NULL, NULL, NULL),
(5863, 183, 'Spironolactone ', 'Duloxetine', ' Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.', NULL, NULL, NULL),
(5864, 183, 'Spironolactone ', 'Eplerenone', ' May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.', NULL, NULL, NULL),
(5865, 183, 'Spironolactone ', 'Fentanyl', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5866, 183, 'Spironolactone ', 'Heparin', ' May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.', NULL, NULL, NULL),
(5867, 183, 'Spironolactone ', 'Heptabarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(5868, 183, 'Spironolactone ', 'Hexobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(5869, 183, 'Spironolactone ', 'Hydrocodone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5870, 183, 'Spironolactone ', 'Hydromorphone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5871, 183, 'Spironolactone ', 'Levonordefrin', ' May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.', NULL, NULL, NULL),
(5872, 183, 'Spironolactone ', 'Levorphanol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5873, 183, 'Spironolactone ', 'Methadone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5874, 183, 'Spironolactone ', 'Methohexital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(5875, 183, 'Spironolactone ', 'Methylphenidate', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(5876, 183, 'Spironolactone ', 'Mitotane', ' Spironolactone may diminish the therapeutic effect of Mitotane.', NULL, NULL, NULL),
(5877, 183, 'Spironolactone ', 'Morphine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5878, 183, 'Spironolactone ', 'Nalbuphine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5879, 183, 'Spironolactone ', 'Nitrofurantoin', ' May enhance the hyperkalemic effect of Spironolactone.', NULL, NULL, NULL),
(5880, 183, 'Spironolactone ', 'Norepinephrine', ' May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.', NULL, NULL, NULL),
(5881, 183, 'Spironolactone ', 'Obinutuzumab', ' Antihypertensives may enhance the hypotensive effect of Obinutuzumab.', NULL, NULL, NULL),
(5882, 183, 'Spironolactone ', 'Oxycodone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5883, 183, 'Spironolactone ', 'Oxymorphone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5884, 183, 'Spironolactone ', 'Pancuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(5885, 183, 'Spironolactone ', 'Pentobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(5886, 183, 'Spironolactone ', 'Pentoxifylline', ' May enhance the hypotensive effect of Antihypertensives.', NULL, NULL, NULL),
(5887, 183, 'Spironolactone ', 'Pethidine', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5888, 183, 'Spironolactone ', 'Primidone', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(5889, 183, 'Spironolactone ', 'Pseudoephedrine', ' May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.', NULL, NULL, NULL),
(5890, 183, 'Spironolactone ', 'Quinidine', ' Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.', NULL, NULL, NULL),
(5891, 183, 'Spironolactone ', 'Remifentanil', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5892, 183, 'Spironolactone ', 'Risperidone', ' Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.', NULL, NULL, NULL),
(5893, 183, 'Spironolactone ', 'Rituximab', ' Antihypertensives may enhance the hypotensive effect of RiTUXimab.', NULL, NULL, NULL),
(5894, 183, 'Spironolactone ', 'Rocuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(5895, 183, 'Spironolactone ', 'Secobarbital', ' May enhance the hypotensive effect of Hypotensive Agents.', NULL, NULL, NULL),
(5896, 183, 'Spironolactone ', 'Sufentanil', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5897, 183, 'Spironolactone ', 'Sulfamethoxazole', ' Trimethoprim may enhance the hyperkalemic effect of Spironolactone.', NULL, NULL, NULL),
(5898, 183, 'Spironolactone ', 'Tadalafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(5899, 183, 'Spironolactone ', 'Tapentadol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5900, 183, 'Spironolactone ', 'Tolvaptan', ' May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.', NULL, NULL, NULL),
(5901, 183, 'Spironolactone ', 'Tramadol', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(5902, 183, 'Spironolactone ', 'Triamterene', ' Triamterene may enhance the hyperkalemic effect of Spironolactone.', NULL, NULL, NULL),
(5903, 183, 'Spironolactone ', 'Trimethoprim', ' May enhance the hyperkalemic effect of Spironolactone.', NULL, NULL, NULL),
(5904, 183, 'Spironolactone ', 'Triprolidine', ' May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.', NULL, NULL, NULL),
(5905, 183, 'Spironolactone ', 'Vardenafil', ' May enhance the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(5906, 183, 'Spironolactone ', 'Vecuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(5907, 183, 'Spironolactone ', 'Yohimbine', ' May diminish the antihypertensive effect of Antihypertensives.', NULL, NULL, NULL),
(5908, 184, 'Streptomycin sulfate ', '0', '0', NULL, NULL, NULL),
(5909, 185, 'Sulfasalazine ', '0', '0', NULL, NULL, NULL),
(5910, 185, 'Sulfasalazine ', 'Folic Acid', ' May decrease the serum concentration of Folic Acid.', NULL, NULL, NULL),
(5911, 185, 'Sulfasalazine ', 'Heparin', ' 5-ASA Derivatives may enhance the adverse/toxic effect of Heparin. Specifically~ the risk for bleeding/bruising may be increased.', NULL, NULL, NULL),
(5912, 185, 'Sulfasalazine ', 'Methotrexate', ' May enhance the hepatotoxic effect of Methotrexate.', NULL, NULL, NULL),
(5913, 185, 'Sulfasalazine ', 'Nitric Oxide', ' May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.', NULL, NULL, NULL),
(5914, 185, 'Sulfasalazine ', 'Prilocaine', ' Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.', NULL, NULL, NULL),
(5915, 186, 'Sumatriptan Succinate ', '0', '0', NULL, NULL, NULL),
(5916, 187, 'Tamoxifen Citrate ', '0', '0', NULL, NULL, NULL),
(5917, 188, 'Tamsulosin Hydrochloride ', '0', '0', NULL, NULL, NULL),
(5918, 189, 'Tenofovir ', '0', '0', NULL, NULL, NULL),
(5919, 189, 'Tenofovir ', 'Aciclovir', ' Acyclovir-Valacyclovir may decrease the excretion of Tenofovir.', NULL, NULL, NULL),
(5920, 189, 'Tenofovir ', 'Adefovir Dipivoxil', ' Adefovir may diminish the therapeutic effect of Tenofovir. Specifically~ adefovir-associated mutations in Hepatitis B viral reverse transcriptase may decrease viral susceptibility to tenofovir. Adefovir may increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Adefovir.', NULL, NULL, NULL),
(5921, 189, 'Tenofovir ', 'Amikacin', ' Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5922, 189, 'Tenofovir ', 'Arbekacin', ' Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5923, 189, 'Tenofovir ', 'Atazanavir', ' May increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Atazanavir.', NULL, NULL, NULL),
(5924, 189, 'Tenofovir ', 'Celecoxib', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5925, 189, 'Tenofovir ', 'Cidofovir', ' May decrease the excretion of Tenofovir.', NULL, NULL, NULL),
(5926, 189, 'Tenofovir ', 'Darunavir', ' May increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Darunavir.', NULL, NULL, NULL),
(5927, 189, 'Tenofovir ', 'Didanosine', ' Tenofovir may diminish the therapeutic effect of Didanosine. Tenofovir may increase the serum concentration of Didanosine.', NULL, NULL, NULL),
(5928, 189, 'Tenofovir ', 'Diflunisal', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5929, 189, 'Tenofovir ', 'Etodolac', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5930, 189, 'Tenofovir ', 'Fenoprofen', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5931, 189, 'Tenofovir ', 'Floctafenine', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5932, 189, 'Tenofovir ', 'Framycetin', ' Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5933, 189, 'Tenofovir ', 'Gentamicin', ' Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5934, 189, 'Tenofovir ', 'Ibuprofen', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5935, 189, 'Tenofovir ', 'Indomethacin', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5936, 189, 'Tenofovir ', 'Kanamycin', ' Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5937, 189, 'Tenofovir ', 'Ketoprofen', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5938, 189, 'Tenofovir ', 'Ketorolac', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5939, 189, 'Tenofovir ', 'Ledipasvir', ' May increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5940, 189, 'Tenofovir ', 'Lopinavir', ' May enhance the nephrotoxic effect of Tenofovir. Lopinavir may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5941, 189, 'Tenofovir ', 'Mefenamic acid', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5942, 189, 'Tenofovir ', 'Meloxicam', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5943, 189, 'Tenofovir ', 'Nabumetone', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5944, 189, 'Tenofovir ', 'Naproxen', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5945, 189, 'Tenofovir ', 'Neomycin', ' Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5946, 189, 'Tenofovir ', 'Netilmicin', ' Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5947, 189, 'Tenofovir ', 'Oxaprozin', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5948, 189, 'Tenofovir ', 'Piroxicam', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5949, 189, 'Tenofovir ', 'Ribostamycin', ' Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5950, 189, 'Tenofovir ', 'Simeprevir', ' May increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Simeprevir.', NULL, NULL, NULL),
(5951, 189, 'Tenofovir ', 'Spectinomycin', ' Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5952, 189, 'Tenofovir ', 'Streptomycin', ' Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5953, 189, 'Tenofovir ', 'Sulindac', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5954, 189, 'Tenofovir ', 'Telaprevir', ' May increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5955, 189, 'Tenofovir ', 'Tiaprofenic acid', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5956, 189, 'Tenofovir ', 'Tipranavir', ' Tenofovir may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5957, 189, 'Tenofovir ', 'Tobramycin', ' Tenofovir may increase the serum concentration of Aminoglycosides. Aminoglycosides may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5958, 189, 'Tenofovir ', 'Tolmetin', ' Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tenofovir.', NULL, NULL, NULL),
(5959, 189, 'Tenofovir ', 'Valganciclovir', ' May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir.', NULL, NULL, NULL),
(5960, 190, 'Terbinafine Hydrochloride ', '0', '0', NULL, NULL, NULL),
(5961, 191, 'Terbutaline ', '0', '0', NULL, NULL, NULL),
(5962, 191, 'Terbutaline ', 'Acebutolol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5963, 191, 'Terbutaline ', 'Aminophylline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5964, 191, 'Terbutaline ', 'Amphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5965, 191, 'Terbutaline ', 'Arformoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5966, 191, 'Terbutaline ', 'armodafinil', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5967, 191, 'Terbutaline ', 'Articaine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5968, 191, 'Terbutaline ', 'Atomoxetine', ' AtoMOXetine may enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(5969, 191, 'Terbutaline ', 'Benzphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5970, 191, 'Terbutaline ', 'Betahistine', ' May diminish the therapeutic effect of Beta2-Agonists.', NULL, NULL, NULL),
(5971, 191, 'Terbutaline ', 'Caffeine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5972, 191, 'Terbutaline ', 'Chlorphentermine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5973, 191, 'Terbutaline ', 'Clenbuterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5974, 191, 'Terbutaline ', 'Cocaine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5975, 191, 'Terbutaline ', 'Dexmethylphenidate', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5976, 191, 'Terbutaline ', 'Dextroamphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5977, 191, 'Terbutaline ', 'Diethylpropion', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5978, 191, 'Terbutaline ', 'Dihydrocodeine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5979, 191, 'Terbutaline ', 'Dipivefrin', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5980, 191, 'Terbutaline ', 'Dobutamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5981, 191, 'Terbutaline ', 'Dopamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5982, 191, 'Terbutaline ', 'Doxapram', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5983, 191, 'Terbutaline ', 'Dronabinol', ' Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(5984, 191, 'Terbutaline ', 'Epinephrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5985, 191, 'Terbutaline ', 'Fenoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5986, 191, 'Terbutaline ', 'Fluticasone furoate', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5987, 191, 'Terbutaline ', 'Formoterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5988, 191, 'Terbutaline ', 'Indacaterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5989, 191, 'Terbutaline ', 'Iobenguane', ' May diminish the therapeutic effect of Iobenguane I 123.', NULL, NULL, NULL),
(5990, 191, 'Terbutaline ', 'Ipratropium bromide', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5991, 191, 'Terbutaline ', 'Isometheptene', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5992, 191, 'Terbutaline ', 'Isoprenaline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5993, 191, 'Terbutaline ', 'Labetalol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5994, 191, 'Terbutaline ', 'Levonordefrin', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5995, 191, 'Terbutaline ', 'Linezolid', ' Linezolid may enhance the hypertensive effect of Sympathomimetics.', NULL, NULL, NULL),
(5996, 191, 'Terbutaline ', 'Lisdexamfetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5997, 191, 'Terbutaline ', 'Loxapine', ' Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically~ the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.', NULL, NULL, NULL),
(5998, 191, 'Terbutaline ', 'Mephentermine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(5999, 191, 'Terbutaline ', 'Metaraminol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6000, 191, 'Terbutaline ', 'Methamphetamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6001, 191, 'Terbutaline ', 'Methoxamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6002, 191, 'Terbutaline ', 'Methylphenidate', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6003, 191, 'Terbutaline ', 'Midodrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6004, 191, 'Terbutaline ', 'Modafinil', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6005, 191, 'Terbutaline ', 'Nabilone', ' Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(6006, 191, 'Terbutaline ', 'Naphazoline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6007, 191, 'Terbutaline ', 'Norepinephrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6008, 191, 'Terbutaline ', 'Orciprenaline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6009, 191, 'Terbutaline ', 'Oxymetazoline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6010, 191, 'Terbutaline ', 'Phendimetrazine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6011, 191, 'Terbutaline ', 'Pheniramine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6012, 191, 'Terbutaline ', 'Phenmetrazine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6013, 191, 'Terbutaline ', 'Phentermine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6014, 191, 'Terbutaline ', 'Phenylephrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6015, 191, 'Terbutaline ', 'Phenylpropanolamine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6016, 191, 'Terbutaline ', 'Pirbuterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6017, 191, 'Terbutaline ', 'Propylhexedrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6018, 191, 'Terbutaline ', 'Pseudoephedrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6019, 191, 'Terbutaline ', 'Ritodrine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6020, 191, 'Terbutaline ', 'Salbutamol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6021, 191, 'Terbutaline ', 'Salmeterol', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6022, 191, 'Terbutaline ', 'Tedizolid Phosphate', ' Tedizolid may enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.', NULL, NULL, NULL),
(6023, 191, 'Terbutaline ', 'Theophylline', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6024, 191, 'Terbutaline ', 'Triprolidine', ' May enhance the adverse/toxic effect of other Sympathomimetics.', NULL, NULL, NULL),
(6025, 192, 'Tetracaine Hydrochloride ', '0', '0', NULL, NULL, NULL),
(6026, 193, 'Thioguanil ', '0', '0', NULL, NULL, NULL),
(6027, 194, 'Thiopental ', '0', '0', NULL, NULL, NULL),
(6028, 194, 'Thiopental ', 'Aminophylline', ' Aminophylline may diminish the therapeutic effect of Thiopental.', NULL, NULL, NULL),
(6029, 194, 'Thiopental ', 'Chlorpromazine', ' Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.', NULL, NULL, NULL),
(6030, 194, 'Thiopental ', 'Diazoxide', ' May enhance the hypotensive effect of Diazoxide.', NULL, NULL, NULL),
(6031, 194, 'Thiopental ', 'Ketamine', ' Ketamine may enhance the adverse/toxic effect of Thiopental.', NULL, NULL, NULL),
(6032, 194, 'Thiopental ', 'Mefloquine', ' Mefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.', NULL, NULL, NULL),
(6033, 194, 'Thiopental ', 'Orlistat', ' Orlistat may decrease the serum concentration of Anticonvulsants. Exceptions: Fosphenytoin; PENTobarbital; Thiopental.', NULL, NULL, NULL),
(6034, 194, 'Thiopental ', 'Perphenazine', ' Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.', NULL, NULL, NULL),
(6035, 194, 'Thiopental ', 'Pipotiazine', ' Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.', NULL, NULL, NULL),
(6036, 194, 'Thiopental ', 'Prochlorperazine', ' Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.', NULL, NULL, NULL),
(6037, 194, 'Thiopental ', 'Promazine', ' Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.', NULL, NULL, NULL),
(6038, 194, 'Thiopental ', 'Sulfisoxazole', ' SulfiSOXAZOLE may enhance the therapeutic effect of Thiopental.', NULL, NULL, NULL),
(6039, 194, 'Thiopental ', 'Thioridazine', ' Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.', NULL, NULL, NULL),
(6040, 194, 'Thiopental ', 'Trifluoperazine', ' Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.', NULL, NULL, NULL),
(6041, 195, 'Thioridazine ', '0', '0', NULL, NULL, NULL),
(6042, 195, 'Thioridazine ', 'Abiraterone', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6043, 195, 'Thioridazine ', 'Aclidinium', ' May enhance the anticholinergic effect of Anticholinergic Agents.', NULL, NULL, NULL),
(6044, 195, 'Thioridazine ', 'Almotriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6045, 195, 'Thioridazine ', 'Aluminum hydroxide', ' May decrease the absorption of Antipsychotic Agents (Phenothiazines).', NULL, NULL, NULL),
(6046, 195, 'Thioridazine ', 'Amiodarone', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6047, 195, 'Thioridazine ', 'Amisulpride', ' Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride.', NULL, NULL, NULL),
(6048, 195, 'Thioridazine ', 'Amitriptyline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6049, 195, 'Thioridazine ', 'Amoxapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6050, 195, 'Thioridazine ', 'Amphetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(6051, 195, 'Thioridazine ', 'Aripiprazole', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(6052, 195, 'Thioridazine ', 'Artemether', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6053, 195, 'Thioridazine ', 'Atomoxetine', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.', NULL, NULL, NULL),
(6054, 195, 'Thioridazine ', 'Benzphetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(6055, 195, 'Thioridazine ', 'Buprenorphine', ' CNS Depressants may enhance the CNS depressant effect of Buprenorphine.', NULL, NULL, NULL),
(6056, 195, 'Thioridazine ', 'Bupropion', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6057, 195, 'Thioridazine ', 'Buspirone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6058, 195, 'Thioridazine ', 'Cabergoline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6059, 195, 'Thioridazine ', 'Calcium carbonate', ' May decrease the absorption of Antipsychotic Agents (Phenothiazines).', NULL, NULL, NULL),
(6060, 195, 'Thioridazine ', 'Cathinone', ' Antipsychotic Agents may diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(6061, 195, 'Thioridazine ', 'Celecoxib', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6062, 195, 'Thioridazine ', 'Chloroquine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6063, 195, 'Thioridazine ', 'Chlorphenamine', ' Chlorpheniramine may enhance the arrhythmogenic effect of Thioridazine. Thioridazine may increase the serum concentration of Chlorpheniramine.', NULL, NULL, NULL),
(6064, 195, 'Thioridazine ', 'Chlorpromazine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6065, 195, 'Thioridazine ', 'Cimetidine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6066, 195, 'Thioridazine ', 'Cinacalcet', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6067, 195, 'Thioridazine ', 'Citalopram', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6068, 195, 'Thioridazine ', 'Clobazam', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(6069, 195, 'Thioridazine ', 'Clomipramine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6070, 195, 'Thioridazine ', 'Clozapine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6071, 195, 'Thioridazine ', 'Cocaine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6072, 195, 'Thioridazine ', 'Codeine', ' CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.', NULL, NULL, NULL),
(6073, 195, 'Thioridazine ', 'Cyclobenzaprine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6074, 195, 'Thioridazine ', 'Dapoxetine', ' May enhance the arrhythmogenic effect of Thioridazine. Dapoxetine may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6075, 195, 'Thioridazine ', 'Darifenacin', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6076, 195, 'Thioridazine ', 'Darunavir', ' May increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(6077, 195, 'Thioridazine ', 'Delavirdine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6078, 195, 'Thioridazine ', 'Desipramine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6079, 195, 'Thioridazine ', 'Desvenlafaxine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6080, 195, 'Thioridazine ', 'Dextroamphetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(6081, 195, 'Thioridazine ', 'Dextromethorphan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6082, 195, 'Thioridazine ', 'Dihydroergotamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6083, 195, 'Thioridazine ', 'Donepezil', ' Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.', NULL, NULL, NULL),
(6084, 195, 'Thioridazine ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(6085, 195, 'Thioridazine ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(6086, 195, 'Thioridazine ', 'Dronedarone', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6087, 195, 'Thioridazine ', 'Duloxetine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6088, 195, 'Thioridazine ', 'Eletriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6089, 195, 'Thioridazine ', 'Eliglustat', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6090, 195, 'Thioridazine ', 'Ergoloid mesylate', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6091, 195, 'Thioridazine ', 'Ergonovine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6092, 195, 'Thioridazine ', 'Ergotamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6093, 195, 'Thioridazine ', 'Escitalopram', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6094, 195, 'Thioridazine ', 'Fentanyl', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6095, 195, 'Thioridazine ', 'Fesoterodine', ' CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.', NULL, NULL, NULL),
(6096, 195, 'Thioridazine ', 'Fluoxetine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6097, 195, 'Thioridazine ', 'Fluvoxamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6098, 195, 'Thioridazine ', 'Frovatriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6099, 195, 'Thioridazine ', 'Galantamine', ' Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.', NULL, NULL, NULL),
(6100, 195, 'Thioridazine ', 'Haloperidol', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6101, 195, 'Thioridazine ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(6102, 195, 'Thioridazine ', 'Imipramine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6103, 195, 'Thioridazine ', 'Isocarboxazid', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6104, 195, 'Thioridazine ', 'Isoniazid', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6105, 195, 'Thioridazine ', 'Itopride', ' Anticholinergic Agents may diminish the therapeutic effect of Itopride.', NULL, NULL, NULL),
(6106, 195, 'Thioridazine ', 'Levomilnacipran', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6107, 195, 'Thioridazine ', 'Linezolid', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6108, 195, 'Thioridazine ', 'Lisdexamfetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(6109, 195, 'Thioridazine ', 'Lithium', ' Lithium may enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.', NULL, NULL, NULL),
(6110, 195, 'Thioridazine ', 'Lopinavir', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6111, 195, 'Thioridazine ', 'Lorcaserin', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6112, 195, 'Thioridazine ', 'Lumefantrine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6113, 195, 'Thioridazine ', 'Magnesium oxide', ' May decrease the absorption of Antipsychotic Agents (Phenothiazines).', NULL, NULL, NULL),
(6114, 195, 'Thioridazine ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(6115, 195, 'Thioridazine ', 'Maprotiline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6116, 195, 'Thioridazine ', 'Mequitazine', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine.', NULL, NULL, NULL),
(6117, 195, 'Thioridazine ', 'Methadone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6118, 195, 'Thioridazine ', 'Methamphetamine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(6119, 195, 'Thioridazine ', 'Methotrimeprazine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6120, 195, 'Thioridazine ', 'Methylergometrine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6121, 195, 'Thioridazine ', 'Methylphenidate', ' May enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents.', NULL, NULL, NULL),
(6122, 195, 'Thioridazine ', 'Metoclopramide', ' May enhance the adverse/toxic effect of Antipsychotic Agents.', NULL, NULL, NULL),
(6123, 195, 'Thioridazine ', 'Metoprolol', ' CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.', NULL, NULL, NULL),
(6124, 195, 'Thioridazine ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(6125, 195, 'Thioridazine ', 'Mifepristone', ' May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.', NULL, NULL, NULL),
(6126, 195, 'Thioridazine ', 'Milnacipran', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6127, 195, 'Thioridazine ', 'Mirabegron', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6128, 195, 'Thioridazine ', 'Moclobemide', ' May increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6129, 195, 'Thioridazine ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(6130, 195, 'Thioridazine ', 'Naratriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6131, 195, 'Thioridazine ', 'Nebivolol', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.', NULL, NULL, NULL),
(6132, 195, 'Thioridazine ', 'Nefazodone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6133, 195, 'Thioridazine ', 'Nilotinib', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6134, 195, 'Thioridazine ', 'Nortriptyline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6135, 195, 'Thioridazine ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(6136, 195, 'Thioridazine ', 'Panobinostat', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6137, 195, 'Thioridazine ', 'Paroxetine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6138, 195, 'Thioridazine ', 'Peginterferon alfa-2b', ' May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.', NULL, NULL, NULL),
(6139, 195, 'Thioridazine ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(6140, 195, 'Thioridazine ', 'Pethidine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6141, 195, 'Thioridazine ', 'Phendimetrazine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(6142, 195, 'Thioridazine ', 'Phenelzine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6143, 195, 'Thioridazine ', 'Phentermine', ' May diminish the stimulatory effect of Amphetamines.', NULL, NULL, NULL),
(6144, 195, 'Thioridazine ', 'Pimozide', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(6145, 195, 'Thioridazine ', 'Porfimer', ' Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.', NULL, NULL, NULL),
(6146, 195, 'Thioridazine ', 'Potassium Chloride', ' Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.', NULL, NULL, NULL),
(6147, 195, 'Thioridazine ', 'Pramlintide', ' May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.', NULL, NULL, NULL),
(6148, 195, 'Thioridazine ', 'Procarbazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6149, 195, 'Thioridazine ', 'Promazine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6150, 195, 'Thioridazine ', 'Promethazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6151, 195, 'Thioridazine ', 'Protriptyline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6152, 195, 'Thioridazine ', 'Quinidine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6153, 195, 'Thioridazine ', 'Quinine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6154, 195, 'Thioridazine ', 'Rasagiline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6155, 195, 'Thioridazine ', 'Ritonavir', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6156, 195, 'Thioridazine ', 'Rivastigmine', ' Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.', NULL, NULL, NULL),
(6157, 195, 'Thioridazine ', 'Rizatriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6158, 195, 'Thioridazine ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(6159, 195, 'Thioridazine ', 'Secretin', ' Anticholinergic Agents may diminish the therapeutic effect of Secretin.', NULL, NULL, NULL),
(6160, 195, 'Thioridazine ', 'Selegiline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6161, 195, 'Thioridazine ', 'Sertraline', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6162, 195, 'Thioridazine ', 'Sulpiride', ' Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride.', NULL, NULL, NULL),
(6163, 195, 'Thioridazine ', 'Sumatriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6164, 195, 'Thioridazine ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(6165, 195, 'Thioridazine ', 'Tamoxifen', ' CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically~ strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.', NULL, NULL, NULL),
(6166, 195, 'Thioridazine ', 'Tamsulosin', ' CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.', NULL, NULL, NULL),
(6167, 195, 'Thioridazine ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(6168, 195, 'Thioridazine ', 'Tedizolid Phosphate', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6169, 195, 'Thioridazine ', 'Tetrabenazine', ' Tetrabenazine may enhance the adverse/toxic effect of Antipsychotic Agents.', NULL, NULL, NULL),
(6170, 195, 'Thioridazine ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(6171, 195, 'Thioridazine ', 'Thiopental', ' Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental.', NULL, NULL, NULL),
(6172, 195, 'Thioridazine ', 'Ticlopidine', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6173, 195, 'Thioridazine ', 'Tiotropium', ' Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.', NULL, NULL, NULL),
(6174, 195, 'Thioridazine ', 'Tipranavir', ' CYP2D6 Inhibitors may increase the serum concentration of Thioridazine.', NULL, NULL, NULL),
(6175, 195, 'Thioridazine ', 'Topiramate', ' Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.', NULL, NULL, NULL),
(6176, 195, 'Thioridazine ', 'Tramadol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6177, 195, 'Thioridazine ', 'Tranylcypromine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6178, 195, 'Thioridazine ', 'Trimipramine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6179, 195, 'Thioridazine ', 'Venlafaxine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6180, 195, 'Thioridazine ', 'Verteporfin', ' Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.', NULL, NULL, NULL),
(6181, 195, 'Thioridazine ', 'Vilazodone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6182, 195, 'Thioridazine ', 'Zolmitriptan', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6183, 195, 'Thioridazine ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(6184, 196, 'Timolol Maleate ', '0', '0', NULL, NULL, NULL),
(6185, 197, 'Tinidazole ', '0', '0', NULL, NULL, NULL),
(6186, 197, 'Tinidazole ', 'Disulfiram', ' May enhance the adverse/toxic effect of Disulfiram.', NULL, NULL, NULL),
(6187, 197, 'Tinidazole ', 'Ethanol', ' May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.', NULL, NULL, NULL),
(6188, 198, 'Tramadol ', '0', '0', NULL, NULL, NULL),
(6189, 198, 'Tramadol ', 'Abiraterone', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6190, 198, 'Tramadol ', 'Acenocoumarol', ' May enhance the anticoagulant effect of Vitamin K Antagonists.', NULL, NULL, NULL),
(6191, 198, 'Tramadol ', 'Acepromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6192, 198, 'Tramadol ', 'Acetazolamide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6193, 198, 'Tramadol ', 'Acetophenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6194, 198, 'Tramadol ', 'Alosetron', ' Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.', NULL, NULL, NULL),
(6195, 198, 'Tramadol ', 'Alvimopan', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e.~ more than 7 days) opiates prior to alvimopan initiation.', NULL, NULL, NULL),
(6196, 198, 'Tramadol ', 'Amiloride', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6197, 198, 'Tramadol ', 'Amiodarone', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6198, 198, 'Tramadol ', 'Amisulpride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6199, 198, 'Tramadol ', 'Amitriptyline', ' Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6200, 198, 'Tramadol ', 'Ammonium chloride', ' May increase the excretion of Analgesics (Opioid).', NULL, NULL, NULL),
(6201, 198, 'Tramadol ', 'Amoxapine', ' Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6202, 198, 'Tramadol ', 'Amphetamine', ' May enhance the analgesic effect of Analgesics (Opioid).', NULL, NULL, NULL),
(6203, 198, 'Tramadol ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6204, 198, 'Tramadol ', 'Aripiprazole', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6205, 198, 'Tramadol ', 'Artemether', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6206, 198, 'Tramadol ', 'Bendroflumethiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6207, 198, 'Tramadol ', 'Benzquinamide', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6208, 198, 'Tramadol ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6209, 198, 'Tramadol ', 'Bumetanide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6210, 198, 'Tramadol ', 'Bupropion', ' CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6211, 198, 'Tramadol ', 'Carbamazepine', ' TraMADol may enhance the CNS depressant effect of CarBAMazepine. TraMADol may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of TraMADol.', NULL, NULL, NULL),
(6212, 198, 'Tramadol ', 'Carphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6213, 198, 'Tramadol ', 'Cathinone', ' May enhance the analgesic effect of Analgesics (Opioid).', NULL, NULL, NULL),
(6214, 198, 'Tramadol ', 'Celecoxib', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6215, 198, 'Tramadol ', 'Chlormezanone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6216, 198, 'Tramadol ', 'Chloroquine', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6217, 198, 'Tramadol ', 'Chlorothiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6218, 198, 'Tramadol ', 'Chlorpromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6219, 198, 'Tramadol ', 'Chlorprothixene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6220, 198, 'Tramadol ', 'Chlorthalidone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6221, 198, 'Tramadol ', 'Cimetidine', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6222, 198, 'Tramadol ', 'Cinacalcet', ' CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6223, 198, 'Tramadol ', 'Citalopram', ' Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.', NULL, NULL, NULL),
(6224, 198, 'Tramadol ', 'Clobazam', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6225, 198, 'Tramadol ', 'Clomipramine', ' Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6226, 198, 'Tramadol ', 'Clozapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6227, 198, 'Tramadol ', 'Cocaine', ' CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6228, 198, 'Tramadol ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6229, 198, 'Tramadol ', 'Cyclobenzaprine', ' May enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. Cyclobenzaprine may enhance the serotonergic effect of TraMADol. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6230, 198, 'Tramadol ', 'Cyclothiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6231, 198, 'Tramadol ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6232, 198, 'Tramadol ', 'Dapoxetine', ' May enhance the adverse/toxic effect of Serotonin Modulators.', NULL, NULL, NULL),
(6233, 198, 'Tramadol ', 'Darifenacin', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6234, 198, 'Tramadol ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6235, 198, 'Tramadol ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6236, 198, 'Tramadol ', 'Desipramine', ' Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6237, 198, 'Tramadol ', 'Desmopressin', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.', NULL, NULL, NULL),
(6238, 198, 'Tramadol ', 'Dolasetron', ' Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.', NULL, NULL, NULL),
(6239, 198, 'Tramadol ', 'Doxylamine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(6240, 198, 'Tramadol ', 'Dronabinol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(6241, 198, 'Tramadol ', 'Dronedarone', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6242, 198, 'Tramadol ', 'Droperidol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6243, 198, 'Tramadol ', 'Eliglustat', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6244, 198, 'Tramadol ', 'Escitalopram', ' Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.', NULL, NULL, NULL),
(6245, 198, 'Tramadol ', 'Ethacrynic acid', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6246, 198, 'Tramadol ', 'Ethoxzolamide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6247, 198, 'Tramadol ', 'Fencamfamine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6248, 198, 'Tramadol ', 'Fluoxetine', ' Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.', NULL, NULL, NULL),
(6249, 198, 'Tramadol ', 'Flupentixol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6250, 198, 'Tramadol ', 'Fluphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6251, 198, 'Tramadol ', 'Fluspirilene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6252, 198, 'Tramadol ', 'Fluvoxamine', ' Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.', NULL, NULL, NULL),
(6253, 198, 'Tramadol ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6254, 198, 'Tramadol ', 'Furosemide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6255, 198, 'Tramadol ', 'Granisetron', ' Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.', NULL, NULL, NULL),
(6256, 198, 'Tramadol ', 'Haloperidol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6257, 198, 'Tramadol ', 'Hydrochlorothiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6258, 198, 'Tramadol ', 'Hydrocodone', ' CNS Depressants may enhance the CNS depressant effect of Hydrocodone.', NULL, NULL, NULL),
(6259, 198, 'Tramadol ', 'Hydroflumethiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6260, 198, 'Tramadol ', 'Hydroxyzine', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(6261, 198, 'Tramadol ', 'Imipramine', ' Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6262, 198, 'Tramadol ', 'Indapamide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6263, 198, 'Tramadol ', 'Isocarboxazid', ' May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.', NULL, NULL, NULL),
(6264, 198, 'Tramadol ', 'Isoniazid', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6265, 198, 'Tramadol ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6266, 198, 'Tramadol ', 'Linezolid', ' May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.', NULL, NULL, NULL),
(6267, 198, 'Tramadol ', 'Loxapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6268, 198, 'Tramadol ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6269, 198, 'Tramadol ', 'Lumefantrine', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6270, 198, 'Tramadol ', 'Magnesium Sulfate', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(6271, 198, 'Tramadol ', 'Mesoridazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6272, 198, 'Tramadol ', 'Methotrimeprazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6273, 198, 'Tramadol ', 'Metoclopramide', ' Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.', NULL, NULL, NULL),
(6274, 198, 'Tramadol ', 'Metolazone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(6275, 198, 'Tramadol ', 'Metyrosine', ' CNS Depressants may enhance the sedative effect of Metyrosine.', NULL, NULL, NULL),
(6276, 198, 'Tramadol ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6277, 198, 'Tramadol ', 'Mirabegron', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6278, 198, 'Tramadol ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6279, 198, 'Tramadol ', 'Moclobemide', ' May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.', NULL, NULL, NULL),
(6280, 198, 'Tramadol ', 'Molindone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6281, 198, 'Tramadol ', 'Nabilone', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(6282, 198, 'Tramadol ', 'Naltrexone', ' May diminish the therapeutic effect of Analgesics (Opioid).', NULL, NULL, NULL),
(6283, 198, 'Tramadol ', 'Nilotinib', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6284, 198, 'Tramadol ', 'Nortriptyline', ' Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6285, 198, 'Tramadol ', 'Olanzapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6286, 198, 'Tramadol ', 'Ondansetron', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6287, 198, 'Tramadol ', 'Orphenadrine', ' CNS Depressants may enhance the CNS depressant effect of Orphenadrine.', NULL, NULL, NULL),
(6288, 198, 'Tramadol ', 'Paliperidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6289, 198, 'Tramadol ', 'Palonosetron', ' Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.', NULL, NULL, NULL),
(6290, 198, 'Tramadol ', 'Panobinostat', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6291, 198, 'Tramadol ', 'Paroxetine', ' Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.', NULL, NULL, NULL),
(6292, 198, 'Tramadol ', 'Pegvisomant', ' Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.', NULL, NULL, NULL),
(6293, 198, 'Tramadol ', 'Perampanel', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(6294, 198, 'Tramadol ', 'Perphenazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6295, 198, 'Tramadol ', 'Phenelzine', ' May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.', NULL, NULL, NULL),
(6296, 198, 'Tramadol ', 'Pimozide', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6297, 198, 'Tramadol ', 'Piperacetazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6298, 198, 'Tramadol ', 'Pramipexole', ' CNS Depressants may enhance the sedative effect of Pramipexole.', NULL, NULL, NULL),
(6299, 198, 'Tramadol ', 'Procarbazine', ' May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.', NULL, NULL, NULL),
(6300, 198, 'Tramadol ', 'Prochlorperazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6301, 198, 'Tramadol ', 'Promazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6302, 198, 'Tramadol ', 'Protriptyline', ' Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6303, 198, 'Tramadol ', 'Quetiapine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6304, 198, 'Tramadol ', 'Quinidine', ' CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6305, 198, 'Tramadol ', 'Quinine', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6306, 198, 'Tramadol ', 'Rasagiline', ' May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.', NULL, NULL, NULL),
(6307, 198, 'Tramadol ', 'Remoxipride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6308, 198, 'Tramadol ', 'Reserpine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6309, 198, 'Tramadol ', 'Risperidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6310, 198, 'Tramadol ', 'Ropinirole', ' CNS Depressants may enhance the sedative effect of ROPINIRole.', NULL, NULL, NULL),
(6311, 198, 'Tramadol ', 'Rotigotine', ' CNS Depressants may enhance the sedative effect of Rotigotine.', NULL, NULL, NULL),
(6312, 198, 'Tramadol ', 'Rufinamide', ' May enhance the adverse/toxic effect of CNS Depressants. Specifically~ sleepiness and dizziness may be enhanced.', NULL, NULL, NULL),
(6313, 198, 'Tramadol ', 'Selegiline', ' May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.', NULL, NULL, NULL),
(6314, 198, 'Tramadol ', 'Sertindole', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6315, 198, 'Tramadol ', 'Sertraline', ' Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.', NULL, NULL, NULL),
(6316, 198, 'Tramadol ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6317, 198, 'Tramadol ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6318, 198, 'Tramadol ', 'Spironolactone', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6319, 198, 'Tramadol ', 'Succinylcholine', ' May enhance the bradycardic effect of Analgesics (Opioid).', NULL, NULL, NULL),
(6320, 198, 'Tramadol ', 'Sulpiride', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6321, 198, 'Tramadol ', 'Suvorexant', ' CNS Depressants may enhance the CNS depressant effect of Suvorexant.', NULL, NULL, NULL),
(6322, 198, 'Tramadol ', 'Tapentadol', ' May enhance the CNS depressant effect of CNS Depressants.', NULL, NULL, NULL),
(6323, 198, 'Tramadol ', 'Tedizolid Phosphate', ' May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.', NULL, NULL, NULL),
(6324, 198, 'Tramadol ', 'Thalidomide', ' CNS Depressants may enhance the CNS depressant effect of Thalidomide.', NULL, NULL, NULL),
(6325, 198, 'Tramadol ', 'Thioridazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6326, 198, 'Tramadol ', 'Thiothixene', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6327, 198, 'Tramadol ', 'Ticlopidine', ' CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6328, 198, 'Tramadol ', 'Ticrynafen', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6329, 198, 'Tramadol ', 'Tipranavir', ' CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.', NULL, NULL, NULL),
(6330, 198, 'Tramadol ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6331, 198, 'Tramadol ', 'Torasemide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6332, 198, 'Tramadol ', 'Tranylcypromine', ' May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.', NULL, NULL, NULL),
(6333, 198, 'Tramadol ', 'Triamterene', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6334, 198, 'Tramadol ', 'Trichlormethiazide', ' Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.', NULL, NULL, NULL),
(6335, 198, 'Tramadol ', 'Trifluoperazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6336, 198, 'Tramadol ', 'Triflupromazine', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6337, 198, 'Tramadol ', 'Trimipramine', ' Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6338, 198, 'Tramadol ', 'Vilazodone', ' Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.', NULL, NULL, NULL),
(6339, 198, 'Tramadol ', 'Ziprasidone', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6340, 198, 'Tramadol ', 'Zolpidem', ' CNS Depressants may enhance the CNS depressant effect of Zolpidem.', NULL, NULL, NULL),
(6341, 198, 'Tramadol ', 'Zuclopenthixol', ' Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically~ serotonin modulators may enhance dopamine blockade~ possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.', NULL, NULL, NULL),
(6342, 199, 'Trifluridine ', '0', '0', NULL, NULL, NULL),
(6343, 200, 'Valproic acid ', '0', '0', NULL, NULL, NULL),
(6344, 201, 'Vecuronium Bromide ', '0', '0', NULL, NULL, NULL),
(6345, 202, 'Verapamil ', '0', '0', NULL, NULL, NULL),
(6346, 202, 'Verapamil ', 'Aliskiren', ' May increase the serum concentration of Aliskiren.', NULL, NULL, NULL),
(6347, 202, 'Verapamil ', 'Amobarbital', ' Barbiturates may increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(6348, 202, 'Verapamil ', 'Atorvastatin', ' AtorvaSTATin may increase the serum concentration of Verapamil. Verapamil may increase the serum concentration of AtorvaSTATin.', NULL, NULL, NULL),
(6349, 202, 'Verapamil ', 'Atracurium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(6350, 202, 'Verapamil ', 'Butabarbital', ' Barbiturates may increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(6351, 202, 'Verapamil ', 'Butalbital', ' Barbiturates may increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(6352, 202, 'Verapamil ', 'Calcium Acetate', ' Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(6353, 202, 'Verapamil ', 'Calcium carbonate', ' Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(6354, 202, 'Verapamil ', 'Calcium Chloride', ' Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(6355, 202, 'Verapamil ', 'Cimetidine', ' Cimetidine may increase the serum concentration of Calcium Channel Blockers.', NULL, NULL, NULL),
(6356, 202, 'Verapamil ', 'Cisatracurium Besylate', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(6357, 202, 'Verapamil ', 'Clarithromycin', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(6358, 202, 'Verapamil ', 'Clopidogrel', ' May diminish the therapeutic effect of Clopidogrel. Exceptions: Clevidipine.', NULL, NULL, NULL),
(6359, 202, 'Verapamil ', 'Dabigatran etexilate', ' May increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.', NULL, NULL, NULL),
(6360, 202, 'Verapamil ', 'Disopyramide', ' May enhance the adverse/toxic effect of Disopyramide. Of particular concern is the potential for profound depression of myocardial contractility.', NULL, NULL, NULL),
(6361, 202, 'Verapamil ', 'Dofetilide', ' May increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(6362, 202, 'Verapamil ', 'Doxazosin', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(6363, 202, 'Verapamil ', 'Ethanol', ' May increase the serum concentration of Alcohol (Ethyl).', NULL, NULL, NULL),
(6364, 202, 'Verapamil ', 'Fexofenadine', ' May increase the bioavailability of Fexofenadine.', NULL, NULL, NULL),
(6365, 202, 'Verapamil ', 'Fingolimod', ' May enhance the bradycardic effect of Fingolimod.', NULL, NULL, NULL),
(6366, 202, 'Verapamil ', 'Flecainide', ' May enhance the adverse/toxic effect of Flecainide. In particular~ this combination may significantly impair myocardial contractility and AV nodal conduction.', NULL, NULL, NULL),
(6367, 202, 'Verapamil ', 'Fluconazole', ' Fluconazole may increase the serum concentration of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(6368, 202, 'Verapamil ', 'Fosphenytoin', ' May increase the serum concentration of Fosphenytoin.', NULL, NULL, NULL),
(6369, 202, 'Verapamil ', 'Itraconazole', ' Antifungal Agents (Azole Derivatives~ Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically~ itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.', NULL, NULL, NULL),
(6370, 202, 'Verapamil ', 'Lovastatin', ' May increase the serum concentration of Lovastatin.', NULL, NULL, NULL),
(6371, 202, 'Verapamil ', 'Magnesium oxide', ' May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(6372, 202, 'Verapamil ', 'Magnesium salicylate', ' May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(6373, 202, 'Verapamil ', 'Metformin', ' May diminish the therapeutic effect of MetFORMIN.', NULL, NULL, NULL),
(6374, 202, 'Verapamil ', 'Methohexital', ' Barbiturates may increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(6375, 202, 'Verapamil ', 'Nafcillin', ' Nafcillin may increase the metabolism of Calcium Channel Blockers. Exceptions: Clevidipine.', NULL, NULL, NULL),
(6376, 202, 'Verapamil ', 'Nitroprusside', ' May enhance the hypotensive effect of Nitroprusside.', NULL, NULL, NULL),
(6377, 202, 'Verapamil ', 'Pancuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(6378, 202, 'Verapamil ', 'Pentobarbital', ' Barbiturates may increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(6379, 202, 'Verapamil ', 'Phenobarbital', ' Barbiturates may increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(6380, 202, 'Verapamil ', 'Phenoxybenzamine', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(6381, 202, 'Verapamil ', 'Phentolamine', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(6382, 202, 'Verapamil ', 'Phenytoin', ' May increase the serum concentration of Phenytoin.', NULL, NULL, NULL),
(6383, 202, 'Verapamil ', 'Posaconazole', ' Antifungal Agents (Azole Derivatives~ Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically~ itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.', NULL, NULL, NULL),
(6384, 202, 'Verapamil ', 'Prazosin', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(6385, 202, 'Verapamil ', 'Quinidine', ' QuiNIDine may enhance the hypotensive effect of Verapamil. Verapamil may increase the serum concentration of QuiNIDine.', NULL, NULL, NULL),
(6386, 202, 'Verapamil ', 'Rifampicin', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(6387, 202, 'Verapamil ', 'Rifapentine', ' Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.', NULL, NULL, NULL),
(6388, 202, 'Verapamil ', 'Risperidone', ' May increase the serum concentration of RisperiDONE.', NULL, NULL, NULL),
(6389, 202, 'Verapamil ', 'Rocuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(6390, 202, 'Verapamil ', 'Secobarbital', ' Barbiturates may increase the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(6391, 202, 'Verapamil ', 'Silodosin', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(6392, 202, 'Verapamil ', 'Simvastatin', ' May increase the serum concentration of Simvastatin.', NULL, NULL, NULL),
(6393, 202, 'Verapamil ', 'Sulfisoxazole', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(6394, 202, 'Verapamil ', 'Tamsulosin', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(6395, 202, 'Verapamil ', 'Telithromycin', ' Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.', NULL, NULL, NULL),
(6396, 202, 'Verapamil ', 'Terazosin', ' Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.', NULL, NULL, NULL),
(6397, 202, 'Verapamil ', 'Vecuronium', ' May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).', NULL, NULL, NULL),
(6398, 202, 'Verapamil ', 'Voriconazole', ' Antifungal Agents (Azole Derivatives~ Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically~ itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives~ Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.', NULL, NULL, NULL),
(6399, 203, 'Vinblastine ', '0', '0', NULL, NULL, NULL),
(6400, 203, 'Vinblastine ', 'Afatinib', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.', NULL, NULL, NULL),
(6401, 203, 'Vinblastine ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6402, 203, 'Vinblastine ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(6403, 203, 'Vinblastine ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6404, 203, 'Vinblastine ', 'Brentuximab vedotin', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Brentuximab Vedotin. Specifically~ concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.', NULL, NULL, NULL),
(6405, 203, 'Vinblastine ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(6406, 203, 'Vinblastine ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6407, 203, 'Vinblastine ', 'Dabigatran etexilate', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.', NULL, NULL, NULL),
(6408, 203, 'Vinblastine ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6409, 203, 'Vinblastine ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6410, 203, 'Vinblastine ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6411, 203, 'Vinblastine ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(6412, 203, 'Vinblastine ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(6413, 203, 'Vinblastine ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6414, 203, 'Vinblastine ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(6415, 203, 'Vinblastine ', 'Itraconazole', ' May increase the serum concentration of VinBLAStine.', NULL, NULL, NULL),
(6416, 203, 'Vinblastine ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6417, 203, 'Vinblastine ', 'Ledipasvir', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir.', NULL, NULL, NULL),
(6418, 203, 'Vinblastine ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(6419, 203, 'Vinblastine ', 'Linagliptin', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.', NULL, NULL, NULL),
(6420, 203, 'Vinblastine ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(6421, 203, 'Vinblastine ', 'Lopinavir', ' May increase the serum concentration of VinBLAStine.', NULL, NULL, NULL),
(6422, 203, 'Vinblastine ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6423, 203, 'Vinblastine ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6424, 203, 'Vinblastine ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6425, 203, 'Vinblastine ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(6426, 203, 'Vinblastine ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(6427, 203, 'Vinblastine ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(6428, 203, 'Vinblastine ', 'Posaconazole', ' May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).', NULL, NULL, NULL),
(6429, 203, 'Vinblastine ', 'Ritonavir', ' Ritonavir may increase the serum concentration of VinBLAStine.', NULL, NULL, NULL),
(6430, 203, 'Vinblastine ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(6431, 203, 'Vinblastine ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6432, 203, 'Vinblastine ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6433, 203, 'Vinblastine ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(6434, 203, 'Vinblastine ', 'Sofosbuvir', ' P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir.', NULL, NULL, NULL),
(6435, 203, 'Vinblastine ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6436, 203, 'Vinblastine ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(6437, 203, 'Vinblastine ', 'Tolterodine', ' VinBLAStine may increase the serum concentration of Tolterodine.', NULL, NULL, NULL),
(6438, 203, 'Vinblastine ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(6439, 203, 'Vinblastine ', 'Voriconazole', ' May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).', NULL, NULL, NULL),
(6440, 204, 'Vincristine ', '0', '0', NULL, NULL, NULL),
(6441, 204, 'Vincristine ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6442, 204, 'Vincristine ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(6443, 204, 'Vincristine ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6444, 204, 'Vincristine ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6445, 204, 'Vincristine ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6446, 204, 'Vincristine ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6447, 204, 'Vincristine ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6448, 204, 'Vincristine ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(6449, 204, 'Vincristine ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(6450, 204, 'Vincristine ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6451, 204, 'Vincristine ', 'Fosphenytoin', ' May decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Fosphenytoin.', NULL, NULL, NULL),
(6452, 204, 'Vincristine ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(6453, 204, 'Vincristine ', 'Itraconazole', ' May enhance the adverse/toxic effect of VinCRIStine. Itraconazole may increase the serum concentration of VinCRIStine.', NULL, NULL, NULL),
(6454, 204, 'Vincristine ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6455, 204, 'Vincristine ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(6456, 204, 'Vincristine ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(6457, 204, 'Vincristine ', 'Lopinavir', ' May increase the serum concentration of VinCRIStine.', NULL, NULL, NULL),
(6458, 204, 'Vincristine ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6459, 204, 'Vincristine ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6460, 204, 'Vincristine ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6461, 204, 'Vincristine ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(6462, 204, 'Vincristine ', 'Nifedipine', ' May increase the serum concentration of VinCRIStine.', NULL, NULL, NULL),
(6463, 204, 'Vincristine ', 'Phenytoin', ' Phenytoin may decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Phenytoin.', NULL, NULL, NULL),
(6464, 204, 'Vincristine ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(6465, 204, 'Vincristine ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(6466, 204, 'Vincristine ', 'Posaconazole', ' May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).', NULL, NULL, NULL),
(6467, 204, 'Vincristine ', 'Ritonavir', ' Ritonavir may increase the serum concentration of VinCRIStine.', NULL, NULL, NULL),
(6468, 204, 'Vincristine ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(6469, 204, 'Vincristine ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6470, 204, 'Vincristine ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6471, 204, 'Vincristine ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(6472, 204, 'Vincristine ', 'Teniposide', ' Teniposide may enhance the neurotoxic effect of VinCRIStine.', NULL, NULL, NULL),
(6473, 204, 'Vincristine ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6474, 204, 'Vincristine ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(6475, 204, 'Vincristine ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(6476, 204, 'Vincristine ', 'Voriconazole', ' May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).', NULL, NULL, NULL),
(6477, 205, 'Vinorelbine ', '0', '0', NULL, NULL, NULL),
(6478, 205, 'Vinorelbine ', 'Aprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6479, 205, 'Vinorelbine ', 'Aripiprazole', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.', NULL, NULL, NULL),
(6480, 205, 'Vinorelbine ', 'Bosentan', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6481, 205, 'Vinorelbine ', 'Cisplatin', ' May enhance the adverse/toxic effect of Vinorelbine. Specifically~ the combination may be associated with a higher risk of granulocytopenia.', NULL, NULL, NULL),
(6482, 205, 'Vinorelbine ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(6483, 205, 'Vinorelbine ', 'Conivaptan', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6484, 205, 'Vinorelbine ', 'Dabrafenib', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6485, 205, 'Vinorelbine ', 'Dasatinib', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6486, 205, 'Vinorelbine ', 'Deferasirox', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6487, 205, 'Vinorelbine ', 'Denosumab', ' May enhance the adverse/toxic effect of Immunosuppressants. Specifically~ the risk for serious infections may be increased.', NULL, NULL, NULL),
(6488, 205, 'Vinorelbine ', 'Dofetilide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide.', NULL, NULL, NULL),
(6489, 205, 'Vinorelbine ', 'Fosaprepitant', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6490, 205, 'Vinorelbine ', 'Gefitinib', ' Gefitinib may enhance the neutropenic effect of Vinorelbine.', NULL, NULL, NULL),
(6491, 205, 'Vinorelbine ', 'Hydrocodone', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.', NULL, NULL, NULL),
(6492, 205, 'Vinorelbine ', 'Itraconazole', ' May enhance the adverse/toxic effect of Vinorelbine. Itraconazole may increase the serum concentration of Vinorelbine.', NULL, NULL, NULL),
(6493, 205, 'Vinorelbine ', 'Ivacaftor', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6494, 205, 'Vinorelbine ', 'Leflunomide', ' Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically~ the risk for hematologic toxicity such as pancytopenia~ agranulocytosis~ and/or thrombocytopenia may be increased.', NULL, NULL, NULL),
(6495, 205, 'Vinorelbine ', 'Lomitapide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.', NULL, NULL, NULL),
(6496, 205, 'Vinorelbine ', 'LULICONAZOLE', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6497, 205, 'Vinorelbine ', 'Mifepristone', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6498, 205, 'Vinorelbine ', 'Mitotane', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6499, 205, 'Vinorelbine ', 'Natalizumab', ' Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically~ the risk of concurrent infection may be increased.', NULL, NULL, NULL),
(6500, 205, 'Vinorelbine ', 'Pimecrolimus', ' May enhance the adverse/toxic effect of Immunosuppressants.', NULL, NULL, NULL),
(6501, 205, 'Vinorelbine ', 'Pimozide', ' CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.', NULL, NULL, NULL),
(6502, 205, 'Vinorelbine ', 'Posaconazole', ' May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).', NULL, NULL, NULL),
(6503, 205, 'Vinorelbine ', 'Roflumilast', ' May enhance the immunosuppressive effect of Immunosuppressants.', NULL, NULL, NULL),
(6504, 205, 'Vinorelbine ', 'Siltuximab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6505, 205, 'Vinorelbine ', 'Simeprevir', ' May increase the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6506, 205, 'Vinorelbine ', 'Sipuleucel-T', ' Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.', NULL, NULL, NULL),
(6507, 205, 'Vinorelbine ', 'Tocilizumab', ' May decrease the serum concentration of CYP3A4 Substrates.', NULL, NULL, NULL),
(6508, 205, 'Vinorelbine ', 'Tofacitinib', ' Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.', NULL, NULL, NULL),
(6509, 205, 'Vinorelbine ', 'Trastuzumab', ' May enhance the neutropenic effect of Immunosuppressants.', NULL, NULL, NULL),
(6510, 205, 'Vinorelbine ', 'Voriconazole', ' May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).', NULL, NULL, NULL),
(6511, 206, 'Warfarin ', '0', '0', NULL, NULL, NULL),
(6512, 206, 'Warfarin ', 'Abciximab', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6513, 206, 'Warfarin ', 'Acenocoumarol', ' May enhance the anticoagulant effect of other Anticoagulants.', NULL, NULL, NULL),
(6514, 206, 'Warfarin ', 'Acetylsalicylic acid', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6515, 206, 'Warfarin ', 'Adalimumab', ' Adalimumab may decrease the serum concentration of Warfarin.', NULL, NULL, NULL),
(6516, 206, 'Warfarin ', 'Alteplase', ' Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6517, 206, 'Warfarin ', 'Aminosalicylic Acid', ' Salicylates may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6518, 206, 'Warfarin ', 'Anagrelide', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6519, 206, 'Warfarin ', 'Apixaban', ' Apixaban may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6520, 206, 'Warfarin ', 'Aprepitant', ' Aprepitant may decrease the serum concentration of Warfarin.', NULL, NULL, NULL),
(6521, 206, 'Warfarin ', 'Argatroban', ' May enhance the anticoagulant effect of other Anticoagulants.', NULL, NULL, NULL),
(6522, 206, 'Warfarin ', 'Atazanavir', ' Atazanavir may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6523, 206, 'Warfarin ', 'Bismuth Subsalicylate', ' Salicylates may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6524, 206, 'Warfarin ', 'Bivalirudin', ' May enhance the anticoagulant effect of other Anticoagulants.', NULL, NULL, NULL),
(6525, 206, 'Warfarin ', 'Boceprevir', ' Boceprevir may decrease the serum concentration of Warfarin. Boceprevir may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6526, 206, 'Warfarin ', 'Celecoxib', ' Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6527, 206, 'Warfarin ', 'Choline', ' Fenofibrate and Derivatives may enhance the anticoagulant effect of Warfarin. Fenofibrate and Derivatives may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6528, 206, 'Warfarin ', 'Cilostazol', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6529, 206, 'Warfarin ', 'Citalopram', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6530, 206, 'Warfarin ', 'Clopidogrel', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6531, 206, 'Warfarin ', 'Corticotropin', ' Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.', NULL, NULL, NULL),
(6532, 206, 'Warfarin ', 'Cortisone acetate', ' Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.', NULL, NULL, NULL),
(6533, 206, 'Warfarin ', 'Cyproterone acetate', ' Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6534, 206, 'Warfarin ', 'Dabigatran etexilate', ' Dabigatran Etexilate may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6535, 206, 'Warfarin ', 'Dalteparin', ' May enhance the anticoagulant effect of other Anticoagulants.', NULL, NULL, NULL),
(6536, 206, 'Warfarin ', 'Danaparoid', ' May enhance the anticoagulant effect of other Anticoagulants.', NULL, NULL, NULL),
(6537, 206, 'Warfarin ', 'Darunavir', ' Darunavir may decrease the serum concentration of Warfarin.', NULL, NULL, NULL),
(6538, 206, 'Warfarin ', 'Dasatinib', ' Dasatinib may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6539, 206, 'Warfarin ', 'Deferasirox', ' May enhance the adverse/toxic effect of Deferasirox. Specifically~ the risk for GI ulceration/irritation or GI bleeding may be increased.', NULL, NULL, NULL),
(6540, 206, 'Warfarin ', 'Desogestrel', ' Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6541, 206, 'Warfarin ', 'Desvenlafaxine', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6542, 206, 'Warfarin ', 'Diflunisal', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6543, 206, 'Warfarin ', 'Dipyridamole', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6544, 206, 'Warfarin ', 'Drospirenone', ' Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6545, 206, 'Warfarin ', 'Duloxetine', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6546, 206, 'Warfarin ', 'Enoxaparin', ' May enhance the anticoagulant effect of other Anticoagulants.', NULL, NULL, NULL),
(6547, 206, 'Warfarin ', 'Enzalutamide', ' Enzalutamide may decrease the serum concentration of Warfarin. More specifically~ enzalutamide may decrease concentrations of the S-warfarin enantiomer.', NULL, NULL, NULL),
(6548, 206, 'Warfarin ', 'Epoprostenol', ' Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically~ the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.', NULL, NULL, NULL),
(6549, 206, 'Warfarin ', 'Eptifibatide', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6550, 206, 'Warfarin ', 'Erlotinib', ' Erlotinib may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6551, 206, 'Warfarin ', 'Escitalopram', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6552, 206, 'Warfarin ', 'Estropipate', ' Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6553, 206, 'Warfarin ', 'Ethinyl Estradiol', ' Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6554, 206, 'Warfarin ', 'Ethynodiol', ' Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6555, 206, 'Warfarin ', 'Etodolac', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL);
INSERT INTO `test_drug_interations` (`id`, `drug_id`, `drug_name`, `drug_interacting_name`, `interaction`, `created_at`, `updated_at`, `deleted_at`) VALUES
(6556, 206, 'Warfarin ', 'Etonogestrel', ' Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6557, 206, 'Warfarin ', 'Fenofibrate', ' Fenofibrate and Derivatives may enhance the anticoagulant effect of Warfarin. Fenofibrate and Derivatives may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6558, 206, 'Warfarin ', 'Fenoprofen', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6559, 206, 'Warfarin ', 'Floctafenine', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6560, 206, 'Warfarin ', 'Fludrocortisone', ' Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.', NULL, NULL, NULL),
(6561, 206, 'Warfarin ', 'Fluoxetine', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6562, 206, 'Warfarin ', 'Fluvoxamine', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6563, 206, 'Warfarin ', 'Fondaparinux sodium', ' May enhance the anticoagulant effect of other Anticoagulants.', NULL, NULL, NULL),
(6564, 206, 'Warfarin ', 'Fosamprenavir', ' Fosamprenavir may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6565, 206, 'Warfarin ', 'Fosaprepitant', ' Fosaprepitant may decrease the serum concentration of Warfarin. The active metabolite aprepitant is likely responsible for this effect.', NULL, NULL, NULL),
(6566, 206, 'Warfarin ', 'Gemcitabine', ' Gemcitabine may enhance the anticoagulant effect of Warfarin.', NULL, NULL, NULL),
(6567, 206, 'Warfarin ', 'Heparin', ' May enhance the anticoagulant effect of other Anticoagulants.', NULL, NULL, NULL),
(6568, 206, 'Warfarin ', 'Homoharringtonine', ' May enhance the adverse/toxic effect of Omacetaxine. Specifically~ the risk for bleeding-related events may be increased.', NULL, NULL, NULL),
(6569, 206, 'Warfarin ', 'Ibritumomab', ' May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.', NULL, NULL, NULL),
(6570, 206, 'Warfarin ', 'Ibuprofen', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6571, 206, 'Warfarin ', 'Icosapent', ' Omega-3 Fatty Acids may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6572, 206, 'Warfarin ', 'Icosapent ethyl', ' Omega-3 Fatty Acids may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6573, 206, 'Warfarin ', 'Iloprost', ' Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically~ the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.', NULL, NULL, NULL),
(6574, 206, 'Warfarin ', 'Indomethacin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6575, 206, 'Warfarin ', 'Ketoprofen', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6576, 206, 'Warfarin ', 'Ketorolac', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6577, 206, 'Warfarin ', 'Levomilnacipran', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6578, 206, 'Warfarin ', 'Levonorgestrel', ' Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6579, 206, 'Warfarin ', 'Lomitapide', ' Lomitapide may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6580, 206, 'Warfarin ', 'Lopinavir', ' Lopinavir may decrease the serum concentration of Warfarin.', NULL, NULL, NULL),
(6581, 206, 'Warfarin ', 'Magnesium salicylate', ' Salicylates may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6582, 206, 'Warfarin ', 'Medroxyprogesterone Acetate', ' Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6583, 206, 'Warfarin ', 'Mefenamic acid', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6584, 206, 'Warfarin ', 'Megestrol acetate', ' Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6585, 206, 'Warfarin ', 'Meloxicam', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6586, 206, 'Warfarin ', 'Mestranol', ' Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6587, 206, 'Warfarin ', 'Methylprednisolone', ' Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.', NULL, NULL, NULL),
(6588, 206, 'Warfarin ', 'Metreleptin', ' Metreleptin may decrease the serum concentration of Warfarin. Metreleptin may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6589, 206, 'Warfarin ', 'Miconazole', ' Miconazole (Oral) may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6590, 206, 'Warfarin ', 'Milnacipran', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6591, 206, 'Warfarin ', 'Mirtazapine', ' Mirtazapine may enhance the anticoagulant effect of Warfarin.', NULL, NULL, NULL),
(6592, 206, 'Warfarin ', 'Nabumetone', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6593, 206, 'Warfarin ', 'Nadroparin', ' May enhance the anticoagulant effect of other Anticoagulants.', NULL, NULL, NULL),
(6594, 206, 'Warfarin ', 'Naproxen', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6595, 206, 'Warfarin ', 'Nelfinavir', ' Nelfinavir may decrease the serum concentration of Warfarin. Nelfinavir may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6596, 206, 'Warfarin ', 'Norelgestromin', ' Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6597, 206, 'Warfarin ', 'Norethindrone', ' Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6598, 206, 'Warfarin ', 'Norgestimate', ' Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6599, 206, 'Warfarin ', 'Obinutuzumab', ' May enhance the adverse/toxic effect of Obinutuzumab. Specifically~ the risk of serious bleeding-related events may be increased.', NULL, NULL, NULL),
(6600, 206, 'Warfarin ', 'Orlistat', ' Orlistat may enhance the anticoagulant effect of Warfarin.', NULL, NULL, NULL),
(6601, 206, 'Warfarin ', 'Oxaprozin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6602, 206, 'Warfarin ', 'Paroxetine', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6603, 206, 'Warfarin ', 'Pentosan Polysulfate', ' Pentosan Polysulfate Sodium may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6604, 206, 'Warfarin ', 'Piperazine', ' Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6605, 206, 'Warfarin ', 'Piroxicam', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6606, 206, 'Warfarin ', 'Prasugrel', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6607, 206, 'Warfarin ', 'Prednisone', ' Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.', NULL, NULL, NULL),
(6608, 206, 'Warfarin ', 'Progesterone', ' Progestins may diminish the therapeutic effect of Anticoagulants. More specifically~ the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.', NULL, NULL, NULL),
(6609, 206, 'Warfarin ', 'Proguanil', ' Proguanil may enhance the anticoagulant effect of Warfarin.', NULL, NULL, NULL),
(6610, 206, 'Warfarin ', 'Ranitidine', ' Ranitidine may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6611, 206, 'Warfarin ', 'Regorafenib', ' May enhance the adverse/toxic effect of Regorafenib. Specifically~ the risk for bleeding may be increased.', NULL, NULL, NULL),
(6612, 206, 'Warfarin ', 'Reteplase', ' Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6613, 206, 'Warfarin ', 'Ritonavir', ' Ritonavir may decrease the serum concentration of Warfarin.', NULL, NULL, NULL),
(6614, 206, 'Warfarin ', 'Rivaroxaban', ' May enhance the anticoagulant effect of Rivaroxaban.', NULL, NULL, NULL),
(6615, 206, 'Warfarin ', 'Salsalate', ' Salicylates may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6616, 206, 'Warfarin ', 'Saquinavir', ' Saquinavir may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6617, 206, 'Warfarin ', 'Sertraline', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6618, 206, 'Warfarin ', 'Sorafenib', ' SORAfenib may enhance the anticoagulant effect of Warfarin. SORAfenib may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6619, 206, 'Warfarin ', 'Sulindac', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6620, 206, 'Warfarin ', 'Telaprevir', ' Telaprevir may decrease the serum concentration of Warfarin. Telaprevir may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6621, 206, 'Warfarin ', 'Tenecteplase', ' Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6622, 206, 'Warfarin ', 'Teriflunomide', ' Teriflunomide may decrease the serum concentration of Warfarin.', NULL, NULL, NULL),
(6623, 206, 'Warfarin ', 'Tiaprofenic acid', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6624, 206, 'Warfarin ', 'Ticagrelor', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6625, 206, 'Warfarin ', 'Ticlopidine', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6626, 206, 'Warfarin ', 'Tigecycline', ' Tigecycline may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6627, 206, 'Warfarin ', 'Tinzaparin', ' May enhance the anticoagulant effect of other Anticoagulants.', NULL, NULL, NULL),
(6628, 206, 'Warfarin ', 'Tipranavir', ' Tipranavir may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6629, 206, 'Warfarin ', 'Tirofiban', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6630, 206, 'Warfarin ', 'Tolmetin', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6631, 206, 'Warfarin ', 'Tolterodine', ' Tolterodine may enhance the anticoagulant effect of Warfarin.', NULL, NULL, NULL),
(6632, 206, 'Warfarin ', 'Torasemide', ' Torsemide may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6633, 206, 'Warfarin ', 'Tositumomab', ' May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically~ the risk of bleeding-related adverse effects may be increased.', NULL, NULL, NULL),
(6634, 206, 'Warfarin ', 'Treprostinil', ' Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically~ the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.', NULL, NULL, NULL),
(6635, 206, 'Warfarin ', 'Vemurafenib', ' Vemurafenib may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6636, 206, 'Warfarin ', 'Venlafaxine', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6637, 206, 'Warfarin ', 'Vilazodone', ' Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.', NULL, NULL, NULL),
(6638, 206, 'Warfarin ', 'Vitamin E', ' Vitamin E may enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.', NULL, NULL, NULL),
(6639, 206, 'Warfarin ', 'Vorapaxar', ' Vorapaxar may enhance the adverse/toxic effect of Anticoagulants. More specifically~ this combination is expected to increase the risk of bleeding.', NULL, NULL, NULL),
(6640, 206, 'Warfarin ', 'Zileuton', ' Zileuton may increase the serum concentration of Warfarin.', NULL, NULL, NULL),
(6641, 207, 'xylometazoline ', '0', '0', NULL, NULL, NULL),
(6642, 208, 'Zelodronic acid ', '0', '0', NULL, NULL, NULL),
(6643, 209, 'Zidovudine ', '0', '0', NULL, NULL, NULL),
(6644, 209, 'Zidovudine ', 'Aciclovir', ' Acyclovir-Valacyclovir may enhance the CNS depressant effect of Zidovudine.', NULL, NULL, NULL),
(6645, 209, 'Zidovudine ', 'Atazanavir', ' Protease Inhibitors may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6646, 209, 'Zidovudine ', 'Batimastat', ' May decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6647, 209, 'Zidovudine ', 'Clarithromycin', ' May enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6648, 209, 'Zidovudine ', 'Clozapine', ' Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically~ the risk for agranulocytosis may be increased.', NULL, NULL, NULL),
(6649, 209, 'Zidovudine ', 'Darunavir', ' Protease Inhibitors may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6650, 209, 'Zidovudine ', 'Fluconazole', ' Fluconazole may decrease the metabolism of Zidovudine.', NULL, NULL, NULL),
(6651, 209, 'Zidovudine ', 'Fosamprenavir', ' Protease Inhibitors may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6652, 209, 'Zidovudine ', 'Indinavir', ' Protease Inhibitors may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6653, 209, 'Zidovudine ', 'Interferon alfa-n3', ' Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.', NULL, NULL, NULL),
(6654, 209, 'Zidovudine ', 'Interferon alfacon-1', ' Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.', NULL, NULL, NULL),
(6655, 209, 'Zidovudine ', 'Interferon beta-1a', ' Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.', NULL, NULL, NULL),
(6656, 209, 'Zidovudine ', 'Interferon beta-1b', ' Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.', NULL, NULL, NULL),
(6657, 209, 'Zidovudine ', 'Interferon gamma-1b', ' Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.', NULL, NULL, NULL),
(6658, 209, 'Zidovudine ', 'Isoflurophate', ' May decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6659, 209, 'Zidovudine ', 'Lopinavir', ' Protease Inhibitors may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6660, 209, 'Zidovudine ', 'Methadone', ' Methadone may increase the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6661, 209, 'Zidovudine ', 'Nelfinavir', ' Protease Inhibitors may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6662, 209, 'Zidovudine ', 'Peginterferon alfa-2a', ' Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.', NULL, NULL, NULL),
(6663, 209, 'Zidovudine ', 'Peginterferon alfa-2b', ' Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.', NULL, NULL, NULL),
(6664, 209, 'Zidovudine ', 'Probenecid', ' May decrease the metabolism of Zidovudine.', NULL, NULL, NULL),
(6665, 209, 'Zidovudine ', 'Raltegravir', ' May enhance the myopathic (rhabdomyolysis) effect of Zidovudine.', NULL, NULL, NULL),
(6666, 209, 'Zidovudine ', 'Ribavirin', ' Zidovudine may enhance the adverse/toxic effect of Ribavirin. Specifically~ the risk/severity of anemia may be increased.', NULL, NULL, NULL),
(6667, 209, 'Zidovudine ', 'Rifampicin', ' Rifamycin Derivatives may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6668, 209, 'Zidovudine ', 'Rifapentine', ' Rifamycin Derivatives may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6669, 209, 'Zidovudine ', 'Ritonavir', ' Protease Inhibitors may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6670, 209, 'Zidovudine ', 'Saquinavir', ' Protease Inhibitors may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6671, 209, 'Zidovudine ', 'Simeprevir', ' May decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6672, 209, 'Zidovudine ', 'Stavudine', ' Zidovudine may diminish the therapeutic effect of Stavudine.', NULL, NULL, NULL),
(6673, 209, 'Zidovudine ', 'Teriflunomide', ' May increase the serum concentration of OAT3 Substrates.', NULL, NULL, NULL),
(6674, 209, 'Zidovudine ', 'Tipranavir', ' Protease Inhibitors may decrease the serum concentration of Zidovudine.', NULL, NULL, NULL),
(6675, 209, 'Zidovudine ', 'Valproic Acid', ' Valproic Acid and Derivatives may decrease the metabolism of Zidovudine.', NULL, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `transfer`
--

DROP TABLE IF EXISTS `transfer`;
CREATE TABLE IF NOT EXISTS `transfer` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `source` int(11) NOT NULL,
  `destination` int(11) NOT NULL,
  `date` date NOT NULL,
  `transfered_by` varchar(150) NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `transfers`
--

DROP TABLE IF EXISTS `transfers`;
CREATE TABLE IF NOT EXISTS `transfers` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `source` int(11) NOT NULL,
  `destination` int(11) NOT NULL,
  `date` date NOT NULL,
  `transfered_by` varchar(150) NOT NULL,
  `status` varchar(20) NOT NULL DEFAULT 'active',
  `updated_at` date NOT NULL,
  `created_at` date NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=150 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `transfers`
--

INSERT INTO `transfers` (`id`, `source`, `destination`, `date`, `transfered_by`, `status`, `updated_at`, `created_at`) VALUES
(94, 1, 2, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(95, 1, 2, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(96, 2, 1, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(97, 1, 2, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(98, 1, 2, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(99, 1, 2, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(100, 2, 1, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(101, 2, 1, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(102, 2, 1, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(103, 2, 1, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(104, 2, 1, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(105, 2, 1, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(106, 2, 1, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(107, 2, 1, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(108, 2, 1, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(109, 2, 1, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(110, 2, 1, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(111, 2, 1, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(112, 1, 2, '2019-04-22', '1', 'active', '2019-04-22', '2019-04-22'),
(113, 2, 1, '2019-04-23', '1', 'active', '2019-04-22', '2019-04-22'),
(114, 2, 1, '2019-04-26', '1', 'active', '2019-04-26', '2019-04-26'),
(115, 1, 2, '2019-04-26', '1', 'active', '2019-04-26', '2019-04-26'),
(116, 1, 2, '2019-04-26', '1', 'active', '2019-04-26', '2019-04-26'),
(117, 1, 2, '2019-04-26', '1', 'active', '2019-04-26', '2019-04-26'),
(118, 1, 2, '2019-04-26', '1', 'active', '2019-04-26', '2019-04-26'),
(119, 2, 1, '2019-04-26', '1', 'active', '2019-04-26', '2019-04-26'),
(120, 1, 2, '2019-04-27', '1', 'active', '2019-04-27', '2019-04-27'),
(121, 1, 2, '2019-04-27', '1', 'active', '2019-04-27', '2019-04-27'),
(122, 1, 2, '2019-04-27', '1', 'active', '2019-04-27', '2019-04-27'),
(123, 1, 2, '2019-04-27', '1', 'void', '2019-04-27', '2019-04-27'),
(124, 1, 2, '2019-04-29', '1', 'void', '2019-04-29', '2019-04-29'),
(125, 1, 2, '2019-04-29', '1', 'void', '2019-04-29', '2019-04-29'),
(126, 1, 2, '2019-05-01', '1', 'active', '2019-05-01', '2019-05-01'),
(127, 1, 2, '2019-05-01', '1', 'active', '2019-05-01', '2019-05-01'),
(128, 2, 1, '2019-05-01', '1', 'active', '2019-05-01', '2019-05-01'),
(129, 2, 1, '2019-05-01', '1', 'active', '2019-05-01', '2019-05-01'),
(130, 2, 1, '2019-05-01', '1', 'active', '2019-05-01', '2019-05-01'),
(131, 2, 1, '2019-05-01', '1', 'active', '2019-05-01', '2019-05-01'),
(132, 2, 1, '2019-05-01', '1', 'active', '2019-05-01', '2019-05-01'),
(133, 1, 2, '2019-05-01', '1', 'active', '2019-05-01', '2019-05-01'),
(134, 1, 2, '2019-05-01', '1', 'active', '2019-05-01', '2019-05-01'),
(135, 1, 1, '2019-05-01', '1', 'active', '2019-05-01', '2019-05-01'),
(136, 1, 1, '2019-05-01', '1', 'active', '2019-05-01', '2019-05-01'),
(138, 1, 2, '2020-04-24', '1', 'active', '2020-04-24', '2020-04-24'),
(139, 1, 2, '2020-04-25', '1', 'active', '2020-04-25', '2020-04-25'),
(140, 1, 2, '2020-04-25', '1', 'active', '2020-04-25', '2020-04-25'),
(143, 2, 1, '2020-04-25', '1', 'active', '2020-04-25', '2020-04-25'),
(144, 2, 1, '2020-04-25', '1', 'active', '2020-04-25', '2020-04-25'),
(146, 2, 1, '2020-04-25', '1', 'active', '2020-04-25', '2020-04-25'),
(147, 2, 1, '2020-04-25', '1', 'active', '2020-04-25', '2020-04-25'),
(148, 2, 1, '2020-04-25', '1', 'active', '2020-04-25', '2020-04-25'),
(149, 2, 1, '2020-05-29', '1', 'active', '2020-05-29', '2020-05-29');

-- --------------------------------------------------------

--
-- Table structure for table `transfer_items`
--

DROP TABLE IF EXISTS `transfer_items`;
CREATE TABLE IF NOT EXISTS `transfer_items` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `transfer_id` int(11) NOT NULL,
  `item` int(11) NOT NULL,
  `amount` decimal(10,2) NOT NULL,
  `status` varchar(20) NOT NULL DEFAULT 'active',
  `barcode` varchar(100) DEFAULT NULL,
  `updated_at` date DEFAULT NULL,
  `created_at` date DEFAULT NULL,
  `variant` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=132 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `transfer_items`
--

INSERT INTO `transfer_items` (`id`, `transfer_id`, `item`, `amount`, `status`, `barcode`, `updated_at`, `created_at`, `variant`) VALUES
(77, 94, 413, '10.00', 'active', 'no-barcode', '2019-04-22', '2019-04-22', NULL),
(78, 95, 413, '10.00', 'active', 'no-barcode', '2019-04-22', '2019-04-22', NULL),
(79, 96, 413, '30.00', 'active', 'no-barcode', '2019-04-22', '2019-04-22', NULL),
(80, 97, 426, '2.00', 'active', 'no-barcode', '2019-04-22', '2019-04-22', NULL),
(81, 98, 426, '2.00', 'active', NULL, '2019-04-22', '2019-04-22', NULL),
(82, 99, 426, '2.00', 'active', '10001842601', '2019-04-22', '2019-04-22', NULL),
(83, 100, 413, '20.00', 'active', NULL, '2019-04-22', '2019-04-22', NULL),
(84, 101, 413, '20.00', 'active', NULL, '2019-04-22', '2019-04-22', NULL),
(85, 102, 413, '20.00', 'active', NULL, '2019-04-22', '2019-04-22', NULL),
(86, 103, 413, '20.00', 'active', NULL, '2019-04-22', '2019-04-22', NULL),
(87, 104, 413, '20.00', 'active', NULL, '2019-04-22', '2019-04-22', NULL),
(88, 105, 413, '20.00', 'active', NULL, '2019-04-22', '2019-04-22', NULL),
(89, 106, 413, '20.00', 'active', NULL, '2019-04-22', '2019-04-22', NULL),
(90, 107, 413, '20.00', 'active', 'no barcode', '2019-04-22', '2019-04-22', NULL),
(91, 108, 413, '20.00', 'active', 'no barcode', '2019-04-22', '2019-04-22', NULL),
(92, 109, 413, '20.00', 'active', 'no-barcode', '2019-04-22', '2019-04-22', NULL),
(93, 110, 413, '20.00', 'active', 'no-barcode', '2019-04-22', '2019-04-22', NULL),
(94, 111, 413, '20.00', 'active', 'no-barcode', '2019-04-22', '2019-04-22', NULL),
(95, 112, 413, '5.00', 'active', 'no-barcode', '2019-04-22', '2019-04-22', NULL),
(96, 113, 425, '15.00', 'active', 'no-barcode', '2019-04-22', '2019-04-22', NULL),
(97, 114, 413, '10.00', 'active', 'no-barcode', '2019-04-26', '2019-04-26', NULL),
(98, 115, 413, '10.00', 'active', 'no-barcode', '2019-04-26', '2019-04-26', NULL),
(99, 116, 413, '10.00', 'active', 'no-barcode', '2019-04-26', '2019-04-26', NULL),
(100, 117, 413, '10.00', 'active', 'no-barcode', '2019-04-26', '2019-04-26', NULL),
(101, 118, 413, '5.00', 'active', 'no-barcode', '2019-04-26', '2019-04-26', NULL),
(102, 119, 413, '15.00', 'active', 'no-barcode', '2019-04-26', '2019-04-26', NULL),
(103, 120, 413, '5.00', 'active', 'no-barcode', '2019-04-27', '2019-04-27', NULL),
(104, 121, 413, '5.00', 'active', 'no-barcode', '2019-04-27', '2019-04-27', NULL),
(105, 122, 413, '5.00', 'active', 'no-barcode', '2019-04-27', '2019-04-27', NULL),
(106, 123, 413, '5.00', 'void', 'no-barcode', '2019-04-27', '2019-04-27', NULL),
(107, 124, 413, '10.00', 'void', 'no-barcode', '2019-04-29', '2019-04-29', NULL),
(108, 125, 413, '10.00', 'void', 'no-barcode', '2019-04-29', '2019-04-29', NULL),
(109, 126, 413, '100.00', 'active', '12154545', '2019-05-01', '2019-05-01', NULL),
(110, 127, 442, '100.00', 'active', '12154545', '2019-05-01', '2019-05-01', NULL),
(111, 128, 413, '100.00', 'active', '12154545', '2019-05-01', '2019-05-01', NULL),
(112, 129, 413, '100.00', 'active', '12154545', '2019-05-01', '2019-05-01', NULL),
(113, 130, 413, '100.00', 'active', '10001941301', '2019-05-01', '2019-05-01', NULL),
(114, 131, 413, '100.00', 'active', '10001941301', '2019-05-01', '2019-05-01', NULL),
(115, 132, 413, '100.00', 'active', '10001941301', '2019-05-01', '2019-05-01', NULL),
(116, 133, 413, '60.00', 'active', '10001941301', '2019-05-01', '2019-05-01', NULL),
(117, 134, 413, '60.00', 'active', '10001941301', '2019-05-01', '2019-05-01', NULL),
(118, 135, 413, '60.00', 'active', '10001941301', '2019-05-01', '2019-05-01', NULL),
(119, 136, 413, '10.00', 'active', '10001941301', '2019-05-01', '2019-05-01', NULL),
(120, 138, 1, '3.00', 'active', NULL, '2020-04-24', '2020-04-24', 283),
(121, 139, 1, '4.00', 'active', NULL, '2020-04-25', '2020-04-25', 283),
(122, 140, 1, '1.00', 'active', NULL, '2020-04-25', '2020-04-25', 283),
(125, 143, 1, '2.00', 'active', NULL, '2020-04-25', '2020-04-25', 283),
(126, 144, 1, '2.00', 'active', NULL, '2020-04-25', '2020-04-25', 283),
(128, 146, 1, '1.00', 'active', NULL, '2020-04-25', '2020-04-25', 283),
(129, 147, 1, '2.00', 'active', NULL, '2020-04-25', '2020-04-25', 283),
(130, 148, 1, '2.00', 'active', NULL, '2020-04-25', '2020-04-25', 283),
(131, 149, 1, '2.00', 'active', NULL, '2020-05-29', '2020-05-29', 318);

-- --------------------------------------------------------

--
-- Table structure for table `uom`
--

DROP TABLE IF EXISTS `uom`;
CREATE TABLE IF NOT EXISTS `uom` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `name` varchar(45) DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `users`
--

DROP TABLE IF EXISTS `users`;
CREATE TABLE IF NOT EXISTS `users` (
  `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT,
  `name` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `email` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `email_verified_at` timestamp NULL DEFAULT NULL,
  `password` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `remember_token` varchar(100) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`),
  UNIQUE KEY `users_email_unique` (`email`)
) ENGINE=InnoDB AUTO_INCREMENT=8 DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `users`
--

INSERT INTO `users` (`id`, `name`, `email`, `email_verified_at`, `password`, `remember_token`, `created_at`, `updated_at`) VALUES
(1, 'simon', 'simon', NULL, '$2y$10$c8b1wb6y.S/ADXoaphSINehUVWxMmiQ76A6/2Wcwq0L0qfBHgHp3S', NULL, '2019-04-01 14:22:11', '2019-04-01 14:22:11'),
(2, 'Simon', 'simona', NULL, '$2y$10$57Xd2DH3s7S0SPyCkMGK2.BONq2VKrB80YEofC8pmb.C0k1aw0d9q', NULL, '2019-04-04 06:32:04', '2019-04-04 06:32:04'),
(3, 'simon123', 'simon123', NULL, '$2y$10$dOy5Od9M5IqAz9yneadrK.Gz4T8NPWz.gtgP0bp2nKcusayPMevk.', NULL, '2019-04-04 06:34:39', '2019-04-04 06:34:39'),
(4, 'admin', 'admin', NULL, '$2y$10$PQKHu78uzABieTVPLdKUheipx4YrlNj4DosynW9JcZMSRJIfyBpYe', NULL, '2019-04-06 08:39:06', '2019-04-06 08:39:06'),
(5, 'merhawi', 'merhawi', NULL, '$2y$10$BKDaTZS4UUaMyG2BcUiB0.D82YHQBDM21qw4lu2n.BmuN8WGNhG5W', NULL, '2019-04-09 13:35:16', '2019-04-09 13:35:16'),
(6, 'merhawi', 'merhawi123', NULL, '$2y$10$lmPqjaR7juz.1o.sj/.3L.9iSPk3sQbJSGFcFYLARXj8z.PFY9BsK', NULL, '2019-04-11 12:25:20', '2019-04-11 12:25:20'),
(7, 'Administrators', 'admin1', NULL, '$2y$10$aoSQc0DKewysDnSj/nTCj.JSrJdzAaiPVOcjsQ.UC.xW07FfaSOxO', NULL, '2019-04-19 01:25:08', '2019-04-19 01:25:08');

-- --------------------------------------------------------

--
-- Table structure for table `variant_default`
--

DROP TABLE IF EXISTS `variant_default`;
CREATE TABLE IF NOT EXISTS `variant_default` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `variant_id` int(11) NOT NULL,
  `freq` varchar(30) NOT NULL,
  `dosage` varchar(30) NOT NULL,
  `duration_time` varchar(30) NOT NULL,
  `duration_day` varchar(30) NOT NULL,
  `uom` varchar(30) NOT NULL,
  `route` varchar(30) NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM AUTO_INCREMENT=23 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `variant_default`
--

INSERT INTO `variant_default` (`id`, `variant_id`, `freq`, `dosage`, `duration_time`, `duration_day`, `uom`, `route`) VALUES
(20, 314, 'Twice a day(BID)', '100', '50', 'weeks', 'mg', 'tablet'),
(21, 309, 'Four times a day(QID)', '800', '500', 'months', 'mg', 'syrup'),
(22, 317, 'Twice a day(BID)', '100', '20', 'days', 'mg', 'syrup');

-- --------------------------------------------------------

--
-- Table structure for table `vendors`
--

DROP TABLE IF EXISTS `vendors`;
CREATE TABLE IF NOT EXISTS `vendors` (
  `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT,
  `first_name` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `middle_name` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `last_name` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `account_number` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `mobile` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `address` varchar(191) COLLATE utf8mb4_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `vital_signs`
--

DROP TABLE IF EXISTS `vital_signs`;
CREATE TABLE IF NOT EXISTS `vital_signs` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `customer` int(11) DEFAULT NULL,
  `date` date DEFAULT NULL,
  `spo2` varchar(50) DEFAULT NULL,
  `temp` varchar(50) DEFAULT NULL,
  `bp_sys` varchar(50) DEFAULT NULL,
  `bp_dys` varchar(50) DEFAULT NULL,
  `pulse` varchar(50) DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT CURRENT_TIMESTAMP,
  `created_at` timestamp NULL DEFAULT CURRENT_TIMESTAMP ON UPDATE CURRENT_TIMESTAMP,
  `sugar` varchar(50) DEFAULT NULL,
  `weight` varchar(50) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB AUTO_INCREMENT=100 DEFAULT CHARSET=latin1;

--
-- Dumping data for table `vital_signs`
--

INSERT INTO `vital_signs` (`id`, `customer`, `date`, `spo2`, `temp`, `bp_sys`, `bp_dys`, `pulse`, `updated_at`, `created_at`, `sugar`, `weight`) VALUES
(92, 24, '2020-02-25', NULL, '50', '10', '20', '40', '2020-02-25 03:06:52', '2020-02-25 03:06:52', '30', '60'),
(94, 24, '2020-02-25', NULL, '55', '11', '22', '44', '2020-02-25 03:07:33', '2020-02-25 03:07:33', '33', '66'),
(95, 26, '2020-02-25', NULL, '88', '10', '20', '77', '2020-02-25 05:33:11', '2020-02-25 05:33:11', '330', '45'),
(96, 18, '2020-02-25', NULL, '50', '10', '20', '40', '2020-02-25 05:33:35', '2020-02-25 05:33:35', '30', '60'),
(97, 26, '2020-02-29', NULL, '38', '120', '80', '66', '2020-02-29 02:32:38', '2020-02-29 02:32:38', '55', '89'),
(98, 26, '2020-03-02', NULL, '39', '130', '90', '70', '2020-02-29 02:37:33', '2020-02-29 02:37:33', '58', '93'),
(99, 26, '2020-03-03', NULL, '39.5', '125', '88', '72', '2020-02-29 02:38:13', '2020-02-29 02:38:13', '60', '95');

--
-- Constraints for dumped tables
--

--
-- Constraints for table `sale_items`
--
ALTER TABLE `sale_items`
  ADD CONSTRAINT `sale_items_sale_id_foreign` FOREIGN KEY (`sale_id`) REFERENCES `sales` (`id`);
COMMIT;

/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
